{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "eDz-SEkqPXTR"
      },
      "source": [
        "https://clinicaltrials.gov/data-api/api\n",
        "\n",
        "\n",
        "https://www.ncbi.nlm.nih.gov/home/develop/api/"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ovtzPMULng_1"
      },
      "outputs": [],
      "source": [
        "%pip install requests pandas matplotlib seaborn tqdm sqlite3\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "7FWE6wPMqbFF"
      },
      "source": [
        "ClinicalTrials.gov API test"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 401
        },
        "id": "19-Knu0LqfV4",
        "outputId": "e8a49c2e-281a-4558-9f15-d18a7ed09fa9"
      },
      "outputs": [
        {
          "ename": "JSONDecodeError",
          "evalue": "Expecting value: line 1 column 1 (char 0)",
          "output_type": "error",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mJSONDecodeError\u001b[0m                           Traceback (most recent call last)",
            "\u001b[0;32m/usr/local/lib/python3.11/dist-packages/requests/models.py\u001b[0m in \u001b[0;36mjson\u001b[0;34m(self, **kwargs)\u001b[0m\n\u001b[1;32m    973\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 974\u001b[0;31m             \u001b[0;32mreturn\u001b[0m \u001b[0mcomplexjson\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mloads\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtext\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    975\u001b[0m         \u001b[0;32mexcept\u001b[0m \u001b[0mJSONDecodeError\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.11/json/__init__.py\u001b[0m in \u001b[0;36mloads\u001b[0;34m(s, cls, object_hook, parse_float, parse_int, parse_constant, object_pairs_hook, **kw)\u001b[0m\n\u001b[1;32m    345\u001b[0m             parse_constant is None and object_pairs_hook is None and not kw):\n\u001b[0;32m--> 346\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0m_default_decoder\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdecode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0ms\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    347\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mcls\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.11/json/decoder.py\u001b[0m in \u001b[0;36mdecode\u001b[0;34m(self, s, _w)\u001b[0m\n\u001b[1;32m    336\u001b[0m         \"\"\"\n\u001b[0;32m--> 337\u001b[0;31m         \u001b[0mobj\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mend\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mraw_decode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0ms\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0midx\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0m_w\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0ms\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;36m0\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    338\u001b[0m         \u001b[0mend\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0m_w\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0ms\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mend\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.11/json/decoder.py\u001b[0m in \u001b[0;36mraw_decode\u001b[0;34m(self, s, idx)\u001b[0m\n\u001b[1;32m    354\u001b[0m         \u001b[0;32mexcept\u001b[0m \u001b[0mStopIteration\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0merr\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 355\u001b[0;31m             \u001b[0;32mraise\u001b[0m \u001b[0mJSONDecodeError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"Expecting value\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ms\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0merr\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mfrom\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    356\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mobj\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mend\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mJSONDecodeError\u001b[0m: Expecting value: line 1 column 1 (char 0)",
            "\nDuring handling of the above exception, another exception occurred:\n",
            "\u001b[0;31mJSONDecodeError\u001b[0m                           Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-10-1b0bda4cd763>\u001b[0m in \u001b[0;36m<cell line: 0>\u001b[0;34m()\u001b[0m\n\u001b[1;32m     21\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     22\u001b[0m \u001b[0;31m# Example: Fetch trials for Pancreatic Cancer\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 23\u001b[0;31m \u001b[0mget_active_trials\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"Pancreatic Cancer\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
            "\u001b[0;32m<ipython-input-10-1b0bda4cd763>\u001b[0m in \u001b[0;36mget_active_trials\u001b[0;34m(disease)\u001b[0m\n\u001b[1;32m     11\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     12\u001b[0m     \u001b[0mresponse\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mrequests\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mbase_url\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mparams\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mparams\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 13\u001b[0;31m     \u001b[0mdata\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mresponse\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mjson\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     14\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     15\u001b[0m     \u001b[0;32mfor\u001b[0m \u001b[0mstudy\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mdata\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"studies\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.11/dist-packages/requests/models.py\u001b[0m in \u001b[0;36mjson\u001b[0;34m(self, **kwargs)\u001b[0m\n\u001b[1;32m    976\u001b[0m             \u001b[0;31m# Catch JSON-related errors and raise as requests.JSONDecodeError\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    977\u001b[0m             \u001b[0;31m# This aliases json.JSONDecodeError and simplejson.JSONDecodeError\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 978\u001b[0;31m             \u001b[0;32mraise\u001b[0m \u001b[0mRequestsJSONDecodeError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0me\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmsg\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdoc\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mpos\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    979\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    980\u001b[0m     \u001b[0;34m@\u001b[0m\u001b[0mproperty\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mJSONDecodeError\u001b[0m: Expecting value: line 1 column 1 (char 0)"
          ]
        }
      ],
      "source": [
        "import requests\n",
        "\n",
        "def get_active_trials(disease):\n",
        "    base_url = \"https://clinicaltrials.gov/api/v2/studies\"\n",
        "    params = {\n",
        "        \"conditions\": disease,  # Disease name\n",
        "        \"status\": \"Recruiting\",  # Get only active trials\n",
        "        \"format\": \"json\",\n",
        "        \"count\": 5  # Get a small sample first\n",
        "    }\n",
        "\n",
        "    response = requests.get(base_url, params=params)\n",
        "    data = response.json()\n",
        "\n",
        "    for study in data.get(\"studies\", []):\n",
        "        print(f\"Title: {study['title']}\")\n",
        "        print(f\"Status: {study['study_status']}\")\n",
        "        print(f\"Phase: {study.get('phase', 'Not Specified')}\")\n",
        "        print(f\"Start Date: {study.get('start_date', 'N/A')}\")\n",
        "        print(f\"Funded By: {study.get('sponsor_agency_class', 'Unknown')}\\n\")\n",
        "\n",
        "# Example: Fetch trials for Pancreatic Cancer\n",
        "get_active_trials(\"Pancreatic Cancer\")\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Q01UHbfhnXdX"
      },
      "source": [
        "PubMed API Test"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "AcMCzAmjnTPx"
      },
      "outputs": [],
      "source": [
        "base_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/\"\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "S1szo2rnnrP2"
      },
      "outputs": [],
      "source": [
        "import time\n",
        "\n",
        "def safe_request(url, params=None, retries=3, timeout=10):\n",
        "    for _ in range(retries):\n",
        "        try:\n",
        "            response = requests.get(url, params=params, timeout=timeout)\n",
        "            if response.status_code == 200:\n",
        "                return response.json()\n",
        "        except requests.exceptions.RequestException as e:\n",
        "            print(f\"Request failed: {e}. Retrying...\")\n",
        "            time.sleep(5)  # Wait before retrying\n",
        "    return None  # Return None if all retries fail\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "R3HgcG4-uK3-",
        "outputId": "a6be05db-ea46-442f-885a-54157effe159"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "<class 'requests.models.Response'>\n",
            "<!DOCTYPE html>\n",
            "\n",
            "<html lang=\"en\" data-critters-container>\n",
            "<head><link rel=\"preconnect\" href=\"https://fonts.gstatic.com\" crossorigin>\n",
            "  <meta charset=\"UTF-8\">\n",
            "  <script type=\"text/javascript\">\n",
            "    window.ncbi_startTime = new Date();\n",
            "  </script>\n",
            "  <meta http-equiv=\"X-UA-Compatible\" content=\"IE=edge\">\n",
            "\n",
            "  <!-- Mobile properties -->\n",
            "  <meta name=\"HandheldFriendly\" content=\"True\">\n",
            "  <meta name=\"MobileOptimized\" content=\"320\">\n",
            "  <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0, minimum-scale=1\">\n",
            "\n",
            "  <style>@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3GUBGEe.woff2) format('woff2');unicode-range:U+0460-052F, U+1C80-1C8A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3iUBGEe.woff2) format('woff2');unicode-range:U+0301, U+0400-045F, U+0490-0491, U+04B0-04B1, U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3CUBGEe.woff2) format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3-UBGEe.woff2) format('woff2');unicode-range:U+0370-0377, U+037A-037F, U+0384-038A, U+038C, U+038E-03A1, U+03A3-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMawCUBGEe.woff2) format('woff2');unicode-range:U+0302-0303, U+0305, U+0307-0308, U+0310, U+0312, U+0315, U+031A, U+0326-0327, U+032C, U+032F-0330, U+0332-0333, U+0338, U+033A, U+0346, U+034D, U+0391-03A1, U+03A3-03A9, U+03B1-03C9, U+03D1, U+03D5-03D6, U+03F0-03F1, U+03F4-03F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, U+2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1, U+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U+2192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+2216-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+2395, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7, U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-2AFF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7FF, U+1EE00-1EEFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMaxKUBGEe.woff2) format('woff2');unicode-range:U+0001-000C, U+000E-001F, U+007F-009F, U+20DD-20E0, U+20E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U+21F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-24FF, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-2BFF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+101D0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F000-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U+1F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U+1F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4-1F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U+1F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F453, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF, U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U+1F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F512-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U+1F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC, U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC, U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887, U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F946, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89, U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3OUBGEe.woff2) format('woff2');unicode-range:U+0102-0103, U+0110-0111, U+0128-0129, U+0168-0169, U+01A0-01A1, U+01AF-01B0, U+0300-0301, U+0303-0304, U+0308-0309, U+0323, U+0329, U+1EA0-1EF9, U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3KUBGEe.woff2) format('woff2');unicode-range:U+0100-02BA, U+02BD-02C5, U+02C7-02CC, U+02CE-02D7, U+02DD-02FF, U+0304, U+0308, U+0329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3yUBA.woff2) format('woff2');unicode-range:U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+0304, U+0308, U+0329, U+2000-206F, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3GUBGEe.woff2) format('woff2');unicode-range:U+0460-052F, U+1C80-1C8A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3iUBGEe.woff2) format('woff2');unicode-range:U+0301, U+0400-045F, U+0490-0491, U+04B0-04B1, U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3CUBGEe.woff2) format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3-UBGEe.woff2) format('woff2');unicode-range:U+0370-0377, U+037A-037F, U+0384-038A, U+038C, U+038E-03A1, U+03A3-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMawCUBGEe.woff2) format('woff2');unicode-range:U+0302-0303, U+0305, U+0307-0308, U+0310, U+0312, U+0315, U+031A, U+0326-0327, U+032C, U+032F-0330, U+0332-0333, U+0338, U+033A, U+0346, U+034D, U+0391-03A1, U+03A3-03A9, U+03B1-03C9, U+03D1, U+03D5-03D6, U+03F0-03F1, U+03F4-03F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, U+2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1, U+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U+2192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+2216-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+2395, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7, U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-2AFF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7FF, U+1EE00-1EEFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMaxKUBGEe.woff2) format('woff2');unicode-range:U+0001-000C, U+000E-001F, U+007F-009F, U+20DD-20E0, U+20E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U+21F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-24FF, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-2BFF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+101D0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F000-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U+1F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U+1F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4-1F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U+1F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F453, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF, U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U+1F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F512-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U+1F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC, U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC, U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887, U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F946, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89, U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3OUBGEe.woff2) format('woff2');unicode-range:U+0102-0103, U+0110-0111, U+0128-0129, U+0168-0169, U+01A0-01A1, U+01AF-01B0, U+0300-0301, U+0303-0304, U+0308-0309, U+0323, U+0329, U+1EA0-1EF9, U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3KUBGEe.woff2) format('woff2');unicode-range:U+0100-02BA, U+02BD-02C5, U+02C7-02CC, U+02CE-02D7, U+02DD-02FF, U+0304, U+0308, U+0329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3yUBA.woff2) format('woff2');unicode-range:U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+0304, U+0308, U+0329, U+2000-206F, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3GUBGEe.woff2) format('woff2');unicode-range:U+0460-052F, U+1C80-1C8A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3iUBGEe.woff2) format('woff2');unicode-range:U+0301, U+0400-045F, U+0490-0491, U+04B0-04B1, U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3CUBGEe.woff2) format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3-UBGEe.woff2) format('woff2');unicode-range:U+0370-0377, U+037A-037F, U+0384-038A, U+038C, U+038E-03A1, U+03A3-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMawCUBGEe.woff2) format('woff2');unicode-range:U+0302-0303, U+0305, U+0307-0308, U+0310, U+0312, U+0315, U+031A, U+0326-0327, U+032C, U+032F-0330, U+0332-0333, U+0338, U+033A, U+0346, U+034D, U+0391-03A1, U+03A3-03A9, U+03B1-03C9, U+03D1, U+03D5-03D6, U+03F0-03F1, U+03F4-03F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, U+2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1, U+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U+2192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+2216-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+2395, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7, U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-2AFF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7FF, U+1EE00-1EEFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMaxKUBGEe.woff2) format('woff2');unicode-range:U+0001-000C, U+000E-001F, U+007F-009F, U+20DD-20E0, U+20E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U+21F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-24FF, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-2BFF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+101D0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F000-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U+1F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U+1F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4-1F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U+1F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F453, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF, U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U+1F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F512-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U+1F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC, U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC, U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887, U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F946, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89, U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3OUBGEe.woff2) format('woff2');unicode-range:U+0102-0103, U+0110-0111, U+0128-0129, U+0168-0169, U+01A0-01A1, U+01AF-01B0, U+0300-0301, U+0303-0304, U+0308-0309, U+0323, U+0329, U+1EA0-1EF9, U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3KUBGEe.woff2) format('woff2');unicode-range:U+0100-02BA, U+02BD-02C5, U+02C7-02CC, U+02CE-02D7, U+02DD-02FF, U+0304, U+0308, U+0329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3yUBA.woff2) format('woff2');unicode-range:U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+0304, U+0308, U+0329, U+2000-206F, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3GUBGEe.woff2) format('woff2');unicode-range:U+0460-052F, U+1C80-1C8A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3iUBGEe.woff2) format('woff2');unicode-range:U+0301, U+0400-045F, U+0490-0491, U+04B0-04B1, U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3CUBGEe.woff2) format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3-UBGEe.woff2) format('woff2');unicode-range:U+0370-0377, U+037A-037F, U+0384-038A, U+038C, U+038E-03A1, U+03A3-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMawCUBGEe.woff2) format('woff2');unicode-range:U+0302-0303, U+0305, U+0307-0308, U+0310, U+0312, U+0315, U+031A, U+0326-0327, U+032C, U+032F-0330, U+0332-0333, U+0338, U+033A, U+0346, U+034D, U+0391-03A1, U+03A3-03A9, U+03B1-03C9, U+03D1, U+03D5-03D6, U+03F0-03F1, U+03F4-03F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, U+2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1, U+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U+2192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+2216-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+2395, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7, U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-2AFF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7FF, U+1EE00-1EEFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMaxKUBGEe.woff2) format('woff2');unicode-range:U+0001-000C, U+000E-001F, U+007F-009F, U+20DD-20E0, U+20E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U+21F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-24FF, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-2BFF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+101D0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F000-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U+1F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U+1F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4-1F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U+1F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F453, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF, U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U+1F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F512-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U+1F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC, U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC, U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887, U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F946, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89, U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3OUBGEe.woff2) format('woff2');unicode-range:U+0102-0103, U+0110-0111, U+0128-0129, U+0168-0169, U+01A0-01A1, U+01AF-01B0, U+0300-0301, U+0303-0304, U+0308-0309, U+0323, U+0329, U+1EA0-1EF9, U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3KUBGEe.woff2) format('woff2');unicode-range:U+0100-02BA, U+02BD-02C5, U+02C7-02CC, U+02CE-02D7, U+02DD-02FF, U+0304, U+0308, U+0329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3yUBA.woff2) format('woff2');unicode-range:U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+0304, U+0308, U+0329, U+2000-206F, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD;}</style>\n",
            "  <style>@font-face{font-family:'Material Icons';font-style:normal;font-weight:400;src:url(https://fonts.gstatic.com/s/materialicons/v143/flUhRq6tzZclQEJ-Vdg-IuiaDsNc.woff2) format('woff2');}.material-icons{font-family:'Material Icons';font-weight:normal;font-style:normal;font-size:24px;line-height:1;letter-spacing:normal;text-transform:none;display:inline-block;white-space:nowrap;word-wrap:normal;direction:ltr;-webkit-font-feature-settings:'liga';-webkit-font-smoothing:antialiased;}</style>\n",
            "  <script src=\"https://maps.googleapis.com/maps/api/js?key=AIzaSyC3PtSiQNBORX_rM0MRLHNA9VybME6zF1A&amp;libraries=places&amp;region=US&amp;language=en\"></script>\n",
            "\n",
            "  <title>ClinicalTrials.gov</title>\n",
            "  <base href=\"/\">\n",
            "\n",
            "  <!-- Favicons -->\n",
            "  <link rel=\"shortcut icon\" type=\"image/svg\" href=\"assets/favicons/favicon.svg\">\n",
            "  <link rel=\"icon\" type=\"image/svg\" href=\"assets/favicons/favicon.svg\">\n",
            "\n",
            "  <!-- 192x192, as recommended for Android\n",
            "  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android\n",
            "  -->\n",
            "  <link rel=\"icon\" type=\"image/svg\" sizes=\"192x192\" href=\"assets/favicons/favicon.svg\">\n",
            "\n",
            "  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->\n",
            "  <link rel=\"apple-touch-icon-precomposed\" href=\"assets/favicons/favicon.svg\">\n",
            "  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->\n",
            "  <link rel=\"apple-touch-icon-precomposed\" sizes=\"72x72\" href=\"assets/favicons/favicon.svg\">\n",
            "  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->\n",
            "  <link rel=\"apple-touch-icon-precomposed\" sizes=\"114x114\" href=\"assets/favicons/favicon.svg\">\n",
            "  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->\n",
            "  <link rel=\"apple-touch-icon-precomposed\" sizes=\"144x144\" href=\"assets/favicons/favicon.svg\">\n",
            "\n",
            "\n",
            "  <!-- Page description -->\n",
            "  <meta name=\"description\" content>\n",
            "\n",
            "  <meta property=\"og:title\" content>\n",
            "  <meta property=\"og:description\" content>\n",
            "\n",
            "  <meta name=\"twitter:title\" content>\n",
            "  <meta name=\"twitter:description\" content>\n",
            "  <meta name=\"twitter:card\" content=\"summary\">\n",
            "\n",
            "  <!-- robots -->\n",
            "  <meta name=\"robots\" content=\"index, follow\">\n",
            "\n",
            "  <!-- Pinger -->\n",
            "  <meta name=\"ncbi_app\" content=\"ctgov2\">\n",
            "  <meta name=\"ncbi_db\" content>\n",
            "  <meta name=\"ncbi_pinger_track_stat\" content=\"false\">\n",
            "  <meta name=\"ncbi_pinger_ga_track\" content=\"true\">\n",
            "  <meta name=\"ncbi_pinger_ga_tracking_id\" content=\"UA-68648221-4\">\n",
            "  <meta name=\"ncbi_pinger_url_query_strip\" content=\"lat,lng,locStr\">\n",
            "  <meta name=\"ncbi_pinger_click_use_capture\" content=\"true\">\n",
            "  <meta name=\"ncbi_pinger_gtm_track\" content=\"true\">\n",
            "\n",
            "  <meta name=\"ncbi_app_version\" content>\n",
            "<style>:root{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica,Arial,sans-serif,\"Apple Color Emoji\",\"Segoe UI Emoji\",Segoe UI Symbol;--font-family:-apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, Helvetica, Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\";--surface-a:#ffffff;--surface-b:#f8f9fa;--surface-c:#e9ecef;--surface-d:#dee2e6;--surface-e:#ffffff;--surface-f:#ffffff;--text-color:#495057;--text-color-secondary:#6c757d;--primary-color:#2196F3;--primary-color-text:#ffffff;--surface-0:#ffffff;--surface-50:#fafafa;--surface-100:#f5f5f5;--surface-200:#eeeeee;--surface-300:#e0e0e0;--surface-400:#bdbdbd;--surface-500:#9e9e9e;--surface-600:#757575;--surface-700:#616161;--surface-800:#424242;--surface-900:#212121;--gray-50:#fafafa;--gray-100:#f5f5f5;--gray-200:#eeeeee;--gray-300:#e0e0e0;--gray-400:#bdbdbd;--gray-500:#9e9e9e;--gray-600:#757575;--gray-700:#616161;--gray-800:#424242;--gray-900:#212121;--content-padding:1rem;--inline-spacing:.5rem;--border-radius:3px;--surface-ground:#f8f9fa;--surface-section:#ffffff;--surface-card:#ffffff;--surface-overlay:#ffffff;--surface-border:#dee2e6;--surface-hover:#e9ecef;--maskbg:rgba(0, 0, 0, .4);--highlight-bg:#E3F2FD;--highlight-text-color:#495057;--focus-ring:0 0 0 .2rem #a6d5fa;color-scheme:light}:root{--blue-50:#f4fafe;--blue-100:#cae6fc;--blue-200:#a0d2fa;--blue-300:#75bef8;--blue-400:#4baaf5;--blue-500:#2196f3;--blue-600:#1c80cf;--blue-700:#1769aa;--blue-800:#125386;--blue-900:#0d3c61;--green-50:#f6fbf6;--green-100:#d4ecd5;--green-200:#b2ddb4;--green-300:#90cd93;--green-400:#6ebe71;--green-500:#4caf50;--green-600:#419544;--green-700:#357b38;--green-800:#2a602c;--green-900:#1e4620;--yellow-50:#fffcf5;--yellow-100:#fef0cd;--yellow-200:#fde4a5;--yellow-300:#fdd87d;--yellow-400:#fccc55;--yellow-500:#fbc02d;--yellow-600:#d5a326;--yellow-700:#b08620;--yellow-800:#8a6a19;--yellow-900:#644d12;--cyan-50:#f2fcfd;--cyan-100:#c2eff5;--cyan-200:#91e2ed;--cyan-300:#61d5e4;--cyan-400:#30c9dc;--cyan-500:#00bcd4;--cyan-600:#00a0b4;--cyan-700:#008494;--cyan-800:#006775;--cyan-900:#004b55;--pink-50:#fef4f7;--pink-100:#fac9da;--pink-200:#f69ebc;--pink-300:#f1749e;--pink-400:#ed4981;--pink-500:#e91e63;--pink-600:#c61a54;--pink-700:#a31545;--pink-800:#801136;--pink-900:#5d0c28;--indigo-50:#f5f6fb;--indigo-100:#d1d5ed;--indigo-200:#acb4df;--indigo-300:#8893d1;--indigo-400:#6372c3;--indigo-500:#3f51b5;--indigo-600:#36459a;--indigo-700:#2c397f;--indigo-800:#232d64;--indigo-900:#192048;--teal-50:#f2faf9;--teal-100:#c2e6e2;--teal-200:#91d2cc;--teal-300:#61beb5;--teal-400:#30aa9f;--teal-500:#009688;--teal-600:#008074;--teal-700:#00695f;--teal-800:#00534b;--teal-900:#003c36;--orange-50:#fff8f2;--orange-100:#fde0c2;--orange-200:#fbc791;--orange-300:#f9ae61;--orange-400:#f79530;--orange-500:#f57c00;--orange-600:#d06900;--orange-700:#ac5700;--orange-800:#874400;--orange-900:#623200;--bluegray-50:#f7f9f9;--bluegray-100:#d9e0e3;--bluegray-200:#bbc7cd;--bluegray-300:#9caeb7;--bluegray-400:#7e96a1;--bluegray-500:#607d8b;--bluegray-600:#526a76;--bluegray-700:#435861;--bluegray-800:#35454c;--bluegray-900:#263238;--purple-50:#faf4fb;--purple-100:#e7cbec;--purple-200:#d4a2dd;--purple-300:#c279ce;--purple-400:#af50bf;--purple-500:#9c27b0;--purple-600:#852196;--purple-700:#6d1b7b;--purple-800:#561561;--purple-900:#3e1046;--red-50:#fff5f5;--red-100:#ffd1ce;--red-200:#ffada7;--red-300:#ff8980;--red-400:#ff6459;--red-500:#ff4032;--red-600:#d9362b;--red-700:#b32d23;--red-800:#8c231c;--red-900:#661a14;--primary-50:#f4fafe;--primary-100:#cae6fc;--primary-200:#a0d2fa;--primary-300:#75bef8;--primary-400:#4baaf5;--primary-500:#2196f3;--primary-600:#1c80cf;--primary-700:#1769aa;--primary-800:#125386;--primary-900:#0d3c61}@layer primeng{*{box-sizing:border-box}}@layer primeng{button{border-radius:0}}:root{--fa-style-family-brands:\"Font Awesome 6 Brands\";--fa-font-brands:normal 400 1em/1 \"Font Awesome 6 Brands\"}@font-face{font-family:\"Font Awesome 6 Brands\";font-style:normal;font-weight:400;font-display:block;src:url(fa-brands-400.87587a681474fe69.woff2) format(\"woff2\"),url(fa-brands-400.5d18d427c08f12c3.ttf) format(\"truetype\")}:root{--fa-style-family-classic:\"Font Awesome 6 Free\";--fa-font-regular:normal 400 1em/1 \"Font Awesome 6 Free\"}@font-face{font-family:\"Font Awesome 6 Free\";font-style:normal;font-weight:400;font-display:block;src:url(fa-regular-400.3ccdbd3d093918cb.woff2) format(\"woff2\"),url(fa-regular-400.81482cd4d93fbfd4.ttf) format(\"truetype\")}:root{--fa-style-family-classic:\"Font Awesome 6 Free\";--fa-font-solid:normal 900 1em/1 \"Font Awesome 6 Free\"}@font-face{font-family:\"Font Awesome 6 Free\";font-style:normal;font-weight:900;font-display:block;src:url(fa-solid-900.0b0cc8a6df2a4fc7.woff2) format(\"woff2\"),url(fa-solid-900.69d3141ae4b2f721.ttf) format(\"truetype\")}html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}a{background-color:transparent}button,input{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button{text-transform:none}button{-webkit-appearance:button}button::-moz-focus-inner{border-style:none;padding:0}button:-moz-focusring{outline:1px dotted ButtonText}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}body{color:#1b1b1b;background-color:#fff;overflow-x:hidden}input:not([disabled]):focus,button:not([disabled]):focus{outline:.25rem solid #2491ff;outline-offset:0}[href]:focus{outline:.25rem solid #2491ff;outline-offset:0}*,*:before,*:after{box-sizing:inherit}html{font-feature-settings:\"kern\" 1;font-kerning:normal;font-family:Roboto,sans-serif;font-size:100%}.usa-sr-only{position:absolute;left:-999em;right:auto}.usa-dark-background{-moz-osx-font-smoothing:grayscale;-webkit-font-smoothing:antialiased;background-color:#3d4551}.usa-dark-background p,.usa-dark-background span,.usa-dark-background a,.usa-dark-background a:visited{color:#fff}.usa-dark-background a:hover{color:#f0f0f0}.usa-icon{display:inline-block;fill:currentColor;height:1em;position:relative;width:1em}input[type=search]{box-sizing:border-box;appearance:none}[type=search]{padding-bottom:0;padding-top:0;border-bottom-right-radius:0;border-right:none;border-top-right-radius:0;box-sizing:border-box;float:left;font-size:.93rem;height:2rem;margin:0}:root{--ctgl-color-base-lightest:#f0f0f0;--ctgl-color-base-lighter:#dfe1e2;--ctgl-color-base-light:#a9aeb1;--ctgl-color-base:#71767a;--ctgl-color-base-dark:#565c65;--ctgl-color-base-darker:#3d4551;--ctgl-color-base-darkest:#1b1b1b;--ctgl-color-primary-lighter:#d9e8f6;--ctgl-color-primary-light:#73b3e7;--ctgl-color-primary:#0071bc;--ctgl-color-primary-vivid:#0050d8;--ctgl-color-primary-dark:#1a4480;--ctgl-color-primary-darker:#205493;--ctgl-color-primary-darkest:#112e51;--ctgl-color-secondary-lighter:#f3e1e4;--ctgl-color-secondary-light:#f2938c;--ctgl-color-secondary:#d83933;--ctgl-color-secondary-vivid:#e41d3d;--ctgl-color-secondary-dark:#b50909;--ctgl-color-secondary-darker:#8b0a03;--ctgl-color-accent-warm-lighter:#f2e4d4;--ctgl-color-accent-warm-light:#ffbc78;--ctgl-color-accent-warm:#fa9441;--ctgl-color-accent-warm-dark:#c05600;--ctgl-color-accent-warm-darker:#775540;--ctgl-color-accent-cool-lighter:#e1f3f8;--ctgl-color-accent-cool-light:#97d4ea;--ctgl-color-accent-cool:#00bde3;--ctgl-color-accent-cool-dark:#28a0cb;--ctgl-color-accent-cool-darker:#07648d;--ctgl-color-error-lighter:#f4e3db;--ctgl-color-error-light:#f39268;--ctgl-color-error:#d54309;--ctgl-color-error-dark:#b50909;--ctgl-color-error-darker:#6f3331;--ctgl-color-warning-lighter:#faf3d1;--ctgl-color-warning-light:#fee685;--ctgl-color-warning:#ffbe2e;--ctgl-color-warning-dark:#e5a000;--ctgl-color-warning-darker:#936f38;--ctgl-color-success-lighter:#ecf3ec;--ctgl-color-success-light:#70e17b;--ctgl-color-success:#00a91c;--ctgl-color-success-dark:#008817;--ctgl-color-success-darker:#216e1f;--ctgl-color-info-lighter:#e7f6f8;--ctgl-color-info-light:#99deea;--ctgl-color-info:#00bde3;--ctgl-color-info-dark:#009ec1;--ctgl-color-info-darker:#2e6276;--ctgl-color-disabled-light:#e6e6e6;--ctgl-color-disabled:#c9c9c9;--ctgl-color-disabled-dark:#adadad;--ctgl-color-emergency:#9c3d10;--ctgl-color-emergency-dark:#332d29;--ctgl-color-red-cool-5:#f8eff1;--ctgl-color-red-cool-10:#f3e1e4;--ctgl-color-red-cool-20:#ecbec6;--ctgl-color-red-cool-30:#e09aa6;--ctgl-color-red-cool-40:#e16b80;--ctgl-color-red-cool-50:#cd425b;--ctgl-color-red-cool-60:#9e394b;--ctgl-color-red-cool-70:#68363f;--ctgl-color-red-cool-80:#40282c;--ctgl-color-red-cool-90:#1e1517;--ctgl-color-red-cool-5v:#fff2f5;--ctgl-color-red-cool-10v:#f8dfe2;--ctgl-color-red-cool-20v:#f8b9c5;--ctgl-color-red-cool-30v:#fd8ba0;--ctgl-color-red-cool-40v:#f45d79;--ctgl-color-red-cool-50v:#e41d3d;--ctgl-color-red-cool-60v:#b21d38;--ctgl-color-red-cool-70v:#822133;--ctgl-color-red-cool-80v:#4f1c24;--ctgl-color-red-5:#f9eeee;--ctgl-color-red-10:#f8e1de;--ctgl-color-red-20:#f7bbb1;--ctgl-color-red-30:#f2938c;--ctgl-color-red-40:#e9695f;--ctgl-color-red-50:#d83933;--ctgl-color-red-60:#a23737;--ctgl-color-red-70:#6f3331;--ctgl-color-red-80:#3e2927;--ctgl-color-red-90:#1b1616;--ctgl-color-red-5v:#fff3f2;--ctgl-color-red-10v:#fde0db;--ctgl-color-red-20v:#fdb8ae;--ctgl-color-red-30v:#ff8d7b;--ctgl-color-red-40v:#fb5a47;--ctgl-color-red-50v:#e52207;--ctgl-color-red-60v:#b50909;--ctgl-color-red-70v:#8b0a03;--ctgl-color-red-80v:#5c1111;--ctgl-color-red-warm-5:#f6efea;--ctgl-color-red-warm-10:#f4e3db;--ctgl-color-red-warm-20:#ecc0a7;--ctgl-color-red-warm-30:#dca081;--ctgl-color-red-warm-40:#d27a56;--ctgl-color-red-warm-50:#c3512c;--ctgl-color-red-warm-60:#805039;--ctgl-color-red-warm-70:#524236;--ctgl-color-red-warm-80:#332d29;--ctgl-color-red-warm-90:#1f1c18;--ctgl-color-red-warm-5v:#fff5ee;--ctgl-color-red-warm-10v:#fce1d4;--ctgl-color-red-warm-20v:#f6bd9c;--ctgl-color-red-warm-30v:#f39268;--ctgl-color-red-warm-40v:#ef5e25;--ctgl-color-red-warm-50v:#d54309;--ctgl-color-red-warm-60v:#9c3d10;--ctgl-color-red-warm-70v:#63340f;--ctgl-color-red-warm-80v:#3e2a1e;--ctgl-color-orange-warm-5:#faeee5;--ctgl-color-orange-warm-10:#fbe0d0;--ctgl-color-orange-warm-20:#f7bca2;--ctgl-color-orange-warm-30:#f3966d;--ctgl-color-orange-warm-40:#e17141;--ctgl-color-orange-warm-50:#bd5727;--ctgl-color-orange-warm-60:#914734;--ctgl-color-orange-warm-70:#633a32;--ctgl-color-orange-warm-80:#3d2925;--ctgl-color-orange-warm-90:#1c1615;--ctgl-color-orange-warm-5v:#fff3ea;--ctgl-color-orange-warm-10v:#ffe2d1;--ctgl-color-orange-warm-20v:#fbbaa7;--ctgl-color-orange-warm-30v:#fc906d;--ctgl-color-orange-warm-40v:#ff580a;--ctgl-color-orange-warm-50v:#cf4900;--ctgl-color-orange-warm-60v:#a72f10;--ctgl-color-orange-warm-70v:#782312;--ctgl-color-orange-warm-80v:#3d231d;--ctgl-color-orange-5:#f6efe9;--ctgl-color-orange-10:#f2e4d4;--ctgl-color-orange-20:#f3bf90;--ctgl-color-orange-30:#f09860;--ctgl-color-orange-40:#dd7533;--ctgl-color-orange-50:#a86437;--ctgl-color-orange-60:#775540;--ctgl-color-orange-70:#524236;--ctgl-color-orange-80:#332d27;--ctgl-color-orange-90:#1b1614;--ctgl-color-orange-5v:#fef2e4;--ctgl-color-orange-10v:#fce2c5;--ctgl-color-orange-20v:#ffbc78;--ctgl-color-orange-30v:#fa9441;--ctgl-color-orange-40v:#e66f0e;--ctgl-color-orange-50v:#c05600;--ctgl-color-orange-60v:#8c471c;--ctgl-color-orange-70v:#5f3617;--ctgl-color-orange-80v:#352313;--ctgl-color-gold-5:#f5f0e6;--ctgl-color-gold-10:#f1e5cd;--ctgl-color-gold-20:#dec69a;--ctgl-color-gold-30:#c7a97b;--ctgl-color-gold-40:#ad8b65;--ctgl-color-gold-50:#8e704f;--ctgl-color-gold-60:#6b5947;--ctgl-color-gold-70:#4d4438;--ctgl-color-gold-80:#322d26;--ctgl-color-gold-90:#191714;--ctgl-color-gold-5v:#fef0c8;--ctgl-color-gold-10v:#ffe396;--ctgl-color-gold-20v:#ffbe2e;--ctgl-color-gold-30v:#e5a000;--ctgl-color-gold-40v:#c2850c;--ctgl-color-gold-50v:#936f38;--ctgl-color-gold-60v:#7a591a;--ctgl-color-gold-70v:#5c410a;--ctgl-color-gold-80v:#3b2b15;--ctgl-color-yellow-5:#faf3d1;--ctgl-color-yellow-10:#f5e6af;--ctgl-color-yellow-20:#e6c74c;--ctgl-color-yellow-30:#c9ab48;--ctgl-color-yellow-40:#a88f48;--ctgl-color-yellow-50:#8a7237;--ctgl-color-yellow-60:#6b5a39;--ctgl-color-yellow-70:#504332;--ctgl-color-yellow-80:#332d27;--ctgl-color-yellow-90:#1a1614;--ctgl-color-yellow-5v:#fff5c2;--ctgl-color-yellow-10v:#fee685;--ctgl-color-yellow-20v:#face00;--ctgl-color-yellow-30v:#ddaa01;--ctgl-color-yellow-40v:#b38c00;--ctgl-color-yellow-50v:#947100;--ctgl-color-yellow-60v:#776017;--ctgl-color-yellow-70v:#5c4809;--ctgl-color-yellow-80v:#422d19;--ctgl-color-green-warm-5:#f1f4d7;--ctgl-color-green-warm-10:#e7eab7;--ctgl-color-green-warm-20:#cbd17a;--ctgl-color-green-warm-30:#a6b557;--ctgl-color-green-warm-40:#8a984b;--ctgl-color-green-warm-50:#6f7a41;--ctgl-color-green-warm-60:#5a5f38;--ctgl-color-green-warm-70:#45472f;--ctgl-color-green-warm-80:#2d2f21;--ctgl-color-green-warm-90:#171712;--ctgl-color-green-warm-5v:#f5fbc1;--ctgl-color-green-warm-10v:#e7f434;--ctgl-color-green-warm-20v:#c5d30a;--ctgl-color-green-warm-30v:#a3b72c;--ctgl-color-green-warm-40v:#7e9c1d;--ctgl-color-green-warm-50v:#6a7d00;--ctgl-color-green-warm-60v:#5a6613;--ctgl-color-green-warm-70v:#4b4e10;--ctgl-color-green-warm-80v:#38380b;--ctgl-color-green-5:#eaf4dd;--ctgl-color-green-10:#dfeacd;--ctgl-color-green-20:#b8d293;--ctgl-color-green-30:#9bb672;--ctgl-color-green-40:#7d9b4e;--ctgl-color-green-50:#607f35;--ctgl-color-green-60:#4c6424;--ctgl-color-green-70:#3c4a29;--ctgl-color-green-80:#293021;--ctgl-color-green-90:#161814;--ctgl-color-green-5v:#ddf9c7;--ctgl-color-green-10v:#c5ee93;--ctgl-color-green-20v:#98d035;--ctgl-color-green-30v:#7fb135;--ctgl-color-green-40v:#719f2a;--ctgl-color-green-50v:#538200;--ctgl-color-green-60v:#466c04;--ctgl-color-green-70v:#2f4a0b;--ctgl-color-green-80v:#243413;--ctgl-color-green-cool-5:#ecf3ec;--ctgl-color-green-cool-10:#dbebde;--ctgl-color-green-cool-20:#b4d0b9;--ctgl-color-green-cool-30:#86b98e;--ctgl-color-green-cool-40:#5e9f69;--ctgl-color-green-cool-50:#4d8055;--ctgl-color-green-cool-60:#446443;--ctgl-color-green-cool-70:#37493b;--ctgl-color-green-cool-80:#28312a;--ctgl-color-green-cool-90:#1a1f1a;--ctgl-color-green-cool-5v:#e3f5e1;--ctgl-color-green-cool-10v:#b7f5bd;--ctgl-color-green-cool-20v:#70e17b;--ctgl-color-green-cool-30v:#21c834;--ctgl-color-green-cool-40v:#00a91c;--ctgl-color-green-cool-50v:#008817;--ctgl-color-green-cool-60v:#216e1f;--ctgl-color-green-cool-70v:#154c21;--ctgl-color-green-cool-80v:#19311e;--ctgl-color-mint-5:#dbf6ed;--ctgl-color-mint-10:#c7efe2;--ctgl-color-mint-20:#92d9bb;--ctgl-color-mint-30:#5abf95;--ctgl-color-mint-40:#34a37e;--ctgl-color-mint-50:#2e8367;--ctgl-color-mint-60:#286846;--ctgl-color-mint-70:#204e34;--ctgl-color-mint-80:#193324;--ctgl-color-mint-90:#0d1a12;--ctgl-color-mint-5v:#c9fbeb;--ctgl-color-mint-10v:#83fcd4;--ctgl-color-mint-20v:#0ceda6;--ctgl-color-mint-30v:#04c585;--ctgl-color-mint-40v:#00a871;--ctgl-color-mint-50v:#008659;--ctgl-color-mint-60v:#146947;--ctgl-color-mint-70v:#0c4e29;--ctgl-color-mint-80v:#0d351e;--ctgl-color-mint-cool-5:#e0f7f6;--ctgl-color-mint-cool-10:#c4eeeb;--ctgl-color-mint-cool-20:#9bd4cf;--ctgl-color-mint-cool-30:#6fbab3;--ctgl-color-mint-cool-40:#4f9e99;--ctgl-color-mint-cool-50:#40807e;--ctgl-color-mint-cool-60:#376462;--ctgl-color-mint-cool-70:#2a4b45;--ctgl-color-mint-cool-80:#203131;--ctgl-color-mint-cool-90:#111818;--ctgl-color-mint-cool-5v:#d5fbf3;--ctgl-color-mint-cool-10v:#7efbe1;--ctgl-color-mint-cool-20v:#29e1cb;--ctgl-color-mint-cool-30v:#1dc2ae;--ctgl-color-mint-cool-40v:#00a398;--ctgl-color-mint-cool-50v:#008480;--ctgl-color-mint-cool-60v:#0f6460;--ctgl-color-mint-cool-70v:#0b4b3f;--ctgl-color-mint-cool-80v:#123131;--ctgl-color-cyan-5:#e7f6f8;--ctgl-color-cyan-10:#ccecf2;--ctgl-color-cyan-20:#99deea;--ctgl-color-cyan-30:#5dc0d1;--ctgl-color-cyan-40:#449dac;--ctgl-color-cyan-50:#168092;--ctgl-color-cyan-60:#2a646d;--ctgl-color-cyan-70:#2c4a4e;--ctgl-color-cyan-80:#203133;--ctgl-color-cyan-90:#111819;--ctgl-color-cyan-5v:#e5faff;--ctgl-color-cyan-10v:#a8f2ff;--ctgl-color-cyan-20v:#52daf2;--ctgl-color-cyan-30v:#00bde3;--ctgl-color-cyan-40v:#009ec1;--ctgl-color-cyan-50v:#0081a1;--ctgl-color-cyan-60v:#00687d;--ctgl-color-cyan-70v:#0e4f5c;--ctgl-color-cyan-80v:#093b44;--ctgl-color-blue-cool-5:#e7f2f5;--ctgl-color-blue-cool-10:#dae9ee;--ctgl-color-blue-cool-20:#adcfdc;--ctgl-color-blue-cool-30:#82b4c9;--ctgl-color-blue-cool-40:#6499af;--ctgl-color-blue-cool-50:#3a7d95;--ctgl-color-blue-cool-60:#2e6276;--ctgl-color-blue-cool-70:#224a58;--ctgl-color-blue-cool-80:#14333d;--ctgl-color-blue-cool-90:#0f191c;--ctgl-color-blue-cool-5v:#e1f3f8;--ctgl-color-blue-cool-10v:#c3ebfa;--ctgl-color-blue-cool-20v:#97d4ea;--ctgl-color-blue-cool-30v:#59b9de;--ctgl-color-blue-cool-40v:#28a0cb;--ctgl-color-blue-cool-50v:#0d7ea2;--ctgl-color-blue-cool-60v:#07648d;--ctgl-color-blue-cool-70v:#074b69;--ctgl-color-blue-cool-80v:#002d3f;--ctgl-color-blue-5:#eff6fb;--ctgl-color-blue-10:#d9e8f6;--ctgl-color-blue-20:#aacdec;--ctgl-color-blue-30:#73b3e7;--ctgl-color-blue-40:#4f97d1;--ctgl-color-blue-50:#2378c3;--ctgl-color-blue-60:#2c608a;--ctgl-color-blue-70:#274863;--ctgl-color-blue-80:#1f303e;--ctgl-color-blue-90:#11181d;--ctgl-color-blue-5v:#e8f5ff;--ctgl-color-blue-10v:#cfe8ff;--ctgl-color-blue-20v:#a1d3ff;--ctgl-color-blue-30v:#58b4ff;--ctgl-color-blue-40v:#2491ff;--ctgl-color-blue-50v:#0076d6;--ctgl-color-blue-60v:#005ea2;--ctgl-color-blue-70v:#0b4778;--ctgl-color-blue-80v:#112f4e;--ctgl-color-blue-warm-5:#ecf1f7;--ctgl-color-blue-warm-10:#e1e7f1;--ctgl-color-blue-warm-20:#bbcae4;--ctgl-color-blue-warm-30:#98afd2;--ctgl-color-blue-warm-40:#7292c7;--ctgl-color-blue-warm-50:#4a77b4;--ctgl-color-blue-warm-60:#345d96;--ctgl-color-blue-warm-70:#2f4668;--ctgl-color-blue-warm-80:#252f3e;--ctgl-color-blue-warm-90:#13171f;--ctgl-color-blue-warm-5v:#edf5ff;--ctgl-color-blue-warm-10v:#d4e5ff;--ctgl-color-blue-warm-20v:#adcdff;--ctgl-color-blue-warm-30v:#81aefc;--ctgl-color-blue-warm-40v:#5994f6;--ctgl-color-blue-warm-50v:#2672de;--ctgl-color-blue-warm-60v:#0050d8;--ctgl-color-blue-warm-70v:#1a4480;--ctgl-color-blue-warm-80v:#162e51;--ctgl-color-indigo-cool-5:#eef0f9;--ctgl-color-indigo-cool-10:#e1e6f9;--ctgl-color-indigo-cool-20:#bbc8f5;--ctgl-color-indigo-cool-30:#96abee;--ctgl-color-indigo-cool-40:#6b8ee8;--ctgl-color-indigo-cool-50:#496fd8;--ctgl-color-indigo-cool-60:#3f57a6;--ctgl-color-indigo-cool-70:#374274;--ctgl-color-indigo-cool-80:#292d42;--ctgl-color-indigo-cool-90:#151622;--ctgl-color-indigo-cool-5v:#edf0ff;--ctgl-color-indigo-cool-10v:#dee5ff;--ctgl-color-indigo-cool-20v:#b8c8ff;--ctgl-color-indigo-cool-30v:#94adff;--ctgl-color-indigo-cool-40v:#628ef4;--ctgl-color-indigo-cool-50v:#4866ff;--ctgl-color-indigo-cool-60v:#3e4ded;--ctgl-color-indigo-cool-70v:#222fbf;--ctgl-color-indigo-cool-80v:#1b2b85;--ctgl-color-indigo-5:#efeff8;--ctgl-color-indigo-10:#e5e4fa;--ctgl-color-indigo-20:#c5c5f3;--ctgl-color-indigo-30:#a5a8eb;--ctgl-color-indigo-40:#8889db;--ctgl-color-indigo-50:#676cc8;--ctgl-color-indigo-60:#4d52af;--ctgl-color-indigo-70:#3d4076;--ctgl-color-indigo-80:#2b2c40;--ctgl-color-indigo-90:#16171f;--ctgl-color-indigo-5v:#f0f0ff;--ctgl-color-indigo-10v:#e0e0ff;--ctgl-color-indigo-20v:#ccceff;--ctgl-color-indigo-30v:#a3a7fa;--ctgl-color-indigo-40v:#8289ff;--ctgl-color-indigo-50v:#656bd7;--ctgl-color-indigo-60v:#4a50c4;--ctgl-color-indigo-70v:#3333a3;--ctgl-color-indigo-80v:#212463;--ctgl-color-indigo-warm-5:#f1eff7;--ctgl-color-indigo-warm-10:#e7e3fa;--ctgl-color-indigo-warm-20:#cbc4f2;--ctgl-color-indigo-warm-30:#afa5e8;--ctgl-color-indigo-warm-40:#9287d8;--ctgl-color-indigo-warm-50:#7665d1;--ctgl-color-indigo-warm-60:#5e519e;--ctgl-color-indigo-warm-70:#453c7b;--ctgl-color-indigo-warm-80:#2e2c40;--ctgl-color-indigo-warm-90:#18161d;--ctgl-color-indigo-warm-5v:#f5f2ff;--ctgl-color-indigo-warm-10v:#e4deff;--ctgl-color-indigo-warm-20v:#cfc4fd;--ctgl-color-indigo-warm-30v:#b69fff;--ctgl-color-indigo-warm-40v:#967efb;--ctgl-color-indigo-warm-50v:#745fe9;--ctgl-color-indigo-warm-60v:#5942d2;--ctgl-color-indigo-warm-70v:#3d2c9d;--ctgl-color-indigo-warm-80v:#261f5b;--ctgl-color-violet-5:#f4f1f9;--ctgl-color-violet-10:#ebe3f9;--ctgl-color-violet-20:#d0c3e9;--ctgl-color-violet-30:#b8a2e3;--ctgl-color-violet-40:#9d84d2;--ctgl-color-violet-50:#8168b3;--ctgl-color-violet-60:#665190;--ctgl-color-violet-70:#4c3d69;--ctgl-color-violet-80:#312b3f;--ctgl-color-violet-90:#18161d;--ctgl-color-violet-5v:#f7f2ff;--ctgl-color-violet-10v:#ede3ff;--ctgl-color-violet-20v:#d5bfff;--ctgl-color-violet-30v:#c39deb;--ctgl-color-violet-40v:#ad79e9;--ctgl-color-violet-50v:#9355dc;--ctgl-color-violet-60v:#783cb9;--ctgl-color-violet-70v:#54278f;--ctgl-color-violet-80v:#39215e;--ctgl-color-violet-warm-5:#f8f0f9;--ctgl-color-violet-warm-10:#f6dff8;--ctgl-color-violet-warm-20:#e2bee4;--ctgl-color-violet-warm-30:#d29ad8;--ctgl-color-violet-warm-40:#bf77c8;--ctgl-color-violet-warm-50:#b04abd;--ctgl-color-violet-warm-60:#864381;--ctgl-color-violet-warm-70:#5c395a;--ctgl-color-violet-warm-80:#382936;--ctgl-color-violet-warm-90:#1b151b;--ctgl-color-violet-warm-5v:#fef2ff;--ctgl-color-violet-warm-10v:#fbdcff;--ctgl-color-violet-warm-20v:#f4b2ff;--ctgl-color-violet-warm-30v:#ee83ff;--ctgl-color-violet-warm-40v:#d85bef;--ctgl-color-violet-warm-50v:#be32d0;--ctgl-color-violet-warm-60v:#93348c;--ctgl-color-violet-warm-70v:#711e6c;--ctgl-color-violet-warm-80v:#481441;--ctgl-color-magenta-5:#f9f0f2;--ctgl-color-magenta-10:#f6e1e8;--ctgl-color-magenta-20:#f0bbcc;--ctgl-color-magenta-30:#e895b3;--ctgl-color-magenta-40:#e0699f;--ctgl-color-magenta-50:#c84281;--ctgl-color-magenta-60:#8b4566;--ctgl-color-magenta-70:#66364b;--ctgl-color-magenta-80:#402731;--ctgl-color-magenta-90:#1b1617;--ctgl-color-magenta-5v:#fff2f5;--ctgl-color-magenta-10v:#ffddea;--ctgl-color-magenta-20v:#ffb4cf;--ctgl-color-magenta-30v:#ff87b2;--ctgl-color-magenta-40v:#fd4496;--ctgl-color-magenta-50v:#d72d79;--ctgl-color-magenta-60v:#ab2165;--ctgl-color-magenta-70v:#731f44;--ctgl-color-magenta-80v:#4f172e;--ctgl-color-gray-cool-1:#fbfcfd;--ctgl-color-gray-cool-2:#f7f9fa;--ctgl-color-gray-cool-3:#f5f6f7;--ctgl-color-gray-cool-4:#f1f3f6;--ctgl-color-gray-cool-5:#edeff0;--ctgl-color-gray-cool-10:#dfe1e2;--ctgl-color-gray-cool-20:#c6cace;--ctgl-color-gray-cool-30:#a9aeb1;--ctgl-color-gray-cool-40:#8d9297;--ctgl-color-gray-cool-50:#71767a;--ctgl-color-gray-cool-60:#565c65;--ctgl-color-gray-cool-70:#3d4551;--ctgl-color-gray-cool-80:#2d2e2f;--ctgl-color-gray-cool-90:#1c1d1f;--ctgl-color-gray-1:#fcfcfc;--ctgl-color-gray-2:#f9f9f9;--ctgl-color-gray-3:#f6f6f6;--ctgl-color-gray-4:#f3f3f3;--ctgl-color-gray-5:#f0f0f0;--ctgl-color-gray-10:#e6e6e6;--ctgl-color-gray-20:#c9c9c9;--ctgl-color-gray-30:#adadad;--ctgl-color-gray-40:#919191;--ctgl-color-gray-50:#757575;--ctgl-color-gray-60:#5c5c5c;--ctgl-color-gray-70:#454545;--ctgl-color-gray-80:#2e2e2e;--ctgl-color-gray-90:#1b1b1b;--ctgl-color-gray-100:#000000;--ctgl-color-gray-warm-1:#fcfcfb;--ctgl-color-gray-warm-2:#f9f9f7;--ctgl-color-gray-warm-3:#f6f6f2;--ctgl-color-gray-warm-4:#f5f5f0;--ctgl-color-gray-warm-5:#f0f0ec;--ctgl-color-gray-warm-10:#e6e6e2;--ctgl-color-gray-warm-20:#cac9c0;--ctgl-color-gray-warm-30:#afaea2;--ctgl-color-gray-warm-40:#929285;--ctgl-color-gray-warm-50:#76766a;--ctgl-color-gray-warm-60:#5d5d52;--ctgl-color-gray-warm-70:#454540;--ctgl-color-gray-warm-80:#2e2e2a;--ctgl-color-gray-warm-90:#171716;--ctgl-color-black-transparent-5:rgba(0, 0, 0, .01);--ctgl-color-black-transparent-10:rgba(0, 0, 0, .1);--ctgl-color-black-transparent-20:rgba(0, 0, 0, .2);--ctgl-color-black-transparent-30:rgba(0, 0, 0, .3);--ctgl-color-black-transparent-40:rgba(0, 0, 0, .4);--ctgl-color-black-transparent-50:rgba(0, 0, 0, .5);--ctgl-color-black-transparent-60:rgba(0, 0, 0, .6);--ctgl-color-black-transparent-70:rgba(0, 0, 0, .7);--ctgl-color-black-transparent-80:rgba(0, 0, 0, .8);--ctgl-color-black-transparent-90:rgba(0, 0, 0, .9);--ctgl-color-white-transparent-5:rgba(255, 255, 255, .01);--ctgl-color-white-transparent-10:rgba(255, 255, 255, .1);--ctgl-color-white-transparent-20:rgba(255, 255, 255, .2);--ctgl-color-white-transparent-30:rgba(255, 255, 255, .3);--ctgl-color-white-transparent-40:rgba(255, 255, 255, .4);--ctgl-color-white-transparent-50:rgba(255, 255, 255, .5);--ctgl-color-white-transparent-60:rgba(255, 255, 255, .6);--ctgl-color-white-transparent-70:rgba(255, 255, 255, .7);--ctgl-color-white-transparent-80:rgba(255, 255, 255, .8);--ctgl-color-white-transparent-90:rgba(255, 255, 255, .9)}:root{--ctgl-breakpoint-card:10rem;--ctgl-breakpoint-card-lg:15rem;--ctgl-breakpoint-mobile:20rem;--ctgl-breakpoint-mobile-lg:30rem;--ctgl-breakpoint-tablet:40rem;--ctgl-breakpoint-tablet-lg:55rem;--ctgl-breakpoint-desktop:64rem;--ctgl-breakpoint-desktop-lg:75rem;--ctgl-breakpoint-widescreen:87.5rem}:root{font-family:Roboto,sans-serif}html{--mat-ripple-color:rgba(0, 0, 0, .1)}html{--mat-option-selected-state-label-text-color:#0071bc;--mat-option-label-text-color:rgba(0, 0, 0, .87);--mat-option-hover-state-layer-color:rgba(0, 0, 0, .04);--mat-option-focus-state-layer-color:rgba(0, 0, 0, .04);--mat-option-selected-state-layer-color:rgba(0, 0, 0, .04)}html{--mat-optgroup-label-text-color:rgba(0, 0, 0, .87)}html{--mat-full-pseudo-checkbox-selected-icon-color:#448aff;--mat-full-pseudo-checkbox-selected-checkmark-color:#fafafa;--mat-full-pseudo-checkbox-unselected-icon-color:rgba(0, 0, 0, .54);--mat-full-pseudo-checkbox-disabled-selected-checkmark-color:#fafafa;--mat-full-pseudo-checkbox-disabled-unselected-icon-color:#b0b0b0;--mat-full-pseudo-checkbox-disabled-selected-icon-color:#b0b0b0;--mat-minimal-pseudo-checkbox-selected-checkmark-color:#448aff;--mat-minimal-pseudo-checkbox-disabled-selected-checkmark-color:#b0b0b0}html{--mat-app-background-color:#fafafa;--mat-app-text-color:rgba(0, 0, 0, .87)}html{--mdc-elevated-card-container-shape:4px;--mdc-outlined-card-container-shape:4px;--mdc-outlined-card-outline-width:1px}html{--mdc-elevated-card-container-color:white;--mdc-elevated-card-container-elevation:0px 2px 1px -1px rgba(0, 0, 0, .2), 0px 1px 1px 0px rgba(0, 0, 0, .14), 0px 1px 3px 0px rgba(0, 0, 0, .12);--mdc-outlined-card-container-color:white;--mdc-outlined-card-outline-color:rgba(0, 0, 0, .12);--mdc-outlined-card-container-elevation:0px 0px 0px 0px rgba(0, 0, 0, .2), 0px 0px 0px 0px rgba(0, 0, 0, .14), 0px 0px 0px 0px rgba(0, 0, 0, .12);--mat-card-subtitle-text-color:rgba(0, 0, 0, .54)}html{--mdc-linear-progress-active-indicator-height:4px;--mdc-linear-progress-track-height:4px;--mdc-linear-progress-track-shape:0}html{--mdc-plain-tooltip-container-shape:4px;--mdc-plain-tooltip-supporting-text-line-height:16px}html{--mdc-plain-tooltip-container-color:#616161;--mdc-plain-tooltip-supporting-text-color:#fff}html{--mdc-filled-text-field-active-indicator-height:1px;--mdc-filled-text-field-focus-active-indicator-height:2px;--mdc-filled-text-field-container-shape:4px;--mdc-outlined-text-field-outline-width:1px;--mdc-outlined-text-field-focus-outline-width:2px;--mdc-outlined-text-field-container-shape:4px}html{--mdc-filled-text-field-caret-color:#0071bc;--mdc-filled-text-field-focus-active-indicator-color:#0071bc;--mdc-filled-text-field-focus-label-text-color:rgba(0, 113, 188, .87);--mdc-filled-text-field-container-color:whitesmoke;--mdc-filled-text-field-disabled-container-color:#fafafa;--mdc-filled-text-field-label-text-color:rgba(0, 0, 0, .6);--mdc-filled-text-field-hover-label-text-color:rgba(0, 0, 0, .6);--mdc-filled-text-field-disabled-label-text-color:rgba(0, 0, 0, .38);--mdc-filled-text-field-input-text-color:rgba(0, 0, 0, .87);--mdc-filled-text-field-disabled-input-text-color:rgba(0, 0, 0, .38);--mdc-filled-text-field-input-text-placeholder-color:rgba(0, 0, 0, .6);--mdc-filled-text-field-error-hover-label-text-color:#f44336;--mdc-filled-text-field-error-focus-label-text-color:#f44336;--mdc-filled-text-field-error-label-text-color:#f44336;--mdc-filled-text-field-error-caret-color:#f44336;--mdc-filled-text-field-active-indicator-color:rgba(0, 0, 0, .42);--mdc-filled-text-field-disabled-active-indicator-color:rgba(0, 0, 0, .06);--mdc-filled-text-field-hover-active-indicator-color:rgba(0, 0, 0, .87);--mdc-filled-text-field-error-active-indicator-color:#f44336;--mdc-filled-text-field-error-focus-active-indicator-color:#f44336;--mdc-filled-text-field-error-hover-active-indicator-color:#f44336;--mdc-outlined-text-field-caret-color:#0071bc;--mdc-outlined-text-field-focus-outline-color:#0071bc;--mdc-outlined-text-field-focus-label-text-color:rgba(0, 113, 188, .87);--mdc-outlined-text-field-label-text-color:rgba(0, 0, 0, .6);--mdc-outlined-text-field-hover-label-text-color:rgba(0, 0, 0, .6);--mdc-outlined-text-field-disabled-label-text-color:rgba(0, 0, 0, .38);--mdc-outlined-text-field-input-text-color:rgba(0, 0, 0, .87);--mdc-outlined-text-field-disabled-input-text-color:rgba(0, 0, 0, .38);--mdc-outlined-text-field-input-text-placeholder-color:rgba(0, 0, 0, .6);--mdc-outlined-text-field-error-caret-color:#f44336;--mdc-outlined-text-field-error-focus-label-text-color:#f44336;--mdc-outlined-text-field-error-label-text-color:#f44336;--mdc-outlined-text-field-error-hover-label-text-color:#f44336;--mdc-outlined-text-field-outline-color:rgba(0, 0, 0, .38);--mdc-outlined-text-field-disabled-outline-color:rgba(0, 0, 0, .06);--mdc-outlined-text-field-hover-outline-color:rgba(0, 0, 0, .87);--mdc-outlined-text-field-error-focus-outline-color:#f44336;--mdc-outlined-text-field-error-hover-outline-color:#f44336;--mdc-outlined-text-field-error-outline-color:#f44336;--mat-form-field-focus-select-arrow-color:rgba(0, 113, 188, .87);--mat-form-field-disabled-input-text-placeholder-color:rgba(0, 0, 0, .38);--mat-form-field-state-layer-color:rgba(0, 0, 0, .87);--mat-form-field-error-text-color:#f44336;--mat-form-field-select-option-text-color:inherit;--mat-form-field-select-disabled-option-text-color:GrayText;--mat-form-field-leading-icon-color:unset;--mat-form-field-disabled-leading-icon-color:unset;--mat-form-field-trailing-icon-color:unset;--mat-form-field-disabled-trailing-icon-color:unset;--mat-form-field-error-focus-trailing-icon-color:unset;--mat-form-field-error-hover-trailing-icon-color:unset;--mat-form-field-error-trailing-icon-color:unset;--mat-form-field-enabled-select-arrow-color:rgba(0, 0, 0, .54);--mat-form-field-disabled-select-arrow-color:rgba(0, 0, 0, .38);--mat-form-field-hover-state-layer-opacity:.04;--mat-form-field-focus-state-layer-opacity:.08}html{--mat-form-field-container-height:56px;--mat-form-field-filled-label-display:block;--mat-form-field-container-vertical-padding:16px;--mat-form-field-filled-with-label-container-padding-top:24px;--mat-form-field-filled-with-label-container-padding-bottom:8px}html{--mat-select-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12)}html{--mat-select-panel-background-color:white;--mat-select-enabled-trigger-text-color:rgba(0, 0, 0, .87);--mat-select-disabled-trigger-text-color:rgba(0, 0, 0, .38);--mat-select-placeholder-text-color:rgba(0, 0, 0, .6);--mat-select-enabled-arrow-color:rgba(0, 0, 0, .54);--mat-select-disabled-arrow-color:rgba(0, 0, 0, .38);--mat-select-focused-arrow-color:rgba(0, 113, 188, .87);--mat-select-invalid-arrow-color:rgba(244, 67, 54, .87)}html{--mat-select-arrow-transform:translateY(-8px)}html{--mat-autocomplete-container-shape:4px;--mat-autocomplete-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12)}html{--mat-autocomplete-background-color:white}html{--mdc-dialog-container-elevation-shadow:0px 11px 15px -7px rgba(0, 0, 0, .2), 0px 24px 38px 3px rgba(0, 0, 0, .14), 0px 9px 46px 8px rgba(0, 0, 0, .12);--mdc-dialog-container-shadow-color:#000;--mdc-dialog-container-shape:4px;--mat-dialog-container-max-width:80vw;--mat-dialog-container-small-max-width:80vw;--mat-dialog-container-min-width:0;--mat-dialog-actions-alignment:start;--mat-dialog-actions-padding:8px;--mat-dialog-content-padding:20px 24px;--mat-dialog-with-actions-content-padding:20px 24px;--mat-dialog-headline-padding:0 24px 9px}html{--mdc-dialog-container-color:white;--mdc-dialog-subhead-color:rgba(0, 0, 0, .87);--mdc-dialog-supporting-text-color:rgba(0, 0, 0, .6)}html{--mdc-switch-disabled-selected-icon-opacity:.38;--mdc-switch-disabled-track-opacity:.12;--mdc-switch-disabled-unselected-icon-opacity:.38;--mdc-switch-handle-height:20px;--mdc-switch-handle-shape:10px;--mdc-switch-handle-width:20px;--mdc-switch-selected-icon-size:18px;--mdc-switch-track-height:14px;--mdc-switch-track-shape:7px;--mdc-switch-track-width:36px;--mdc-switch-unselected-icon-size:18px;--mdc-switch-selected-focus-state-layer-opacity:.12;--mdc-switch-selected-hover-state-layer-opacity:.04;--mdc-switch-selected-pressed-state-layer-opacity:.1;--mdc-switch-unselected-focus-state-layer-opacity:.12;--mdc-switch-unselected-hover-state-layer-opacity:.04;--mdc-switch-unselected-pressed-state-layer-opacity:.1;--mat-switch-disabled-selected-handle-opacity:.38;--mat-switch-disabled-unselected-handle-opacity:.38;--mat-switch-unselected-handle-size:20px;--mat-switch-selected-handle-size:20px;--mat-switch-pressed-handle-size:20px;--mat-switch-with-icon-handle-size:20px;--mat-switch-selected-handle-horizontal-margin:0;--mat-switch-selected-with-icon-handle-horizontal-margin:0;--mat-switch-selected-pressed-handle-horizontal-margin:0;--mat-switch-unselected-handle-horizontal-margin:0;--mat-switch-unselected-with-icon-handle-horizontal-margin:0;--mat-switch-unselected-pressed-handle-horizontal-margin:0;--mat-switch-visible-track-opacity:1;--mat-switch-hidden-track-opacity:1;--mat-switch-visible-track-transition:transform 75ms 0ms cubic-bezier(0, 0, .2, 1);--mat-switch-hidden-track-transition:transform 75ms 0ms cubic-bezier(.4, 0, .6, 1);--mat-switch-track-outline-width:1px;--mat-switch-track-outline-color:transparent;--mat-switch-selected-track-outline-width:1px;--mat-switch-disabled-unselected-track-outline-width:1px;--mat-switch-disabled-unselected-track-outline-color:transparent}html{--mdc-switch-selected-focus-state-layer-color:#3949ab;--mdc-switch-selected-handle-color:#3949ab;--mdc-switch-selected-hover-state-layer-color:#3949ab;--mdc-switch-selected-pressed-state-layer-color:#3949ab;--mdc-switch-selected-focus-handle-color:#112e51;--mdc-switch-selected-hover-handle-color:#112e51;--mdc-switch-selected-pressed-handle-color:#112e51;--mdc-switch-selected-focus-track-color:#80b8dd;--mdc-switch-selected-hover-track-color:#80b8dd;--mdc-switch-selected-pressed-track-color:#80b8dd;--mdc-switch-selected-track-color:#80b8dd;--mdc-switch-disabled-selected-handle-color:#424242;--mdc-switch-disabled-selected-icon-color:#fff;--mdc-switch-disabled-selected-track-color:#424242;--mdc-switch-disabled-unselected-handle-color:#424242;--mdc-switch-disabled-unselected-icon-color:#fff;--mdc-switch-disabled-unselected-track-color:#424242;--mdc-switch-handle-surface-color:var(--mdc-theme-surface, #fff);--mdc-switch-handle-elevation-shadow:0px 2px 1px -1px rgba(0, 0, 0, .2), 0px 1px 1px 0px rgba(0, 0, 0, .14), 0px 1px 3px 0px rgba(0, 0, 0, .12);--mdc-switch-handle-shadow-color:black;--mdc-switch-disabled-handle-elevation-shadow:0px 0px 0px 0px rgba(0, 0, 0, .2), 0px 0px 0px 0px rgba(0, 0, 0, .14), 0px 0px 0px 0px rgba(0, 0, 0, .12);--mdc-switch-selected-icon-color:#fff;--mdc-switch-unselected-focus-handle-color:#212121;--mdc-switch-unselected-focus-state-layer-color:#424242;--mdc-switch-unselected-focus-track-color:#e0e0e0;--mdc-switch-unselected-handle-color:#616161;--mdc-switch-unselected-hover-handle-color:#212121;--mdc-switch-unselected-hover-state-layer-color:#424242;--mdc-switch-unselected-hover-track-color:#e0e0e0;--mdc-switch-unselected-icon-color:#fff;--mdc-switch-unselected-pressed-handle-color:#212121;--mdc-switch-unselected-pressed-state-layer-color:#424242;--mdc-switch-unselected-pressed-track-color:#e0e0e0;--mdc-switch-unselected-track-color:#e0e0e0;--mdc-switch-disabled-label-text-color:rgba(0, 0, 0, .38)}html{--mdc-switch-state-layer-size:40px}html{--mdc-radio-disabled-selected-icon-opacity:.38;--mdc-radio-disabled-unselected-icon-opacity:.38;--mdc-radio-state-layer-size:40px}html{--mdc-radio-state-layer-size:40px;--mat-radio-touch-target-display:block}html{--mat-slider-value-indicator-width:auto;--mat-slider-value-indicator-height:32px;--mat-slider-value-indicator-caret-display:block;--mat-slider-value-indicator-border-radius:4px;--mat-slider-value-indicator-padding:0 12px;--mat-slider-value-indicator-text-transform:none;--mat-slider-value-indicator-container-transform:translateX(-50%);--mdc-slider-active-track-height:6px;--mdc-slider-active-track-shape:9999px;--mdc-slider-handle-height:20px;--mdc-slider-handle-shape:50%;--mdc-slider-handle-width:20px;--mdc-slider-inactive-track-height:4px;--mdc-slider-inactive-track-shape:9999px;--mdc-slider-with-overlap-handle-outline-width:1px;--mdc-slider-with-tick-marks-active-container-opacity:.6;--mdc-slider-with-tick-marks-container-shape:50%;--mdc-slider-with-tick-marks-container-size:2px;--mdc-slider-with-tick-marks-inactive-container-opacity:.6}html{--mdc-slider-handle-color:#0071bc;--mdc-slider-focus-handle-color:#0071bc;--mdc-slider-hover-handle-color:#0071bc;--mdc-slider-active-track-color:#0071bc;--mdc-slider-inactive-track-color:#0071bc;--mdc-slider-with-tick-marks-inactive-container-color:#0071bc;--mdc-slider-with-tick-marks-active-container-color:white;--mdc-slider-disabled-active-track-color:#000;--mdc-slider-disabled-handle-color:#000;--mdc-slider-disabled-inactive-track-color:#000;--mdc-slider-label-container-color:#000;--mdc-slider-label-label-text-color:#fff;--mdc-slider-with-overlap-handle-outline-color:#fff;--mdc-slider-with-tick-marks-disabled-container-color:#000;--mdc-slider-handle-elevation:0px 2px 1px -1px rgba(0, 0, 0, .2), 0px 1px 1px 0px rgba(0, 0, 0, .14), 0px 1px 3px 0px rgba(0, 0, 0, .12);--mat-slider-ripple-color:#0071bc;--mat-slider-hover-state-layer-color:rgba(0, 113, 188, .05);--mat-slider-focus-state-layer-color:rgba(0, 113, 188, .2);--mat-slider-value-indicator-opacity:.6}html{--mat-menu-container-shape:4px;--mat-menu-divider-bottom-spacing:0;--mat-menu-divider-top-spacing:0;--mat-menu-item-spacing:16px;--mat-menu-item-icon-size:24px;--mat-menu-item-leading-spacing:16px;--mat-menu-item-trailing-spacing:16px;--mat-menu-item-with-icon-leading-spacing:16px;--mat-menu-item-with-icon-trailing-spacing:16px}html{--mat-menu-item-label-text-color:rgba(0, 0, 0, .87);--mat-menu-item-icon-color:rgba(0, 0, 0, .87);--mat-menu-item-hover-state-layer-color:rgba(0, 0, 0, .04);--mat-menu-item-focus-state-layer-color:rgba(0, 0, 0, .04);--mat-menu-container-color:white;--mat-menu-divider-color:rgba(0, 0, 0, .12)}html{--mdc-list-list-item-container-shape:0;--mdc-list-list-item-leading-avatar-shape:50%;--mdc-list-list-item-container-color:transparent;--mdc-list-list-item-selected-container-color:transparent;--mdc-list-list-item-leading-avatar-color:transparent;--mdc-list-list-item-leading-icon-size:24px;--mdc-list-list-item-leading-avatar-size:40px;--mdc-list-list-item-trailing-icon-size:24px;--mdc-list-list-item-disabled-state-layer-color:transparent;--mdc-list-list-item-disabled-state-layer-opacity:0;--mdc-list-list-item-disabled-label-text-opacity:.38;--mdc-list-list-item-disabled-leading-icon-opacity:.38;--mdc-list-list-item-disabled-trailing-icon-opacity:.38;--mat-list-active-indicator-color:transparent;--mat-list-active-indicator-shape:4px}html{--mdc-list-list-item-label-text-color:rgba(0, 0, 0, .87);--mdc-list-list-item-supporting-text-color:rgba(0, 0, 0, .54);--mdc-list-list-item-leading-icon-color:rgba(0, 0, 0, .38);--mdc-list-list-item-trailing-supporting-text-color:rgba(0, 0, 0, .38);--mdc-list-list-item-trailing-icon-color:rgba(0, 0, 0, .38);--mdc-list-list-item-selected-trailing-icon-color:rgba(0, 0, 0, .38);--mdc-list-list-item-disabled-label-text-color:black;--mdc-list-list-item-disabled-leading-icon-color:black;--mdc-list-list-item-disabled-trailing-icon-color:black;--mdc-list-list-item-hover-label-text-color:rgba(0, 0, 0, .87);--mdc-list-list-item-hover-leading-icon-color:rgba(0, 0, 0, .38);--mdc-list-list-item-hover-trailing-icon-color:rgba(0, 0, 0, .38);--mdc-list-list-item-focus-label-text-color:rgba(0, 0, 0, .87);--mdc-list-list-item-hover-state-layer-color:black;--mdc-list-list-item-hover-state-layer-opacity:.04;--mdc-list-list-item-focus-state-layer-color:black;--mdc-list-list-item-focus-state-layer-opacity:.12}html{--mdc-list-list-item-one-line-container-height:48px;--mdc-list-list-item-two-line-container-height:64px;--mdc-list-list-item-three-line-container-height:88px;--mat-list-list-item-leading-icon-start-space:16px;--mat-list-list-item-leading-icon-end-space:32px}html{--mat-paginator-container-text-color:rgba(0, 0, 0, .87);--mat-paginator-container-background-color:white;--mat-paginator-enabled-icon-color:rgba(0, 0, 0, .54);--mat-paginator-disabled-icon-color:rgba(0, 0, 0, .12)}html{--mat-paginator-container-size:56px;--mat-paginator-form-field-container-height:40px;--mat-paginator-form-field-container-vertical-padding:8px}html{--mdc-tab-indicator-active-indicator-height:2px;--mdc-tab-indicator-active-indicator-shape:0;--mdc-secondary-navigation-tab-container-height:48px;--mat-tab-header-divider-color:transparent;--mat-tab-header-divider-height:0}html{--mdc-checkbox-disabled-selected-checkmark-color:#fff;--mdc-checkbox-selected-focus-state-layer-opacity:.16;--mdc-checkbox-selected-hover-state-layer-opacity:.04;--mdc-checkbox-selected-pressed-state-layer-opacity:.16;--mdc-checkbox-unselected-focus-state-layer-opacity:.16;--mdc-checkbox-unselected-hover-state-layer-opacity:.04;--mdc-checkbox-unselected-pressed-state-layer-opacity:.16}html{--mdc-checkbox-disabled-selected-icon-color:rgba(0, 0, 0, .38);--mdc-checkbox-disabled-unselected-icon-color:rgba(0, 0, 0, .38);--mdc-checkbox-selected-checkmark-color:white;--mdc-checkbox-selected-focus-icon-color:#448aff;--mdc-checkbox-selected-hover-icon-color:#448aff;--mdc-checkbox-selected-icon-color:#448aff;--mdc-checkbox-selected-pressed-icon-color:#448aff;--mdc-checkbox-unselected-focus-icon-color:#212121;--mdc-checkbox-unselected-hover-icon-color:#212121;--mdc-checkbox-unselected-icon-color:rgba(0, 0, 0, .54);--mdc-checkbox-unselected-pressed-icon-color:rgba(0, 0, 0, .54);--mdc-checkbox-selected-focus-state-layer-color:#448aff;--mdc-checkbox-selected-hover-state-layer-color:#448aff;--mdc-checkbox-selected-pressed-state-layer-color:#448aff;--mdc-checkbox-unselected-focus-state-layer-color:black;--mdc-checkbox-unselected-hover-state-layer-color:black;--mdc-checkbox-unselected-pressed-state-layer-color:black;--mat-checkbox-disabled-label-color:rgba(0, 0, 0, .38)}html{--mdc-checkbox-state-layer-size:40px;--mat-checkbox-touch-target-display:block}html{--mdc-text-button-container-shape:4px;--mdc-text-button-keep-touch-target:false;--mdc-filled-button-container-shape:4px;--mdc-filled-button-keep-touch-target:false;--mdc-protected-button-container-shape:4px;--mdc-protected-button-keep-touch-target:false;--mdc-outlined-button-keep-touch-target:false;--mdc-outlined-button-outline-width:1px;--mdc-outlined-button-container-shape:4px;--mat-text-button-horizontal-padding:8px;--mat-text-button-with-icon-horizontal-padding:8px;--mat-text-button-icon-spacing:8px;--mat-text-button-icon-offset:0;--mat-filled-button-horizontal-padding:16px;--mat-filled-button-icon-spacing:8px;--mat-filled-button-icon-offset:-4px;--mat-protected-button-horizontal-padding:16px;--mat-protected-button-icon-spacing:8px;--mat-protected-button-icon-offset:-4px;--mat-outlined-button-horizontal-padding:15px;--mat-outlined-button-icon-spacing:8px;--mat-outlined-button-icon-offset:-4px}html{--mdc-text-button-label-text-color:black;--mdc-text-button-disabled-label-text-color:rgba(0, 0, 0, .38);--mat-text-button-state-layer-color:black;--mat-text-button-disabled-state-layer-color:black;--mat-text-button-ripple-color:rgba(0, 0, 0, .1);--mat-text-button-hover-state-layer-opacity:.04;--mat-text-button-focus-state-layer-opacity:.12;--mat-text-button-pressed-state-layer-opacity:.12;--mdc-filled-button-container-color:white;--mdc-filled-button-label-text-color:black;--mdc-filled-button-disabled-container-color:rgba(0, 0, 0, .12);--mdc-filled-button-disabled-label-text-color:rgba(0, 0, 0, .38);--mat-filled-button-state-layer-color:black;--mat-filled-button-disabled-state-layer-color:black;--mat-filled-button-ripple-color:rgba(0, 0, 0, .1);--mat-filled-button-hover-state-layer-opacity:.04;--mat-filled-button-focus-state-layer-opacity:.12;--mat-filled-button-pressed-state-layer-opacity:.12;--mdc-protected-button-container-color:white;--mdc-protected-button-label-text-color:black;--mdc-protected-button-disabled-container-color:rgba(0, 0, 0, .12);--mdc-protected-button-disabled-label-text-color:rgba(0, 0, 0, .38);--mdc-protected-button-container-elevation-shadow:0px 3px 1px -2px rgba(0, 0, 0, .2), 0px 2px 2px 0px rgba(0, 0, 0, .14), 0px 1px 5px 0px rgba(0, 0, 0, .12);--mdc-protected-button-disabled-container-elevation-shadow:0px 0px 0px 0px rgba(0, 0, 0, .2), 0px 0px 0px 0px rgba(0, 0, 0, .14), 0px 0px 0px 0px rgba(0, 0, 0, .12);--mdc-protected-button-focus-container-elevation-shadow:0px 2px 4px -1px rgba(0, 0, 0, .2), 0px 4px 5px 0px rgba(0, 0, 0, .14), 0px 1px 10px 0px rgba(0, 0, 0, .12);--mdc-protected-button-hover-container-elevation-shadow:0px 2px 4px -1px rgba(0, 0, 0, .2), 0px 4px 5px 0px rgba(0, 0, 0, .14), 0px 1px 10px 0px rgba(0, 0, 0, .12);--mdc-protected-button-pressed-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-protected-button-container-shadow-color:#000;--mat-protected-button-state-layer-color:black;--mat-protected-button-disabled-state-layer-color:black;--mat-protected-button-ripple-color:rgba(0, 0, 0, .1);--mat-protected-button-hover-state-layer-opacity:.04;--mat-protected-button-focus-state-layer-opacity:.12;--mat-protected-button-pressed-state-layer-opacity:.12;--mdc-outlined-button-disabled-outline-color:rgba(0, 0, 0, .12);--mdc-outlined-button-disabled-label-text-color:rgba(0, 0, 0, .38);--mdc-outlined-button-label-text-color:black;--mdc-outlined-button-outline-color:rgba(0, 0, 0, .12);--mat-outlined-button-state-layer-color:black;--mat-outlined-button-disabled-state-layer-color:black;--mat-outlined-button-ripple-color:rgba(0, 0, 0, .1);--mat-outlined-button-hover-state-layer-opacity:.04;--mat-outlined-button-focus-state-layer-opacity:.12;--mat-outlined-button-pressed-state-layer-opacity:.12}html{--mdc-text-button-container-height:36px;--mdc-filled-button-container-height:36px;--mdc-outlined-button-container-height:36px;--mdc-protected-button-container-height:36px;--mat-text-button-touch-target-display:block;--mat-filled-button-touch-target-display:block;--mat-protected-button-touch-target-display:block;--mat-outlined-button-touch-target-display:block}html{--mdc-icon-button-icon-size:24px}html{--mdc-icon-button-icon-color:inherit;--mdc-icon-button-disabled-icon-color:rgba(0, 0, 0, .38);--mat-icon-button-state-layer-color:black;--mat-icon-button-disabled-state-layer-color:black;--mat-icon-button-ripple-color:rgba(0, 0, 0, .1);--mat-icon-button-hover-state-layer-opacity:.04;--mat-icon-button-focus-state-layer-opacity:.12;--mat-icon-button-pressed-state-layer-opacity:.12}html{--mat-icon-button-touch-target-display:block}html{--mdc-fab-container-shape:50%;--mdc-fab-icon-size:24px;--mdc-fab-small-container-shape:50%;--mdc-fab-small-icon-size:24px;--mdc-extended-fab-container-height:48px;--mdc-extended-fab-container-shape:24px}html{--mdc-fab-container-color:white;--mdc-fab-container-elevation-shadow:0px 3px 5px -1px rgba(0, 0, 0, .2), 0px 6px 10px 0px rgba(0, 0, 0, .14), 0px 1px 18px 0px rgba(0, 0, 0, .12);--mdc-fab-focus-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-fab-hover-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-fab-pressed-container-elevation-shadow:0px 7px 8px -4px rgba(0, 0, 0, .2), 0px 12px 17px 2px rgba(0, 0, 0, .14), 0px 5px 22px 4px rgba(0, 0, 0, .12);--mdc-fab-container-shadow-color:#000;--mat-fab-foreground-color:black;--mat-fab-state-layer-color:black;--mat-fab-disabled-state-layer-color:black;--mat-fab-ripple-color:rgba(0, 0, 0, .1);--mat-fab-hover-state-layer-opacity:.04;--mat-fab-focus-state-layer-opacity:.12;--mat-fab-pressed-state-layer-opacity:.12;--mat-fab-disabled-state-container-color:rgba(0, 0, 0, .12);--mat-fab-disabled-state-foreground-color:rgba(0, 0, 0, .38);--mdc-fab-small-container-color:white;--mdc-fab-small-container-elevation-shadow:0px 3px 5px -1px rgba(0, 0, 0, .2), 0px 6px 10px 0px rgba(0, 0, 0, .14), 0px 1px 18px 0px rgba(0, 0, 0, .12);--mdc-fab-small-focus-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-fab-small-hover-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-fab-small-pressed-container-elevation-shadow:0px 7px 8px -4px rgba(0, 0, 0, .2), 0px 12px 17px 2px rgba(0, 0, 0, .14), 0px 5px 22px 4px rgba(0, 0, 0, .12);--mdc-fab-small-container-shadow-color:#000;--mat-fab-small-foreground-color:black;--mat-fab-small-state-layer-color:black;--mat-fab-small-disabled-state-layer-color:black;--mat-fab-small-ripple-color:rgba(0, 0, 0, .1);--mat-fab-small-hover-state-layer-opacity:.04;--mat-fab-small-focus-state-layer-opacity:.12;--mat-fab-small-pressed-state-layer-opacity:.12;--mat-fab-small-disabled-state-container-color:rgba(0, 0, 0, .12);--mat-fab-small-disabled-state-foreground-color:rgba(0, 0, 0, .38);--mdc-extended-fab-container-elevation-shadow:0px 3px 5px -1px rgba(0, 0, 0, .2), 0px 6px 10px 0px rgba(0, 0, 0, .14), 0px 1px 18px 0px rgba(0, 0, 0, .12);--mdc-extended-fab-focus-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-extended-fab-hover-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-extended-fab-pressed-container-elevation-shadow:0px 7px 8px -4px rgba(0, 0, 0, .2), 0px 12px 17px 2px rgba(0, 0, 0, .14), 0px 5px 22px 4px rgba(0, 0, 0, .12);--mdc-extended-fab-container-shadow-color:#000}html{--mat-fab-touch-target-display:block;--mat-fab-small-touch-target-display:block}html{--mdc-snackbar-container-shape:4px}html{--mdc-snackbar-container-color:#333333;--mdc-snackbar-supporting-text-color:rgba(255, 255, 255, .87);--mat-snack-bar-button-color:#448aff}html{--mat-table-row-item-outline-width:1px}html{--mat-table-background-color:white;--mat-table-header-headline-color:rgba(0, 0, 0, .87);--mat-table-row-item-label-text-color:rgba(0, 0, 0, .87);--mat-table-row-item-outline-color:rgba(0, 0, 0, .12)}html{--mat-table-header-container-height:56px;--mat-table-footer-container-height:52px;--mat-table-row-item-container-height:52px}html{--mdc-circular-progress-active-indicator-width:4px;--mdc-circular-progress-size:48px}html{--mdc-circular-progress-active-indicator-color:#0071bc}html{--mat-badge-container-shape:50%;--mat-badge-container-size:unset;--mat-badge-small-size-container-size:unset;--mat-badge-large-size-container-size:unset;--mat-badge-legacy-container-size:22px;--mat-badge-legacy-small-size-container-size:16px;--mat-badge-legacy-large-size-container-size:28px;--mat-badge-container-offset:-11px 0;--mat-badge-small-size-container-offset:-8px 0;--mat-badge-large-size-container-offset:-14px 0;--mat-badge-container-overlap-offset:-11px;--mat-badge-small-size-container-overlap-offset:-8px;--mat-badge-large-size-container-overlap-offset:-14px;--mat-badge-container-padding:0;--mat-badge-small-size-container-padding:0;--mat-badge-large-size-container-padding:0}html{--mat-badge-background-color:#0071bc;--mat-badge-text-color:white;--mat-badge-disabled-state-background-color:#b9b9b9;--mat-badge-disabled-state-text-color:rgba(0, 0, 0, .38)}html{--mat-bottom-sheet-container-shape:4px}html{--mat-bottom-sheet-container-text-color:rgba(0, 0, 0, .87);--mat-bottom-sheet-container-background-color:white}html{--mat-legacy-button-toggle-height:36px;--mat-legacy-button-toggle-shape:2px;--mat-legacy-button-toggle-focus-state-layer-opacity:1;--mat-standard-button-toggle-shape:4px;--mat-standard-button-toggle-hover-state-layer-opacity:.04;--mat-standard-button-toggle-focus-state-layer-opacity:.12}html{--mat-legacy-button-toggle-text-color:rgba(0, 0, 0, .38);--mat-legacy-button-toggle-state-layer-color:rgba(0, 0, 0, .12);--mat-legacy-button-toggle-selected-state-text-color:rgba(0, 0, 0, .54);--mat-legacy-button-toggle-selected-state-background-color:#e0e0e0;--mat-legacy-button-toggle-disabled-state-text-color:rgba(0, 0, 0, .26);--mat-legacy-button-toggle-disabled-state-background-color:#eeeeee;--mat-legacy-button-toggle-disabled-selected-state-background-color:#bdbdbd;--mat-standard-button-toggle-text-color:rgba(0, 0, 0, .87);--mat-standard-button-toggle-background-color:white;--mat-standard-button-toggle-state-layer-color:black;--mat-standard-button-toggle-selected-state-background-color:#e0e0e0;--mat-standard-button-toggle-selected-state-text-color:rgba(0, 0, 0, .87);--mat-standard-button-toggle-disabled-state-text-color:rgba(0, 0, 0, .26);--mat-standard-button-toggle-disabled-state-background-color:white;--mat-standard-button-toggle-disabled-selected-state-text-color:rgba(0, 0, 0, .87);--mat-standard-button-toggle-disabled-selected-state-background-color:#bdbdbd;--mat-standard-button-toggle-divider-color:#e0e0e0}html{--mat-standard-button-toggle-height:48px}html{--mat-datepicker-calendar-container-shape:4px;--mat-datepicker-calendar-container-touch-shape:4px;--mat-datepicker-calendar-container-elevation-shadow:0px 2px 4px -1px rgba(0, 0, 0, .2), 0px 4px 5px 0px rgba(0, 0, 0, .14), 0px 1px 10px 0px rgba(0, 0, 0, .12);--mat-datepicker-calendar-container-touch-elevation-shadow:0px 11px 15px -7px rgba(0, 0, 0, .2), 0px 24px 38px 3px rgba(0, 0, 0, .14), 0px 9px 46px 8px rgba(0, 0, 0, .12)}html{--mat-datepicker-calendar-date-selected-state-text-color:white;--mat-datepicker-calendar-date-selected-state-background-color:#0071bc;--mat-datepicker-calendar-date-selected-disabled-state-background-color:rgba(0, 113, 188, .4);--mat-datepicker-calendar-date-today-selected-state-outline-color:white;--mat-datepicker-calendar-date-focus-state-background-color:rgba(0, 113, 188, .3);--mat-datepicker-calendar-date-hover-state-background-color:rgba(0, 113, 188, .3);--mat-datepicker-toggle-active-state-icon-color:#0071bc;--mat-datepicker-calendar-date-in-range-state-background-color:rgba(0, 113, 188, .2);--mat-datepicker-calendar-date-in-comparison-range-state-background-color:rgba(249, 171, 0, .2);--mat-datepicker-calendar-date-in-overlap-range-state-background-color:#a8dab5;--mat-datepicker-calendar-date-in-overlap-range-selected-state-background-color:#46a35e;--mat-datepicker-toggle-icon-color:rgba(0, 0, 0, .54);--mat-datepicker-calendar-body-label-text-color:rgba(0, 0, 0, .54);--mat-datepicker-calendar-period-button-text-color:black;--mat-datepicker-calendar-period-button-icon-color:rgba(0, 0, 0, .54);--mat-datepicker-calendar-navigation-button-icon-color:rgba(0, 0, 0, .54);--mat-datepicker-calendar-header-divider-color:rgba(0, 0, 0, .12);--mat-datepicker-calendar-header-text-color:rgba(0, 0, 0, .54);--mat-datepicker-calendar-date-today-outline-color:rgba(0, 0, 0, .38);--mat-datepicker-calendar-date-today-disabled-state-outline-color:rgba(0, 0, 0, .18);--mat-datepicker-calendar-date-text-color:rgba(0, 0, 0, .87);--mat-datepicker-calendar-date-outline-color:transparent;--mat-datepicker-calendar-date-disabled-state-text-color:rgba(0, 0, 0, .38);--mat-datepicker-calendar-date-preview-state-outline-color:rgba(0, 0, 0, .24);--mat-datepicker-range-input-separator-color:rgba(0, 0, 0, .87);--mat-datepicker-range-input-disabled-state-separator-color:rgba(0, 0, 0, .38);--mat-datepicker-range-input-disabled-state-text-color:rgba(0, 0, 0, .38);--mat-datepicker-calendar-container-background-color:white;--mat-datepicker-calendar-container-text-color:rgba(0, 0, 0, .87)}html{--mat-divider-width:1px}html{--mat-divider-color:rgba(0, 0, 0, .12)}html{--mat-expansion-container-shape:4px;--mat-expansion-legacy-header-indicator-display:inline-block;--mat-expansion-header-indicator-display:none}html{--mat-expansion-container-background-color:white;--mat-expansion-container-text-color:rgba(0, 0, 0, .87);--mat-expansion-actions-divider-color:rgba(0, 0, 0, .12);--mat-expansion-header-hover-state-layer-color:rgba(0, 0, 0, .04);--mat-expansion-header-focus-state-layer-color:rgba(0, 0, 0, .04);--mat-expansion-header-disabled-state-text-color:rgba(0, 0, 0, .26);--mat-expansion-header-text-color:rgba(0, 0, 0, .87);--mat-expansion-header-description-color:rgba(0, 0, 0, .54);--mat-expansion-header-indicator-color:rgba(0, 0, 0, .54)}html{--mat-expansion-header-collapsed-state-height:48px;--mat-expansion-header-expanded-state-height:64px}html{--mat-icon-color:inherit}html{--mat-sidenav-container-shape:0;--mat-sidenav-container-elevation-shadow:0px 8px 10px -5px rgba(0, 0, 0, .2), 0px 16px 24px 2px rgba(0, 0, 0, .14), 0px 6px 30px 5px rgba(0, 0, 0, .12);--mat-sidenav-container-width:auto}html{--mat-sidenav-container-divider-color:rgba(0, 0, 0, .12);--mat-sidenav-container-background-color:white;--mat-sidenav-container-text-color:rgba(0, 0, 0, .87);--mat-sidenav-content-background-color:#fafafa;--mat-sidenav-content-text-color:rgba(0, 0, 0, .87);--mat-sidenav-scrim-color:rgba(0, 0, 0, .6)}html{--mat-stepper-header-icon-foreground-color:white;--mat-stepper-header-selected-state-icon-background-color:#0071bc;--mat-stepper-header-selected-state-icon-foreground-color:white;--mat-stepper-header-done-state-icon-background-color:#0071bc;--mat-stepper-header-done-state-icon-foreground-color:white;--mat-stepper-header-edit-state-icon-background-color:#0071bc;--mat-stepper-header-edit-state-icon-foreground-color:white;--mat-stepper-container-color:white;--mat-stepper-line-color:rgba(0, 0, 0, .12);--mat-stepper-header-hover-state-layer-color:rgba(0, 0, 0, .04);--mat-stepper-header-focus-state-layer-color:rgba(0, 0, 0, .04);--mat-stepper-header-label-text-color:rgba(0, 0, 0, .54);--mat-stepper-header-optional-label-text-color:rgba(0, 0, 0, .54);--mat-stepper-header-selected-state-label-text-color:rgba(0, 0, 0, .87);--mat-stepper-header-error-state-label-text-color:#f44336;--mat-stepper-header-icon-background-color:rgba(0, 0, 0, .54);--mat-stepper-header-error-state-icon-foreground-color:#f44336;--mat-stepper-header-error-state-icon-background-color:transparent}html{--mat-stepper-header-height:72px}html{--mat-sort-arrow-color:#757575}html{--mat-toolbar-container-background-color:whitesmoke;--mat-toolbar-container-text-color:rgba(0, 0, 0, .87)}html{--mat-toolbar-standard-height:64px;--mat-toolbar-mobile-height:56px}html{--mat-tree-container-background-color:white;--mat-tree-node-text-color:rgba(0, 0, 0, .87)}html{--mat-tree-node-min-height:48px}p{line-height:1.62!important}html{box-sizing:border-box}*,*:after,*:before{box-sizing:inherit}@media print{.glossary{display:none}.hide-glossary .usa-icon{height:1.5rem;width:1.5rem;margin-top:4px}}:root{--ctg-removed-background-color:#f4a4b1;--ctg-added-background-color:#99cfa2}@charset \"UTF-8\";.glossary{background:#112e51;color:#fff;width:300px;position:fixed;top:0;bottom:0;right:0;overflow-y:auto;padding:2.4rem;transition:right .2s;z-index:10001}@media screen and (min-width: 481px){.glossary{width:364px}}.glossary ul{padding:0}.glossary input[type=search]{box-sizing:inherit;margin-bottom:4rem;min-width:220px}.glossary label{margin-top:2.6rem}.glossary a{color:#fff;text-decoration:underline}.glossary[aria-hidden=true]{right:-300px}@media screen and (min-width: 481px){.glossary[aria-hidden=true]{right:-364px}}.glossary-heading{display:inline;font-size:22px;margin-top:0}.js-glossary-toggle{border-bottom:none;color:#0071bc;font-size:1.5rem;font-weight:700;line-height:initial;width:initial}.js-glossary-toggle:hover{color:#205493}.js-glossary-toggle svg{margin-right:2px}.js-glossary-close{border:none;font-size:20px;background-color:transparent;float:right;width:initial}.js-glossary-search::-webkit-search-cancel-button{-webkit-appearance:searchfield-cancel-button!important}.usa-sr-only{position:absolute;left:-999em}.clearable-input{position:relative;display:inline-block}.clearable-input>input{padding-right:1.4em}.clearable-input>input::-ms-clear{display:none}</style><link rel=\"stylesheet\" href=\"styles.83e3bba4c1055117.css\" media=\"print\" onload=\"this.media='all'\"><noscript><link rel=\"stylesheet\" href=\"styles.83e3bba4c1055117.css\"></noscript></head>\n",
            "<body>\n",
            "<div id=\"glossary\" class=\"glossary usa-dark-background\" aria-describedby=\"glossary-result\" aria-hidden=\"true\">\n",
            "  <button title=\"Close glossary\" class=\"js-glossary-close button button--close js-glossary-toggle usa-button-unstyled hide-glossary\"><span class=\"usa-sr-only\">Hide glossary</span>\n",
            "    <svg class=\"usa-icon\" aria-hidden=\"true\" focusable=\"false\" role=\"img\">\n",
            "      <use href=\"/assets/uswds/img/sprite.svg#close\"/>\n",
            "    </svg>\n",
            "  </button>\n",
            "  <h4 class=\"glossary-heading\">Glossary</h4>\n",
            "  <p>\n",
            "  Study record managers: refer to the <a href=\"/policy#data-element-definitions\"><span style=\"text-decoration:underline\">Data Element Definitions</span></a> if submitting registration or results information.\n",
            "  </p>\n",
            "  <p>\n",
            "  <label for=\"glossary-search\" class=\"label\">Search for terms</label>\n",
            "  </p>\n",
            "  <span class=\"clearable-input\">\n",
            "  <input id=\"glossary-search\" class=\"js-glossary-search\" type=\"search\">\n",
            "  </span>\n",
            "  <div class=\"glossary__content\" id=\"glossary-result\">\n",
            "    <ul class=\"js-glossary-list\"></ul>\n",
            "  </div>\n",
            "</div>\n",
            "\n",
            "<app-root></app-root>\n",
            "\n",
            "<script type=\"text/javascript\" src=\"https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js\"></script>\n",
            "\n",
            "<script src=\"runtime.1e1da86390b74fbc.js\" type=\"module\"></script><script src=\"polyfills.779d77443fdc493d.js\" type=\"module\"></script><script src=\"scripts.a415e2a2b3a92985.js\" defer></script><script src=\"main.9fa49f8a8ab29449.js\" type=\"module\"></script></body>\n",
            "\n",
            "<!-- JavaScript -->\n",
            "\n",
            "<script src=\"https://code.jquery.com/jquery-3.5.1.min.js\" integrity=\"sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=\" crossorigin=\"anonymous\">\n",
            "</script>\n",
            "<script>\n",
            "  var fallbackJquery = \"https://www.ncbi.nlm.nih.gov/style-guide/static/base/js/jquery-3.5.0.min.js\";\n",
            "  window.jQuery || document.write(\"<script src=\" + fallbackJquery + \">\\x3C/script>\")\n",
            "</script>\n",
            "\n",
            "\n",
            "\n",
            "<!--<script  type=\"text/javascript\" src=\"assets/core/alerts/alerts.js\"> </script>-->\n",
            "\n",
            "<!--<script  type=\"text/javascript\" src=\"https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js\"> </script>-->\n",
            "\n",
            "\n",
            "<!-- - - - - -\n",
            "\n",
            "- - - - - -->\n",
            "\n",
            "<script type=\"text/javascript\">\n",
            "  var alertsUrl = \"/core/alerts/alerts.js\";\n",
            "  if (typeof ncbiBaseUrl !== 'undefined') {\n",
            "    alertsUrl = ncbiBaseUrl + alertsUrl;\n",
            "  } else {\n",
            "    alertsUrl = \"https://www.ncbi.nlm.nih.gov\" + alertsUrl;\n",
            "  }\n",
            "</script>\n",
            "\n",
            "<!--\n",
            "<script src=\"https://www.ncbi.nlm.nih.gov/coreutils/ncbi-banner/ncbi-banner-experiment.js\"></script>\n",
            "-->\n",
            "\n",
            "</html>\n",
            "\n"
          ]
        }
      ],
      "source": [
        "# https://clinicaltrials.gov/data-api/api\n",
        "\n",
        "import requests\n",
        "\n",
        "def get_study_info(search_term, max_results=1):\n",
        "    base_url = \"https://clinicaltrials.gov/data-api/api/v2\"\n",
        "    params = {\n",
        "        \"query\": search_term,\n",
        "        \"pageSize\": max_results\n",
        "    }\n",
        "\n",
        "    headers = {\"content-type\": \"application/json\"}\n",
        "\n",
        "\n",
        "    response = requests.get(base_url, params=params, headers = headers)\n",
        "\n",
        "    if response.status_code == 200:\n",
        "        return response\n",
        "    else:\n",
        "        print(f\"Error: {response.status_code}\")\n",
        "        return None\n",
        "\n",
        "if __name__ == \"__main__\":\n",
        "    search_term = \"cancer\"  # Example search term\n",
        "    studies = get_study_info(search_term)\n",
        "    print(type(studies))\n",
        "    print(studies.text)\n",
        "\n",
        "    # if studies:\n",
        "    #     for study in studies.get(\"studies\", []):\n",
        "    #         print(f\"Study ID: {study.get('nctId')}\")\n",
        "    #         print(f\"Title: {study.get('title')}\")\n",
        "    #         print(f\"Status: {study.get('status')}\")\n",
        "    #         print(\"-\" * 40)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "8EoykWQbuxz9",
        "outputId": "b9f4f229-09cb-4a1b-9f5e-52d8b7e7110e"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "<!DOCTYPE html>\n",
            "\n",
            "<html lang=\"en\" data-critters-container>\n",
            "<head><link rel=\"preconnect\" href=\"https://fonts.gstatic.com\" crossorigin>\n",
            "  <meta charset=\"UTF-8\">\n",
            "  <script type=\"text/javascript\">\n",
            "    window.ncbi_startTime = new Date();\n",
            "  </script>\n",
            "  <meta http-equiv=\"X-UA-Compatible\" content=\"IE=edge\">\n",
            "\n",
            "  <!-- Mobile properties -->\n",
            "  <meta name=\"HandheldFriendly\" content=\"True\">\n",
            "  <meta name=\"MobileOptimized\" content=\"320\">\n",
            "  <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0, minimum-scale=1\">\n",
            "\n",
            "  <style>@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3GUBGEe.woff2) format('woff2');unicode-range:U+0460-052F, U+1C80-1C8A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3iUBGEe.woff2) format('woff2');unicode-range:U+0301, U+0400-045F, U+0490-0491, U+04B0-04B1, U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3CUBGEe.woff2) format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3-UBGEe.woff2) format('woff2');unicode-range:U+0370-0377, U+037A-037F, U+0384-038A, U+038C, U+038E-03A1, U+03A3-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMawCUBGEe.woff2) format('woff2');unicode-range:U+0302-0303, U+0305, U+0307-0308, U+0310, U+0312, U+0315, U+031A, U+0326-0327, U+032C, U+032F-0330, U+0332-0333, U+0338, U+033A, U+0346, U+034D, U+0391-03A1, U+03A3-03A9, U+03B1-03C9, U+03D1, U+03D5-03D6, U+03F0-03F1, U+03F4-03F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, U+2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1, U+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U+2192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+2216-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+2395, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7, U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-2AFF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7FF, U+1EE00-1EEFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMaxKUBGEe.woff2) format('woff2');unicode-range:U+0001-000C, U+000E-001F, U+007F-009F, U+20DD-20E0, U+20E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U+21F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-24FF, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-2BFF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+101D0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F000-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U+1F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U+1F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4-1F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U+1F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F453, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF, U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U+1F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F512-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U+1F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC, U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC, U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887, U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F946, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89, U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3OUBGEe.woff2) format('woff2');unicode-range:U+0102-0103, U+0110-0111, U+0128-0129, U+0168-0169, U+01A0-01A1, U+01AF-01B0, U+0300-0301, U+0303-0304, U+0308-0309, U+0323, U+0329, U+1EA0-1EF9, U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3KUBGEe.woff2) format('woff2');unicode-range:U+0100-02BA, U+02BD-02C5, U+02C7-02CC, U+02CE-02D7, U+02DD-02FF, U+0304, U+0308, U+0329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3yUBA.woff2) format('woff2');unicode-range:U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+0304, U+0308, U+0329, U+2000-206F, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3GUBGEe.woff2) format('woff2');unicode-range:U+0460-052F, U+1C80-1C8A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3iUBGEe.woff2) format('woff2');unicode-range:U+0301, U+0400-045F, U+0490-0491, U+04B0-04B1, U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3CUBGEe.woff2) format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3-UBGEe.woff2) format('woff2');unicode-range:U+0370-0377, U+037A-037F, U+0384-038A, U+038C, U+038E-03A1, U+03A3-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMawCUBGEe.woff2) format('woff2');unicode-range:U+0302-0303, U+0305, U+0307-0308, U+0310, U+0312, U+0315, U+031A, U+0326-0327, U+032C, U+032F-0330, U+0332-0333, U+0338, U+033A, U+0346, U+034D, U+0391-03A1, U+03A3-03A9, U+03B1-03C9, U+03D1, U+03D5-03D6, U+03F0-03F1, U+03F4-03F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, U+2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1, U+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U+2192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+2216-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+2395, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7, U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-2AFF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7FF, U+1EE00-1EEFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMaxKUBGEe.woff2) format('woff2');unicode-range:U+0001-000C, U+000E-001F, U+007F-009F, U+20DD-20E0, U+20E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U+21F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-24FF, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-2BFF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+101D0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F000-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U+1F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U+1F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4-1F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U+1F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F453, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF, U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U+1F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F512-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U+1F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC, U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC, U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887, U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F946, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89, U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3OUBGEe.woff2) format('woff2');unicode-range:U+0102-0103, U+0110-0111, U+0128-0129, U+0168-0169, U+01A0-01A1, U+01AF-01B0, U+0300-0301, U+0303-0304, U+0308-0309, U+0323, U+0329, U+1EA0-1EF9, U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3KUBGEe.woff2) format('woff2');unicode-range:U+0100-02BA, U+02BD-02C5, U+02C7-02CC, U+02CE-02D7, U+02DD-02FF, U+0304, U+0308, U+0329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3yUBA.woff2) format('woff2');unicode-range:U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+0304, U+0308, U+0329, U+2000-206F, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3GUBGEe.woff2) format('woff2');unicode-range:U+0460-052F, U+1C80-1C8A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3iUBGEe.woff2) format('woff2');unicode-range:U+0301, U+0400-045F, U+0490-0491, U+04B0-04B1, U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3CUBGEe.woff2) format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3-UBGEe.woff2) format('woff2');unicode-range:U+0370-0377, U+037A-037F, U+0384-038A, U+038C, U+038E-03A1, U+03A3-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMawCUBGEe.woff2) format('woff2');unicode-range:U+0302-0303, U+0305, U+0307-0308, U+0310, U+0312, U+0315, U+031A, U+0326-0327, U+032C, U+032F-0330, U+0332-0333, U+0338, U+033A, U+0346, U+034D, U+0391-03A1, U+03A3-03A9, U+03B1-03C9, U+03D1, U+03D5-03D6, U+03F0-03F1, U+03F4-03F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, U+2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1, U+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U+2192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+2216-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+2395, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7, U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-2AFF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7FF, U+1EE00-1EEFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMaxKUBGEe.woff2) format('woff2');unicode-range:U+0001-000C, U+000E-001F, U+007F-009F, U+20DD-20E0, U+20E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U+21F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-24FF, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-2BFF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+101D0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F000-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U+1F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U+1F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4-1F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U+1F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F453, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF, U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U+1F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F512-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U+1F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC, U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC, U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887, U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F946, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89, U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3OUBGEe.woff2) format('woff2');unicode-range:U+0102-0103, U+0110-0111, U+0128-0129, U+0168-0169, U+01A0-01A1, U+01AF-01B0, U+0300-0301, U+0303-0304, U+0308-0309, U+0323, U+0329, U+1EA0-1EF9, U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3KUBGEe.woff2) format('woff2');unicode-range:U+0100-02BA, U+02BD-02C5, U+02C7-02CC, U+02CE-02D7, U+02DD-02FF, U+0304, U+0308, U+0329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:500;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3yUBA.woff2) format('woff2');unicode-range:U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+0304, U+0308, U+0329, U+2000-206F, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3GUBGEe.woff2) format('woff2');unicode-range:U+0460-052F, U+1C80-1C8A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3iUBGEe.woff2) format('woff2');unicode-range:U+0301, U+0400-045F, U+0490-0491, U+04B0-04B1, U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3CUBGEe.woff2) format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3-UBGEe.woff2) format('woff2');unicode-range:U+0370-0377, U+037A-037F, U+0384-038A, U+038C, U+038E-03A1, U+03A3-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMawCUBGEe.woff2) format('woff2');unicode-range:U+0302-0303, U+0305, U+0307-0308, U+0310, U+0312, U+0315, U+031A, U+0326-0327, U+032C, U+032F-0330, U+0332-0333, U+0338, U+033A, U+0346, U+034D, U+0391-03A1, U+03A3-03A9, U+03B1-03C9, U+03D1, U+03D5-03D6, U+03F0-03F1, U+03F4-03F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, U+2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1, U+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U+2192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+2216-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+2395, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7, U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-2AFF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7FF, U+1EE00-1EEFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMaxKUBGEe.woff2) format('woff2');unicode-range:U+0001-000C, U+000E-001F, U+007F-009F, U+20DD-20E0, U+20E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U+21F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-24FF, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-2BFF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+101D0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F000-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U+1F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U+1F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4-1F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U+1F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F453, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF, U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U+1F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F512-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U+1F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC, U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC, U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887, U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F946, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89, U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3OUBGEe.woff2) format('woff2');unicode-range:U+0102-0103, U+0110-0111, U+0128-0129, U+0168-0169, U+01A0-01A1, U+01AF-01B0, U+0300-0301, U+0303-0304, U+0308-0309, U+0323, U+0329, U+1EA0-1EF9, U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3KUBGEe.woff2) format('woff2');unicode-range:U+0100-02BA, U+02BD-02C5, U+02C7-02CC, U+02CE-02D7, U+02DD-02FF, U+0304, U+0308, U+0329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;font-stretch:100%;font-display:swap;src:url(https://fonts.gstatic.com/s/roboto/v47/KFO7CnqEu92Fr1ME7kSn66aGLdTylUAMa3yUBA.woff2) format('woff2');unicode-range:U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+0304, U+0308, U+0329, U+2000-206F, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD;}</style>\n",
            "  <style>@font-face{font-family:'Material Icons';font-style:normal;font-weight:400;src:url(https://fonts.gstatic.com/s/materialicons/v143/flUhRq6tzZclQEJ-Vdg-IuiaDsNc.woff2) format('woff2');}.material-icons{font-family:'Material Icons';font-weight:normal;font-style:normal;font-size:24px;line-height:1;letter-spacing:normal;text-transform:none;display:inline-block;white-space:nowrap;word-wrap:normal;direction:ltr;-webkit-font-feature-settings:'liga';-webkit-font-smoothing:antialiased;}</style>\n",
            "  <script src=\"https://maps.googleapis.com/maps/api/js?key=AIzaSyC3PtSiQNBORX_rM0MRLHNA9VybME6zF1A&amp;libraries=places&amp;region=US&amp;language=en\"></script>\n",
            "\n",
            "  <title>ClinicalTrials.gov</title>\n",
            "  <base href=\"/\">\n",
            "\n",
            "  <!-- Favicons -->\n",
            "  <link rel=\"shortcut icon\" type=\"image/svg\" href=\"assets/favicons/favicon.svg\">\n",
            "  <link rel=\"icon\" type=\"image/svg\" href=\"assets/favicons/favicon.svg\">\n",
            "\n",
            "  <!-- 192x192, as recommended for Android\n",
            "  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android\n",
            "  -->\n",
            "  <link rel=\"icon\" type=\"image/svg\" sizes=\"192x192\" href=\"assets/favicons/favicon.svg\">\n",
            "\n",
            "  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->\n",
            "  <link rel=\"apple-touch-icon-precomposed\" href=\"assets/favicons/favicon.svg\">\n",
            "  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->\n",
            "  <link rel=\"apple-touch-icon-precomposed\" sizes=\"72x72\" href=\"assets/favicons/favicon.svg\">\n",
            "  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->\n",
            "  <link rel=\"apple-touch-icon-precomposed\" sizes=\"114x114\" href=\"assets/favicons/favicon.svg\">\n",
            "  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->\n",
            "  <link rel=\"apple-touch-icon-precomposed\" sizes=\"144x144\" href=\"assets/favicons/favicon.svg\">\n",
            "\n",
            "\n",
            "  <!-- Page description -->\n",
            "  <meta name=\"description\" content>\n",
            "\n",
            "  <meta property=\"og:title\" content>\n",
            "  <meta property=\"og:description\" content>\n",
            "\n",
            "  <meta name=\"twitter:title\" content>\n",
            "  <meta name=\"twitter:description\" content>\n",
            "  <meta name=\"twitter:card\" content=\"summary\">\n",
            "\n",
            "  <!-- robots -->\n",
            "  <meta name=\"robots\" content=\"index, follow\">\n",
            "\n",
            "  <!-- Pinger -->\n",
            "  <meta name=\"ncbi_app\" content=\"ctgov2\">\n",
            "  <meta name=\"ncbi_db\" content>\n",
            "  <meta name=\"ncbi_pinger_track_stat\" content=\"false\">\n",
            "  <meta name=\"ncbi_pinger_ga_track\" content=\"true\">\n",
            "  <meta name=\"ncbi_pinger_ga_tracking_id\" content=\"UA-68648221-4\">\n",
            "  <meta name=\"ncbi_pinger_url_query_strip\" content=\"lat,lng,locStr\">\n",
            "  <meta name=\"ncbi_pinger_click_use_capture\" content=\"true\">\n",
            "  <meta name=\"ncbi_pinger_gtm_track\" content=\"true\">\n",
            "\n",
            "  <meta name=\"ncbi_app_version\" content>\n",
            "<style>:root{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica,Arial,sans-serif,\"Apple Color Emoji\",\"Segoe UI Emoji\",Segoe UI Symbol;--font-family:-apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, Helvetica, Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\";--surface-a:#ffffff;--surface-b:#f8f9fa;--surface-c:#e9ecef;--surface-d:#dee2e6;--surface-e:#ffffff;--surface-f:#ffffff;--text-color:#495057;--text-color-secondary:#6c757d;--primary-color:#2196F3;--primary-color-text:#ffffff;--surface-0:#ffffff;--surface-50:#fafafa;--surface-100:#f5f5f5;--surface-200:#eeeeee;--surface-300:#e0e0e0;--surface-400:#bdbdbd;--surface-500:#9e9e9e;--surface-600:#757575;--surface-700:#616161;--surface-800:#424242;--surface-900:#212121;--gray-50:#fafafa;--gray-100:#f5f5f5;--gray-200:#eeeeee;--gray-300:#e0e0e0;--gray-400:#bdbdbd;--gray-500:#9e9e9e;--gray-600:#757575;--gray-700:#616161;--gray-800:#424242;--gray-900:#212121;--content-padding:1rem;--inline-spacing:.5rem;--border-radius:3px;--surface-ground:#f8f9fa;--surface-section:#ffffff;--surface-card:#ffffff;--surface-overlay:#ffffff;--surface-border:#dee2e6;--surface-hover:#e9ecef;--maskbg:rgba(0, 0, 0, .4);--highlight-bg:#E3F2FD;--highlight-text-color:#495057;--focus-ring:0 0 0 .2rem #a6d5fa;color-scheme:light}:root{--blue-50:#f4fafe;--blue-100:#cae6fc;--blue-200:#a0d2fa;--blue-300:#75bef8;--blue-400:#4baaf5;--blue-500:#2196f3;--blue-600:#1c80cf;--blue-700:#1769aa;--blue-800:#125386;--blue-900:#0d3c61;--green-50:#f6fbf6;--green-100:#d4ecd5;--green-200:#b2ddb4;--green-300:#90cd93;--green-400:#6ebe71;--green-500:#4caf50;--green-600:#419544;--green-700:#357b38;--green-800:#2a602c;--green-900:#1e4620;--yellow-50:#fffcf5;--yellow-100:#fef0cd;--yellow-200:#fde4a5;--yellow-300:#fdd87d;--yellow-400:#fccc55;--yellow-500:#fbc02d;--yellow-600:#d5a326;--yellow-700:#b08620;--yellow-800:#8a6a19;--yellow-900:#644d12;--cyan-50:#f2fcfd;--cyan-100:#c2eff5;--cyan-200:#91e2ed;--cyan-300:#61d5e4;--cyan-400:#30c9dc;--cyan-500:#00bcd4;--cyan-600:#00a0b4;--cyan-700:#008494;--cyan-800:#006775;--cyan-900:#004b55;--pink-50:#fef4f7;--pink-100:#fac9da;--pink-200:#f69ebc;--pink-300:#f1749e;--pink-400:#ed4981;--pink-500:#e91e63;--pink-600:#c61a54;--pink-700:#a31545;--pink-800:#801136;--pink-900:#5d0c28;--indigo-50:#f5f6fb;--indigo-100:#d1d5ed;--indigo-200:#acb4df;--indigo-300:#8893d1;--indigo-400:#6372c3;--indigo-500:#3f51b5;--indigo-600:#36459a;--indigo-700:#2c397f;--indigo-800:#232d64;--indigo-900:#192048;--teal-50:#f2faf9;--teal-100:#c2e6e2;--teal-200:#91d2cc;--teal-300:#61beb5;--teal-400:#30aa9f;--teal-500:#009688;--teal-600:#008074;--teal-700:#00695f;--teal-800:#00534b;--teal-900:#003c36;--orange-50:#fff8f2;--orange-100:#fde0c2;--orange-200:#fbc791;--orange-300:#f9ae61;--orange-400:#f79530;--orange-500:#f57c00;--orange-600:#d06900;--orange-700:#ac5700;--orange-800:#874400;--orange-900:#623200;--bluegray-50:#f7f9f9;--bluegray-100:#d9e0e3;--bluegray-200:#bbc7cd;--bluegray-300:#9caeb7;--bluegray-400:#7e96a1;--bluegray-500:#607d8b;--bluegray-600:#526a76;--bluegray-700:#435861;--bluegray-800:#35454c;--bluegray-900:#263238;--purple-50:#faf4fb;--purple-100:#e7cbec;--purple-200:#d4a2dd;--purple-300:#c279ce;--purple-400:#af50bf;--purple-500:#9c27b0;--purple-600:#852196;--purple-700:#6d1b7b;--purple-800:#561561;--purple-900:#3e1046;--red-50:#fff5f5;--red-100:#ffd1ce;--red-200:#ffada7;--red-300:#ff8980;--red-400:#ff6459;--red-500:#ff4032;--red-600:#d9362b;--red-700:#b32d23;--red-800:#8c231c;--red-900:#661a14;--primary-50:#f4fafe;--primary-100:#cae6fc;--primary-200:#a0d2fa;--primary-300:#75bef8;--primary-400:#4baaf5;--primary-500:#2196f3;--primary-600:#1c80cf;--primary-700:#1769aa;--primary-800:#125386;--primary-900:#0d3c61}@layer primeng{*{box-sizing:border-box}}@layer primeng{button{border-radius:0}}:root{--fa-style-family-brands:\"Font Awesome 6 Brands\";--fa-font-brands:normal 400 1em/1 \"Font Awesome 6 Brands\"}@font-face{font-family:\"Font Awesome 6 Brands\";font-style:normal;font-weight:400;font-display:block;src:url(fa-brands-400.87587a681474fe69.woff2) format(\"woff2\"),url(fa-brands-400.5d18d427c08f12c3.ttf) format(\"truetype\")}:root{--fa-style-family-classic:\"Font Awesome 6 Free\";--fa-font-regular:normal 400 1em/1 \"Font Awesome 6 Free\"}@font-face{font-family:\"Font Awesome 6 Free\";font-style:normal;font-weight:400;font-display:block;src:url(fa-regular-400.3ccdbd3d093918cb.woff2) format(\"woff2\"),url(fa-regular-400.81482cd4d93fbfd4.ttf) format(\"truetype\")}:root{--fa-style-family-classic:\"Font Awesome 6 Free\";--fa-font-solid:normal 900 1em/1 \"Font Awesome 6 Free\"}@font-face{font-family:\"Font Awesome 6 Free\";font-style:normal;font-weight:900;font-display:block;src:url(fa-solid-900.0b0cc8a6df2a4fc7.woff2) format(\"woff2\"),url(fa-solid-900.69d3141ae4b2f721.ttf) format(\"truetype\")}html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}a{background-color:transparent}button,input{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button{text-transform:none}button{-webkit-appearance:button}button::-moz-focus-inner{border-style:none;padding:0}button:-moz-focusring{outline:1px dotted ButtonText}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}body{color:#1b1b1b;background-color:#fff;overflow-x:hidden}input:not([disabled]):focus,button:not([disabled]):focus{outline:.25rem solid #2491ff;outline-offset:0}[href]:focus{outline:.25rem solid #2491ff;outline-offset:0}*,*:before,*:after{box-sizing:inherit}html{font-feature-settings:\"kern\" 1;font-kerning:normal;font-family:Roboto,sans-serif;font-size:100%}.usa-sr-only{position:absolute;left:-999em;right:auto}.usa-dark-background{-moz-osx-font-smoothing:grayscale;-webkit-font-smoothing:antialiased;background-color:#3d4551}.usa-dark-background p,.usa-dark-background span,.usa-dark-background a,.usa-dark-background a:visited{color:#fff}.usa-dark-background a:hover{color:#f0f0f0}.usa-icon{display:inline-block;fill:currentColor;height:1em;position:relative;width:1em}input[type=search]{box-sizing:border-box;appearance:none}[type=search]{padding-bottom:0;padding-top:0;border-bottom-right-radius:0;border-right:none;border-top-right-radius:0;box-sizing:border-box;float:left;font-size:.93rem;height:2rem;margin:0}:root{--ctgl-color-base-lightest:#f0f0f0;--ctgl-color-base-lighter:#dfe1e2;--ctgl-color-base-light:#a9aeb1;--ctgl-color-base:#71767a;--ctgl-color-base-dark:#565c65;--ctgl-color-base-darker:#3d4551;--ctgl-color-base-darkest:#1b1b1b;--ctgl-color-primary-lighter:#d9e8f6;--ctgl-color-primary-light:#73b3e7;--ctgl-color-primary:#0071bc;--ctgl-color-primary-vivid:#0050d8;--ctgl-color-primary-dark:#1a4480;--ctgl-color-primary-darker:#205493;--ctgl-color-primary-darkest:#112e51;--ctgl-color-secondary-lighter:#f3e1e4;--ctgl-color-secondary-light:#f2938c;--ctgl-color-secondary:#d83933;--ctgl-color-secondary-vivid:#e41d3d;--ctgl-color-secondary-dark:#b50909;--ctgl-color-secondary-darker:#8b0a03;--ctgl-color-accent-warm-lighter:#f2e4d4;--ctgl-color-accent-warm-light:#ffbc78;--ctgl-color-accent-warm:#fa9441;--ctgl-color-accent-warm-dark:#c05600;--ctgl-color-accent-warm-darker:#775540;--ctgl-color-accent-cool-lighter:#e1f3f8;--ctgl-color-accent-cool-light:#97d4ea;--ctgl-color-accent-cool:#00bde3;--ctgl-color-accent-cool-dark:#28a0cb;--ctgl-color-accent-cool-darker:#07648d;--ctgl-color-error-lighter:#f4e3db;--ctgl-color-error-light:#f39268;--ctgl-color-error:#d54309;--ctgl-color-error-dark:#b50909;--ctgl-color-error-darker:#6f3331;--ctgl-color-warning-lighter:#faf3d1;--ctgl-color-warning-light:#fee685;--ctgl-color-warning:#ffbe2e;--ctgl-color-warning-dark:#e5a000;--ctgl-color-warning-darker:#936f38;--ctgl-color-success-lighter:#ecf3ec;--ctgl-color-success-light:#70e17b;--ctgl-color-success:#00a91c;--ctgl-color-success-dark:#008817;--ctgl-color-success-darker:#216e1f;--ctgl-color-info-lighter:#e7f6f8;--ctgl-color-info-light:#99deea;--ctgl-color-info:#00bde3;--ctgl-color-info-dark:#009ec1;--ctgl-color-info-darker:#2e6276;--ctgl-color-disabled-light:#e6e6e6;--ctgl-color-disabled:#c9c9c9;--ctgl-color-disabled-dark:#adadad;--ctgl-color-emergency:#9c3d10;--ctgl-color-emergency-dark:#332d29;--ctgl-color-red-cool-5:#f8eff1;--ctgl-color-red-cool-10:#f3e1e4;--ctgl-color-red-cool-20:#ecbec6;--ctgl-color-red-cool-30:#e09aa6;--ctgl-color-red-cool-40:#e16b80;--ctgl-color-red-cool-50:#cd425b;--ctgl-color-red-cool-60:#9e394b;--ctgl-color-red-cool-70:#68363f;--ctgl-color-red-cool-80:#40282c;--ctgl-color-red-cool-90:#1e1517;--ctgl-color-red-cool-5v:#fff2f5;--ctgl-color-red-cool-10v:#f8dfe2;--ctgl-color-red-cool-20v:#f8b9c5;--ctgl-color-red-cool-30v:#fd8ba0;--ctgl-color-red-cool-40v:#f45d79;--ctgl-color-red-cool-50v:#e41d3d;--ctgl-color-red-cool-60v:#b21d38;--ctgl-color-red-cool-70v:#822133;--ctgl-color-red-cool-80v:#4f1c24;--ctgl-color-red-5:#f9eeee;--ctgl-color-red-10:#f8e1de;--ctgl-color-red-20:#f7bbb1;--ctgl-color-red-30:#f2938c;--ctgl-color-red-40:#e9695f;--ctgl-color-red-50:#d83933;--ctgl-color-red-60:#a23737;--ctgl-color-red-70:#6f3331;--ctgl-color-red-80:#3e2927;--ctgl-color-red-90:#1b1616;--ctgl-color-red-5v:#fff3f2;--ctgl-color-red-10v:#fde0db;--ctgl-color-red-20v:#fdb8ae;--ctgl-color-red-30v:#ff8d7b;--ctgl-color-red-40v:#fb5a47;--ctgl-color-red-50v:#e52207;--ctgl-color-red-60v:#b50909;--ctgl-color-red-70v:#8b0a03;--ctgl-color-red-80v:#5c1111;--ctgl-color-red-warm-5:#f6efea;--ctgl-color-red-warm-10:#f4e3db;--ctgl-color-red-warm-20:#ecc0a7;--ctgl-color-red-warm-30:#dca081;--ctgl-color-red-warm-40:#d27a56;--ctgl-color-red-warm-50:#c3512c;--ctgl-color-red-warm-60:#805039;--ctgl-color-red-warm-70:#524236;--ctgl-color-red-warm-80:#332d29;--ctgl-color-red-warm-90:#1f1c18;--ctgl-color-red-warm-5v:#fff5ee;--ctgl-color-red-warm-10v:#fce1d4;--ctgl-color-red-warm-20v:#f6bd9c;--ctgl-color-red-warm-30v:#f39268;--ctgl-color-red-warm-40v:#ef5e25;--ctgl-color-red-warm-50v:#d54309;--ctgl-color-red-warm-60v:#9c3d10;--ctgl-color-red-warm-70v:#63340f;--ctgl-color-red-warm-80v:#3e2a1e;--ctgl-color-orange-warm-5:#faeee5;--ctgl-color-orange-warm-10:#fbe0d0;--ctgl-color-orange-warm-20:#f7bca2;--ctgl-color-orange-warm-30:#f3966d;--ctgl-color-orange-warm-40:#e17141;--ctgl-color-orange-warm-50:#bd5727;--ctgl-color-orange-warm-60:#914734;--ctgl-color-orange-warm-70:#633a32;--ctgl-color-orange-warm-80:#3d2925;--ctgl-color-orange-warm-90:#1c1615;--ctgl-color-orange-warm-5v:#fff3ea;--ctgl-color-orange-warm-10v:#ffe2d1;--ctgl-color-orange-warm-20v:#fbbaa7;--ctgl-color-orange-warm-30v:#fc906d;--ctgl-color-orange-warm-40v:#ff580a;--ctgl-color-orange-warm-50v:#cf4900;--ctgl-color-orange-warm-60v:#a72f10;--ctgl-color-orange-warm-70v:#782312;--ctgl-color-orange-warm-80v:#3d231d;--ctgl-color-orange-5:#f6efe9;--ctgl-color-orange-10:#f2e4d4;--ctgl-color-orange-20:#f3bf90;--ctgl-color-orange-30:#f09860;--ctgl-color-orange-40:#dd7533;--ctgl-color-orange-50:#a86437;--ctgl-color-orange-60:#775540;--ctgl-color-orange-70:#524236;--ctgl-color-orange-80:#332d27;--ctgl-color-orange-90:#1b1614;--ctgl-color-orange-5v:#fef2e4;--ctgl-color-orange-10v:#fce2c5;--ctgl-color-orange-20v:#ffbc78;--ctgl-color-orange-30v:#fa9441;--ctgl-color-orange-40v:#e66f0e;--ctgl-color-orange-50v:#c05600;--ctgl-color-orange-60v:#8c471c;--ctgl-color-orange-70v:#5f3617;--ctgl-color-orange-80v:#352313;--ctgl-color-gold-5:#f5f0e6;--ctgl-color-gold-10:#f1e5cd;--ctgl-color-gold-20:#dec69a;--ctgl-color-gold-30:#c7a97b;--ctgl-color-gold-40:#ad8b65;--ctgl-color-gold-50:#8e704f;--ctgl-color-gold-60:#6b5947;--ctgl-color-gold-70:#4d4438;--ctgl-color-gold-80:#322d26;--ctgl-color-gold-90:#191714;--ctgl-color-gold-5v:#fef0c8;--ctgl-color-gold-10v:#ffe396;--ctgl-color-gold-20v:#ffbe2e;--ctgl-color-gold-30v:#e5a000;--ctgl-color-gold-40v:#c2850c;--ctgl-color-gold-50v:#936f38;--ctgl-color-gold-60v:#7a591a;--ctgl-color-gold-70v:#5c410a;--ctgl-color-gold-80v:#3b2b15;--ctgl-color-yellow-5:#faf3d1;--ctgl-color-yellow-10:#f5e6af;--ctgl-color-yellow-20:#e6c74c;--ctgl-color-yellow-30:#c9ab48;--ctgl-color-yellow-40:#a88f48;--ctgl-color-yellow-50:#8a7237;--ctgl-color-yellow-60:#6b5a39;--ctgl-color-yellow-70:#504332;--ctgl-color-yellow-80:#332d27;--ctgl-color-yellow-90:#1a1614;--ctgl-color-yellow-5v:#fff5c2;--ctgl-color-yellow-10v:#fee685;--ctgl-color-yellow-20v:#face00;--ctgl-color-yellow-30v:#ddaa01;--ctgl-color-yellow-40v:#b38c00;--ctgl-color-yellow-50v:#947100;--ctgl-color-yellow-60v:#776017;--ctgl-color-yellow-70v:#5c4809;--ctgl-color-yellow-80v:#422d19;--ctgl-color-green-warm-5:#f1f4d7;--ctgl-color-green-warm-10:#e7eab7;--ctgl-color-green-warm-20:#cbd17a;--ctgl-color-green-warm-30:#a6b557;--ctgl-color-green-warm-40:#8a984b;--ctgl-color-green-warm-50:#6f7a41;--ctgl-color-green-warm-60:#5a5f38;--ctgl-color-green-warm-70:#45472f;--ctgl-color-green-warm-80:#2d2f21;--ctgl-color-green-warm-90:#171712;--ctgl-color-green-warm-5v:#f5fbc1;--ctgl-color-green-warm-10v:#e7f434;--ctgl-color-green-warm-20v:#c5d30a;--ctgl-color-green-warm-30v:#a3b72c;--ctgl-color-green-warm-40v:#7e9c1d;--ctgl-color-green-warm-50v:#6a7d00;--ctgl-color-green-warm-60v:#5a6613;--ctgl-color-green-warm-70v:#4b4e10;--ctgl-color-green-warm-80v:#38380b;--ctgl-color-green-5:#eaf4dd;--ctgl-color-green-10:#dfeacd;--ctgl-color-green-20:#b8d293;--ctgl-color-green-30:#9bb672;--ctgl-color-green-40:#7d9b4e;--ctgl-color-green-50:#607f35;--ctgl-color-green-60:#4c6424;--ctgl-color-green-70:#3c4a29;--ctgl-color-green-80:#293021;--ctgl-color-green-90:#161814;--ctgl-color-green-5v:#ddf9c7;--ctgl-color-green-10v:#c5ee93;--ctgl-color-green-20v:#98d035;--ctgl-color-green-30v:#7fb135;--ctgl-color-green-40v:#719f2a;--ctgl-color-green-50v:#538200;--ctgl-color-green-60v:#466c04;--ctgl-color-green-70v:#2f4a0b;--ctgl-color-green-80v:#243413;--ctgl-color-green-cool-5:#ecf3ec;--ctgl-color-green-cool-10:#dbebde;--ctgl-color-green-cool-20:#b4d0b9;--ctgl-color-green-cool-30:#86b98e;--ctgl-color-green-cool-40:#5e9f69;--ctgl-color-green-cool-50:#4d8055;--ctgl-color-green-cool-60:#446443;--ctgl-color-green-cool-70:#37493b;--ctgl-color-green-cool-80:#28312a;--ctgl-color-green-cool-90:#1a1f1a;--ctgl-color-green-cool-5v:#e3f5e1;--ctgl-color-green-cool-10v:#b7f5bd;--ctgl-color-green-cool-20v:#70e17b;--ctgl-color-green-cool-30v:#21c834;--ctgl-color-green-cool-40v:#00a91c;--ctgl-color-green-cool-50v:#008817;--ctgl-color-green-cool-60v:#216e1f;--ctgl-color-green-cool-70v:#154c21;--ctgl-color-green-cool-80v:#19311e;--ctgl-color-mint-5:#dbf6ed;--ctgl-color-mint-10:#c7efe2;--ctgl-color-mint-20:#92d9bb;--ctgl-color-mint-30:#5abf95;--ctgl-color-mint-40:#34a37e;--ctgl-color-mint-50:#2e8367;--ctgl-color-mint-60:#286846;--ctgl-color-mint-70:#204e34;--ctgl-color-mint-80:#193324;--ctgl-color-mint-90:#0d1a12;--ctgl-color-mint-5v:#c9fbeb;--ctgl-color-mint-10v:#83fcd4;--ctgl-color-mint-20v:#0ceda6;--ctgl-color-mint-30v:#04c585;--ctgl-color-mint-40v:#00a871;--ctgl-color-mint-50v:#008659;--ctgl-color-mint-60v:#146947;--ctgl-color-mint-70v:#0c4e29;--ctgl-color-mint-80v:#0d351e;--ctgl-color-mint-cool-5:#e0f7f6;--ctgl-color-mint-cool-10:#c4eeeb;--ctgl-color-mint-cool-20:#9bd4cf;--ctgl-color-mint-cool-30:#6fbab3;--ctgl-color-mint-cool-40:#4f9e99;--ctgl-color-mint-cool-50:#40807e;--ctgl-color-mint-cool-60:#376462;--ctgl-color-mint-cool-70:#2a4b45;--ctgl-color-mint-cool-80:#203131;--ctgl-color-mint-cool-90:#111818;--ctgl-color-mint-cool-5v:#d5fbf3;--ctgl-color-mint-cool-10v:#7efbe1;--ctgl-color-mint-cool-20v:#29e1cb;--ctgl-color-mint-cool-30v:#1dc2ae;--ctgl-color-mint-cool-40v:#00a398;--ctgl-color-mint-cool-50v:#008480;--ctgl-color-mint-cool-60v:#0f6460;--ctgl-color-mint-cool-70v:#0b4b3f;--ctgl-color-mint-cool-80v:#123131;--ctgl-color-cyan-5:#e7f6f8;--ctgl-color-cyan-10:#ccecf2;--ctgl-color-cyan-20:#99deea;--ctgl-color-cyan-30:#5dc0d1;--ctgl-color-cyan-40:#449dac;--ctgl-color-cyan-50:#168092;--ctgl-color-cyan-60:#2a646d;--ctgl-color-cyan-70:#2c4a4e;--ctgl-color-cyan-80:#203133;--ctgl-color-cyan-90:#111819;--ctgl-color-cyan-5v:#e5faff;--ctgl-color-cyan-10v:#a8f2ff;--ctgl-color-cyan-20v:#52daf2;--ctgl-color-cyan-30v:#00bde3;--ctgl-color-cyan-40v:#009ec1;--ctgl-color-cyan-50v:#0081a1;--ctgl-color-cyan-60v:#00687d;--ctgl-color-cyan-70v:#0e4f5c;--ctgl-color-cyan-80v:#093b44;--ctgl-color-blue-cool-5:#e7f2f5;--ctgl-color-blue-cool-10:#dae9ee;--ctgl-color-blue-cool-20:#adcfdc;--ctgl-color-blue-cool-30:#82b4c9;--ctgl-color-blue-cool-40:#6499af;--ctgl-color-blue-cool-50:#3a7d95;--ctgl-color-blue-cool-60:#2e6276;--ctgl-color-blue-cool-70:#224a58;--ctgl-color-blue-cool-80:#14333d;--ctgl-color-blue-cool-90:#0f191c;--ctgl-color-blue-cool-5v:#e1f3f8;--ctgl-color-blue-cool-10v:#c3ebfa;--ctgl-color-blue-cool-20v:#97d4ea;--ctgl-color-blue-cool-30v:#59b9de;--ctgl-color-blue-cool-40v:#28a0cb;--ctgl-color-blue-cool-50v:#0d7ea2;--ctgl-color-blue-cool-60v:#07648d;--ctgl-color-blue-cool-70v:#074b69;--ctgl-color-blue-cool-80v:#002d3f;--ctgl-color-blue-5:#eff6fb;--ctgl-color-blue-10:#d9e8f6;--ctgl-color-blue-20:#aacdec;--ctgl-color-blue-30:#73b3e7;--ctgl-color-blue-40:#4f97d1;--ctgl-color-blue-50:#2378c3;--ctgl-color-blue-60:#2c608a;--ctgl-color-blue-70:#274863;--ctgl-color-blue-80:#1f303e;--ctgl-color-blue-90:#11181d;--ctgl-color-blue-5v:#e8f5ff;--ctgl-color-blue-10v:#cfe8ff;--ctgl-color-blue-20v:#a1d3ff;--ctgl-color-blue-30v:#58b4ff;--ctgl-color-blue-40v:#2491ff;--ctgl-color-blue-50v:#0076d6;--ctgl-color-blue-60v:#005ea2;--ctgl-color-blue-70v:#0b4778;--ctgl-color-blue-80v:#112f4e;--ctgl-color-blue-warm-5:#ecf1f7;--ctgl-color-blue-warm-10:#e1e7f1;--ctgl-color-blue-warm-20:#bbcae4;--ctgl-color-blue-warm-30:#98afd2;--ctgl-color-blue-warm-40:#7292c7;--ctgl-color-blue-warm-50:#4a77b4;--ctgl-color-blue-warm-60:#345d96;--ctgl-color-blue-warm-70:#2f4668;--ctgl-color-blue-warm-80:#252f3e;--ctgl-color-blue-warm-90:#13171f;--ctgl-color-blue-warm-5v:#edf5ff;--ctgl-color-blue-warm-10v:#d4e5ff;--ctgl-color-blue-warm-20v:#adcdff;--ctgl-color-blue-warm-30v:#81aefc;--ctgl-color-blue-warm-40v:#5994f6;--ctgl-color-blue-warm-50v:#2672de;--ctgl-color-blue-warm-60v:#0050d8;--ctgl-color-blue-warm-70v:#1a4480;--ctgl-color-blue-warm-80v:#162e51;--ctgl-color-indigo-cool-5:#eef0f9;--ctgl-color-indigo-cool-10:#e1e6f9;--ctgl-color-indigo-cool-20:#bbc8f5;--ctgl-color-indigo-cool-30:#96abee;--ctgl-color-indigo-cool-40:#6b8ee8;--ctgl-color-indigo-cool-50:#496fd8;--ctgl-color-indigo-cool-60:#3f57a6;--ctgl-color-indigo-cool-70:#374274;--ctgl-color-indigo-cool-80:#292d42;--ctgl-color-indigo-cool-90:#151622;--ctgl-color-indigo-cool-5v:#edf0ff;--ctgl-color-indigo-cool-10v:#dee5ff;--ctgl-color-indigo-cool-20v:#b8c8ff;--ctgl-color-indigo-cool-30v:#94adff;--ctgl-color-indigo-cool-40v:#628ef4;--ctgl-color-indigo-cool-50v:#4866ff;--ctgl-color-indigo-cool-60v:#3e4ded;--ctgl-color-indigo-cool-70v:#222fbf;--ctgl-color-indigo-cool-80v:#1b2b85;--ctgl-color-indigo-5:#efeff8;--ctgl-color-indigo-10:#e5e4fa;--ctgl-color-indigo-20:#c5c5f3;--ctgl-color-indigo-30:#a5a8eb;--ctgl-color-indigo-40:#8889db;--ctgl-color-indigo-50:#676cc8;--ctgl-color-indigo-60:#4d52af;--ctgl-color-indigo-70:#3d4076;--ctgl-color-indigo-80:#2b2c40;--ctgl-color-indigo-90:#16171f;--ctgl-color-indigo-5v:#f0f0ff;--ctgl-color-indigo-10v:#e0e0ff;--ctgl-color-indigo-20v:#ccceff;--ctgl-color-indigo-30v:#a3a7fa;--ctgl-color-indigo-40v:#8289ff;--ctgl-color-indigo-50v:#656bd7;--ctgl-color-indigo-60v:#4a50c4;--ctgl-color-indigo-70v:#3333a3;--ctgl-color-indigo-80v:#212463;--ctgl-color-indigo-warm-5:#f1eff7;--ctgl-color-indigo-warm-10:#e7e3fa;--ctgl-color-indigo-warm-20:#cbc4f2;--ctgl-color-indigo-warm-30:#afa5e8;--ctgl-color-indigo-warm-40:#9287d8;--ctgl-color-indigo-warm-50:#7665d1;--ctgl-color-indigo-warm-60:#5e519e;--ctgl-color-indigo-warm-70:#453c7b;--ctgl-color-indigo-warm-80:#2e2c40;--ctgl-color-indigo-warm-90:#18161d;--ctgl-color-indigo-warm-5v:#f5f2ff;--ctgl-color-indigo-warm-10v:#e4deff;--ctgl-color-indigo-warm-20v:#cfc4fd;--ctgl-color-indigo-warm-30v:#b69fff;--ctgl-color-indigo-warm-40v:#967efb;--ctgl-color-indigo-warm-50v:#745fe9;--ctgl-color-indigo-warm-60v:#5942d2;--ctgl-color-indigo-warm-70v:#3d2c9d;--ctgl-color-indigo-warm-80v:#261f5b;--ctgl-color-violet-5:#f4f1f9;--ctgl-color-violet-10:#ebe3f9;--ctgl-color-violet-20:#d0c3e9;--ctgl-color-violet-30:#b8a2e3;--ctgl-color-violet-40:#9d84d2;--ctgl-color-violet-50:#8168b3;--ctgl-color-violet-60:#665190;--ctgl-color-violet-70:#4c3d69;--ctgl-color-violet-80:#312b3f;--ctgl-color-violet-90:#18161d;--ctgl-color-violet-5v:#f7f2ff;--ctgl-color-violet-10v:#ede3ff;--ctgl-color-violet-20v:#d5bfff;--ctgl-color-violet-30v:#c39deb;--ctgl-color-violet-40v:#ad79e9;--ctgl-color-violet-50v:#9355dc;--ctgl-color-violet-60v:#783cb9;--ctgl-color-violet-70v:#54278f;--ctgl-color-violet-80v:#39215e;--ctgl-color-violet-warm-5:#f8f0f9;--ctgl-color-violet-warm-10:#f6dff8;--ctgl-color-violet-warm-20:#e2bee4;--ctgl-color-violet-warm-30:#d29ad8;--ctgl-color-violet-warm-40:#bf77c8;--ctgl-color-violet-warm-50:#b04abd;--ctgl-color-violet-warm-60:#864381;--ctgl-color-violet-warm-70:#5c395a;--ctgl-color-violet-warm-80:#382936;--ctgl-color-violet-warm-90:#1b151b;--ctgl-color-violet-warm-5v:#fef2ff;--ctgl-color-violet-warm-10v:#fbdcff;--ctgl-color-violet-warm-20v:#f4b2ff;--ctgl-color-violet-warm-30v:#ee83ff;--ctgl-color-violet-warm-40v:#d85bef;--ctgl-color-violet-warm-50v:#be32d0;--ctgl-color-violet-warm-60v:#93348c;--ctgl-color-violet-warm-70v:#711e6c;--ctgl-color-violet-warm-80v:#481441;--ctgl-color-magenta-5:#f9f0f2;--ctgl-color-magenta-10:#f6e1e8;--ctgl-color-magenta-20:#f0bbcc;--ctgl-color-magenta-30:#e895b3;--ctgl-color-magenta-40:#e0699f;--ctgl-color-magenta-50:#c84281;--ctgl-color-magenta-60:#8b4566;--ctgl-color-magenta-70:#66364b;--ctgl-color-magenta-80:#402731;--ctgl-color-magenta-90:#1b1617;--ctgl-color-magenta-5v:#fff2f5;--ctgl-color-magenta-10v:#ffddea;--ctgl-color-magenta-20v:#ffb4cf;--ctgl-color-magenta-30v:#ff87b2;--ctgl-color-magenta-40v:#fd4496;--ctgl-color-magenta-50v:#d72d79;--ctgl-color-magenta-60v:#ab2165;--ctgl-color-magenta-70v:#731f44;--ctgl-color-magenta-80v:#4f172e;--ctgl-color-gray-cool-1:#fbfcfd;--ctgl-color-gray-cool-2:#f7f9fa;--ctgl-color-gray-cool-3:#f5f6f7;--ctgl-color-gray-cool-4:#f1f3f6;--ctgl-color-gray-cool-5:#edeff0;--ctgl-color-gray-cool-10:#dfe1e2;--ctgl-color-gray-cool-20:#c6cace;--ctgl-color-gray-cool-30:#a9aeb1;--ctgl-color-gray-cool-40:#8d9297;--ctgl-color-gray-cool-50:#71767a;--ctgl-color-gray-cool-60:#565c65;--ctgl-color-gray-cool-70:#3d4551;--ctgl-color-gray-cool-80:#2d2e2f;--ctgl-color-gray-cool-90:#1c1d1f;--ctgl-color-gray-1:#fcfcfc;--ctgl-color-gray-2:#f9f9f9;--ctgl-color-gray-3:#f6f6f6;--ctgl-color-gray-4:#f3f3f3;--ctgl-color-gray-5:#f0f0f0;--ctgl-color-gray-10:#e6e6e6;--ctgl-color-gray-20:#c9c9c9;--ctgl-color-gray-30:#adadad;--ctgl-color-gray-40:#919191;--ctgl-color-gray-50:#757575;--ctgl-color-gray-60:#5c5c5c;--ctgl-color-gray-70:#454545;--ctgl-color-gray-80:#2e2e2e;--ctgl-color-gray-90:#1b1b1b;--ctgl-color-gray-100:#000000;--ctgl-color-gray-warm-1:#fcfcfb;--ctgl-color-gray-warm-2:#f9f9f7;--ctgl-color-gray-warm-3:#f6f6f2;--ctgl-color-gray-warm-4:#f5f5f0;--ctgl-color-gray-warm-5:#f0f0ec;--ctgl-color-gray-warm-10:#e6e6e2;--ctgl-color-gray-warm-20:#cac9c0;--ctgl-color-gray-warm-30:#afaea2;--ctgl-color-gray-warm-40:#929285;--ctgl-color-gray-warm-50:#76766a;--ctgl-color-gray-warm-60:#5d5d52;--ctgl-color-gray-warm-70:#454540;--ctgl-color-gray-warm-80:#2e2e2a;--ctgl-color-gray-warm-90:#171716;--ctgl-color-black-transparent-5:rgba(0, 0, 0, .01);--ctgl-color-black-transparent-10:rgba(0, 0, 0, .1);--ctgl-color-black-transparent-20:rgba(0, 0, 0, .2);--ctgl-color-black-transparent-30:rgba(0, 0, 0, .3);--ctgl-color-black-transparent-40:rgba(0, 0, 0, .4);--ctgl-color-black-transparent-50:rgba(0, 0, 0, .5);--ctgl-color-black-transparent-60:rgba(0, 0, 0, .6);--ctgl-color-black-transparent-70:rgba(0, 0, 0, .7);--ctgl-color-black-transparent-80:rgba(0, 0, 0, .8);--ctgl-color-black-transparent-90:rgba(0, 0, 0, .9);--ctgl-color-white-transparent-5:rgba(255, 255, 255, .01);--ctgl-color-white-transparent-10:rgba(255, 255, 255, .1);--ctgl-color-white-transparent-20:rgba(255, 255, 255, .2);--ctgl-color-white-transparent-30:rgba(255, 255, 255, .3);--ctgl-color-white-transparent-40:rgba(255, 255, 255, .4);--ctgl-color-white-transparent-50:rgba(255, 255, 255, .5);--ctgl-color-white-transparent-60:rgba(255, 255, 255, .6);--ctgl-color-white-transparent-70:rgba(255, 255, 255, .7);--ctgl-color-white-transparent-80:rgba(255, 255, 255, .8);--ctgl-color-white-transparent-90:rgba(255, 255, 255, .9)}:root{--ctgl-breakpoint-card:10rem;--ctgl-breakpoint-card-lg:15rem;--ctgl-breakpoint-mobile:20rem;--ctgl-breakpoint-mobile-lg:30rem;--ctgl-breakpoint-tablet:40rem;--ctgl-breakpoint-tablet-lg:55rem;--ctgl-breakpoint-desktop:64rem;--ctgl-breakpoint-desktop-lg:75rem;--ctgl-breakpoint-widescreen:87.5rem}:root{font-family:Roboto,sans-serif}html{--mat-ripple-color:rgba(0, 0, 0, .1)}html{--mat-option-selected-state-label-text-color:#0071bc;--mat-option-label-text-color:rgba(0, 0, 0, .87);--mat-option-hover-state-layer-color:rgba(0, 0, 0, .04);--mat-option-focus-state-layer-color:rgba(0, 0, 0, .04);--mat-option-selected-state-layer-color:rgba(0, 0, 0, .04)}html{--mat-optgroup-label-text-color:rgba(0, 0, 0, .87)}html{--mat-full-pseudo-checkbox-selected-icon-color:#448aff;--mat-full-pseudo-checkbox-selected-checkmark-color:#fafafa;--mat-full-pseudo-checkbox-unselected-icon-color:rgba(0, 0, 0, .54);--mat-full-pseudo-checkbox-disabled-selected-checkmark-color:#fafafa;--mat-full-pseudo-checkbox-disabled-unselected-icon-color:#b0b0b0;--mat-full-pseudo-checkbox-disabled-selected-icon-color:#b0b0b0;--mat-minimal-pseudo-checkbox-selected-checkmark-color:#448aff;--mat-minimal-pseudo-checkbox-disabled-selected-checkmark-color:#b0b0b0}html{--mat-app-background-color:#fafafa;--mat-app-text-color:rgba(0, 0, 0, .87)}html{--mdc-elevated-card-container-shape:4px;--mdc-outlined-card-container-shape:4px;--mdc-outlined-card-outline-width:1px}html{--mdc-elevated-card-container-color:white;--mdc-elevated-card-container-elevation:0px 2px 1px -1px rgba(0, 0, 0, .2), 0px 1px 1px 0px rgba(0, 0, 0, .14), 0px 1px 3px 0px rgba(0, 0, 0, .12);--mdc-outlined-card-container-color:white;--mdc-outlined-card-outline-color:rgba(0, 0, 0, .12);--mdc-outlined-card-container-elevation:0px 0px 0px 0px rgba(0, 0, 0, .2), 0px 0px 0px 0px rgba(0, 0, 0, .14), 0px 0px 0px 0px rgba(0, 0, 0, .12);--mat-card-subtitle-text-color:rgba(0, 0, 0, .54)}html{--mdc-linear-progress-active-indicator-height:4px;--mdc-linear-progress-track-height:4px;--mdc-linear-progress-track-shape:0}html{--mdc-plain-tooltip-container-shape:4px;--mdc-plain-tooltip-supporting-text-line-height:16px}html{--mdc-plain-tooltip-container-color:#616161;--mdc-plain-tooltip-supporting-text-color:#fff}html{--mdc-filled-text-field-active-indicator-height:1px;--mdc-filled-text-field-focus-active-indicator-height:2px;--mdc-filled-text-field-container-shape:4px;--mdc-outlined-text-field-outline-width:1px;--mdc-outlined-text-field-focus-outline-width:2px;--mdc-outlined-text-field-container-shape:4px}html{--mdc-filled-text-field-caret-color:#0071bc;--mdc-filled-text-field-focus-active-indicator-color:#0071bc;--mdc-filled-text-field-focus-label-text-color:rgba(0, 113, 188, .87);--mdc-filled-text-field-container-color:whitesmoke;--mdc-filled-text-field-disabled-container-color:#fafafa;--mdc-filled-text-field-label-text-color:rgba(0, 0, 0, .6);--mdc-filled-text-field-hover-label-text-color:rgba(0, 0, 0, .6);--mdc-filled-text-field-disabled-label-text-color:rgba(0, 0, 0, .38);--mdc-filled-text-field-input-text-color:rgba(0, 0, 0, .87);--mdc-filled-text-field-disabled-input-text-color:rgba(0, 0, 0, .38);--mdc-filled-text-field-input-text-placeholder-color:rgba(0, 0, 0, .6);--mdc-filled-text-field-error-hover-label-text-color:#f44336;--mdc-filled-text-field-error-focus-label-text-color:#f44336;--mdc-filled-text-field-error-label-text-color:#f44336;--mdc-filled-text-field-error-caret-color:#f44336;--mdc-filled-text-field-active-indicator-color:rgba(0, 0, 0, .42);--mdc-filled-text-field-disabled-active-indicator-color:rgba(0, 0, 0, .06);--mdc-filled-text-field-hover-active-indicator-color:rgba(0, 0, 0, .87);--mdc-filled-text-field-error-active-indicator-color:#f44336;--mdc-filled-text-field-error-focus-active-indicator-color:#f44336;--mdc-filled-text-field-error-hover-active-indicator-color:#f44336;--mdc-outlined-text-field-caret-color:#0071bc;--mdc-outlined-text-field-focus-outline-color:#0071bc;--mdc-outlined-text-field-focus-label-text-color:rgba(0, 113, 188, .87);--mdc-outlined-text-field-label-text-color:rgba(0, 0, 0, .6);--mdc-outlined-text-field-hover-label-text-color:rgba(0, 0, 0, .6);--mdc-outlined-text-field-disabled-label-text-color:rgba(0, 0, 0, .38);--mdc-outlined-text-field-input-text-color:rgba(0, 0, 0, .87);--mdc-outlined-text-field-disabled-input-text-color:rgba(0, 0, 0, .38);--mdc-outlined-text-field-input-text-placeholder-color:rgba(0, 0, 0, .6);--mdc-outlined-text-field-error-caret-color:#f44336;--mdc-outlined-text-field-error-focus-label-text-color:#f44336;--mdc-outlined-text-field-error-label-text-color:#f44336;--mdc-outlined-text-field-error-hover-label-text-color:#f44336;--mdc-outlined-text-field-outline-color:rgba(0, 0, 0, .38);--mdc-outlined-text-field-disabled-outline-color:rgba(0, 0, 0, .06);--mdc-outlined-text-field-hover-outline-color:rgba(0, 0, 0, .87);--mdc-outlined-text-field-error-focus-outline-color:#f44336;--mdc-outlined-text-field-error-hover-outline-color:#f44336;--mdc-outlined-text-field-error-outline-color:#f44336;--mat-form-field-focus-select-arrow-color:rgba(0, 113, 188, .87);--mat-form-field-disabled-input-text-placeholder-color:rgba(0, 0, 0, .38);--mat-form-field-state-layer-color:rgba(0, 0, 0, .87);--mat-form-field-error-text-color:#f44336;--mat-form-field-select-option-text-color:inherit;--mat-form-field-select-disabled-option-text-color:GrayText;--mat-form-field-leading-icon-color:unset;--mat-form-field-disabled-leading-icon-color:unset;--mat-form-field-trailing-icon-color:unset;--mat-form-field-disabled-trailing-icon-color:unset;--mat-form-field-error-focus-trailing-icon-color:unset;--mat-form-field-error-hover-trailing-icon-color:unset;--mat-form-field-error-trailing-icon-color:unset;--mat-form-field-enabled-select-arrow-color:rgba(0, 0, 0, .54);--mat-form-field-disabled-select-arrow-color:rgba(0, 0, 0, .38);--mat-form-field-hover-state-layer-opacity:.04;--mat-form-field-focus-state-layer-opacity:.08}html{--mat-form-field-container-height:56px;--mat-form-field-filled-label-display:block;--mat-form-field-container-vertical-padding:16px;--mat-form-field-filled-with-label-container-padding-top:24px;--mat-form-field-filled-with-label-container-padding-bottom:8px}html{--mat-select-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12)}html{--mat-select-panel-background-color:white;--mat-select-enabled-trigger-text-color:rgba(0, 0, 0, .87);--mat-select-disabled-trigger-text-color:rgba(0, 0, 0, .38);--mat-select-placeholder-text-color:rgba(0, 0, 0, .6);--mat-select-enabled-arrow-color:rgba(0, 0, 0, .54);--mat-select-disabled-arrow-color:rgba(0, 0, 0, .38);--mat-select-focused-arrow-color:rgba(0, 113, 188, .87);--mat-select-invalid-arrow-color:rgba(244, 67, 54, .87)}html{--mat-select-arrow-transform:translateY(-8px)}html{--mat-autocomplete-container-shape:4px;--mat-autocomplete-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12)}html{--mat-autocomplete-background-color:white}html{--mdc-dialog-container-elevation-shadow:0px 11px 15px -7px rgba(0, 0, 0, .2), 0px 24px 38px 3px rgba(0, 0, 0, .14), 0px 9px 46px 8px rgba(0, 0, 0, .12);--mdc-dialog-container-shadow-color:#000;--mdc-dialog-container-shape:4px;--mat-dialog-container-max-width:80vw;--mat-dialog-container-small-max-width:80vw;--mat-dialog-container-min-width:0;--mat-dialog-actions-alignment:start;--mat-dialog-actions-padding:8px;--mat-dialog-content-padding:20px 24px;--mat-dialog-with-actions-content-padding:20px 24px;--mat-dialog-headline-padding:0 24px 9px}html{--mdc-dialog-container-color:white;--mdc-dialog-subhead-color:rgba(0, 0, 0, .87);--mdc-dialog-supporting-text-color:rgba(0, 0, 0, .6)}html{--mdc-switch-disabled-selected-icon-opacity:.38;--mdc-switch-disabled-track-opacity:.12;--mdc-switch-disabled-unselected-icon-opacity:.38;--mdc-switch-handle-height:20px;--mdc-switch-handle-shape:10px;--mdc-switch-handle-width:20px;--mdc-switch-selected-icon-size:18px;--mdc-switch-track-height:14px;--mdc-switch-track-shape:7px;--mdc-switch-track-width:36px;--mdc-switch-unselected-icon-size:18px;--mdc-switch-selected-focus-state-layer-opacity:.12;--mdc-switch-selected-hover-state-layer-opacity:.04;--mdc-switch-selected-pressed-state-layer-opacity:.1;--mdc-switch-unselected-focus-state-layer-opacity:.12;--mdc-switch-unselected-hover-state-layer-opacity:.04;--mdc-switch-unselected-pressed-state-layer-opacity:.1;--mat-switch-disabled-selected-handle-opacity:.38;--mat-switch-disabled-unselected-handle-opacity:.38;--mat-switch-unselected-handle-size:20px;--mat-switch-selected-handle-size:20px;--mat-switch-pressed-handle-size:20px;--mat-switch-with-icon-handle-size:20px;--mat-switch-selected-handle-horizontal-margin:0;--mat-switch-selected-with-icon-handle-horizontal-margin:0;--mat-switch-selected-pressed-handle-horizontal-margin:0;--mat-switch-unselected-handle-horizontal-margin:0;--mat-switch-unselected-with-icon-handle-horizontal-margin:0;--mat-switch-unselected-pressed-handle-horizontal-margin:0;--mat-switch-visible-track-opacity:1;--mat-switch-hidden-track-opacity:1;--mat-switch-visible-track-transition:transform 75ms 0ms cubic-bezier(0, 0, .2, 1);--mat-switch-hidden-track-transition:transform 75ms 0ms cubic-bezier(.4, 0, .6, 1);--mat-switch-track-outline-width:1px;--mat-switch-track-outline-color:transparent;--mat-switch-selected-track-outline-width:1px;--mat-switch-disabled-unselected-track-outline-width:1px;--mat-switch-disabled-unselected-track-outline-color:transparent}html{--mdc-switch-selected-focus-state-layer-color:#3949ab;--mdc-switch-selected-handle-color:#3949ab;--mdc-switch-selected-hover-state-layer-color:#3949ab;--mdc-switch-selected-pressed-state-layer-color:#3949ab;--mdc-switch-selected-focus-handle-color:#112e51;--mdc-switch-selected-hover-handle-color:#112e51;--mdc-switch-selected-pressed-handle-color:#112e51;--mdc-switch-selected-focus-track-color:#80b8dd;--mdc-switch-selected-hover-track-color:#80b8dd;--mdc-switch-selected-pressed-track-color:#80b8dd;--mdc-switch-selected-track-color:#80b8dd;--mdc-switch-disabled-selected-handle-color:#424242;--mdc-switch-disabled-selected-icon-color:#fff;--mdc-switch-disabled-selected-track-color:#424242;--mdc-switch-disabled-unselected-handle-color:#424242;--mdc-switch-disabled-unselected-icon-color:#fff;--mdc-switch-disabled-unselected-track-color:#424242;--mdc-switch-handle-surface-color:var(--mdc-theme-surface, #fff);--mdc-switch-handle-elevation-shadow:0px 2px 1px -1px rgba(0, 0, 0, .2), 0px 1px 1px 0px rgba(0, 0, 0, .14), 0px 1px 3px 0px rgba(0, 0, 0, .12);--mdc-switch-handle-shadow-color:black;--mdc-switch-disabled-handle-elevation-shadow:0px 0px 0px 0px rgba(0, 0, 0, .2), 0px 0px 0px 0px rgba(0, 0, 0, .14), 0px 0px 0px 0px rgba(0, 0, 0, .12);--mdc-switch-selected-icon-color:#fff;--mdc-switch-unselected-focus-handle-color:#212121;--mdc-switch-unselected-focus-state-layer-color:#424242;--mdc-switch-unselected-focus-track-color:#e0e0e0;--mdc-switch-unselected-handle-color:#616161;--mdc-switch-unselected-hover-handle-color:#212121;--mdc-switch-unselected-hover-state-layer-color:#424242;--mdc-switch-unselected-hover-track-color:#e0e0e0;--mdc-switch-unselected-icon-color:#fff;--mdc-switch-unselected-pressed-handle-color:#212121;--mdc-switch-unselected-pressed-state-layer-color:#424242;--mdc-switch-unselected-pressed-track-color:#e0e0e0;--mdc-switch-unselected-track-color:#e0e0e0;--mdc-switch-disabled-label-text-color:rgba(0, 0, 0, .38)}html{--mdc-switch-state-layer-size:40px}html{--mdc-radio-disabled-selected-icon-opacity:.38;--mdc-radio-disabled-unselected-icon-opacity:.38;--mdc-radio-state-layer-size:40px}html{--mdc-radio-state-layer-size:40px;--mat-radio-touch-target-display:block}html{--mat-slider-value-indicator-width:auto;--mat-slider-value-indicator-height:32px;--mat-slider-value-indicator-caret-display:block;--mat-slider-value-indicator-border-radius:4px;--mat-slider-value-indicator-padding:0 12px;--mat-slider-value-indicator-text-transform:none;--mat-slider-value-indicator-container-transform:translateX(-50%);--mdc-slider-active-track-height:6px;--mdc-slider-active-track-shape:9999px;--mdc-slider-handle-height:20px;--mdc-slider-handle-shape:50%;--mdc-slider-handle-width:20px;--mdc-slider-inactive-track-height:4px;--mdc-slider-inactive-track-shape:9999px;--mdc-slider-with-overlap-handle-outline-width:1px;--mdc-slider-with-tick-marks-active-container-opacity:.6;--mdc-slider-with-tick-marks-container-shape:50%;--mdc-slider-with-tick-marks-container-size:2px;--mdc-slider-with-tick-marks-inactive-container-opacity:.6}html{--mdc-slider-handle-color:#0071bc;--mdc-slider-focus-handle-color:#0071bc;--mdc-slider-hover-handle-color:#0071bc;--mdc-slider-active-track-color:#0071bc;--mdc-slider-inactive-track-color:#0071bc;--mdc-slider-with-tick-marks-inactive-container-color:#0071bc;--mdc-slider-with-tick-marks-active-container-color:white;--mdc-slider-disabled-active-track-color:#000;--mdc-slider-disabled-handle-color:#000;--mdc-slider-disabled-inactive-track-color:#000;--mdc-slider-label-container-color:#000;--mdc-slider-label-label-text-color:#fff;--mdc-slider-with-overlap-handle-outline-color:#fff;--mdc-slider-with-tick-marks-disabled-container-color:#000;--mdc-slider-handle-elevation:0px 2px 1px -1px rgba(0, 0, 0, .2), 0px 1px 1px 0px rgba(0, 0, 0, .14), 0px 1px 3px 0px rgba(0, 0, 0, .12);--mat-slider-ripple-color:#0071bc;--mat-slider-hover-state-layer-color:rgba(0, 113, 188, .05);--mat-slider-focus-state-layer-color:rgba(0, 113, 188, .2);--mat-slider-value-indicator-opacity:.6}html{--mat-menu-container-shape:4px;--mat-menu-divider-bottom-spacing:0;--mat-menu-divider-top-spacing:0;--mat-menu-item-spacing:16px;--mat-menu-item-icon-size:24px;--mat-menu-item-leading-spacing:16px;--mat-menu-item-trailing-spacing:16px;--mat-menu-item-with-icon-leading-spacing:16px;--mat-menu-item-with-icon-trailing-spacing:16px}html{--mat-menu-item-label-text-color:rgba(0, 0, 0, .87);--mat-menu-item-icon-color:rgba(0, 0, 0, .87);--mat-menu-item-hover-state-layer-color:rgba(0, 0, 0, .04);--mat-menu-item-focus-state-layer-color:rgba(0, 0, 0, .04);--mat-menu-container-color:white;--mat-menu-divider-color:rgba(0, 0, 0, .12)}html{--mdc-list-list-item-container-shape:0;--mdc-list-list-item-leading-avatar-shape:50%;--mdc-list-list-item-container-color:transparent;--mdc-list-list-item-selected-container-color:transparent;--mdc-list-list-item-leading-avatar-color:transparent;--mdc-list-list-item-leading-icon-size:24px;--mdc-list-list-item-leading-avatar-size:40px;--mdc-list-list-item-trailing-icon-size:24px;--mdc-list-list-item-disabled-state-layer-color:transparent;--mdc-list-list-item-disabled-state-layer-opacity:0;--mdc-list-list-item-disabled-label-text-opacity:.38;--mdc-list-list-item-disabled-leading-icon-opacity:.38;--mdc-list-list-item-disabled-trailing-icon-opacity:.38;--mat-list-active-indicator-color:transparent;--mat-list-active-indicator-shape:4px}html{--mdc-list-list-item-label-text-color:rgba(0, 0, 0, .87);--mdc-list-list-item-supporting-text-color:rgba(0, 0, 0, .54);--mdc-list-list-item-leading-icon-color:rgba(0, 0, 0, .38);--mdc-list-list-item-trailing-supporting-text-color:rgba(0, 0, 0, .38);--mdc-list-list-item-trailing-icon-color:rgba(0, 0, 0, .38);--mdc-list-list-item-selected-trailing-icon-color:rgba(0, 0, 0, .38);--mdc-list-list-item-disabled-label-text-color:black;--mdc-list-list-item-disabled-leading-icon-color:black;--mdc-list-list-item-disabled-trailing-icon-color:black;--mdc-list-list-item-hover-label-text-color:rgba(0, 0, 0, .87);--mdc-list-list-item-hover-leading-icon-color:rgba(0, 0, 0, .38);--mdc-list-list-item-hover-trailing-icon-color:rgba(0, 0, 0, .38);--mdc-list-list-item-focus-label-text-color:rgba(0, 0, 0, .87);--mdc-list-list-item-hover-state-layer-color:black;--mdc-list-list-item-hover-state-layer-opacity:.04;--mdc-list-list-item-focus-state-layer-color:black;--mdc-list-list-item-focus-state-layer-opacity:.12}html{--mdc-list-list-item-one-line-container-height:48px;--mdc-list-list-item-two-line-container-height:64px;--mdc-list-list-item-three-line-container-height:88px;--mat-list-list-item-leading-icon-start-space:16px;--mat-list-list-item-leading-icon-end-space:32px}html{--mat-paginator-container-text-color:rgba(0, 0, 0, .87);--mat-paginator-container-background-color:white;--mat-paginator-enabled-icon-color:rgba(0, 0, 0, .54);--mat-paginator-disabled-icon-color:rgba(0, 0, 0, .12)}html{--mat-paginator-container-size:56px;--mat-paginator-form-field-container-height:40px;--mat-paginator-form-field-container-vertical-padding:8px}html{--mdc-tab-indicator-active-indicator-height:2px;--mdc-tab-indicator-active-indicator-shape:0;--mdc-secondary-navigation-tab-container-height:48px;--mat-tab-header-divider-color:transparent;--mat-tab-header-divider-height:0}html{--mdc-checkbox-disabled-selected-checkmark-color:#fff;--mdc-checkbox-selected-focus-state-layer-opacity:.16;--mdc-checkbox-selected-hover-state-layer-opacity:.04;--mdc-checkbox-selected-pressed-state-layer-opacity:.16;--mdc-checkbox-unselected-focus-state-layer-opacity:.16;--mdc-checkbox-unselected-hover-state-layer-opacity:.04;--mdc-checkbox-unselected-pressed-state-layer-opacity:.16}html{--mdc-checkbox-disabled-selected-icon-color:rgba(0, 0, 0, .38);--mdc-checkbox-disabled-unselected-icon-color:rgba(0, 0, 0, .38);--mdc-checkbox-selected-checkmark-color:white;--mdc-checkbox-selected-focus-icon-color:#448aff;--mdc-checkbox-selected-hover-icon-color:#448aff;--mdc-checkbox-selected-icon-color:#448aff;--mdc-checkbox-selected-pressed-icon-color:#448aff;--mdc-checkbox-unselected-focus-icon-color:#212121;--mdc-checkbox-unselected-hover-icon-color:#212121;--mdc-checkbox-unselected-icon-color:rgba(0, 0, 0, .54);--mdc-checkbox-unselected-pressed-icon-color:rgba(0, 0, 0, .54);--mdc-checkbox-selected-focus-state-layer-color:#448aff;--mdc-checkbox-selected-hover-state-layer-color:#448aff;--mdc-checkbox-selected-pressed-state-layer-color:#448aff;--mdc-checkbox-unselected-focus-state-layer-color:black;--mdc-checkbox-unselected-hover-state-layer-color:black;--mdc-checkbox-unselected-pressed-state-layer-color:black;--mat-checkbox-disabled-label-color:rgba(0, 0, 0, .38)}html{--mdc-checkbox-state-layer-size:40px;--mat-checkbox-touch-target-display:block}html{--mdc-text-button-container-shape:4px;--mdc-text-button-keep-touch-target:false;--mdc-filled-button-container-shape:4px;--mdc-filled-button-keep-touch-target:false;--mdc-protected-button-container-shape:4px;--mdc-protected-button-keep-touch-target:false;--mdc-outlined-button-keep-touch-target:false;--mdc-outlined-button-outline-width:1px;--mdc-outlined-button-container-shape:4px;--mat-text-button-horizontal-padding:8px;--mat-text-button-with-icon-horizontal-padding:8px;--mat-text-button-icon-spacing:8px;--mat-text-button-icon-offset:0;--mat-filled-button-horizontal-padding:16px;--mat-filled-button-icon-spacing:8px;--mat-filled-button-icon-offset:-4px;--mat-protected-button-horizontal-padding:16px;--mat-protected-button-icon-spacing:8px;--mat-protected-button-icon-offset:-4px;--mat-outlined-button-horizontal-padding:15px;--mat-outlined-button-icon-spacing:8px;--mat-outlined-button-icon-offset:-4px}html{--mdc-text-button-label-text-color:black;--mdc-text-button-disabled-label-text-color:rgba(0, 0, 0, .38);--mat-text-button-state-layer-color:black;--mat-text-button-disabled-state-layer-color:black;--mat-text-button-ripple-color:rgba(0, 0, 0, .1);--mat-text-button-hover-state-layer-opacity:.04;--mat-text-button-focus-state-layer-opacity:.12;--mat-text-button-pressed-state-layer-opacity:.12;--mdc-filled-button-container-color:white;--mdc-filled-button-label-text-color:black;--mdc-filled-button-disabled-container-color:rgba(0, 0, 0, .12);--mdc-filled-button-disabled-label-text-color:rgba(0, 0, 0, .38);--mat-filled-button-state-layer-color:black;--mat-filled-button-disabled-state-layer-color:black;--mat-filled-button-ripple-color:rgba(0, 0, 0, .1);--mat-filled-button-hover-state-layer-opacity:.04;--mat-filled-button-focus-state-layer-opacity:.12;--mat-filled-button-pressed-state-layer-opacity:.12;--mdc-protected-button-container-color:white;--mdc-protected-button-label-text-color:black;--mdc-protected-button-disabled-container-color:rgba(0, 0, 0, .12);--mdc-protected-button-disabled-label-text-color:rgba(0, 0, 0, .38);--mdc-protected-button-container-elevation-shadow:0px 3px 1px -2px rgba(0, 0, 0, .2), 0px 2px 2px 0px rgba(0, 0, 0, .14), 0px 1px 5px 0px rgba(0, 0, 0, .12);--mdc-protected-button-disabled-container-elevation-shadow:0px 0px 0px 0px rgba(0, 0, 0, .2), 0px 0px 0px 0px rgba(0, 0, 0, .14), 0px 0px 0px 0px rgba(0, 0, 0, .12);--mdc-protected-button-focus-container-elevation-shadow:0px 2px 4px -1px rgba(0, 0, 0, .2), 0px 4px 5px 0px rgba(0, 0, 0, .14), 0px 1px 10px 0px rgba(0, 0, 0, .12);--mdc-protected-button-hover-container-elevation-shadow:0px 2px 4px -1px rgba(0, 0, 0, .2), 0px 4px 5px 0px rgba(0, 0, 0, .14), 0px 1px 10px 0px rgba(0, 0, 0, .12);--mdc-protected-button-pressed-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-protected-button-container-shadow-color:#000;--mat-protected-button-state-layer-color:black;--mat-protected-button-disabled-state-layer-color:black;--mat-protected-button-ripple-color:rgba(0, 0, 0, .1);--mat-protected-button-hover-state-layer-opacity:.04;--mat-protected-button-focus-state-layer-opacity:.12;--mat-protected-button-pressed-state-layer-opacity:.12;--mdc-outlined-button-disabled-outline-color:rgba(0, 0, 0, .12);--mdc-outlined-button-disabled-label-text-color:rgba(0, 0, 0, .38);--mdc-outlined-button-label-text-color:black;--mdc-outlined-button-outline-color:rgba(0, 0, 0, .12);--mat-outlined-button-state-layer-color:black;--mat-outlined-button-disabled-state-layer-color:black;--mat-outlined-button-ripple-color:rgba(0, 0, 0, .1);--mat-outlined-button-hover-state-layer-opacity:.04;--mat-outlined-button-focus-state-layer-opacity:.12;--mat-outlined-button-pressed-state-layer-opacity:.12}html{--mdc-text-button-container-height:36px;--mdc-filled-button-container-height:36px;--mdc-outlined-button-container-height:36px;--mdc-protected-button-container-height:36px;--mat-text-button-touch-target-display:block;--mat-filled-button-touch-target-display:block;--mat-protected-button-touch-target-display:block;--mat-outlined-button-touch-target-display:block}html{--mdc-icon-button-icon-size:24px}html{--mdc-icon-button-icon-color:inherit;--mdc-icon-button-disabled-icon-color:rgba(0, 0, 0, .38);--mat-icon-button-state-layer-color:black;--mat-icon-button-disabled-state-layer-color:black;--mat-icon-button-ripple-color:rgba(0, 0, 0, .1);--mat-icon-button-hover-state-layer-opacity:.04;--mat-icon-button-focus-state-layer-opacity:.12;--mat-icon-button-pressed-state-layer-opacity:.12}html{--mat-icon-button-touch-target-display:block}html{--mdc-fab-container-shape:50%;--mdc-fab-icon-size:24px;--mdc-fab-small-container-shape:50%;--mdc-fab-small-icon-size:24px;--mdc-extended-fab-container-height:48px;--mdc-extended-fab-container-shape:24px}html{--mdc-fab-container-color:white;--mdc-fab-container-elevation-shadow:0px 3px 5px -1px rgba(0, 0, 0, .2), 0px 6px 10px 0px rgba(0, 0, 0, .14), 0px 1px 18px 0px rgba(0, 0, 0, .12);--mdc-fab-focus-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-fab-hover-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-fab-pressed-container-elevation-shadow:0px 7px 8px -4px rgba(0, 0, 0, .2), 0px 12px 17px 2px rgba(0, 0, 0, .14), 0px 5px 22px 4px rgba(0, 0, 0, .12);--mdc-fab-container-shadow-color:#000;--mat-fab-foreground-color:black;--mat-fab-state-layer-color:black;--mat-fab-disabled-state-layer-color:black;--mat-fab-ripple-color:rgba(0, 0, 0, .1);--mat-fab-hover-state-layer-opacity:.04;--mat-fab-focus-state-layer-opacity:.12;--mat-fab-pressed-state-layer-opacity:.12;--mat-fab-disabled-state-container-color:rgba(0, 0, 0, .12);--mat-fab-disabled-state-foreground-color:rgba(0, 0, 0, .38);--mdc-fab-small-container-color:white;--mdc-fab-small-container-elevation-shadow:0px 3px 5px -1px rgba(0, 0, 0, .2), 0px 6px 10px 0px rgba(0, 0, 0, .14), 0px 1px 18px 0px rgba(0, 0, 0, .12);--mdc-fab-small-focus-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-fab-small-hover-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-fab-small-pressed-container-elevation-shadow:0px 7px 8px -4px rgba(0, 0, 0, .2), 0px 12px 17px 2px rgba(0, 0, 0, .14), 0px 5px 22px 4px rgba(0, 0, 0, .12);--mdc-fab-small-container-shadow-color:#000;--mat-fab-small-foreground-color:black;--mat-fab-small-state-layer-color:black;--mat-fab-small-disabled-state-layer-color:black;--mat-fab-small-ripple-color:rgba(0, 0, 0, .1);--mat-fab-small-hover-state-layer-opacity:.04;--mat-fab-small-focus-state-layer-opacity:.12;--mat-fab-small-pressed-state-layer-opacity:.12;--mat-fab-small-disabled-state-container-color:rgba(0, 0, 0, .12);--mat-fab-small-disabled-state-foreground-color:rgba(0, 0, 0, .38);--mdc-extended-fab-container-elevation-shadow:0px 3px 5px -1px rgba(0, 0, 0, .2), 0px 6px 10px 0px rgba(0, 0, 0, .14), 0px 1px 18px 0px rgba(0, 0, 0, .12);--mdc-extended-fab-focus-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-extended-fab-hover-container-elevation-shadow:0px 5px 5px -3px rgba(0, 0, 0, .2), 0px 8px 10px 1px rgba(0, 0, 0, .14), 0px 3px 14px 2px rgba(0, 0, 0, .12);--mdc-extended-fab-pressed-container-elevation-shadow:0px 7px 8px -4px rgba(0, 0, 0, .2), 0px 12px 17px 2px rgba(0, 0, 0, .14), 0px 5px 22px 4px rgba(0, 0, 0, .12);--mdc-extended-fab-container-shadow-color:#000}html{--mat-fab-touch-target-display:block;--mat-fab-small-touch-target-display:block}html{--mdc-snackbar-container-shape:4px}html{--mdc-snackbar-container-color:#333333;--mdc-snackbar-supporting-text-color:rgba(255, 255, 255, .87);--mat-snack-bar-button-color:#448aff}html{--mat-table-row-item-outline-width:1px}html{--mat-table-background-color:white;--mat-table-header-headline-color:rgba(0, 0, 0, .87);--mat-table-row-item-label-text-color:rgba(0, 0, 0, .87);--mat-table-row-item-outline-color:rgba(0, 0, 0, .12)}html{--mat-table-header-container-height:56px;--mat-table-footer-container-height:52px;--mat-table-row-item-container-height:52px}html{--mdc-circular-progress-active-indicator-width:4px;--mdc-circular-progress-size:48px}html{--mdc-circular-progress-active-indicator-color:#0071bc}html{--mat-badge-container-shape:50%;--mat-badge-container-size:unset;--mat-badge-small-size-container-size:unset;--mat-badge-large-size-container-size:unset;--mat-badge-legacy-container-size:22px;--mat-badge-legacy-small-size-container-size:16px;--mat-badge-legacy-large-size-container-size:28px;--mat-badge-container-offset:-11px 0;--mat-badge-small-size-container-offset:-8px 0;--mat-badge-large-size-container-offset:-14px 0;--mat-badge-container-overlap-offset:-11px;--mat-badge-small-size-container-overlap-offset:-8px;--mat-badge-large-size-container-overlap-offset:-14px;--mat-badge-container-padding:0;--mat-badge-small-size-container-padding:0;--mat-badge-large-size-container-padding:0}html{--mat-badge-background-color:#0071bc;--mat-badge-text-color:white;--mat-badge-disabled-state-background-color:#b9b9b9;--mat-badge-disabled-state-text-color:rgba(0, 0, 0, .38)}html{--mat-bottom-sheet-container-shape:4px}html{--mat-bottom-sheet-container-text-color:rgba(0, 0, 0, .87);--mat-bottom-sheet-container-background-color:white}html{--mat-legacy-button-toggle-height:36px;--mat-legacy-button-toggle-shape:2px;--mat-legacy-button-toggle-focus-state-layer-opacity:1;--mat-standard-button-toggle-shape:4px;--mat-standard-button-toggle-hover-state-layer-opacity:.04;--mat-standard-button-toggle-focus-state-layer-opacity:.12}html{--mat-legacy-button-toggle-text-color:rgba(0, 0, 0, .38);--mat-legacy-button-toggle-state-layer-color:rgba(0, 0, 0, .12);--mat-legacy-button-toggle-selected-state-text-color:rgba(0, 0, 0, .54);--mat-legacy-button-toggle-selected-state-background-color:#e0e0e0;--mat-legacy-button-toggle-disabled-state-text-color:rgba(0, 0, 0, .26);--mat-legacy-button-toggle-disabled-state-background-color:#eeeeee;--mat-legacy-button-toggle-disabled-selected-state-background-color:#bdbdbd;--mat-standard-button-toggle-text-color:rgba(0, 0, 0, .87);--mat-standard-button-toggle-background-color:white;--mat-standard-button-toggle-state-layer-color:black;--mat-standard-button-toggle-selected-state-background-color:#e0e0e0;--mat-standard-button-toggle-selected-state-text-color:rgba(0, 0, 0, .87);--mat-standard-button-toggle-disabled-state-text-color:rgba(0, 0, 0, .26);--mat-standard-button-toggle-disabled-state-background-color:white;--mat-standard-button-toggle-disabled-selected-state-text-color:rgba(0, 0, 0, .87);--mat-standard-button-toggle-disabled-selected-state-background-color:#bdbdbd;--mat-standard-button-toggle-divider-color:#e0e0e0}html{--mat-standard-button-toggle-height:48px}html{--mat-datepicker-calendar-container-shape:4px;--mat-datepicker-calendar-container-touch-shape:4px;--mat-datepicker-calendar-container-elevation-shadow:0px 2px 4px -1px rgba(0, 0, 0, .2), 0px 4px 5px 0px rgba(0, 0, 0, .14), 0px 1px 10px 0px rgba(0, 0, 0, .12);--mat-datepicker-calendar-container-touch-elevation-shadow:0px 11px 15px -7px rgba(0, 0, 0, .2), 0px 24px 38px 3px rgba(0, 0, 0, .14), 0px 9px 46px 8px rgba(0, 0, 0, .12)}html{--mat-datepicker-calendar-date-selected-state-text-color:white;--mat-datepicker-calendar-date-selected-state-background-color:#0071bc;--mat-datepicker-calendar-date-selected-disabled-state-background-color:rgba(0, 113, 188, .4);--mat-datepicker-calendar-date-today-selected-state-outline-color:white;--mat-datepicker-calendar-date-focus-state-background-color:rgba(0, 113, 188, .3);--mat-datepicker-calendar-date-hover-state-background-color:rgba(0, 113, 188, .3);--mat-datepicker-toggle-active-state-icon-color:#0071bc;--mat-datepicker-calendar-date-in-range-state-background-color:rgba(0, 113, 188, .2);--mat-datepicker-calendar-date-in-comparison-range-state-background-color:rgba(249, 171, 0, .2);--mat-datepicker-calendar-date-in-overlap-range-state-background-color:#a8dab5;--mat-datepicker-calendar-date-in-overlap-range-selected-state-background-color:#46a35e;--mat-datepicker-toggle-icon-color:rgba(0, 0, 0, .54);--mat-datepicker-calendar-body-label-text-color:rgba(0, 0, 0, .54);--mat-datepicker-calendar-period-button-text-color:black;--mat-datepicker-calendar-period-button-icon-color:rgba(0, 0, 0, .54);--mat-datepicker-calendar-navigation-button-icon-color:rgba(0, 0, 0, .54);--mat-datepicker-calendar-header-divider-color:rgba(0, 0, 0, .12);--mat-datepicker-calendar-header-text-color:rgba(0, 0, 0, .54);--mat-datepicker-calendar-date-today-outline-color:rgba(0, 0, 0, .38);--mat-datepicker-calendar-date-today-disabled-state-outline-color:rgba(0, 0, 0, .18);--mat-datepicker-calendar-date-text-color:rgba(0, 0, 0, .87);--mat-datepicker-calendar-date-outline-color:transparent;--mat-datepicker-calendar-date-disabled-state-text-color:rgba(0, 0, 0, .38);--mat-datepicker-calendar-date-preview-state-outline-color:rgba(0, 0, 0, .24);--mat-datepicker-range-input-separator-color:rgba(0, 0, 0, .87);--mat-datepicker-range-input-disabled-state-separator-color:rgba(0, 0, 0, .38);--mat-datepicker-range-input-disabled-state-text-color:rgba(0, 0, 0, .38);--mat-datepicker-calendar-container-background-color:white;--mat-datepicker-calendar-container-text-color:rgba(0, 0, 0, .87)}html{--mat-divider-width:1px}html{--mat-divider-color:rgba(0, 0, 0, .12)}html{--mat-expansion-container-shape:4px;--mat-expansion-legacy-header-indicator-display:inline-block;--mat-expansion-header-indicator-display:none}html{--mat-expansion-container-background-color:white;--mat-expansion-container-text-color:rgba(0, 0, 0, .87);--mat-expansion-actions-divider-color:rgba(0, 0, 0, .12);--mat-expansion-header-hover-state-layer-color:rgba(0, 0, 0, .04);--mat-expansion-header-focus-state-layer-color:rgba(0, 0, 0, .04);--mat-expansion-header-disabled-state-text-color:rgba(0, 0, 0, .26);--mat-expansion-header-text-color:rgba(0, 0, 0, .87);--mat-expansion-header-description-color:rgba(0, 0, 0, .54);--mat-expansion-header-indicator-color:rgba(0, 0, 0, .54)}html{--mat-expansion-header-collapsed-state-height:48px;--mat-expansion-header-expanded-state-height:64px}html{--mat-icon-color:inherit}html{--mat-sidenav-container-shape:0;--mat-sidenav-container-elevation-shadow:0px 8px 10px -5px rgba(0, 0, 0, .2), 0px 16px 24px 2px rgba(0, 0, 0, .14), 0px 6px 30px 5px rgba(0, 0, 0, .12);--mat-sidenav-container-width:auto}html{--mat-sidenav-container-divider-color:rgba(0, 0, 0, .12);--mat-sidenav-container-background-color:white;--mat-sidenav-container-text-color:rgba(0, 0, 0, .87);--mat-sidenav-content-background-color:#fafafa;--mat-sidenav-content-text-color:rgba(0, 0, 0, .87);--mat-sidenav-scrim-color:rgba(0, 0, 0, .6)}html{--mat-stepper-header-icon-foreground-color:white;--mat-stepper-header-selected-state-icon-background-color:#0071bc;--mat-stepper-header-selected-state-icon-foreground-color:white;--mat-stepper-header-done-state-icon-background-color:#0071bc;--mat-stepper-header-done-state-icon-foreground-color:white;--mat-stepper-header-edit-state-icon-background-color:#0071bc;--mat-stepper-header-edit-state-icon-foreground-color:white;--mat-stepper-container-color:white;--mat-stepper-line-color:rgba(0, 0, 0, .12);--mat-stepper-header-hover-state-layer-color:rgba(0, 0, 0, .04);--mat-stepper-header-focus-state-layer-color:rgba(0, 0, 0, .04);--mat-stepper-header-label-text-color:rgba(0, 0, 0, .54);--mat-stepper-header-optional-label-text-color:rgba(0, 0, 0, .54);--mat-stepper-header-selected-state-label-text-color:rgba(0, 0, 0, .87);--mat-stepper-header-error-state-label-text-color:#f44336;--mat-stepper-header-icon-background-color:rgba(0, 0, 0, .54);--mat-stepper-header-error-state-icon-foreground-color:#f44336;--mat-stepper-header-error-state-icon-background-color:transparent}html{--mat-stepper-header-height:72px}html{--mat-sort-arrow-color:#757575}html{--mat-toolbar-container-background-color:whitesmoke;--mat-toolbar-container-text-color:rgba(0, 0, 0, .87)}html{--mat-toolbar-standard-height:64px;--mat-toolbar-mobile-height:56px}html{--mat-tree-container-background-color:white;--mat-tree-node-text-color:rgba(0, 0, 0, .87)}html{--mat-tree-node-min-height:48px}p{line-height:1.62!important}html{box-sizing:border-box}*,*:after,*:before{box-sizing:inherit}@media print{.glossary{display:none}.hide-glossary .usa-icon{height:1.5rem;width:1.5rem;margin-top:4px}}:root{--ctg-removed-background-color:#f4a4b1;--ctg-added-background-color:#99cfa2}@charset \"UTF-8\";.glossary{background:#112e51;color:#fff;width:300px;position:fixed;top:0;bottom:0;right:0;overflow-y:auto;padding:2.4rem;transition:right .2s;z-index:10001}@media screen and (min-width: 481px){.glossary{width:364px}}.glossary ul{padding:0}.glossary input[type=search]{box-sizing:inherit;margin-bottom:4rem;min-width:220px}.glossary label{margin-top:2.6rem}.glossary a{color:#fff;text-decoration:underline}.glossary[aria-hidden=true]{right:-300px}@media screen and (min-width: 481px){.glossary[aria-hidden=true]{right:-364px}}.glossary-heading{display:inline;font-size:22px;margin-top:0}.js-glossary-toggle{border-bottom:none;color:#0071bc;font-size:1.5rem;font-weight:700;line-height:initial;width:initial}.js-glossary-toggle:hover{color:#205493}.js-glossary-toggle svg{margin-right:2px}.js-glossary-close{border:none;font-size:20px;background-color:transparent;float:right;width:initial}.js-glossary-search::-webkit-search-cancel-button{-webkit-appearance:searchfield-cancel-button!important}.usa-sr-only{position:absolute;left:-999em}.clearable-input{position:relative;display:inline-block}.clearable-input>input{padding-right:1.4em}.clearable-input>input::-ms-clear{display:none}</style><link rel=\"stylesheet\" href=\"styles.83e3bba4c1055117.css\" media=\"print\" onload=\"this.media='all'\"><noscript><link rel=\"stylesheet\" href=\"styles.83e3bba4c1055117.css\"></noscript></head>\n",
            "<body>\n",
            "<div id=\"glossary\" class=\"glossary usa-dark-background\" aria-describedby=\"glossary-result\" aria-hidden=\"true\">\n",
            "  <button title=\"Close glossary\" class=\"js-glossary-close button button--close js-glossary-toggle usa-button-unstyled hide-glossary\"><span class=\"usa-sr-only\">Hide glossary</span>\n",
            "    <svg class=\"usa-icon\" aria-hidden=\"true\" focusable=\"false\" role=\"img\">\n",
            "      <use href=\"/assets/uswds/img/sprite.svg#close\"/>\n",
            "    </svg>\n",
            "  </button>\n",
            "  <h4 class=\"glossary-heading\">Glossary</h4>\n",
            "  <p>\n",
            "  Study record managers: refer to the <a href=\"/policy#data-element-definitions\"><span style=\"text-decoration:underline\">Data Element Definitions</span></a> if submitting registration or results information.\n",
            "  </p>\n",
            "  <p>\n",
            "  <label for=\"glossary-search\" class=\"label\">Search for terms</label>\n",
            "  </p>\n",
            "  <span class=\"clearable-input\">\n",
            "  <input id=\"glossary-search\" class=\"js-glossary-search\" type=\"search\">\n",
            "  </span>\n",
            "  <div class=\"glossary__content\" id=\"glossary-result\">\n",
            "    <ul class=\"js-glossary-list\"></ul>\n",
            "  </div>\n",
            "</div>\n",
            "\n",
            "<app-root></app-root>\n",
            "\n",
            "<script type=\"text/javascript\" src=\"https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js\"></script>\n",
            "\n",
            "<script src=\"runtime.1e1da86390b74fbc.js\" type=\"module\"></script><script src=\"polyfills.779d77443fdc493d.js\" type=\"module\"></script><script src=\"scripts.a415e2a2b3a92985.js\" defer></script><script src=\"main.9fa49f8a8ab29449.js\" type=\"module\"></script></body>\n",
            "\n",
            "<!-- JavaScript -->\n",
            "\n",
            "<script src=\"https://code.jquery.com/jquery-3.5.1.min.js\" integrity=\"sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=\" crossorigin=\"anonymous\">\n",
            "</script>\n",
            "<script>\n",
            "  var fallbackJquery = \"https://www.ncbi.nlm.nih.gov/style-guide/static/base/js/jquery-3.5.0.min.js\";\n",
            "  window.jQuery || document.write(\"<script src=\" + fallbackJquery + \">\\x3C/script>\")\n",
            "</script>\n",
            "\n",
            "\n",
            "\n",
            "<!--<script  type=\"text/javascript\" src=\"assets/core/alerts/alerts.js\"> </script>-->\n",
            "\n",
            "<!--<script  type=\"text/javascript\" src=\"https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js\"> </script>-->\n",
            "\n",
            "\n",
            "<!-- - - - - -\n",
            "\n",
            "- - - - - -->\n",
            "\n",
            "<script type=\"text/javascript\">\n",
            "  var alertsUrl = \"/core/alerts/alerts.js\";\n",
            "  if (typeof ncbiBaseUrl !== 'undefined') {\n",
            "    alertsUrl = ncbiBaseUrl + alertsUrl;\n",
            "  } else {\n",
            "    alertsUrl = \"https://www.ncbi.nlm.nih.gov\" + alertsUrl;\n",
            "  }\n",
            "</script>\n",
            "\n",
            "<!--\n",
            "<script src=\"https://www.ncbi.nlm.nih.gov/coreutils/ncbi-banner/ncbi-banner-experiment.js\"></script>\n",
            "-->\n",
            "\n",
            "</html>\n",
            "\n"
          ]
        }
      ],
      "source": [
        "import requests\n",
        "\n",
        "base_url = 'https://clinicaltrials.gov/data-api/api/v2'\n",
        "\n",
        "# Define the search parameters\n",
        "params = {\n",
        "    'query': 'cancer',\n",
        "    # 'fields': 'NCTId,BriefTitle,Condition,StudyType',\n",
        "    'pageSize': 1,  # Number of results per page\n",
        "    # 'pageToken': ''   # Token for pagination\n",
        "}\n",
        "\n",
        "# Make the API request\n",
        "response = requests.get(base_url, params=params)\n",
        "print(response.text)\n",
        "\n",
        "# # Check if the request was successful\n",
        "# if response.status_code == 200:\n",
        "#     data = response.json()\n",
        "#     studies = data.get('studies', [])\n",
        "#     for study in studies:\n",
        "#         print(f\"NCT ID: {study.get('NCTId')}\")\n",
        "#         print(f\"Title: {study.get('BriefTitle')}\")\n",
        "#         print(f\"Condition: {study.get('Condition')}\")\n",
        "#         print(f\"Study Type: {study.get('StudyType')}\")\n",
        "#         print('-' * 40)\n",
        "# else:\n",
        "#     print(f\"Error: {response.status_code}\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "uwrxWxQayiI_",
        "outputId": "84f0db1b-fa6a-4e2f-8b5e-9ecb06a0b654"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.titles=Diabetes&pageSize=100\n",
            "{'studies': [{'protocolSection': {'identificationModule': {'nctId': 'NCT06529965', 'orgStudyIdInfo': {'id': 'covivio RCT 2024'}, 'organization': {'fullName': 'Gaia AG', 'class': 'INDUSTRY'}, 'briefTitle': 'Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DM', 'officialTitle': 'Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With Type 2 Diabetes Mellitus: Randomized Controlled Trial', 'acronym': 'EASE-T2DM'}, 'statusModule': {'statusVerifiedDate': '2024-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-10-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-04-09', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-04-09', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-07-26', 'studyFirstSubmitQcDate': '2024-07-26', 'studyFirstPostDateStruct': {'date': '2024-07-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-11-06', 'lastUpdatePostDateStruct': {'date': '2024-11-08', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Gaia AG', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'University Hospital Schleswig-Holstein', 'class': 'OTHER'}, {'name': 'Philipps University Marburg', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"This randomized controlled trial (RCT) with 250 patients suffering from type 2 diabetes mellitus (T2DM) aims to investigate the effectiveness of the self-guided digital therapeutic covivio. Inclusion criteria are: male, female or non-binary; age ≥ 18 years; confirmed diagnosis of T2DM; elevated levels of diabetes-specific emotional distress (Problem Areas in Diabetes \\\\[PAID\\\\]-20 score ≥ 33); consent to participate; sufficient German language skills. Exclusion criteria are: a diagnosis of type 1 diabetes mellitus (T1DM); current use of continuous glucose monitoring (CGM) as part of one's diabetes treatment; changes or planned changes in medication within 4 weeks before the baseline visit or in the subsequent 6 months; a bariatric operation within 4 weeks before the baseline visit or such an operation planned in the subsequent 6 months; changes or planned changes in psychotherapeutic treatment within 4 weeks before the baseline visit or in the subsequent 6 months. In addition, participants will be excluded from the study if they did not wear the CGM sensor for at least 6 of 7 days at baseline (before randomization), providing a minimum of 96 hours of glucose values including at least 24 hours overnight.\\n\\nPatients will be randomized and allocated in a 1:1 ratio to either an intervention group, in which they will receive access to covivio in addition to treatment as usual (TAU, n = 125), or to a control group, in which they will receive only TAU (n = 125).\\n\\nCo-primary endpoints of this trial will be the between-groups difference in the PAID-20 total score in the intervention and control group at six months, adjusted for the PAID-20 baseline score as well as the glucose management indicator (estimated HbA1c) assessed using continuous glucose monitoring devices (for a period of 7 days) at six months, adjusted for the baseline score.\\n\\nSecondary endpoints will be diabetes self-management skills, body mass index (BMI), and quality of life.\"}, 'conditionsModule': {'conditions': ['Glucose Metabolism Disorders (Including Diabetes Mellitus)', 'Metabolic Disease', 'Endocrine System Diseases', 'Diabetes Mellitus, Type 2'], 'keywords': ['type 2 diabetes', 'covivio', 'diabetes self-management', 'digital health application']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'randomized controlled trial with two arms: (i) online intervention in addition to treatment-as-usual versus (ii) treatment-as-usual', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 250, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Intervention/Treatment', 'type': 'EXPERIMENTAL', 'description': 'Experimental: covivio + TAU\\n\\nParticipants allocated to the intervention group will receive access to covivio in addition to treatment as usual (TAU).\\n\\ncovivio is a digital health application designed for individuals with type 2 diabetes mellitus who suffer from elevated levels of diabetes-specific emotional distress, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by covivio are disease literacy, physical activity and exercise, nutrition, stress management, sleep management, mood problems, and social resources.\\n\\nThe program operates through interactive \"dialogues\", which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days.', 'interventionNames': ['Behavioral: covivio']}, {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'No Intervention: TAU\\n\\nParticipants allocated to the control group will receive access to treatment as usual (TAU).'}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'covivio', 'description': 'Participants will receive access to the digital health intervention covivio in addition to TAU.', 'armGroupLabels': ['Intervention/Treatment']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Diabetes-specific emotional distress', 'description': 'Assessed with the Problem Areas in Diabetes Questionnaire (PAID-20). Total score ranging from 0-100; higher scores indicate higher diabetes-specific emotional distress (worse outcome).', 'timeFrame': '6 months'}, {'measure': 'Glucose management indicator', 'description': 'The glucose management indicator (GMI) is an estimation of HbA1c from CGM. It is calculated as follows: GMI (%) = 3.31 + 0.02392 x \\\\[mean glucose in mg/dL\\\\].', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Diabetes-specific emotional distress', 'description': 'Assessed with the Problem Areas in Diabetes Questionnaire (PAID-20). Total score ranging from 0-100; higher scores indicate higher diabetes-specific emotional distress (worse outcome).', 'timeFrame': '3 months'}, {'measure': 'Diet self-management skills', 'description': 'Assessed with the Diet Subscale of the Summary of Diabetes Self-Care Activities Measure (SDSCA). The diet subscale contains four items and the score may range from 0-28; higher scores indicate higher diet self-management skills (better outcome).', 'timeFrame': '3 months; 6 months'}, {'measure': 'Exercise self-management skills', 'description': 'Assessed with the Exercise Subscale of the Summary of Diabetes Self-Care Activities (SDSCA). The exercise subscale contains two items and the score may range from 0-14; higher scores indicate higher exercise self-management skills (better outcome).', 'timeFrame': '3 months; 6 months'}, {'measure': 'Health-related quality of life', 'description': 'Quantified with the Assessment of Quality of Life - 8 Dimensions (AQoL-8D). Total score ranging from 0-100; higher scores indicate a higher quality of life (better outcome).', 'timeFrame': '3 months; 6 months'}, {'measure': 'Body mass index (BMI)', 'description': \"The BMI will be computed according to the following formula: kg/m2, where kg is a person's weight in kilograms and m2 is their height in meters squared. If necessary, height will be converted into meters and weight will be converted into kilograms.\", 'timeFrame': '3 months; 6 months'}], 'otherOutcomes': [{'measure': 'Time in range (TIR) derived from CGM', 'description': 'Defined as time spent in the target range between 70 and 180 mg/dL. TIR will be assessed in hours and minutes for a 7-day period, and also expressed as percent.', 'timeFrame': '6 months'}, {'measure': 'Mean sensor glucose derived from CGM', 'description': 'Mean sensor glucose will be calculated over the 7 days of glucose measurements.', 'timeFrame': '6 months'}, {'measure': 'Coefficient of variation derived from CGM', 'description': 'The coefficient of variation will be used to quantify glycemic variability.', 'timeFrame': '6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* male, female or non-binary\\n* age ≥ 18 years\\n* diagnosis of T2DM secured via submission of a medical certificate attesting to the presence of at least one of the following ICD-10-GM diagnoses of T2DM: E11.20, E11.30, E11.40, E11.50, E11.60, E11.72, E11.74, E11.80, E11.90\\n* elevated levels of diabetes-specific emotional distress: cut-off ≥ 33 on the PAID-20\\n* access to CGM-compatible smartphone\\n* consent to participate\\n* sufficient knowledge of the German language\\n\\nExclusion Criteria:\\n\\n* diagnosis of type 1 diabetes mellitus (T1DM)\\n* change in medication (type, frequency of use or dosage) within 4 weeks before the baseline visit or planned within the subsequent 6 months\\n* recent or planned bariatric operation within 4 weeks before the baseline visit or within the subsequent 6 months\\n* change in psychotherapeutic treatment within 4 weeks before the baseline visit or planned within the subsequent 6 months\\n* current use of continuous glucose monitoring (CGM) as part of one's diabetes treatment\\n* experiencing problems with the CGM sensor or insufficient CGM data quality at baseline (T0) (i.e., wearing the CGM sensor on less than 6 of 7 days, providing less than a minimum of 96 hours of glucose values, providing less than 24 hours overnight CGM data)\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Gitta A Jacob, PhD', 'role': 'CONTACT', 'phone': '+49 40 349930-374', 'email': 'gitta.jacob@gaia-group.com'}, {'name': 'Katharina M Rischer, PhD', 'role': 'CONTACT', 'email': 'katharina.rischer@gaia-group.com'}], 'overallOfficials': [{'name': 'Kamila Jauch-Chara, Dr. med.', 'affiliation': 'Zentrum für Integrative Psychiatrie, Universitätsklinikum Schleswig-Holstein', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'GAIA AG', 'status': 'RECRUITING', 'city': 'Hamburg', 'zip': '22085', 'country': 'Germany', 'contacts': [{'name': 'Gitta A Jacob, PhD', 'role': 'CONTACT'}, {'name': 'Katharina M Rischer, PhD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 53.57532, 'lon': 10.01534}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'asFound': 'Metabolic Diseases', 'relevance': 'HIGH'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'asFound': 'Glucose Metabolism Disorders', 'relevance': 'HIGH'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'asFound': 'Endocrine System Diseases', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06097065', 'orgStudyIdInfo': {'id': 'Zhujiangzx'}, 'organization': {'fullName': 'Zhujiang Hospital', 'class': 'OTHER'}, 'briefTitle': 'Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.', 'officialTitle': 'Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.'}, 'statusModule': {'statusVerifiedDate': '2023-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-05-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-10-09', 'studyFirstSubmitQcDate': '2023-10-18', 'studyFirstPostDateStruct': {'date': '2023-10-24', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-10-18', 'lastUpdatePostDateStruct': {'date': '2023-10-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Zhujiang Hospital', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Through the MALDI-TOF MS platform, explore the proteomics and peptidomics differences of fasting serum/plasma and urine between non pregnant people with normal glucose tolerance test and prediabetes /diabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively; To explore the role of its proteomics and peptidomics differences in the diagnosis of prediabetes and diabetes, and to establish a new method of differential diagnosis by using the omics data and key characteristic peaks to find potential new diagnostic markers.', 'detailedDescription': 'Prediabetes is a stage of abnormal glucose metabolism between normal blood glucose level and diabetes, which is a \"gray zone\" between normal and abnormal, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both. It is a very important high-risk group of diabetes. Diabetes is a group of metabolic diseases characterized by hyperglycemia caused by a variety of causes. Gestational diabetes mellitus refers to varying degrees of abnormal glucose metabolism that occur during pregnancy. This project aims to detect differential feature peaks through MALDI-TOF MS technology between non pregnant people with normal glucose tolerance test and prediabetes/diabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively and to establish a clinical predictive diagnostic model based on differences, and to evaluate the model.'}, 'conditionsModule': {'conditions': ['Prediabetes', 'Diabetes Mellitus', 'Gestational Diabetes Mellitus', 'Proteomics']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'OTHER'}, 'enrollmentInfo': {'count': 2860, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Non pregnant people with prediabetes or diabetes', 'description': 'Non pregnancy meeting the diagnosis of prediabetes or diabetes.', 'interventionNames': ['Diagnostic Test: Oral Glucose Tolerance Test']}, {'label': 'Non pregnant people with normal glucose tolerance', 'description': 'Non pregnant population with normal Oral Glucose Tolerance Test results.', 'interventionNames': ['Diagnostic Test: Oral Glucose Tolerance Test']}, {'label': 'pregnant people with gestational diabetes mellitus', 'description': 'Pregnant people who meet the diagnosis of gestational diabetes.', 'interventionNames': ['Diagnostic Test: Oral Glucose Tolerance Test']}, {'label': 'pregnant people with normal glucose tolerance', 'description': 'Pregnant people with normal Oral Glucose Tolerance Test results.', 'interventionNames': ['Diagnostic Test: Oral Glucose Tolerance Test']}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'Oral Glucose Tolerance Test', 'description': 'Grouping based on detected oral glucose tolerance test results without any other intervention.', 'armGroupLabels': ['Non pregnant people with normal glucose tolerance', 'Non pregnant people with prediabetes or diabetes', 'pregnant people with gestational diabetes mellitus', 'pregnant people with normal glucose tolerance']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number and types of proteins/peptides differential characteristic peaks', 'description': 'Obtain the number and types of proteins/peptides differential characteristic peaks between the case group and the control group through data analysis.', 'timeFrame': 'one year'}], 'secondaryOutcomes': [{'measure': 'ROC curve and area under curve AUC of clinical predictive diagnostic model', 'description': 'Construct a clinical predictive diagnostic model based on the obtained proteins/peptides differential feature peaks and calculate the area under the ROC curve AUC to evaluate the predictive effect of the model.', 'timeFrame': 'one year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Inclusion criteria for cases:\\n\\n   Non pregnant people: the remaining fasting serum/plasma and urine samples of prediabetes/diabetes patients (prediabetes: IFG: FPG 6.1-6.9mmol/L, Blood glucose 2h after meal\\\\<7.8mmol/L（WHO）; IGT: FPG\\\\<7.0mmol/L, Blood glucose 2h after meal 7.8-11.1mmol/L（WHO）; diabetes: Typical symptoms of diabetes, FPG \\\\>= 7.0mmol/L or 75g OGTT 2h blood glucose \\\\>= 11.1mmol/L).\\n\\n   Pregnant people: the remaining fasting serum/plasma and urine samples of gestational diabetes patients (75g OGTT test FPG \\\\>= 5.1mmol/L or 1h blood glucose \\\\>= 10.0mmol/L or 2h blood glucose \\\\>= 8.5mmol/L（IADPSG; ADA)).\\n2. Inclusion criteria of the controls were as follows:\\n\\nNon pregnant people: the remaining fasting serum/plasma and urine samples of normal population for glucose tolerance test (FPG 3.9-6.1mmol/L,75g OGTT test 1h blood glucose 6.7-11.1mmol/L,75g OGTT test 2h blood glucose 3.6-7.8mmol/L).\\n\\nPregnant people: the remaining fasting serum/plasma and urine samples of people who do not meet the diagnostic criteria for gestational diabetes (3.9\\\\<=75g OGTT test FPG\\\\<5.1mmol/L,6.7 \\\\<= 1h blood glucose\\\\<10.0mmol/L,3.6\\\\<=2h blood glucose\\\\<8.5mmol/L).\\n\\n-\\n\\nExclusion Criteria:\\n\\nCommon exclusion criteria for cases and control were as follows: The sample volume of serum/plasma/urine is less than 300ul; Improper storage of samples or repeated freezing and thawing; The serum /plasma has obvious hemolysis, lipemia or jaundice.\\n\\n-', 'healthyVolunteers': True, 'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'studyPopulation': '(1) cases: Non pregnant people: the remaining fasting serum/plasma and urine samples of prediabetes/diabetes patients; Pregnant people: the remaining fasting serum/plasma and urine samples of gestational diabetes patients. (2) controls: (Non)pregnant people: the remaining fasting serum/plasma and urine samples of normal population.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Nianyi Zeng', 'role': 'CONTACT', 'phone': '13928801657', 'phoneExt': '+86', 'email': 'zengny1@i.smu.edu.cn'}, {'name': 'Hongwei Zhou, Professor', 'role': 'CONTACT', 'phone': '18688489622', 'phoneExt': '+86', 'email': 'hzhou@smu.edu.cn'}], 'overallOfficials': [{'name': 'Hongwei Zhou, Professor', 'affiliation': 'Zhujiang Hospital', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Zhujiang Hospital of Southern Medical University', 'status': 'RECRUITING', 'city': 'Guangzhou', 'state': 'Guangdong', 'zip': '510000', 'country': 'China', 'contacts': [{'name': 'Nianyi Zeng', 'role': 'CONTACT', 'phone': '13928801657', 'phoneExt': '+86', 'email': 'zengny1@i.smu.edu.cn'}], 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016640', 'term': 'Diabetes, Gestational'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D011236', 'term': 'Prediabetic State'}, {'id': 'D018149', 'term': 'Glucose Intolerance'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D011248', 'term': 'Pregnancy Complications'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D006943', 'term': 'Hyperglycemia'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M19012', 'name': 'Diabetes, Gestational', 'asFound': 'Gestational Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M14117', 'name': 'Prediabetic State', 'asFound': 'Prediabetes', 'relevance': 'HIGH'}, {'id': 'M20295', 'name': 'Glucose Intolerance', 'asFound': 'Prediabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M9994', 'name': 'Hyperglycemia', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02373865', 'orgStudyIdInfo': {'id': 'DIA-2-REDESIGN'}, 'organization': {'fullName': 'GWT-TUD GmbH', 'class': 'OTHER'}, 'briefTitle': 'Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes', 'officialTitle': 'Randomized Double Blind Parallel Design Study Comparing Risk of Nocturnal Hypoglycemia and Critical Arrhythmia With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy'}, 'statusModule': {'statusVerifiedDate': '2018-10', 'overallStatus': 'TERMINATED', 'whyStopped': 'Premature termination due to insufficient patient recruitement..', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2015-09'}, 'primaryCompletionDateStruct': {'date': '2017-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2017-01', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2015-01-08', 'studyFirstSubmitQcDate': '2015-02-22', 'studyFirstPostDateStruct': {'date': '2015-02-27', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2017-09-27', 'resultsFirstSubmitQcDate': '2018-10-19', 'resultsFirstPostDateStruct': {'date': '2019-02-27', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-10-19', 'lastUpdatePostDateStruct': {'date': '2019-02-27', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'GWT-TUD GmbH', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'This exploratory double blind randomized active controlled study is designed to assess the effects of a treatment with therapeutical dosage of sitagliptin versus therapeutical dosage of glimepiride as add on therapy in patients with diabetes mellitus type 2 (T2DM) patients inadequately controlled on metformin monotherapy.', 'detailedDescription': 'Type 2 Diabetes is associated with an increased cardiovascular morbidity and mortality. Among patients insufficiently controlled with metformin multimorbidity and polypharmacy is common that makes the patients frail for cardiovascular complications related to hypoglycemic events.\\n\\nThis exploratory double blind randomized active controlled study is designed to assess the effects of a treatment with therapeutical dosage of sitagliptin versus therapeutical dosage of glimepiride as add on therapy in patients with T2DM patients inadequately controlled on metformin monotherapy.\\n\\nExaminations will be performed as a 5 day recording of subcutaneous glucose concentration (CGMS) and holder ECG (AMEDTEC) at baseline and after a 12 weeks treatment with sitagliptin or glimepiride as active comparators used in combination with metformin.\\n\\nWith recording of nocturnal hypoglycemia and arrhythmias it is aimed to evaluate favorable glycemic profile under treatment with sitagliptin compared to glimepiride. The primary objective is risk of serious HE for both drugs.\\n\\nThe glycemic profile of sitagliptin as add-on therapy to metformin seems to be favorable compared to sulfonylureass such as glimepiride. Treatment with sitagliptin as add-on to metformin therapy causes less glycemic fluctuations and may be associated with lower oxidative stress and down regulation of low grade inflammation. This hypothesis will be tested as an explorative double blind study.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus Type 2'], 'keywords': ['Diabetes mellitus type 2', 'nocturnal hypoglycemia', 'metformin monotherapy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 4, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Arm A', 'type': 'EXPERIMENTAL', 'description': 'Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)', 'interventionNames': ['Drug: Sitagliptin', 'Drug: Glimepiride-Placebo']}, {'label': 'Arm B', 'type': 'ACTIVE_COMPARATOR', 'description': 'Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo', 'interventionNames': ['Drug: Glimepiride', 'Drug: Sitagliptin-Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Sitagliptin', 'description': 'Sitagliptin will be given in a daily dosage of 100 mg', 'armGroupLabels': ['Arm A']}, {'type': 'DRUG', 'name': 'Glimepiride', 'description': 'Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg', 'armGroupLabels': ['Arm B']}, {'type': 'DRUG', 'name': 'Sitagliptin-Placebo', 'description': 'Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg', 'armGroupLabels': ['Arm B']}, {'type': 'DRUG', 'name': 'Glimepiride-Placebo', 'description': 'Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg', 'armGroupLabels': ['Arm A']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Hypoglycemic Episodes (HE) Under Treatment With Sitagliptin Compared to Glimepiride', 'description': 'measurement of hypoglycemic episodes including event duration at baseline and EOT after 12 weeks of treatment and measurement of time spent below critical values for hypoglycemic episodes are the primary objectives of this study. We will calculate overall episodes/time (5 days) and nocturnal episodes.', 'timeFrame': '12 weeks (at baseline and at EOT)'}], 'secondaryOutcomes': [{'measure': 'Occurence and Number of Nocturnal Ventricular Arrhythmias', 'description': 'measurement of nocturnal ventricular arrhythmias at baseline and EOT (after 12 weeks of treatment) - per patient, couplets per patient, triplets per patient)', 'timeFrame': '12 weeks (at baseline and at EOT)'}, {'measure': 'Glycemic Variability (Profile) of Sitagliptin Compared to Glimepiride', 'description': 'The glycemic profile is defined as the area under the glucose-timeprofile obtained by continuous glucose monitoring (5 days baseline and 5 days after 12 weeks of each treatment)', 'timeFrame': '12 weeks (at baseline and at EOT)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* type 2 diabetes\\n* age 40-80 years\\n* stable dose of ≥ 1500 mg metformin or maximal tolerated dose of metformin for \\\\> 6 weeks\\n* HbA1c ≥ 7 % - ≤ 9.0% for age \\\\< 65 years and ≥ 7.5 % - ≤ 9.0% for age ≥ 65 years\\n* able and trained to perform SMBG\\n* the informed consent form must be signed before any study specific tests or procedures are done\\n* ability to understand and follow study-related instructions\\n\\nExclusion Criteria:\\n\\n* Type 1 diabetes\\n* previous treatment with insulin, GLP1 analogues and SU in \\\\< 6 month\\n* HbA1c \\\\> 9 % or FPG \\\\> 15 mmol/l at randomization\\n* renal impairment with eGFR \\\\< 60 ml/min\\n* medical history of severe hypoglycemia defined as necessity of medical assistance in \\\\< 1 year\\n* major cardiovascular event (MACE) in medical history \\\\< 6 months\\n* preexisting atrial fibrillation, , AV block ≥II degree, pace-maker, implanted defibrillator\\n* major cardiovascular event in medical history \\\\< 6 months\\n* heart failure NYHA ≥ III\\n* contraindications to glimepiride and sitagliptin or to any excipients according to product information\\n* severe cognitive deficits\\n* Patients who are disable to read and understand informative aspects of the trial\\n* Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s)\\n* Inability to comply with study procedures\\n* Pregnant or breast-feeding woman and woman without adequate method of contraception', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '40 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Markolf Hanefeld, Prof. Dr.', 'affiliation': 'GWT-TUD GmbH', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'GWT-TUD GmbH / Studienzentrum Hanefeld', 'city': 'Dresden', 'zip': '01307', 'country': 'Germany', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'no pre-assignment details are available for this study', 'recruitmentDetails': 'In the time period between the start of the clinical trial (march 2015 (approval of German competent authority) and the premature termination (Jan 2017) only 4 patients of originally planned 68 patients could be recruited. Recruitment period started at 09.11.2015 when first patient was enrolled into study.', 'groups': [{'id': 'FG000', 'title': 'Arm A', 'description': 'Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)\\n\\nSitagliptin: Sitagliptin will be given in a daily dosage of 100 mg\\n\\nGlimepiride-Placebo: Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg'}, {'id': 'FG001', 'title': 'Arm B', 'description': 'Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo\\n\\nGlimepiride: Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg\\n\\nSitagliptin-Placebo: Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Arm A: Sitagliptin 100 mg+ Glimepiride-placebo (Adapted Dose)', 'description': 'Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)\\n\\nSitagliptin: Sitagliptin will be given in a daily dosage of 100 mg\\n\\nGlimepiride-Placebo: Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg'}, {'id': 'BG001', 'title': 'Arm B: Glimepiride (Adapted Dose) + Sitagliptin 100 mg Placebo', 'description': 'Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo\\n\\nGlimepiride: Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg\\n\\nSitagliptin-Placebo: Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '4'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '59', 'spread': '2.82'}, {'groupId': 'BG001', 'value': '69', 'spread': '9.89'}, {'groupId': 'BG002', 'value': '64', 'spread': '6.35'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '4'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'Germany', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '4'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Hypoglycemic Episodes (HE) Under Treatment With Sitagliptin Compared to Glimepiride', 'description': 'measurement of hypoglycemic episodes including event duration at baseline and EOT after 12 weeks of treatment and measurement of time spent below critical values for hypoglycemic episodes are the primary objectives of this study. We will calculate overall episodes/time (5 days) and nocturnal episodes.', 'populationDescription': 'Due to an impeded recruitment of patients the study was terminated. Between start (March 2015) and premature termination (Jan 2017) only 4 patients could be recruited. The reason for \"0\" Participants Analyzed provided in the Analysis Population Description is intended to report that data were not reported due to the termination of the study.', 'reportingStatus': 'POSTED', 'timeFrame': '12 weeks (at baseline and at EOT)', 'groups': [{'id': 'OG000', 'title': 'Arm A', 'description': 'Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)\\n\\nSitagliptin: Sitagliptin will be given in a daily dosage of 100 mg\\n\\nGlimepiride-Placebo: Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg'}, {'id': 'OG001', 'title': 'Arm B', 'description': 'Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo\\n\\nGlimepiride: Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg\\n\\nSitagliptin-Placebo: Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}]}]}, {'type': 'SECONDARY', 'title': 'Occurence and Number of Nocturnal Ventricular Arrhythmias', 'description': 'measurement of nocturnal ventricular arrhythmias at baseline and EOT (after 12 weeks of treatment) - per patient, couplets per patient, triplets per patient)', 'populationDescription': 'Due to an impeded recruitment of patients the study was terminated. Between start (March 2015) and premature termination (Jan 2017) only 4 patients could be recruited. The reason for \"0\" Participants Analyzed provided in the Analysis Population Description is intended to report that data were not reported due to the termination of the study.', 'reportingStatus': 'POSTED', 'timeFrame': '12 weeks (at baseline and at EOT)', 'groups': [{'id': 'OG000', 'title': 'Arm A', 'description': 'Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)\\n\\nSitagliptin: Sitagliptin will be given in a daily dosage of 100 mg\\n\\nGlimepiride-Placebo: Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg'}, {'id': 'OG001', 'title': 'Arm B', 'description': 'Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo\\n\\nGlimepiride: Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg\\n\\nSitagliptin-Placebo: Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}]}]}, {'type': 'SECONDARY', 'title': 'Glycemic Variability (Profile) of Sitagliptin Compared to Glimepiride', 'description': 'The glycemic profile is defined as the area under the glucose-timeprofile obtained by continuous glucose monitoring (5 days baseline and 5 days after 12 weeks of each treatment)', 'populationDescription': 'Due to an impeded recruitment of patients the study was terminated. Between start (March 2015) and premature termination (Jan 2017) only 4 patients could be recruited. The reason for \"0\" Participants Analyzed provided in the Analysis Population Description is intended to report that data were not reported due to the termination of the study.', 'reportingStatus': 'POSTED', 'timeFrame': '12 weeks (at baseline and at EOT)', 'groups': [{'id': 'OG000', 'title': 'Arm A', 'description': 'Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)\\n\\nSitagliptin: Sitagliptin will be given in a daily dosage of 100 mg\\n\\nGlimepiride-Placebo: Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg'}, {'id': 'OG001', 'title': 'Arm B', 'description': 'Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo\\n\\nGlimepiride: Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg\\n\\nSitagliptin-Placebo: Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '0', 'eventGroups': [{'id': 'EG000', 'title': 'Arm A: Sitagliptin 100 mg+ Glimepiride-placebo (Adapted Dose)', 'description': 'Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)\\n\\nSitagliptin: Sitagliptin will be given in a daily dosage of 100 mg\\n\\nGlimepiride-Placebo: Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg', 'deathsNumAffected': 0, 'deathsNumAtRisk': 2, 'seriousNumAffected': 0, 'seriousNumAtRisk': 2, 'otherNumAffected': 0, 'otherNumAtRisk': 2}, {'id': 'EG001', 'title': 'Arm B: Glimepiride (Adapted Dose) + Sitagliptin 100 mg Placebo', 'description': 'Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo\\n\\nGlimepiride: Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg\\n\\nSitagliptin-Placebo: Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg', 'deathsNumAffected': 0, 'deathsNumAtRisk': 2, 'seriousNumAffected': 0, 'seriousNumAtRisk': 2, 'otherNumAffected': 0, 'otherNumAtRisk': 2}]}, 'moreInfoModule': {'limitationsAndCaveats': {'description': 'Limitations of the study: deceleration of patient recruitment, break up of patient recruitment, descriptive reporting of patient characteristics of 4 enrolled patients (no statistically reliable results are available)'}, 'certainAgreement': {'piSponsorEmployee': True}, 'pointOfContact': {'title': 'Prof. Dr. Markolf Hanefeld', 'organization': 'GWT-TUD GmbH, Study center Prof. Hanefeld', 'email': 'Markolf.Hanefeld@gwtonline.de', 'phone': '+49 351 44005', 'phoneExt': '82'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D007003', 'term': 'Hypoglycemia'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus Type 2', 'relevance': 'HIGH'}, {'id': 'M4453', 'name': 'Arrhythmias, Cardiac', 'relevance': 'LOW'}, {'id': 'M10053', 'name': 'Hypoglycemia', 'asFound': 'Hypoglycemia', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068900', 'term': 'Sitagliptin Phosphate'}, {'id': 'C057619', 'term': 'Glimepiride'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D054795', 'term': 'Incretins'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D054873', 'term': 'Dipeptidyl-Peptidase IV Inhibitors'}, {'id': 'D011480', 'term': 'Protease Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000889', 'term': 'Anti-Arrhythmia Agents'}, {'id': 'D007166', 'term': 'Immunosuppressive Agents'}, {'id': 'D007155', 'term': 'Immunologic Factors'}], 'browseLeaves': [{'id': 'M11667', 'name': 'Metformin', 'relevance': 'LOW'}, {'id': 'M335', 'name': 'Sitagliptin Phosphate', 'asFound': '0.1', 'relevance': 'HIGH'}, {'id': 'M252104', 'name': 'Glimepiride', 'asFound': 'Kinase', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M27905', 'name': 'Incretins', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}, {'id': 'M27957', 'name': 'Dipeptidyl-Peptidase IV Inhibitors', 'relevance': 'LOW'}, {'id': 'M19609', 'name': 'HIV Protease Inhibitors', 'relevance': 'LOW'}, {'id': 'M14343', 'name': 'Protease Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M4213', 'name': 'Anti-Arrhythmia Agents', 'relevance': 'LOW'}, {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'}, {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AnArAg', 'name': 'Anti-Arrhythmia Agents'}, {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03709966', 'orgStudyIdInfo': {'id': '2017-2018-07'}, 'organization': {'fullName': 'Laval University', 'class': 'OTHER'}, 'briefTitle': 'Portable Monitoring Device, Physical Activity Motivation and Patients With Type 2 Diabetes', 'officialTitle': 'Using a Portable Monitoring Device to Increase Motivation for Physical Activity in Patients With Type 2 Diabetes', 'acronym': 'DBFitbit'}, 'statusModule': {'statusVerifiedDate': '2020-10', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2017-12-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-03-31', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2019-03-31', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-10-15', 'studyFirstSubmitQcDate': '2018-10-15', 'studyFirstPostDateStruct': {'date': '2018-10-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-10-14', 'lastUpdatePostDateStruct': {'date': '2020-10-19', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Caroline', 'investigatorTitle': 'Principal investigator', 'investigatorAffiliation': 'Laval University'}, 'leadSponsor': {'name': 'Laval University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The intervention proposed for this project aims to improve the practice of physical activity (PA) for people with type 2 diabetes by increasing their motivation using a portable device to monitor PA (FitBit). This study will provide preliminary data to assess the feasibility of the intervention, its acceptability for patients with type 2 diabetes, and its potential impact of PA motivation and PA level.', 'detailedDescription': \"It is recognized that the adoption of healthy lifestyle habits, such as the practice of physical activity (PA) on a regular and constant basis, contributes significantly to reducing the prevalence of diabetes and its complications. The use of portable technological support to monitor PA can contribute to a favorable behavioral change in people with chronic diseases such as diabetes. Objective: The intervention proposed for this project aims to improve the practice of PA for people with type 2 diabetes, by increasing their motivation using a portable device tracking of PA (FitBit). The device is similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status. The information recorded by the watch can be synchronized and transmitted directly to the FitBit application, allowing it to be viewed and tracked on a daily basis, and also the ability to produce weekly and monthly reports and adjust personal goals. Methods: This study consists in a pilot randomized controlled trial of 30 Type 2 diabetes patients already followed by health professionals from a University-affiliated Family Medicine Group (GMF-U Quatre-Bourgeois). Patients are randomly assigned to one of these two conditions: routine follow-up, including a PA promotion intervention supported by a kinesiologist from the research center of the Institut de cardiologie et de pneumologie de Québec (CRIUCPQ) or FitBit follow-up, which consists of routine follow-up with the adding the portable PA tracking device. We plan to recruit 15 patients per group. The randomization is done by a statistician from CRIUCPQ. Inclusion and Exclusion Criteria: To participate in the study, participants must meet the following inclusion criteria: to be in a stable medical condition, sedentary and type 2 diabetic man or woman between the ages of 18 and 90 years of age. People with acute renal failure, FG below 30 ml and those under 18 years of age are excluded. Intervention: The intervention lasts 3 months and involves a total of 3 appointments. The first appointment takes place with the physician in charge of the study in order to evaluate the patient's record and to validate their eligibility. The glycated hemoglobin data and cardiometabolic measurements taken by the attending physician of each participant will be collected by the physician and clinical researcher in charge of the project. These same measures will be taken at the 3-month follow-up prescribed to each participant and this data will be collected a second and last time by the physician in charge of the project, at the very end of the intervention. Following their visit to the physician in charge of the study, the participants will meet the research professional who will be responsible for explaining the project in more details and obtaining their consent. The second appointment is attended by a kinesiologist who will distribute a physical activity motivation questionnaire, a physical activity questionnaire and a logbook to the participants. A personalized physical activity program will also be proposed to all participants. At the 6th week of the intervention, the kinesiologist will follow up with all participants to verify the integration of the physical activity program. A third appointment is planned at the very end of the intervention with the kinesiologist. Participants will be asked to complete the same questionnaires as for visit # 2 and submit their completed logbook. The participants in the experimental group will have a satisfaction questionnaire / appreciation of the technology to be completed in addition to the other questionnaires. They will also have to bring back their Fitbit material during this appointment.\"}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2', 'Physical Activity', 'Motivation'], 'keywords': ['Portable monitoring device']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'The methodology used for this study consists of a pilot randomized controlled trial of 30 Type 2 diabetes patients already followed by health professionals from GMF-U Quatre-Bourgeois', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 30, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'FitBit', 'type': 'EXPERIMENTAL', 'description': 'Portable technological support to monitor physical activity, similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status.', 'interventionNames': ['Device: Portable monitoring device']}, {'label': 'Routine', 'type': 'ACTIVE_COMPARATOR', 'description': 'Physical activity promotion supported by a kinesiologist', 'interventionNames': ['Behavioral: Routine']}], 'interventions': [{'type': 'DEVICE', 'name': 'Portable monitoring device', 'description': 'similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status', 'armGroupLabels': ['FitBit'], 'otherNames': ['FitBit']}, {'type': 'BEHAVIORAL', 'name': 'Routine', 'description': 'Physical activity promotion supported by a kinesiologist', 'armGroupLabels': ['Routine'], 'otherNames': ['PA promotion']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Physical activity measurements', 'description': 'Godin Leisure-Time Exercise Questionnaire', 'timeFrame': '3 months'}], 'secondaryOutcomes': [{'measure': 'Motivation and auto-regulation of physical activity', 'description': 'Behavioral Regulation in Exercise Questionnaire (BREQ) version 2', 'timeFrame': '3 months'}], 'otherOutcomes': [{'measure': 'Acceptability, satisfaction of the portable monitoring device and compliance', 'description': 'Homade questionnaire with 10 questions', 'timeFrame': '3 months'}, {'measure': 'Cardiometabolic measurements: glycated hemoglobin', 'description': 'Blood test', 'timeFrame': 'Before and after the clinical intervention: 3 months'}, {'measure': 'Cardiometabolic measurements: systolic and diastolic blood pressure', 'description': 'Taken with standard apparel', 'timeFrame': 'Before and after the clinical intervention: 3 months'}, {'measure': 'Cardiometabolic measurements: Weight', 'description': 'measured with a bioimpedance balance InBody', 'timeFrame': 'Before and after the clinical intervention: 3 months'}, {'measure': 'Cardiometabolic measurements: fat percentage', 'description': 'measured with a bioimpedance balance InBody', 'timeFrame': 'Before and after the clinical intervention: 3 months'}, {'measure': 'Cardiometabolic measurement: Triglycerides', 'description': 'Blood test', 'timeFrame': 'Before and after the clinical intervention: 3 months'}, {'measure': 'Cardiometabolic measurement: High-density lipoprotein cholesterol (HDL)', 'description': 'Blood test', 'timeFrame': 'Before and after the clinical intervention: 3 months'}, {'measure': 'Cardiometabolic measurement: Low-density lipoprotein cholesterol (LDL)', 'description': 'Blood test', 'timeFrame': 'Before and after the clinical intervention: 3 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* To be in a stable medical condition, sedentary, type 2 diabetic man or woman between the ages of 18 and 90 years of age\\n\\nExclusion Criteria:\\n\\n* People with acute renal failure FG below 30 ml and those under 18 years of age.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '90 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Caroline Rhéaume, MD-PhD', 'affiliation': 'Laval University', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Caroline Rhéaume, MD-PhD', 'affiliation': 'Laval University', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'GMF-UMF Laval-Québec', 'city': 'Québec', 'zip': 'G1V0B7', 'country': 'Canada', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05389566', 'orgStudyIdInfo': {'id': 'N-20190004'}, 'organization': {'fullName': 'Aalborg University Hospital', 'class': 'OTHER'}, 'briefTitle': 'Diabetes, Falls, and Fractures', 'officialTitle': 'Diabetes, Falls, and Fractures', 'acronym': 'DIAFALL'}, 'statusModule': {'statusVerifiedDate': '2024-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-05-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-05-20', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2022-09-01', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2022-05-06', 'studyFirstSubmitQcDate': '2022-05-20', 'studyFirstPostDateStruct': {'date': '2022-05-25', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-08-07', 'lastUpdatePostDateStruct': {'date': '2024-08-09', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Nicklas Højgaard-hessellund Rasmussen', 'investigatorTitle': 'Postdoc and researcher', 'investigatorAffiliation': 'Aalborg University Hospital'}, 'leadSponsor': {'name': 'Aalborg University Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'Aalborg University', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Comparing severity of diabetic peripheral neuropathy (small and large fibers including autonomic neuroapthy) to postural control and vestibular measurements'}, 'conditionsModule': {'conditions': ['Diabetic Peripheral Neuropathy', 'Diabetes', 'Balance; Distorted', 'Vestibular Neuropathy', 'Muscle Weakness', 'Sarcopenia', 'Autonomic Neuropathy, Diabetic', 'Small Fiber Neuropathy'], 'keywords': ['Diabetes', 'Balance', 'Vestibular', 'Neuropathy', 'Muscle Weakness', 'Autonomic Neuropathy', 'Small Fiber Neuropathy', 'Postural control']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 110, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Type 1 diabetes', 'description': 'People with type 1 diabetes above 40 years', 'interventionNames': ['Diagnostic Test: Quantative Sensory Testing', 'Diagnostic Test: NCStat-DPN-Check', 'Diagnostic Test: Composite Autonomic Symptom Score 31', 'Diagnostic Test: Computerized dynamic posturography', 'Diagnostic Test: Video Head Impulse Test', 'Diagnostic Test: Accelerometer', 'Diagnostic Test: Handgrip strength', 'Diagnostic Test: Dual Energy X-ray Absorbtimetry scan', 'Diagnostic Test: Force Plate Platform']}, {'label': 'People with type 2 diabetes', 'description': 'People with type 2 diabetes above 50 years', 'interventionNames': ['Diagnostic Test: Quantative Sensory Testing', 'Diagnostic Test: NCStat-DPN-Check', 'Diagnostic Test: Composite Autonomic Symptom Score 31', 'Diagnostic Test: Computerized dynamic posturography', 'Diagnostic Test: Video Head Impulse Test', 'Diagnostic Test: Accelerometer', 'Diagnostic Test: Handgrip strength', 'Diagnostic Test: Dual Energy X-ray Absorbtimetry scan', 'Diagnostic Test: Force Plate Platform']}, {'label': 'Healthy controls', 'description': 'Healthy controls without diabetes', 'interventionNames': ['Diagnostic Test: Quantative Sensory Testing', 'Diagnostic Test: NCStat-DPN-Check', 'Diagnostic Test: Composite Autonomic Symptom Score 31', 'Diagnostic Test: Computerized dynamic posturography', 'Diagnostic Test: Video Head Impulse Test', 'Diagnostic Test: Accelerometer', 'Diagnostic Test: Handgrip strength', 'Diagnostic Test: Dual Energy X-ray Absorbtimetry scan', 'Diagnostic Test: Force Plate Platform']}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'Quantative Sensory Testing', 'description': 'Evaluation of small fiber neuropathy', 'armGroupLabels': ['Healthy controls', 'People with type 2 diabetes', 'Type 1 diabetes']}, {'type': 'DIAGNOSTIC_TEST', 'name': 'NCStat-DPN-Check', 'description': 'Evaluation of large fiber neuropathy', 'armGroupLabels': ['Healthy controls', 'People with type 2 diabetes', 'Type 1 diabetes']}, {'type': 'DIAGNOSTIC_TEST', 'name': 'Composite Autonomic Symptom Score 31', 'description': 'Evaluation of autonomic neuropathy', 'armGroupLabels': ['Healthy controls', 'People with type 2 diabetes', 'Type 1 diabetes']}, {'type': 'DIAGNOSTIC_TEST', 'name': 'Computerized dynamic posturography', 'description': 'Evaluation of dynamic postural control', 'armGroupLabels': ['Healthy controls', 'People with type 2 diabetes', 'Type 1 diabetes'], 'otherNames': ['Bertec']}, {'type': 'DIAGNOSTIC_TEST', 'name': 'Video Head Impulse Test', 'description': 'Evaluation of vertigo and the vestibular organ', 'armGroupLabels': ['Healthy controls', 'People with type 2 diabetes', 'Type 1 diabetes'], 'otherNames': ['V-Hit']}, {'type': 'DIAGNOSTIC_TEST', 'name': 'Accelerometer', 'description': 'Evaluation of gait pattern', 'armGroupLabels': ['Healthy controls', 'People with type 2 diabetes', 'Type 1 diabetes'], 'otherNames': ['Sens Innovation, Copenhagen Denmark']}, {'type': 'DIAGNOSTIC_TEST', 'name': 'Handgrip strength', 'description': 'Evaluation of muscle strength', 'armGroupLabels': ['Healthy controls', 'People with type 2 diabetes', 'Type 1 diabetes'], 'otherNames': ['Hydraulic dynamometer, Saehan Coorporation, Gyungnam, South Korea']}, {'type': 'DIAGNOSTIC_TEST', 'name': 'Dual Energy X-ray Absorbtimetry scan', 'description': 'Evaluation of body composition', 'armGroupLabels': ['Healthy controls', 'People with type 2 diabetes', 'Type 1 diabetes'], 'otherNames': ['Dexa, Hollogic Horizon (4500 Hollogic Inc., Marlborough, MA, USA)']}, {'type': 'DIAGNOSTIC_TEST', 'name': 'Force Plate Platform', 'description': 'Evaluation of balance while standing still', 'armGroupLabels': ['Healthy controls', 'People with type 2 diabetes', 'Type 1 diabetes'], 'otherNames': ['Plux Biosignals, S.A, Arruda dos Vinhos, Portugal']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Co-existence of peripheral- and vestiubular neuropathy in people with diabetes', 'description': 'Vestibular neuropathy (measured by pathological video head impulse test (v-Hit) (one-sided, two-sided or specific arcways)) will be compared with peripheral neuropathy (measured by quantitative sensory testing, nerve conduction and COMPASS-33) in the population with diabetes.', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'Co-existence of peripheral neuropathy and impaired dynamic postural control in people with diabetes', 'description': 'Dynamic balance (measured by Bertec) will be compared with peripheral neuropathy (measured by quantitative sensory testing, nerve conduction and COMPASS-33) in the population with diabetes.', 'timeFrame': 'through study completion, an average of 2 years'}], 'secondaryOutcomes': [{'measure': 'Correlation between the severity of peripheral neuropathy and the severity of vestibular in terms of degree of pathological video head impulse testingneuropathy', 'description': 'QST / NC-Stat DPNCheck vs v-Hit', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'Correlation between distal neuropathy and dynamic postural control (including patterns)', 'description': 'QST / NC-Stat DPNCheck vs accelerometer / Bertec', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'The impact of peripheral neuropathy on postural control (In quite stance)', 'description': 'QST / Correlation between muscle strength and peripheral neuropathy vs Force Plate', 'timeFrame': 'through study completion, an average of 2 years'}], 'otherOutcomes': [{'measure': 'Exploratory', 'description': 'accelerometer (SENS Innovation, Copenhagen, Denmark) measures (postural control during walking)', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'Exploratory', 'description': 'Correlations between different outcomes of Bertec and v-Hit vs peripheral neuropathy (all individual examinations and arcways)', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'Muscle strength and peripheral neuropathy', 'description': 'Correlation between muscle strength and peripheral neuropathy (DEXA-scans, hand grup strength, QST, Correlation between muscle strength and peripheral neuropathy', 'timeFrame': 'through study completion, an average of 2 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Men and women with minimum 40 years of age and maximum 70 years of age.\\n2. Diagnosis of T1D or T2D\\n3. Diagnosis of diabetes with at least one year prior to inclusion of the study\\n4. Signed the informed consent.\\n\\nExclusion Criteria:\\n\\n1. Severe decreased liver function (Alanin amino-transaminase (ALAT)\\\\>250u/l, GammaGlutamyltransferase (GGT)\\\\>150u/l)\\n2. Moderate to severe kidney dysfunction, estimated Glomerular Filtration Rate (eGFR) \\\\<15mmol/L/1,73m2\\n3. Pregnancy or breast feeding\\n4. Active malignancy or terminal ill.\\n5. Current or previous alcohol- or drug abuse\\n\\n8. Not being able to understand Danish written and/or verbally 9. Terms according to investigators judgement that makes subjects unsuitable to participate including lack of understanding or reduced physical ability. 10. Participating in other clinical studies 11. Maximum of 10 hours of weekly exercise.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '40 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'People with type 1 or 2 diabetes from general practice or outpatient clinic at Steno Diabetes Center North Denmark', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'locations': [{'facility': 'Aalborg University Hospital', 'city': 'Aalborg', 'zip': '9000', 'country': 'Denmark', 'geoPoint': {'lat': 57.048, 'lon': 9.9187}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED', 'description': 'Possible requirement for external data analysis'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D018908', 'term': 'Muscle Weakness'}, {'id': 'D020338', 'term': 'Vestibular Neuronitis'}, {'id': 'D010523', 'term': 'Peripheral Nervous System Diseases'}, {'id': 'D055948', 'term': 'Sarcopenia'}, {'id': 'D010291', 'term': 'Paresis'}, {'id': 'D000071075', 'term': 'Small Fiber Neuropathy'}, {'id': 'D003929', 'term': 'Diabetic Neuropathies'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009133', 'term': 'Muscular Atrophy'}, {'id': 'D020879', 'term': 'Neuromuscular Manifestations'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D001284', 'term': 'Atrophy'}, {'id': 'D020763', 'term': 'Pathological Conditions, Anatomical'}, {'id': 'D009135', 'term': 'Muscular Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D048909', 'term': 'Diabetes Complications'}, {'id': 'D000160', 'term': 'Vestibulocochlear Nerve Diseases'}, {'id': 'D012181', 'term': 'Retrocochlear Diseases'}, {'id': 'D004427', 'term': 'Ear Diseases'}, {'id': 'D010038', 'term': 'Otorhinolaryngologic Diseases'}, {'id': 'D003389', 'term': 'Cranial Nerve Diseases'}], 'browseLeaves': [{'id': 'M28396', 'name': 'Sarcopenia', 'asFound': 'Sarcopenia', 'relevance': 'HIGH'}, {'id': 'M26370', 'name': 'Fractures, Bone', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M20944', 'name': 'Muscle Weakness', 'asFound': 'Muscle Weakness', 'relevance': 'HIGH'}, {'id': 'M4554', 'name': 'Asthenia', 'relevance': 'LOW'}, {'id': 'M13432', 'name': 'Peripheral Nervous System Diseases', 'asFound': 'Neuropathy', 'relevance': 'HIGH'}, {'id': 'M13204', 'name': 'Paresis', 'asFound': 'Muscle Weakness', 'relevance': 'HIGH'}, {'id': 'M697', 'name': 'Small Fiber Neuropathy', 'asFound': 'Small Fiber Neuropathy', 'relevance': 'HIGH'}, {'id': 'M22145', 'name': 'Vestibular Neuronitis', 'asFound': 'Vestibular Neuropathy', 'relevance': 'HIGH'}, {'id': 'M7124', 'name': 'Diabetic Neuropathies', 'asFound': 'Autonomic Neuropathy, Diabetic', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M12090', 'name': 'Muscular Atrophy', 'relevance': 'LOW'}, {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'}, {'id': 'M22619', 'name': 'Neuromuscular Manifestations', 'relevance': 'LOW'}, {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'}, {'id': 'M22519', 'name': 'Pathological Conditions, Anatomical', 'relevance': 'LOW'}, {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M26004', 'name': 'Diabetes Complications', 'relevance': 'LOW'}, {'id': 'M3519', 'name': 'Vestibulocochlear Nerve Diseases', 'relevance': 'LOW'}, {'id': 'M15016', 'name': 'Retrocochlear Diseases', 'relevance': 'LOW'}, {'id': 'M7601', 'name': 'Ear Diseases', 'relevance': 'LOW'}, {'id': 'M12961', 'name': 'Otorhinolaryngologic Diseases', 'relevance': 'LOW'}, {'id': 'M6605', 'name': 'Cranial Nerve Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC26', 'name': 'Wounds and Injuries'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC09', 'name': 'Ear, Nose, and Throat Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01816165', 'orgStudyIdInfo': {'id': '11-0649'}, 'secondaryIdInfos': [{'id': '6181', 'type': 'OTHER', 'domain': 'CTRC'}], 'organization': {'fullName': 'University of Colorado, Denver', 'class': 'OTHER'}, 'briefTitle': 'Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes', 'officialTitle': 'Role of Lipotoxicity in Insulin Resistance, Vascular, and Mitochondrial Dysfunction in Type 1 Diabetes', 'acronym': 'AcT1'}, 'statusModule': {'statusVerifiedDate': '2021-12', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2011-06'}, 'primaryCompletionDateStruct': {'date': '2015-06-24', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2015-06-24', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2012-06-13', 'studyFirstSubmitQcDate': '2013-03-18', 'studyFirstPostDateStruct': {'date': '2013-03-22', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2021-11-09', 'resultsFirstSubmitQcDate': '2021-12-21', 'resultsFirstPostDateStruct': {'date': '2022-01-21', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-12-21', 'lastUpdatePostDateStruct': {'date': '2022-01-21', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'University of Colorado, Denver', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). Non-esterified fatty acid elevation is a significant contributor to IR in T1D and may be a target of intervention. The hypothesis of the study is that isolated fatty acid lowering with acipimox will improve insulin action and blood vessel function and have the benefit of reducing mitochondrial oxidant generation and improving mitochondrial function in T1D. Targeting IR through fatty acid lowering is a novel approach to T1D treatment that may significantly improve current management of TID and of cardiovascular disease (CVD) risk in this high risk population.'}, 'conditionsModule': {'conditions': ['Type 1 Diabetes'], 'keywords': ['diabetes', 'insulin', 'blood vessel', 'type 1']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 28, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Acipimox', 'type': 'EXPERIMENTAL', 'description': 'Drug: acipimox', 'interventionNames': ['Drug: Acipimox']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Drug: Placebo', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Acipimox', 'description': 'Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.', 'armGroupLabels': ['Acipimox'], 'otherNames': ['Olbetam']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Insulin Sensitivity: M-value From Hyperinsulinemic Euglycemia Clamp Study', 'description': 'Evaluate the impact of Non esterified fatty acid (NEFA)-lowering on insulin sensitivity in T1D versus non-DM. Glucose infusion rate is reported normalized to lean body weight in kg and to final insulin concentration.\\n\\nThe unit of measure reflects the rate at which glucose needs to be infused to maintain a normal blood sugar in the setting of a given serum insulin level from an insulin infusion. As such, a higher number means more glucose was needed and indicates greater sensitivity to insulin.', 'timeFrame': 'day 8 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': '24 Hour Mean Fatty Acid Levels', 'description': 'Assesses whether fatty acid level is consistently lowered by acipimox. Mean of fatty acid levels measured 22 times over 24 hours (hourly except 0100 and 0300 hours).', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Percent Flow-mediated Brachial Artery Dilation', 'description': 'To determine the effects of NEFA lowering and insulin sensitization on endothelial function. Measures percent change in brachial artery diameter with hyperemia after occlusion.', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'State 3 Mitochondrial Oxygen Consumption', 'description': 'Measures skeletal muscle mitochondrial function and effects of acipimox thereon, carbohydrate \\\\& lipid substrates. State 3 is fully active coupled oxygen flux using PMG or PMGS (pyruvate, malate, glutamate, +/- succinate) or OCMS (octanyl carnitine, malate, +/- succinate) as substrates. FCCP is added as an uncoupler to measure maximum possible O2 flux. Higher values reflect better mitochondrial function.', 'timeFrame': 'muscle biopsy on day 7 of each weeklong intervention period; max 16 weeks post enrollment'}], 'secondaryOutcomes': [{'measure': 'Oxidative Stress and Inflammatory Markers: Interleukin 6 (IL6)', 'description': 'Interleukin 6 (IL6)', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Oxidative Stress and Inflammatory Markers: TNFalpha', 'description': 'TNFalpha', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Oxidative Stress and Inflammatory Markers: High-sensitivity C-reactive Protein (hsCRP)', 'description': 'high-sensitivity C-reactive protein (hsCRP)', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Oxidative Stress and Inflammatory Markers: Adiponectin', 'description': 'adiponectin', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Oxidative Stress and Inflammatory Markers: Plasminogen Activator Inhibitor (PAI-1)', 'description': 'Plasminogen activator inhibitor (PAI-1)', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Heart Rate Variability', 'description': 'Measure of autonomic function; ratio of fastest to slowest heart rate during valsalva maneuver.', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Arterial Stiffness (PWV)', 'description': 'Pulse wave velocity by Sphygmacor as a measure of aortic stiffness in m/sec. Higher values reflect a stiffer vasculature.', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Arterial Stiffness (AI)', 'description': 'Augmentation index by Sphygmacor is a measure of aortic arterial stiffness. AI@75 is the ratio of augmented pressure/pulse pressure adjusted to a heart rate of 75.\\n\\nHigher values indicate stiffer vessels', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Metabolic Markers: Continuous Glucose Monitoring Measures', 'description': 'Continuous glucose monitoring measures for 3 days before clamp. Collected for participants with T1 Diabetes only.', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Metabolic Markers: Mean 24 Hour Triglyceride and Glucose Levels', 'description': 'mean glucose and triglycerides for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300).', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Metabolic Markers: Insulin', 'description': 'mean insulin for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300).', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Metabolic Markers: Glycerol', 'description': 'mean glycerol for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300).', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Vascular Markers', 'description': 'endothelin 1 measured as a marker of vascular damage', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}], 'otherOutcomes': [{'measure': 'Other Mitochondrial Measures: Mito Content and Electron Transport Chain Complexes', 'description': 'Mito content and electron transport chain complexes by western blot analysis.', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Oxidative Stress and Inflammatory Markers: Exploratory (Not Collected)', 'description': 'thiobarbituric acid reactive substances (TBARs), glutathione disulfide (GSSG): reduced Glutathione (GSH) ratio; amplex red assay of hydrogen peroxide (H2O2) production,', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}, {'measure': 'Counterregulatory Hormones', 'description': 'Planned glucagon and cortisol as a markers of counteregulation, but not done due to financial limitations', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Men and women, with and without type 1 diabetes between 25-59 years of age,\\n2. HbA1c 6.0-9.5 (T1D only),\\n3. Subjects who are willing to commit to:\\n\\n   * 14 days of prescribed diet,\\n   * two 44 hour inpatient stays, and\\n   * two muscle biopsies.\\n\\nExclusion Criteria:\\n\\n1. Any comorbid condition associated with inflammation, insulin resistance, or dyslipidemia,\\n2. Tobacco use,\\n3. Pregnancy,\\n4. Steroid use,\\n5. Scheduled physical activity \\\\>3 days a week,\\n6. Angina or any other cardiovascular or pulmonary disease,\\n7. History of chronic obstructive pulmonary disease or asthma,\\n8. Systolic blood pressure \\\\>190 at rest or \\\\>250 with exercise, or\\n9. Diastolic pressure \\\\>95 at rest, or \\\\>105 with exercise,\\n10. Proteinuria (urine protein \\\\>200 mg/dl), or\\n11. Creatinine \\\\> 2 mg/dl, suggestive of severe renal disease,\\n12. Severe Proliferative retinopathy,\\n13. Niacin treatment,\\n14. History of peptic ulcers,\\n15. History of hereditary angioedema, and\\n16. C1 esterase deficiency.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '25 Years', 'maximumAge': '59 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Irene Schauer, MD, PhD', 'affiliation': 'University of Colorado, Denver', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Colorado Denver', 'city': 'Aurora', 'state': 'Colorado', 'zip': '80045', 'country': 'United States', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}]}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': '10 participants (7 withdrawals, 3 screen fails) were excluded from the study after enrollment, but prior to beginning the study. One T1D acipimox to placebo was withdrawn during the acipimox phase due to an SAE.', 'groups': [{'id': 'FG000', 'title': 'Participants With T1 Diabetes: Acipimox, Then Placebo', 'description': 'Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day, followed by placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'FG001', 'title': 'Participants Without T1 Diabetes: Acipimox, Then Placebo', 'description': 'Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day, followed by placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'FG002', 'title': 'Participants With T1 Diabetes: Placebo, Then Acipimox', 'description': 'Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day, followed by acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'FG003', 'title': 'Participants Without T1 Diabetes: Placebo, Then Acipimox', 'description': 'Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day, followed by acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '4'}]}, {'type': 'Completed Intervention 1', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '4'}]}, {'type': 'Completed ~2 Week Washout', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '4'}]}, {'type': 'Started Second Intervention', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '4'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '4'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'All Participants With T1 Diabetes', 'description': 'Acipimox, Then Placebo: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day, followed by placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.\\n\\nPlacebo, then Acipimox :Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day, followed by acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'BG001', 'title': 'All Participants Without T1 Diabetes', 'description': 'Placebo, then Acipimox :Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day, followed by acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.\\n\\nAcipimox, Then Placebo: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day, followed by placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '10'}, {'groupId': 'BG001', 'value': '8'}, {'groupId': 'BG002', 'value': '18'}]}], 'measures': [{'title': 'Age, Categorical', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'groupId': 'BG000', 'value': '10'}, {'groupId': 'BG001', 'value': '8'}, {'groupId': 'BG002', 'value': '18'}]}, {'title': '>=65 years', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '7'}, {'groupId': 'BG001', 'value': '5'}, {'groupId': 'BG002', 'value': '12'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '3'}, {'groupId': 'BG001', 'value': '3'}, {'groupId': 'BG002', 'value': '6'}]}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '10'}, {'groupId': 'BG001', 'value': '8'}, {'groupId': 'BG002', 'value': '18'}]}]}]}, {'title': 'Race (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '2'}]}, {'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '10'}, {'groupId': 'BG001', 'value': '6'}, {'groupId': 'BG002', 'value': '16'}]}, {'title': 'More than one race', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '10'}, {'groupId': 'BG001', 'value': '8'}, {'groupId': 'BG002', 'value': '18'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Insulin Sensitivity: M-value From Hyperinsulinemic Euglycemia Clamp Study', 'description': 'Evaluate the impact of Non esterified fatty acid (NEFA)-lowering on insulin sensitivity in T1D versus non-DM. Glucose infusion rate is reported normalized to lean body weight in kg and to final insulin concentration.\\n\\nThe unit of measure reflects the rate at which glucose needs to be infused to maintain a normal blood sugar in the setting of a given serum insulin level from an insulin infusion. As such, a higher number means more glucose was needed and indicates greater sensitivity to insulin.', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'mg/kg*minute*microIU/mL*100', 'timeFrame': 'day 8 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.65', 'spread': '1.52'}, {'groupId': 'OG001', 'value': '3.67', 'spread': '1.45'}, {'groupId': 'OG002', 'value': '8.8', 'spread': '3.04'}, {'groupId': 'OG003', 'value': '9.05', 'spread': '2.88'}]}]}]}, {'type': 'PRIMARY', 'title': '24 Hour Mean Fatty Acid Levels', 'description': 'Assesses whether fatty acid level is consistently lowered by acipimox. Mean of fatty acid levels measured 22 times over 24 hours (hourly except 0100 and 0300 hours).', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'microEq/L', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '343', 'spread': '122'}, {'groupId': 'OG001', 'value': '297', 'spread': '56'}, {'groupId': 'OG002', 'value': '298', 'spread': '90'}, {'groupId': 'OG003', 'value': '335', 'spread': '65'}]}]}]}, {'type': 'PRIMARY', 'title': 'Percent Flow-mediated Brachial Artery Dilation', 'description': 'To determine the effects of NEFA lowering and insulin sensitization on endothelial function. Measures percent change in brachial artery diameter with hyperemia after occlusion.', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Percent change in BA diameter', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8.21', 'spread': '3.02'}, {'groupId': 'OG001', 'value': '8.82', 'spread': '4.40'}, {'groupId': 'OG002', 'value': '5.88', 'spread': '4.17'}, {'groupId': 'OG003', 'value': '7.32', 'spread': '4.25'}]}]}]}, {'type': 'PRIMARY', 'title': 'State 3 Mitochondrial Oxygen Consumption', 'description': 'Measures skeletal muscle mitochondrial function and effects of acipimox thereon, carbohydrate \\\\& lipid substrates. State 3 is fully active coupled oxygen flux using PMG or PMGS (pyruvate, malate, glutamate, +/- succinate) or OCMS (octanyl carnitine, malate, +/- succinate) as substrates. FCCP is added as an uncoupler to measure maximum possible O2 flux. Higher values reflect better mitochondrial function.', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison. Another participant did not have a muscle biopsy collected (T1D, Acipimox).', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'pmoles/mg/s', 'timeFrame': 'muscle biopsy on day 7 of each weeklong intervention period; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '8'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'title': 'PMG State 3 Oxygen Flux', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '26.1', 'spread': '8.3'}, {'groupId': 'OG001', 'value': '24.9', 'spread': '7.6'}, {'groupId': 'OG002', 'value': '30.2', 'spread': '9.8'}, {'groupId': 'OG003', 'value': '29.7', 'spread': '10.0'}]}]}, {'title': 'PMGS State 3 Oxygen Flux', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '38.0', 'spread': '11.8'}, {'groupId': 'OG001', 'value': '36.9', 'spread': '12.7'}, {'groupId': 'OG002', 'value': '42.5', 'spread': '15.0'}, {'groupId': 'OG003', 'value': '42.5', 'spread': '11.8'}]}]}, {'title': 'PMGS Uncoupled Max Oxygen Flux', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '65.2', 'spread': '18.4'}, {'groupId': 'OG001', 'value': '62.1', 'spread': '16.3'}, {'groupId': 'OG002', 'value': '77.8', 'spread': '26.3'}, {'groupId': 'OG003', 'value': '80.2', 'spread': '28.9'}]}]}, {'title': 'OCM State 3 Oxygen Flux', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '14.0', 'spread': '5.8'}, {'groupId': 'OG001', 'value': '15.0', 'spread': '5.6'}, {'groupId': 'OG002', 'value': '18.8', 'spread': '8.6'}, {'groupId': 'OG003', 'value': '17.3', 'spread': '4.4'}]}]}, {'title': 'OCMS State 3 Oxygen Flux', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '38.6', 'spread': '14.6'}, {'groupId': 'OG001', 'value': '38.5', 'spread': '11.2'}, {'groupId': 'OG002', 'value': '43.8', 'spread': '13.3'}, {'groupId': 'OG003', 'value': '41.7', 'spread': '9.9'}]}]}, {'title': 'OCMS Uncoupled Max Oxygen Flux', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '51.8', 'spread': '22.9'}, {'groupId': 'OG001', 'value': '56.4', 'spread': '20.0'}, {'groupId': 'OG002', 'value': '80.1', 'spread': '24.8'}, {'groupId': 'OG003', 'value': '73.1', 'spread': '18.8'}]}]}]}, {'type': 'SECONDARY', 'title': 'Oxidative Stress and Inflammatory Markers: Interleukin 6 (IL6)', 'description': 'Interleukin 6 (IL6)', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'picograms/mL', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.8', 'spread': '1.6'}, {'groupId': 'OG001', 'value': '4.2', 'spread': '3.2'}, {'groupId': 'OG002', 'value': '2.6', 'spread': '2.4'}, {'groupId': 'OG003', 'value': '3.5', 'spread': '1.3'}]}]}]}, {'type': 'SECONDARY', 'title': 'Oxidative Stress and Inflammatory Markers: TNFalpha', 'description': 'TNFalpha', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison. Two other participants (T1D, Acipimox; No T1D Acipimox) did not have data collected.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'picograms/mL', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '8'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '7'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.76', 'spread': '1.08'}, {'groupId': 'OG001', 'value': '1.71', 'spread': '.80'}, {'groupId': 'OG002', 'value': '1.56', 'spread': '.95'}, {'groupId': 'OG003', 'value': '.91', 'spread': '.46'}]}]}]}, {'type': 'SECONDARY', 'title': 'Oxidative Stress and Inflammatory Markers: High-sensitivity C-reactive Protein (hsCRP)', 'description': 'high-sensitivity C-reactive protein (hsCRP)', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison. Another participant from the Non T1D Placebo group did not have data collected.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'mg/L', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '7'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.19', 'spread': '3.84'}, {'groupId': 'OG001', 'value': '1.98', 'spread': '1.64'}, {'groupId': 'OG002', 'value': '1.43', 'spread': '1.11'}, {'groupId': 'OG003', 'value': '1.44', 'spread': '1.42'}]}]}]}, {'type': 'SECONDARY', 'title': 'Oxidative Stress and Inflammatory Markers: Adiponectin', 'description': 'adiponectin', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison. Two participants (one in each of the Non-T1D study phases) did not have data collected.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'micrograms/mL', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '7'}, {'groupId': 'OG003', 'value': '7'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '11.6', 'spread': '7.7'}, {'groupId': 'OG001', 'value': '14.9', 'spread': '10.8'}, {'groupId': 'OG002', 'value': '7.3', 'spread': '5.0'}, {'groupId': 'OG003', 'value': '5.8', 'spread': '2.1'}]}]}]}, {'type': 'SECONDARY', 'title': 'Oxidative Stress and Inflammatory Markers: Plasminogen Activator Inhibitor (PAI-1)', 'description': 'Plasminogen activator inhibitor (PAI-1)', 'populationDescription': 'Measure was not collected due to funding limitations.', 'reportingStatus': 'POSTED', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}, {'groupId': 'OG003', 'value': '0'}]}]}, {'type': 'SECONDARY', 'title': 'Heart Rate Variability', 'description': 'Measure of autonomic function; ratio of fastest to slowest heart rate during valsalva maneuver.', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'ratio', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1D: Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1D: Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1D: Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1D: Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.37', 'spread': '.17'}, {'groupId': 'OG001', 'value': '1.43', 'spread': '.14'}, {'groupId': 'OG002', 'value': '1.59', 'spread': '.19'}, {'groupId': 'OG003', 'value': '1.69', 'spread': '.30'}]}]}]}, {'type': 'SECONDARY', 'title': 'Arterial Stiffness (PWV)', 'description': 'Pulse wave velocity by Sphygmacor as a measure of aortic stiffness in m/sec. Higher values reflect a stiffer vasculature.', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison. Additionally, one participant in each of the T1D study phases did not have data collected.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'm/sec', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1D: Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1D: Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1D: Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1D: Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '8'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '9.24', 'spread': '2.46'}, {'groupId': 'OG001', 'value': '9.91', 'spread': '3.30'}, {'groupId': 'OG002', 'value': '6.97', 'spread': '1.71'}, {'groupId': 'OG003', 'value': '7.4', 'spread': '1.00'}]}]}]}, {'type': 'SECONDARY', 'title': 'Arterial Stiffness (AI)', 'description': 'Augmentation index by Sphygmacor is a measure of aortic arterial stiffness. AI@75 is the ratio of augmented pressure/pulse pressure adjusted to a heart rate of 75.\\n\\nHigher values indicate stiffer vessels', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison. Additionally, one participant in each of the T1D study phases did not have data collected.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'ratio', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1D: Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1D: Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1D: Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1D: Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '8'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '21.4', 'spread': '8.4'}, {'groupId': 'OG001', 'value': '19.7', 'spread': '10.0'}, {'groupId': 'OG002', 'value': '11.1', 'spread': '13.0'}, {'groupId': 'OG003', 'value': '12.4', 'spread': '12.7'}]}]}]}, {'type': 'SECONDARY', 'title': 'Metabolic Markers: Continuous Glucose Monitoring Measures', 'description': 'Continuous glucose monitoring measures for 3 days before clamp. Collected for participants with T1 Diabetes only.', 'populationDescription': '1 participant was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'mmol/L', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1D: Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1D: Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}]}], 'classes': [{'title': 'Average Glucose', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8.82', 'spread': '1.2'}, {'groupId': 'OG001', 'value': '9.09', 'spread': '0.72'}]}]}, {'title': 'Glycemic Variability', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.64', 'spread': '0.92'}, {'groupId': 'OG001', 'value': '3.64', 'spread': '0.66'}]}]}]}, {'type': 'SECONDARY', 'title': 'Metabolic Markers: Mean 24 Hour Triglyceride and Glucose Levels', 'description': 'mean glucose and triglycerides for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300).', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'mg/dL', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'title': 'glucose', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '135', 'spread': '28'}, {'groupId': 'OG001', 'value': '131', 'spread': '31'}, {'groupId': 'OG002', 'value': '87', 'spread': '10'}, {'groupId': 'OG003', 'value': '89', 'spread': '8'}]}]}, {'title': 'triglycerides', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '59', 'spread': '29'}, {'groupId': 'OG001', 'value': '68', 'spread': '33'}, {'groupId': 'OG002', 'value': '67', 'spread': '20'}, {'groupId': 'OG003', 'value': '83', 'spread': '27'}]}]}]}, {'type': 'SECONDARY', 'title': 'Metabolic Markers: Insulin', 'description': 'mean insulin for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300).', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'microIU/mL', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '48', 'spread': '25'}, {'groupId': 'OG001', 'value': '47', 'spread': '26'}, {'groupId': 'OG002', 'value': '20', 'spread': '6'}, {'groupId': 'OG003', 'value': '21', 'spread': '10'}]}]}]}, {'type': 'SECONDARY', 'title': 'Metabolic Markers: Glycerol', 'description': 'mean glycerol for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300).', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'micromoles/L', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '86', 'spread': '25'}, {'groupId': 'OG001', 'value': '75', 'spread': '20'}, {'groupId': 'OG002', 'value': '63', 'spread': '12'}, {'groupId': 'OG003', 'value': '69', 'spread': '14'}]}]}]}, {'type': 'SECONDARY', 'title': 'Vascular Markers', 'description': 'endothelin 1 measured as a marker of vascular damage', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison. in addition, the last nonDM subjects did not have this collected due to funding limitations and futility based on prior results.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'pg/mL', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '6'}, {'groupId': 'OG003', 'value': '6'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.92', 'spread': '1.56'}, {'groupId': 'OG001', 'value': '4.9', 'spread': '0.91'}, {'groupId': 'OG002', 'value': '4.83', 'spread': '0.92'}, {'groupId': 'OG003', 'value': '4.12', 'spread': '1.00'}]}]}]}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Other Mitochondrial Measures: Mito Content and Electron Transport Chain Complexes', 'description': 'Mito content and electron transport chain complexes by western blot analysis.', 'populationDescription': 'Originally described as secondary but were actually exploratory. Not done due to funding and tissue limitations.', 'reportingStatus': 'POSTED', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox Acipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo Placebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}, {'groupId': 'OG003', 'value': '0'}]}]}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Oxidative Stress and Inflammatory Markers: Exploratory (Not Collected)', 'description': 'thiobarbituric acid reactive substances (TBARs), glutathione disulfide (GSSG): reduced Glutathione (GSH) ratio; amplex red assay of hydrogen peroxide (H2O2) production,', 'populationDescription': 'These oxidative stress and inflammatory markers were collected, but assays were found to be unreliable. These measurements were originally erroneously described as secondary outcome measures, but are exploratory.', 'reportingStatus': 'POSTED', 'timeFrame': 'day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}]}]}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Counterregulatory Hormones', 'description': 'Planned glucagon and cortisol as a markers of counteregulation, but not done due to financial limitations', 'populationDescription': '1 participant in the T1 Diabetes groups was excluded from the analysis because data was only collected in the Acipimox phase and matching Placebo data would have been required for comparison. Incorrectly listed as secondary outcome. This was an exploratory outcome.', 'reportingStatus': 'POSTED', 'timeFrame': 'day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment', 'groups': [{'id': 'OG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG001', 'title': 'T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}, {'id': 'OG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.'}, {'id': 'OG003', 'title': 'No T1 Diabetes, Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}, {'groupId': 'OG003', 'value': '0'}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'timeFrame': 'Up to about Week 16', 'eventGroups': [{'id': 'EG000', 'title': 'T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.', 'deathsNumAffected': 0, 'deathsNumAtRisk': 10, 'seriousNumAffected': 1, 'seriousNumAtRisk': 10, 'otherNumAffected': 0, 'otherNumAtRisk': 10}, {'id': 'EG001', 'title': 'T1 Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day', 'deathsNumAffected': 0, 'deathsNumAtRisk': 9, 'seriousNumAffected': 0, 'seriousNumAtRisk': 9, 'otherNumAffected': 0, 'otherNumAtRisk': 9}, {'id': 'EG002', 'title': 'No T1 Diabetes, Acipimox', 'description': 'Drug: acipimox\\n\\nAcipimox: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.', 'deathsNumAffected': 0, 'deathsNumAtRisk': 8, 'seriousNumAffected': 0, 'seriousNumAtRisk': 8, 'otherNumAffected': 0, 'otherNumAtRisk': 8}, {'id': 'EG003', 'title': 'No T1 Placebo', 'description': 'Drug: Placebo\\n\\nPlacebo: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day', 'deathsNumAffected': 0, 'deathsNumAtRisk': 8, 'seriousNumAffected': 0, 'seriousNumAtRisk': 8, 'otherNumAffected': 0, 'otherNumAtRisk': 8}], 'seriousEvents': [{'term': 'bradycardia', 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 10}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 8}]}]}, 'moreInfoModule': {'limitationsAndCaveats': {'description': 'This study was stopped early for two reasons: one was the serious adverse event and the other was the fact that the fatty acid lowering effect of acipimox was more short-lived than expected and we did not see the intended overall fatty acid lowering.'}, 'certainAgreement': {'piSponsorEmployee': True}, 'pointOfContact': {'title': 'Irene Schauer, MD', 'organization': 'University of Colorado Denver', 'email': 'clinicaresearchsupportcenter@ucdenver.edu', 'phone': '3037241111'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M10370', 'name': 'Insulin Resistance', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C027696', 'term': 'Acipimox'}], 'ancestors': [{'id': 'D000960', 'term': 'Hypolipidemic Agents'}, {'id': 'D000963', 'term': 'Antimetabolites'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D057847', 'term': 'Lipid Regulating Agents'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M229334', 'name': 'Acipimox', 'asFound': 'Head & Neck', 'relevance': 'HIGH'}, {'id': 'M4278', 'name': 'Hypolipidemic Agents', 'relevance': 'LOW'}, {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'}, {'id': 'M28883', 'name': 'Lipid Regulating Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Lipd', 'name': 'Lipid Regulating Agents'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04572165', 'orgStudyIdInfo': {'id': 'NN9535-4447'}, 'secondaryIdInfos': [{'id': 'U1111-1214-6228', 'type': 'OTHER', 'domain': 'World Health Organization (WHO)'}, {'id': 'EUPAS37258', 'type': 'REGISTRY', 'domain': 'EU PAS Register'}], 'organization': {'fullName': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}, 'briefTitle': 'Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data', 'officialTitle': 'Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data'}, 'statusModule': {'statusVerifiedDate': '2023-12', 'overallStatus': 'ENROLLING_BY_INVITATION', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-01-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2020-09-30', 'studyFirstSubmitQcDate': '2020-09-30', 'studyFirstPostDateStruct': {'date': '2020-10-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-12-29', 'lastUpdatePostDateStruct': {'date': '2024-01-02', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Department of Public Health, University of Southern Denmark', 'class': 'UNKNOWN'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The aim of this study is to evaluate whether exposure to semaglutide influences the risk of pancreatic cancer in patients with type 2 diabetes. This is achieved by estimating the risk of pancreatic cancer associated with semaglutide use as compared to use of other non-incretin antidiabetic drugs used at a similar stage as Ozempic® or Rybelsus® in the treatment of type 2 diabetes. A multi-national, non-interventional study based on health care data from Denmark, Sweden, and Norway is conducted covering the period 2018-2023. A cohort study design is used comparing new users of semaglutide with new users of other antidiabetic drugs used at a similar stage as Ozempic® or Rybelsus® in the treatment of type 2 diabetes (active comparators). Active comparators will include the following non-incretin antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin subdivided into i) basal insulin only and ii) basal + bolus insulin or premix insulin. Propensity scores are used to match new users of semaglutide with new users of active comparators. National prescription-, cancer- and patient registries are used to identify exposure to antidiabetic agents, pancreatic cancer cases, and covariates to be used in propensity score matching. This study is a post-authorisation safety study (PASS).'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 600000, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'semaglutide', 'description': 'New users of Ozempic® or Rybelsus®', 'interventionNames': ['Drug: Ozempic®', 'Drug: Rybelsus®']}, {'label': 'Active comparator', 'description': 'First-time ever users of an active comparator drug', 'interventionNames': ['Drug: Active Comparator']}], 'interventions': [{'type': 'DRUG', 'name': 'Ozempic®', 'description': 'Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.', 'armGroupLabels': ['semaglutide']}, {'type': 'DRUG', 'name': 'Active Comparator', 'description': 'Patients have been treated with commercially available active comparators according to local label and to routine clinical practice at the discretion of the treating physician. Active comparators will include the following antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin. The decision to initiate treatment with commercially available active comparators had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.', 'armGroupLabels': ['Active comparator']}, {'type': 'DRUG', 'name': 'Rybelsus®', 'description': 'Patients have been treated with commercially available Rybelsus® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Rybelsus® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.', 'armGroupLabels': ['semaglutide']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Occurrence of first time malignant neoplasm of pancreas', 'description': 'Incidence', 'timeFrame': 'From when semaglutide entered the market in Denmark, Sweden, and Norway (Q3/Q4 2018) until December 31, 2023'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Use of semaglutide or initiation of active comparators from when the first subject is dispensed semaglutide in the respective country (2018) until December 31, 2022. Initiation is defined as no previous prescription of a drug with the same active ingredient in the past 10 years as recorded in the national prescription registries. Previous use of the same class of drug is however accepted. Further, a patient who shift from Ozempic® to Rybelsus® or vice versa will be considered a continued user in the semaglutide group.\\n* At least two prescriptions of either semaglutide or active comparators (at the level of the active ingredient) with the second prescription filled less than one year after the initial prescription. Two prescriptions filled at first day of treatment will, however, only be counted as one prescription.\\n* 18 years or older at the cohort entry date. The cohort entry date is defined as the dispensing date of the initial prescription (i.e. treatment initiation).\\n* Ten years or more of continuous residency in the country of residence before initiation of semaglutide or active comparators.\\n\\nExclusion Criteria:\\n\\nPatients with rare but strong risk factors for developing pancreatic cancer are excluded. Therefore, patients with any history of the following conditions (identified according to 10th version of International Classification of Diseases \\\\[ICD-10\\\\]) before cohort entry date (based on the last 10 years of data or more) are excluded:\\n\\n* A history of any cancer except non-melanoma skin cancer\\n* Acute pancreatitis\\n* Alcohol-induced chronic pancreatitis\\n* Other chronic pancreatitis\\n* Cystic fibrosis\\n* Other phacomatoses, not elsewhere classified (including Peutz-Jeghers syndrome and Von Hippel-Lindau syndrome)\\n* Neurofibromatosis (non-malignant, Von Recklinghausen disease)\\n\\nIn addition, the following patients are excluded:\\n\\n* Patients with a history of pancreatic cancer as these patients are no longer at risk for an incident pancreatic cancer\\n* Patients who initially started insulin as first-line antidiabetic treatment and who did not add on or switch to non-insulin treatment within 3 months. Those initiating insulin as first-line treatment during the study period is disregarded in terms of study inclusion, although they may be included upon initiating additional therapy, provided it is started within three months.\\n* Patients with polycystic ovary syndrome (PCOS)\\n* Patients with gestational diabetes\\n* Patients who meet one of the conditions used as exclusion criteria listed above (except acute and chronic pancreatitis) after cohort entry date but before start of follow-up (i.e. during the first year after treatment initiation)', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'The risk of pancreatic cancer is compared in a cohort of first-time ever users of semaglutide relative to a cohort of first-time ever users of the other antidiabetic drugs used at a similar stage as Ozempic® or Rybelsus® in the treatment of type 2 diabetes.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Clinical Transparency (1452)', 'affiliation': 'Novo Nordisk A/S', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Novo Nordisk Investigational Site', 'city': 'Odense', 'zip': '5000', 'country': 'Denmark', 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'According to the Novo Nordisk disclosure commitment on novonordisk-trials.com', 'url': 'http://novonordisk-trials.com'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M13110', 'name': 'Pancreatic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'T4387', 'name': 'Pancreatic Cancer', 'asFound': 'Pancreatic Cancer', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000591245', 'term': 'Semaglutide'}], 'ancestors': [{'id': 'D000097789', 'term': 'Glucagon-Like Peptide-1 Receptor Agonists'}, {'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M353561', 'name': 'Semaglutide', 'asFound': 'ICF', 'relevance': 'HIGH'}, {'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M1691', 'name': 'Sodium-Glucose Transporter 2 Inhibitors', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M3401', 'name': 'Glucagon-Like Peptide-1 Receptor Agonists', 'relevance': 'LOW'}, {'id': 'M9043', 'name': 'Glucagon', 'relevance': 'LOW'}, {'id': 'M26997', 'name': 'Glucagon-Like Peptide 1', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02971865', 'orgStudyIdInfo': {'id': '1000CWC'}, 'organization': {'fullName': 'Community Wellness Center, West Linn, OR', 'class': 'OTHER'}, 'briefTitle': 'Effect of Manual Medicine or Cognitive Behavioral Therapy With Chronic Uncontrolled Diabetes', 'officialTitle': 'Effect of Manual Medicine or Cognitive Behavioral Therapy With Chronic Uncontrolled Diabetes Within a Shared Primary Care Visit (A Randomized Clinical Trial)'}, 'statusModule': {'statusVerifiedDate': '2016-11', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2015-06'}, 'primaryCompletionDateStruct': {'date': '2016-07', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2016-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2016-11-14', 'studyFirstSubmitQcDate': '2016-11-20', 'studyFirstPostDateStruct': {'date': '2016-11-23', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2016-11-20', 'lastUpdatePostDateStruct': {'date': '2016-11-23', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Ryan Bellacov', 'investigatorTitle': 'Chairman of the board', 'investigatorAffiliation': 'Community Wellness Center, West Linn, OR'}, 'leadSponsor': {'name': 'Community Wellness Center, West Linn, OR', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'Effects of manual medicine or cognitive behavioral therapy with chronic uncontrolled diabetes within a shared primary care visit. An evaluation of the effectiveness of manual therapy vs cognitive behavioral therapy (CBT) vs traditional primary care visit care is in need.', 'detailedDescription': \"Integrating cognitive behavioral health nutritional therapy (hereafter CBT) and primary care services plays an important role in healthcare outcomes and the prevalence of chronic disorders treated in primary care. The Center of Disease Control has published some disturbing numbers: 9.3% of the U.S. population is affected by diabetes. Ninety-five percent of these individuals will receive treatment from their primary care provider, less than 5% will consult with a dietitian or behavioral health provider. Diabetes is projected to triple in the US despite numerous treatment options and greatly increased medical resources devoted to this problem. There is need for treatments that demonstrate an effectiveness that is low risk and wide spread.\\n\\nA person's state of mind can play an important role in physical and psychosocial health conditions such as diabetes. Depression and diabetes share a bidirectional association. A recent meta-analysis reported that depressed individuals have a 60% increased risk of developing diabetes. An association was found between the risks of developing diabetes and non-severe depression, persistent depression, and untreated depression. Cognitive behavioral therapy, among others, has demonstrated effectiveness for a variety of chronic conditions.\\n\\nBy implementing a shared visit with primary care we encourage the advancement of this new approach. A focus on stress reduction by using mindfulness to encourage patients to think of their body as a whole and heal through not only the use of CBT, but with nutrition and manual therapy. Demonstrating the beneficial effects CBT has on uncontrolled diabetes will offer another psychosocial treatment option for the large number of suffering US residents. CBT and other mindfulness-based interventions have been recognized as helpful for a range of conditions including chronic pain. However, only 1 large randomized clinical trial (RCT) has evaluated CBT for chronic low back pain, and that trial was limited to older adults.\\n\\nThis clinical trial also includes chiropractic manipulative treatment (CMT) with uncontrolled diabetes patients. This study is unique due to the lack of any pre-existing trials of this nature. CMT has demonstrated improvement in physical function. A compromise of the peripheral nervous system is a common long-term complication of diabetes. In severe cases, this can lead to limb amputations and sudden cardiac death secondary to autonomic polyneuropathy. Proper recognition of the musculoskeletal manifestations of patients with diabetes will aid the treating chiropractor and alert them to the possible neurological consequences of diabetes.\"}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2'], 'keywords': ['Cognitive Behavior Therapy', 'Chiropractic', 'Diabetes Mellitus, Type 2', 'Primary care shared visit']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 72, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'CBT/CMT', 'type': 'EXPERIMENTAL', 'description': 'The CBT/CMT program does not focus specifically on a particular condition such as diabetes. All treatment included patient education on nutrition content and mindfulness practice (emotions, and sensations in the present moment without trying to change them, awareness of breathing, and social economic problems) with manual therapy.', 'interventionNames': ['Behavioral: CBT/CMT']}, {'label': 'traditional primary care visit', 'type': 'ACTIVE_COMPARATOR', 'description': 'Provide high quality primary care for men, women, and children of all ages. Our providers work together to ensure that you receive the most comprehensive care possible. Primary care is described as the medical setting in which patients receive most of their medical care and, therefore, is typically their first source for treatment', 'interventionNames': ['Other: Control group traditional primary care']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'CBT/CMT', 'description': 'Cognitive Behavioral Therapy (CBT - training to change nutritional thoughts and behaviors) and Chiropractic Manipulative Therapy (CMT - High Velocity, low amplitude chiropractic manipulation) were delivered in average total 8 visits in a year. The interventions were comparable in format (individual visit), duration (30 minute visits), frequency (monthly), and number of participants per group (see intervention details). Each intervention was delivered according to a protocol in which all instructors were trained. (Figure 3: Chiropractic/Behavioral health and Primary care Integration Protocol.) Routine care varied with patient complaints at the time of visit.', 'armGroupLabels': ['CBT/CMT'], 'otherNames': ['Cognitive Behavioral Therapy', 'Chiropractic Manipulative Therapy']}, {'type': 'OTHER', 'name': 'Control group traditional primary care', 'description': 'No change in care usually given', 'armGroupLabels': ['traditional primary care visit']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'hemoglobin A1c', 'description': 'lab values (\\\\[hemoglobin A1c\\\\]; range, 1-20%', 'timeFrame': 'One year'}, {'measure': 'Consumer Assessment of Healthcare Providers and Systems (CAHPS)', 'description': '31 questions with three categories version 3.0 done at one year', 'timeFrame': 'One year'}], 'secondaryOutcomes': [{'measure': 'Patient Health Questionnaire-9 (PHQ-9', 'description': 'PHQ-9; range, 0-27; higher scores indicate greater severity).15 The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders. 14 The PHQ-9 is the depression module, which scores each of the 9 Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria as \"0\" (not at all) to \"3\" (nearly every day).', 'timeFrame': 'One year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\nHemoglobin A1c above 9%\\n\\nExclusion Criteria:\\n\\n* 0-18 years old', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Community Wellness Center', 'city': 'West Linn', 'state': 'Oregon', 'zip': '97068', 'country': 'United States', 'geoPoint': {'lat': 45.36568, 'lon': -122.61231}}]}, 'referencesModule': {'references': [{'pmid': '19033418', 'type': 'RESULT', 'citation': 'Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008 Dec;31(12):2383-90. doi: 10.2337/dc08-0985.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Plan to share individual participant data with other researchers via Journal of Manipulative and Physiological Therapeutics (JMPT). Also, annual collaborative of primary care providers in Oregon.'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'T1303', 'name': 'Chronic Graft Versus Host Disease', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05479565', 'orgStudyIdInfo': {'id': 'Arterial stiffness, GDM'}, 'organization': {'fullName': 'University of Mostar', 'class': 'OTHER'}, 'briefTitle': 'Relationship of Reduced Arterial Stiffness and Hs-CRP With GDM.', 'officialTitle': 'The Association of Reduced Arterial Stiffness and Highly Sensitive C-reactive Protein With Gestational Diabetes Mellitus.'}, 'statusModule': {'statusVerifiedDate': '2023-12', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2020-09-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-09-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2023-09-01', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2022-07-14', 'studyFirstSubmitQcDate': '2022-07-26', 'studyFirstPostDateStruct': {'date': '2022-07-29', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-12-02', 'lastUpdatePostDateStruct': {'date': '2023-12-05', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Ana Dugandžić Šimić', 'investigatorTitle': 'mr. sc. Ana Dugandžić Šimić, ob/gyn specialist', 'investigatorAffiliation': 'University of Mostar'}, 'leadSponsor': {'name': 'University of Mostar', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Research hypotheses\\n\\n1. The arterial stiffness in pregnant women with gestational diabetes is reduced compared to healthy pregnant women.\\n2. The values of highly sensitive CRP in pregnant women with gestational diabetes are higher compared to healthy pregnant women.\\n3. The arterial stiffness in test subjects with previous gestational diabetes was reduced compared to test subjects with a previously normal OGTT during pregnancy.\\n4. The values of highly sensitive CRP in subjects with previous gestational diabetes are higher compared to subjects with previously normal OGTT during pregnancy.', 'detailedDescription': \"Gestational diabetes is a growing problem at the global level, and it brings with it numerous perinatal and maternal complications. In addition, it is associated with a higher risk of developing type 2 diabetes and cardiovascular disease later in life. However, the mechanisms by which this happens have not been fully elucidated, which is why the possibilities of prevention are limited. Insulin resistance is recognized as a cause of GDM and associated with a decrease in arterial elasticity due to its pro-inflammatory pathogenesis, which is manifested by an increase in pro-inflammatory biomarkers, such as hs CRP. However, the application of these findings has not yet taken root in practice.\\n\\nIt is necessary to find reliable methods of screening pregnant women with GDM who have an increased risk of developing complications both during pregnancy and later in life.\\n\\nReduced arterial elasticity is recognized as a predictor of cardiovascular diseases, and its measurement is recommended to be introduced into clinical practice. On the other hand, measuring hsCRP is simple and available, but its practical application is still questionable and additional research is needed. Several studies have attempted to link GDM with reduced arterial elasticity and/or increased hs CRP, but the conclusions are contradictory, probably due to the small number of subjects. On the other hand, I did not find studies that measured the mentioned parameters just after delivery for the purpose of predicting cardiovascular risk (80-82 ref from MR).\\n\\nThis research will try to prove the association of GDM with reduced arterial stiffness and elevated hsCRP values. The results will attempt to justify the introduction into clinical practice of measuring arterial elasticity and hsCRP in order to find pregnant women at risk of developing complications during and after pregnancy.\\n\\nResearch objectives\\n\\nMain goals:\\n\\n* To compare the arterial stiffness in pregnant women with gestational diabetes and healthy pregnant women.\\n* To compare the values of highly sensitive CRP in pregnant women with gestational diabetes and healthy pregnant women\\n* To determine whether the occurrence of cardiovascular diseases during pregnancy can be predicted by measuring the arterial stiffness and hs CRP in healthy pregnant women and pregnant women with GDM\\n\\nSecondary objectives:\\n\\n* To compare the occurrence of pregnancy complications and perinatal outcome in pregnant women with gestational diabetes and healthy pregnant women.\\n* To compare the srterial stiffness and the values of highly sensitive CRP in two groups of subjects 2-6 months after pregnancy.\\n\\nThe purpose of the research\\n\\nMeasurement of arterial stiffness and high-sensitivity CRP values could, based on the results of this study, be introduced into clinical practice as predictors of GDM-related complications in pregnancy and later in life.\\n\\nResearch hypotheses\\n\\n1. The arterial stiffness in pregnant women with gestational diabetes is reduced compared to healthy pregnant women.\\n2. The values of highly sensitive CRP in pregnant women with gestational diabetes are higher compared to healthy pregnant women.\\n3. The arterial stiffness in test subjects with previous gestational diabetes was reduced compared to test subjects with a previously normal OGTT during pregnancy.\\n4. The values of highly sensitive CRP in subjects with previous gestational diabetes are higher compared to subjects with previously normal OGTT during pregnancy.\\n\\nRespondents:\\n\\n1. 100 pregnant women from the 28th to the 40th week of pregnancy (in the third trimester), who, as part of regular perinatal care, took the oral glucose tolerance test (OGTT), divided into two groups:\\n\\n   * 50 pregnant women with pathological findings of OGTT i\\n   * 50 pregnant women with regular OGTT.\\n\\n   The diagnosis of gestational diabetes will be made on the basis of the pathological findings of the OGTT, according to WHO criteria from 2013: the OGTT will be performed with 75 g of glucose, and it is sufficient that only one of the stated concentrations of glucose taken from the mother's venous blood plasma is equal to or higher from borderline:\\n   * fasting glycemia ≥ 5.1 mmol/l,\\n   * glycemia after 1h ≥ 10 mmol/l,\\n   * glycemia after 2h ≥ 8.5mmol/l.\\n\\n   At the same time, the glycemic values must not meet the criteria for manifest diabetes:\\n   * fasting glycemia ≥ 7.0 mmol/l,\\n   * glycemia after 2 h ≥ 11.1 mmol/l,\\n   * glycemia at any time ≥ 11.1 mmol/l with the presence of diabetes symptoms.\\n\\n   Criteria for the inclusion of test subjects:\\n   * age between 18 and 35 years\\n   * previously healthy women\\n   * previously normal course of pregnancy\\n   * singleton pregnancies\\n   * non-smokers\\n\\n   Exclusion criteria:\\n   * pregestational diabetes\\n   * gestational diabetes and/or hypertensive disorders in pregnancy in previous pregnancies\\n   * hypertensive disorders during pregnancy at the time of examination\\n   * chronic diseases\\n   * pregnant women whose partner previously had a partner with preeclampsia.\\n2. Two to six months after delivery of the same test subjects, divided into the same two groups: 50 test subjects with previous normal OGTT during pregnancy and 50 test subjects with previous gestational diabetes.\\n\\nThe test subjects will have a venous blood sample taken to determine the value of highly sensitive C-reactive C protein from the serum and measure the arterial stiffness.\\n\\nThe non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness.\\n\\nThe indicators of arterial stiffnesses, which will be used in the analysis, will be:\\n\\n* pulse wave speed,\\n* central systolic pressure,\\n* peripheral and central values of the augmentation index,\\n* peripheral and central pulse pressure values.\\n\\nPregnant women will then be monitored until delivery, in order to determine whether they will develop the following pregnancy complications:\\n\\n* hypertensive disorders (gestational hypertension, preeclampsia, eclampsia)\\n* induction of labor (iatrogenic labor induction)\\n* operative completion of childbirth (caesarean section or vacuum extraction)\\n\\nAlso, it will be determined what the perinatal outcome of the newborn will be, i.e. whether there will be:\\n\\n* macrosomia (newborn weight above 4000 g),\\n* a newborn large for gestational age, a newborn weighing more than the 90th percentile for gestational age.\\n* trauma during childbirth (shoulder dystocia, clavicle fracture, brachial plexus injuries),\\n* metabolic disorders of the newborn (hypoglycemia, hypomagnesemia, hypocalcemia, hyperviscosity syndrome, occurrence of neonatal jaundice),\\n* stay in the Neonatal Intensive Care Unit.\"}, 'conditionsModule': {'conditions': ['Gestational Diabetes']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Peripheral blood.'}, 'enrollmentInfo': {'count': 100, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': '50 pregnant women with patological OGTT', 'description': '50 pregnant women with patological OGTT ( glucose load test) and after delivery - 50 women with GDM in previous pregnancy.', 'interventionNames': ['Diagnostic Test: venous blood sample for determining the value of highly sensitive C-reactive C protein from serum']}, {'label': '50 pregnant women with regular OGTT', 'description': '50 pregnant women with regular OGTT ( glucose load test) and after delivery - 50 women without GDM in previous pregnancy', 'interventionNames': ['Diagnostic Test: venous blood sample for determining the value of highly sensitive C-reactive C protein from serum']}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'venous blood sample for determining the value of highly sensitive C-reactive C protein from serum', 'description': 'The non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness. In a quiet room at room temperature, the subjects will lie relaxed for 15 minutes before the start of the measurement. After that, the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, will be measured with a gynecological compass, and the resulting value will be entered into the device.', 'armGroupLabels': ['50 pregnant women with patological OGTT', '50 pregnant women with regular OGTT'], 'otherNames': ['measuring the arterial stiffness']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The arterial stiffness in pregnant women with gestational diabetes is reduced compared to healthy pregnant women.', 'description': 'The non-invasive oscillometric device Arteriograph will be used to measure the arterial stiffness.The examiners will use a gynecological divider to measure the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, and the obtained value will be entered into the device', 'timeFrame': 'between 28 and 40 weeks of gestation'}, {'measure': 'The values of highly sensitive CRP in pregnant women with gestational diabetes are higher compared to healthy pregnant women.', 'description': 'The test subjects will have a venous blood sample taken to determine the value of highly sensitive C-reactive C protein from the serum.', 'timeFrame': 'between 28 and 40 weeks of gestation'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* age between 18 and 35 years\\n* previously healthy women\\n* previously normal course of pregnancy\\n* singleton pregnancies\\n* non-smokers\\n\\nExclusion Criteria:\\n\\n* pregestational diabetes\\n* gestational diabetes and/or hypertensive disorders in pregnancy in previous pregnancies\\n* hypertensive disorders during pregnancy at the time of examination\\n* chronic diseases\\n* pregnant women whose partner previously had a partner with preeclampsia', 'healthyVolunteers': True, 'sex': 'FEMALE', 'genderBased': True, 'minimumAge': '18 Years', 'maximumAge': '35 Years', 'stdAges': ['ADULT'], 'studyPopulation': '* age between 18 and 35 years\\n* previously healthy women\\n* previously normal course of pregnancy\\n* singleton pregnancies\\n* non-smokers', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Vajdana Tomić, prof.dr.sc.', 'affiliation': 'Faculty of Health Studies, Mostar', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'University of Mostar', 'city': 'Mostar', 'zip': '88000', 'country': 'Bosnia and Herzegovina', 'geoPoint': {'lat': 43.34333, 'lon': 17.80806}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'All of the individual participant data collected during the trial, after deidentification.', 'infoTypes': ['STUDY_PROTOCOL', 'ICF', 'CSR', 'ANALYTIC_CODE'], 'timeFrame': 'Beginning 3 months and ending 5 Years folowing article publication.', 'accessCriteria': 'Investigators whose proposed use the Data has been approved by an Independent review committee identified for this purpose.'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016640', 'term': 'Diabetes, Gestational'}], 'ancestors': [{'id': 'D011248', 'term': 'Pregnancy Complications'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M19012', 'name': 'Diabetes, Gestational', 'asFound': 'Gestational Diabetes', 'relevance': 'HIGH'}, {'id': 'M10018', 'name': 'Hypersensitivity', 'relevance': 'LOW'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00335465', 'orgStudyIdInfo': {'id': 'HOE901_4053'}, 'secondaryIdInfos': [{'id': 'EUDRACT # : 2004-002729-34'}], 'organization': {'fullName': 'Sanofi', 'class': 'INDUSTRY'}, 'briefTitle': 'Lantus Effect on Myocardial Glucose Metabolism in T2', 'officialTitle': 'Pilot Study for the Evaluation of the Effects of Insulin Treatment on Myocardial Function, Perfusion, and Glucose Metabolism in Patients With Primary Left Ventricular Dysfunction and Type 2 Diabetes.'}, 'statusModule': {'statusVerifiedDate': '2009-12', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2005-09'}, 'primaryCompletionDateStruct': {'date': '2008-06', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2008-06', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2006-06-08', 'studyFirstSubmitQcDate': '2006-06-08', 'studyFirstPostDateStruct': {'date': '2006-06-09', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2009-12-04', 'lastUpdatePostDateStruct': {'date': '2009-12-07', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Medical Affairs Study Director', 'oldOrganization': 'sanofi-aventis'}, 'leadSponsor': {'name': 'Sanofi', 'class': 'INDUSTRY'}}, 'descriptionModule': {'briefSummary': 'The primary objective of the present study is to assess changes of myocardial glucose uptake (MGU) during clamp studies using positron emission tomography (PET) scanning in patients with type 2 diabetes and idiopathic left ventricular dysfunction (LVD).\\n\\nThe secondary objectives of the study are: assessment of changes of myocardial microcirculation at rest and during adenosine stimulation using PET; assessment of changes in myocardial structure and function evaluated by magnetic resonance imaging (MRI); assessment of glycaemic control by measurement of HbA1c, fasting blood glucose and insulin levels; assessment of safety (adverse event profile, laboratory data).'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 15, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'interventions': [{'type': 'DRUG', 'name': 'Insulin glargine', 'description': 'once a daily, sc injection, 100IU/ml'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'effect of insulin treatment on myocardial function, perfusion and glucose metabolism.', 'timeFrame': 'assessed before and after treatment'}, {'measure': 'adverse events', 'timeFrame': 'throughout the study'}], 'secondaryOutcomes': [{'measure': 'changes of myocardial structure and left ventricular systolic and diastolic function', 'timeFrame': 'at baseline and at the end of the study'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* LV systolic dysfunction (2D-Echo LVEF \\\\< 50%) with or without LV dilation (2D-Echo LV EDD \\\\> 56 mm) or left ventricular end-diastolic diameter (LVEDD) \\\\>55mm with or without LV dysfunction\\n* angiographically normal coronary arteries (\\\\< 50% vessel narrowing);\\n* newly diagnosed type 2 diabetes;\\n* previously diagnosed: OAD treated type 2 diabetic patients able to take part in the study after a one-month wash-out period and insulin treated type 2 diabetic patients able to take part in the study after one week wash-out period.\\n\\nExclusion Criteria:\\n\\n* evidence of congenital or valvular cardiac diseases, hypertrophic cardiomyopathy, overt heart failure (NYHA class III-IV);\\n* moderate to severe hypertension (diastolic aortic pressure \\\\> 100 mmHg);\\n* hypotension (systolic aortic pressure \\\\< 100 mmHg);\\n* nephropathy (serum creatinine \\\\> 3 mg/dL);\\n* other systemic and/or infective diseases;\\n* severe dyslipidemia;\\n* peripheral vasculopathy;\\n* necessity of vasoactive medical treatment in the last 48 hours;\\n* atrial fibrillation;\\n* Refusal or impossibility to give written informed consent;\\n* patients diagnosed with type 1 insulin dependent diabetes;\\n* clinically relevant cardiovascular, hepatic, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult;\\n* patients with medical history positive for cerebrovascular accidents, including Transient Ischaemic Attack (TIA);\\n* women who are lactating, pregnant, or planning to become pregnant during the study;\\n* history of hypersensitivity to the investigational products or to drugs with similar chemical structures;\\n* likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol;\\n* treatment with any investigational product in the last 30 days or 5 half-lives (whichever is longer) before study entry;\\n* current use of investigational agents or participation in any other investigational studies during study period;\\n* history of drug or alcohol abuse;\\n* impaired hepatic function, as shown by Alamine AminoTransferase (ALT) \\\\> 2,5 times the upper limit of the normal laboratory range;\\n* mental condition making the subject unable to understand the nature, scope, and possible consequences of the study;\\n* patients unable to understand dosing directions;\\n* subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study procedures;\\n* receipt of an experimental drug or use of an experimental device within the 30 days prior to study entry;\\n* previous enrollment in the present study.\\n\\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Georges Paizis, MD', 'affiliation': 'Sanofi', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Sanofi-Aventis Administrative Office', 'city': 'Milan', 'country': 'Italy', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}]}, 'referencesModule': {'references': [{'pmid': '22752026', 'type': 'DERIVED', 'citation': 'Masi S, Lautamaki R, Guiducci L, Di Cecco P, Porciello C, Pardini S, Morales MA, Chubuchny V, Salvadori PA, Emdin M, Sironi AM, Knuuti J, Neglia D, Nuutila P, Ferrannini E, Iozzo P. Similar patterns of myocardial metabolism and perfusion in patients with type 2 diabetes and heart disease of ischaemic and non-ischaemic origin. Diabetologia. 2012 Sep;55(9):2494-500. doi: 10.1007/s00125-012-2631-0. Epub 2012 Jul 1.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M20824', 'name': 'Ventricular Dysfunction', 'relevance': 'LOW'}, {'id': 'M20591', 'name': 'Ventricular Dysfunction, Left', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069036', 'term': 'Insulin Glargine'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M347', 'name': 'Insulin Glargine', 'asFound': 'Oral administration', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00491465', 'orgStudyIdInfo': {'id': 'rmc074301ctil'}, 'organization': {'fullName': 'Rabin Medical Center', 'class': 'OTHER'}, 'briefTitle': 'The Role of Physical Activity in the Treatment of Children With Type 1 Diabetes.', 'officialTitle': 'Randomized,Controlled,Open,Cross-Over Intervention Study for Evaluating the Role of Physical Activity in the Treatment of Children With Type 1 Diabetes.', 'acronym': '4301'}, 'statusModule': {'statusVerifiedDate': '2007-06', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2007-07'}, 'completionDateStruct': {'date': '2009-07', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2007-06-25', 'studyFirstSubmitQcDate': '2007-06-25', 'studyFirstPostDateStruct': {'date': '2007-06-26', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2007-06-25', 'lastUpdatePostDateStruct': {'date': '2007-06-26', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Rabin Medical Center', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Randomized, controlled, open, comparative intervention study in two groups, each consisting of 25 children with type 1 diabetes that will undergo twelve weeks of exercise program (intensive arm) and twelve weeks of regular activity (non intensive arm) separated by four week of washout period. The study will be conducted in a crossover manner: one group starting with the intensive arm followed by the non intensive arm and vice versa. Blood glucose, HbA1C, Fructosamine, 3 days continuous glucose monitoring system (CGMS), total daily insulin dose, fasting lipid profile, body impedance and BMR will be measured. Self esteem and quality of life questionnaires will be filled.', 'detailedDescription': \"Randomized, controlled, open, comparative, cross-over, intervention study in 50 children with type 1 diabetes.\\n\\nobjectives:\\n\\nPrimary objective To evaluate the efficacy and safety of physical activity for metabolic control in children with type I diabetes.\\n\\nSecondary objectives\\n\\n1. To characterize the severity and pattern of occurrence of hypo and hyperglycemic episodes during and after exercise program in type I diabetic children.\\n2. To evaluate changes in insulin sensitivity during and after periods of exercise in type I diabetic children.\\n3. To evaluate the short term effect of exercise on BMI and body composition in type I diabetic children.\\n4. To evaluate the short term effect of exercise on lipid profile in type I diabetic children.\\n5. To evaluate differences in self esteem and quality of life between exercising and non exercising type I diabetic children.\\n\\nRandomization:\\n\\nChildren will be randomly allocated into two groups of 25.The study will be conducted in a crossover manner:one group starting with the intensive arm followed by the non intensive arm and vice versa.\\n\\nmethods:\\n\\n1. The study will have an intensive arm and a non intensive arm, each lasting 12 weeks.\\n2. Children fulfilling the inclusion and exclusion criteria will be randomly assigned to two groups. Each group will include 25 patients.\\n3. Participants will fill questionnaires regarding physical activity.\\n4. The first group will start with the intensive arm, followed by one month washout, and then the non intensive arm.\\n5. The second group will start the study with the non intensive arm, followed by one month washout and then the intensive arm .\\n6. The intensive arm will consist of an exercise program which will include high intensity progressive exercise (75% maximum age adjusted heart rate HRmax) 3 days a week for 90 minutes. The 90 min exercise will be a combination of aerobic exercise 45min. and resistance exercise 45 min.\\n7. The exercise program will be planned and carried out by professional sports instructors.\\n8. During the non intensive arm the participants will resume regular daily activity. They will keep records of their weekly physical activity and will get a weekly phone call from the treating doctor, addressing specifically physical activity performed during the past week and glucose levels before and after exercise.\\n9. The following parameters will be measured for both groups at the beginning and the end of the intensive and non intensive arm and once again 12 weeks afterwards : Weight, height, pulse, blood pressure, waist circumference, skin folds, HbA1C , fructosamine ,3 days CGMS +3 day SBGM profile (will be measured to 40% of participants chosen randomly) ,total daily insulin dose ,blood sample for fasting lipid profile ,Body impedance and BMR , self esteem and quality of life questionnaires .\\n10. Study participants will be required to measure blood glucose by glucometer at least 4 times a day and to record hypo and hyperglycemic events and their severity.\\n\\n15.Both children and investigators will be blinded to CGMS results. 16.During the 3 day CGMS recording, the children's parents will be asked to monitor SBGM once during the night (in the intensive arm, following the exercise day).\"}, 'conditionsModule': {'conditions': ['Type 1 Diabetes'], 'keywords': ['Type 1 Diabetes, physical activity, pediatric, metabolic control']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 2007, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'interventions': [{'type': 'BEHAVIORAL', 'name': 'Intensive Physical activity'}, {'type': 'BEHAVIORAL', 'name': 'Control- regular physical activity'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1C', 'timeFrame': '0,3 monthes'}, {'measure': 'fructosamine', 'timeFrame': '0,3 monthes'}], 'secondaryOutcomes': [{'measure': 'Body composition & BMR', 'timeFrame': '0,3 monthes'}, {'measure': 'Self esteem & QOL questionnaires', 'timeFrame': 'o, 3 monthes'}, {'measure': '3 days CGMS & SBGM profile', 'timeFrame': '0,3 monthes'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Type I diabetic children\\n2. Tanner stage II-IV\\n3. Patients of the Schneider's national institute of childhood diabetes. Duration of diabetes\\n4. more than one year.\\n5. HbA1C between 8 and 12 at time 0.\\n6. Mandatory 4 daily self blood glucose measurements and daily recording of adverse events.\\n7. A signed informed consent of the parents and child.\\n\\nExclusion Criteria:\\n\\n1. Additional chronic significant disease such as cardiac, liver, renal disease .\\n2. Children who exercise regularly more than 180 min per week.\\n3. Cardiac symptoms: history of chest pain , syncope , palpitations or dyspnea during exercise.\\n4. Eating disorders.\\n5. Participation in a study during the past month.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '8 Years', 'maximumAge': '16 Years', 'stdAges': ['CHILD']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Ravital Nimri, MD', 'role': 'CONTACT', 'phone': '972-39253778', 'phoneExt': 'direct', 'email': 'ravitaln@clalit.org.il'}], 'overallOfficials': [{'name': 'Ravital Nimri, MD', 'affiliation': 'Rabin Medical Center', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Moshe Phillip, Prof', 'affiliation': 'Rabin Medical Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': \"Schnider children's medical center\", 'city': 'Petach-Tikva', 'country': 'Israel', 'contacts': [{'name': 'Ravital Nimri, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Moshe Phillip, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Rachel Frumkin, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Neomi Weintrob, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Shlomit Shalitin, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Nesia Nagelberg, MA', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}, {'id': 'T4202', 'name': 'Oculocerebral Syndrome With Hypopigmentation', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01918865', 'orgStudyIdInfo': {'id': 'ISIS 404173-CS2'}, 'organization': {'fullName': 'Ionis Pharmaceuticals, Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes', 'officialTitle': 'A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 404173 Administered Once Weekly to Obese Patients With Type 2 Diabetes Mellitus Being Treated With Metformin or Metformin Plus Sulfonylurea'}, 'statusModule': {'statusVerifiedDate': '2014-09', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-08'}, 'primaryCompletionDateStruct': {'date': '2014-10', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2015-02', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2013-08-05', 'studyFirstSubmitQcDate': '2013-08-07', 'studyFirstPostDateStruct': {'date': '2013-08-08', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-02-27', 'lastUpdatePostDateStruct': {'date': '2015-03-03', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Ionis Pharmaceuticals, Inc.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus', 'Obese'], 'keywords': ['Type 2 Diabetes Mellitus', 'T2DM']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 92, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'ISIS-PTP1BRx', 'type': 'EXPERIMENTAL', 'description': 'Weekly Dosing for 26 Weeks', 'interventionNames': ['Drug: ISIS-PTP1BRx', 'Drug: daily OAD (metformin and/or sulfonylurea)']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Weekly Dosing for 26 Weeks', 'interventionNames': ['Drug: Placebo', 'Drug: daily OAD (metformin and/or sulfonylurea)']}], 'interventions': [{'type': 'DRUG', 'name': 'ISIS-PTP1BRx', 'armGroupLabels': ['ISIS-PTP1BRx']}, {'type': 'DRUG', 'name': 'Placebo', 'armGroupLabels': ['Placebo']}, {'type': 'DRUG', 'name': 'daily OAD (metformin and/or sulfonylurea)', 'armGroupLabels': ['ISIS-PTP1BRx', 'Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence, severity, dose-relationship of adverse effects, and changes in laboratory evaluations as a measure of safety', 'timeFrame': '38 weeks'}, {'measure': 'Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy', 'timeFrame': '27 weeks'}], 'secondaryOutcomes': [{'measure': 'Change in FPG, weekly average SMPG, seven-point glucose profile, lipid profile, body weight, & BMI at Week 27 compared to Baseline as a measure of efficacy', 'timeFrame': '27 Weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Body mass index (BMI) \\\\>/= 27 kg/m2\\n* HbA1c between 7.5% and 10.5% (inclusive)\\n* C-Peptide (fasting) greater than or equal to 500 pmol/L\\n* On stable dose of metformin alone or in combination with a stable dose of sulfonylurea for \\\\>/= 3 months prior to screening, and remain on stable dose throughout the study\\n* Agree to conduct home-based (fasted) blood glucose testing as directed\\n\\nExclusion Criteria:\\n\\n* Clinically significant abnormalities in medical history or physical exam\\n* Serum creatinine \\\\> ULN at Screening\\n* Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT or AST \\\\> 1.5x ULN at Screening\\n* History of renal transplantation or renal dialysis\\n* GFR \\\\< 60 mL/min at Screening\\n* History of diabetic ketoacidosis\\n* History of greater than 3 episodes of severe hypoglycemia within 6 months of screening\\n* Allergy to sulfur containing drugs\\n* Treatment with other drugs or medications not allowed per study specific Disallowed Concomitant Medicines\\n* Any other significant illness or condition that may interfere with the patient participating or completing the study\\n* Inability or unwillingness to comply with protocol or study procedures', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Isis Investigative Site', 'city': 'Mar del Plata', 'state': 'Buenos Aires', 'zip': 'B7600FZN', 'country': 'Argentina', 'geoPoint': {'lat': -38.00228, 'lon': -57.55754}}, {'facility': 'Isis Investigative Site', 'city': 'Rosario', 'state': 'Santa Fe', 'zip': 'S2000CVD', 'country': 'Argentina', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'facility': 'Isis Investigational Site', 'city': 'Edmonton', 'state': 'Alberta', 'zip': 'T6G 2E1', 'country': 'Canada', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'facility': 'Isis Investigational Site', 'city': 'Kelowna', 'state': 'British Columbia', 'zip': 'V1Y 3G8', 'country': 'Canada', 'geoPoint': {'lat': 49.88307, 'lon': -119.48568}}, {'facility': 'Isis Investigational Site', 'city': 'Vancouver', 'state': 'British Columbia', 'zip': 'V6J 1S3', 'country': 'Canada', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'facility': 'Isis Investigational Site', 'city': 'Etobicoke', 'state': 'Ontario', 'zip': 'M9R 4E1', 'country': 'Canada', 'geoPoint': {'lat': 43.65421, 'lon': -79.56711}}, {'facility': 'Isis Investigational Site', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M4G 3E8', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Isis Investigative Site', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M9V 4B4', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Isis Investigational Site', 'city': 'Saskatoon', 'state': 'Saskatchewan', 'zip': 'S7K 3H3', 'country': 'Canada', 'geoPoint': {'lat': 52.13238, 'lon': -106.66892}}, {'facility': 'Isis Investigational Site', 'city': 'Centurion', 'state': 'Gauteng', 'zip': '0154', 'country': 'South Africa', 'geoPoint': {'lat': -25.85891, 'lon': 28.18577}}, {'facility': 'Isis Investigational Site', 'city': 'Mamelodi', 'state': 'Gauteng', 'zip': '0122', 'country': 'South Africa', 'geoPoint': {'lat': -25.71301, 'lon': 28.36534}}, {'facility': 'Isis Investigational Site', 'city': 'Pretoria', 'state': 'Gauteng', 'zip': '0001', 'country': 'South Africa', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'facility': 'Isis Investigational Site', 'city': 'Port Elizabeth', 'state': 'Korsten', 'country': 'South Africa', 'geoPoint': {'lat': -33.91799, 'lon': 25.57007}}, {'facility': 'Isis Investigational Site', 'city': 'Durban', 'state': 'KwaZulu-Natal', 'country': 'South Africa', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'facility': 'Isis Investigational Site', 'city': 'Middelburg', 'state': 'Mpumalanga', 'country': 'South Africa', 'geoPoint': {'lat': -25.77507, 'lon': 29.46482}}, {'facility': 'Isis Investigational Site', 'city': 'Limpopo', 'state': 'Thabazimbi', 'zip': '0380', 'country': 'South Africa'}, {'facility': 'Isis Investigational Site', 'city': 'Cape Town', 'state': 'Western Cape', 'zip': '7570', 'country': 'South Africa', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'facility': 'Isis Investigational Site', 'city': 'Cape Town', 'state': 'Western Cape', 'country': 'South Africa', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'facility': 'Isis Investigational Site', 'city': 'Benoni', 'zip': '1500', 'country': 'South Africa', 'geoPoint': {'lat': -26.18848, 'lon': 28.32078}}, {'facility': 'Isis Investigational Site', 'city': 'Bloemfontein', 'zip': '9301', 'country': 'South Africa', 'geoPoint': {'lat': -29.12107, 'lon': 26.214}}, {'facility': 'Isis Investigational Site', 'city': 'Pretoria', 'zip': '0184', 'country': 'South Africa', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}]}, 'referencesModule': {'references': [{'pmid': '29439147', 'type': 'DERIVED', 'citation': 'Digenio A, Pham NC, Watts LM, Morgan ES, Jung SW, Baker BF, Geary RS, Bhanot S. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes. Diabetes Care. 2018 Apr;41(4):807-814. doi: 10.2337/dc17-2132. Epub 2018 Feb 9.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D008687', 'term': 'Metformin'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M11667', 'name': 'Metformin', 'asFound': 'Tumor', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01935765', 'orgStudyIdInfo': {'id': 'P111009'}, 'organization': {'fullName': 'Assistance Publique - Hôpitaux de Paris', 'class': 'OTHER'}, 'briefTitle': 'Sleep Apnea in Type 1 Diabetes', 'officialTitle': 'Sleep Apnea in Type 1 Diabetes : Prevalence, Role of Glycemic Control and Autonomic Neuropathy', 'acronym': 'DIASOM'}, 'statusModule': {'statusVerifiedDate': '2019-12', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-06', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2019-09', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2013-09-02', 'studyFirstSubmitQcDate': '2013-09-02', 'studyFirstPostDateStruct': {'date': '2013-09-05', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-12-04', 'lastUpdatePostDateStruct': {'date': '2019-12-05', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Assistance Publique - Hôpitaux de Paris', 'class': 'OTHER'}, 'collaborators': [{'name': 'Ministry of Health, France', 'class': 'OTHER_GOV'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Sleep apnea syndrome is strongly associated to type 2 diabet, partly and this is partly due to obesity. Treatment of sleep apnea may improve hypertension, cardiovascular risk and in some studies diabetes status. Few data are available for type 1 diabetes but suggest that the prevalence of sleep apnea syndrome may be high. We plan to compare the prevalence of sleep apnea syndrome assessed by polysomnography in a sample of type 1 diabetic patients and a control group matched by age, gender and body mass index. The secondary objective is to determine if the presence of an autonomic neuropathy or poorly controlled diabetes (assessed by glycosylated haemoglobin) may or not contribute to the presence of sleep apnea in the diabetic group.', 'detailedDescription': 'Diagnostic protocol designed to evaluate if if sleep apnea syndrome is more frequent in type 1 diabetes than in general population and therefore deserves to be more systematically suspected and actively diagnosed in this patients. Sleep apnea syndrome is a heavy burden as a matter of quality of life: it is responsible for fatigue, diurnal sleepiness, cognitive impairment, poor and /or non restorative sleep, morning headaches, depressive mood...Adequate treatment provides a rapid and, most of the time, complete relief of these symptoms.\\n\\nOn an other hand, Sleep Apnea is and independent risk factor for cardiovascular mortality and morbidity in young and middle aged subjects, also reversed by treatment. It might be therefore important for type 1 diabetic patients who have already an increased cardiovascular risk to be properly diagnosed for sleep apnea. A systematic screening for sleep apnea is already recommended for patients with type 2 diabetes by experts.\\n\\nA secondary objective is to determine if the presence of a sleep apnea syndrome in type 1 diabetic patients is associated to an autonomic neuropathy, a poor glycemic control , a poorer quality of life , a poorer quality of sleep, more severe cardiovascular consequences and biological impairment.'}, 'conditionsModule': {'conditions': ['Type 1 Diabetes, Sleep Apnea Syndrome'], 'keywords': ['Type 1 diabetes, sleep apnea, polysomnography,', 'autonomic neuropathy, intima media thickness']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 94, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Diabetes people', 'type': 'EXPERIMENTAL', 'description': '99 Type 1 diabetic patients aged 18 to 60 years, diagnosed since at least a year', 'interventionNames': ['Other: Polysomnography', 'Other: Evaluation of the autonomous nervous system', 'Other: Clinical examination of the sleep', 'Other: Clinical examination of diabetology', 'Other: Biological dosages', 'Other: Electrocardiogram (ECG)', 'Other: Carotid echography', 'Other: Blood pressure']}, {'label': 'healthy volunteers (controll group)', 'type': 'EXPERIMENTAL', 'description': '46 healthy volunteers matched by age, gender and body mass index', 'interventionNames': ['Other: Polysomnography', 'Other: Evaluation of the autonomous nervous system', 'Other: Clinical examination of the sleep', 'Other: Biological dosages', 'Other: Electrocardiogram (ECG)', 'Other: Carotid echography', 'Other: Blood pressure']}], 'interventions': [{'type': 'OTHER', 'name': 'Polysomnography', 'description': 'Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital', 'armGroupLabels': ['Diabetes people', 'healthy volunteers (controll group)']}, {'type': 'OTHER', 'name': 'Evaluation of the autonomous nervous system', 'description': 'blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic', 'armGroupLabels': ['Diabetes people', 'healthy volunteers (controll group)']}, {'type': 'OTHER', 'name': 'Clinical examination of the sleep', 'description': 'Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD', 'armGroupLabels': ['Diabetes people', 'healthy volunteers (controll group)']}, {'type': 'OTHER', 'name': 'Clinical examination of diabetology', 'description': 'history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire', 'armGroupLabels': ['Diabetes people']}, {'type': 'OTHER', 'name': 'Biological dosages', 'description': 'Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test', 'armGroupLabels': ['Diabetes people', 'healthy volunteers (controll group)']}, {'type': 'OTHER', 'name': 'Electrocardiogram (ECG)', 'description': 'Electrocardiogram (ECG)', 'armGroupLabels': ['Diabetes people', 'healthy volunteers (controll group)']}, {'type': 'OTHER', 'name': 'Carotid echography', 'description': 'Carotid echography', 'armGroupLabels': ['Diabetes people', 'healthy volunteers (controll group)']}, {'type': 'OTHER', 'name': 'Blood pressure', 'description': 'Blood pressure', 'armGroupLabels': ['Diabetes people', 'healthy volunteers (controll group)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Compare the prevalence of sleep apnea syndrome by polysomnography between type 1 diabetic patients and healthy volunteers', 'description': \"Determine if prevalence of the sleep apnea syndrome is more raised at the patient's diabetics of type 1 (DT1) than in the general population and to collect elements to specify the determiners of this association (presence of an autonomous neuropathy and glycemic balance).\\n\\nsleep apnea syndrome as defined by the International Classification of Sleep Disorders 2\", 'timeFrame': '3 months'}], 'secondaryOutcomes': [{'measure': 'Precise if glycemic balance as defined by glycosylated hemoglobin<7% during the last three months is associated or not to sleep apnea syndrome', 'description': 'Compare diabetic subjects with or without sleep apnea regarding the rate of poorly controlled diabetes (determined by the level of glycosylated haemoglobin)', 'timeFrame': '3 months'}, {'measure': 'Precise if the presence of an autonomic neuropathy (positive at 2 tests) is associated or not to sleep apnea syndrome', 'description': 'Compare diabetic subjects with or without sleep apnea regarding presence of autonomic neuropathy determined by clinical assessment', 'timeFrame': '3 months'}, {'measure': 'Compare the patients with or without sleep apnea regarding consequences especially cardiovascular markers and coagulation factors', 'description': 'Compare diabetic subjects with or without sleep apnea regarding other cardiovascular risk factors and consequences (intima media thickness)', 'timeFrame': '3 months'}, {'measure': 'Determine if the presence of sleep apnea syndrome has an impact upon quality of life and diabetes complications, micro or macroangiopathy', 'description': 'Compare diabetic subjects with or without sleep apnea regarding quality of sleep', 'timeFrame': '3 months'}, {'measure': 'Precise clinical symptoms in DT1 patients with Sleep apnea syndrome', 'timeFrame': '3 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* 99 Type 1 diabetic patients\\n\\n  * man or woman aged 18 to 60 years\\n  * diagnosed since at least a year\\n  * having signed a consent\\n  * with in a national insurance scheme\\n* and 46 healthy volunteers matched by age , gender and body mass index\\n\\n  * man or woman aged 18 to 60 years\\n  * having signed a consent\\n  * with in a national insurance scheme\\n\\nExclusion Criteria:\\n\\nfor both\\n\\n* sleep apnea syndrome already known\\n* acute respiratory or cardiovascular disease\\n* impairment of consciousness\\n* sepsis\\n* cirrhosis\\n* hypnotic, opiate or psychotropic drug treatment 2 weeks ago\\n* Pregnant or breast-feeding woman\\n* Do not speak French\\n* Benefiting from a legal protective measure\\n* diabet 1 or 2 just for volunteers people', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '60 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Véronique Viot-Blanc, MD', 'affiliation': 'Lariboisiere Hospital, APHP', 'role': 'STUDY_DIRECTOR'}, {'name': 'Pierre-Jean Guillausseau, MD, PhD', 'affiliation': 'Lariboisiere Hopistal, APHP', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Véronique Viot-Blanc', 'city': 'Paris', 'state': 'Ile De France', 'zip': '75010', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001049', 'term': 'Apnea'}, {'id': 'D012891', 'term': 'Sleep Apnea Syndromes'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D012120', 'term': 'Respiration Disorders'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D012818', 'term': 'Signs and Symptoms, Respiratory'}, {'id': 'D020919', 'term': 'Sleep Disorders, Intrinsic'}, {'id': 'D020920', 'term': 'Dyssomnias'}, {'id': 'D012893', 'term': 'Sleep Wake Disorders'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'}, {'id': 'M4361', 'name': 'Apnea', 'asFound': 'Apnea', 'relevance': 'HIGH'}, {'id': 'M15694', 'name': 'Sleep Apnea Syndromes', 'asFound': 'Sleep Apnea', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M14957', 'name': 'Respiration Disorders', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M15623', 'name': 'Signs and Symptoms, Respiratory', 'relevance': 'LOW'}, {'id': 'M22242', 'name': 'Parasomnias', 'relevance': 'LOW'}, {'id': 'M22654', 'name': 'Sleep Disorders, Intrinsic', 'relevance': 'LOW'}, {'id': 'M22655', 'name': 'Dyssomnias', 'relevance': 'LOW'}, {'id': 'M15696', 'name': 'Sleep Wake Disorders', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M207501', 'name': 'Chrysarobin', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'}, {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'}, {'abbrev': 'Analg', 'name': 'Analgesics'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00004266', 'orgStudyIdInfo': {'id': '199/11643'}, 'secondaryIdInfos': [{'id': 'UMN-1967', 'type': 'OTHER', 'domain': 'Hennepin County Medical Center, Minneapolis'}, {'id': 'R01DK047112', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/R01DK047112'}], 'organization': {'fullName': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}, 'briefTitle': 'Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes', 'officialTitle': 'Randomized Study of Antihypertensives and Antilipemics in American Indians With Non-Insulin-Dependent Diabetes Mellitus at High Risk of Developing Nephropathy and Cardiovascular Disease'}, 'statusModule': {'statusVerifiedDate': '2018-03', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '1993-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '1999-07', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '1999-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '1999-10-18', 'studyFirstSubmitQcDate': '1999-10-18', 'studyFirstPostDateStruct': {'date': '1999-10-19', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2018-03-05', 'lastUpdatePostDateStruct': {'date': '2018-03-07', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}, 'collaborators': [{'name': 'Hennepin County Medical Center, Minneapolis', 'class': 'OTHER'}]}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'OBJECTIVES:\\n\\nI. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community.\\n\\nII. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria.\\n\\nIII. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.', 'detailedDescription': 'PROTOCOL OUTLINE:\\n\\nPatients are randomly assigned to 1 of 4 treatment groups; therapy continues for 3 years. All patients receive instruction on diet, exercise, and smoking cessation.\\n\\nThe first group receives daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.\\n\\nThe second group receives daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.\\n\\nThe third group receives daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.\\n\\nThe fourth group receives lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.'}, 'conditionsModule': {'conditions': ['Diabetic Nephropathy'], 'keywords': ['diabetic nephropathy', 'rare disease', 'renal and genitourinary disorders']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 160, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Nifedipine', 'type': 'EXPERIMENTAL', 'description': 'Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.', 'interventionNames': ['Drug: Nifedipine']}, {'label': 'Lisinopril', 'type': 'EXPERIMENTAL', 'description': 'Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.', 'interventionNames': ['Drug: Lisinopril']}, {'label': 'Nifedipine and simvastatin', 'type': 'EXPERIMENTAL', 'description': 'Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.', 'interventionNames': ['Drug: Nifedipine', 'Drug: Simvastatin']}, {'label': 'Lisinopril and simvastatin', 'type': 'EXPERIMENTAL', 'description': 'Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.', 'interventionNames': ['Drug: Lisinopril', 'Drug: Simvastatin']}], 'interventions': [{'type': 'DRUG', 'name': 'Lisinopril', 'armGroupLabels': ['Lisinopril', 'Lisinopril and simvastatin']}, {'type': 'DRUG', 'name': 'Nifedipine', 'armGroupLabels': ['Nifedipine', 'Nifedipine and simvastatin']}, {'type': 'DRUG', 'name': 'Simvastatin', 'armGroupLabels': ['Lisinopril and simvastatin', 'Nifedipine and simvastatin']}]}, 'eligibilityModule': {'eligibilityCriteria': 'PROTOCOL ENTRY CRITERIA:\\n\\n--Disease Characteristics-- Non-insulin-dependent diabetes mellitus with documented fasting hyperglycemia Microalbuminuria OR clinically detectable albuminuria; Urine albumin excretion rate at least 30 mg/24 hours Low-density lipoproteins (fasting) at least 80 mg/dL Recruitment from American Indian population at Red Lake and Leech Lake reservations\\n\\n--Prior/Concurrent Therapy-- At least 5 days since antihypertensives or antilipemics\\n\\n--Patient Characteristics-- Renal: Urine albumin-to-creatinine ratio at least 30 mg/g; Creatinine clearance or estimated creatinine clearance at least 30 mL/min; No active urine sediment suggestive of glomerulonephritis, i.e.: No RBCs greater than 10/high-power field; No WBCs greater than 15/high-power field; No RBC casts\\n\\nCardiovascular: No symptomatic orthostatic hypotension; No poorly-compensated congestive heart failure; No requirement for angiotensin-converting enzyme inhibitors; No angina pectoris requiring nifedipine; No unstable angina; No episodes of angina occurring more than once a month; No chest pain of undetermined cause within 1 month; No severe hypertension requiring multiple antihypertensives; No myocardial infarction within 1 year; No stroke or transient ischemic attack within 1 year\\n\\nOther: No known allergy to nifedipine, lisinopril, or simvastatin; No untreated proliferative retinopathy; Documented retinal exam within 1 year prior to entry; No alcohol or drug abuse affecting compliance; No other debilitating or acute illness; No pregnant or nursing women; Effective contraception required of fertile women', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Bertram L. Kasiske', 'affiliation': 'Hennepin County Medical Center, Minneapolis', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Hennepin County Medical Center', 'city': 'Minneapolis', 'state': 'Minnesota', 'zip': '55415', 'country': 'United States', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D003928', 'term': 'Diabetic Nephropathies'}], 'ancestors': [{'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D048909', 'term': 'Diabetes Complications'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}, {'id': 'M10024', 'name': 'Hypertension', 'relevance': 'LOW'}, {'id': 'M10698', 'name': 'Kidney Diseases', 'asFound': 'Nephropathy', 'relevance': 'HIGH'}, {'id': 'M7123', 'name': 'Diabetic Nephropathies', 'asFound': 'Diabetic Nephropathy', 'relevance': 'HIGH'}, {'id': 'M9988', 'name': 'Hypercholesterolemia', 'relevance': 'LOW'}, {'id': 'M24518', 'name': 'Rare Diseases', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M17319', 'name': 'Urologic Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M26004', 'name': 'Diabetes Complications', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D017706', 'term': 'Lisinopril'}, {'id': 'D009543', 'term': 'Nifedipine'}, {'id': 'D019821', 'term': 'Simvastatin'}], 'ancestors': [{'id': 'D000924', 'term': 'Anticholesteremic Agents'}, {'id': 'D000960', 'term': 'Hypolipidemic Agents'}, {'id': 'D000963', 'term': 'Antimetabolites'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D057847', 'term': 'Lipid Regulating Agents'}, {'id': 'D019161', 'term': 'Hydroxymethylglutaryl-CoA Reductase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D002121', 'term': 'Calcium Channel Blockers'}, {'id': 'D049990', 'term': 'Membrane Transport Modulators'}, {'id': 'D000077264', 'term': 'Calcium-Regulating Hormones and Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D014665', 'term': 'Vasodilator Agents'}, {'id': 'D015149', 'term': 'Tocolytic Agents'}, {'id': 'D012102', 'term': 'Reproductive Control Agents'}, {'id': 'D000806', 'term': 'Angiotensin-Converting Enzyme Inhibitors'}, {'id': 'D011480', 'term': 'Protease Inhibitors'}, {'id': 'D000959', 'term': 'Antihypertensive Agents'}, {'id': 'D002316', 'term': 'Cardiotonic Agents'}, {'id': 'D020011', 'term': 'Protective Agents'}], 'browseLeaves': [{'id': 'M7411', 'name': 'Diuretics', 'relevance': 'LOW'}, {'id': 'M17952', 'name': 'Gemfibrozil', 'relevance': 'LOW'}, {'id': 'M4277', 'name': 'Antihypertensive Agents', 'relevance': 'LOW'}, {'id': 'M21713', 'name': 'Simvastatin', 'asFound': 'Vascular', 'relevance': 'HIGH'}, {'id': 'M19924', 'name': 'Lisinopril', 'asFound': 'Inside', 'relevance': 'HIGH'}, {'id': 'M6032', 'name': 'Cholestyramine Resin', 'relevance': 'LOW'}, {'id': 'M12483', 'name': 'Nifedipine', 'asFound': 'Limit', 'relevance': 'HIGH'}, {'id': 'M19586', 'name': 'Doxazosin', 'relevance': 'LOW'}, {'id': 'M4278', 'name': 'Hypolipidemic Agents', 'relevance': 'LOW'}, {'id': 'M4243', 'name': 'Anticholesteremic Agents', 'relevance': 'LOW'}, {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'}, {'id': 'M28883', 'name': 'Lipid Regulating Agents', 'relevance': 'LOW'}, {'id': 'M21155', 'name': 'Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M5381', 'name': 'Calcium', 'relevance': 'LOW'}, {'id': 'M5398', 'name': 'Calcium, Dietary', 'relevance': 'LOW'}, {'id': 'M5384', 'name': 'Calcium Channel Blockers', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M17412', 'name': 'Vasodilator Agents', 'relevance': 'LOW'}, {'id': 'M17869', 'name': 'Tocolytic Agents', 'relevance': 'LOW'}, {'id': 'M4134', 'name': 'Angiotensin-Converting Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M19609', 'name': 'HIV Protease Inhibitors', 'relevance': 'LOW'}, {'id': 'M14343', 'name': 'Protease Inhibitors', 'relevance': 'LOW'}, {'id': 'M5572', 'name': 'Cardiotonic Agents', 'relevance': 'LOW'}, {'id': 'M21869', 'name': 'Protective Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Lipd', 'name': 'Lipid Regulating Agents'}, {'abbrev': 'AnAg', 'name': 'Antihypertensive Agents'}, {'abbrev': 'CaAg', 'name': 'Cardiotonic Agents'}, {'abbrev': 'ChanBlk', 'name': 'Channel Blockers'}, {'abbrev': 'VaDiAg', 'name': 'Vasodilator Agents'}, {'abbrev': 'Repr', 'name': 'Reproductive Control Agents'}, {'abbrev': 'BDCA', 'name': 'Bone Density Conservation Agents'}, {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00570466', 'orgStudyIdInfo': {'id': 'DK66724 (completed)'}, 'secondaryIdInfos': [{'id': 'U44DK066724', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/U44DK066724'}, {'id': 'U01DK061231', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/U01DK061231'}], 'organization': {'fullName': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}, 'briefTitle': 'Computer Based Intervention for Type 2 Diabetes in Youth', 'officialTitle': 'Computer Based Intervention for Type 2 Diabetes in Youth: Phase 2'}, 'statusModule': {'statusVerifiedDate': '2014-09', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2008-01'}, 'primaryCompletionDateStruct': {'date': '2009-05', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2011-12', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2007-12-06', 'studyFirstSubmitQcDate': '2007-12-07', 'studyFirstPostDateStruct': {'date': '2007-12-11', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-09-25', 'lastUpdatePostDateStruct': {'date': '2017-09-27', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}, 'collaborators': [{'name': 'Baylor College of Medicine', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': \"Interactive multimedia programs have been demonstrated to produce substantial change in children's dietary behaviors. This SBIR-Phase 2 protocol will evaluate the two video game interventions designed to change diabetes related behaviors, including diet and physical activity: Escape from Diab! and Nanoswarm that were developed in Phase 1. The primary hypotheses for this SBIR-Phase 2 protocol are:\\n\\n1. The two video games will result in greater dietary and physical activity change than a knowledge based control group.\\n2. The effects of the video games will be mediated by changes in child preferences for FV and PA, self-efficacy to change FV intake and PA, and intrinsic motivation to eat FV and PA.\\n\\nWe will test these hypotheses by evaluating the two video games in a randomized experiment. To minimize costs, we will evaluate the impact of the games on behavior (diet and PA), BMI and related psychosocial variables, but not blood values. Our long-term goal is reducing the incidence of Type 2 diabetes and related health problems in youth.\", 'detailedDescription': \"Increasing numbers of minority youth are at risk for developing Type 2 Diabetes (T2D) because of family history and overweight. While precise incidence and prevalence rates for T2D among children are not available, the prevalence has increased substantially in the last ten years, likely due to parallel increases in obesity among children. These cases are expected to progress to end organ damage at an early age, with the resultant increased personal and societal costs. Probable risk factors for T2DM include ethnicity (African American, Hispanic, Native American), family history of diabetes, and obesity. Prevention is key to reducing risks for T2D. The only modifiable risk factor is weight, which reflects dietary and physical activity practices. A diet high in fruit and vegetables, and appropriate in total calories and low in dietary fat are likely protective against both obesity and T2D. Although national data suggest the percentage of kilocalories (kcal) from fat consumed by children aged 2-17 decreased between 1989 and 1995 (now at 33% of total kcal), actual fat intakes did not decrease. Kcal intake, however, increased. Children's current intake of fruit and vegetables is less than one-half of the 5-A-Day goal. Changing the diet and physical activity practices to impact adiposity among children 10 to 12 years old before the onset of obesity or early in obesity holds great promise of preventing T2D. Furthermore, it is approximately this age that children assume more responsibility for their diet and physical activity, and thereby the intervention can be expected to have a greater impact on behavior. Children at the 50%tile or higher BMI are those most likely to progress to obesity, and thereby provide an important target group for obesity prevention.\\n\\nVideo games focused on promoting T2D-related changes in diet and physical activity, based on the most current theories of health behavior, hold the promise of preventing T2D among children, and thereby reducing lifelong disease burden. Unlike traditional media-based interventions (print, graphic, audio/visual, television broadcast), computer technology provides opportunities to influence behavior change through direct, personalized interactive experiences.\\n\\nAs part of a SBIR-Phase I, we created two video games: Escape from Diab! and Nanoswarm - Invasion from Inner Space. These intervention video games propose to increase fruit and vegetable intake to reduce total calories by displacing high fat, high calorie foods; increase water intake to decrease sweetened beverage consumption and total calories; increase physical activity; and decrease inactivity (e.g., TV watching, playing commercial video games). The behavioral and educational objectives address national behavior change objectives, including:\\n\\n* Three to five servings of fruit (F) or 100% fruit juice (J) per day and Four to seven servings of vegetables (V) per day (based on child recommended calorie intake for age and weight),\\n* Five to eight glasses of water (W) per day,\\n* Moderate to vigorous Physical Activity (PA) of at least 60 min/day, and\\n* Physical Inactivity (PI) (TV, e-games, telephone) of no more than 2 hours per day.\\n\\nBoth games use an adventure storyline to capture the children's interest and attention, and thereby enhance their desire to keep coming back to the game across multiple sessions (between which behavior change goals are attempted). The storylines provide messages that reinforce the diet and physical activity change objectives. Seamlessly woven into each adventure session are programmed procedures for promoting behavior change (goal setting, goal review), which were tailored to characteristics of the child obtained through self report. Behavior change knowledge games, seamlessly woven into the storyline, are used to provide the basis for effective goal setting; and energy balance games, also seamlessly woven into the storyline, are used to provide the knowledge necessary to effectively self control caloric intake and output.\"}, 'conditionsModule': {'conditions': ['Type 2 Diabetes'], 'keywords': ['Type 2 Diabetes', 'Prevention', 'Children', 'Diet', 'Physical Activity']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 153, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Video games', 'type': 'EXPERIMENTAL', 'description': 'Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit, vegetable and water intake, physical activity and decrease TV viewing.', 'interventionNames': ['Behavioral: Video Games']}, {'label': 'Web and DVD knowledge', 'type': 'PLACEBO_COMPARATOR', 'description': 'Parallel web and DVD based knowledge games on fruit, vegetable, water, physical activity and physical inactivity.', 'interventionNames': ['Behavioral: Web and DVD knowledge']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Video Games', 'description': 'Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.', 'armGroupLabels': ['Video games']}, {'type': 'BEHAVIORAL', 'name': 'Web and DVD knowledge', 'description': 'Web and DVD based knowledge games', 'armGroupLabels': ['Web and DVD knowledge']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Dietary intake of servings of fruit and vegetables as measured by three 24-hour dietary recalls; and minutes of moderate to vigorous physical activity as measured by 5 days of accelerometry.', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Height, weight, waist circumference, propylthiouracil (PROP) sensitivity status and nutrition and physical activity psychosocial questionnaires.', 'timeFrame': '6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Healthy 10-12 year old African-American, Hispanic-American, Anglo or Asian children.\\n2. Able to fluently speak, read and write English.\\n3. Able to play computer video games.\\n4. DSL or high-speed internet connection at home.\\n5. No dietary restrictions that limit their intake of fruit \\\\& vegetables or water.\\n6. No medical, physical handicaps or other reasons that would limit their physical activity.\\n7. Greater than 50% BMI, but less than 95% BMI.\\n\\nExclusion Criteria:\\n\\n1. Children who are not in the target age range of 10-12 years old.\\n2. Not able to fluently speak, read and write English.\\n3. Not able to play computer video games.\\n4. No DSL or high-speed internet connection at home.\\n5. Dietary restrictions that limit their intake of fruit \\\\& vegetables or water.\\n6. Medical, physical handicaps or other reasons that would limit their physical activity.\\n7. Less than 50% BMI or greater than 95% BMI.\\n8. History of epileptic seizures.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '10 Years', 'maximumAge': '12 Years', 'stdAges': ['CHILD']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Tom Baranowski, Ph.D.', 'affiliation': 'Baylor College of Medicine', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Baylor College of Medicine', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}]}, 'referencesModule': {'references': [{'pmid': '21146765', 'type': 'RESULT', 'citation': 'Baranowski T, Baranowski J, Thompson D, Buday R, Jago R, Griffith MJ, Islam N, Nguyen N, Watson KB. Video game play, child diet, and physical activity behavior change a randomized clinical trial. Am J Prev Med. 2011 Jan;40(1):33-8. doi: 10.1016/j.amepre.2010.09.029.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01421966', 'orgStudyIdInfo': {'id': 'MC-102'}, 'organization': {'fullName': 'Macrocure Ltd.', 'class': 'INDUSTRY'}, 'briefTitle': 'Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes', 'officialTitle': 'A Phase III Multicenter, Randomized, Double-Blind, Parallel-Group, Sham-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Wound Care in Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2015-12', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2011-08'}, 'primaryCompletionDateStruct': {'date': '2015-02', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2015-10', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2011-08-21', 'studyFirstSubmitQcDate': '2011-08-22', 'studyFirstPostDateStruct': {'date': '2011-08-23', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-12-03', 'lastUpdatePostDateStruct': {'date': '2015-12-07', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Macrocure Ltd.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Amarex Clinical Research', 'class': 'OTHER'}, {'name': 'ICON plc', 'class': 'INDUSTRY'}, {'name': 'ARANZ Medical', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'Chronic foot ulcers are particularly prevalent in patients with underlying diabetes mellitus. These ulcers are reported to be the leading cause of hospitalization among people with diabetes.\\n\\nThe purpose of this study is to evaluate CureXcell® in treating chronic lower extremity ulcers in adults with diabetes mellitus. CureXcell® is a cell based therapy, containing activated homologous white blood cells prepared from donated healthy whole blood. A total of 280 patients will be randomized to receive either CureXcell® or sham.', 'detailedDescription': 'Chronic foot ulcers are particularly prevalent in patients with underlying diabetes mellitus. The prevalence of diabetes mellitus is growing at epidemic rates in Europe, United States and in general worldwide. Foot ulceration is a serious complication of diabetes mellitus associated with increased risk of infection, gangrene and amputation. These ulcers are reported to be the leading cause of hospitalization among people with diabetes. Despite existing ulcer therapies and technologies, there continues to be a great necessity for new wound healing technologies that will further improve healing rates for these chronic ulcers that remain a major source of morbidity, concern, and cost. This Phase 3 multinational, multicenter, randomized, double-blind, controlled study is designed to evaluate CureXcell® in treating lower extremity chronic ulcers in adults with Diabetes Mellitus.\\n\\nCureXcell® is a cell based therapy obtained from donated whole blood. The blood are collected from healthy, young adult (age 18-40), the cells separated and then activated by hypo-osmotic shock.\\n\\nA total of 280 patients, in approximately 35 sites in the US, Canada and Israel, will be randomized to receive either CureXcell® or control.\\n\\nThe primary objective of the study is to evaluate the clinical benefit of CureXcell® (study biologic) compared to control, as adjunct to Good Ulcer Care. Additional objectives are to demonstrate safety, tolerability and durability of CureXcell® compared to control.\\n\\nThe study has two phases: a core double-blind phase and a follow up phase.'}, 'conditionsModule': {'conditions': ['Lower Extremity Chronic Ulcers in Diabetics'], 'keywords': ['chronic ulcers', 'diabetic foot ulcers']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 285, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'CureXcell®', 'type': 'EXPERIMENTAL', 'interventionNames': ['Biological: CureXcell®']}, {'label': 'Sham injection', 'type': 'SHAM_COMPARATOR', 'interventionNames': ['Biological: Sham injection']}], 'interventions': [{'type': 'BIOLOGICAL', 'name': 'CureXcell®', 'description': 'CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.', 'armGroupLabels': ['CureXcell®']}, {'type': 'BIOLOGICAL', 'name': 'Sham injection', 'description': 'The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed', 'armGroupLabels': ['Sham injection']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of patients with complete healing/closure of their target ulcer at any time during the 16-week double-blind core treatment period with sustained complete closure for 4 additional weeks of follow-up.', 'timeFrame': 'up to 20 weeks'}], 'secondaryOutcomes': [{'measure': 'Time to complete closure of the Target Ulcer during the core double blind treatment phase with sustained complete closure for 4 additional weeks of follow-up.', 'timeFrame': 'up to 20 weeks'}, {'measure': 'Proportion of patients with at least 50% closure of target ulcer during the 16-week core treatment period.', 'timeFrame': '16 weeks'}, {'measure': 'Proportion of patients whose Target Ulcer completely closed during the core double blind treatment phase and remained closed at the FU12 follow-up visit.', 'timeFrame': 'up to 28 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Males or females at least 18 years of age with diabetes type 1 or type 2;\\n2. Patients with HbA1c ≤ 12%;\\n3. Patients with at least one lower extremity (on or below the malleolus (ankle bone)), at least full-thickness ulcer (penetrating through the whole layer of the skin), which has been unresponsive to any treatment for at least 4 weeks;\\n4. Ulcers with an area between ≥ 1 cm2 and ≤ 20 cm2 (after sharp debridement of free, non-viable, hyperkeratotic and fibrotic tissue to the extent possible);\\n5. Ankle Brachial Index ≥ 0.65;\\n\\nExclusion Criteria:\\n\\n1. Patients with more than two ulcers on the same foot or more than a total of three chronic ulcers;\\n2. Patients with ulcers primarily caused by venous insufficiency;\\n3. Patients whose target ulcer has decreased \\\\> 25% in size from screening to baseline;\\n4. Malignancy within the past 5 years excluding successfully treated basal cell carcinoma;\\n5. Significantly compromised immunity for any reason including radiation therapy, chemotherapy or HIV;\\n6. Current clinical osteomyelitis;\\n7. Acute Charcot foot;\\n8. Current sepsis;', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Vickie Driver, MS, DPM, FACFAS', 'affiliation': 'VA New England Health Care Division', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'city': 'Glendale', 'state': 'Arizona', 'country': 'United States', 'geoPoint': {'lat': 33.53865, 'lon': -112.18599}}, {'city': 'Mesa', 'state': 'Arizona', 'country': 'United States', 'geoPoint': {'lat': 33.42227, 'lon': -111.82264}}, {'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'city': 'Tucson', 'state': 'Arizona', 'country': 'United States', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'city': 'Fresno', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 36.74773, 'lon': -119.77237}}, {'city': 'San Francisco', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'city': 'San Fransisco', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'city': 'Sylmar', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 34.30778, 'lon': -118.44925}}, {'city': 'Gulf Breeze', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 30.35714, 'lon': -87.16386}}, {'city': 'Hialeah', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 25.8576, 'lon': -80.27811}}, {'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'city': 'South Miami', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 25.7076, 'lon': -80.29338}}, {'city': 'Evans', 'state': 'Georgia', 'country': 'United States', 'geoPoint': {'lat': 33.53375, 'lon': -82.13067}}, {'city': 'Arlington Heights', 'state': 'Illinois', 'country': 'United States', 'geoPoint': {'lat': 42.08836, 'lon': -87.98063}}, {'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'city': 'Oak Park', 'state': 'Illinois', 'country': 'United States', 'geoPoint': {'lat': 41.88503, 'lon': -87.7845}}, {'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'city': 'Wichita', 'state': 'Kansas', 'country': 'United States', 'geoPoint': {'lat': 37.69224, 'lon': -97.33754}}, {'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'city': 'Kansas City', 'state': 'Missouri', 'country': 'United States', 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'city': 'Toms River', 'state': 'New Jersey', 'country': 'United States', 'geoPoint': {'lat': 39.95373, 'lon': -74.19792}}, {'city': 'Mineola', 'state': 'New York', 'country': 'United States', 'geoPoint': {'lat': 40.74927, 'lon': -73.64068}}, {'city': 'New York', 'state': 'New York', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'city': 'Lima', 'state': 'Ohio', 'country': 'United States', 'geoPoint': {'lat': 40.74255, 'lon': -84.10523}}, {'city': 'Aiken', 'state': 'South Carolina', 'country': 'United States', 'geoPoint': {'lat': 33.56042, 'lon': -81.71955}}, {'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'city': 'Lewisville', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 33.04623, 'lon': -96.99417}}, {'city': 'McAllen', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 26.20341, 'lon': -98.23001}}, {'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'city': 'Norfolk', 'state': 'Virginia', 'country': 'United States', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'city': 'Winnipeg', 'state': 'Manitoba', 'country': 'Canada', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'city': 'Boucherville', 'state': 'Quebec', 'country': 'Canada', 'geoPoint': {'lat': 45.59104, 'lon': -73.43605}}, {'city': 'Haifa', 'country': 'Israel', 'geoPoint': {'lat': 32.81841, 'lon': 34.9885}}, {'city': 'Holon', 'country': 'Israel', 'geoPoint': {'lat': 32.01034, 'lon': 34.77918}}, {'city': 'Jerusalem', 'country': 'Israel', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'city': 'Tel Aviv', 'country': 'Israel', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014456', 'term': 'Ulcer'}], 'ancestors': [{'id': 'D010335', 'term': 'Pathologic Processes'}], 'browseLeaves': [{'id': 'M17685', 'name': 'Wounds and Injuries', 'relevance': 'LOW'}, {'id': 'M19933', 'name': 'Diabetic Foot', 'relevance': 'LOW'}, {'id': 'M18919', 'name': 'Foot Ulcer', 'relevance': 'LOW'}, {'id': 'M17206', 'name': 'Ulcer', 'asFound': 'Ulcer', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'T1303', 'name': 'Chronic Graft Versus Host Disease', 'asFound': 'Chronic', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC26', 'name': 'Wounds and Injuries'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03893266', 'orgStudyIdInfo': {'id': '69HCL18_0824'}, 'organization': {'fullName': 'Hospices Civils de Lyon', 'class': 'OTHER'}, 'briefTitle': 'Diabetic Patients Needs in Therapeutic Education About Work. TE-DIW (Therapeutic Education of DIabetic Working People)', 'officialTitle': 'Exploratory Study of the Needs of Type 1 Diabetic Patients in Therapeutic Education in Order to Reconcile Diabetes and Work.', 'acronym': 'ET-DIT'}, 'statusModule': {'statusVerifiedDate': '2020-03', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-04-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-12-03', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2019-12-03', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2019-03-26', 'studyFirstSubmitQcDate': '2019-03-26', 'studyFirstPostDateStruct': {'date': '2019-03-28', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-03-27', 'lastUpdatePostDateStruct': {'date': '2020-03-31', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Hospices Civils de Lyon', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"Diabetes mellitus is an important disease around the world and the number of diabetic people increase every day. The type 1 diabetes often occurred in the youth and people have to learn to work with it and its complication. Conversely, diabetic people sometimes have trouble to manage their diabetes with working obligation. Actually, French therapeutic education don't teach how to reconcile diabetes and work. The study hypothesis is that type 1 diabetic people can be helped by therapeutic education in order to reconcile the management of their diabetes and their work. This study is a qualitative study. Interviews will help to find the needs of the type 1 diabetic patients to reconcile diabetes and work.\"}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 1']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 15, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'interventions': [{'type': 'OTHER', 'name': 'Interviews', 'description': 'An interview will be realized with each patient in order to precise the issues they have to reconcile their diabetes and their work. Some questions will be posed to the patients and they respond as they wish.'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Collection of the needs of type 1 diabetic patients in therapeutic education in order to reconcile diabetes and work.', 'description': 'It is a qualitative study consisting of type 1 diabetic patients semi-structured interviews in order to identify and describe their needs in therapeutic education in order to reconcile diabetes and work.', 'timeFrame': 'Expected duration of interviews is around 1 hour, when no new idea appear in an interview.'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Age\\\\>18 years old\\n* To be diagnosed with type 1 diabetes according to the criteria of the French High Authority of Health and confirmed by an endocrinologist\\n* To have paid employment with an employment contract during the study\\n* to be informed and having no opposition to the study\\n\\nExclusion Criteria:\\n\\n* self-employed person\\n* to be unemployed\\n* To be diagnosed with an other disease wich could damage cognition or motricity and could interfere with work (cancer, neurodegenerative disorder, etc)\\n* To have legal guardian.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Adult person with a type 1 diabetes and having paid employment', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'locations': [{'facility': 'Médecine et santé au travail - Hôpital Cardiologique Louis Pradel - Groupement hospitalier Est', 'city': 'Bron', 'zip': '69677', 'country': 'France', 'geoPoint': {'lat': 45.73333, 'lon': 4.91667}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Diabetes Mellitus, Type 1', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M8601', 'name': 'Fluoxetine', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'PsychDr', 'name': 'Psychotropic Drugs'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04083820', 'orgStudyIdInfo': {'id': 'NN9535-4495'}, 'secondaryIdInfos': [{'id': 'U1111-1222-5620', 'type': 'OTHER', 'domain': 'World Health Organization (WHO)'}], 'organization': {'fullName': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}, 'briefTitle': 'A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)', 'officialTitle': 'A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes', 'acronym': 'SURE FRANCE'}, 'statusModule': {'statusVerifiedDate': '2023-03', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-09-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-09-27', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2021-09-27', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2019-09-06', 'studyFirstSubmitQcDate': '2019-09-06', 'studyFirstPostDateStruct': {'date': '2019-09-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-03-24', 'lastUpdatePostDateStruct': {'date': '2023-03-28', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 521, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Semaglutide s.c. once-weekly', 'description': \"Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.\", 'interventionNames': ['Drug: semaglutide']}], 'interventions': [{'type': 'DRUG', 'name': 'semaglutide', 'description': \"Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.\", 'armGroupLabels': ['Semaglutide s.c. once-weekly']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Glycated Haemoglobin A1c (HbA1c)', 'description': 'Measured in % point', 'timeFrame': 'Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)'}, {'measure': 'Change in Glycated Haemoglobin A1c (HbA1c)', 'description': 'Measured in mmol/mol', 'timeFrame': 'Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)'}], 'secondaryOutcomes': [{'measure': 'Change in body weight', 'description': 'Measured in kg', 'timeFrame': 'Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)'}, {'measure': 'Change in body weight', 'description': 'Measured in %', 'timeFrame': 'Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)'}, {'measure': 'Change in waist circumference', 'description': 'Measured in cm', 'timeFrame': 'Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)'}, {'measure': 'HbA1c level below 8.0% (64 mmol/mol) (yes/no)', 'description': 'Number of participants', 'timeFrame': 'At end of study (week 28 to 38)'}, {'measure': 'HbA1c level below 7.5% (59 mmol/mol) (yes/no)', 'description': 'Number of participants', 'timeFrame': 'At end of study (week 28 to 38)'}, {'measure': 'HbA1c level below 7.0% (53 mmol/mol) (yes/no)', 'description': 'Number of participants', 'timeFrame': 'At end of study (week 28 to 38)'}, {'measure': 'Reduction in HbA1c of 1.0% point or more (yes/no)', 'description': 'Number of participants who achieved/not achieved reduction in HbA1c of 1.0% point or more', 'timeFrame': 'Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)'}, {'measure': 'Weight reduction of 3.0% or more (yes/no)', 'description': 'Number of participants who achieved/not achieved weight reduction of 3.0% or more', 'timeFrame': 'Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)'}, {'measure': 'Weight reduction of 5.0% or more (yes/no)', 'description': 'Number of participants who achieved/not achieved weight reduction of 5.0% or more', 'timeFrame': 'Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)'}, {'measure': 'HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)', 'description': 'Number of participants who achieved/not achieved HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more', 'timeFrame': 'Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)'}, {'measure': 'Patient reported severe or documented hypoglycaemia (yes/no)', 'description': 'Number of participants', 'timeFrame': 'Between baseline (week 0), end of study (week 28-38)'}, {'measure': 'Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction', 'description': 'The status version (DTSQs) provides a measure of how satisfied patients are with their current diabetes treatment. It consists of 8 questions, which are to be answered on a Likert scale from 0 to 6 (0 = very dissatisfied to 6 = very satisfied). Six questions are summed to produce a total Treatment Satisfaction score. The remaining two questions are concerning perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia, respectively', 'timeFrame': 'Baseline (week 0), end of study (week 28 to 38)'}, {'measure': 'Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction', 'description': 'The change version (DTSQc) has the same 8 items as the status version, but is reworded to direct the patients to compare the experience of the current treatment with the experience of previous treatment. Each question is scored on a scale of -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change', 'timeFrame': 'Baseline (week 0), end of study (week 28 to 38)'}, {'measure': 'Change in score for Short Form (SF)-36 v2: Physical summary component', 'description': 'The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health).', 'timeFrame': 'Baseline (week 0), end of study (week 28 to 38)'}, {'measure': 'Change in score for SF-36 v2: Mental summary component', 'description': 'The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health).', 'timeFrame': 'Baseline (week 0), end of study (week 28 to 38)'}, {'measure': 'Patient completed the study under treatment with semaglutide (yes/no)', 'description': 'Number of participants', 'timeFrame': 'At end of study (week 28 to 38)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)\\n* The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study\\n* Male or female, age greater than or equal to 18 years at the time of signing informed consent\\n* Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion\\n* Available and documented haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment\\n\\nExclusion Criteria:\\n\\n* Previous participation in this study. Participation is defined as having given informed consent in this study\\n* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation\\n* Treatment with any investigational drug within 90 days prior to enrolment into the study\\n* Hypersensitivity to semaglutide or to any of the excipients', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Participants with type 2 diabetes', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Clinical Reporting Anchor and Disclosure (1452)', 'affiliation': 'Novo Nordisk A/S', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Novo Nordisk Investigational Site', 'city': 'Angers', 'zip': '37540', 'country': 'France', 'geoPoint': {'lat': 47.46667, 'lon': -0.55}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Annecy', 'zip': '74600', 'country': 'France', 'geoPoint': {'lat': 45.9, 'lon': 6.11667}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Auffay', 'zip': '76720', 'country': 'France', 'geoPoint': {'lat': 49.7254, 'lon': 0.68696}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Avignon', 'zip': '84902', 'country': 'France', 'geoPoint': {'lat': 43.94834, 'lon': 4.80892}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Besançon', 'zip': '25000', 'country': 'France', 'geoPoint': {'lat': 47.24878, 'lon': 6.01815}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Bethoncourt', 'zip': '25200', 'country': 'France', 'geoPoint': {'lat': 47.53512, 'lon': 6.80504}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Beze', 'zip': '21310', 'country': 'France', 'geoPoint': {'lat': 47.46794, 'lon': 5.27119}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Bourgoin-jallieu', 'zip': '38302', 'country': 'France', 'geoPoint': {'lat': 45.58611, 'lon': 5.27361}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Bry sur Marne', 'zip': '94360', 'country': 'France', 'geoPoint': {'lat': 48.83811, 'lon': 2.52488}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Caen', 'zip': '14033', 'country': 'France', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Challes les Eaux', 'zip': '73190', 'country': 'France', 'geoPoint': {'lat': 45.55195, 'lon': 5.98171}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Chalon sur Saone', 'zip': '71100', 'country': 'France', 'geoPoint': {'lat': 46.78333, 'lon': 4.85}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Chalons Sur Saone', 'zip': '71100', 'country': 'France'}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Charleville-Mézières', 'zip': '08000', 'country': 'France', 'geoPoint': {'lat': 49.76667, 'lon': 4.71667}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Chelles', 'zip': '77500', 'country': 'France', 'geoPoint': {'lat': 48.88109, 'lon': 2.59295}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Clichy', 'zip': '92110', 'country': 'France', 'geoPoint': {'lat': 48.90018, 'lon': 2.30952}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Colmar', 'zip': '68000', 'country': 'France', 'geoPoint': {'lat': 48.08333, 'lon': 7.36667}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Colmar', 'zip': '68024', 'country': 'France', 'geoPoint': {'lat': 48.08333, 'lon': 7.36667}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'DIJON cedex', 'zip': '21079', 'country': 'France', 'geoPoint': {'lat': 47.31667, 'lon': 5.01667}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Dijon', 'zip': '21000', 'country': 'France', 'geoPoint': {'lat': 47.31667, 'lon': 5.01667}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Dole', 'zip': '39100', 'country': 'France', 'geoPoint': {'lat': 47.1, 'lon': 5.5}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Doudeville', 'zip': '76560', 'country': 'France', 'geoPoint': {'lat': 49.72268, 'lon': 0.78479}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Elancourt', 'zip': '78990', 'country': 'France', 'geoPoint': {'lat': 48.78421, 'lon': 1.9552}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Guiscard', 'zip': '60640', 'country': 'France', 'geoPoint': {'lat': 49.6566, 'lon': 3.05127}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'La Bouëxière', 'zip': '35340', 'country': 'France', 'geoPoint': {'lat': 48.18333, 'lon': -1.43333}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'La Madeleine', 'zip': '59110', 'country': 'France', 'geoPoint': {'lat': 50.64603, 'lon': 3.07585}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Lambersart', 'zip': '59130', 'country': 'France', 'geoPoint': {'lat': 50.65, 'lon': 3.03333}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Le Puy en Velay', 'zip': '43000', 'country': 'France', 'geoPoint': {'lat': 45.04366, 'lon': 3.88523}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Lomme', 'zip': '59462', 'country': 'France', 'geoPoint': {'lat': 50.64358, 'lon': 2.98715}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Lyon', 'zip': '69007', 'country': 'France', 'geoPoint': {'lat': 45.74848, 'lon': 4.84669}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Maison-Alfort', 'zip': '94700', 'country': 'France'}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Marseille', 'zip': '13006', 'country': 'France', 'geoPoint': {'lat': 43.29551, 'lon': 5.38958}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'MONTPELLIER cedex 5', 'zip': '34295', 'country': 'France', 'geoPoint': {'lat': 43.61092, 'lon': 3.87723}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Montélimar', 'zip': '26200', 'country': 'France', 'geoPoint': {'lat': 44.55838, 'lon': 4.75094}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Nevers', 'zip': '58000', 'country': 'France', 'geoPoint': {'lat': 46.98956, 'lon': 3.159}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'NICE cedex 3', 'zip': '06202', 'country': 'France', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Noisy le Grand', 'zip': '93160', 'country': 'France', 'geoPoint': {'lat': 48.84979, 'lon': 2.56266}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Orry-la-ville', 'zip': '60560', 'country': 'France', 'geoPoint': {'lat': 49.13345, 'lon': 2.51139}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Paris', 'zip': '75010', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Paris', 'zip': '75014', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Paris', 'zip': '75877', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Pessac', 'zip': '33600', 'country': 'France', 'geoPoint': {'lat': 44.81011, 'lon': -0.64129}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Pierre-Bénite', 'zip': '69495', 'country': 'France', 'geoPoint': {'lat': 45.7009, 'lon': 4.82511}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Six Fours les plages', 'zip': '83140', 'country': 'France', 'geoPoint': {'lat': 43.1, 'lon': 5.85}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Ste Foy Lès Lyon', 'zip': '69110', 'country': 'France'}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Strasbourg', 'zip': '67000', 'country': 'France', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Toulouse', 'zip': '31300', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Tours', 'zip': '37000', 'country': 'France', 'geoPoint': {'lat': 47.38333, 'lon': 0.68333}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Valence', 'zip': '26000', 'country': 'France', 'geoPoint': {'lat': 44.93333, 'lon': 4.9}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Venissieux', 'zip': '69200', 'country': 'France', 'geoPoint': {'lat': 45.70254, 'lon': 4.87147}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Vichy', 'zip': '03207', 'country': 'France', 'geoPoint': {'lat': 46.11667, 'lon': 3.41667}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Vienne', 'zip': '38500', 'country': 'France', 'geoPoint': {'lat': 45.51667, 'lon': 4.86667}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Vitré', 'zip': '35500', 'country': 'France', 'geoPoint': {'lat': 48.11776, 'lon': -1.20577}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Yerres', 'zip': '91330', 'country': 'France', 'geoPoint': {'lat': 48.71785, 'lon': 2.49338}}]}, 'referencesModule': {'references': [{'pmid': '36869853', 'type': 'BACKGROUND', 'citation': 'Mohammedi K, Belhatem N, Berentzen TL, Catarig AM, Potier L. Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study. Diabetes Obes Metab. 2023 Jul;25(7):1855-1864. doi: 10.1111/dom.15045. Epub 2023 Mar 28.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'According to the Novo Nordisk disclosure commitment on novonordisk-trials.com', 'url': 'http://novonordisk-trials.com'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000591245', 'term': 'Semaglutide'}], 'ancestors': [{'id': 'D000097789', 'term': 'Glucagon-Like Peptide-1 Receptor Agonists'}, {'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M353561', 'name': 'Semaglutide', 'asFound': 'Electrodes', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M3401', 'name': 'Glucagon-Like Peptide-1 Receptor Agonists', 'relevance': 'LOW'}, {'id': 'M9043', 'name': 'Glucagon', 'relevance': 'LOW'}, {'id': 'M26997', 'name': 'Glucagon-Like Peptide 1', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05378620', 'orgStudyIdInfo': {'id': 'IRB-22-7886'}, 'secondaryIdInfos': [{'id': 'KL2TR002552', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/KL2TR002552'}], 'organization': {'fullName': 'Scripps Whittier Diabetes Institute', 'class': 'OTHER'}, 'briefTitle': 'Project Dulce for Filipino-Americans With Type 2 Diabetes', 'officialTitle': 'Project Dulce for Filipino-Americans With Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2025-01', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-10-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-05-10', 'studyFirstSubmitQcDate': '2022-05-13', 'studyFirstPostDateStruct': {'date': '2022-05-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-01-31', 'lastUpdatePostDateStruct': {'date': '2025-02-04', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Athena Philis-Tsimikas', 'investigatorTitle': 'Corporate Vice President', 'investigatorAffiliation': 'Scripps Whittier Diabetes Institute'}, 'leadSponsor': {'name': 'Scripps Whittier Diabetes Institute', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Center for Advancing Translational Sciences (NCATS)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This study aims to culturally adapt an existing American Diabetes Association (ADA)-recognized diabetes self-management and support or DSMES (Diabetes Self Management Education Support) program (Project Dulce) and integrate an evidence-based text messaging program (Dulce Digital) for implementation in Filipino Americans (FAs) with type 2 diabetes mellitus (T2DM). Cultural adaptations aims to facilitate and enhance patient centered approaches and increase participant engagement by addressing barriers to DSMES unique to FAs, such as linguistic challenges, health literacy and numeracy, cultural beliefs and values, and technology access and use. In addition, this study aims to examine the effectiveness of the culturally and digitally adapted Project Dulce + Dulce Digital in improving diabetes knowledge, belief, attitudes, hemoglobin A1C (glycosylated hemoglobin), and self-management behaviors at baseline to 3 months and 6 months. The unprecedented increase of T2DM prevalence among racial and ethnic minority populations including FAs in recent decades demands for effective strategies to meet the needs in DSMES in this population. The outcomes of the current study will demonstrate that the culturally adapted Project Dulce and integration of Dulce Digital is effective in addressing the needs FAs, an underserved racial and ethnic minority group in high need of culturally appropriate DSMES.', 'detailedDescription': 'Type 2 diabetes mellitus (T2DM) disproportionately affects racial and ethnic minority populations. Among Asian Americans, Filipino Americans (FA) have the second highest T2DM prevalence and have an increased risk for developing complications due to lack of engagement in health protective behaviors (e.g., eating healthfully, obtaining adequate activity) and increased social and environmental barriers to optimal self-management (e.g., access to culturally appropriate education programs). While diabetes self-management education (DSME) programs have been shown to significantly improve T2DM outcomes, fewer than 10% of newly-diagnosed individuals receive DSMES within the first year of diagnosis.\\n\\nProject Dulce is an American Diabetes Association (ADA)-recognized adult T2DM management program developed to address the needs of a racially and ethnically diverse San Diego population. Project Dulce includes a multi-disciplinary team with peer educators delivering DSMES. Previous trials have shown Project Dulce team-care improves clinical management and reduces costs (e.g., Philis-Tsimikas et al., 2004; Gilmer et al., 2005), and that the peer education alone improves clinical outcomes in Hispanics with T2DM (Philis-Tsimikas et al., 2011). The program has been disseminated locally, nationally, and internationally to White and Hispanic populations and has now served over 20,000 people. More recently, the peer education content was adapted via the Dulce Digital program to extend the reach of the care team through text messages derived from the Project Dulce curriculum, including medication reminders, and blood glucose monitoring prompts. This program led to a significant reduction of hemoglobin AHbA1c across 10 months versus usual care in Hispanics with diabetes (Fortmann et al., 2017). While Project Dulce has been adapted and demonstrated improvements in clinical and cost outcomes in Hispanic patients, cultural and digital adaptations are needed to increase and facilitate use in other racial and ethnic minority groups including FAs.\\n\\nUsing a Community-Based Participatory Research (CBPR) approach, this study will adapt Project Dulce + Dulce Digital for implementation in FA adults with T2DM. Cultural adaptations aims to facilitate and enhance patient-centered approaches by addressing barriers to DSMES unique to this population, such as linguistic challenges, health literacy and numeracy, cultural beliefs and values, and technology access and use. In addition, ADA has recommended the use of digital technologies as effective methods to deliver DSMES and mitigate barriers to participation. The adaptation process will be demonstrated in partnership with a local Federally Qualified Health Center (FQHC) serving a large number of FAs from diverse socioeconomic backgrounds. This study aims to culturally adapt Project Dulce and Dulce Digital for FAs with T2DM. Specifically, this study aims to:\\n\\n1. examine the effectiveness of the culturally adapted Project Dulce + Dulce Digital in improving diabetes knowledge, attitudes, and beliefs among FAs with T2DM;\\n2. examine the effectiveness of the culturally adapted Project Dulce + Dulce Digital in improving HbA1C and self-management behaviors (i.e., diet, physical activity, medication adherence, foot care, blood glucose monitoring from baseline to 3- and 6-months; and\\n3. evaluate the acceptability and feasibility of the culturally adapted Project Dulce + Dulce Digital when delivered by FA peer educator to FA patients with T2DM.'}, 'conditionsModule': {'conditions': ['Diabetes Type 2'], 'keywords': ['Diabetes', 'Self-Management', 'Education']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 48, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Project Dulce + Dulce Digital', 'type': 'OTHER', 'description': 'Patients will participate in a peer-led group diabetes self-management education and support program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.', 'interventionNames': ['Behavioral: Project Dulce + Dulce Digital']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Project Dulce + Dulce Digital', 'description': 'Project Dulce will consist of a group diabetes self-management program consisting of a 5-week curriculum delivered by a peer educator in Tagalog. The curriculum provides new knowledge as well as skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants will learn and practice self-management skills, and help one another address family, cultural, or health system barriers to managing your diabetes. Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Tagalog.', 'armGroupLabels': ['Project Dulce + Dulce Digital']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from Baseline Diabetes Knowledge at 3 months', 'description': 'Diabetes Knowledge Test (Fitzgerald, Funnell, Anderson, et al., 2016) is a 23-item measure of diabetes knowledge, with general questions related to symptoms, self-management (e.g., diet, exercise, foot care, blood glucose monitoring, insulin) , and complications (e.g., low and high blood sugar). Greater scores indicate greater diabetes knowledge.', 'timeFrame': '3 months'}, {'measure': 'Change from Baseline Diabetes Knowledge at 6 months', 'description': 'Diabetes Knowledge Test (Fitzgerald, Funnell, Anderson, et al., 2016) is a 23-item measure of diabetes knowledge, with general questions related to symptoms, self-management (e.g., diet, exercise, foot care, blood glucose monitoring, insulin) , and complications (e.g., low and high blood sugar). Greater scores indicate greater diabetes knowledge.', 'timeFrame': '6 months'}, {'measure': 'Change in Baseline Self-Efficacy for Diabetes Scale at 3 months', 'description': 'Stanford Self-Efficacy for Diabetes Scale (Lorig, Stewart, Ritter, et al., 1996) is comprised of 8 items that measure the confidence of a participant in performing self-care activities such as eating meals every 4 to 5 hours, following a healthful diet, exercising, and blood glucose monitoring. Response options range from 1=not at all confident to 10=totally confident, with higher scores indicating greater self-efficacy.', 'timeFrame': '3 months'}, {'measure': 'Change in Baseline Self-Efficacy for Diabetes Scale at 6 months', 'description': 'Stanford Self-Efficacy for Diabetes Scale (Lorig, Stewart, Ritter, et al., 1996) is comprised of 8 items that measure the confidence of a participant in performing self-care activities such as eating meals every 4 to 5 hours, following a healthful diet, exercising, and blood glucose monitoring. Response options range from 1=not at all confident to 10=totally confident, with higher scores indicating greater self-efficacy.', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Change in Baseline Summary of Diabetes Self-Care Activities at 3 months', 'description': 'Summary of Diabetes Self-Care Activities measure (Toobert, Hampson, \\\\& Glassgow, 2000) is a 13-item brief questionnaire that assesses respondents adherence to self-management behavior recommendations in the past 7 days, including general and specific diet, exercise, blood glucose testing, foot care, medication adherence, and smoking, with greater scores indicating greater adherence.', 'timeFrame': '3 months'}, {'measure': 'Change in Baseline Summary of Diabetes Self-Care Activities at 6 months', 'description': 'Summary of Diabetes Self-Care Activities measure (Toobert, Hampson, \\\\& Glassgow, 2000) is a 13-item brief questionnaire that assesses respondents adherence to self-management behavior recommendations in the past 7 days, including general and specific diet, exercise, blood glucose testing, foot care, medication adherence, and smoking, with greater scores indicating greater adherence.', 'timeFrame': '6 months'}, {'measure': 'Change in Baseline Block Food Frequency Questionnaire at 3 months', 'description': 'Block Food Frequency Questionnaire (Block et al., 1995) measures frequency of fruit, vegetable and fiber consumption, and fat (and saturated fat) consumption each week using seven frequency categories ranging from less than once a week to 2 or more a day. Minor modifications were included to add food items commonly consumed in a Filipino diet (e.g., \"Any other vegetables such as corn broccoli, zucchini, or vegetables commonly used Filipino cooking such as sitaw, kalabasa, sayote, upo, monggo, malunggay, amapalaya, pechay, kangkong, okra, etc.)', 'timeFrame': '3 months'}, {'measure': 'Change in Baseline Block Food Frequency Questionnaire at 6 months', 'description': 'Block Food Frequency Questionnaire (Block et al., 1995) measures frequency of fruit, vegetable and fiber consumption, and fat (and saturated fat) consumption each week using seven frequency categories ranging from less than once a week to 2 or more a day. Minor modifications were included to add food items commonly consumed in a Filipino diet (e.g., \"Any other vegetables such as corn broccoli, zucchini, or vegetables commonly used Filipino cooking such as sitaw, kalabasa, sayote, upo, monggo, malunggay, amapalaya, pechay, kangkong, okra, etc.)', 'timeFrame': '6 months'}, {'measure': 'Change in Baseline International Physical Activity Questionnaire-Short Form at 3 months', 'description': 'International Physical Activity -Short Form (Craig et al., 2003) assesses the amount of physical activity (work, leisure, and other) and sedentary time in the past 7 days.', 'timeFrame': '3 months'}, {'measure': 'Change in Baseline International Physical Activity Questionnaire-Short Form at 6 months', 'description': 'International Physical Activity -Short Form (Craig et al., 2003) assesses the amount of physical activity (work, leisure, and other) and sedentary time in the past 7 days.', 'timeFrame': '6 months'}, {'measure': 'Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 3 months; % Units', 'description': 'HbA1c is measure of blood sugar level and assessed using blood samples following a 12-hour fast. Samples will be processed by Quest Diagnostics Inc and assayed by Immunoturbidimetry (Integra 800, Roche).', 'timeFrame': '3 months'}, {'measure': 'Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months; % Units', 'description': 'HbA1c is measure of blood sugar level and assessed using blood samples following a 12-hour fast. Samples will be processed by Quest Diagnostics Inc and assayed by Immunoturbidimetry (Integra 800, Roche).', 'timeFrame': '6 months'}], 'otherOutcomes': [{'measure': 'Recruitment and Retention', 'description': 'Recruitment rate is the number of participants recruited divided by the maximum number of sites (n=1), divided by the number of months recruiting.\\n\\nRetention rate is the number of participants who remained in the study at the last wave of data collection (6 months) as the proportion of the number of participants enrolled at the baseline assessment.', 'timeFrame': '6 months'}, {'measure': 'Participant Satisfaction', 'description': 'Study-adapted focus group questionnaire evaluates participant experiences and satisfaction related to specific aspects of the peer-led diabetes education program (e.g., curriculum, handouts and PowerPoint Slides, peer educator) and text messaging component (e.g., content of text messages, receiving and responding to text messages, follow-up phone calls from the peer educator).', 'timeFrame': '6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Self-identified Filipino\\n* Diagnosed with T2DM\\n* Registered at Scripps Health or San Ysidro Health (or willing to register)\\n* HbA1c ≥7.5% and/or systolic blood pressure ≥ 140, and/or LDL-C ≥ 100 mg/dL within 90 days\\n* Able to speak, read, write, and comprehend in English and Tagalog\\n* Have access to a cell phone that can receive/send text messages throughout the study\\n\\nExclusion Criteria:\\n\\n* Severe illness precluding frequent visits to clinic\\n* Liver function tests (ALT and AST) \\\\> 3 times the upper limit of normal\\n* Body mass index ≤ 23 kg/cm\\n* History of malignancy, except subjects who have been disease-free for \\\\>years, or whose only malignancy has been basal or squamous cell skin carcinoma\\n* Creatinine \\\\>3.5\\n* History of drug or alcohol abuse within 12 months prior to enrollment\\n* Not a permanent resident in the area\\n* Current enrollee in Project Dulce\\n* Blood donation of one pint or more within the past 30 days, or plasma donation within 7 days prior to screening\\n* Anemia\\n* Type 1 or gestational diabetes\\n* Pregnant\\n* Are currently participating in another diabetes-related study', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Emily Rose N. San Diego, PhD', 'role': 'CONTACT', 'phone': '858-209-5233', 'email': 'sandiego.emily@scrippshealth.org'}, {'name': 'Athena Philis-Tsimikas, MD', 'role': 'CONTACT', 'phone': '877-944-8843', 'email': 'philis-tsimikas.athena@scrippshealth.org'}], 'overallOfficials': [{'name': 'Emily Rose N. San Diego, PhD', 'affiliation': 'Scripps Whittier Diabetes Institute', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'San Ysidro Health', 'status': 'RECRUITING', 'city': 'National City', 'state': 'California', 'zip': '91950', 'country': 'United States', 'contacts': [{'name': 'Emily Rose N. San Diego, PhD', 'role': 'CONTACT', 'phone': '858-209-5233', 'email': 'sandiego.emily@scrippshealth.org'}], 'geoPoint': {'lat': 32.67811, 'lon': -117.0992}}, {'facility': 'Scripps Whittier Diabetes Institute', 'status': 'RECRUITING', 'city': 'San Diego', 'state': 'California', 'zip': '92037', 'country': 'United States', 'contacts': [{'name': 'Emily Rose N. San Diego, PhD', 'role': 'CONTACT', 'phone': '858-209-5233', 'email': 'sandiego.emily@scrippshealth.org'}], 'geoPoint': {'lat': 32.71533, 'lon': -117.15726}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06483620', 'orgStudyIdInfo': {'id': 'P.T.REC/012/005051'}, 'organization': {'fullName': 'Cairo University', 'class': 'OTHER'}, 'briefTitle': 'Cross-cultural Adaptation and Validity of the Arabic-translated NEUROPATHY-SPECIFIC QUALITY of LIFE Questionnaire', 'officialTitle': 'Neuropathy and Foot Ulcer_ Specific Quality of Life Instrument (Neuro QOL) Arabic Version: Cross-cultural Adaptation, Validity, and Reliability for Patients with Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2024-07', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-02-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12-10', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-01-15', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-06-11', 'studyFirstSubmitQcDate': '2024-07-01', 'studyFirstPostDateStruct': {'date': '2024-07-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-10-28', 'lastUpdatePostDateStruct': {'date': '2024-10-30', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Engy Badreldin Saleh Moustafa, PhD', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'Cairo University'}, 'leadSponsor': {'name': 'Cairo University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'PURPOSE: This study will translate, culturally adapt, validate, and test the reliability of the Neuro Qol Arabic version to be used with diabetic patients in Arabic countries.\\n\\nBackground: The Neuropathy- and Foot Ulcer-Specific Quality of Life instrument is a multidimensional scale was developed to assess the QoL of diabetic patients with peripheral neuropathy. Producing Arabic versions of the Translating Scale can help researchers investigate offloading treatment among the Arabic population with DFUs.\\n\\nHypotheses: The study design was a cross-cultural validation of NeuroQol, the Arabic version, for patients with DFUs.\\n\\nResearch Question: Will there be cultural adaptation, validation, and reliability between the (Neuro Qol) Arabic version and the original language?', 'detailedDescription': \"The Neuropathy- and Foot Ulcer-Specific Quality of Life instrument (Neuro QOL) is used worldwide to assess the QOL of diabetic patients with peripheral neuropathy. There is no Arabic version of NeuroQOL for use in Egypt.\\n\\nThe study design will be a cross-cultural validation of Neuro Qol the Arabic version for patients with DFUs. Three expert panels were involved in this study to test the face and content validity of Neuro Qol Arabic version. All experts had experience of not less than 10 years or at least a master's degree in physical therapy; a major part of their work is with Arabic population; and they were also fluent in Arabic and English.\\n\\nTen patients per item were chosen to estimate the sample size for testing the psychometric properties of the Neuro Qol Arabic version. So 290 patients (145 male patients and 145 female patients), were chosen according to the following criteria: Their age ranged between 18-70 years , with type 2 diabetes referred by physician, conscious and ambulant, and being able to read and write in Arabic.\\n\\nPatients suffering from congenital deformities, fixed spinal deformity, rheumatoid arthritis, bone disease, or infection were excluded from the study.\\n\\nParticipants will be identified, approached, and recruited from outpatient clinics at the Faculty of Physical Therapy, Nahda University, and El-Salam University. The study will be advertised through posters and word of mouth. Participants will receive a participant information sheet and a self-screening eligibility form, and they will be asked to contact the Principal Investigator (SG) no sooner than 48 hours if they wish to volunteer to participate in the study, which consisted of two visits to the clinic.\\n\\nDuring study visit 1, participants will be briefed about the study, screened for eligibility, and enrolled in the study by signing a consent form.\\n\\nDemographic data, such as age, weight, and height, will also be collected to describe the sample. The principal investigator will apply the clinical examination for the foot and assess any problems such as lost or reduced feeling in your extremities, pain, discomfort, and/or ulcers (open sores) on your feet, and, in some cases, unsteadiness while walking or standing. Participants will then complete the Arabic NeuroQOL. A nurse assisted participants with reading difficulties.\\n\\nParticipants will return for study visit 2 after 7-14 days and will complete the Michigan Diabetic Neuropathy Scale (MDNS)-Arabic version. Participants will also be required to report other symptoms and complications associated with diabetes.\\n\\nThe translation process will follow the Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcome Measures using the following steps:\\n\\n1. Preparation: Four bilingual translators who are fluent in Arabic and English will be selected. Three translators are clinicians and one translator is a university academic.\\n2. Forward translation: the NeuroQOL will be given to all translators to translate into Arabic.\\n3. Reconciliation: The four translated documents will be shared between all translators, and discrepancies, ambiguities, and issues arising will be discussed and resolved and a final draft Arabic version of the NeuroQOL will be produced.\\n4. Backward translation and review: The final draft Arabic version of the NeuroQOL will be translated back into English by a translator who had not been involved in forward translation and who was blind to the original English version of the NeuroQOL.\\n5. Harmonization, cognitive debriefing and reviewing of results: The back-translated The English version of the NeuroQOL will be compared with the original NeuroQOL, and discrepancies, ambiguities, and typographic and/or grammatical errors will be discussed within the group and in the final draft of the Arabic version.\\n6. Proofreading and final report: When the authenticity of the translation has been agreed upon by consensus, the final version of the Arabic-NeuroQOL will be produced.\"}, 'conditionsModule': {'conditions': ['Diabetic Neuropathies', 'Diabetic Peripheral Neuropathy']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 290, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Diabetic Neuropathy group', 'description': \"The study design was a cross-cultural validation of Neuro Qol the Arabic version, for patients with DFUs. Three expert panels were involved in this study to test the face and content validity of the NeuroQol Arabic version. All experts had experience of not less than 10 years or at least a master's degree in physical therapy; a major part of their work is with the Arabic population; and they were also fluent in Arabic and English.\\n\\nTen patients per item were chosen to estimate the sample size for testing the psychometric properties of the Neuro Qol Arabic version. So 290 patients (145 male patients and 145 female patients), were chosen according to specific eligibility criteria.\", 'interventionNames': ['Diagnostic Test: Neuropathy - and Foot Ulcer - Specific Quality of Life instrument (Neuro Qol)']}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'Neuropathy - and Foot Ulcer - Specific Quality of Life instrument (Neuro Qol)', 'description': 'The NeuroQoL questionnaire is a valid, reliable, and self-reported questionnaire. It has 35-items with six domains namely, painful symptoms and paresthesia (items 1-7), reduction or loss of ability to feel (items 8-10), unsteadiness while walking/standing/diffuse sensory-motor symptoms (items 11-13), limitation in daily living (items 14 - 16), interpersonal problems (items 17-20), emotional distress (items 21- 27) and end with an overall assessment of quality of life or satisfaction with experiences in the above six domains \\\\[1 item in each domains, i.e. additional 6 items (items 28-33)\\\\]. The two final items (items 34-35) assess overall impact of neuropathy on QoL \\\\[5\\\\]. The scoring of the questionnaire is according to a five-point Likert scale, all the time, most of the time, some of the time, occasionally, never. Each domain has a maximum score 5 and minimum 1, where 5 means that the QoL is affected all the time because of the foot problem while 1 means never it affects their QoL', 'armGroupLabels': ['Diabetic Neuropathy group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Cross-cultural validation of the Arabic-translated NEURQOL Questionnaire.', 'description': 'Cross-cultural validation involves three main phases: 1) translation and verification of its equivalence; traditional translation simply involves translation of the original instrument by a bilingual researcher or professional translator. 2) empirical verification of the validity of the translated version; it involves the participation of a number of bilingual people familiar with the field in which the instrument is to be used, which also limits the biases of a single researcher. and 3) adaptation of the scores to the cultural context, and the development of standards. It involves having a preliminary translated version of the instrument translated back into the original language by a second person. The discrepancies between the original version and the retranslated version help identify problematic items.', 'timeFrame': 'Baseline and through study completion, an average of 6 months.'}, {'measure': 'Reliability of the Arabic-translated NEURQOL Questionnaire.', 'description': 'It considers the extent to which the questions used in the NeurQoL questionnaire consistently elicit the same results each time it is asked in the same situation on repeated occasions. test-retest reliability. This involves administering the questionnaire to the eligible participants and repeating the survey with the same group at the end of the questionnaire validation. We then compare the responses at the two time points.', 'timeFrame': 'Baseline and through study completion, an average of 6 months.'}, {'measure': 'Cross-cultural adaptation of the Arabic-translated NEURQOL Questionnaire.', 'description': 'The process of translating and adapting questionnaires from one cultural context to another involves much more than converting the items from the source language to the target language. The questionnaire must be equivalent to the original, considering the new cultural context in which it will be applied. After translation, the scales were evaluated in meetings of a committee of experts in different scientific fields of interest, translators, and language professors. The updated questionnaire was then sent to six experts to assess the relevance of each item, the language, and the adopted response scales, and then to participants from the academic community and organizations human resources to improve item clarity.', 'timeFrame': 'Baseline and through study completion, an average of 6 months.'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Arabic is their first language The absence of any other neurological diagnosis affecting the sensory and motor system, such as stroke or multiple sclerosis\\n* Age ranges between 18 and 70 years,\\n* History of DM diagnosed by a physician and confirmed by either hemoglobin A1c ≥6.5% or the use of hypoglycemic agents.\\n\\nExclusion Criteria:\\n\\n* A hospital inpatient\\n* Had pre-existing comorbidities such as cancer, shingles or other neuropathic pain entity that predated diabetes or can mimic or cause a neuropathic pain that is not arising as a result of diabetes.\\n* Pregnant patients as diabetes may be of gestational type\\n* Had recently experienced physical trauma that may have contributed to neuropathic pain had trauma or dermatological diseases of the skin as this could affect skin sensitivity (e.g. wounds, psoriasis and eczema).', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'The study design will be a cross-cultural validation of Neuro Qol the Arabic version for patients with DFUs.\\n\\nParticipants will be identified, approached, and recruited from outpatient clinic at Faculty of Physical Therapy, Nahda University and Elsalam university. Ten patients per item were chosen to estimate the sample size for testing the psychometric properties of the Neuro Qol Arabic version (Sousa \\\\& Rojjanasrirat, 2011). So 290 patients (145 male patients and 145 female patients), were chosen according to specific criterea.', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Engy BadrEldin S Moustafa, PhD', 'role': 'CONTACT', 'phone': '00201099445112', 'email': 'engybm.saleh@cu.edu.eg'}, {'name': 'Shimaa T. AbulKasem, PhD', 'role': 'CONTACT', 'phone': '00201229823327', 'email': 'dr.shymaelshazly@yahoo.com'}], 'overallOfficials': [{'name': 'Engy BadrEldin S Moustafa, PhD', 'affiliation': 'Faculty of Physical Therapy, Cairo University, Egypt', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Faculty of Physical Therapy, Cairo University', 'status': 'RECRUITING', 'city': 'Cairo', 'state': 'Giza', 'zip': '11432', 'country': 'Egypt', 'contacts': [{'name': 'Engy BadrEldin S Moustafa, PhD', 'role': 'CONTACT', 'phone': '00201099445112', 'email': 'engybm.saleh@cu.edu.eg'}, {'name': 'Shimaa T. AbulKasem, PhD', 'role': 'CONTACT', 'phone': '00201229823327', 'email': 'dr.shymaelshazly@yahoo.com'}], 'geoPoint': {'lat': 30.06263, 'lon': 31.24967}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010523', 'term': 'Peripheral Nervous System Diseases'}, {'id': 'D003929', 'term': 'Diabetic Neuropathies'}], 'ancestors': [{'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D048909', 'term': 'Diabetes Complications'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M18919', 'name': 'Foot Ulcer', 'relevance': 'LOW'}, {'id': 'M17206', 'name': 'Ulcer', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}, {'id': 'M7124', 'name': 'Diabetic Neuropathies', 'asFound': 'Diabetic Neuropathy', 'relevance': 'HIGH'}, {'id': 'M13432', 'name': 'Peripheral Nervous System Diseases', 'asFound': 'Neuropathy', 'relevance': 'HIGH'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M26004', 'name': 'Diabetes Complications', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'T6034', 'name': 'Quality of Life', 'asFound': 'Quality of Life', 'relevance': 'HIGH'}, {'id': 'T4202', 'name': 'Oculocerebral Syndrome With Hypopigmentation', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02180620', 'orgStudyIdInfo': {'id': 'exertime'}, 'organization': {'fullName': 'University of Missouri-Columbia', 'class': 'OTHER'}, 'briefTitle': 'Pre-dinner vs. Post-dinner Exercise on Glycemic Control', 'officialTitle': 'Exercise Timing and Postprandial Glycemia in Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2017-06', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-09'}, 'primaryCompletionDateStruct': {'date': '2014-04', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2014-04', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2014-06-30', 'studyFirstSubmitQcDate': '2014-07-01', 'studyFirstPostDateStruct': {'date': '2014-07-02', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-06-06', 'lastUpdatePostDateStruct': {'date': '2017-06-08', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Jill Kanaley', 'investigatorTitle': 'professor', 'investigatorAffiliation': 'University of Missouri-Columbia'}, 'leadSponsor': {'name': 'University of Missouri-Columbia', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'With many medications we prescribe them relative to time of day or a meal. This study established if pre dinner vs post dinner exercise was more effective at altering post dinner glucose and triglyceride levels vs no exercise at all.', 'detailedDescription': 'All participants completed three trials in a random order in which they consumed a standardized dinner meal with 1) no RE (NoRE), 2) pre-dinner RE (RE→M), and 3) post-dinner RE beginning 45 min after dinner (M→RE). Diet was standardized during the day of testing. Participants reported to the lab for testing sometime between 3 - 5:30 p.m. and upon arrival a venous catheter was inserted into a forearm vein. Frequent blood sampling, indirect calorimetry measurements, and subjective well-being measurements ensued for \\\\~5.75 h while the participants were in the lab.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes'], 'keywords': ['GIP', 'GLP-1', 'exercise timing', 'resistance exercise', 'glucose concentrations']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 13, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'No exercise', 'type': 'EXPERIMENTAL', 'description': 'participants will remain sedentary during testing', 'interventionNames': ['Other: No exercise']}, {'label': 'Meal then exercise', 'type': 'EXPERIMENTAL', 'description': '45 min of resistance training will be performed after a standard meal', 'interventionNames': ['Other: Meal then exercise']}, {'label': 'exercise then meal', 'type': 'EXPERIMENTAL', 'description': '45 min of resistance training will be performed prior to a standard meal', 'interventionNames': ['Other: exercise then meal']}], 'interventions': [{'type': 'OTHER', 'name': 'No exercise', 'description': 'During the no exercise trial (NoEX), the participants will remain sedentary during testing.', 'armGroupLabels': ['No exercise'], 'otherNames': ['NoEX']}, {'type': 'OTHER', 'name': 'Meal then exercise', 'description': 'During the post-meal exercise trial (M→EX), 45 min of resistance training will be performed', 'armGroupLabels': ['Meal then exercise'], 'otherNames': ['M-EX']}, {'type': 'OTHER', 'name': 'exercise then meal', 'description': 'During the exercise prior to the meal trial (EX→M), 45 min of resistance training will be performed', 'armGroupLabels': ['exercise then meal'], 'otherNames': ['EX-M']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'glucose concentrations', 'timeFrame': 'Blood samples were taken every 5-10 min during the first 3.7 h of testing and every 30 min during the last 2 h'}], 'secondaryOutcomes': [{'measure': 'triglyceride concentrations', 'timeFrame': 'Blood samples were taken every 5-10 min during the first 3.7 h of testing and every 30 min during the last 2 h'}], 'otherOutcomes': [{'measure': 'GLP-1 concentrations', 'timeFrame': 'Blood samples were taken every 5-10 min during the first 3.7 h of testing and every 30 min during the last 2 h'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Obese ( body mass index 30-45 kg/m2)\\n* Physician diagnosed with type 2 diabetes receiving standard medical care\\n* Non-smokers\\n* Pregnancy\\n* Lactating mothers\\n\\nExclusion Criteria:\\n\\n* Insulin\\n* Surgical weight loss\\n* Orthopedic limitations to exercise\\n* Weight loss in the previous 3 months', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '25 Years', 'maximumAge': '55 Years', 'stdAges': ['ADULT']}, 'referencesModule': {'references': [{'pmid': '28970202', 'type': 'DERIVED', 'citation': 'Heden TD, Liu Y, Kanaley JA. A comparison of adipose tissue interstitial glucose and venous blood glucose during postprandial resistance exercise in patients with type 2 diabetes. J Appl Physiol (1985). 2018 Apr 1;124(4):1054-1061. doi: 10.1152/japplphysiol.00475.2017. Epub 2017 Sep 28.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M26997', 'name': 'Glucagon-Like Peptide 1', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01339520', 'orgStudyIdInfo': {'id': 'DiabetesScorecardStudy'}, 'organization': {'fullName': 'George Washington University', 'class': 'OTHER'}, 'briefTitle': 'Diabetes Scorecard Educational Intervention Study', 'officialTitle': 'Use of a Card to Improve Risk Factor Control in Patients With Type II Diabetes'}, 'statusModule': {'statusVerifiedDate': '2017-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2008-11'}, 'primaryCompletionDateStruct': {'date': '2010-05', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2010-05', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2011-04-19', 'studyFirstSubmitQcDate': '2011-04-19', 'studyFirstPostDateStruct': {'date': '2011-04-20', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-08-10', 'lastUpdatePostDateStruct': {'date': '2017-08-11', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Michael Irwig', 'investigatorTitle': 'Attending Physician', 'investigatorAffiliation': 'George Washington University'}, 'leadSponsor': {'name': 'George Washington University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to see if the use of a diabetic scorecard during clinic visits can improve glycemic control, blood pressure control, LDL-cholesterol, aspirin usage, and amount of exercise in adults over age 40 with uncontrolled Type II diabetes.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 104, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Scorecard', 'type': 'EXPERIMENTAL', 'description': 'Score of points for variables.', 'interventionNames': ['Behavioral: Scorecard', 'Behavioral: Control']}, {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'Standard of care for diabetes subjects'}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Scorecard', 'description': 'Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.', 'armGroupLabels': ['Scorecard']}, {'type': 'BEHAVIORAL', 'name': 'Control', 'description': 'Standard of care for diabetes subjects', 'armGroupLabels': ['Scorecard']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in total score', 'description': 'The total score was calculated by points assigned to variables (systolic blood pressure, diastolic blood pressure, HbA1c, aspirin usage and daily exercise). The maximal score of 100 corresponds to all variables at target. Fewer points were assigned to higher blood pressure, worse HbA1c levels, less exercise, etc.', 'timeFrame': '9 months'}], 'secondaryOutcomes': [{'measure': 'LDL-cholesterol', 'timeFrame': '9 months'}, {'measure': 'HbA1c', 'description': 'Measure of glycemic control', 'timeFrame': '9 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Uncontrolled Type II diabetes (HbA1c ≥ 8%)\\n\\nExclusion Criteria:\\n\\n* Type I Diabetes\\n* HbA1c \\\\< 8%\\n* Inability to understand the diabetes scorecard due to condition (i.e. dementia, mental retardation, etc) or language barrier\\n* Pregnancy\\n* Planning to move within the next year', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '40 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Medical Faculty Associates, George Washington University', 'city': 'Washington, D.C.', 'state': 'District of Columbia', 'zip': '20037', 'country': 'United States', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}]}, 'referencesModule': {'references': [{'pmid': '22332914', 'type': 'DERIVED', 'citation': 'Irwig MS, Sood P, Ni D, Amass T, Khurana PS, Jayanthi VV, Wang L, Adler SM. A diabetes scorecard does not improve HbA(1c), blood pressure, lipids, aspirin usage, exercise and diabetes knowledge over 9 months: a randomized controlled trial. Diabet Med. 2012 Sep;29(9):1206-12. doi: 10.1111/j.1464-5491.2012.03610.x.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M4548', 'name': 'Aspirin', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Antipy', 'name': 'Antipyretics'}, {'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'}, {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'}, {'abbrev': 'FiAg', 'name': 'Fibrinolytic Agents'}, {'abbrev': 'Analg', 'name': 'Analgesics'}, {'abbrev': 'PlAggInh', 'name': 'Platelet Aggregation Inhibitors'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03620266', 'orgStudyIdInfo': {'id': 'BioDiaMI'}, 'organization': {'fullName': 'Region Örebro County', 'class': 'OTHER'}, 'briefTitle': 'Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI', 'officialTitle': 'Effects of Bilberry and Oat Intake on Plasma Lipid Profile, Inflammation, and Exercise Capacity in Patients With Type 2 Diabetes and/or Myocardial Infarction (BioDiaMI): a Randomized, Double-blind, Placebo-controlled Trial', 'acronym': 'BioDiaMI'}, 'statusModule': {'statusVerifiedDate': '2024-04', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-09-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2018-08-02', 'studyFirstSubmitQcDate': '2018-08-02', 'studyFirstPostDateStruct': {'date': '2018-08-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-04-11', 'lastUpdatePostDateStruct': {'date': '2024-04-15', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Ole Frobert, MD, PhD', 'investigatorTitle': 'Professor', 'investigatorAffiliation': 'Region Örebro County'}, 'leadSponsor': {'name': 'Ole Frobert, MD, PhD', 'class': 'OTHER'}, 'collaborators': [{'name': 'Region Västmanland', 'class': 'OTHER'}, {'name': 'Region Skane', 'class': 'OTHER'}, {'name': 'Chalmers University of Technology', 'class': 'OTHER'}, {'name': 'Värmland County Council, Sweden', 'class': 'OTHER_GOV'}, {'name': 'Vastra Gotaland Region', 'class': 'OTHER_GOV'}, {'name': 'Aarhus University Hospital', 'class': 'OTHER'}, {'name': 'Odense University Hospital', 'class': 'OTHER'}, {'name': 'Falu Hospital', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Background:\\n\\nBilberries from Sweden, rich in polyphenols, have shown cholesterol-lowering effects in small studies, and the cholesterol-lowering properties of oats, with abundant beta-glucans and potentially bioactive phytochemicals, are well established. Both may provide cardiometabolic benefits for patients with manifest chronic cardiometabolic disease, such as type 2 diabets mellitus (T2DM) and myocardial infarction (MI). However, large studies of adequate statistical power and appropriate duration are needed to confirm clinically relevant treatment effects. No previous study has evaluated the potential additive or synergistic effects of bilberry combined with oats on cardiometabolic risk factors.\\n\\nDesign:\\n\\nThis is a double-blind, randomized, placebo-controlled clinical trial. Our primary objective is to assess cardioprotective effects of diet supplementation with dried bilberry and with bioprocessed oat bran, with a secondary explorative objective of assessing their combination, compared with a neutral isocaloric reference supplement, for patients diagnosed with T2DM and/or MI. Patients will be randomized 1:1:1:1 to a three-month intervention. The primary endpoint is the difference in LDL cholesterol change between the intervention groups after three months. The major secondary endpoint is exercise capacity at three months. Other secondary endpoints include plasma concentrations of biochemical markers of inflammation, glycaemia, and gut microbiota composition after three months.\\n\\nImplications:\\n\\nSecondary prevention after cardiometabolic disease, including T2DM and MI, has improved during the last decades but diabetes complications, readmissions and cadiovascular related deaths following these conditions remain large health care challenges. Controlling hyperlipidemia, hyperglycaemia, hypertension and inflammation is critical to preventing (new) cardiovascular events, but novel pharmacological treatments for these conditions are expensive and associated with negative side effects. If bilberry and/or oat, in addition to standard medical therapy, can lower LDL cholesterol and inflammation more than standard therapy alone, this could be a cost-effective and safe dietary strategy for secondary prevention in high-risk patients or risk prevention in subjects with T2DM.'}, 'conditionsModule': {'conditions': ['Myocardial Infarction'], 'keywords': ['acute myocardial infarction', 'diet therapy', 'anthocyanin', 'bilberry bush', 'exercise capacity', 'cholesterol', 'beta glucans', 'type 2 diabetes mellitus']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 900, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Bilberry', 'type': 'EXPERIMENTAL', 'description': 'Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.', 'interventionNames': ['Dietary Supplement: Bilberry']}, {'label': 'Reference/Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Dietary supplement with reference shakes 2 times daily for 3 months (containing no active bilberry or no active oats, but with similar texture and taste as both bilberry and oat). Product development in collaboration with Glucanova AB.', 'interventionNames': ['Dietary Supplement: Placebo']}, {'label': 'Bioprocessed oat bran', 'type': 'EXPERIMENTAL', 'description': 'Dietary supplement with bioprocessed oat bran shakes 2 times daily for 3 months (containing beta glucans from the Glucanova® technology, invented by Glucanova AB).Product development in collaboration with Glucanova AB.', 'interventionNames': ['Dietary Supplement: Bioprocessed oat bran']}, {'label': 'Combination of oat and bilberry', 'type': 'EXPERIMENTAL', 'description': 'Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.', 'interventionNames': ['Dietary Supplement: Combination bilberry/oats']}], 'interventions': [{'type': 'DIETARY_SUPPLEMENT', 'name': 'Bilberry', 'description': 'The dietary intervention will continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.', 'armGroupLabels': ['Bilberry']}, {'type': 'DIETARY_SUPPLEMENT', 'name': 'Placebo', 'description': 'The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.', 'armGroupLabels': ['Reference/Placebo']}, {'type': 'DIETARY_SUPPLEMENT', 'name': 'Bioprocessed oat bran', 'description': 'The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.', 'armGroupLabels': ['Bioprocessed oat bran']}, {'type': 'DIETARY_SUPPLEMENT', 'name': 'Combination bilberry/oats', 'description': 'The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.', 'armGroupLabels': ['Combination of oat and bilberry']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Plasma levels of LDL cholesterol', 'description': 'The effect of intervention on difference between the groups of LDL cholesterol after three months', 'timeFrame': 'Three months'}], 'secondaryOutcomes': [{'measure': 'Plasma lipid profile', 'description': 'The effect of intervention on differences between the groups of fasting lipid profile including HDL, triglycerides, total cholesterol, small-dense LDL cholesterol, apo A, apo B, Lp(a) and oxidized LDL.', 'timeFrame': 'Three months'}, {'measure': 'Symptom-limited bicycle ergometer test', 'description': 'The effect of intervention on exercise capacity (measured as maximal workload in Watts and as estimated maximal oxygen uptake (VO2 max))', 'timeFrame': 'Three months'}, {'measure': 'Dynamic unilateral heel-lft and unilateral shoulder flexion tests', 'description': 'The effect of intervention on muscle endurance', 'timeFrame': 'Three months'}, {'measure': 'Self-reported physical activity level', 'description': 'The effect of intervention on the Frändin/Grimby activity scale (6 levels of physical activity, min:1 (low activity) max:6 (heavy activity)) and the Haskell physical activity scale (\"For how many days were you physically active during the last week for at least 20 minutes?\", min:0 max:7)', 'timeFrame': 'Three months'}, {'measure': 'Plasma concentrations of inflammatory and heart function markers', 'description': 'The effect of intervention on plasma concentrations of biochemical markers of troponin, NT-proBNP, hs_CRP (high sensitivity C-reactive protein), IL-6 and HbA1c (glycosylated hemoglobin).', 'timeFrame': 'Three months'}, {'measure': 'Plasma concentrations of other biochemical markers', 'description': 'The effect if intervention on plasma concentrations of biochemical markers of insulin, creatinine, Cystatin C, glucose and C-peptide', 'timeFrame': 'Three months'}, {'measure': 'Untargeted plasma metabolome', 'description': 'Untargeted plasma metabolomics will be employed to exploratively assess alterations in endogenous and exposome-related metabolites and to identify metabolites that may differ with treatment.', 'timeFrame': 'Three months'}, {'measure': 'Fecal samples of gut microbiota composition', 'description': 'These exploratory analyses of will allow to investigate the extent to which gut microbiota composition and activity differs between responders and non-responders to the interventions.', 'timeFrame': 'Three months'}, {'measure': 'Left ventricular systolic function', 'description': 'The effect of intervention on left ventricular function. Baseline left ventricular systolic function, expressed as global ejection fraction in percent according to the biplane Simpson method, will be evaluated by echocardiography by the discharging physician. The procedure will be repeated after three months by an experienced echocardiography technician blinded to results of the initial examinations', 'timeFrame': 'Three months'}, {'measure': 'Resting heart rate', 'description': 'The effect of intervention on resting heart rate', 'timeFrame': 'Three months'}, {'measure': 'Systolic and diastolic blood pressure', 'description': 'The effect of intervention on blood pressure (mmHg)', 'timeFrame': 'Three months'}, {'measure': 'Urine albumin-creatinine ratio', 'description': 'Urine albumin-creatinine ratio will be measured for for T2DM only', 'timeFrame': 'Three months'}, {'measure': 'Continuous glucose monitoring with Continuous Glucose Monitors (CGM) - FreeStyle model 2', 'description': 'Continuous glucose monitoring (in a subset of T2DM only, n=80 in total)', 'timeFrame': 'Three months'}, {'measure': 'Body composition with multi-frequency biothesiometry', 'description': 'Body composition willbe measured with multi-frequency biothesiometry (for T2DM only)', 'timeFrame': 'Three months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion criteria\\n\\n* Confirmed T2DM diagnosis (any treatment modality accepted) and/or within 3 years post STEMI or NSTEMI\\n* Completed coronary angiography/PCI\\n* Male and female subjects ≥18 years\\n* Allocated to atorvastatin at a daily dose of 80 mg (only eligible for patients enrolled up to 7 days post MI and not for T2D subjects)\\n* Written informed consent\\n\\nExclusion criteria\\n\\n* Emergency coronary artery bypass grafting\\n* \\\\<18 years of age\\n* LDL cholesterol \\\\<2.0 mmol/L\\n* Daily intake or the intent to initiate daily intake of bilberry in any form or daily intake of \\\\>15 g of oatmeal or equivalent\\n* Food allergy/intolerance to gluten, bilberries or legumes\\n* Previous randomization in the BioDiaMI trial\\n* Inability to provide informed consent', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Ole Frobert, Prof', 'role': 'CONTACT', 'phone': '+46 19 602 543', 'email': 'ole.frobert@regionorebrolan.se'}, {'name': 'Cecilia Bergh, PhD', 'role': 'CONTACT', 'phone': '+46 730 68 28 92', 'email': 'cecilia.bergh@regionorebrolan.se'}], 'overallOfficials': [{'name': 'Ole Frobert, Prof', 'affiliation': 'Department of Cardiology, Örebro Univerity Hospital, 701 85 Örebro, Sweden', 'role': 'STUDY_DIRECTOR'}, {'name': 'Cecilia Bergh, PhD', 'affiliation': 'Clinical Epidemiology and Biostatistics, School of medical Sciences, örebro University, Sweden', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Steno Diabetes center', 'status': 'NOT_YET_RECRUITING', 'city': 'Aarhus', 'country': 'Denmark', 'contacts': [{'name': 'Sören Gregersen, Prof', 'role': 'CONTACT'}], 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}, {'facility': 'Odense University Hospital', 'status': 'RECRUITING', 'city': 'Odense', 'country': 'Denmark', 'contacts': [{'name': 'Mona El Faramawi, MD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}, {'facility': 'Falu lasarett', 'status': 'NOT_YET_RECRUITING', 'city': 'Falun', 'country': 'Sweden', 'contacts': [{'name': 'Kristina Hambreaus, MD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 60.60357, 'lon': 15.62597}}, {'facility': 'Sahlgrenska Universitetssjukhuset', 'status': 'RECRUITING', 'city': 'Gothenburg', 'country': 'Sweden', 'contacts': [{'name': 'Carlo Pirazzi, MD, PhD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 57.70716, 'lon': 11.96679}}, {'facility': 'Karlstad general hospital', 'status': 'RECRUITING', 'city': 'Karlstad', 'country': 'Sweden', 'contacts': [{'name': 'Payam Khalili, MD, PhD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 59.3793, 'lon': 13.50357}}, {'facility': 'Department of Cardiology, Skånes universitetssjukhus', 'status': 'RECRUITING', 'city': 'Lund', 'zip': '221 00', 'country': 'Sweden', 'contacts': [{'name': 'David Ehrlinge, prof', 'role': 'CONTACT', 'phone': 'tel:+46 46 17 25 97', 'email': 'david.erlinge@med.lu.se'}], 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}, {'facility': 'Cardiology Clinic, Västmanlands sjukhus', 'status': 'RECRUITING', 'city': 'Västerås', 'zip': '721 89', 'country': 'Sweden', 'contacts': [{'name': 'Amra Kåregren, MD', 'role': 'CONTACT', 'phone': '+46 21 17 52 04', 'email': 'amra.karegren@ltv.se'}], 'geoPoint': {'lat': 59.61617, 'lon': 16.55276}}, {'facility': 'Department of Cardiology, Örebro University Hospital', 'status': 'RECRUITING', 'city': 'Örebro', 'zip': '701 85', 'country': 'Sweden', 'contacts': [{'name': 'Ole Frobert, prof', 'role': 'CONTACT', 'phone': '+46 19 602 54 13', 'email': 'ole.frobert@regionorebrolan.se'}, {'name': 'Cecilia Bergh, PhD', 'role': 'CONTACT', 'phone': '+46 730 68 28 92', 'email': 'cecilia.bergh@regionorebrolan.se'}], 'geoPoint': {'lat': 59.27412, 'lon': 15.2066}}]}, 'referencesModule': {'references': [{'pmid': '33971938', 'type': 'DERIVED', 'citation': 'Bergh C, Landberg R, Andersson K, Heyman-Linden L, Rascon A, Magnuson A, Khalili P, Karegren A, Nilsson J, Pirazzi C, Erlinge D, Frobert O. Effects of Bilberry and Oat intake on lipids, inflammation and exercise capacity after Acute Myocardial Infarction (BIOAMI): study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2021 May 10;22(1):338. doi: 10.1186/s13063-021-05287-5.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009203', 'term': 'Myocardial Infarction'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D007238', 'term': 'Infarction'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D007511', 'term': 'Ischemia'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D009336', 'term': 'Necrosis'}, {'id': 'D017202', 'term': 'Myocardial Ischemia'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}], 'browseLeaves': [{'id': 'M10293', 'name': 'Inflammation', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M10282', 'name': 'Infarction', 'asFound': 'Infarction', 'relevance': 'HIGH'}, {'id': 'M12155', 'name': 'Myocardial Infarction', 'asFound': 'Myocardial Infarction', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}, {'id': 'M12284', 'name': 'Necrosis', 'relevance': 'LOW'}, {'id': 'M6546', 'name': 'Coronary Artery Disease', 'relevance': 'LOW'}, {'id': 'M19506', 'name': 'Myocardial Ischemia', 'relevance': 'LOW'}, {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}, {'id': 'T170', 'name': 'Acute Graft Versus Host Disease', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'T24', 'name': 'Anthocyanidin', 'relevance': 'LOW'}, {'id': 'T68', 'name': 'Bilberry', 'asFound': 'Day surgery', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'Fl', 'name': 'Flavonoid'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'HB', 'name': 'Herbal and Botanical'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05145465', 'orgStudyIdInfo': {'id': '716/23-09-2021'}, 'organization': {'fullName': 'University of Thessaly', 'class': 'OTHER'}, 'briefTitle': 'The Effect of a Supervised Home-based Tele-rehabilitation Program on Patients With Type 2 Diabetes', 'officialTitle': 'Double Blinded Randomized Controlled Trial , Investigating the Efficacy of Telerehabilitation, Type 2 Diabetes Telerehabilitation,'}, 'statusModule': {'statusVerifiedDate': '2021-12', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-09-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2022-02', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-11-21', 'studyFirstSubmitQcDate': '2021-12-02', 'studyFirstPostDateStruct': {'date': '2021-12-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-12-02', 'lastUpdatePostDateStruct': {'date': '2021-12-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Garyfallia Pepera', 'investigatorTitle': 'Assistant Professor in Cardiovascular Physiotherapy/Cardiac Rehabilitation', 'investigatorAffiliation': 'University of Thessaly'}, 'leadSponsor': {'name': 'University of Thessaly', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"Tele-rehabilitation (TR) which carries health services distant through using electronic communication systems is an important treatment option. Although TR studies in musculoskeletal system, neurologic and cardio-pulmonary diseases are effective TR studies in type 2 DM patients are limited. TR interventions in patients with type 2 diabetes has not yet sufficiently defined and more studies with different exercise protocols will be an important step for the clinical value of this intervention but also for it's application in clinical practice.\\n\\nObjective: The aim of this study is to evaluate the effectiveness of a telerehabilitation program on glucose control, functional capacity, muscle strength and quality of life in patients with type 2 diabetes.\\n\\nStudy design: It is a supervised-double blind randomized controlled trial, comparing two groups (a control group and a telerehabilitation group). The duration of the intervention will last 6 weeks.\\n\\nSetting: home-based patients environments , only the first session in University of Thessaly for educational reason\\n\\nParticipants: A total of 22 patients with type 2 diabetes, regardless sex, aged 40 years and older will randomly assign to a telerehabilitation group (n = 11) and a control group (n = 11).\\n\\nMeasurements /Assessments Study data will be collected at baseline and after the intervention period ( 6 weeks) by two blinded physiotherapists, in University of Thessaly).\", 'detailedDescription': 'Procedure:\\n\\nThe intervention program will last for 6 weeks and the patients in telerehabilitation-group will receive home based exercise program (by video-call with the supervision of a physiotherapist), 3 times per week and the total duration of each session will last for 60 minutes.\\n\\nThe control group will not receive any exercise intervention during that period but only an educational session.\\n\\nClinical assessments wiil be conducted before and 6 weeks after intervention and will include:\\n\\n1. Functional capacity assesment tool : six minutes walking test ( 6MWT)\\n2. Physical activity\\\\] assesment tool : International Physical Activity Questionnaire (IPAQ).\\n3. Quality of life assesment tool : 36-Item Short Form Survey (SF-36) sf36\\n4. Hand grip strength assesment tool : Jamar Hydraulic Hand Dynamometer\\n5. Leg strength and endurance assesment tool 30 second chair stand test\\n6. Weight, hip , waist and BMI measurements\\n7. HbA1c level assesment tool : blood test'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2', 'Telerehabilitation'], 'keywords': ['Supervised Exercise', 'Functional capacity', 'Hand grip']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 24, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Telerehabilitation group', 'type': 'EXPERIMENTAL', 'description': 'Participants will undertake the first training session in the University of Thessaly under the supervision of a specialized physiotherapist in order to precept the exercises. All the other sessions will proceed via telerehabilitation program at their home. Participants will undergo an exercise home based program 3 times/week.\\n\\nThe program will start with 10 minutes warm up exercise , 20 minutes continuous aerobic exercise ( 60-80% of target heart rate), 20 minutes resistance training exercise ( 30-50% 1RM), 5 minutes cool down and breathing exercises. For their safety patients will monitor glucose, blood pressure, pulse-oxygen and heart rate via, blood pressure monitor, pulse oximeter and smart-watch devices. They will be assessed at the beginning of the study and after the intervention ( at 6 weeks)', 'interventionNames': ['Other: Telerehabilitation group']}, {'label': 'control group', 'type': 'NO_INTERVENTION', 'description': 'The participants in this group will just receive the education session and they will continue their current medical therapies.They will be assessed at the beginning of the study and after the intervention ( at 6 weeks).'}], 'interventions': [{'type': 'OTHER', 'name': 'Telerehabilitation group', 'description': 'All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.\\n\\nThe target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not.', 'armGroupLabels': ['Telerehabilitation group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Exercise capacity', 'description': 'The 6-min walk (6MW) test is commonly used to assess exercise capacity in patients and to track functional change resulting from disease progression or therapeutic intervention.', 'timeFrame': '6 weeks'}, {'measure': 'Physical activity', 'description': 'International Physical Activity Questionnaire - Short Form This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting.', 'timeFrame': '6 weeks'}, {'measure': 'Hand grip strength', 'description': 'Jamar Hydraulic Hand Dynamometer The Jamar Hydraulic Hand Dynamometer can be used to measure isometric force and peak strength with five adjustable grip positions. The handle easily adjusts from 1 3/8\" - 3 3/8\" in half-inch increments. This helps track strength and rehabilitation over time.', 'timeFrame': '6 weeks'}, {'measure': 'Leg strength and endurance', 'description': '30 second chair stand test Equipment: A chair with a straight back without arm rests (seat 17\" high), and a stopwatch and count the number of times the patient comes to a full standing position in 30 seconds.', 'timeFrame': '6 weeks'}, {'measure': 'Quality of life (QOL)', 'description': '36-Item Short Form Survey (SF-36) The RAND 36-Item Health Survey taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions.Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.', 'timeFrame': '6 weeks'}, {'measure': 'HbA1c', 'description': 'HbA1c test, also known as the haemoglobin A1c or glycated haemoglobin test, is an important blood test that gives a good indication of how well your diabetes is being controlled', 'timeFrame': '6 weeks'}, {'measure': 'Body weight (kg)', 'description': 'Body weight will be calculated by a weighing scale and the unit of measurement will be in kilograms (kg)', 'timeFrame': '6 weeks'}, {'measure': 'Body height (cm)', 'description': 'Body height will be calculated by a stadiometer and the unit of measurement will be in centimeters (cm)', 'timeFrame': '6 weeks'}, {'measure': 'Hip size (cm)', 'description': 'hip measurements will be calculated by tape measure and the unit of measurement will be in centimeters ( cm)', 'timeFrame': '6 weeks'}, {'measure': 'Waist size (cm)', 'description': 'Waist measurements will be calculated by tape measure and the unit of measurement will be in centimeters ( cm)', 'timeFrame': '6 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* diabetes type 2\\n* regulated blood sugar\\n* treatment by doctor\\n* greek language\\n\\nExclusion Criteria:\\n\\n* no internet connection\\n* diabetes type 1\\n* recently surgery\\n* mental health problems', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '40 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'University of Thessaly', 'city': 'Lamia', 'zip': '35100', 'country': 'Greece', 'geoPoint': {'lat': 38.9, 'lon': 22.43333}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M10295', 'name': 'Influenza, Human', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M3671', 'name': 'Adrenergic beta-Antagonists', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02034266', 'orgStudyIdInfo': {'id': 'T1DM Omega-3 study'}, 'organization': {'fullName': 'University Health Network, Toronto', 'class': 'OTHER'}, 'briefTitle': 'The Effect of Omega-3 Supplementation on Nerve Structure and Function in Type 1 Diabetes', 'officialTitle': 'Phase 2 Study of the Effects of Omega-3 Fatty Acid Supplementation on Nerve Structure and Function in Type 1 Diabetes Mellitus - A Clinical Pilot Study'}, 'statusModule': {'statusVerifiedDate': '2017-04', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2014-01'}, 'primaryCompletionDateStruct': {'date': '2016-08', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2016-08', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2014-01-09', 'studyFirstSubmitQcDate': '2014-01-09', 'studyFirstPostDateStruct': {'date': '2014-01-13', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-04-26', 'lastUpdatePostDateStruct': {'date': '2017-04-28', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Eduardo Ng', 'investigatorTitle': 'Clinical Research Manager', 'investigatorAffiliation': 'University Health Network, Toronto'}, 'leadSponsor': {'name': 'Eduardo Ng', 'class': 'OTHER'}, 'collaborators': [{'name': 'Canadian Diabetes Association', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Nerves are made of different fats including omega-3s and omega-6s; however, dietary intakes of omega-6s are very high and omega-3 intakes are very low. We hypothesize that omega-3 supplementation will stop diabetes related changes in cornea nerve structure in patients with type 1 diabetes to stop the development of nerve injury associated with future risk of neuropathy, and reflect changes in the degree of nerve injury over time. As such, we anticipate that patients in the study will maintain Corneal Nerve Fiber Length (CNFL), the primary outcome measure.', 'detailedDescription': 'This study will test the use of an omega-3 supplement as a potential way to stop nerve damage that has been observed in individuals with type 1 diabetes Nerves supply signals to all structures in the body and take signals back to the spinal cord and brain. Both small and large nerve fibres can be affected in disease states, such as diabetes. Since defects of small nerve fibre activity have important consequences (painful symptoms, erectile dysfunction, cardiac rhythm disturbances, bladder and gastrointestinal dysfunction), it is important to determine new ways to maintain their function to help individuals maintain a high quality of life.\\n\\nUntil now, researchers have only tested the effect of omega-3 supplementation in animals with diabetes and have found this nutrient to lessen nerve damage while maintaining the function of nerves. However, there has not been any research on the use of omega-3s on nerve structure and function in humans with type 1 diabetes.\\n\\nCurrent standard of care for type 1 diabetes is to manage glycemic control and any painful symptoms through medication. The use of omega-3 supplements for prevent or limit nerve damage in diabetes is not within the current standard of care. In this study omega-3 supplementation is experimental and has been approved by Health Canada for use in this study.'}, 'conditionsModule': {'conditions': ['Type 1 Diabetes'], 'keywords': ['Type one diabetes', 'nerve damage', 'neuropathy', 'omega-3 fatty acid', 'supplementation', 'nutrition']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'open label study with no placebo.', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Omega-3 supplementation', 'type': 'EXPERIMENTAL', 'description': 'Participants will take an oral 5 mL serving (1 tbsp) of mammalian omega-3 seal oil (375 mg EPA, 280 mg DPA and 510 mg DHA) (Auum Inc., Timmons, On) twice daily. Total daily essential fatty acid load - 2330 mg.', 'interventionNames': ['Dietary Supplement: Omega-3 supplementation']}], 'interventions': [{'type': 'DIETARY_SUPPLEMENT', 'name': 'Omega-3 supplementation', 'description': '5 mL twice daily, administered under the tongue', 'armGroupLabels': ['Omega-3 supplementation'], 'otherNames': ['Auum Omega-3 oil']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in corneal nerve fibre length', 'description': \"Participants will undergo examination of nerve fibres adjacent to the Bowman's layer of the cornea in both eyes using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine corneal IVCM corneal nerve fibre length (CNFL).\", 'timeFrame': 'Baseline and 12 months'}], 'secondaryOutcomes': [{'measure': 'Nerve Conduction Studies', 'description': 'Nerve conduction studies will be conducted using standardized testing of the left median, ulnar, peroneal, and sural sensory nerves for signal amplitude and conduction velocity.', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Corneal Nerve Fibre Length', 'description': 'Interim measures of CNFL will be measured as a secondary outcome to track progressive changes with supplementation.', 'timeFrame': '4 months and 8 months'}, {'measure': 'Laser Doppler Imaging Flare (LDI Flare) sympathetic skin response', 'description': 'The purpose of this measure is to document, separate from the corneal IVCM parameters, small nerve fiber function. LDI Flare measurement will be conducted on MoorLDI2 Laser Doppler blood perfusion imager.', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Vibration Perception Threshold', 'description': 'Vibration perception threshold will be performed using the Neurothesiometer to evaluate sensory nerve function.', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Cooling Detection Threshold Testing', 'description': 'Cooling detection threshold testing will evaluate peripheral sensory nerve function.', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Omega-3 status', 'description': 'Red blood cell omega-3 content will be determined using gas-flame chromatography.', 'timeFrame': 'Baseline, 4, 8 and 12 months'}, {'measure': 'Heart Rate Variability', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'R-R interval', 'timeFrame': 'Baseline and 12 months'}], 'otherOutcomes': [{'measure': 'Glycated hemoglobin A1c', 'description': 'Measure of glycemic control', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Serum lipids', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Thyroid stimulating hormone', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Creatinine', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Vitamin B12', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Serum Folate', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Uric acid', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Urinary albumin excretion', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Serum protein electrophoresis', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Serum C-reactive protein', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Serum fatty acid profile', 'timeFrame': 'Baseline and 12 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\nA. Patients of any gender or race aged 18 or above B. Type 1 diabetes mellitus as defined by the 2008 Canadian Diabetes Association C. Toronto Clinical Neuropathy Score ≥1 D. Ability to understand and cooperate with study procedures\\n\\nExclusion Criteria:\\n\\nA. Current eye infection or damage of cornea B. Severe movement disorder C. History of allergy to proparacaine (the ocular topical anaesthetic used for the corneal confocal microscopy exam) D. Inability to sit and lie supine comfortably for 45-60 minutes E. Major medical or psychiatric illness that would preclude successful participation in the study F. Unwillingness to sign informed consent. G. Confirmed neuropathy secondary to non-diabetic causes (examples include polyneuropathy owing to alcohol abuse, B12 deficiency, folate deficiency, chronic renal failure, hypothyroidism, or neurotoxic drug use such as chemotherapy).\\n\\nH. Current or previous regular (\\\\>3 times per week) consumption of omega-3 supplements within the past month I. Consistently consuming fish \\\\>2 times per week in the past month J. Performing regular exercise \\\\>3 times per week in the past 3 months', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Vera Bril, MD', 'affiliation': 'University Health Network, Toronto', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University Health Network, Division of Neurology, Toronto General Hospital', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M5G 2C4', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}]}, 'referencesModule': {'references': [{'pmid': '28515269', 'type': 'DERIVED', 'citation': 'Lewis EJH, Perkins BA, Lovblom LE, Bazinet RP, Wolever TMS, Bril V. Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial. Neurology. 2017 Jun 13;88(24):2294-2301. doi: 10.1212/WNL.0000000000004033. Epub 2017 May 17.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'T415', 'name': 'Omega 3 Fatty Acid', 'asFound': 'Cord', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03738865', 'orgStudyIdInfo': {'id': 'XSGP-304'}, 'organization': {'fullName': 'Xeris Pharmaceuticals', 'class': 'INDUSTRY'}, 'briefTitle': 'G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes', 'officialTitle': 'G-Pen (Glucagon Injection) Compared to GlucaGen® Hypokit® (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety'}, 'statusModule': {'statusVerifiedDate': '2020-05', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-09-27', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-03-29', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2019-04-02', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-11-08', 'studyFirstSubmitQcDate': '2018-11-08', 'studyFirstPostDateStruct': {'date': '2018-11-13', 'type': 'ACTUAL'}, 'resultsFirstSubmitDate': '2020-03-26', 'resultsFirstSubmitQcDate': '2020-05-01', 'resultsFirstPostDateStruct': {'date': '2020-05-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-05-12', 'lastUpdatePostDateStruct': {'date': '2020-05-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Xeris Pharmaceuticals', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Empiristat, Inc.', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is a multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus. The study involves two daytime clinical research center (CRC) visits with random assignment to receive G-Pen glucagon 1 mg during one period and Novo Glucagon 1 mg during the other. Each daytime visit is preceded by an overnight stay in the CRC. In the morning of the inpatient study visit, the subject is brought into a state of severe hypoglycemia through IV administration of regular insulin diluted in normal saline. After a hypoglycemic state with plasma glucose \\\\< 54 mg/dL (3 mmol/L) is verified, the subject is administered a dose of G-Pen or Novo Glucagon via subcutaneous injection. Plasma glucose levels are monitored for up to 180 minutes post-dosing, with a value of \\\\>70.0 mg/dL (3.89 mmol/L) or an increase of \\\\> 20 mg/dL (\\\\>1.11 mmol/L) within 30 minutes of glucagon administration indicating a positive response. After 3 hours, the subject is given a meal and discharged when medically stable. After a wash-out period of 7 to 28 days, subjects return to the CRC, and the procedures are repeated with each subject crossed over to the other treatment. A follow-up visit as a safety check is conducted 2-7 days following administration of the final dose of study drug.'}, 'conditionsModule': {'conditions': ['Insulin Hypoglycemia', 'Type 1 Diabetes Mellitus', 'Severe Hypoglycemia'], 'keywords': ['glucagon', 'hypoglycemia']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 132, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'G-Pen followed by Novo Glucagon', 'type': 'EXPERIMENTAL', 'description': '1 mg G-Pen at the first treatment visit followed by 1 mg Novo Glucagon at the second treatment visit', 'interventionNames': ['Drug: G-Pen', 'Drug: Novo Glucagon']}, {'label': 'Novo Glucagon followed by G-Pen', 'type': 'ACTIVE_COMPARATOR', 'description': '1 mg Novo Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit', 'interventionNames': ['Drug: G-Pen', 'Drug: Novo Glucagon']}], 'interventions': [{'type': 'DRUG', 'name': 'G-Pen', 'description': '1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector', 'armGroupLabels': ['G-Pen followed by Novo Glucagon', 'Novo Glucagon followed by G-Pen'], 'otherNames': ['glucagon']}, {'type': 'DRUG', 'name': 'Novo Glucagon', 'description': '1 mg subcutaneous injection of Novo Glucagon (glucagon injection)', 'armGroupLabels': ['G-Pen followed by Novo Glucagon', 'Novo Glucagon followed by G-Pen'], 'otherNames': ['Glucagen Hypokit']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Severe Hypoglycemia Rescue', 'description': 'Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) or an increase in plasma glucose concentration \\\\> 20 mg/dL (\\\\> 1.11 mmol/L) within 30 minutes after administration of glucagon', 'timeFrame': 'At 30 minutes following administration of study drug'}], 'secondaryOutcomes': [{'measure': 'Plasma Glucose Response 1', 'description': 'Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) within 30 minutes of a decision to dose', 'timeFrame': 'At 30 minutes following a decision to administer study drug'}, {'measure': 'Plasma Glucose Response 2', 'description': 'Number of subjects with an increase in plasma glucose concentration \\\\> 20 mg/dL (\\\\> 1.11 mmol/L) after administration of glucagon.', 'timeFrame': 'At 0-30 minutes following a decision to administer study drug'}, {'measure': 'Administration Time', 'description': 'Mean time (minutes) to administer study drug from a decision to dose', 'timeFrame': 'At 0-10 minutes from a decision to administer study drug'}, {'measure': 'Hypoglycemia Resolution', 'description': 'Mean time (minutes) to complete resolution of the overall sensation of hypoglycemia from a decision to dose', 'timeFrame': 'At 0-90 minutes following administration of study drug'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Males and non-pregnant females diagnosed with type 1 diabetes (T1D) for at least 24 months.\\n2. Current usage of daily insulin treatment that includes having an assigned \"correction factor\" for managing hyperglycemia.\\n3. Age 18 to 75 years, inclusive.\\n4. Random serum C-peptide concentration \\\\< 0.6 ng/mL.\\n5. Willingness to follow all study procedures, including attending all clinic visits.\\n6. Subject has provided informed consent as evidenced by a signed and dated informed consent form (ICF) completed before any trial-related activities occur.\\n\\nExclusion Criteria:\\n\\n1. Pregnancy\\n2. Glycated hemoglobin (HbA1c) \\\\> 10% at Screening.\\n3. Body mass index (BMI) \\\\> 40 kg/m2.\\n4. Renal insufficiency (serum creatinine greater than 3.0 mg/dL) or end-stage renal disease requiring renal replacement therapy.\\n5. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal to or greater than 3 times the upper limit of normal.\\n6. Hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL.\\n7. Hematocrit \\\\< 30%.\\n8. Blood pressure (BP) readings at Screening where systolic blood pressure (SBP) \\\\< 90 or \\\\> 150 mm Hg, and diastolic blood pressure (DBP) \\\\< 50 or \\\\> 100 mm Hg.\\n9. Clinically significant electrocardiogram (ECG) abnormalities.\\n10. Use of total insulin dose per day \\\\> 2 U/kg.\\n11. Inadequate venous access.\\n12. Congestive heart failure, New York Heart Association (NYHA) class III or IV.\\n13. History of myocardial infarction, unstable angina, or revascularization within the past 6 months.\\n14. History of a cerebrovascular accident in the past 6 months or with major neurological deficits.\\n15. Active malignancy within 5 years from Screening, except basal cell or squamous cell skin cancers. Any history of breast cancer or malignant melanoma will be exclusionary.\\n16. Major surgical operation within 30 days prior to Screening.\\n17. Current seizure disorder (other than with suspect or documented hypoglycemia).\\n18. Current bleeding disorder, treatment with warfarin, or platelet count below 50 × 109 per liter.\\n19. History of pheochromocytoma or disorder with increased risk of pheochromocytoma (multiple endocrine neoplasia type 2 (MEN 2), neurofibromatosis, or Von Hippel-Lindau disease).\\n20. History of insulinoma.\\n21. History of allergies to glucagon or glucagon-like products, or any history of significant hypersensitivity to glucagon or any related products or to any of the excipients (DMSO and trehalose) in the investigational formulation.\\n22. History of glycogen storage disease.\\n23. Subject tests positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection (hepatitis B surface antigen positive \\\\[HBsAg+\\\\]) at Screening.\\n24. Active substance other than tetrahydrocannabinol (THC) or alcohol abuse (more than 21 drinks per week for male subjects or 14 drinks per week for female subject).\\n25. Administration of glucagon within 7 days of Screening.\\n26. Participation in other studies involving administration of an investigational drug or device within 30 days or 5 half-lives, whichever is longer, before Screening for the current study and during participation in the current study.\\n27. Any other reason the Investigator deems exclusionary.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Diablo Clinical Research', 'city': 'Walnut Creek', 'state': 'California', 'zip': '94598', 'country': 'United States', 'geoPoint': {'lat': 37.90631, 'lon': -122.06496}}, {'facility': 'Atlanta Diabetes Associates', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30318', 'country': 'United States', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': 'PPD-Las Vegas Clinical Research Unit', 'city': 'Las Vegas', 'state': 'Nevada', 'zip': '89113', 'country': 'United States', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'facility': 'Rainier Research Center', 'city': 'Renton', 'state': 'Washington', 'zip': '98057', 'country': 'United States', 'geoPoint': {'lat': 47.48288, 'lon': -122.21707}}, {'facility': 'Medizinische Universität Graz-Center for Medical Research', 'city': 'Graz', 'zip': '8010', 'country': 'Austria', 'geoPoint': {'lat': 47.06667, 'lon': 15.45}}, {'facility': 'LMC Diabetes & Endocrinology', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M4G 3E8', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'AltaSciences', 'city': 'Montréal', 'state': 'Quebec', 'zip': 'H3P 3P1', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}]}, 'referencesModule': {'references': [{'pmid': '35322535', 'type': 'DERIVED', 'citation': 'Pieber TR, Aronson R, Christiansen MP, Bode B, Junaidi K, Conoscenti V. Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready-to-use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin-induced severe hypoglycaemia in adults with type 1 diabetes. Diabetes Obes Metab. 2022 Jul;24(7):1394-1397. doi: 10.1111/dom.14699. Epub 2022 Apr 28. No abstract available.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': '132 subjects were randomized, however 1 subject withdrew prior to dosing, therefore 131 subjects received study drug.', 'groups': [{'id': 'FG000', 'title': 'G-Pen, Then Novo Glucagon', 'description': 'Participants first received G-Pen 1 mg subcutaneous injection each. After a washout period of 7-28 days, they then received Novo Glucagon 1 mg subcutaneous injection'}, {'id': 'FG001', 'title': 'Novo Glucagon, Then G-Pen', 'description': 'Participants first received Novo Glucagon 1 mg subcutaneous injection each. After a washout period of 7-28 days, they then received G-Pen 1 mg subcutaneous injection'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '66'}, {'groupId': 'FG001', 'numSubjects': '66'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '61'}, {'groupId': 'FG001', 'numSubjects': '62'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '4'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'populationDescription': 'All Randomized Population', 'groups': [{'id': 'BG000', 'title': 'G-Pen, Then Novo Glucagon', 'description': 'Participants first received G-Pen 1 mg subcutaneous injection each. After a washout period of 7-28 days, they then received Novo Glucagon 1 mg subcutaneous injection.'}, {'id': 'BG001', 'title': 'Novo Glucagon, Then G-Pen', 'description': 'Participants first received Novo Glucagon 1 mg subcutaneous injection each. After a washout period of 7-28 days, they then received G-Pen 1 mg subcutaneous injection.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '66'}, {'groupId': 'BG001', 'value': '66'}, {'groupId': 'BG002', 'value': '132'}]}], 'measures': [{'title': 'Age, Categorical', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'groupId': 'BG000', 'value': '63'}, {'groupId': 'BG001', 'value': '63'}, {'groupId': 'BG002', 'value': '126'}]}, {'title': '>=65 years', 'measurements': [{'groupId': 'BG000', 'value': '3'}, {'groupId': 'BG001', 'value': '3'}, {'groupId': 'BG002', 'value': '6'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '29'}, {'groupId': 'BG001', 'value': '33'}, {'groupId': 'BG002', 'value': '62'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '37'}, {'groupId': 'BG001', 'value': '33'}, {'groupId': 'BG002', 'value': '70'}]}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '3'}, {'groupId': 'BG002', 'value': '4'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '65'}, {'groupId': 'BG001', 'value': '63'}, {'groupId': 'BG002', 'value': '128'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Race (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '3'}, {'groupId': 'BG001', 'value': '3'}, {'groupId': 'BG002', 'value': '6'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '1'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '2'}]}, {'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '62'}, {'groupId': 'BG001', 'value': '61'}, {'groupId': 'BG002', 'value': '123'}]}, {'title': 'More than one race', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Severe Hypoglycemia Rescue', 'description': 'Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) or an increase in plasma glucose concentration \\\\> 20 mg/dL (\\\\> 1.11 mmol/L) within 30 minutes after administration of glucagon', 'populationDescription': 'Intent-to-Treat Population', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'At 30 minutes following administration of study drug', 'groups': [{'id': 'OG000', 'title': 'G-Pen', 'description': 'Participants received G-Pen 1 mg subcutaneous injection each.'}, {'id': 'OG001', 'title': 'Novo Glucagon', 'description': 'Participants received Novo Glucagon 1 mg subcutaneous injection each.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '128'}, {'groupId': 'OG001', 'value': '123'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '127'}, {'groupId': 'OG001', 'value': '123'}]}]}]}, {'type': 'SECONDARY', 'title': 'Plasma Glucose Response 1', 'description': 'Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) within 30 minutes of a decision to dose', 'populationDescription': 'Intent-to-Treat Population', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'At 30 minutes following a decision to administer study drug', 'groups': [{'id': 'OG000', 'title': 'G-Pen', 'description': 'Participants received G-Pen 1 mg subcutaneous injection each.'}, {'id': 'OG001', 'title': 'Novo Glucagon', 'description': 'Participants received Novo Glucagon 1 mg subcutaneous injection each.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '128'}, {'groupId': 'OG001', 'value': '123'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '127'}, {'groupId': 'OG001', 'value': '123'}]}]}]}, {'type': 'SECONDARY', 'title': 'Plasma Glucose Response 2', 'description': 'Number of subjects with an increase in plasma glucose concentration \\\\> 20 mg/dL (\\\\> 1.11 mmol/L) after administration of glucagon.', 'populationDescription': 'Intent-to-Treat Population', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'At 0-30 minutes following a decision to administer study drug', 'groups': [{'id': 'OG000', 'title': 'G-Pen', 'description': 'Participants received G-Pen 1 mg subcutaneous injection each.'}, {'id': 'OG001', 'title': 'Novo Glucagon', 'description': 'Participants received Novo Glucagon 1 mg subcutaneous injection each.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '128'}, {'groupId': 'OG001', 'value': '123'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '127'}, {'groupId': 'OG001', 'value': '123'}]}]}]}, {'type': 'SECONDARY', 'title': 'Administration Time', 'description': 'Mean time (minutes) to administer study drug from a decision to dose', 'populationDescription': 'Intent-to-Treat Population', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'minutes', 'timeFrame': 'At 0-10 minutes from a decision to administer study drug', 'groups': [{'id': 'OG000', 'title': 'G-Pen', 'description': 'Participants received G-Pen 1 mg subcutaneous injection each.'}, {'id': 'OG001', 'title': 'Novo Glucagon', 'description': 'Participants received Novo Glucagon 1 mg subcutaneous injection each.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '128'}, {'groupId': 'OG001', 'value': '123'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.79', 'spread': '0.530'}, {'groupId': 'OG001', 'value': '1.76', 'spread': '0.678'}]}]}]}, {'type': 'SECONDARY', 'title': 'Hypoglycemia Resolution', 'description': 'Mean time (minutes) to complete resolution of the overall sensation of hypoglycemia from a decision to dose', 'populationDescription': 'Intent-to-Treat Population', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'minutes', 'timeFrame': 'At 0-90 minutes following administration of study drug', 'groups': [{'id': 'OG000', 'title': 'G-Pen', 'description': 'Participants received G-Pen 1 mg subcutaneous injection each.'}, {'id': 'OG001', 'title': 'Novo Glucagon', 'description': 'Participants received Novo Glucagon 1 mg subcutaneous injection each.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '128'}, {'groupId': 'OG001', 'value': '123'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '15.69', 'spread': '7.428'}, {'groupId': 'OG001', 'value': '15.32', 'spread': '8.479'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'timeFrame': 'Adverse events were collected for up to 5 weeks, from the time of consent through the follow-up visit.', 'description': 'Treatment-Emergent Adverse Events (TEAE) Note: Some subjects experienced multiple adverse events. Consequently, the sum of the number of subjects experiencing each individual adverse events is greater than the number of unique subjects experiencing at least one adverse event', 'eventGroups': [{'id': 'EG000', 'title': 'G-Pen', 'description': 'G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector', 'deathsNumAffected': 0, 'deathsNumAtRisk': 127, 'seriousNumAffected': 0, 'seriousNumAtRisk': 127, 'otherNumAffected': 67, 'otherNumAtRisk': 127}, {'id': 'EG001', 'title': 'Novo Glucagon', 'description': 'Novo Glucagon: 1 mg subcutaneous injection of Novo Glucagon (glucagon injection)', 'deathsNumAffected': 0, 'deathsNumAtRisk': 123, 'seriousNumAffected': 0, 'seriousNumAtRisk': 123, 'otherNumAffected': 57, 'otherNumAtRisk': 123}], 'otherEvents': [{'term': 'Nausea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA (20.0)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 54, 'numAtRisk': 127}, {'groupId': 'EG001', 'numAffected': 55, 'numAtRisk': 123}]}, {'term': 'Vomiting', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA (20.0)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 16, 'numAtRisk': 127}, {'groupId': 'EG001', 'numAffected': 17, 'numAtRisk': 123}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA (20.0)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 7, 'numAtRisk': 127}, {'groupId': 'EG001', 'numAffected': 9, 'numAtRisk': 123}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictionType': 'OTHER', 'restrictiveAgreement': True, 'otherDetails': 'Neither the Institution nor the principal investigator may submit for publication or presentation, the results of this trial without prior written consent of the sponsor.'}, 'pointOfContact': {'title': 'Chelsea Boundy', 'organization': 'Xeris Pharmaceuticals, Inc.', 'email': 'cboundy@xerispharma.com', 'phone': '312-517-1466'}}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot', 'hasProtocol': True, 'hasSap': False, 'hasIcf': False, 'label': 'Study Protocol', 'date': '2018-12-17', 'uploadDate': '2020-03-10T11:23', 'filename': 'Prot_000.pdf', 'size': 1389642}, {'typeAbbrev': 'SAP', 'hasProtocol': False, 'hasSap': True, 'hasIcf': False, 'label': 'Statistical Analysis Plan', 'date': '2019-04-04', 'uploadDate': '2020-03-10T11:24', 'filename': 'SAP_001.pdf', 'size': 604012}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28', 'removedCountries': ['Germany'], 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2020-04-09', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}, {'id': 'D007003', 'term': 'Hypoglycemia'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M10053', 'name': 'Hypoglycemia', 'asFound': 'Hypoglycemia', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D005934', 'term': 'Glucagon'}, {'id': 'D052216', 'term': 'Glucagon-Like Peptide 1'}], 'ancestors': [{'id': 'D005765', 'term': 'Gastrointestinal Agents'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D054795', 'term': 'Incretins'}], 'browseLeaves': [{'id': 'M9043', 'name': 'Glucagon', 'asFound': 'Vivo', 'relevance': 'HIGH'}, {'id': 'M26997', 'name': 'Glucagon-Like Peptide 1', 'asFound': 'Vivo', 'relevance': 'HIGH'}, {'id': 'M8881', 'name': 'Gastrointestinal Agents', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}, {'id': 'M27905', 'name': 'Incretins', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06051565', 'orgStudyIdInfo': {'id': 'DJTCSCYHT-I-03'}, 'organization': {'fullName': 'Chia Tai Tianqing Pharmaceutical Group Co., Ltd.', 'class': 'INDUSTRY'}, 'briefTitle': 'Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients', 'officialTitle': 'Open-label, Single-dose Study of Polysaccharide Superparamagnetic Iron Oxide Injection for Contrast-enhanced Cardiovascular Magnetic Resonance Imaging in Patients With Type 2 Diabetes and Chronic Kidney Disease.'}, 'statusModule': {'statusVerifiedDate': '2021-10', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-11-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-06-13', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2022-09-15', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2023-09-18', 'studyFirstSubmitQcDate': '2023-09-18', 'studyFirstPostDateStruct': {'date': '2023-09-25', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-09-27', 'lastUpdatePostDateStruct': {'date': '2023-09-29', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Chia Tai Tianqing Pharmaceutical Group Co., Ltd.', 'class': 'INDUSTRY'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is an open-label, single-center, single-dose study aims to evaluate the effect and safety of polymeric superparamagnetic iron oxide in cardiovascular magnetic resonance imaging for diabetic patients with concomitant chronic kidney disease.'}, 'conditionsModule': {'conditions': ['Diabetes', 'Magnetic Resonance Imaging']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 12, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Polysaccharide superparamagnetic iron oxide injection', 'type': 'EXPERIMENTAL', 'description': 'Intravenous injected polysaccharide superparamagnetic iron oxide injection at 3 mg/kg dose', 'interventionNames': ['Drug: Polysaccharide superparamagnetic iron oxide injection']}], 'interventions': [{'type': 'DRUG', 'name': 'Polysaccharide superparamagnetic iron oxide injection', 'description': 'Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.', 'armGroupLabels': ['Polysaccharide superparamagnetic iron oxide injection']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The number of vascular segments with lesions', 'description': 'The number of vascular segments with lesions after administration', 'timeFrame': '0 hour after administration'}, {'measure': 'Lesion length', 'description': 'Vascular lesion length', 'timeFrame': '0 hour after administration'}, {'measure': 'Degree of vascular stenosis', 'description': 'Vascular stenosis degree', 'timeFrame': '0 hour after administration'}], 'secondaryOutcomes': [{'measure': 'Image quality scores', 'description': 'Vascular image quality was scored on a 4-point scale. 1 = Vessels not assessable due to poor image quality; 2 = Vessels visualized but only gross features (size/patency) confidently assessable; 3 = Vessels well defined and evaluable for structural pathology with high confidence; 4 = Excellent vessel definition with sharp borders such that fine details can be evaluated with high confidence.', 'timeFrame': '0 hour after administration'}, {'measure': 'Myocardium T1 values', 'description': 'Changes from baseline in the longitudinal relaxation value of myocardial tissue.', 'timeFrame': '0 hour after administration'}, {'measure': 'Signal-to-noise ratio', 'description': 'The strength of a signal relative to the background noise.', 'timeFrame': '0 hour after administration'}, {'measure': 'Contrast-to-noise ratio', 'description': 'The visibility and distinguishability of structures or features of interest in an image in the presence of noise.', 'timeFrame': '0 hour after administration'}, {'measure': 'Adverse event rate', 'description': 'The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).', 'timeFrame': 'Baseline up to 24 hours after administration'}, {'measure': 'Serum iron', 'description': 'Changes from baseline in the amount of circulating iron that is bound to transferrin and freely circulate in the blood.', 'timeFrame': 'Baseline up to 24 hours after administration'}, {'measure': 'Serum ferritin', 'description': 'Changes from baseline in the concentration of plasma (or serum) ferritin.', 'timeFrame': 'Baseline up to 30 days and 60 days after administration'}, {'measure': 'Total iron-binding capacity', 'description': 'Changes from baseline in the total amount of iron that can be bound by transferrin proteins in the blood.', 'timeFrame': 'Baseline up to 30 days and 60 days after administration'}, {'measure': 'Serum transferrin saturation', 'description': 'Changes from baseline in the value of serum iron divided by the total iron-binding.', 'timeFrame': 'Baseline up to 30 days and 60 days after administration'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Aged ≥ 18 years, ≤ 80 years.\\n* Patients who have been diagnosed with chronic kidney disease (CKD) according to diagnostic criteria, meeting at least one CKD diagnostic criterion.\\n* Patients with a confirmed history of atherosclerosis and/or chronic venous disease (including deep vein thrombosis, thrombotic venous inflammation, lower limb varicose veins, etc.) either in their medical history or diagnosed during hospital admission, and within the past year, at least one imaging examination has confirmed the presence of at least one of the following vascular abnormalities in at least one vascular bed:\\n\\n  1. ≥50% vascular stenosis;\\n  2. Arterial aneurysm;\\n  3. Arterial dissection;\\n  4. Arteriovenous malformation;\\n  5. Arteriovenous fistula;\\n  6. Vascular developmental abnormalities;\\n  7. Varicose veins, etc. For details, please refer to the inclusion criteria section.\\n* Patients capable of self-care in daily life.\\n* Patients who voluntarily agree to participate in this study, sign an informed consent form, have a full understanding of the trial's content, procedures, and potential adverse reactions, and demonstrate good compliance.\\n* Patients who are unwilling to sign an informed consent form for the exploratory research can still be enrolled in the main study.\\n* Subjects who have no plans for pregnancy for at least 2 weeks before self-administration of the investigational drug and for at least 6 months after the last use of the investigational drug and voluntarily agree to adopt effective contraceptive measures.\\n\\nExclusion Criteria:\\n\\n* Patients who have undergone stent implantation for vascular treatment in the target vascular bed.\\n* Patients who have had or currently have malignant tumors within the last 3 years.\\n* Serum ferritin \\\\> 1000 μg/L.\\n* Patients who are planned to undergo magnetic resonance imaging (MRI) examination for various reasons during the trial.\\n* Blood donation or significant blood loss (\\\\> 450 ml) within the two months before medication.\\n* Patients with a history of substance abuse involving psychotropic drugs and are unable to quit or have psychiatric disorders.\\n* Patients with any severe and/or uncontrolled diseases, including:\\n\\n  1. Outpatients diagnosed through medical history; inpatients diagnosed based on past medical history and current medical history indicating ≥ Grade 2 myocardial ischemia or myocardial infarction, ≥ Grade 2 congestive heart failure (New York Heart Association (NYHA) classification).\\n  2. Active or uncontrolled severe systemic infections (≥ Common Terminology Criteria for Adverse Events (CTCAE) 5.0 Grade 2).\\n* Infectious diseases such as cirrhosis, active hepatitis\\\\*, syphilis, human immunodeficiency virus (HIV), etc. \\\\*Reference for hepatitis B: hepatitis B surface antigen (HBsAg) positive and Hepatitis B Virus (HBV) DNA test value exceeds the upper limit of normal; Reference for hepatitis C: Hepatitis C Virus (HCV) antibody positive and HCV viral titer test value exceeds the upper limit of normal.\\n* History of immunodeficiency, acquired or congenital immunodeficiency diseases, or organ transplantation.\\n* Pregnancy or currently breastfeeding or planning to breastfeed during the study.\\n* Presence of metal objects in the body (dentures, contraceptive rings, metal implants, metal clips, etc.) and claustrophobia.\\n* Allergic reactions to the investigational drug, its metabolites, or excipients.\\n* Use of the investigational drug or participation in drug clinical trials within the two months before medication.\\n* Difficulty with or intolerance to MRI scans.\\n* Subjects who cannot or will not comply with the hospital management regulations.\\n* According to the investigator's judgment, patients with accompanying diseases that pose a serious risk to patient safety or may interfere with the completion of the study, or patients deemed unsuitable for inclusion for other reasons.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Beijing Luhe Hospital, Capital Medical University', 'city': 'Beijing', 'state': 'Beijing', 'zip': '101149', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}, {'id': 'M10698', 'name': 'Kidney Diseases', 'relevance': 'LOW'}, {'id': 'T1303', 'name': 'Chronic Graft Versus Host Disease', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10533', 'name': 'Iron', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Micro', 'name': 'Micronutrients'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01007266', 'orgStudyIdInfo': {'id': '100002'}, 'secondaryIdInfos': [{'id': '10-DK-0002'}], 'organization': {'fullName': 'National Institutes of Health Clinical Center (CC)', 'class': 'NIH'}, 'briefTitle': 'Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study', 'officialTitle': 'Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study'}, 'statusModule': {'statusVerifiedDate': '2016-04-14', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2009-10-09'}, 'completionDateStruct': {'date': '2013-01-24', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2009-11-03', 'studyFirstSubmitQcDate': '2009-11-03', 'studyFirstPostDateStruct': {'date': '2009-11-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-12-14', 'lastUpdatePostDateStruct': {'date': '2019-12-17', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}}, 'descriptionModule': {'briefSummary': 'Background:\\n\\n* Type 2 diabetes mellitus (T2DM) is becoming more common among youth, particularly in minority populations. Few drug treatments are approved for T2DM in adolescents, and behavioral and lifestyle factors may contribute to their difficulties in following strict treatment regimens.\\n* It is unknown whether a minimally invasive patient partner ( buddy ) program, which has been developed to help improve diabetes control and quality of life, will be successful in a population of pediatric patients with T2DM.\\n\\nObjectives:\\n\\n* To evaluate the effect of a minimally invasive intervention (being assigned a patient partner, or buddy ) on blood sugar levels in adolescents with T2DM.\\n* To assess changes between groups in body weight, number of home glucose monitor checks, compliance with medications, adherence to visit schedule, and psychological well-being.\\n\\nEligibility:\\n\\n- Adolescents and young adults between 12 and 20 years of age who have been diagnosed with type 2 diabetes and whose blood glucose control needs improvement.\\n\\nDesign:\\n\\n* Participants will be divided by chance into two groups: in one group, participants will have a buddy and receive standard care; while in the other group, participants will receive standard care alone.\\n* The buddy is not a health care professional and is not authorized to provide any medical advice.\\n* Participants will be followed in the study for a total of 6 months. All study participants will receive standard treatment for T2DM.\\n* All patients will be asked to fill out a screening questionnaire (on paper or online) at the beginning of the study and a quality of life and eating behaviors questionnaire at the beginning and at the end of the study. These forms will include questions on medical history, emotions, well-being, and eating habits.\\n* Participants in both groups will have one diabetes clinic visit at the NIH Clinical Center or at Children s National Medical Center (CNMC) at the beginning of the study and two follow-up visits at the NIH or CNMC approximately 3 months apart. All visits include a physical examination, detailed medical history, and laboratory testing which is part of routine care for diabetes.\\n* Participants assigned to the buddy group will receive phone or online messages from the buddy once a week and will meet with the buddy once a month for less than 1 hour. The purpose of the in-person visit is to get to know each other better outside the usual hospital or clinic environment. The visits should take place at home, but may also take place elsewhere, for example, at schools, cafes, or libraries chosen by both the participant and the buddy. These face-to-face meetings may also take place at NIH or at CNMC if this is more convenient.', 'detailedDescription': 'Background\\n\\nType 2 diabetes mellitus (T2DM) is becoming increasingly prevalent among youth, particularly in minority populations. Few pharmacologic agents are approved for the treatment of T2DM in adolescents, and behavioral and lifestyle factors may contribute to adolescents difficulty adhering to treatment regimens. A minimally-invasive buddy-intervention (to help improve diabetes control and to foster improvement in quality of life) has not been systematically evaluated in a population of pediatric patients with T2DM.\\n\\nObjectives\\n\\n1. To evaluate the effect of a minimally invasive intervention the buddy on hemoglobin A1c (HbA1c) levels in adolescents with T2DM.\\n2. To assess changes between groups in body weight, number of home glucose monitor checks, compliance with medications, adherence to visit schedule, and psychological well-being.\\n\\nMethods\\n\\nPatients will be randomized to conventional treatment versus interventional group (buddy arm), and will be followed for 6 months. During this period, all patients should undergo two visits including laboratory testing (HbA1c) approximately 3 months apart. Those in the buddy arm will have weekly phone or online contact and once-monthly home visits from the buddy (a volunteer patient partner), with the use of systematic questionnaires and a secure database for data collection and maintenance.'}, 'conditionsModule': {'conditions': ['Obesity', 'Diabetes Mellitus, Type 2', 'Abnormal Glucose Metabolism', 'Type 2 Diabetes'], 'keywords': ['Type 2 Diabetes Mellitus', 'Adolescents', 'Pediatric', 'Patient Partner', 'Buddy', 'Obesity', 'Type 2 Diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 10, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Group A', 'type': 'OTHER', 'description': 'Buddy Group - Individuals with type 2 diabetes receive conventional diabetes treatment and are assigned a patient partner (Buddy)', 'interventionNames': ['Behavioral: Assignment of a Lay Patient Partner']}, {'label': 'Group B', 'type': 'ACTIVE_COMPARATOR', 'description': 'Individuals receive conventional treatment for type 2 diabetes', 'interventionNames': ['Behavioral: Assignment of a Lay Patient Partner']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Assignment of a Lay Patient Partner', 'armGroupLabels': ['Group A', 'Group B']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To evaluate the effect of a minimally invasive intervention (the buddy system) on hemoglobin A1c levels in adolescents with T2DM.', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'To assess changes between groups in body weight, number of home glucose monitor checks, compliance with medications, adherence to visit schedule, and psychological well-being.', 'timeFrame': '6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': \"* INCLUSION CRITERIA:\\n\\nAny patient with type 2 diabetes mellitus as documented by his or her primary physician\\n\\n1. Age 12-20 years at enrollment\\n2. Most recent HbA1c greater than or equal to 7%\\n\\nEXCLUSION CRITERIA:\\n\\n1. Significant comorbidity that, in the opinion of the investigators, may limit adequate study participation\\n2. Significant psychiatric or cognitive disorder, or communication difficulty that will, in the opinion of the investigators, limit the subject's ability to interact with the patient assistant or may present a danger to the patient assistant; patients with current suicidal or homicidal ideation, history of arrest for violent behavior, or history of school suspension/expulsion for violent behavior will be excluded.\\n3. Pregnancy or intention to become pregnant within 6 months\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '12 Years', 'maximumAge': '20 Years', 'stdAges': ['CHILD', 'ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Kristina I Rother, M.D.', 'affiliation': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Childrens National Medical Center', 'city': 'Washington', 'state': 'District of Columbia', 'country': 'United States', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'facility': 'National Institutes of Health Clinical Center, 9000 Rockville Pike', 'city': 'Bethesda', 'state': 'Maryland', 'zip': '20892', 'country': 'United States', 'geoPoint': {'lat': 38.98067, 'lon': -77.10026}}]}, 'referencesModule': {'references': [{'pmid': '9135953', 'type': 'BACKGROUND', 'citation': 'Yokoyama H, Okudaira M, Otani T, Takaike H, Miura J, Saeki A, Uchigata Y, Omori Y. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care. 1997 May;20(5):844-7. doi: 10.2337/diacare.20.5.844.'}, {'pmid': '10358675', 'type': 'BACKGROUND', 'citation': 'Krieger J, Collier C, Song L, Martin D. Linking community-based blood pressure measurement to clinical care: a randomized controlled trial of outreach and tracking by community health workers. Am J Public Health. 1999 Jun;89(6):856-61. doi: 10.2105/ajph.89.6.856.'}, {'pmid': '16651496', 'type': 'BACKGROUND', 'citation': 'Duncan GE. Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med. 2006 May;160(5):523-8. doi: 10.1001/archpedi.160.5.523.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02122666', 'orgStudyIdInfo': {'id': 'HRPO201311099'}, 'organization': {'fullName': 'Washington University School of Medicine', 'class': 'OTHER'}, 'briefTitle': 'Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome', 'officialTitle': 'Modulating Physiologic Effects Of Phospholipid Metabolism In Obesity And Diabetes; AIM 4: Composition and Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome', 'acronym': 'COMP-SR'}, 'statusModule': {'statusVerifiedDate': '2024-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2014-03'}, 'primaryCompletionDateStruct': {'date': '2024-02-15', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2024-02-15', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2014-04-22', 'studyFirstSubmitQcDate': '2014-04-22', 'studyFirstPostDateStruct': {'date': '2014-04-24', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2024-02-15', 'resultsFirstSubmitQcDate': '2024-08-08', 'resultsFirstPostDateStruct': {'date': '2024-10-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-08-08', 'lastUpdatePostDateStruct': {'date': '2024-10-26', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Washington University School of Medicine', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The investigators previous research has suggested that lipid (fatty) composition in the muscle cells of mice plays a key role in their insulin sensitivity. The purpose of this study is to determine whether these specific fat signatures translate to humans by comparing the muscle of healthy patients to those with pre-diabetes, or \"the metabolic syndrome\".', 'detailedDescription': \"The Comp-SR study explores the role of lipid metabolism in key metabolic pathways in skeletal muscle. It is a translation of previous research done in mice studying the effects and functions of certain key enzymes involved in lipid metabolism found to be associated with insulin resistance. These enzymes are fatty acid synthase (FAS), choline/ethanolamine phosphotransferase 1 (CEPT1) and sarcoplasmic-endoplasmic reticulum ATPase (SERCA). Based on the investigators research, it appears that the activity and function of these enzymes determines the ratio of certain phospholipids in the sarcoplasmic reticulum (SR), namely phosphatidylethanolamine (PE) and phosphatidylcholine (PC). Furthermore, the investigators have found that the ratio of these phospholipids correlates with the mouse's sensitivity to insulin.\\n\\nBased on the muscle biopsies of four healthy persons, it was found that human muscle contains similar phospholipids and phospholipid ratios to mice. It is hypothesized that these phospholipid signatures may be predictive of the metabolic status of humans as well. The specific aims of this study are to determine if the composition and function of the sarcoplasmic reticulum is altered in persons with the metabolic syndrome compared to lean controls. This knowledge could provide new understanding of impediments to effective therapy, novel biomarkers of disease progression, and innovative treatment targets for diabetes.\"}, 'conditionsModule': {'conditions': ['Metabolic Syndrome'], 'keywords': ['Metabolic Syndrome', 'Pre-diabetes', 'impaired glucose tolerance', 'Phospholipids']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'whole blood and frozen tissue'}, 'enrollmentInfo': {'count': 27, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Metabolic Syndrome', 'description': 'Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass', 'interventionNames': ['Procedure: muscle biopsy']}, {'label': 'Control', 'description': 'Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass', 'interventionNames': ['Procedure: muscle biopsy']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'muscle biopsy', 'description': \"A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\", 'armGroupLabels': ['Control', 'Metabolic Syndrome']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Sarcoplasmic Reticulum Composition', 'description': \"We will take a muscle tissue sample from the subject's thigh (vastus lateralis) to quantify phosphatidylcholine to phosphatidylethanolamine ratio of the sarcoplasmic reticulum.\", 'timeFrame': 'Study Visit Week 4'}], 'secondaryOutcomes': [{'measure': 'Insulin Sensitivity', 'description': 'The homeostatic model assessment for insulin resistance (HOMA-IR) is a calculated value using fasting glucose and insulin levels. It provides a measure of insulin resistance. HOMA-IR values between 0.5 and 1.4 are considered normal and values \\\\>2.9 indicate insulin resistance. The Matsuda Index reflects insulin sensitivity. It is calculated from glucose and insulin levels drawn fasting and during an OGTT. Matsuda Index values of 2.5 or higher are normal and indicate lack of insulin resistance or normal insulin sensitivity. Results of these measures are displayed graphically in the published paper.', 'timeFrame': 'Study visit week 4'}, {'measure': 'Lean and Fat Body Mass', 'description': 'We will perform a Duel Energy X-ray absorptiometry (DEXA) scan to approximate lean and fat body mass of study subjects.', 'timeFrame': 'Study Visit week 4'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Control subjects\\n\\nInclusion:\\n\\nSedentary: No routine exercise, walking \\\\<10,000 steps per day Age \\\\>18 and \\\\<65 Body Mass Index (BMI) \\\\<32 Healthy by physical exam (patient is devoid of major acute or chronic illness) No significant abnormality in screening labs\\n\\nExclusion:\\n\\nCurrently on any significant prescription medications other than oral contraceptives in women Currently Pregnant Current Tobacco Use\\n\\nSubjects with the Metabolic Syndrome\\n\\nInclusion:\\n\\nSedentary: No routine exercise, walking \\\\<10,000 steps per day Age \\\\>18 and \\\\<65 Body Mass Index (BMI) \\\\>30\\n\\nMeet at least three of the following Adult Treatment Panel (ATP) III criteria for the metabolic syndrome:\\n\\nwaist circumference \\\\> or = 40 inches in men, \\\\> or = 35 inches in women blood triglycerides \\\\> or = 150 mg/dL blood HDL cholesterol \\\\<40 mg/dL in men, \\\\<50 in women blood pressure \\\\> or = 130 mmHg systolic, or \\\\> or = 85 mmHg diastolic fasting blood sugar \\\\> or = 100 mg/dL\\n\\nExclusion:\\n\\nDiagnosed with Type 2 diabetes, coronary artery disease, cancer, liver, lung, or kidney disease or any other major illness\\n\\nCurrently on any significant prescription medications other than:\\n\\noral contraceptives in women More than two standard medication for stage 1 hypertension in men or women (blood pressure 140-159/90-99) Currently Pregnant Current Tobacco Use', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'primary care clinic, community sample', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Clay F. Semenkovich, M.D.', 'affiliation': 'Washington University School of Medicine', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Janet B McGill, M.D.', 'affiliation': 'Washington University School of Medicine', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Washington University School of Medicine', 'city': 'Saint Louis', 'state': 'Missouri', 'zip': '63110', 'country': 'United States', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}]}, 'referencesModule': {'references': [{'pmid': '23245604', 'type': 'BACKGROUND', 'citation': \"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0. Erratum In: Lancet. 2013 Feb 23;381(9867):628. AlMazroa, Mohammad A [added]; Memish, Ziad A [added].\"}, {'pmid': '21295846', 'type': 'BACKGROUND', 'citation': 'Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011 Feb 12;377(9765):557-67. doi: 10.1016/S0140-6736(10)62037-5. Epub 2011 Feb 3.'}, {'pmid': '11559268', 'type': 'BACKGROUND', 'citation': 'Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001 Sep 12;286(10):1218-27. doi: 10.1001/jama.286.10.1218.'}, {'pmid': '7658949', 'type': 'BACKGROUND', 'citation': 'Regensteiner JG, Sippel J, McFarling ET, Wolfel EE, Hiatt WR. Effects of non-insulin-dependent diabetes on oxygen consumption during treadmill exercise. Med Sci Sports Exerc. 1995 Jun;27(6):875-81.'}, {'pmid': '23376793', 'type': 'BACKGROUND', 'citation': 'Funai K, Song H, Yin L, Lodhi IJ, Wei X, Yoshino J, Coleman T, Semenkovich CF. Muscle lipogenesis balances insulin sensitivity and strength through calcium signaling. J Clin Invest. 2013 Mar;123(3):1229-40. doi: 10.1172/JCI65726. Epub 2013 Feb 8. Erratum In: J Clin Invest. 2013 Aug 1;123(8):3634.'}, {'pmid': '1439783', 'type': 'BACKGROUND', 'citation': 'McGarry JD. What if Minkowski had been ageusic? An alternative angle on diabetes. Science. 1992 Oct 30;258(5083):766-70. doi: 10.1126/science.1439783.'}, {'pmid': '16371598', 'type': 'BACKGROUND', 'citation': 'Kiens B. Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiol Rev. 2006 Jan;86(1):205-43. doi: 10.1152/physrev.00023.2004.'}], 'seeAlsoLinks': [{'label': 'Washington U in St. Louis, Endocrinology Current Clinical Studies', 'url': 'http://endo.wustl.edu/current-clinical-studies/'}, {'label': 'Clay F. Semenkovich, MD', 'url': 'http://endo.wustl.edu/clay-f-semenkovich-m-d/'}, {'label': 'Washington U in St. Louis; Research Participant Registry', 'url': 'https://vfh.wustl.edu/'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}, 'resultsSection': {'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Metabolic Syndrome', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\"}, {'id': 'FG001', 'title': 'Control', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\"}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '15'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '15'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Metabolic Syndrome', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\"}, {'id': 'BG001', 'title': 'Control', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\"}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '12'}, {'groupId': 'BG001', 'value': '15'}, {'groupId': 'BG002', 'value': '27'}]}], 'measures': [{'title': 'Age, Categorical', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'groupId': 'BG000', 'value': '12'}, {'groupId': 'BG001', 'value': '15'}, {'groupId': 'BG002', 'value': '27'}]}, {'title': '>=65 years', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '51.3', 'spread': '8.4'}, {'groupId': 'BG001', 'value': '39.5', 'spread': '16.4'}, {'groupId': 'BG002', 'value': '44.8', 'spread': '14.5'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '7'}, {'groupId': 'BG001', 'value': '9'}, {'groupId': 'BG002', 'value': '16'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '5'}, {'groupId': 'BG001', 'value': '6'}, {'groupId': 'BG002', 'value': '11'}]}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '1'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '12'}, {'groupId': 'BG001', 'value': '13'}, {'groupId': 'BG002', 'value': '25'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '1'}]}]}]}, {'title': 'Race (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '4'}, {'groupId': 'BG001', 'value': '3'}, {'groupId': 'BG002', 'value': '7'}]}, {'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '8'}, {'groupId': 'BG001', 'value': '12'}, {'groupId': 'BG002', 'value': '20'}]}, {'title': 'More than one race', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '12'}, {'groupId': 'BG001', 'value': '15'}, {'groupId': 'BG002', 'value': '27'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Sarcoplasmic Reticulum Composition', 'description': \"We will take a muscle tissue sample from the subject's thigh (vastus lateralis) to quantify phosphatidylcholine to phosphatidylethanolamine ratio of the sarcoplasmic reticulum.\", 'populationDescription': 'Samples not included were lost during tissue processing. Metabolic syndrome (n=10); Control (n=13)', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'PC:PE ratio', 'timeFrame': 'Study Visit Week 4', 'groups': [{'id': 'OG000', 'title': 'Metabolic Syndrome', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\"}, {'id': 'OG001', 'title': 'Control', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '10'}, {'groupId': 'OG001', 'value': '13'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.0', 'spread': '0.2'}, {'groupId': 'OG001', 'value': '2.2', 'spread': '0.2'}]}]}]}, {'type': 'SECONDARY', 'title': 'Insulin Sensitivity', 'description': 'The homeostatic model assessment for insulin resistance (HOMA-IR) is a calculated value using fasting glucose and insulin levels. It provides a measure of insulin resistance. HOMA-IR values between 0.5 and 1.4 are considered normal and values \\\\>2.9 indicate insulin resistance. The Matsuda Index reflects insulin sensitivity. It is calculated from glucose and insulin levels drawn fasting and during an OGTT. Matsuda Index values of 2.5 or higher are normal and indicate lack of insulin resistance or normal insulin sensitivity. Results of these measures are displayed graphically in the published paper.', 'populationDescription': 'Oral glucose tolerance tests were performed on 15 controls and 11 metabolic syndrome participants. The insulin data was lost for one metabolic syndrome participant.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Matsuda Index', 'timeFrame': 'Study visit week 4', 'groups': [{'id': 'OG000', 'title': 'Metabolic Syndrome', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\"}, {'id': 'OG001', 'title': 'Control', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '11'}, {'groupId': 'OG001', 'value': '15'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.5', 'spread': '1.9'}, {'groupId': 'OG001', 'value': '5.6', 'spread': '2.2'}]}]}]}, {'type': 'SECONDARY', 'title': 'Lean and Fat Body Mass', 'description': 'We will perform a Duel Energy X-ray absorptiometry (DEXA) scan to approximate lean and fat body mass of study subjects.', 'populationDescription': 'All study participants received DEXAs and data were reported.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Total body fat (%)', 'timeFrame': 'Study Visit week 4', 'groups': [{'id': 'OG000', 'title': 'Metabolic Syndrome', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\"}, {'id': 'OG001', 'title': 'Control', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '12'}, {'groupId': 'OG001', 'value': '15'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '43.7', 'spread': '5.0'}, {'groupId': 'OG001', 'value': '30.6', 'spread': '7.5'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '0', 'timeFrame': 'Individual study participation: 4-6 weeks Study duration of entire cohort: 9 years, 11 months', 'description': 'Our definition of adverse / serious adverse events do not differ from clinicaltrials.gov.', 'eventGroups': [{'id': 'EG000', 'title': 'Metabolic Syndrome', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\", 'deathsNumAffected': 0, 'deathsNumAtRisk': 12, 'seriousNumAffected': 0, 'seriousNumAtRisk': 12, 'otherNumAffected': 0, 'otherNumAtRisk': 12}, {'id': 'EG001', 'title': 'Control', 'description': \"Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass\\n\\nmuscle biopsy: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).\", 'deathsNumAffected': 0, 'deathsNumAtRisk': 15, 'seriousNumAffected': 0, 'seriousNumAtRisk': 15, 'otherNumAffected': 0, 'otherNumAtRisk': 15}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': True}, 'pointOfContact': {'title': 'Samantha Adamson, MD, PhD', 'organization': 'Washington University School of Medicine', 'email': 'sadamson@wustl.edu', 'phone': '314-362-3500'}}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot_SAP', 'hasProtocol': True, 'hasSap': True, 'hasIcf': False, 'label': 'Study Protocol and Statistical Analysis Plan', 'date': '2021-02-01', 'uploadDate': '2024-08-07T16:49', 'filename': 'Prot_SAP_000.pdf', 'size': 511813}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D024821', 'term': 'Metabolic Syndrome'}, {'id': 'D013577', 'term': 'Syndrome'}], 'ancestors': [{'id': 'D004194', 'term': 'Disease'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D007333', 'term': 'Insulin Resistance'}, {'id': 'D006946', 'term': 'Hyperinsulinism'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'}, {'id': 'M23005', 'name': 'Metabolic Syndrome', 'asFound': 'Metabolic Syndrome', 'relevance': 'HIGH'}, {'id': 'M16355', 'name': 'Syndrome', 'asFound': 'Syndrome', 'relevance': 'HIGH'}, {'id': 'M14117', 'name': 'Prediabetic State', 'relevance': 'LOW'}, {'id': 'M20295', 'name': 'Glucose Intolerance', 'relevance': 'LOW'}, {'id': 'M10370', 'name': 'Insulin Resistance', 'relevance': 'LOW'}, {'id': 'M9997', 'name': 'Hyperinsulinism', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01375166', 'orgStudyIdInfo': {'id': 'OPHT-070111'}, 'organization': {'fullName': 'Medical University of Vienna', 'class': 'OTHER'}, 'briefTitle': 'Coupling of Neural Activity and Retinal Blood Flow in Diabetes'}, 'statusModule': {'statusVerifiedDate': '2020-02', 'overallStatus': 'TERMINATED', 'whyStopped': 'not enough subjects recruited', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-03-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2013-03-06', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2013-03-06', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2011-04-11', 'studyFirstSubmitQcDate': '2011-06-15', 'studyFirstPostDateStruct': {'date': '2011-06-17', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2020-02-19', 'lastUpdatePostDateStruct': {'date': '2020-02-20', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Gerhard Garhofer', 'investigatorTitle': 'Assoc. Prof. Priv. - Doz. Dr', 'investigatorAffiliation': 'Medical University of Vienna'}, 'leadSponsor': {'name': 'Medical University of Vienna', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'The prevalence of diabetes is increasing and the management of the disease is nowadays considered a major challenge. Affected patients have increased mortality and morbidity as well as a significant drop in the quality of life. The complications of diabetes can be classified as microvascular (e.g. nephropathy, neuropathy or retinopathy) or macrovascular (e.g. cardiovascular or cerebrovascular).\\n\\nSeveral large-scale epidemiologic studies indicating that wider retinal venous caliber is strongly associated with the fasting glucose level as well as with diabetes. Another retinal vascular abnormality that is associated with diabetes is an abnormal retinal vascular response to flicker stimulation. Retinal vessel dilatation in response to stimulation with diffuse flicker light occurs due to a phenomenon called neurovascular coupling. This means that increased activity of neurons is associated with an increased retinal metabolism. This leads to a release of endogenous vasodilator substances and increased blood flow. However, previous studies were limited by the fact that retinal vessel diameters and blood flow were not measured simultaneously.\\n\\nThe present study aims to investigate whether the response of retinal vessel diameters and blood flow velocities to flicker stimulation is altered in patients with diabetes. Both parameters will be measured in real time using Fourier Domain Doppler OCT.'}, 'conditionsModule': {'conditions': ['Diabetic Retinopathy']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 1, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Diabetic retinopathy', 'description': 'Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy'}, {'label': 'healthy', 'description': 'healthy control subjects'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Retinal vessel diameters', 'timeFrame': '18 months'}, {'measure': 'Retinal blood flow velocities', 'timeFrame': '18 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Men and women aged over 18 years, nonsmokers\\n* Normal findings in the medical history (except diabetes) and physical examination unless the investigator considers an abnormality to be clinically irrelevant\\n* normal laboratory findings (except diabetes associated parameters) unless the investigator considers the abnormality to be clinically irrelevant\\n* normal ophthalmic findings (except mild diabetic retinopathy), Ametropia less than 6 diopters\\n* inclusion criterion of patients is type I diabetes with non or mild non-proliferative retinopathy\\n\\nExclusion criteria\\n\\nAny of the following will exclude a healthy subject from the study:\\n\\n* Regular use of vasoactive drugs\\n* Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study\\n* Symptoms of a clinically relevant illness in the 3 weeks before the first study day\\n* Blood donation during the previous 3 weeks\\n* History or presence of any ocular pathology\\n* History or family history of epilepsy\\n* Systemic hypertension defined as systolic blood pressure \\\\>150mmHg, diastolic blood pressure \\\\>90mmHg\\n* Pregnancy\\n\\nAny of the following will exclude a subject with diabetes from the study:\\n\\n* Presence of non-insulin dependent diabetes, maturity onset diabetes of the young (MODY diabetes)\\n* History or presence of any other diabetes induced vascular pathologies or any other ocular condition other then diabetic retinopathy\\n* Best corrected visual acuity \\\\<0.8\\n* Previous laser photocoagulation treatment\\n* Systemic hypertension defined as systolic blood pressure \\\\>150mmHg, diastolic blood pressure \\\\>90mmHg\\n* History or family history of epilepsy\\n* Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study\\n* Symptoms of a clinically relevant illness in the 3 weeks before the first study day\\n* Blood donation during the previous 3 weeks\\n* Pregnancy', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': '24 patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy, non-smokers 24 age and sex matched healthy controls, non-smokers', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Gerhard Garhöfer, MD', 'affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Department of Clinical Pharmacology', 'city': 'Vienna', 'zip': '1090', 'country': 'Austria', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003930', 'term': 'Diabetic Retinopathy'}], 'ancestors': [{'id': 'D012164', 'term': 'Retinal Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}, {'id': 'D003925', 'term': 'Diabetic Angiopathies'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D048909', 'term': 'Diabetes Complications'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M14999', 'name': 'Retinal Diseases', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7125', 'name': 'Diabetic Retinopathy', 'asFound': 'Diabetic Retinopathy', 'relevance': 'HIGH'}, {'id': 'M8271', 'name': 'Eye Diseases', 'relevance': 'LOW'}, {'id': 'M7120', 'name': 'Diabetic Angiopathies', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}, {'id': 'M26004', 'name': 'Diabetes Complications', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC11', 'name': 'Eye Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05899166', 'orgStudyIdInfo': {'id': 'IRB-P00044330'}, 'organization': {'fullName': \"Boston Children's Hospital\", 'class': 'OTHER'}, 'briefTitle': 'Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes', 'officialTitle': 'Effect of Dietary Carbohydrate on Diabetes Control and Beta Cell Function in Children With Newly Diagnosed Diabetes'}, 'statusModule': {'statusVerifiedDate': '2024-05', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-04-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2029-04-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2030-04-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-02-01', 'studyFirstSubmitQcDate': '2023-06-01', 'studyFirstPostDateStruct': {'date': '2023-06-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-05-02', 'lastUpdatePostDateStruct': {'date': '2024-05-03', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Belinda Lennerz', 'investigatorTitle': 'Assistant Professor in Pediatrics', 'investigatorAffiliation': \"Boston Children's Hospital\"}, 'leadSponsor': {'name': \"Boston Children's Hospital\", 'class': 'OTHER'}, 'collaborators': [{'name': 'University of South Florida', 'class': 'OTHER'}, {'name': 'Indiana University', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to test the effects of a ketogenic diet on the progression and control of type 1 diabetes in children with newly diagnosed diabetes. The main questions to answer are:\\n\\n* Does a ketogenic diet prolong the honeymoon period of type 1 diabetes?\\n* Does a ketogenic diet improve diabetes control?\\n* Is a ketogenic diet safe, acceptable and sustainable in children with newly diagnosed diabetes?\\n* What are the microbiome, inflammatory and metabolic changes linking diet to β-cell function?\\n\\nParticipants will receive a combination of free meals, groceries, micronutrient supplements, and intensive diet and diabetes education for 9 months.\\n\\n* Diabetes care devices will be connected for cloud-based data collection.\\n* Bi-weekly data downloads and remote check-ins will assess dietary intake, satisfaction with diet and study procedures, and possible safety concerns.\\n* During five study visits held at at baseline, 1, 5, 9 and 24 months, an intravenous catheter (IV) will be placed for collection of 5 blood samples before and up to 2 hours after a liquid test meal (protein shake) to assess insulin response. A stool sample will also be collected to assess microbiome changes.\\n* Children and their caregivers will participate in a semi-structured interview, and online questionnaires to assess their experience with the diet and diabetes care, general well-being and quality of life.\\n\\nComparison will be made between a ketogenic vs standard diet.', 'detailedDescription': 'Type I diabetes is caused by an autoimmune destruction of insulin producing β-cells in the pancreas, resulting in absolute insulin deficiency. In the first months after diagnosis, a small number of β-cells typically remain and, by producing insulin, significantly improve diabetes control and reduce disease burden.\\n\\nPreliminary data suggest that this early disease stage entitled the \"honeymoon period\" might be extended by a ketogenic diet, which would provide a major therapeutic advantage and may reduce chronic disease burden.\\n\\nTo test the hypothesis that a ketogenic vs. standard diet will extend the honeymoon period and improve diabetes control in children, the researchers are conducting a study employing education and food deliveries of a ketogenic or standard diet to children and their families. Fifty-two children aged 5 to 12 years with newly diagnosed diabetes will participate. Children will be assigned by chance (randomized) to receive either a ketogenic or a standard diet for 9 months. Chances to be assigned to either diet are 50:50 like a coin flip, and 26 children will participate in each diet arm.\\n\\nParticipants will receive a combination of free meals, groceries, micronutrient supplements, and intensive diet and diabetes education throughout the 9 months. Continuous glucose monitoring (CGM) and diaries will be used for cloud-based data collection. Bi-weekly data downloads and remote check-ins will be performed to assess dietary intake, satisfaction with diet and study procedures, and possible safety concerns. Participants are instructed to measure blood ketone levels with their home ketone meter anytime blood glucose levels exceed a safety threshold and to call the study physician for persistent low glucose levels or ketones above diet specific safety thresholds.\\n\\nStudy visits are held at at baseline, 1, 5, 9 and 24 months to collect height, weight, stool and blood samples for hormones, metabolites and inflammatory biomarkers. At each visit, an intravenous catheter (IV) will be placed to collect fasting blood samples, followed by a liquid test meal (protein shake) and collection of four additional blood samples from the IV over the course of two hours. Prior to each visit, participants will collect stool samples at home using provided kits. In addition, participants and their families will participate in a semi-structured interview, and online questionnaires to asses their food intake, experience with the diet, diabetes care burden and complications, and general well-being and quality of life.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 1'], 'keywords': ['carbohydrate reduced', 'low-carb', 'diabetes', 'keto']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 52, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'ketogenic diet', 'type': 'EXPERIMENTAL', 'description': 'The diet will be high in protein and healthy fats and comprise meat, fish, fibrous vegetables, nuts, dairy, and berries. Macronutrient composition will be \\\\~ 5% carbohydrate, 20% protein, 70% fat.\\n\\nParticipants will receive a daily multi-vitamin, magnesium supplement, and supplemental salt (bouillon cubes) to ascertain micronutrient sufficiency and help with transition to the diet.', 'interventionNames': ['Other: Ketogenic diet, food delivery and education']}, {'label': 'standard diet', 'type': 'ACTIVE_COMPARATOR', 'description': 'The diet will be consistent with prevailing dietary guidelines and recommendations and contain meat, fish, grains, vegetables, fruit and dairy. At least 50% of grain-based products will be whole grains. Meats will be primarily lean, and dairy products will be fat-free or low-fat. Macronutrient composition will be \\\\~50% carbohydrate (\\\\<10% added sugars), 20% protein, 30% fat.\\n\\nParticipants will receive a daily multi-vitamin supplement to ascertain micronutrient sufficiency.', 'interventionNames': ['Other: Standard diet, food delivery and education']}], 'interventions': [{'type': 'OTHER', 'name': 'Ketogenic diet, food delivery and education', 'description': 'Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.', 'armGroupLabels': ['ketogenic diet']}, {'type': 'OTHER', 'name': 'Standard diet, food delivery and education', 'description': 'Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.', 'armGroupLabels': ['standard diet']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Decline in Beta-cell Function', 'description': 'Change in C-peptide 2-h area under the curve after a mixed-meal tolerance test (ΔCP).', 'timeFrame': 'Change over 1, 5, and 9 months, corrected for baseline'}], 'secondaryOutcomes': [{'measure': 'Time in Range (TIR) 70-180 mg/dl', 'description': 'From continuous glucose monitoring (CGM) - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'Longitudinal Change in Beta-cell Function', 'description': 'C-peptide 2-h area under the curve after a mixed-meal tolerance test.', 'timeFrame': '1, 5, and 24 months'}, {'measure': 'Duration of Clinical Diabetes Remission', 'description': 'Calculated based on percent children with insulin dose corrected HbA1c (IDAA1c) \\\\<9.', 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'Time in low Range (TIR) <70 mg/dl', 'description': 'From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'Time in very low Range (TIR) <55 mg/dl', 'description': 'From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'Time in high Range (TIR) >180 mg/dl', 'description': 'From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation 2-week increments.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'Time in very high Range (TIR) >250 mg/dl', 'description': 'From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'Average Blood Glucose', 'description': 'From CGM - will be computed throughout study participation in 2-week increments.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'Coefficient of Glycemic Variation (CV)', 'description': 'From CGM - will be computed by dividing glucose standard deviation by glucose average throughout study participation in 2-week increments.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'Mean Amplitude of Glycemic Excursions (MAGE)', 'description': 'From CGM - will be computed using published formula throughout study participation in 2-week increments.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'Total Daily Insulin Dose', 'description': 'From insulin administration device uploads - will be computed in units per kg throughout study participation in 2-week increments.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)', 'description': 'Calculated from fasting blood draw \\\\[fasting insulin (µU/ml) × fasting plasma glucose (mg/dl)\\\\]/405.', 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'BMI', 'description': 'Weight divided by height squared.', 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'Lipid panel', 'description': 'Fasting blood - total, LDL and HDL cholesterol, and triglycerides.', 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'HDL to Triglyceride Ratio', 'description': 'Fasting blood', 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'Lipoprotein Subfractions', 'description': 'Fasting blood', 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'Inflammasome, targeted', 'description': 'Interleukins 1β, 17, 23, 6, 10; high sensitivity c-reactive protein; tumor necrosis factor α, interferon gamma', 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'Microbiome, targeted and untargeted', 'description': \"Extraction and sequencing will be performed by Qiagen PowerSoil DNA extraction using Qiagen's DNeasy 96 PowerSoil Pro QIAcube HT Kit (480), followed by whole genome sequencing (WGS) using a miniaturized version of the NEBNext Ultra FS II method.\", 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'Metabolome, targeted and untargeted', 'description': 'Blood samples will be processed using liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR). The LC-MS analyses will be carried out on a Sciex triple quadrupole mass spectrometer couple to an Exion ultra-performance LC system. The targeted analysis will utilize the Biocrates Q500 targeted metabolomics assay which quantifies more than 500 metabolites over 26 chemical classes (Biocrates Inc., Innsbruck, Austria). Data processing to yield metabolite concentrations in micromolar units will utilize the Biocrates MetIDQ software. The NMR data will be acquired on a Bruker Avance NEO 700 MHz NMR equipped with a TCI cryoprobe and a SampleXPress automatic sample changer. The data will be processed using the Chenomx NMR Processor and Profiler packages (Chenomx, Edmonton, CA) to yield quantitative data in millimolar units.', 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'Problem Areas in Diabetes (PAID-Ped) - child', 'description': 'Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate greater burden.', 'timeFrame': '1, 3, 5, 7, 9, and 24 months'}, {'measure': 'Problem Areas in Diabetes (PAID-PR) - parent', 'description': 'Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate greater burden.', 'timeFrame': '1, 3, 5, 7, 9, and 24 months'}, {'measure': 'Pediatric Quality of Life (PEDSQL) General Module - parent', 'description': 'Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate better quality of life.', 'timeFrame': '1, 3, 5, 7, 9, and 24 months'}, {'measure': 'Pediatric Quality of Life (PEDSQL) General Module - child', 'description': 'Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate better quality of life.', 'timeFrame': '1, 3, 5, 7, 9, and 24 months'}, {'measure': 'Pediatric Quality of Life (PEDSQL) Diabetes Module - parent', 'description': 'Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate less problems.', 'timeFrame': '1, 3, 5, 7, 9, and 24 months'}, {'measure': 'Pediatric Quality of Life (PEDSQL) Diabetes Module - child', 'description': 'Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate less problems.', 'timeFrame': '1, 3, 5, 7, 9, and 24 months'}, {'measure': 'Child Eating Disorder Examination Questionnaire (ChEDE-Q8)', 'description': 'Validated questionnaire, scored according to published standards. Scores range 0-42, higher scores are worse.', 'timeFrame': '1, 3, 5, 7, 9, and 24 months'}, {'measure': 'Perceptions on Diet Management of Diabetes', 'description': \"Questionnaire to assess participants' and caregivers' perceptions of the influence of the diet on their diabetes management.\", 'timeFrame': '1, 3, 5, 7, 9, and 24 months'}, {'measure': 'Qualitative patient perspectives, interview - parent', 'description': 'Interviews will be held with children and caregivers separately after implementation and completion of the intervention.', 'timeFrame': '9 months'}, {'measure': 'Qualitative patient perspectives, interview - child', 'description': 'Interviews will be held with children and caregivers separately after implementation and completion of the intervention.', 'timeFrame': '9 months'}], 'otherOutcomes': [{'measure': 'Time in tight Range (TIR) 70-140 mg/dl', 'description': 'From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.', 'timeFrame': 'Over 9 months and at 21 months'}, {'measure': 'Time above tight Range (TIR) >140 mg/dl', 'description': 'From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'BOHB (beta-hydroxybutyrate), fasting blood concentration', 'description': 'Obtained at daily increasing to weekly intervals as effect modifier of beta-cell function.', 'timeFrame': 'Over 9 months and at 24 months'}, {'measure': 'Growth', 'description': 'Safety Measure - Height standard deviation score will be calculated from serial height measurements obtained during study visits using CDC age and sex specific references.', 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'Growth velocity', 'description': 'Safety Measure - Growth velocity will be calculated from serial height measurements obtained during study visits.', 'timeFrame': '1, 5, 9, and 24 months'}, {'measure': 'Weigh-gain', 'description': 'Safety Measure - Weight SDS and gain will be calculated from serial weight measures obtained during study visits with calibrated scale.', 'timeFrame': '1, 5, 9, 24 months'}, {'measure': 'Confirmed Ketoacidosis', 'description': 'Safety Measure - Defined by elevated BOHB, blood pH \\\\<7.3 and serum bicarbonate \\\\<15. Rates will be computed as total number of events divided by total patient years of follow-up.', 'timeFrame': 'Over 9 months'}, {'measure': 'Severe Hypoglycemia', 'description': 'Safety Measure - Defined as blood glucose \\\\< 55 mg/dl and requiring glucagon or resulting in seizure or coma. Rates will be computed as total number of events divided by total patient years of follow-up.', 'timeFrame': 'Over 9 months'}, {'measure': 'Diabetes Related Emergency Visits', 'description': 'Safety Measure - Rates will be computed as total number of events divided by total patient years of follow-up.', 'timeFrame': 'Over 9 months'}, {'measure': 'Diabetes Related Hospitalizations', 'description': 'Safety Measure - Rates will be computed as total number of events divided by total patient years of follow-up.', 'timeFrame': 'Over 9 months'}, {'measure': 'Study termination for disordered eating', 'description': 'Safety Measure - ChEDE-Q8 diagnostic score with clinical confirmation. Total number of events.', 'timeFrame': 'Over 9 months'}, {'measure': 'Study termination for growth deceleration', 'description': 'Safety Measure - Undesired weight loss or significant deceleration in longitudinal growth may warrant termination of study participation. Total number of events will be computed.', 'timeFrame': 'Over 9 months'}, {'measure': 'Study termination for dyslipidemia', 'description': 'Safety Measure - LDL \\\\>200 mg/dl will trigger review of additional risk factors and may prompt diet modification to lower intake of saturated fats. If persistent, study participation may be terminated. Total number of events will be computed.', 'timeFrame': 'Over 9 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Children aged 5 to 12 years.\\n* Within one month of diabetes diagnosis.\\n* Type 1 diabetes confirmed by immediate insulin requirement with autoimmunity markers (≥2 positive antibodies \\\\[glutamate decarboxylase-65, islet-antigen-2, zinc transporter-8, insulin \\\\[prior to first insulin dose\\\\]).\\n* Family committed and able to participate in study education and implement dietary intervention.\\n\\nExclusion Criteria:\\n\\n* Dietary needs or habits incompatible with the study meal plans, (e.g., vegan, major food intolerances/allergies, ketogenic).\\n* Eating disorders as assessed by Chede-Q8.\\n* Major medical illness or use of medications other than insulin that could interfere with metabolic or glycemic variables.\\n* Major psychiatric illness.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '5 Years', 'maximumAge': '12 Years', 'stdAges': ['CHILD']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Belinda Lennerz, MD PhD', 'role': 'CONTACT', 'phone': '857-218-3896', 'email': 'belinda.lennerz@childrens.harvard.edu'}], 'overallOfficials': [{'name': 'Belinda Lennerz', 'affiliation': \"Boston Children's Hospital\", 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': \"Boston Children's Hospital\", 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02115', 'country': 'United States', 'contacts': [{'name': 'Belinda Lennerz', 'role': 'CONTACT'}], 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}]}, 'referencesModule': {'references': [{'pmid': '33393511', 'type': 'BACKGROUND', 'citation': 'Lennerz BS, Koutnik AP, Azova S, Wolfsdorf JI, Ludwig DS. Carbohydrate restriction for diabetes: rediscovering centuries-old wisdom. J Clin Invest. 2021 Jan 4;131(1):e142246. doi: 10.1172/JCI142246.'}, {'pmid': '29735574', 'type': 'BACKGROUND', 'citation': 'Lennerz BS, Barton A, Bernstein RK, Dikeman RD, Diulus C, Hallberg S, Rhodes ET, Ebbeling CB, Westman EC, Yancy WS Jr, Ludwig DS. Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet. Pediatrics. 2018 Jun;141(6):e20173349. doi: 10.1542/peds.2017-3349. Epub 2018 May 7.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Upon publication, de-identified raw data for each original article will be uploaded to the appropriate an NIH maintained repository.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'Study protocol and statistical analysis plan will be shared prior to enrollment of the first participant.\\n\\nDe-identified data will be shared upon manuscript publication.', 'accessCriteria': 'Data will be downloadable.'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Diabetes Mellitus, Type 1', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M17558', 'name': 'Vitamins', 'relevance': 'LOW'}, {'id': 'M21009', 'name': 'Micronutrients', 'relevance': 'LOW'}, {'id': 'M16885', 'name': 'Trace Elements', 'relevance': 'LOW'}, {'id': 'T342', 'name': 'Magnesium Supplement', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Micro', 'name': 'Micronutrients'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Mi', 'name': 'Mineral'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04436666', 'orgStudyIdInfo': {'id': 'seher cevik'}, 'organization': {'fullName': 'Inonu University', 'class': 'OTHER'}, 'briefTitle': 'Virtual Reality, Ice Application and Self-injection and Self-test Fair, Pain and State Anxiety', 'officialTitle': 'The Effect of Virtual Reality and Ice Application on Fear of Self-injection and Self-test, Pain and State Anxiety Levels in Patients With Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2022-12', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2020-07-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-12-30', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2021-06-30', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2020-06-15', 'studyFirstSubmitQcDate': '2020-06-17', 'studyFirstPostDateStruct': {'date': '2020-06-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-12-02', 'lastUpdatePostDateStruct': {'date': '2022-12-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'seher ÇEVİK', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'Inonu University'}, 'leadSponsor': {'name': 'Inonu University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'AİM:The aim of this study is to control the fears and anxieties of Type 2 diabetics in insulin injection and blood glucose measurement with motivational videos and Ice applications to be applied with virtual reality glasses.\\n\\nMaterial and Methods: The research is designed as a semi-experimental model with pretest-posttest control groups. The research will be carried out in the endocrine services located in Turgut Özal Medical Center in Malatya province. The universe of the research will be 2113 Type 2 diabetes patients who are being treated in the hospital specified on the specified dates, who are injecting insulin and following blood sugar. According to the analysis of the power, the sample of the research is composed of an experiment effect of 0.5% with bilateral significance level, 95% confidence interval determined with 5% error level, the experiment group to be applied with 80% Reality with 80% representation power, and the control group with 80 ice application. will create a total of 240 Type 2 diabetes patients.In the collection of the data, the Participant Presentation Form developed by the researcher, Diabetes Fear of Self Injecting and Self-testing Questionnaire-D-FISQ, State Anxiety Scale and VAS will be used.', 'detailedDescription': 'VR is a relatively new human-computer interaction tool in which a person becomes an active participant in a virtual world. Sensory cues of VR, especially the precise control of auditory, tactile and olfactory systems, enhances the reality of the virtual environment. As a result, users feel that they can look around and enter the simulated environment. The virtual environment provides sensory information such as visual, auditory, movement, virtual or artificial, and makes the individual feel similar to real life.\\n\\nIce application has been used as a topical pain reliever for centuries. It works through a variety of mechanisms, such as slowing the transmission of peripheral nerve fibers, promoting sensory competition, and reducing the release of inflammatory and nociceptive mediators. Ice application is cheap, easily accessible and reaches its purpose relatively quickly to skin anesthesia. Apart from these effects, it also reduces pain by activating the Door-Control mechanism, stimulating the touch receptors and increasing the release of endogenous opioids.'}, 'conditionsModule': {'conditions': ['Injection Site Irritation', 'Fear of Pain'], 'keywords': ['Insulin injection', 'fear of injection', 'Ice application', 'Virtual reality']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 159, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Ice Application', 'type': 'EXPERIMENTAL', 'description': 'Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.', 'interventionNames': ['Other: Ice Application']}, {'label': 'Virtual Reality', 'type': 'EXPERIMENTAL', 'description': 'Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.', 'interventionNames': ['Device: motivational video production through virtual reality glasses']}, {'label': 'control', 'type': 'NO_INTERVENTION', 'description': 'No Intervention'}], 'interventions': [{'type': 'DEVICE', 'name': 'motivational video production through virtual reality glasses', 'description': 'Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.', 'armGroupLabels': ['Virtual Reality']}, {'type': 'OTHER', 'name': 'Ice Application', 'description': 'Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.', 'armGroupLabels': ['Ice Application']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Injection fear reduction', 'description': '(Diabetes Fear of Self Injecting and Self-testing Questionnaire-D-FISQ) D-FISQ was developed by Snoek et al. (1997) to measure the fear of self-injection and testing in individuals with diabetes who need insulin. D-FISQ with 15 expressions consists of two sub-dimensions, fear of self-injecting-FSI, 6 expressions, and fear of self-testing (FST, 9 expressions). Each statement has a 4-point Likert-type rating ranging from 1 to 4 (1 = almost never, 2 = sometimes, 3 = often, 4 = almost always). The evaluation of the inquiry form can be done by taking the average or raw score for the two sub-dimensions and the whole form. As the scores obtained from the scale increase, fear levels increase. Internal consistency coefficient of the scale is 0.96.', 'timeFrame': '1 month'}, {'measure': 'anxiety reducation', 'description': 'State Anxiety Scale The scale, which was developed by Spielberger et al in 1970, was adapted to Turkish by Öner and LeCompte (1974). The emotions or behaviors expressed in the scale items are answered by marking one of the options such as (1) none, (2) a little, (3) a lot, and (4) completely. The scale containing twenty expressions contains 10 inverse (1, 2, 5, 8, 10, 11, 15, 16, 19, 20) expressions. While the reverse expressions expressing positive emotions are scored, those in one weight degree are converted into four, and those in four weight degrees into one. In the scoring, the total weighted score of the inverse statements is subtracted from the total weighted score and 50, an unchanged value, is added to this number. The total score value obtained from the scale can range from 20 to 80 points. A high score indicates that the level of anxiety is high. The total score value is evaluated as 20-39 mild anxiety, 40-59 moderate anxiety, and 60-79 severe anxiety.', 'timeFrame': '1 month'}, {'measure': 'pain relief', 'description': '(Visual Analogue Scale -VAS) This scale, which is used to measure subjectively perceived pain, was developed by Price et al. (1983), and has been used in many studies to evaluate the intensity of pain, it has been found to be reliable and valid. It is a 10 cm scale with \"painlessness\" on one end and \"severe pain\" on the other. Individuals participating in the study are asked to mark the level of pain severity they feel at the moment, explaining that the number \"0\" on the scale means that I do not feel any pain and the pain intensity increases as the numbers grow and the number \"10\" means the most severe pain.', 'timeFrame': '1 month'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Being literate,\\n* Injecting insulin at least twice a day,\\n* Following blood sugar at least twice a day,\\n\\nExclusion Criteria:\\n\\n* Having any psychiatric diagnosis,\\n\\n  * communication barriers\\n  * The patient has any diagnosis, such as epilepsy, that will trigger seizures.\\n  * Any diagnosis, such as vertigo, that causes dizziness in the patient.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'seher ÇEVİK', 'affiliation': 'Inonu University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'seher ÇEVİK', 'city': 'Malatya', 'zip': '44280', 'country': 'Turkey', 'geoPoint': {'lat': 38.35018, 'lon': 38.31667}}]}, 'referencesModule': {'references': [{'pmid': '29799614', 'type': 'BACKGROUND', 'citation': 'Cevik S, Yagmur Y. Impact of intolerance of uncertainty on psychological well-being in pregnant women with or without miscarriage risk. Perspect Psychiatr Care. 2018 Jul;54(3):436-440. doi: 10.1111/ppc.12297. Epub 2018 May 25.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}, {'id': 'M4324', 'name': 'Anxiety Disorders', 'relevance': 'LOW'}, {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06821360', 'orgStudyIdInfo': {'id': '338864'}, 'secondaryIdInfos': [{'id': '2410662', 'type': 'OTHER', 'domain': 'Royal Devon University Healthcare NHS Foundation Trust'}], 'organization': {'fullName': 'Royal Devon and Exeter NHS Foundation Trust', 'class': 'OTHER'}, 'briefTitle': 'Assessing Remote Confirmation of Type 1 Diabetes', 'officialTitle': 'Evaluating the Practicalities & Potential Benefits of Using Remote C-peptide Testing in Clinical Practice to Confirm Established Type 1 Diabetes', 'acronym': 'ARC-T1D'}, 'statusModule': {'statusVerifiedDate': '2024-12', 'overallStatus': 'ENROLLING_BY_INVITATION', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-12-03', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-09', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-02-10', 'studyFirstSubmitQcDate': '2025-02-10', 'studyFirstPostDateStruct': {'date': '2025-02-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-02-10', 'lastUpdatePostDateStruct': {'date': '2025-02-12', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Royal Devon and Exeter NHS Foundation Trust', 'class': 'OTHER'}, 'collaborators': [{'name': 'NIHR Exeter Clinical Research Facility', 'class': 'NETWORK'}, {'name': 'NIHR BRC', 'class': 'UNKNOWN'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The aim of this research is to assess the practicalities and potential benefits of collecting home finger prick samples from all patients within a hospital type 1 diabetes service to test how much insulin each patient is producing. To do this we will send detailed study information, sample collection kits and reply-paid return packs to 1500 randomly selected patients, treated as type 1 diabetes, in a hospital clinic (3000 patients in the whole clinic). We will ask participants to consent to take part (either online or by completing a paper consent form returned with their pack) before collecting a finger prick blood sample. We will ask participants to collect the sample between 1 and 5 hours after a meal and to check and record their blood glucose level at the same time. Participants will then return the sample and glucose result, using the pre-paid pack provided, to the hospital clinic laboratory for a test called C-peptide (a measure of how much of their own insulin they are producing). The sample collection process should take no longer than 10 minutes.\\n\\nWe will record the percentage of patients returning samples within 4 weeks of initial contact and determine the number of cases with high C-peptide suggestive of non-type 1 diabetes. If this study shows remote C-peptide testing is a practical and acceptable to patients, it could allow this remote service to be offered to all type 1 diabetes clinics in every hospital in the United Kingdom. An estimated 350,000 people in the United Kingdom have type 1 diabetes. Reclassifying an estimated 1 in 15 people would mean approximately 23,000 people nationally could benefit from being identified as potentially able to stop insulin treatment.', 'detailedDescription': \"Background It can be hard to diagnose type 1 diabetes in adults because the symptoms can overlap with type 2 diabetes and misclassification of type 2 and type 1 diabetes can occur. This matters as type 2 diabetes cases misclassified as having type 1 diabetes potentially receive a lifetime of unnecessary insulin treatment without access to the effective treatment strategies for type 2 diabetes. Whether someone needs treating as type 1 diabetes can be confirmed by measuring their insulin levels using a test called C-peptide. This should be measured when diabetes is longstanding (over 3 years diabetes duration) as, at diagnosis levels of insulin secretion can overlap in type 1 and type 2 diabetes. A study in Scotland measured C-peptide in a clinic of patients with long standing treatment as type 1 diabetes showing around 1 in 15 of cases did not have type 1 diabetes.\\n\\nAs a result, in Scotland all those with longstanding type 1 diabetes now have C-peptide measured and this is likely to be recommended across the UK. For newly diagnosed cases this will occur prospectively as part of patients' ongoing type 1 diabetes care. However, for existing cases, each hospital will need to test C-peptide, on a blood sample collected from a vein, in all patients in their type 1 diabetes clinic. In addition to the burden on clinical staff to collect the samples, this C-peptide test is not measured in many UK laboratories so co-ordinating this testing on all patients within a clinic will be extremely challenging.\\n\\nWe have recently validated a method of testing C-peptide on capillary blood (finger prick) samples. Importantly these can be collected by a patient at their home and can be posted back to any UK laboratory where C-peptide measurement is available. Using this approach means that clinic visits for blood collection are not required and testing can be co-ordinated from a central location, making organising testing in a whole clinic much more straightforward.\\n\\nStudy Aims \\\\& Participation The aim of this research is to assess the practicalities \\\\& potential benefits of collecting home finger prick samples from all patients within a hospital type 1 diabetes service to test how much insulin each patient is producing. To do this we will send detailed study information, sample collection kits and reply-paid return packs to 1500 randomly selected patients from a type 1 diabetes clinic (3000 patients in the whole clinic). We will ask participants to consent to take part (either online or by completing a paper consent form returned with their pack) before collecting a finger prick blood sample. We will ask participants to collect the sample between 1 and 5 hours after a meal and to check and record their blood glucose level at the same time. Participants would then return the sample and glucose result, using the pre-paid pack provided to the hospital clinic laboratory for a test called C-peptide (a measure of how much of their own insulin a person is producing). The sample collection process should take no longer than 10 minutes.\\n\\nWe will record the percentage of patients returning samples within 4 weeks of initial contact and determine the number of cases with high C-peptide suggestive of non-type 1 diabetes. If this study shows remote C-peptide testing is practical, and acceptable to patients, it could lead to remote testing being offered at all type 1 diabetes clinics in every hospital in the United Kingdom. Diabetes UK estimates around 350,000 people in the United Kingdom have type 1 diabetes. Reclassifying 1 in 15 people would mean approximately 23,000 people nationally could benefit from being identified as potentially able to stop insulin treatment.\"}, 'conditionsModule': {'conditions': ['Diabetes', 'Type 1 Diabetes (T1D)'], 'keywords': ['Diabetes diagnosis. Insulin levels. Remote testing. C-peptide. Home finger-prick samples.']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '3 Months', 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 1000, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Main Cohort', 'description': 'Adults treated as Type 1 diabetes (T1D) and under the clinical care of the specialist diabetes team(s) at the Royal Devon University Healthcare NHS Foundation Trust. Diabetes duration \\\\>3 years at the time of study participation. Aged \\\\> 18 at the time of study participation.', 'interventionNames': ['Diagnostic Test: C-peptide test']}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'C-peptide test', 'description': 'Participants collect a single home finger-prick sample and post to the clinical laboratory for C-peptide analysis (a measure of endogenous insulin production).', 'armGroupLabels': ['Main Cohort']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of samples returned', 'description': 'The number of completed samples returned within four weeks of sample pack mailout.', 'timeFrame': 'Within 4 weeks of initial contact'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients with a Type 1 diabetes follow up code OR rapid progression to insulin (within 3 years of diagnosis) to capture miscoded cases.\\n* Under the clinical care of the diabetes team(s) at the Royal Devon University Healthcare NHS Foundation Trust\\n* Duration of diabetes \\\\>3 years\\n* Aged 18 years or older.\\n\\nExclusion Criteria:\\n\\n* Patients considered by their clinical care team to be unsuitable/inappropriate to be invited to take part in this research (e.g. severe sight impairment, reduced capacity to consent)', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Patients with a Type 1 diabetes follow up code OR rapid progression to insulin (within 3 years of diagnosis) to capture miscoded cases. Under the clinical care of the diabetes team(s) at the Royal Devon University Healthcare NHS Foundation Trust', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Nicholas Thomas, PhD MRCP', 'affiliation': 'University of Exeter and Royal Devon University Healthcare NHS Foundation Trust', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'NIHR Exeter Clinical Research Facility', 'city': 'Exeter', 'state': 'Devon', 'zip': 'EX2 5DW', 'country': 'United Kingdom', 'geoPoint': {'lat': 50.7236, 'lon': -3.52751}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05951660', 'orgStudyIdInfo': {'id': 'EMN-2022-08015, SJ-1005'}, 'organization': {'fullName': 'Zealand University Hospital', 'class': 'OTHER'}, 'briefTitle': 'Sex, Psychopharmacology, and Diabetes', 'officialTitle': 'The Effect of Targeted Education on Number, Severity, and Perception of Sexual Side Effects of Patients Suffering From Schizophrenia and Diabetes or Prediabetes.', 'acronym': 'SECRET'}, 'statusModule': {'statusVerifiedDate': '2025-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-08-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-07-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-07-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-07-10', 'studyFirstSubmitQcDate': '2023-07-10', 'studyFirstPostDateStruct': {'date': '2023-07-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-07', 'lastUpdatePostDateStruct': {'date': '2025-02-11', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Zealand University Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'Mental Health Services in the Capital Region, Denmark', 'class': 'OTHER'}, {'name': 'Steno Diabetes Center Sjaelland', 'class': 'OTHER_GOV'}, {'name': 'University College Copenhagen', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The term sexual (SD) dysfunction covers conditions that prevent people from having a satisfactory sex life. SD is a frequent and sometimes debilitating complication of mental illness and a known adverse reaction to psycho-pharmacological treatment. SD is also associated with diabetes, a common somatic comorbidity in psychiatric patients. SD is associated with both reduced quality-of-life and reduced treatment adherence, yet SD is far too rarely addressed between the patient and the healthcare professional in clinical consultations.\\n\\nThe purpose of the study is to investigate whether targeted education of patients with schizophrenia and diabetes/prediabetes and/or their healthcare professionals in causes and management of SD:\\n\\n* Increases the number of systematic examinations of sexual side effects,\\n* Causes changes in the psycho-pharmacological treatment, and\\n* Reduces the severity or perception of sexual side effects.\\n\\nThe study is a multicenter Randomized Controlled Trial (RCT) with four arms, in which the educational intervention is provided to patients, healthcare professionals, or both groups. The effect of the educational intervention is compared to a non-educated control group. The study is expected to include 192 patients recruited from 16 assertive community treatment centers evenly distributed in four Danish regions.\\n\\nThe study is part of an interdisciplinary project named SECRET. The educational intervention was developed in an ethnographic pre-study incorporating stakeholder engagement. Parallel to the present RCT, an ethnographic field study will be carried out to broaden the perspective on the effects of the intervention.'}, 'conditionsModule': {'conditions': ['Schizophrenia', 'Schizophrenia Spectrum and Other Psychotic Disorders', 'Diabetes Mellitus', 'PreDiabetes', 'Sexual Dysfunction', 'Drug-Related Side Effects and Adverse Reactions', 'Education'], 'keywords': ['Randomized Controlled Trial', 'Treatment Adherence and Compliance', 'Antipsychotic Agents', 'Patient Education as Topic']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 256, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'INT1: Only patients are educated', 'type': 'EXPERIMENTAL', 'interventionNames': ['Behavioral: Educational intervention']}, {'label': 'INT2: Only Healthcare Professionals are educated', 'type': 'EXPERIMENTAL', 'interventionNames': ['Behavioral: Educational intervention']}, {'label': 'INT3: Both patients and Healthcare Professionals are educated', 'type': 'EXPERIMENTAL', 'interventionNames': ['Behavioral: Educational intervention']}, {'label': 'Control', 'type': 'NO_INTERVENTION'}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Educational intervention', 'description': 'Different teaching sessions are used for patients and healthcare professionals, respectively.\\n\\nThe teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.\\n\\nThe topics of the teaching sessions are:\\n\\n* What is sexuality?\\n* How psychopharmacology influences sexuality\\n* What can be done?\\n\\nThe topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences.', 'armGroupLabels': ['INT1: Only patients are educated', 'INT2: Only Healthcare Professionals are educated', 'INT3: Both patients and Healthcare Professionals are educated']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Changes from baseline to follow up in the total score of Changes in Sexual Function Questionnaire-14 (CSFQ-14)', 'description': 'Measured by Changes in Sexual Function Questionnaire-14 (CSFQ-14)', 'timeFrame': 'At inclusion and at follow-up, i.e. 6 months after the educational intervention is finished.'}], 'secondaryOutcomes': [{'measure': 'Changes in psycho-pharmacological treatment', 'description': 'Estimated by changes in prescribed medications', 'timeFrame': 'Recorded continuously throughout the entire study period, i.e. from the day of the educational intervention to 6 months after the end of the educational intervention.'}, {'measure': 'The frequency in which sexual issues are discussed in the clinical consultation', 'description': 'The number of systematic examinations of sexual side effects estimated by the number of consultations where sexual side effects are addressed, and whether it is the patient or the healthcare professional, who addresses the subject.', 'timeFrame': 'Recorded continuously throughout the entire study period, i.e. from the day of the educational intervention to 6 months after the end of the educational intervention.'}, {'measure': 'Changes from baseline to follow up in compliance / Adherence to the Pharmacological Treatment', 'description': 'Measured by Rating of Medication Influences (ROMI) Scale', 'timeFrame': 'At inclusion and at follow-up, i.e. 6 months after the educational intervention is finished.'}, {'measure': 'Changes from baseline to follow up in shared decision making', 'description': 'Measured by Shared Decision Making-9 (SDM) measurement tool', 'timeFrame': 'At inclusion and at follow-up, i.e. 6 months after the educational intervention is finished.'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Age ≥ 18 years\\n* A diagnosis in the schizophrenic spectrum (ICD10 F2x)\\n* One of the following:\\n\\n  1. A diagnosis of diabetes (ICD10 E10x, E11x, E12x, E13x, 14x)\\n  2. A current or previous prediabetes defined as an HbA1c between 39-47 mmol/mol (both included) measured in at least two blood samples collected with ≥3 months intervals as part of the patient's routine clinical monitoring\\n  3. Obesity defined as a Body-Mass Index (BMI) ≥30 kg/m2\\n* Ongoing treatment with at least one antipsychotic agent\\n* A SD that can be rated using Changes in Sexual Function Questionnaire-14 (CSFQ-14)\\n\\nExclusion Criteria:\\n\\n* Incapacitated or subject to mental health probation\\n* Unable to speak danish\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Gesche Jürgens, Clinical Professor', 'role': 'CONTACT', 'phone': '+45-93566501', 'email': 'gju@regionsjaelland.dk'}, {'name': 'Rikke Meyer, MD', 'role': 'CONTACT', 'phone': '+45-20419810', 'email': 'rikme@regionsjaelland.dk'}], 'overallOfficials': [{'name': 'Gesche Jürgens, Clinical Professor', 'affiliation': 'Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark', 'role': 'STUDY_CHAIR'}, {'name': 'Annamaria Giraldi, Clinical Professor', 'affiliation': 'Sexological Clinic, Psychiatric Centre Copenhagen, Denmark', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Lise Tarnow, MD, DMSc', 'affiliation': 'Steno Diabetes Center Sjaelland, Denmark', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Charlotte Bredahl Jacobsen, Senior Researcher, PhD.', 'affiliation': 'Institute of Social Work, University College Copenhagen, Copenhagen, Denmark', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Rikke Meyer, MD', 'affiliation': 'Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Assertive Community Centres', 'status': 'RECRUITING', 'city': 'Slagelse', 'country': 'Denmark', 'contacts': [{'name': 'Rikke Meyer, MD', 'role': 'CONTACT', 'phone': '+45-20419810'}], 'geoPoint': {'lat': 55.40276, 'lon': 11.35459}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D011236', 'term': 'Prediabetic State'}, {'id': 'D018149', 'term': 'Glucose Intolerance'}, {'id': 'D064420', 'term': 'Drug-Related Side Effects and Adverse Reactions'}, {'id': 'D012559', 'term': 'Schizophrenia'}, {'id': 'D011618', 'term': 'Psychotic Disorders'}, {'id': 'D019967', 'term': 'Schizophrenia Spectrum and Other Psychotic Disorders'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D006943', 'term': 'Hyperglycemia'}, {'id': 'D064419', 'term': 'Chemically-Induced Disorders'}], 'browseLeaves': [{'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M14117', 'name': 'Prediabetic State', 'asFound': 'Prediabetes', 'relevance': 'HIGH'}, {'id': 'M20295', 'name': 'Glucose Intolerance', 'asFound': 'Prediabetes', 'relevance': 'HIGH'}, {'id': 'M14473', 'name': 'Psychotic Disorders', 'asFound': 'Psychotic Disorders', 'relevance': 'HIGH'}, {'id': 'M15376', 'name': 'Schizophrenia', 'asFound': 'Schizophrenia', 'relevance': 'HIGH'}, {'id': 'M30303', 'name': 'Drug-Related Side Effects and Adverse Reactions', 'asFound': 'Drug-Related Side Effects and Adverse Reactions', 'relevance': 'HIGH'}, {'id': 'M21838', 'name': 'Schizophrenia Spectrum and Other Psychotic Disorders', 'asFound': 'Schizophrenia Spectrum and Other Psychotic Disorders', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M9994', 'name': 'Hyperglycemia', 'relevance': 'LOW'}, {'id': 'M30302', 'name': 'Chemically-Induced Disorders', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC25', 'name': 'Substance Related Disorders'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M16904', 'name': 'Antipsychotic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'}, {'abbrev': 'PsychDr', 'name': 'Psychotropic Drugs'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00505960', 'orgStudyIdInfo': {'id': 'R34DK071957', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/R34DK071957'}, 'organization': {'fullName': 'Johns Hopkins University', 'class': 'OTHER'}, 'briefTitle': 'Culturally Tailored Behavioral Diabetes Care Intervention for Korean Americans', 'officialTitle': 'Diabetes Care for Korean Americans'}, 'statusModule': {'statusVerifiedDate': '2010-12', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2007-09'}, 'primaryCompletionDateStruct': {'date': '2008-09', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2008-09', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2007-07-20', 'studyFirstSubmitQcDate': '2007-07-20', 'studyFirstPostDateStruct': {'date': '2007-07-25', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2010-12-20', 'lastUpdatePostDateStruct': {'date': '2010-12-21', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Miyong T. Kim', 'oldOrganization': 'The Johns Hopkins University'}, 'leadSponsor': {'name': 'Johns Hopkins University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to assess the feasibility and efficacy of a culturally-tailored, comprehensive behavioral intervention program specially designed for linguistically challenged ethnic minority immigrant populations (Korean Americans) with type 2 DM.', 'detailedDescription': 'Korean American immigrants (KAI), one of the most underserved and understudied minority populations in the U.S., suffer from diabetes, which goes under-diagnosed, inadequately treated and has a potential to result in costly and tragic consequences. Language barriers, the lack of self-confidence, and diminished social support that accompany the acculturation process prevent KAI from improving their health-seeking behaviors. Our previous research has indicated that overwhelming numbers of KAI suffer not only from uncontrolled hyperglycemia but also from a loss of self-confidence and social isolation because of language and cultural barriers. They are in urgent need of an intervention to assist them in their efforts to achieve better glycemic control and restore their self-confidence in diabetes and health management so that they are able to adjust successfully in this new environment. Therefore, The purpose of this study is to assess the feasibility and efficacy of a culturally-tailored, comprehensive behavioral intervention program specially designed for linguistically challenged KAIs with type 2 DM.\\n\\nThis pilot project will test the hypothesis: Compared to KAI in the control group, KAI with type 2 DM who receive a comprehensive DM management intervention through structured psycho-behavioral education, home glucose monitoring with a telephone transmission system, and interaction with a bilingual nurse case manager will show: (1) a greater level of glucose control; and (2) a greater level of self-help skills including knowledge related to glucose control, problem-solving skills, heightened confidence and mood/affect, adherence to treatment recommendations, and quality of life. An additional outcome will be to measure and obtain an ideal BP as the proposed intervention focuses on management of multiple risk factors with which many KA DM patients often struggle.'}, 'conditionsModule': {'conditions': ['Diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1', 'type': 'EXPERIMENTAL', 'interventionNames': ['Behavioral: Diabetes Care for Korean Americans']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Diabetes Care for Korean Americans', 'description': 'Intervention group participants receive a 6-week in-class education offered by trained nurses, followed by home glucose monitoring with monthly nurse telephone counseling.', 'armGroupLabels': ['1']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1c', 'description': 'The primary outcome varialbe is hemoglobin A1c level of the study participants to assess the status of blood gluocse management and control during previous 2-3 months.', 'timeFrame': '30 Weeks'}], 'secondaryOutcomes': [{'measure': 'BP control', 'timeFrame': '30 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Self-identified as a first generation Korean American\\n* Age 30 years or older\\n* Resides in Washington-Baltimore area\\n* Expresses willingness to participate in all aspects of the study over its full course\\n* Written consent to participate in the screening/eligibility visit\\n* Self-identified with DM and HbA1c \\\\>= 8% within 6 months of screening\\n* Written consent to participate in the clinical trial: agreeing to participate in study data collection procedures, receiving DM self -help education, using HGMT, and permitting contact with their own medical care provider.\\n\\nExclusion Criteria:\\n\\n* Unable to give informed consent\\n* Physical or mental health conditions that could limit active participation in the study (e.g., blindness in both eyes, severe immobility, psychiatric diseases)\\n* Hematological condition that would affect A1C assay, e.g., hemolytic anemia, sickle cell anemia.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '30 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Miyong T Kim, PhD', 'affiliation': 'Johns Hopkins University School of Nursing', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Korean Resource Center', 'city': 'Ellicott City', 'state': 'Maryland', 'zip': '20143', 'country': 'United States', 'geoPoint': {'lat': 39.26733, 'lon': -76.79831}}]}, 'referencesModule': {'references': [{'pmid': '20651099', 'type': 'BACKGROUND', 'citation': 'Song HJ, Han HR, Lee JE, Kim J, Kim KB, Nguyen T, Kim MT. Translating current dietary guidelines into a culturally tailored nutrition education program for Korean American immigrants with type 2 diabetes. Diabetes Educ. 2010 Sep-Oct;36(5):752-61. doi: 10.1177/0145721710376328. Epub 2010 Jul 22.'}, {'pmid': '19934458', 'type': 'RESULT', 'citation': 'Kim MT, Han HR, Song HJ, Lee JE, Kim J, Ryu JP, Kim KB. A community-based, culturally tailored behavioral intervention for Korean Americans with type 2 diabetes. Diabetes Educ. 2009 Nov-Dec;35(6):986-94. doi: 10.1177/0145721709345774.'}, {'pmid': '22080707', 'type': 'DERIVED', 'citation': 'Nam S, Han HR, Song HJ, Song Y, Kim KB, Kim MT. Utility of a point-of-care device in recruiting ethnic minorities for diabetes research with community partners. J Health Care Poor Underserved. 2011 Nov;22(4):1253-63. doi: 10.1353/hpu.2011.0117.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00676260', 'orgStudyIdInfo': {'id': 'AD4833/EC412'}, 'secondaryIdInfos': [{'id': 'U1111-1114-1082', 'type': 'REGISTRY', 'domain': 'WHO'}], 'organization': {'fullName': 'Takeda', 'class': 'INDUSTRY'}, 'briefTitle': 'Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin', 'officialTitle': 'Effect of Pioglitazone 15 mg or 30 mg on Microcirculation in Type 2 Diabetes Patients Treated With Insulin'}, 'statusModule': {'statusVerifiedDate': '2012-02', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2002-12'}, 'primaryCompletionDateStruct': {'date': '2004-08', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2004-08', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2008-05-09', 'studyFirstSubmitQcDate': '2008-05-09', 'studyFirstPostDateStruct': {'date': '2008-05-13', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2012-02-27', 'lastUpdatePostDateStruct': {'date': '2012-02-28', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Takeda', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to measure microcirculation in type 2 diabetes patients with peripheral edema who are taking pioglitazone, once daily (QD).', 'detailedDescription': 'Pioglitazone is a thiazolidinedione compound with a mode of action as a peroxisome proliferator-activated receptor gamma agonist. Activation of this receptor causes increased transcriptional activity at a number of locations that are important to carbohydrate and lipid (fat) metabolism. Insulin resistance is reversed by enhancing the action of insulin, thereby promoting glucose utilization in peripheral tissues, suppressing gluconeogenesis in the liver, and reducing lipolysis at the adipocyte.\\n\\nIn previous studies of pioglitazone, peripheral edema (swelling in the hands, feet, and legs) was reported as an adverse event more often in pioglitazone groups and appears to be a dose dependent phenomenon with pioglitazone. The incidence of peripheral edema in monotherapy studies was 3.2% in pioglitazone patients compared with 0.7% placebo patients and was reported more by females than males. This incidence was higher when pioglitazone was combined with sulphonylurea or insulin (5.9% and 15.6%, respectively). In comparison, the incidence of edema, when sulphonylurea or insulin was combined with placebo, was 2.1% and 7.5%, respectively.\\n\\nThis study is designed to identify the mechanisms underlying peripheral edema formation with pioglitazone in patients with Type 2 diabetes.\\n\\nIndividuals who participate in this study will provide written informed consent and will be required to commit to a screening visit and approximately 4 additional visits at the study center. Study participation is anticipated to be about 10 to 12 weeks (or approximately 3 months). Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, physical examinations and electrocardiograms.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus'], 'keywords': ['Glucose Metabolism Disorder', 'Dysmetabolic Syndrome', 'Type II Diabetes', 'Diabetes Mellitus', 'Lipoatrophic', 'Dyslipidemia', 'Drug Therapy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 29, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Pioglitazone QD', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Pioglitazone']}, {'label': 'Placebo QD', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Pioglitazone', 'description': 'Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks', 'armGroupLabels': ['Pioglitazone QD'], 'otherNames': ['Actos', 'AD4833']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks', 'armGroupLabels': ['Placebo QD']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Capillary filtration capacity.', 'timeFrame': 'Final Visit'}], 'secondaryOutcomes': [{'measure': 'Isovolumetric venous pressure.', 'timeFrame': 'Final Visit'}, {'measure': 'Capillary pressure.', 'timeFrame': 'Final Visit'}, {'measure': 'Postural vasoconstriction.', 'timeFrame': 'Final Visit'}, {'measure': 'Maximum blood flow.', 'timeFrame': 'Final Visit'}, {'measure': 'Capillary recruitment.', 'timeFrame': 'Final Visit'}, {'measure': '24-hour ambulatory blood pressure.', 'timeFrame': 'Final Visit'}, {'measure': 'Interleukin-6', 'timeFrame': 'Final Visit'}, {'measure': 'C-Reactive Protein.', 'timeFrame': 'Final Visit'}, {'measure': 'Vascular Endothelium Growth Factor.', 'timeFrame': 'Final Visit'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Stable glycemic control glycosylated hemoglobin between 6.5 and 10%) in the two months prior to the study.\\n* Type 2 diabetes treated by diet and stable dose of insulin (alone or with metformin) in the three months prior to the study.\\n* Female patients must have been postmenopausal, had a hysterectomy, or were surgically sterilized.\\n\\nExclusion Criteria:\\n\\n* Has Type 1 diabetes.\\n* Has an episode of hypoglycemia requiring medical assistance three months prior to the study.\\n* Has peripheral artery disease (including Raynaud's syndrome) confirmed by an Ankle Brachial Pressure Index less than 0.9.\\n* Has severe chronic venous insufficiency as evidenced by venous ulceration or subcutaneous serum deposits.\\n* Has vascular autoimmune disease, had received a renal transplant, or were receiving dialysis.\\n* Has had heart failure (New York Heart Association I to IV), left ventricular hypertrophy evident from the ECG, or myocardial infarction 12 months prior to start of study.\\n* Has Subject had uncontrolled hypertension or familial polyposis coli.\\n* Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:\\n\\n  * Non steroidal anti-inflammatory Drugs (except for aspirin at anti-aggregant doses), oral anti-diabetic drugs (except metformin), calcium-channel blockers, and diuretics at anti-edema doses are excluded from the study.\\n  * Treatment with systemic corticosteroids within four weeks prior to enrolment and during the study was not allowed.\\n  * Patients who have taken beta-blockers are to have been on a stable dose for four weeks before entry in the study.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '40 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Medical Director', 'affiliation': 'Takeda', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'city': 'Exeter', 'country': 'United Kingdom', 'geoPoint': {'lat': 50.7236, 'lon': -3.52751}}]}, 'referencesModule': {'references': [{'pmid': '16508777', 'type': 'RESULT', 'citation': 'Tooke JE, Elston LM, Gooding KM, Ball CI, Mawson DM, Piper J, Sriraman R, Urquhart R, Shore AC. The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin. Diabetologia. 2006 May;49(5):1064-70. doi: 10.1007/s00125-006-0168-9. Epub 2006 Mar 1.'}], 'seeAlsoLinks': [{'label': 'ACTOS® Package Insert', 'url': 'http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&fileTypeCode=ACTOSPI'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'}, {'id': 'M26181', 'name': 'Dyslipidemias', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077205', 'term': 'Pioglitazone'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M1693', 'name': 'Pioglitazone', 'asFound': '/min', 'relevance': 'HIGH'}, {'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05416060', 'orgStudyIdInfo': {'id': 'MISP-60691'}, 'secondaryIdInfos': [{'id': 'MISP-60691', 'type': 'OTHER_GRANT', 'domain': 'Merck'}], 'organization': {'fullName': 'Scripps Whittier Diabetes Institute', 'class': 'OTHER'}, 'briefTitle': 'Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age', 'officialTitle': 'Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age', 'acronym': 'Dulce Digital'}, 'statusModule': {'statusVerifiedDate': '2024-05', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-03-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-11-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2024-11-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-06-06', 'studyFirstSubmitQcDate': '2022-06-10', 'studyFirstPostDateStruct': {'date': '2022-06-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-05-29', 'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Scripps Whittier Diabetes Institute', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The proposed research, \"Dulce Digital 2.0,\" will evaluate two mHealth adaptions of Project Dulce that are designed to improve digital health literacy, increase underserved individuals\\' capacity to access and engage with vital digital health information, and in turn, improve clinical and behavioral outcomes in at-risk adults with diabetes. Expanding access to care in populations faced with challenges of low socioeconomic status and health literacy is a step toward reducing health disparities and positively affecting care. The literature shows that identifying which groups of participants are most likely to benefit from telehealth interventions is an important factor in improving the evidence base for digital health literacy. Dulce Digital 2.0 is highly scalable once the technical infrastructure is built. More importantly, by helping to reduce existing inequities in access to diabetes care and accurate digital health information the model could help to improve health outcomes on a larger scale. The use of digital technology in the delivery of healthcare interventions is increasingly common. Barriers to engagement in digital technology exist among those in underserved populations due to language, access to equipment and internet, education level, exposure to and comfort with technology, and pre-existing deficits in health literacy. The proposed research will investigate the effectiveness of two digital approaches to improving the self-management and digital health skills of underserved participants with diabetes compared to tradition in-person self-management education: 1) live self-management education, traditional in-person classes; 2) live self-management education using a telehealth distance learning platform; and 3) a series of text-based messages, not requiring a smart phone or internet connection, that encourage healthy self-management behaviors.', 'detailedDescription': 'Diabetes self-management education using digital platforms including, telehealth group visits, text-based messages and live delivery will result in improvements in diabetes health behaviors, patient engagement, health literacy and HbA1c.\\n\\nDiabetes disproportionately affects racial and ethnic communities. The investigator developed Project Dulce, an American Diabetes Association-recognized and Medicare-approved Diabetes Self-Management Education and Support (DSME/S) program addresses the needs of a racially and ethnically diverse San Diego population and includes a multi-disciplinary team with peer educators delivering DSME/S. Previous trials have shown Project Dulce team-care improves clinical management and reduces costs and that the peer education alone improves clinical outcomes in Hispanics with Type 2 Diabetes across 10 months.\\n\\nMobile health (mHealth) technologies represent a viable way to overcome many of these barriers and extend the reach of DSME/S to participants who need it most.\\n\\nDuring the coronavirus disease (COVID-19) pandemic, Project Dulce was adapted for group telehealth settings and delivered via the electronic medical record (EMR) scheduling system. Additionally, a previously developed text messaging platform-Dulce Digital was offered to extend the reach of the care team through educational and motivational messaging, medication reminders, and blood glucose monitoring prompts. A previous randomized controlled trial of Dulce Digital demonstrated a significant reduction of HbA1c across 10 months versus usual care in Hispanics with diabetes. While live Project Dulce and Dulce Digital programs have demonstrated improvements in clinical and cost outcomes in Hispanic patients, a comparative analysis of live, group telehealth and text messaging programs has not been done. This study will assess a direct comparison of each of these modalities to explore the feasibility, acceptance, and effectiveness of each delivery modality across Hispanic communities living with type 2 diabetes.'}, 'conditionsModule': {'conditions': ['Diabetes Type 2'], 'keywords': ['Diabetes', 'Health Education', 'mHealth Technology', 'Group Education', 'Telehealth', 'Text-Based']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'This is a three-arm, non-blinded, randomized, controlled, parallel-groups, comparative effectiveness trial with N=150 participants.\\n\\nThe protocol was developed in accordance with Good Clinical Practice, SPIRIT, and CONSORT 2013 guidelines.', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'SINGLE', 'maskingDescription': 'This is a three-arm, non-blinded, randomized, controlled, parallel-groups, comparative effectiveness trial with N=150 participants.', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 150, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Dulce Digital', 'type': 'EXPERIMENTAL', 'description': 'Patients will participate in a text-based diabetes self-management educational and support (DSME/S) program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.', 'interventionNames': ['Behavioral: Dulce Digital Text-Based Education']}, {'label': 'Project Dulce Telehealth DSME/S', 'type': 'EXPERIMENTAL', 'description': 'Patients will participate in live a peer-led Telehealth diabetes self-management education and support program.', 'interventionNames': ['Behavioral: Project Dulce Telehealth']}, {'label': 'Project Dulce Live DSME/S', 'type': 'EXPERIMENTAL', 'description': 'Patients will participate in live a peer-led Telehealth diabetes self-management education and support program.', 'interventionNames': ['Behavioral: Project Dulce Live']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Dulce Digital Text-Based Education', 'description': 'Participants will be enrolled in the digital texting platform, Dulce Digital in which they will receive on-going support via text messages for 6 months, derived from the Project Dulce curriculum. Topics include medication reminders, motivational prompts, nutrition and stress reduction tips and request to submit weekly blood glucose numbers.', 'armGroupLabels': ['Dulce Digital']}, {'type': 'BEHAVIORAL', 'name': 'Project Dulce Telehealth', 'description': 'Project Dulce will consist of a group-based telehealth diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.', 'armGroupLabels': ['Project Dulce Telehealth DSME/S']}, {'type': 'BEHAVIORAL', 'name': 'Project Dulce Live', 'description': 'Project Dulce will consist of a group-based diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.', 'armGroupLabels': ['Project Dulce Live DSME/S']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from Baseline in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 3 months', 'description': 'Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 3 months; % Units HbA1c is measure of blood sugar level and assessed using blood samples following a 12-hour fast. Samples will be process by Quest Diagnostics Inc and assayed by Immunoturbidimetry (integra 800, Roche). Higher is worse.', 'timeFrame': '3 months'}, {'measure': 'Change from Baseline in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months', 'description': 'Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months; % Units HbA1c is measure of blood sugar level and assessed using blood samples following a 12-hour fast. Samples will be process by Quest Diagnostics Inc and assayed by Immunoturbidimetry (integra 800, Roche). Higher is worse.', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Change from Baseline Diabetes Distress (DDS-17) at 3 months', 'description': 'The Diabetes Distress Scale (DDS-17) is a self-report instrument for adults with type 2 diabetes. The scaled yields an overall distress score based on the average of response on the 1-6 scale for all 17 items. The DDS-17 identifies three levels of specificity of diabetes distress information for use in clinical care, from overall emotional distress related to diabetes to highly specific sources of diabetes distress. Higher score is worse.', 'timeFrame': '3 months'}, {'measure': 'Change from Baseline Diabetes Distress (DDS-17) at 6 months', 'description': 'The Diabetes Distress Scale (DDS-17) is a self-report instrument for adults with type 2 diabetes. The scaled yields an overall distress score based on the average of response on the 1-6 scale for all 17 items. The DDS-17 identifies three levels of specificity of diabetes distress information for use in clinical care, from overall emotional distress related to diabetes to highly specific sources of diabetes distress.', 'timeFrame': '6 months'}, {'measure': 'Change from Baseline Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 3 months', 'description': 'The DTSQ scale has been shown to be useful in clinical trials evaluation of new technologies and has been used as one outcome indicator in routine audit diabetes care. It is composed of 8 questions, scored by patients on a scale ranging from 0 (\"very dissatisfied\", \"very inconvenient\") to 6 (\"very satisfied\", \"very convenient\"). It is composed of 2 factors. The first factor assesses treatment satisfaction (6 questions). These questions ask about \"satisfaction with current treatment\", \"flexibility\", \"convenience\", \"understanding of diabetes\", \"recommend treatment to others\" and \"willingness to continue\", respectively. The second factor (2 questions) which assess the burden from hyper- and hypoglycemia, respectively (0 \"none of the time\" to 6 \"most of the time\"). Treatment satisfaction is assessed as the sum of scores of 6 questions on the first factor (total score 36). A higher score indicates higher treatment satisfaction.', 'timeFrame': '3 months'}, {'measure': 'Change from Baseline Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 6 months', 'description': 'The DTSQ scale has been shown to be useful in clinical trials evaluation of new technologies and has been used as one outcome indicator in routine audit diabetes care. It is composed of 8 questions, scored by patients on a scale ranging from 0 (\"very dissatisfied\", \"very inconvenient\") to 6 (\"very satisfied\", \"very convenient\"). It is composed of 2 factors. The first factor assesses treatment satisfaction (6 questions). These questions ask about \"satisfaction with current treatment\", \"flexibility\", \"convenience\", \"understanding of diabetes\", \"recommend treatment to others\" and \"willingness to continue\", respectively. The second factor (2 questions) which assess the burden from hyper- and hypoglycemia, respectively (0 \"none of the time\" to 6 \"most of the time\"). Treatment satisfaction is assessed as the sum of scores of 6 questions on the first factor (total score 36). A higher score indicates higher treatment satisfaction.', 'timeFrame': '6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Hispanic/Latino adults who are registered patients of Scripps Health\\n* Diagnosis of Type 2 Diabetes\\n* HbA1c greater than or equal to 8% within the last 60 days\\n\\nExclusion Criteria:\\n\\n* Severe illness precluding visits to clinic\\n* Liver function tests (ALT and AST) \\\\> 3 times the upper limit of normal\\n* Body mass index ≤ 23 kg/cm\\n* History of malignancy, except subjects who have been disease-free for \\\\>2 years, or whose only malignancy has been basal or squamous cell skin carcinoma\\n* Creatinine \\\\>3.5\\n* History of drug or alcohol abuse within 12 months prior to randomization\\n* Current enrollee in DSME/S\\n* Blood donation of one pint or more within the past 30 days, or plasma donation within 7 days prior to screening\\n* Anemia\\n* Lack of minimal literacy needed to participate in the text intervention\\n* Severe auditory or visual problems\\n* Primary language other than Spanish or English\\n* Not willing to carry a mobile phone\\n* Pregnant\\n* Plans to relocate', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Athena Philis-Tsimikas, MD', 'role': 'CONTACT', 'phone': '858-678-7046', 'email': 'philis-tsimikas.athena@scrippshealth.org'}, {'name': 'Monica Ruiz, MA', 'role': 'CONTACT', 'phone': '858-678-7049', 'email': 'ruiz.monica@scrippshealth.org'}], 'overallOfficials': [{'name': 'Athena Philis-Tsimikas, MD', 'affiliation': 'Scripps Health', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Scripps Chula Vista Diabetes Center', 'status': 'RECRUITING', 'city': 'Chula Vista', 'state': 'California', 'zip': '91910', 'country': 'United States', 'contacts': [{'name': 'Athena Philis-Tsimikas, MD', 'role': 'CONTACT', 'phone': '858-678-7046'}, {'name': 'Monica Ruiz, MA', 'role': 'CONTACT', 'phone': '858-678-7049'}], 'geoPoint': {'lat': 32.64005, 'lon': -117.0842}}, {'facility': 'Scripps Whittier Diabetes Institute', 'status': 'RECRUITING', 'city': 'San Diego', 'state': 'California', 'zip': '92121', 'country': 'United States', 'contacts': [{'name': 'Athena Philis-Tsimikas, MD', 'role': 'CONTACT', 'phone': '858-678-7046'}, {'name': 'Monica Ruiz, MA', 'role': 'CONTACT', 'phone': '858-678-7049'}], 'geoPoint': {'lat': 32.71533, 'lon': -117.15726}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00398060', 'orgStudyIdInfo': {'id': 'KTL223-3'}, 'organization': {'fullName': 'Finnish Institute for Health and Welfare', 'class': 'OTHER_GOV'}, 'briefTitle': 'GOAL Life-Style Change Intervention to Prevent Type 2 Diabetes', 'officialTitle': 'GOAL Life-Style Change Implementation Intervention to Prevent Type 2 Diabetes in Primary Health Care'}, 'statusModule': {'statusVerifiedDate': '2008-02', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2003-01'}, 'primaryCompletionDateStruct': {'date': '2004-12', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2007-03', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2006-11-09', 'studyFirstSubmitQcDate': '2006-11-09', 'studyFirstPostDateStruct': {'date': '2006-11-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2008-02-13', 'lastUpdatePostDateStruct': {'date': '2008-02-14', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Senior researcher Pilvikki Absetz', 'oldOrganization': 'National Public Health Institute'}, 'leadSponsor': {'name': 'Finnish Institute for Health and Welfare', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'Academy of Finland', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Life-style change achieved in controlled experimental condition has been shown to prevent type 2 diabetes. The purpose of this study is to evaluate to what extent the life-style change can be achieved in a routine health care setting.', 'detailedDescription': 'The GOAL (Good Ageing in Lahti region) Program Life-style change implementation trial to prevent type 2 diabetes was set to examine and enhance the effectiveness of life-style change counselling in the primary health care. In the intervention, specific nutritional, physical activity and weight loss objectives shown effective in diabetes prevention in an earlier randomised controlled trial are used as a benchmark, embedded in a structured group counselling model with an empowerment-oriented approach and adapted into the primary health care setting. In the trial, effectiveness and process are evaluated, the analyses including gender and socio-economic differences. Participants were 361 middle-aged (50-65 yrs) adults at an increased risk for type 2 diabetes, recruited in 16 primary health care centres in Paijat-Hame, Finland. Intervention and data collection took place in year 2003.'}, 'conditionsModule': {'conditions': ['Obesity', 'Type 2 Diabetes'], 'keywords': ['life-style counseling', 'type 2 diabetes', 'prediabetes', 'physical activity', 'diet', 'cognitive-behavioral']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 389, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'A', 'type': 'EXPERIMENTAL', 'interventionNames': ['Behavioral: Cognitive-behavioral life-style counseling']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Cognitive-behavioral life-style counseling', 'armGroupLabels': ['A']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Nutrition (fat, fiber)', 'timeFrame': '0-1 years'}, {'measure': 'Physical activity', 'timeFrame': '0-3 years'}, {'measure': 'Weight', 'timeFrame': '0-3 years'}], 'secondaryOutcomes': [{'measure': 'Waist circumference', 'timeFrame': '0-3 years'}, {'measure': 'Plasma glucose (fasting, 2 hr challenge)', 'timeFrame': '0-3 years'}, {'measure': 'Serum lipids', 'timeFrame': '0-3 years'}, {'measure': 'Blood pressure (diastolic, systolic)', 'timeFrame': '0-3 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Type 2 diabetes risk test score \\\\> 11 (Lindstrom \\\\& Tuomilehto, 2003)\\n\\nExclusion Criteria:\\n\\n* mental health problem or substance abuse likely to interfere with participation\\n* acute cancer\\n* type 2 diabetes requiring pharmacological treatment\\n* myocardial infarction during the past six months', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '50 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Antti Uutela, PhD', 'affiliation': 'National Public Health Institute', 'role': 'STUDY_DIRECTOR'}, {'name': 'Pilvikki Absetz, PhD', 'affiliation': 'National Public Health Institute', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Martti Talja, PhD', 'affiliation': 'Päijät Häme Central Hospital', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Päijät-Häme Hospital District', 'city': 'Lahti', 'zip': '15850', 'country': 'Finland', 'geoPoint': {'lat': 60.98267, 'lon': 25.66151}}]}, 'referencesModule': {'references': [{'pmid': '14683570', 'type': 'BACKGROUND', 'citation': 'Uutela A, Absetz P, Nissinen A, Valve R, Talja M, Fogelholm M. Health psychological theory in promoting population health in Paijat-Hame, Finland: first steps toward a type 2 diabetes prevention study. J Health Psychol. 2004 Jan;9(1):73-84. doi: 10.1177/1359105304036103.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'}, {'id': 'M14117', 'name': 'Prediabetic State', 'relevance': 'LOW'}, {'id': 'M20295', 'name': 'Glucose Intolerance', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04274660', 'orgStudyIdInfo': {'id': '2S01-058 DWELL'}, 'secondaryIdInfos': [{'id': '10065G00484', 'type': 'OTHER', 'domain': 'Canterbury Christ Church University'}], 'organization': {'fullName': 'Canterbury Christ Church University', 'class': 'OTHER'}, 'briefTitle': 'Evaluation of Diabetes and WELLbeing Programme', 'officialTitle': 'Evaluation of the Diabetes and WELLbeing (DWELL) Programme for People With Type 2 Diabetes', 'acronym': 'DWELL'}, 'statusModule': {'statusVerifiedDate': '2023-02', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2017-09-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-12-31', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2022-12-31', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2020-02-05', 'studyFirstSubmitQcDate': '2020-02-17', 'studyFirstPostDateStruct': {'date': '2020-02-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-13', 'lastUpdatePostDateStruct': {'date': '2024-02-14', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Canterbury Christ Church University', 'class': 'OTHER'}, 'collaborators': [{'name': 'Medway Community Healthcare', 'class': 'UNKNOWN'}, {'name': 'Blackthorn Trust', 'class': 'UNKNOWN'}, {'name': 'Arteveldehogeschool', 'class': 'UNKNOWN'}, {'name': 'Kinetic Analysis', 'class': 'UNKNOWN'}, {'name': 'Centre Hospitalier de Douai', 'class': 'OTHER'}, {'name': 'The Health and Europe Centre', 'class': 'UNKNOWN'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"This study evaluates the impact of 'DWELL' - a 12-week psycho-social education programme designed to help people with type 2 diabetes to better self-manage their condition. Up to 600 patients will participate in the programme, while a non-intervention group will receive routine care for their diabetes\", 'detailedDescription': 'The DWELL (Diabetes and WELLbeing) 12-week programme has been designed to incorporate specific elements of diabetes education and is underpinned by motivational interviewing to ensure it is tailored to individuals. Each of the four elements of the programme - education, nutrition, physical activity and wellbeing - have been carefully selected based on previous research into diabetes education. The Canterbury Christ Church University (CCCU) DWELL Team are responsible for the evaluation of DWELL, which will explore whether the combination of the programme elements is effective in improving self-management. Additionally, a process evaluation and cost effectiveness analysis will be conducted alongside participant outcomes\\n\\nThe programme will be delivered at five sites (two in the UK, one in Belgium, one in France, one in the Netherlands). The CCCU DWELL research team will be responsible for quality assurance, management and analysis of data, sample size assessment and reporting of adverse events. Each delivery site is responsible for adhering to their own Standard Operating Procedures.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes', 'Type 2 Diabetes Treated With Insulin']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'FACTORIAL', 'interventionModelDescription': 'Participants will be invited to take part in the 12-week DWELL Programme (the intervention) based on their eligibility as per the inclusion criteria. They will all receive the psycho-social education element in addition to two motivational interviews. Each element will be evaluated alone and in combination.\\n\\nThe non-intervention group will be recruited in one of two ways - they will either be people with type 2 diabetes who do not wish to participate in the 12-week programme, or they are receiving routine care (which, for UK participants, is a locally commissioned 6-week programme).', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 594, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'DWELL Intervention', 'type': 'EXPERIMENTAL', 'description': 'People with type 2 diabetes participating in the 12-week DWELL (Diabetes and WELLbeing) Programme', 'interventionNames': ['Behavioral: DWELL (Diabetes and WELLbeing) Programme']}, {'label': 'DWELL non-intervention/Control', 'type': 'NO_INTERVENTION', 'description': 'People with type 2 diabetes who are receiving routine care from their GP and healthcare team. People with type 2 diabetes will continue to receive routine standard care. Routine care in this respect constitutes usual health and social care or any other nationally or locally commissioned education programmes'}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'DWELL (Diabetes and WELLbeing) Programme', 'description': '12-week psychoeducational programme', 'armGroupLabels': ['DWELL Intervention']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in diabetes self-management as assessed by the Diabetes Self-Care Activities Measure', 'description': 'Changes in self-management and self-care will be measured using the Diabetes Self-Care Activities Measure at four time points. The SDSCA assesses aspects of the diabetes regimen. Higher scores indicate greater taking of prescribed medication and undertaking footcare regime.', 'timeFrame': 'Baseline, end of programme (3 months), 6 months after programme, 12 months after programme'}], 'secondaryOutcomes': [{'measure': 'Change in quality of life as assessed by the Short Form Health Survey (SF-12)', 'description': 'Changes in health related quality of life will be measured using the Short Form Health Survey (SF-12) at four time points. SF-12 measures eight health domains to assess physical health (min 6, max 20 - higher scores indicate better physical health) and mental health (min 6, max 24 - higher scores indicate better mental health)', 'timeFrame': 'Baseline, end of programme (3 months), 6 months after programme, 12 months after programme'}, {'measure': 'Change in levels of physical activity as assessed by the International Physical Activity Questionnaire (IPAQ)', 'description': 'Changes in levels of physical activity will be measured using the International Physical Activity Questionnaire (IPAQ) at four time points. IPAQ collects information on physical activity participation in three domains as well as sedentary behaviour. There is no min or max score - participants indicate how much exercise they do per week which is converted into MET minutes. Greater MET minutes indicate greater levels of physical activity.', 'timeFrame': 'Baseline, end of programme (3 months), 6 months after programme, 12 months after programme'}, {'measure': 'Change in illness perception as assessed by the Illness Perception Questionnaire (IPQ-R)', 'description': \"Changes in perception and attitudes towards type 2 diabetes will be measured using the Illness Perception Questionnaire (IPQ-R) at four time points. IPQ-R measures an individual's beliefs and feelings about their illness. The IPQ-R is split into 7 sub-scales: Timeline (min 6, max 30 - higher scores indicate participants expect diabetes to last longer); Consequences (min 6, max 30 - higher scores indicate perceived worse consequences of diabetes); Personal Control (min 6, max 30 - higher scores indicate higher perceived control over diabetes); Treatment Control (min 5, max 25 - higher scores indicate higher perceived effect of treatment); Illness Coherence (min 5, max 25 - higher scores indicate better perceived understanding of illness); Timeline Cyclical (min 4, max 20 - higher scores indicate greater unpredictability of diabetes symptoms); Emotional Representations (min 6, max 30 - higher scores indicate more negative emotions associated with diabetes)\", 'timeFrame': 'Baseline, end of programme (3 months), 6 months after programme, 12 months after programme'}, {'measure': 'Change in psychosocial self-efficacy as assessed by the Diabetes Empowerment Scale (DES-SF)', 'description': 'Changes in self-efficacy will be measured using the Diabetes Empowerment Scale (DES-SF) at four time points. DES-SF measures changes in psychosocial self-efficacy. Minimum score is 8, max is 40. Higher scores indicate greater sense of empowerment to self-manage condition.', 'timeFrame': 'Baseline, end of programme (3 months), 6 months after programme, 12 months after programme'}, {'measure': 'Change in eating behaviour as assessed by the Dutch Eating Behaviour Questionnaire (DEBQ)', 'description': 'Changes in eating behaviour will be measured using the Dutch Eating Behaviour Questionnaire (DEBQ) at four time points. DEBQ assesses three distinct eating behaviours in adults: Emotional Eating (min 10, max 50 - higher scores indicate the patient makes more effort to restrain eating) ; External Eating (min 13, max 65 - higher scores indicate patient eats more for emotional reasons); Restrained Eating (min 10, max 50 - higher scores indicate more motivated to eat by external factors, such as the smell and look of food)', 'timeFrame': 'Baseline, end of programme (3 months), 6 months after programme, 12 months after programme'}, {'measure': 'Change in Body Mass Index (BMI) as assessed by height and weight', 'description': 'Changes in height and weight will be combined to report BMI in kg/m\\\\^2 where a lower score indicates an improvement for this outcome', 'timeFrame': 'Baseline, end of programme (3 months), 6 months after programme, 12 months after programme'}, {'measure': 'Change in waist circumference', 'description': 'Changes in waist circumference will be measured and reported in cm where a lower measurement indicates an improvement for this outcome', 'timeFrame': 'Baseline, end of programme (3 months), 6 months after programme, 12 months after programme'}, {'measure': 'Change in average blood glucose levels as assessed by Hemoglobin A1c levels (HbA1c)', 'description': 'Changes in blood glucose (sugar) levels will be assessed by reports of HbA1c blood test results, where a lower score indicates improvement in this outcome', 'timeFrame': 'Baseline, end of programme (3 months), 6 months after programme, 12 months after programme'}, {'measure': 'Quality Adjusted Life Years (QALYs)', 'description': 'Health related quality of life will be measured using the EuroQol Five Dimensions (EQ-5D-5L). The EQ-5D contains 5 sub-scales with a min score of 1 and max score of 3. Higher scores indicate worse mobility, worse ability to self-care, worse ability to perform usual activities, more pain and more anxiety. Utility values will also be multiplied by the time spent in each state to generate QALYs. 1 QALY is equivalent to perfect health while less than perfect health carries a QALY between 0 and 1. The higher the number of QALYs gained the better the health outcomes for people living with type 2 diabetes.', 'timeFrame': '2.5 years'}, {'measure': 'Cost effectiveness', 'description': 'The cost of Quality Adjusted Life Years (QALYs) of people with type 2 diabetes in the intervention group will be compared with the control group to illustrate cost effectiveness of the DWELL Programme', 'timeFrame': '2.5 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Clinical diagnosis of type 2 diabetes\\n* Over the age of 18\\n\\nExclusion Criteria:\\n\\n* Under the age of 18\\n* Pregnant women\\n* Individuals who do not have the mental capacity to participate', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Eleni Hatzidimitriadou, PhD', 'affiliation': 'Canterbury Christ Church University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Arteveldehogeschool', 'city': 'Ghent', 'zip': '9000', 'country': 'Belgium', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'facility': 'Centre Hosptalier Douai', 'city': 'Douai', 'zip': '59507', 'country': 'France', 'geoPoint': {'lat': 50.36667, 'lon': 3.06667}}, {'facility': 'Kinetic Analysis', 'city': 'Breda', 'state': \"'s-Hertogenbosch\", 'zip': '5211 DA', 'country': 'Netherlands', 'geoPoint': {'lat': 51.58656, 'lon': 4.77596}}, {'facility': 'Medway Community Healthcare', 'city': 'Gillingham', 'state': 'Kent', 'zip': 'ME8 0PZ', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.38914, 'lon': 0.54863}}, {'facility': 'Blackthorn Trust', 'city': 'Maidstone', 'state': 'Kent', 'zip': 'ME16 9AN', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.26667, 'lon': 0.51667}}]}, 'referencesModule': {'references': [{'type': 'BACKGROUND', 'citation': 'Hatzidimitriadou, E., Manship, S., Thompson, T., Morris, R., Moore, J. and Hulbert, S. 2023. Evalatuation study of the diabetes and welbeing (DWELL) - Report 1: Evaluation methodology. Canterbury, UK Canterbury Christ Church University.'}, {'type': 'BACKGROUND', 'citation': 'Hatzidimitriadou, E., Manship, S., Thompson, T., Morris, R., Moore, J., Hulbert, S. and Saloniki, E.-C. 2023. Evaluation study of diabetes and wellbeing (DWELL) - Report 2: Participant outcomes. Canterbury, UK Canterbury Christ Church University.'}, {'type': 'BACKGROUND', 'citation': 'Hatzidimitriadou, E., Manship, S., Thompson, T., Morris, R., Moore, J. and Hulbert, S. 2023. Evaluation study of Diabetes and Wellbeing (DWELL) - Report 3: Process evaluation. Canterbury Canterbury Christ Church University.'}, {'type': 'BACKGROUND', 'citation': 'Hatzidimitriadou, E., Manship, S., Thompson, T., Morris, R., Moore, J., Hulbert, S. and Saloniki, E.-C. 2023. Evaluation study of diabetes and wellbeing (DWELL) - Report 4: Workforce training and cost effectiveness. Canterbury. UK Canterbury Christ Church University.'}], 'seeAlsoLinks': [{'label': 'Evaluation study of diabetes and wellbeing (DWELL) - Report 4: Workforce training and cost effectiveness', 'url': 'https://repository.canterbury.ac.uk/item/95w32/evaluation-study-of-diabetes-and-wellbeing-dwell-report-4-workforce-training-and-cost-effectiveness'}, {'label': 'Hatzidimitriadou, E., Manship, S., Thompson, T., Morris, R., Moore, J. and Hulbert, S. 2023. Evaluation study of Diabetes and Wellbeing (DWELL) - Report 3: Process evaluation. Canterbury Canterbury Christ Church University.', 'url': 'https://repository.canterbury.ac.uk/item/95w31/evaluation-study-of-diabetes-and-wellbeing-dwell-report-3-process-evaluation'}, {'label': 'Hatzidimitriadou, E., Manship, S., Thompson, T., Morris, R., Moore, J., Hulbert, S. and Saloniki, E.-C. 2023. Evaluation study of diabetes and wellbeing (DWELL) - Report 2: Participant outcomes. Canterbury, UK Canterbury Christ Church University.', 'url': 'https://repository.canterbury.ac.uk/item/95w2z/evaluation-study-of-diabetes-and-wellbeing-dwell-report-2-participant-outcomes'}, {'label': 'Evalatuation study of the diabetes and welbeing (DWELL) - Report 1: Evaluation methodology', 'url': 'https://repository.canterbury.ac.uk/item/95w2x/evalatuation-study-of-the-diabetes-and-welbeing-dwell-report-1-evaluation-methodology'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Anonymous participant data relating to results in publications with regards to primary and secondary outcome measures will be shared through publishing platforms. Anonymised individual participant datasets may be shared via a suitable public data repository. A final report of the evaluation study will be made available via the Canterbury Christ Church University DWELL Project web page.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'], 'timeFrame': 'It is anticipated that the study protocol will be published in a suitable academic journal by 31 December 2020. Individual participant data sets relating to the study will be made available via an appropriate data repository starting 6 months after formal publication of results.\\n\\nThe final report of the evaluation study will be available on Canterbury Christ Church University DWELL Project web page by 31 March 2023.', 'accessCriteria': 'Anonymised participant data sets relating to publications will be shared through the control measures of the publishing journals, such as full access to subscribers.'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02413060', 'orgStudyIdInfo': {'id': '42500653-9'}, 'organization': {'fullName': 'Huashan Hospital', 'class': 'OTHER'}, 'briefTitle': 'The Impact of Resistance Training on Type 2 Diabetes Patients.'}, 'statusModule': {'statusVerifiedDate': '2015-10', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ENROLLING_BY_INVITATION', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2015-03'}, 'primaryCompletionDateStruct': {'date': '2016-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2016-03', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2015-03-26', 'studyFirstSubmitQcDate': '2015-04-08', 'studyFirstPostDateStruct': {'date': '2015-04-09', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-10-13', 'lastUpdatePostDateStruct': {'date': '2015-10-14', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Yiming Li', 'investigatorTitle': 'Department of endocrinology', 'investigatorAffiliation': 'Huashan Hospital'}, 'leadSponsor': {'name': 'Huashan Hospital', 'class': 'OTHER'}}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine whether the long-term effects of high-intensity progressive resistance training could improve glucose and lipid metabolism in chinese type 2 diabetes.'}, 'conditionsModule': {'conditions': ['Diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 400, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Resistance training', 'type': 'EXPERIMENTAL', 'description': 'Patients of treatment group will undergo resistance training every week sessions', 'interventionNames': ['Other: Resistance training', 'Behavioral: Lifestyle counselling']}, {'label': 'Lifestyle counseling', 'type': 'OTHER', 'description': 'Patients of control group will get the lifestyle counseling every 3 month', 'interventionNames': ['Behavioral: Lifestyle counselling']}], 'interventions': [{'type': 'OTHER', 'name': 'Resistance training', 'description': 'This training consists 4 exercises and every exercises lasts 5 seconds.', 'armGroupLabels': ['Resistance training']}, {'type': 'BEHAVIORAL', 'name': 'Lifestyle counselling', 'description': 'Lifestyle counselling mainly indicates dietary instruction.', 'armGroupLabels': ['Lifestyle counseling', 'Resistance training']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1c', 'timeFrame': 'up to six months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* established type 2 diabetes\\n\\nExclusion Criteria:\\n\\n* severe joint cardiovascular and respiratory system disease, uncontrolled hypertension (160/90 mmHg), severe diabetic nephropathy and neuropathy\\n* with severe liver and kidney dysfunction\\n* with mental system disease\\n* pregnant women or nursing mothers', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Cao jia du community health service centre', 'city': 'Shanghai', 'state': 'Shanghai', 'country': 'China', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03880760', 'orgStudyIdInfo': {'id': 'CMUH107-REC2-036'}, 'organization': {'fullName': 'China Medical University Hospital', 'class': 'OTHER'}, 'briefTitle': 'The Effect of Probiotics on Type 1 Diabetes Mellitus in Children', 'officialTitle': 'The Effect of Probiotics on Type 1 Diabetes Mellitus in Children'}, 'statusModule': {'statusVerifiedDate': '2021-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-08-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-10-31', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2021-01-31', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2019-03-13', 'studyFirstSubmitQcDate': '2019-03-18', 'studyFirstPostDateStruct': {'date': '2019-03-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-08-02', 'lastUpdatePostDateStruct': {'date': '2021-08-04', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Chung-Hsing Wang', 'investigatorTitle': 'Attending physician', 'investigatorAffiliation': 'China Medical University Hospital'}, 'leadSponsor': {'name': 'China Medical University Hospital', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'In this study, investigators try to administer probiotics (Lactobacillus salivarius + Lactobacillus johnsonii + Bifidobacterium lactis from glac biotech Co., Ltd.) to children T1DM patients for 6 months to observe if the inhibition effect of T1DM animal model could be discerned in a short-term period from both change of serum cytokines and beta cells insulin secretion ability.', 'detailedDescription': 'Type 1 (insulin-dependent) Diabetes Mellitus (T1DM) is among the most well studied organ-specific autoimmune diseases which approximately 75% of newly diagnosed DM patients acquire this type before the age of 18. T1DM is well known for as the consequence of selective destruction of pancreatic insulin-producing beta cells within the islets of Langerhans. Basically, autoimmune reactions against beta cells may come from activation of the immune system in genetically susceptible individuals triggered by environmental factors that bear epitopes similar to those expressed by the beta cells. Several mechanisms such as molecular mimicry, metabolic stress on beta cells, cryptic epitope exposure and costimulatory molecule upregulation have been proposed but none of them could be solely responsible for the pathogenesis of T1DM. Recently, T1DM has been considered a consequence of dysregulated or over-activation of immune responses in genetically predisposed individuals, similar to other autoimmune diseases.\\n\\nThe rapid increase in the incidence of T1DM in developed countries including Taiwan during recent decades refers to the role of environmental factors in this disease. Candidate environmental factors influencing T1DM include various microbial and food components encountered at mucosal surfaces as well as gut mucosal parameters such as gut permeability. However, difficulty exists in characterizing the environmental factors and mechanisms in T1DM because of their complexity of interaction, the long lag period between the induction of disease trigger factors and the clinical onset of the disease. Environmental factors in T1DM seem to prevent full penetration of the disease rather than trigger it. It had been reported that high diabetes incidence in germ-free mice and an involvement of innate immune mechanisms in the disease. In this study, investigators try to administer probiotics (Lactobacillus salivarius + Lactobacillus johnsonii + Bifidobacterium lactis from glac biotech Co., Ltd.) to children T1DM patients for 6 months to see if the inhibition effect of T1DM animal model could be discerned in a short-term period from both change of serum cytokines and beta cells insulin secretion ability.\\n\\nSubjects will collect blood before the test and every 3 months after the test for total 4 times. Each time the collected blood volume is about 5\\\\~8cc. A part of the blood sample will be given to the Department of laboratory medicine for the detection of hemoglobin A1c (HbA1c) and fasting blood glucose, and the other part will be centrifuged to separate serum. The serum macrophage inflammatory proteins-1beta (MIP-1β), regulated on activation, normal T cell expressed and secreted (RANTES), interleukin-8 (IL-8), interleukin-17 (IL-17), tumor necrosis factor alpha (TNF-α) and transforming growth factor beta1 (TGF-β1) concentrations will be measured by ELISA.'}, 'conditionsModule': {'conditions': ['Type 1 Diabetes Mellitus'], 'keywords': ['T1DM', 'Autoimmune diseases', 'Microbiota', 'Probiotics']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Probiotics or placebo group', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 64, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Probiotics capsule', 'type': 'EXPERIMENTAL', 'description': 'Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.', 'interventionNames': ['Other: L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32']}, {'label': 'Placebo capsule', 'type': 'PLACEBO_COMPARATOR', 'description': 'Taking 1 placebo capsule twice a day before meals for six months.', 'interventionNames': ['Other: Placebo']}], 'interventions': [{'type': 'OTHER', 'name': 'L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32', 'description': 'Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.', 'armGroupLabels': ['Probiotics capsule']}, {'type': 'OTHER', 'name': 'Placebo', 'description': 'Taking 1 placebo capsule twice a day before meals for six months.', 'armGroupLabels': ['Placebo capsule']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in percentage of HbA1c', 'description': 'Subjects will draw blood once before the test. During the test, every 3 months will draw blood to 6th month, each time the blood volume is about 5 \\\\~ 8cc to detect HbA1c and other blood biochemical values.', 'timeFrame': 'From date of first blood draw after entering the trial until the date of third blood draw, assessed up to 6 months.'}, {'measure': 'Change in concentration of blood glucose (AC)', 'description': 'The study will require subject to record their own daily fasting blood glucose.', 'timeFrame': 'From date of first blood draw after entering the trial until the date of third blood draw, assessed up to 6 months.'}], 'secondaryOutcomes': [{'measure': 'Change in concentration of MIP-1β', 'description': 'Serum was isolated by extra blood draw, serum MIP-1β (pg/ml) concentrations were measured from first blood draw to third blood draw by ELISA.', 'timeFrame': 'From date of first blood draw after entering the trial until the date of third blood draw, assessed up to 6 months.'}, {'measure': 'Change in concentration of RANTES', 'description': 'Serum was isolated by extra blood draw, serum RANTES (pg/ml) concentrations were measured from first blood draw to third blood draw by ELISA.', 'timeFrame': 'From date of first blood draw after entering the trial until the date of third blood draw, assessed up to 6 months.'}, {'measure': 'Change in concentration of IL-8', 'description': 'Serum was isolated by extra blood draw, serum IL-8 (pg/ml) concentrations were measured from first blood draw to third blood draw by ELISA.', 'timeFrame': 'From date of first blood draw after entering the trial until the date of third blood draw, assessed up to 6 months.'}, {'measure': 'Change in concentration of IL-17', 'description': 'Serum was isolated by extra blood draw, serum IL-17 (pg/ml) concentrations were measured from first blood draw to third blood draw by ELISA.', 'timeFrame': 'From date of first blood draw after entering the trial until the date of third blood draw, assessed up to 6 months.'}, {'measure': 'Change in concentration of TNF-α', 'description': 'Serum was isolated by extra blood draw, serum TNF-α (pg/ml) concentrations were measured from first blood draw to third blood draw by ELISA.', 'timeFrame': 'From date of first blood draw after entering the trial until the date of third blood draw, assessed up to 6 months.'}, {'measure': 'Change in concentration of TGF-β1', 'description': 'Serum was isolated by extra blood draw, serum TGF-β1 (pg/ml) concentrations were measured from first blood draw to third blood draw by ELISA.', 'timeFrame': 'From date of first blood draw after entering the trial until the date of third blood draw, assessed up to 6 months.'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Age between 6 to 18 years old.\\n2. T1DM patients confirmed by glucagon tests and/or presence of autoantibody(ies).\\n\\nExclusion Criteria:\\n\\n1. Significant cardiac, renal and hepatic disease.\\n2. The physician diagnosed the immunodeficiency or the immune function was low.\\n3. Currently using probiotics supplements or had ever taken probiotics for more than one month.\\n4. Currently using antibiotics or gastrointestinal medicine.\\n5. Ever allergic reaction(s) to probiotics or prebiotics regimen.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '6 Years', 'maximumAge': '18 Years', 'stdAges': ['CHILD', 'ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Hung-chih Lin', 'affiliation': 'China Medical University Hospital', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'China Medical University Hospital', 'city': 'Taichung', 'zip': '40447', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}]}, 'referencesModule': {'references': [{'pmid': '35299968', 'type': 'DERIVED', 'citation': 'Wang CH, Yen HR, Lu WL, Ho HH, Lin WY, Kuo YW, Huang YY, Tsai SY, Lin HC. Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus. Front Endocrinol (Lausanne). 2022 Mar 1;13:754401. doi: 10.3389/fendo.2022.754401. eCollection 2022.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03363360', 'orgStudyIdInfo': {'id': 'DM20161201'}, 'organization': {'fullName': 'Second Affiliated Hospital of Nanchang University', 'class': 'OTHER'}, 'briefTitle': 'Comprehensive Awareness and Control in Diabetes Patients in China Jiangxi: A Cross-Sectional Survey', 'officialTitle': 'Comprehensive Awareness and Control in Diabetes Patients in China Jiangxi: A Cross-Sectional Survey'}, 'statusModule': {'statusVerifiedDate': '2017-11', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2016-12-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2018-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2017-11-30', 'studyFirstSubmitQcDate': '2017-11-30', 'studyFirstPostDateStruct': {'date': '2017-12-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-11-30', 'lastUpdatePostDateStruct': {'date': '2017-12-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'YunFeng Shen', 'investigatorTitle': 'professor', 'investigatorAffiliation': 'Second Affiliated Hospital of Nanchang University'}, 'leadSponsor': {'name': 'Second Affiliated Hospital of Nanchang University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The study is a multicenter, sub-center contrast, cross-sectional survey.The primary objective of this study was to assess the Comprehensive Awareness and Control of blood glucose, blood pressure, and blood lipids among patients with type 2 diabetes in China Jiangxi. An additional objective was to investigate the impact of hospital type on clinical outcomes.', 'detailedDescription': \"Background: With the continuous improvement of living standards in the past 30 years, the lifestyle and diet of Chinese people have undergone significant changes, leading to a significant increase in the prevalence of diabetes, hypertension and lipid metabolism disorders. Prevention and control work is also increasingly valued. At present, there is no research on the awareness rates and control rates of blood glucose, blood pressure and blood lipids in diabetic patients in Jiangxi Province. During the 13th Five-Year Plan period, the country has vigorously promoted the grading system of chronic non-communicable diseases, but there is a big gap between the levels of disease management in different levels of hospitals.\\n\\nMethods:The province's multi-center, sub-center control, cross-sectional survey, the number of cases planned to be included in 10000 cases. Patient Access: Within 2 years from the date of the study (December 2016), eligible patients were screened out of outpatients in the participating hospitals, and patients were reviewed and informed of the informed consent.Inclusion criteria: in line with the WHO1999 diabetes diagnostic criteria; age 20-80 years; duration of 1 year or more; signed informed consent. Exclusion criteria: at the same time using other experimental drugs or in other clinical trials; gestational diabetes, other special types of diabetes; in acute infection, trauma and other stress conditions and the acute phase of the disease and other anomalies; patients with malignant tumors.\"}, 'conditionsModule': {'conditions': ['To Assess the Level of Control of Blood Glucose, Blood Pressure, and Blood Lipids Among Patients With Type 2 Diabetes in Jiangxi Province']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '1 Day', 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 2000, 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1c', 'description': 'HbA1c \\\\<7%', 'timeFrame': 'The first 30 days or seven days after the visit'}, {'measure': 'TC', 'description': 'TC\\\\<5.2mmol/L', 'timeFrame': 'The first 30 days or seven days after the visit'}, {'measure': 'TG', 'description': 'TG\\\\<1.7mmol/L', 'timeFrame': 'The first 30 days or seven days after the visit'}, {'measure': 'LDL-C', 'description': 'LDL-C\\\\<3.3mmol/L', 'timeFrame': 'The first 30 days or seven days after the visit'}, {'measure': 'HDL-C', 'description': 'HDL-C\\\\>1.0mmol/L', 'timeFrame': 'The first 30 days or seven days after the visit'}], 'secondaryOutcomes': [{'measure': 'blood pressure', 'description': 'systolic blood pressure \\\\<130 mm Hg, diastolic blood pressure \\\\<80 mm Hg', 'timeFrame': 'On the day of the visit'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients aged 20 years to 80 years who were diagnosed with diabetes according to the World Health Organization criteria, at least 1 years before screening,written informed consent\\n\\nExclusion Criteria:\\n\\n* Patients if they were pregnant or Other special types of diabetes, Patients with malignant tumor,participating in any other clinical studies, In phase of acute infection, trauma, such as stress state and acute phase of disease and other anomalies', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '20 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': '20 to 80 - year - old diabetic patients', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Shen YunFeng, professor', 'role': 'CONTACT', 'phone': '18970819455', 'email': '1359112481@qq.com'}, {'name': 'Wang Jun', 'role': 'CONTACT', 'phone': '15797727918', 'email': '1359112481@qq.com'}], 'locations': [{'facility': 'No.1MinDeRoad', 'status': 'RECRUITING', 'city': 'Nanchang', 'state': 'Jiangxi', 'zip': '341000', 'country': 'China', 'contacts': [{'name': 'Shen YenFeng, professor', 'role': 'CONTACT', 'phone': '18970819455', 'email': '1359112481@qq.com'}], 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'In the form of a paper published based on the results of the study', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR', 'ANALYTIC_CODE'], 'timeFrame': 'Within 1 years of completion of the study', 'accessCriteria': 'Researchers who need the results of this study'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'T4202', 'name': 'Oculocerebral Syndrome With Hypopigmentation', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04166760', 'orgStudyIdInfo': {'id': 'TAKE4'}, 'organization': {'fullName': 'University of Aarhus', 'class': 'OTHER'}, 'briefTitle': 'Metabolic Effects of Whey Compounds in Patients With Diabetes Mellitus Type 2.', 'officialTitle': 'Metabolic Effects of Whey Compounds in Patients With Diabetes Mellitus Type 2.'}, 'statusModule': {'statusVerifiedDate': '2019-11', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2020-01-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-06-17', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2020-06-24', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2019-11-14', 'studyFirstSubmitQcDate': '2019-11-14', 'studyFirstPostDateStruct': {'date': '2019-11-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-11-05', 'lastUpdatePostDateStruct': {'date': '2020-11-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'University of Aarhus', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The main objective of our study is to investigate the metabolic effects of a i) ordinary whey protein (WHE) and ii) a specific whey protein fraction (speWHE) when the interventions are ingested by patients with type 2 diabetes 30 minutes prior to an oral glucose tolerance test (OGTT). We will also investigate the glucose response when the patients ingest the interventions at home in their own environment 30 minutes before breakfast and dinner (2days) and also monitor glucose levels without interventions (2 days).'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'interventionModelDescription': 'Double blinded, randomized, crossover design', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 16, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'WHE (regular whey protein)', 'type': 'ACTIVE_COMPARATOR', 'description': \"Regular whey protein. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.\", 'interventionNames': ['Dietary Supplement: WHE']}, {'label': 'speWHE (specific whey protein compound)', 'type': 'EXPERIMENTAL', 'description': \"Specific whey protein compound. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.\", 'interventionNames': ['Dietary Supplement: speWHE']}], 'interventions': [{'type': 'DIETARY_SUPPLEMENT', 'name': 'speWHE', 'description': '25 gram of a specific whey fraction (confidential)', 'armGroupLabels': ['speWHE (specific whey protein compound)']}, {'type': 'DIETARY_SUPPLEMENT', 'name': 'WHE', 'description': '25 gram protein of a regular whey compound', 'armGroupLabels': ['WHE (regular whey protein)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Difference in iAUC for insulin between WHE and speWHE', 'description': 'Difference in iAUC for insulin between WHE and speWHE', 'timeFrame': 'OGTT, 3 hours.'}], 'secondaryOutcomes': [{'measure': 'Differences in iAUC and concentration differences for GIP', 'timeFrame': 'OGTT 3 hours'}, {'measure': 'Differences in iAUC and concentration differences for GLP-1', 'timeFrame': 'OGTT 3 hours'}, {'measure': 'Differences in iAUC and concentration differences for glucagon', 'timeFrame': 'OGTT 3 hours'}, {'measure': 'Differences in iAUC and concentration differences for glucose', 'timeFrame': 'OGTT 3 hours'}, {'measure': 'Differences in iAUC and concentration differences for C-peptid', 'timeFrame': 'OGTT 3 hours'}, {'measure': 'Differences in iAUC and concentration differences for FFA', 'timeFrame': 'OGTT 3 hours'}, {'measure': 'Activity measurements', 'timeFrame': '5 days'}, {'measure': 'continuous glucose measurement (CGM)', 'description': 'CGM with time in normal range 4-10 mmol/l, peak after a meal, AUC in the days with the interventions.', 'timeFrame': '5 days'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Age \\\\> 18 years\\n* Type 2 diabetes (T2D) diagnosis\\n* No medical treatment or metformin/sulfonylureas(SU) alone in the treatment of T2D\\n* No daily use of protein drinks\\n* Hba1c between 40 mmol/mol and 69 mmol/mol\\n* 20 kg/m2 \\\\< BMI \\\\< 35 kg/m2\\n* Screening blood test: 1200 pmol/l \\\\> C-peptid \\\\> 370 pmol/l\\n\\nExclusion Criteria:\\n\\n* Other diabetes medication than metformin/SU (e.g. insulin, GLP-1 analog, DPP-4 inhibitor, SGLT2-inhibitor)\\n* Affected screening blood test assessed by the primary investigator(PI)/sponsor\\n* Does not understand or speak danish\\n* Milk allergy\\n* PI finds the patient not fit (e.g. mental illness, too nervous or other)', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Niels Jessen, Professor', 'affiliation': 'Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital', 'city': 'Aarhus', 'country': 'Denmark', 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'T435', 'name': 'Whey Protein', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04028960', 'orgStudyIdInfo': {'id': 'A16-716'}, 'organization': {'fullName': 'HealthPartners Institute', 'class': 'OTHER'}, 'briefTitle': 'IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase', 'officialTitle': 'Intranasal Insulin: A Novel Therapy for Hypoglycemia Unawareness in Type 1 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2020-05', 'overallStatus': 'TERMINATED', 'whyStopped': 'Funding was rescinded', 'startDateStruct': {'date': '2019-10-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-04-08', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2020-04-08', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2019-07-19', 'studyFirstSubmitQcDate': '2019-07-19', 'studyFirstPostDateStruct': {'date': '2019-07-23', 'type': 'ACTUAL'}, 'resultsFirstSubmitDate': '2021-03-03', 'resultsFirstSubmitQcDate': '2021-04-26', 'resultsFirstPostDateStruct': {'date': '2021-05-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-04-26', 'lastUpdatePostDateStruct': {'date': '2021-05-18', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'HealthPartners Institute', 'class': 'OTHER'}, 'collaborators': [{'name': 'International Diabetes Center at Park Nicollet', 'class': 'OTHER'}, {'name': 'Juvenile Diabetes Research Foundation', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': True}, 'descriptionModule': {'briefSummary': \"The purpose of this study is to determine how Humulin-R regular insulin affects the body's ability to feel low blood sugar (hypoglycemia) when delivered intranasally compared to placebo in subjects with Type 1 Diabetes (T1D) with hypoglycemia awareness. The study will use continuous glucose monitoring (CGM) to collect this information. The study drug or placebo will be administered using an intranasal device.\", 'detailedDescription': 'Hypoglycemia occurs with high frequency among patients with T1D. With repeated episodes of hypoglycemia, the counter-regulatory pathways to restore normal glucose are blunted, and patients can become unaware of the hypoglycemia. It is estimated that 40% of patients with T1D have hypoglycemia unawareness.\\n\\nThe study has the following objectives:\\n\\n1. Primary:\\n\\n   a. To assess non-inferiority of dangerous hypoglycemia with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia.\\n2. Secondary:\\n\\n   1. To describe changes in overall glycemic control with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia\\n   2. To describe changes in hypoglycemia awareness with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia\\n   3. To describe changes in safety endpoints with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia.\\n3. Exploratory:\\n\\n   1. To describe changes in memory, attention and executive function with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia'}, 'conditionsModule': {'conditions': ['Type1diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 4, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'No active drug', 'interventionNames': ['Device: SipNose intranasal device']}, {'label': 'Humulin-R', 'type': 'EXPERIMENTAL', 'description': 'Insulin', 'interventionNames': ['Drug: Regular insulin (Humulin-R), intranasal route', 'Device: SipNose intranasal device']}], 'interventions': [{'type': 'DRUG', 'name': 'Regular insulin (Humulin-R), intranasal route', 'description': 'Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.', 'armGroupLabels': ['Humulin-R']}, {'type': 'DEVICE', 'name': 'SipNose intranasal device', 'description': 'The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.', 'armGroupLabels': ['Humulin-R', 'Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Time With Dangerous Hypoglycemia', 'description': 'Defined using percent time below range (\\\\<54 mg/dL), from real-time continuous glucose monitoring (CGM)', 'timeFrame': 'Two 14-20 day treatment periods'}], 'secondaryOutcomes': [{'measure': 'Percent of Time With Blood Glucose 70-180 mg/dL', 'description': 'Defined using percent of Blood Glucose 70-180 mg/dL from real-time continuous glucose monitoring (CGM)', 'timeFrame': 'Two 14-20 day treatment periods'}, {'measure': 'Percentage of Time With Blood Glucose <70 mg/dL', 'description': 'Defined using percent of Blood Glucose \\\\<70 mg/dL from real-time continuous glucose monitoring (CGM)', 'timeFrame': 'Two 14-20 day treatment periods'}, {'measure': 'Percentage of Time Blood Glucose >180 mg/dL', 'description': 'Percentage of time Blood Glucose \\\\>180 mg/dL from real-time continuous glucose monitoring (CGM)', 'timeFrame': 'Two 14-20 day treatment periods'}, {'measure': 'Percentage of Time With Blood Glucose >250 mg/dL', 'description': 'Percentage of time with Blood Glucose \\\\>250 mg/dL from real-time continuous glucose monitoring (CGM)', 'timeFrame': 'Two 14-20 day treatment periods'}, {'measure': 'Percentage of Time Participant Had Active Sensor Wear', 'description': 'Percentage of time Participant had Active Sensor Wear from real-time continuous glucose monitoring (CGM)', 'timeFrame': 'Two 14-20 day treatment periods'}, {'measure': 'Mean Glucose From the Study Participants', 'description': 'Mean Glucose from the Study Participants from real-time continuous glucose monitoring (CGM)', 'timeFrame': 'Two 14-20 day treatment periods'}, {'measure': 'Coefficient of Variation (%CV) of Blood Glucose Values From CGM Data', 'description': 'The Coefficient of variation was calculated by dividing the standard deviation of blood glucose values by the mean of the blood glucose values based on data from the corresponding CGM readings.', 'timeFrame': 'Two 14-20 day treatment periods'}, {'measure': 'Glucose Management Indicator (GMI)', 'description': 'An approximate HbA1c based upon real-time continuous glucose monitoring (CGM) values', 'timeFrame': 'Two 14-20 day treatment periods'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Adult patients (age ≥18) with type 1 diabetes diagnosis and a duration of diabetes of at least 10 years\\n* Gold score \\\\<4\\n* HbA1c ≥6.5% within the last 3 months or at screen visit\\n* Stable insulin regimen (MDI or insulin pump) for at least 3 months, as deemed stable by principal investigator\\n* Depression/anxiety medications stable for at least 3 months\\n* Ability and willingness to wear CGM continuously during study participation\\n* Participants must use their own smartphone, and have the ability and willingness to use CGM smartphone applications compatible with their smartphone\\n* Ability and willingness to check self-monitoring of blood glucose (SMBG) using own supplies, as instructed by study staff\\n* Ability and willingness to document when having symptoms of hypoglycemia in the CGM smartphone app or in a diary\\n* Willing to operate insulin pump without threshold suspend feature or hybrid closed-loop, if applicable\\n* Proficient in speaking, reading and understanding English in order to complete surveys and testing of cognitive function\\n* Women of child-bearing age must agree to procure and use contraception throughout the study\\n\\nExclusion Criteria:\\n\\n* Pregnancy or planning pregnancy\\n* eGFR ≤ 30 mL/min per 1.73 m2, if available from medical record\\n* Completed any other research study within 6 months of screening date\\n* Current or recent use within 3 months of an insulin delivery system that adjusts insulin in response to continuous glucose monitoring (CGM) data (such as an automated insulin delivery system like hybrid closed-loop insulin pump therapy)\\n* Known dementia or mild cognitive impairment diagnosis\\n* Diabetic ketoacidosis within the last 6 months\\n* Use of non-insulin medications to treat diabetes\\n* Those planning to change diet or exercise regimen during the study\\n* History of trans-sphenoidal surgery or surgery to the upper part of the nasal cavity, chronic sinusitis, severe deviated septum, or difficulty with smell and/or taste\\n* Severe psychiatric illness\\n* Allergy to adhesives, insulin or any components of insulin product\\n* Subject cannot adequately demonstrate ability to use and deploy the devices as determined by investigator\\n* Evidence of suicidality using the Columbia-Suicide Severity Rating Scale (C-SSRS)\\n* Subject has history of any of the following: moderate to severe pulmonary disease, poorly controlled congestive heart failure, significant cardiovascular and/or cerebrovascular events within previous 6 months, condition known to affect absorption, distribution, metabolism, or excretion of drugs such as any hepatic, renal or gastrointestinal disease or any other clinically relevant abnormality or illness that inclusion would pose a safety risk to the subject as determined by investigator.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Anders L Carlson, MD', 'affiliation': 'HealthPartners Institute', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Health Partners Institute dba International Diabetes Center', 'city': 'Minneapolis', 'state': 'Minnesota', 'zip': '55416', 'country': 'United States', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}]}}, 'resultsSection': {'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo, Then Humulin-R Insulin', 'description': 'Participants first received a Placebo using the SipNose device twice daily for 14-20 days. After a washout period of 2 weeks, they received Humulin-R Insulin using the SipNose device twice daily for 14-20 days.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'FG001', 'title': 'Humulin-R Insulin, Then Placebo', 'description': 'Participants first received Humulin-R Insulin using the SipNose device twice daily for 14-20 days. After a washout period of 2 weeks, they received a Placebo using the SipNose device twice daily for 14-20 days.\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'populationDescription': 'Four subjects were enrolled in the study. Two subjects started the study in the placebo arm and the other two started the study in the Humulin-R arm. During the study, each participant crossed over to the opposite arm of the study so that each subject participated in both arms of the study.', 'groups': [{'id': 'BG000', 'title': 'Placebo, Then Humulin-R Insulin', 'description': 'Participants first received a Placebo using the SipNose device twice daily for 14-20 days. After a washout period of 2 weeks, they received Humulin-R Insulin using the SipNose device twice daily for 14-20 days.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'BG001', 'title': 'Humulin-R Insulin, Then Placebo', 'description': 'Participants first received Humilin-R Insulin using the SipNose device twice daily for 14-20 days. After a washout period of 2 weeks, they received a Placebo using the SipNose device twice daily for 14-20 days.\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '4'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '64.5', 'spread': '3.5'}, {'groupId': 'BG001', 'value': '40.5', 'spread': '6.4'}, {'groupId': 'BG002', 'value': '52.5', 'spread': '14.5'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '2'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '2'}]}]}]}, {'title': 'Race (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '4'}]}, {'title': 'More than one race', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '4'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Time With Dangerous Hypoglycemia', 'description': 'Defined using percent time below range (\\\\<54 mg/dL), from real-time continuous glucose monitoring (CGM)', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'percentage of time', 'timeFrame': 'Two 14-20 day treatment periods', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'No active drug\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'OG001', 'title': 'Humulin-R', 'description': 'Insulin\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '4'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.57', 'spread': '0.73'}, {'groupId': 'OG001', 'value': '0.77', 'spread': '1.08'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percent of Time With Blood Glucose 70-180 mg/dL', 'description': 'Defined using percent of Blood Glucose 70-180 mg/dL from real-time continuous glucose monitoring (CGM)', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'percentage of time', 'timeFrame': 'Two 14-20 day treatment periods', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'No active drug\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'OG001', 'title': 'Humulin-R', 'description': 'Insulin\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '4'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '51.6', 'spread': '16.3'}, {'groupId': 'OG001', 'value': '49.5', 'spread': '22.6'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Time With Blood Glucose <70 mg/dL', 'description': 'Defined using percent of Blood Glucose \\\\<70 mg/dL from real-time continuous glucose monitoring (CGM)', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'percentage of time', 'timeFrame': 'Two 14-20 day treatment periods', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'No active drug\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'OG001', 'title': 'Humulin-R', 'description': 'Insulin\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '4'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.0', 'spread': '1.7'}, {'groupId': 'OG001', 'value': '1.6', 'spread': '1.2'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Time Blood Glucose >180 mg/dL', 'description': 'Percentage of time Blood Glucose \\\\>180 mg/dL from real-time continuous glucose monitoring (CGM)', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'percentage of time', 'timeFrame': 'Two 14-20 day treatment periods', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'No active drug\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'OG001', 'title': 'Humulin-R', 'description': 'Insulin\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '4'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '25.2', 'spread': '2.1'}, {'groupId': 'OG001', 'value': '26.3', 'spread': '4.3'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Time With Blood Glucose >250 mg/dL', 'description': 'Percentage of time with Blood Glucose \\\\>250 mg/dL from real-time continuous glucose monitoring (CGM)', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'percentage of time', 'timeFrame': 'Two 14-20 day treatment periods', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'No active drug\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'OG001', 'title': 'Humulin-R', 'description': 'Insulin\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '4'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '20.6', 'spread': '17.7'}, {'groupId': 'OG001', 'value': '21.9', 'spread': '23.6'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Time Participant Had Active Sensor Wear', 'description': 'Percentage of time Participant had Active Sensor Wear from real-time continuous glucose monitoring (CGM)', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'percentage of time', 'timeFrame': 'Two 14-20 day treatment periods', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'No active drug\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'OG001', 'title': 'Humulin-R', 'description': 'Insulin\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '4'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '92.3', 'spread': '9.2'}, {'groupId': 'OG001', 'value': '93.5', 'spread': '4.6'}]}]}]}, {'type': 'SECONDARY', 'title': 'Mean Glucose From the Study Participants', 'description': 'Mean Glucose from the Study Participants from real-time continuous glucose monitoring (CGM)', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'mg/dL', 'timeFrame': 'Two 14-20 day treatment periods', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'No active drug\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'OG001', 'title': 'Humulin-R', 'description': 'Insulin\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '4'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '188.4', 'spread': '38.9'}, {'groupId': 'OG001', 'value': '190.5', 'spread': '50.9'}]}]}]}, {'type': 'SECONDARY', 'title': 'Coefficient of Variation (%CV) of Blood Glucose Values From CGM Data', 'description': 'The Coefficient of variation was calculated by dividing the standard deviation of blood glucose values by the mean of the blood glucose values based on data from the corresponding CGM readings.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'percentage of CV', 'timeFrame': 'Two 14-20 day treatment periods', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'No active drug\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'OG001', 'title': 'Humulin-R', 'description': 'Insulin\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '4'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '40.0', 'spread': '6.5'}, {'groupId': 'OG001', 'value': '37.8', 'spread': '8.7'}]}]}]}, {'type': 'SECONDARY', 'title': 'Glucose Management Indicator (GMI)', 'description': 'An approximate HbA1c based upon real-time continuous glucose monitoring (CGM) values', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'percentage of HbA1c', 'timeFrame': 'Two 14-20 day treatment periods', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'No active drug\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}, {'id': 'OG001', 'title': 'Humulin-R', 'description': 'Insulin\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '4'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7.8', 'spread': '0.9'}, {'groupId': 'OG001', 'value': '7.9', 'spread': '1.2'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '0', 'timeFrame': '5.5 months', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo', 'description': 'No active drug\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.', 'deathsNumAffected': 0, 'deathsNumAtRisk': 4, 'seriousNumAffected': 0, 'seriousNumAtRisk': 4, 'otherNumAffected': 3, 'otherNumAtRisk': 4}, {'id': 'EG001', 'title': 'Humulin-R', 'description': 'Insulin\\n\\nRegular insulin (Humulin-R), intranasal route: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\\n\\nSipNose intranasal device: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.', 'deathsNumAffected': 0, 'deathsNumAtRisk': 4, 'seriousNumAffected': 0, 'seriousNumAtRisk': 4, 'otherNumAffected': 4, 'otherNumAtRisk': 4}], 'otherEvents': [{'term': 'Nose Bleeds', 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 3, 'numAtRisk': 4}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 4}]}, {'term': 'Nasal Irritation', 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 4}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 1, 'numAtRisk': 4}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 4}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 4}]}, {'term': 'Respiratory/Sinus Symptoms', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 1, 'numAtRisk': 4}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 4}]}]}, 'moreInfoModule': {'limitationsAndCaveats': {'description': 'The study team was unable to draw conclusions at this time regarding the cognitive testing performed due to abbreviated funding which led to a small number of subjects analyzed.'}, 'certainAgreement': {'piSponsorEmployee': True}, 'pointOfContact': {'title': 'Anders Carlson, MD', 'organization': 'HealthPartners Institute dba International Diabetes Center', 'email': 'Anders.L.Carlson@HealthPartners.Com', 'phone': '952-993-1927'}}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot_SAP', 'hasProtocol': True, 'hasSap': True, 'hasIcf': False, 'label': 'Study Protocol and Statistical Analysis Plan', 'date': '2020-04-07', 'uploadDate': '2021-03-03T14:44', 'filename': 'Prot_SAP_000.pdf', 'size': 1195384}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2021-03-29', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}, {'id': 'D007003', 'term': 'Hypoglycemia'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M10053', 'name': 'Hypoglycemia', 'asFound': 'Hypoglycemia', 'relevance': 'HIGH'}, {'id': 'M17224', 'name': 'Unconsciousness', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D007328', 'term': 'Insulin'}, {'id': 'C557859', 'term': 'Insulin, Globin Zinc'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'asFound': 'Blood vessels', 'relevance': 'HIGH'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'asFound': 'Blood vessels', 'relevance': 'HIGH'}, {'id': 'M6263', 'name': 'Coal Tar', 'relevance': 'LOW'}, {'id': 'M17768', 'name': 'Zinc', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Derm', 'name': 'Dermatologic Agents'}, {'abbrev': 'Micro', 'name': 'Micronutrients'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04155060', 'orgStudyIdInfo': {'id': 'PROMPT'}, 'organization': {'fullName': 'Shanghai Zhongshan Hospital', 'class': 'OTHER'}, 'briefTitle': 'The Prognostic Value of Lactate is Different Among Septic Patients', 'officialTitle': 'The Prognostic Value of Lactate is Different Among Septic Patients With or Without Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2020-07', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2017-04-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-04-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2019-04-01', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2019-11-05', 'studyFirstSubmitQcDate': '2019-11-05', 'studyFirstPostDateStruct': {'date': '2019-11-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-07-23', 'lastUpdatePostDateStruct': {'date': '2020-07-27', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Shanghai Zhongshan Hospital', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Early diagnosis of sepsis and identification of more severe sepsis is important to improve the outcomes .Therefore, reliable markers are required to early identify the high-risk patients. Currently, lactate is widely applied as the marker for evaluating the severity of sepsis and for outcome predicting. DM affects lactate balance and raised baseline lactate. The objective of this study was to compare the different prognostic value of admission lactate for sepsis patients with or without DM.', 'detailedDescription': 'Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Early diagnosis of sepsis and identification of more severe sepsis is important to improve the outcomes .Therefore, reliable markers are required to early identify the high-risk patients.\\n\\nCurrently, lactate is widely applied as the marker for evaluating the severity of sepsis and for outcome predicting.Nevertheless, the value of lactate for predicting sepsis is still controversial.The reasons for the different cutoff value may be due to the fact that sepsis is a heterogeneous disease which has already been defined by a number of clinical, laboratory and radiologic criteria, rather than specific pathologic findings. Therefore, we hypothesized that the discrepancy clinical value of lactate may be resulted from the heterogeneous feature of sepsis.\\n\\nDM affects lactate balance and raised baseline lactate. The objective of this study was to compare the different prognostic value of admission lactate for sepsis patients with or without DM.'}, 'conditionsModule': {'conditions': ['Sepsis', 'Diabetes Mellitus'], 'keywords': ['hyperlactatemia']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 256, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'DM group , non-DM group', 'description': 'Septic patients were divided into the DM group and non-DM group, based on their comorbidity'}, {'label': 'high lactate group,low lactate group', 'description': 'high lactate group (lactate \\\\> 2 mmol/L) and low lactate group (lactate ≤ 2 mmol/L), according to the admission lactate level.'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The primary outcome was 28-day mortality', 'timeFrame': 'up to at least 28 days'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:18 years or older, informed consent signed, admission serum lactate level obtained, and admission to the hospital with sepsis or septic shock diagnosis.\\n\\n-\\n\\nExclusion Criteria:congenital metabolic and psychiatric diseases and clinical data deficiency.\\n\\n-', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '100 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Septic patients were recruited with lactate level obtained, and admission to the intensive care unit (ICU) .', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'locations': [{'facility': '180 Fenglin Road', 'city': 'Shanghai', 'state': 'Shanghai', 'zip': '200032', 'country': 'China', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M20864', 'name': 'Sepsis', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M16869', 'name': 'Toxemia', 'relevance': 'LOW'}, {'id': 'M30645', 'name': 'Hyperlactatemia', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01427660', 'orgStudyIdInfo': {'id': '1R18HS019256-01', 'type': 'AHRQ', 'link': 'https://reporter.nih.gov/quickSearch/1R18HS019256-01'}, 'organization': {'fullName': 'University of Michigan', 'class': 'OTHER'}, 'briefTitle': 'iDecide.Decido: Diabetes Medication Decision Support Study', 'officialTitle': 'Technologically Enhanced Community Health Worker (CHW) Delivery of Personalized Diabetes Information', 'acronym': 'iDecide'}, 'statusModule': {'statusVerifiedDate': '2014-09', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2011-09'}, 'primaryCompletionDateStruct': {'date': '2013-09', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2013-10', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2011-08-31', 'studyFirstSubmitQcDate': '2011-08-31', 'studyFirstPostDateStruct': {'date': '2011-09-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2014-09-08', 'lastUpdatePostDateStruct': {'date': '2014-09-09', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Rebecca Mase', 'investigatorTitle': 'Project Manager', 'investigatorAffiliation': 'University of Michigan'}, 'leadSponsor': {'name': 'University of Michigan', 'class': 'OTHER'}, 'collaborators': [{'name': 'Agency for Healthcare Research and Quality (AHRQ)', 'class': 'FED'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Two of AHRQ \\'s consumer-focused guides, \"Pills for Type 2 Diabetes\" and \"Premixed Insulin for Type 2 Diabetes\" could be of great use to underserved ethnic and racial minority adults. The presentation of content and delivery mechanisms of these Guides, however, needs to be modified to increase their use and impact among these difficult-to-reach populations.\\n\\nTo achieve this goal, a long-standing collaboration among African American and Latino community organizations, health care centers and systems, public health organizations, and academics (the REACH Detroit Partnership) is joining with leading experts in the development of personally and culturally tailored health decision aids (University of Michigan\\'s Center for Health Communications Research \\\\[CHCR\\\\] and Center for Behavioral and Decision Sciences in Medicine \\\\[CBDSM\\\\]).\\n\\nThe investigators will develop and evaluate a computer tailored online diabetes medication decision aid that will enable community health workers (CHWs) to provide personalized patient education materials to underserved diabetic African American and Latino adults in Detroit, Michigan.', 'detailedDescription': \"The Specific Aims of this study are:\\n\\nAim 1: To use the information in the two diabetes medications consumer CERSGs to build an interactive, computer tailored diabetes medication guide that will enable patients to assess their treatment goals, personal preferences, and side-effect concerns and generate a personally tailored assessment of their current diabetes treatments with, as appropriate, options for improving their diabetes care;\\n\\nAim 2: To determine the extent to which this personally tailored diabetes medication guide compared with the print consumer guides reduces Latino and African American diabetes patients' decisional conflict, through improved knowledge of anti-hyperglycemic medications and satisfaction with information received.\\n\\nAim 3: To examine the computer tailored program's effects on participants' changes in medications (medication intensification), self-reported medication adherence and beliefs and A1C levels between baseline and follow-up compared to participants receiving the print consumer guides.\"}, 'conditionsModule': {'conditions': ['Diabetes, Type 2'], 'keywords': ['Diabetes', 'Decision Aid', 'AntiHyperglycemic Medication', 'Tailored health information', 'Medication information']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 190, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Traditional CERSG Arm', 'type': 'ACTIVE_COMPARATOR', 'description': 'CHWs will provide and review with patients language-appropriate versions of the AHRQ consumer guides. CHWs will highlight key points on each page, review information on each medication and elicit and address questions. They will use the autonomy enhancing, motivational-interviewing based skills. As with the first arm, CHWs will schedule follow-up clinic appointments for participants who note a specific treatment change they would consider and will call participants two times after the session at three and six weeks to address additional questions and to follow up on any goals the participant set.', 'interventionNames': ['Behavioral: Community Health Worker Diabetes Education: Print media']}, {'label': 'Web-Based Materials Arm', 'type': 'EXPERIMENTAL', 'description': 'Participants randomized to this arm will be scheduled within 3 weeks of enrollment to have a one-hour face-to-face session with a CHW who will deliver the ipad platform personally tailored diabetes medication decision aid. Participants will receive a printed tailored preference summary at the completion of this visit. If participants note a specific treatment change they would like to discuss with their providers, the CHW will facilitate scheduling a clinic visit within the next month. Finally, CHWs will call participants two times after the session at 3 and 6 weeks to assess if the participant has additional questions and to follow up on any treatment or other goals the participant set during their session.', 'interventionNames': ['Behavioral: CHW Diabetes Education: tailored web site']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Community Health Worker Diabetes Education: Print media', 'description': \"Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.\", 'armGroupLabels': ['Traditional CERSG Arm'], 'otherNames': ['Print Materials Arm']}, {'type': 'BEHAVIORAL', 'name': 'CHW Diabetes Education: tailored web site', 'description': \"Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.\", 'armGroupLabels': ['Web-Based Materials Arm'], 'otherNames': ['Tailored web based decision aid']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Changes in decisional conflict', 'description': \"We will be measuring subjects' perceptions of: a) uncertainty in choosing options; b) modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making; and c) effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice.\", 'timeFrame': 'baseline and 3 month post intervention'}], 'secondaryOutcomes': [{'measure': 'Medication adherence and intensification', 'description': 'Self-reported medication adherence will be assessed through three well-validated measures. We will assess changes in anti-hyperglycemic medication dosages and/or numbers of medications by patient report and medical record review.', 'timeFrame': 'baseline and 3 month post intervention'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* type 2 diabetes\\n* stated concern about diabetes and diabetes treatment\\n* poor glycemic control\\n* over 21 years of age\\n\\nExclusion Criteria:\\n\\n* blind, deaf, otherwise unable to use the telephone or visual resources\\n* pregnant\\n* currently enrolled in other REACH Detroit research study\\n* in hospice care\\n* current radiation or chemotherapy', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '21 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Michele Heisler, MD', 'affiliation': 'University of Michigan Meidcal School; Ann Arbor VA Center for Clinical Management Research,', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Community Health and Social Service (CHASS)', 'city': 'Detroit', 'state': 'Michigan', 'zip': '48209', 'country': 'United States', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}]}, 'referencesModule': {'references': [{'pmid': '25402398', 'type': 'DERIVED', 'citation': 'Heisler M, Choi H, Palmisano G, Mase R, Richardson C, Fagerlin A, Montori VM, Spencer M, An LC. Comparison of community health worker-led diabetes medication decision-making support for low-income Latino and African American adults with diabetes using e-health tools versus print materials: a randomized, controlled trial. Ann Intern Med. 2014 Nov 18;161(10 Suppl):S13-22. doi: 10.7326/M13-3012.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04556760', 'orgStudyIdInfo': {'id': 'D6470C00005'}, 'organization': {'fullName': 'AstraZeneca', 'class': 'INDUSTRY'}, 'briefTitle': 'Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes', 'officialTitle': 'A Phase 2a Randomised, Double Blind, Multi-centre Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2020-11-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-06-09', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2021-06-09', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2020-09-15', 'studyFirstSubmitQcDate': '2020-09-15', 'studyFirstPostDateStruct': {'date': '2020-09-21', 'type': 'ACTUAL'}, 'resultsFirstSubmitDate': '2022-04-28', 'resultsFirstSubmitQcDate': '2024-02-02', 'resultsFirstPostDateStruct': {'date': '2024-07-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-02', 'lastUpdatePostDateStruct': {'date': '2024-07-18', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'AstraZeneca', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Parexel', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The study is intended to assess the effect on glycaemic control of AZD9567, as measured by the glucose AUC(0-4) versus baseline following a standardised mixed meal tolerance test (MMTT), compared to prednisolone in adults with type 2 diabetes mellitus (T2DM). The study will also evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD9567.', 'detailedDescription': 'This is a randomised, double blind, multi-centre, double dummy, and two-way cross-over study.\\n\\nThere will be a total of three cohorts. Each cohort will be treated for two 72-hour periods in a cross-over design, with a 3-week washout period between treatment periods. The total length of participant engagement (from screening to follow-up) is 79 days.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2'], 'keywords': ['Type 2 Diabetes Mellitus', 'Glucose Homeostasis', 'Pharmacodynamic', 'AZD9567', 'Prednisolone']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': \"Both participants and investigators will be blinded. Investigators will remain blinded to each participant's assigned study intervention throughout the course of the study. In order to maintain this blind, a third party will be responsible for the reconstitution and dispensation of all study interventions.\", 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 46, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cohort 1', 'type': 'EXPERIMENTAL', 'description': 'Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (72 mg AZD9567 followed by 40 mg prednisolone \\\\[AB sequence group\\\\] or 40 mg prednisolone followed by 72 mg AZD9567 \\\\[BA sequence group\\\\]).', 'interventionNames': ['Drug: AZD9567', 'Drug: Prednisolone']}, {'label': 'Cohort 2', 'type': 'EXPERIMENTAL', 'description': 'Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (40 mg AZD9567 followed by 20 mg prednisolone \\\\[AB sequence group\\\\] or 20 mg prednisolone followed by 40 mg AZD9567 \\\\[BA sequence group\\\\]).', 'interventionNames': ['Drug: AZD9567', 'Drug: Prednisolone']}, {'label': 'Cohort 3', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants will be randomised in a ratio of 1:1 to receive placebo and prednisolone over two 72 hour periods in a cross over design (placebo followed by 5 mg prednisolone \\\\[AB sequence group\\\\] or 5 mg prednisolone followed by placebo \\\\[BA sequence group\\\\]).', 'interventionNames': ['Drug: Prednisolone', 'Other: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'AZD9567', 'description': 'Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.', 'armGroupLabels': ['Cohort 1', 'Cohort 2']}, {'type': 'DRUG', 'name': 'Prednisolone', 'description': 'Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.', 'armGroupLabels': ['Cohort 1', 'Cohort 2', 'Cohort 3']}, {'type': 'OTHER', 'name': 'Placebo', 'description': 'Participants will receive placebo for 3 consecutive days of each treatment period in Cohort 3.', 'armGroupLabels': ['Cohort 3']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline in Glucose Area Under the Plasma Concentration Versus Time Curve From Zero to 4 Hours Post-dose AUC(0-4)', 'description': 'The change from baseline in glucose AUC(0-4) was analysed to determine the Pharmacodynamic (PD) effect of AZD9567 compared to Prednisolone following a standardised Mixed meal tolerance test (MMTT).\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Days -1 (baseline), and Days 4 (Treatment period 1 and 2)'}], 'secondaryOutcomes': [{'measure': 'Mean Glucose Level as Determined Via the Continuous Glucose Monitoring (CGM) System', 'description': 'The mean glucose levels in mmol/L at 48-72 h was analysed to determine the effect of AZD9567 on CGM compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': '48 to 72 hours'}, {'measure': 'Rise in Mean Glucose Levels Over 24-hour Periods From Start of IMP Dosing', 'description': 'The mean glucose level in mmol/L was analysed to determine the effect of AZD9567 on CGM compared to prednisolone.\\n\\nFor the calculation of the rise in mean glucose levels, the baseline was the average of the values from -24 hours to first dosing on Day 1 of each period.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'Baseline and up to 72 hours (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline in Fasting Glucose', 'description': 'Pharmacodynamic effects (fasting glucose) of AZD9567 following a MMTT were evaluated as compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline AUC(0-4) on Hormones Related to Glucose Homeostasis (Insulin)', 'description': 'Effects of AZD9567 on insulin AUC(0-4) were assessed following MMTT compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline AUC(0-4) on Hormones Related to Glucose Homeostasis (Glucagon)', 'description': 'Effects of AZD9567 on glucagon AUC(0-4) were assessed following MMTT in comparison to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline AUC(0-4) on Hormones Related to Glucose Homeostasis (Glucagon-like Peptide-1 [GLP-1])', 'description': 'Effects of AZD9567 on GLP-1 AUC(0-4) were assessed following MMTT in comparison to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline AUC(0-4) on Hormones Related to Glucose Homeostasis (Glucose-dependent Insulin Releasing Polypeptide [GIP])', 'description': 'Effects of AZD9567 on GIP AUC(0-4) were assessed following MMTT in comparison to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline in AUC(0-4) on C-peptide', 'description': 'Effects of AZD9567 on C-peptide AUC(0-4) were assessed through a MMTT in comparison to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline in Ratio of Insulin to Glucose Level Between 10 and 0 Minutes (ΔI10/ΔG10)', 'description': 'Effects of AZD9567 on ΔI10/ΔG10 of beta cell function from the MMTT compared to Prednisolone was evaluated.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline in Ratio of Insulin to Glucose Level Between 30 and 0 Minutes [ΔI30/ΔG30])', 'description': 'Effects of AZD9567 on ΔI30/ΔG30 of beta cell function from the MMTT compared to Prednisolone was evaluated.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline in Ratio of C-peptide to Glucose Level Between 10 and 0 Minutes (ΔC10/ΔG10)', 'description': 'Effects of AZD9567 on ΔC10/ΔG10 of beta cell function from the MMTT compared to Prednisolone was evaluated.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline in Ratio of C-peptide to Glucose Level Between 30 and 0 Minutes (ΔC30/ΔG30)', 'description': 'Effects of AZD9567 on ΔC30/ΔG30 of beta cell function from the MMTT compared to Prednisolone was evaluated.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline in 24-hour Urinary Potassium Excretion', 'description': 'The concentration of potassium in urine was measured over 24 hours to determine the effect of AZD9567 on urinary potassium (U-K) excretion compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline in 24-hour Urinary Sodium Excretion', 'description': 'The concentration of sodium in urine was measured over 24 hours to determine the effect of AZD9567 on urinary-sodium (U-Na) excretion compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Quantifiable Concentration (AUClast)', 'description': 'AUClast of AZD9567 following once daily dosing was evaluated.', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours Post-dose [AUC(0-24)]', 'description': 'AUC(0-24) of AZD9567 following once daily dosing was evaluated.', 'timeFrame': '24 hours post dose'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve From Zero to 6 Hours Post-dose [AUC(0-6)]', 'description': 'AUC(0-6) of AZD9567 following once daily dosing was evaluated.', 'timeFrame': '6 hours post dose'}, {'measure': 'Maximum Observed Drug Concentration (Cmax)', 'description': 'Cmax of AZD9567 following once daily dosing was evaluated.', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)'}, {'measure': 'Time to Reach Maximum Observed Drug Concentration (Tmax)', 'description': 'Tmax of AZD9567 following once daily dosing was evaluated.', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)'}, {'measure': 'Terminal Elimination Half-life (t½λz)', 'description': 't½λz of AZD9567 following once daily dosing was evaluated.', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)'}, {'measure': 'Apparent Total Body Clearance of Drug From Plasma After Extravascular (CL/F)', 'description': 'CL/F of AZD9567 following once daily dosing was evaluated.', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)'}, {'measure': 'Apparent Volume of Distribution Following Extravascular Administration (Vz/F)', 'description': 'Vz/F of AZD9567 was derived using standard non-compartmental methods using WinNonLin version 8.1 or higher (Certara).', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)'}, {'measure': 'Tumour Necrosis Factor Alpha (TNFα) Concentrations', 'description': 'Relationship between AZD9567 exposure and inhibition of LPS-stimulated TNFα release for high and low dose comparison (Cohort 1 and Cohort 2) was assessed. LPS-stimulated TNFα concentration was measured.', 'timeFrame': 'On Days 3 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline AUC(0-4) on Hormones Related to Glucose Homeostasis (Free Fatty Acids)', 'description': 'Effects of AZD9567 on free fatty acids were evaluated following a MMTT compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline in Homeostatic Model Assessment- Insulin Resistance (HOMA-IR)', 'description': 'The HOMA-IR was calculated based on glucose and insulin measured prior to MMTT.\\n\\nHOMA-IR= Glucose(mmol/L) x Insulin (mU/L) / 22.5\\n\\nHOMA-IR score estimates the degree of insulin resistance. Higher range indicates greater insulin resistance (i.e. high diabetes risk), while lower range indicates insulin sensitivity (i.e. low diabetes risk)\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Change From Baseline in HOMA-insulin Sensitivity (HOMA-S)', 'description': 'Insulin sensitivity is a term used to indicate the responsiveness of the peripheral tissue cells to insulin, and their resultant capacity to uptake glucose out of the bloodstream.\\n\\nHOMA-S score estimates the degree of insulin sensitivity. HOMA-S was calculated as the reciprocal of HOMA-IR.\\n\\nHigher values indicates greater insulin sensitivity (i.e. low diabetes risk), while lower values indicates insulin resistance (i.e. high diabetes risk)\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)'}, {'measure': 'Number of Participants With Adverse Events', 'description': 'Safety and tolerability of AZD9567 was assessed.', 'timeFrame': 'From screening up to 79 days'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Participants with diagnosis of T2DM for 6 months prior to screening: HbA1c in the diabetes range or fasting plasma glucose 126 -220 mg/dL.\\n* On stable metformin therapy for at least 4 weeks, where no significant dose change (increase or decrease ≥ 500 mg/day) has occurred prior to screening and HbA1c 6% - 9.5%, or on dual therapy with metformin in combination with SGLT2i or DPP4i and HbA1c 6% - 8%. Participants on dual therapy will require 2 weeks wash-out of SGLT2i or DPP4i.\\n* Venous access suitable for multiple cannulations\\n* Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\\n* Female participants must be not lactating and not of childbearing potential.\\n* If sexually active, nonsterilized males who have a female partner of childbearing potential must practice effective contraceptive measures.\\n* Capable of giving signed informed consent.\\n* Provision of informed consent prior to any study specific procedures.\\n\\nExclusion Criteria:\\n\\n* History or presence of type 1 diabetes.\\n* History of severe hypoglycaemia or hypoglycaemia unawareness within the last 6 months.\\n* History or presence of diabetic foot ulcers\\n* Participants with advanced diabetic complications.\\n* History of clinically significant lactic acidosis or ketoacidosis following diagnosis with T2DM.\\n* History of, or known significant infection or positivity at Visit 1, including hepatitis A, B, or C, HIV, tuberculosis that may put the participant at risk during participation in the study.\\n* History and / or presence of COVID-19.\\n* Donation of blood (≥ 450 mL) within 3 months or donation of plasma within 14 days before Visit 1.\\n* History of or current alcohol or drug abuse (including marijuana), as judged by the investigator.\\n* Previous psychiatric disorders.\\n* Any latent, acute, or chronic infections or at risk of infection, or history of skin abscesses within 90 days prior to the first administration of investigational medicinal product (IMP) at the discretion of the investigator.\\n* History of adrenal insufficiency.\\n* History or current inflammatory disorder.\\n* Any other condition that, in the opinion of the investigator, would interfere with evaluations of the IMP or interpretation of participant safety or study results.\\n* History of severe allergy/hypersensitivity to AZD9567 or any of the excipients of the product, or ongoing clinically important allergy/hypersensitivity as judged by the investigator.\\n* Oral or parenteral steroids 8 weeks prior to randomisation and during the study. Topical and inhaled steroids 4 weeks prior to randomisation are acceptable.\\n* Use of any prohibited medication during the study or if the required washout time of such medication was not adhered to.\\n* Receipt of live or live attenuated vaccine within 4 weeks prior to the first administration of IMP.\\n* Planned in-patient surgery, major dental procedure, or hospitalisation during the study.\\n* Previous participation or participation in any other research study within 1 month prior to Visit 1.\\n* Patient treated with any investigational drug within 30 days (or 5 half-lives, whichever is longer) prior to Visit 1.\\n* Uncontrolled hypertension (BP \\\\> 160 mmHg systolic or \\\\> 95 mmHg diastolic).\\n* Diagnosis of heart failure and current symptoms regardless of definition, ie, HfpEF, HfrEF.\\n* Acute coronary syndrome / unstable angina, coronary intervention procedures (percutaneous coronary intervention or coronary artery bypass graft) within the past 6 months.\\n* Stroke within the past 3 months.\\n* QTcF \\\\> 470 ms or family history of long QT-syndrome.\\n* AV-block II-III or sinus node dysfunction with significant pause, not treated with pacemaker.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Tim Heise', 'affiliation': 'Profil Institut fur Stoffwechselforschung GmbH', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Research Site', 'city': 'Mainz', 'zip': '55116', 'country': 'Germany', 'geoPoint': {'lat': 49.98419, 'lon': 8.2791}}, {'facility': 'Research Site', 'city': 'Mannheim', 'zip': '68167', 'country': 'Germany', 'geoPoint': {'lat': 49.4891, 'lon': 8.46694}}, {'facility': 'Research Site', 'city': 'Neuss', 'zip': '41460', 'country': 'Germany', 'geoPoint': {'lat': 51.19807, 'lon': 6.68504}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'Statistical Analysis Plan (SAP)', 'url': 'https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6470C00005&amp;attachmentIdentifier=d1a10878-6b4a-4320-a661-b3f7986b52b2&amp;fileName=AZ_COMPASS_D6470C00005_(PXL_248030)_Final_Draft_SAP_Redacted.pdf&amp;versionIdentifier='}, {'label': 'Protocol', 'url': 'https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6470C00005&amp;attachmentIdentifier=f2221f84-9958-4ffd-8e89-e2f6ca7a105e&amp;fileName=AZ_COMPASS_D6470C00005_(PXL_248030)_Final_Draft_Protocol_Redacted.pdf&amp;versionIdentifier='}, {'label': 'CSR Synopsis', 'url': 'https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6470C00005&amp;attachmentIdentifier=5e02de02-bcd6-4401-ba0c-ae4becfb8118&amp;fileName=AZ_COMPASS_D6470C00005_(PXL_248030)_Final_Draft_CSR_Synopsis_Redacted.pdf&amp;versionIdentifier='}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.', 'accessCriteria': 'When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.\\n\\nAdditionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.', 'url': 'https://astrazenecagroup-dt.pharmacm.com/DT/Home'}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'Patients with type 2 diabetes mellitus who met all the eligibility criteria were randomised in a ratio of 1:1 to a cohort and sequence group. Each cohort was treated for two 72 hour periods in a cross-over design, with a 3-week washout period between treatment periods.', 'recruitmentDetails': 'This study was conducted in Germany between 26 November 2020 and 09 June 2021.', 'groups': [{'id': 'FG000', 'title': 'Cohort 1: 72 mg AZD9567 First, Then 40 mg Prednisolone', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone'}, {'id': 'FG001', 'title': 'Cohort 1:40 mg Prednisolone First, Then 72 mg AZD9567', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'FG002', 'title': 'Cohort 2: 40 mg AZD9567 First, Then 20 mg Prednisolone', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone'}, {'id': 'FG003', 'title': 'Cohort 2: 20mg Prednisolone First, Then 40 mg AZD9567', 'description': 'Patients were randomised in a ratio of 1:1 to receive 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'FG004', 'title': 'Cohort 3: Placebo First, Then 5 mg Prednisolone', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone'}, {'id': 'FG005', 'title': 'Cohort 3: 5 mg Prednisolone First, Then Placebo', 'description': 'Patients were randomised in a ratio of 1:1 to receive 5 mg prednisolone followed by placebo'}], 'periods': [{'title': 'Treatment Period 1 (72 Hours)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '14'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '5'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '13'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': \"Positive SARS-CoV-2 rapid test for patient's daughter\", 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}, {'title': 'Washout Period (3 Weeks)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '13'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '5'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '13'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}, {'title': 'Treatment Period 2 (72 Hours)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '13'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '5'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '13'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'populationDescription': 'Full Analysis Set (FAS) consisted of all randomised patients who received at least 1 dose of study treatment.', 'groups': [{'id': 'BG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'BG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'BG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '27'}, {'groupId': 'BG001', 'value': '8'}, {'groupId': 'BG002', 'value': '9'}, {'groupId': 'BG003', 'value': '44'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'Years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '67.3', 'spread': '6.41'}, {'groupId': 'BG001', 'value': '64.4', 'spread': '9.32'}, {'groupId': 'BG002', 'value': '66.6', 'spread': '5.36'}, {'groupId': 'BG003', 'value': '66.6', 'spread': '6.75'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '4'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '1'}, {'groupId': 'BG003', 'value': '7'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '23'}, {'groupId': 'BG001', 'value': '6'}, {'groupId': 'BG002', 'value': '8'}, {'groupId': 'BG003', 'value': '37'}]}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '27'}, {'groupId': 'BG001', 'value': '8'}, {'groupId': 'BG002', 'value': '9'}, {'groupId': 'BG003', 'value': '44'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}]}]}, {'title': 'Race (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '2'}]}, {'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '26'}, {'groupId': 'BG001', 'value': '7'}, {'groupId': 'BG002', 'value': '9'}, {'groupId': 'BG003', 'value': '42'}]}, {'title': 'More than one race', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in Glucose Area Under the Plasma Concentration Versus Time Curve From Zero to 4 Hours Post-dose AUC(0-4)', 'description': 'The change from baseline in glucose AUC(0-4) was analysed to determine the Pharmacodynamic (PD) effect of AZD9567 compared to Prednisolone following a standardised Mixed meal tolerance test (MMTT).\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'Full Analysis Set (FAS) consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'minute*millimole/liter (min*mmol/L)', 'timeFrame': 'On Days -1 (baseline), and Days 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-190.0296', 'spread': '63.8805'}, {'groupId': 'OG001', 'value': '-182.7172', 'spread': '149.8600'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-57.0768', 'spread': '63.8762'}, {'groupId': 'OG001', 'value': '-40.6842', 'spread': '141.7154'}, {'groupId': 'OG002', 'value': '-184.9677', 'spread': '88.9807'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '-311.8506', 'spread': '88.5443'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.036', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-132.9528', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-256.5082', 'ciUpperLimit': '-9.3973'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.432', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-142.0330', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-554.8722', 'ciUpperLimit': '270.8061'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.030', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-126.8829', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-236.0426', 'ciUpperLimit': '-17.7233'}]}, {'type': 'SECONDARY', 'title': 'Mean Glucose Level as Determined Via the Continuous Glucose Monitoring (CGM) System', 'description': 'The mean glucose levels in mmol/L at 48-72 h was analysed to determine the effect of AZD9567 on CGM compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'millimole/liter (mmol/L) per day', 'timeFrame': '48 to 72 hours', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8.5730', 'spread': '0.3114'}, {'groupId': 'OG001', 'value': '7.7870', 'spread': '0.2517'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '10.0797', 'spread': '0.3150'}, {'groupId': 'OG001', 'value': '8.8969', 'spread': '0.2494'}, {'groupId': 'OG002', 'value': '7.4238', 'spread': '0.2889'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '7.2638', 'spread': '0.2888'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-1.5067', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.0820', 'ciUpperLimit': '-0.9314'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-1.1099', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.7257', 'ciUpperLimit': '-0.4941'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.547', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.1601', 'ciPctValue': '95', 'ciLowerLimit': '-0.6930', 'ciUpperLimit': '0.3729'}]}, {'type': 'SECONDARY', 'title': 'Rise in Mean Glucose Levels Over 24-hour Periods From Start of IMP Dosing', 'description': 'The mean glucose level in mmol/L was analysed to determine the effect of AZD9567 on CGM compared to prednisolone.\\n\\nFor the calculation of the rise in mean glucose levels, the baseline was the average of the values from -24 hours to first dosing on Day 1 of each period.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mmol/L per day', 'timeFrame': 'Baseline and up to 72 hours (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567 (00 to 24 hours [h])', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.2071', 'spread': '0.2869'}, {'groupId': 'OG001', 'value': '0.4070', 'spread': '0.2509'}]}]}, {'title': 'Prednisolone (00 to 24 h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.7086', 'spread': '0.2938'}, {'groupId': 'OG001', 'value': '1.2545', 'spread': '0.2460'}, {'groupId': 'OG002', 'value': '0.3123', 'spread': '0.1549'}]}]}, {'title': 'Placebo (00 to 24 h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '-0.0477', 'spread': '0.1547'}]}]}, {'title': 'AZD9567 (24 to 48 h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.8011', 'spread': '0.2978'}, {'groupId': 'OG001', 'value': '0.5428', 'spread': '0.2483'}]}]}, {'title': 'Prednisolone (24 to 48 h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.6653', 'spread': '0.3044'}, {'groupId': 'OG001', 'value': '1.3206', 'spread': '0.2448'}, {'groupId': 'OG002', 'value': '-0.2415', 'spread': '0.2898'}]}]}, {'title': 'Placebo (24 to 48 h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '-0.3260', 'spread': '0.2894'}]}]}, {'title': 'AZD9567 (48 to 72 h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.8529', 'spread': '0.3210'}, {'groupId': 'OG001', 'value': '0.0744', 'spread': '0.2714'}]}]}, {'title': 'Prednisolone (48 to 72 h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.4527', 'spread': '0.3274'}, {'groupId': 'OG001', 'value': '1.2174', 'spread': '0.2664'}, {'groupId': 'OG002', 'value': '-0.2202', 'spread': '0.2229'}]}]}, {'title': 'Placebo (48 to 72 h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '-0.3500', 'spread': '0.2224'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg \\\\[00 to 24 h\\\\])', 'nonInferiorityType': 'OTHER', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-1.5015', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.2258', 'ciUpperLimit': '-0.7773'}, {'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg \\\\[24 to 48 h\\\\])', 'nonInferiorityType': 'OTHER', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-1.8643', 'ciPctValue': '95', 'ciLowerLimit': '-2.5611', 'ciUpperLimit': '-1.1674'}, {'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg \\\\[48 to 72 h\\\\])', 'nonInferiorityType': 'OTHER', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-1.5998', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.3025', 'ciUpperLimit': '-0.8971'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg \\\\[00 to 24 h\\\\])', 'nonInferiorityType': 'OTHER', 'pValue': '0.013', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.8474', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.4465', 'ciUpperLimit': '-0.2484'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg \\\\[24 to 48 h\\\\])', 'nonInferiorityType': 'OTHER', 'pValue': '0.061', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.7778', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.6022', 'ciUpperLimit': '0.0466'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg \\\\[48 to 72 h\\\\])', 'nonInferiorityType': 'OTHER', 'pValue': '0.003', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-1.1430', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.7622', 'ciUpperLimit': '-0.5238'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5 mg \\\\[00 to 24 h\\\\])', 'nonInferiorityType': 'OTHER', 'pValue': '0.125', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.3600', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.8338', 'ciUpperLimit': '0.1138'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5 mg \\\\[24 to 48 h\\\\])', 'nonInferiorityType': 'OTHER', 'pValue': '0.840', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.0845', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.9706', 'ciUpperLimit': '0.8016'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5 mg \\\\[48 to 72 h\\\\])', 'nonInferiorityType': 'OTHER', 'pValue': '0.571', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.1298', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.6460', 'ciUpperLimit': '0.3864'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Glucose', 'description': 'Pharmacodynamic effects (fasting glucose) of AZD9567 following a MMTT were evaluated as compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mmol/L', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.14', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-0.95', 'spread': '0.36'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.06', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-0.91', 'spread': '0.35'}, {'groupId': 'OG002', 'value': '-1.15', 'spread': '0.20'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '-1.15', 'spread': '0.20'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.753', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.07', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.55', 'ciUpperLimit': '0.40'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.802', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.04', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.46', 'ciUpperLimit': '0.37'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.985', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.00', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.37', 'ciUpperLimit': '0.37'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline AUC(0-4) on Hormones Related to Glucose Homeostasis (Insulin)', 'description': 'Effects of AZD9567 on insulin AUC(0-4) were assessed following MMTT compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'minute*picomole/liter (min*pmole/L)', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '21'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '15319.3857', 'spread': '4165.9135'}, {'groupId': 'OG001', 'value': '13413.1929', 'spread': '4791.9873'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '23'}, {'groupId': 'OG001', 'value': '7'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-5179.3659', 'spread': '3989.2683'}, {'groupId': 'OG001', 'value': '10091.7869', 'spread': '5461.2631'}, {'groupId': 'OG002', 'value': '4915.4115', 'spread': '7049.5460'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '2216.5532', 'spread': '7049.0432'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '20498.7', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '10819.2', 'ciUpperLimit': '30178.2'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.659', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '3321.4', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-12975.8', 'ciUpperLimit': '19618.6'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.521', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-2698.8', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-14849.0', 'ciUpperLimit': '9451.3'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline AUC(0-4) on Hormones Related to Glucose Homeostasis (Glucagon)', 'description': 'Effects of AZD9567 on glucagon AUC(0-4) were assessed following MMTT in comparison to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'min*pmol/L', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-36.9846', 'spread': '216.5777'}, {'groupId': 'OG001', 'value': '552.0634', 'spread': '213.9300'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '965.6018', 'spread': '216.6054'}, {'groupId': 'OG001', 'value': '511.0798', 'spread': '213.5970'}, {'groupId': 'OG002', 'value': '259.9835', 'spread': '298.9801'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '7'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '361.3971', 'spread': '348.5104'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.003', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-1002.5864', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1620.2150', 'ciUpperLimit': '-384.9577'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.865', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '40.9836', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-526.6968', 'ciUpperLimit': '608.6640'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.754', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '101.4137', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-628.8097', 'ciUpperLimit': '831.6370'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline AUC(0-4) on Hormones Related to Glucose Homeostasis (Glucagon-like Peptide-1 [GLP-1])', 'description': 'Effects of AZD9567 on GLP-1 AUC(0-4) were assessed following MMTT in comparison to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'min*pmol/L', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '615.9803', 'spread': '328.8418'}, {'groupId': 'OG001', 'value': '322.5690', 'spread': '454.2028'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1841.8853', 'spread': '328.8877'}, {'groupId': 'OG001', 'value': '789.5492', 'spread': '450.2548'}, {'groupId': 'OG002', 'value': '575.6726', 'spread': '318.1088'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '200.3565', 'spread': '317.6326'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.004', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-1225.9050', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2007.2241', 'ciUpperLimit': '-444.5859'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.313', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-466.9802', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1521.5088', 'ciUpperLimit': '587.5485'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.404', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-375.3161', 'ciPctValue': '95', 'ciLowerLimit': '-1433.6265', 'ciUpperLimit': '682.9943'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline AUC(0-4) on Hormones Related to Glucose Homeostasis (Glucose-dependent Insulin Releasing Polypeptide [GIP])', 'description': 'Effects of AZD9567 on GIP AUC(0-4) were assessed following MMTT in comparison to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'min*pmol/L', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3658.9885', 'spread': '584.5079'}, {'groupId': 'OG001', 'value': '3842.9307', 'spread': '1303.1553'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3293.3563', 'spread': '596.7472'}, {'groupId': 'OG001', 'value': '3654.6947', 'spread': '1289.5516'}, {'groupId': 'OG002', 'value': '3271.5164', 'spread': '823.9967'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '2210.0670', 'spread': '827.7335'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.608', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '365.6323', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1097.7973', 'ciUpperLimit': '1829.0618'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.897', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '188.2360', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-3214.3323', 'ciUpperLimit': '3590.8043'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.381', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-1061.4494', 'ciPctValue': '95', 'ciLowerLimit': '-3588.2233', 'ciUpperLimit': '1465.3244'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in AUC(0-4) on C-peptide', 'description': 'Effects of AZD9567 on C-peptide AUC(0-4) were assessed through a MMTT in comparison to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'minute*nanomole/L (min*nmol/L)', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '85.3305', 'spread': '13.4279'}, {'groupId': 'OG001', 'value': '82.1134', 'spread': '22.9858'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '24.9094', 'spread': '13.4282'}, {'groupId': 'OG001', 'value': '55.6606', 'spread': '22.6155'}, {'groupId': 'OG002', 'value': '24.7245', 'spread': '22.2183'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '0.7002', 'spread': '22.0424'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '60.4211', 'ciPctValue': '95', 'ciLowerLimit': '29.4904', 'ciUpperLimit': '91.3518'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.432', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '26.4529', 'ciPctValue': '95', 'ciLowerLimit': '-44.9414', 'ciUpperLimit': '97.8471'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.282', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-24.0243', 'ciPctValue': '95', 'ciLowerLimit': '-74.0731', 'ciUpperLimit': '26.0245'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Ratio of Insulin to Glucose Level Between 10 and 0 Minutes (ΔI10/ΔG10)', 'description': 'Effects of AZD9567 on ΔI10/ΔG10 of beta cell function from the MMTT compared to Prednisolone was evaluated.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'Ratio', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '16'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.5249', 'spread': '0.6632'}, {'groupId': 'OG001', 'value': 'NA', 'spread': 'NA', 'comment': 'Convergence was not met thus no data are available.'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '18'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '5'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.0774', 'spread': '0.6674'}, {'groupId': 'OG001', 'value': 'NA', 'spread': 'NA', 'comment': 'Convergence was not met thus no data are available.'}, {'groupId': 'OG002', 'value': '-0.8153', 'spread': '0.8305'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '7'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '-0.3532', 'spread': '0.6893'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.531', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.6023', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.5463', 'ciUpperLimit': '1.3416'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.682', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.4621', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.0933', 'ciUpperLimit': '3.0176'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Ratio of Insulin to Glucose Level Between 30 and 0 Minutes [ΔI30/ΔG30])', 'description': 'Effects of AZD9567 on ΔI30/ΔG30 of beta cell function from the MMTT compared to Prednisolone was evaluated.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'Ratio', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.1203', 'spread': '0.0726'}, {'groupId': 'OG001', 'value': '0.1824', 'spread': '0.0773'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '24'}, {'groupId': 'OG001', 'value': '6'}, {'groupId': 'OG002', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.0530', 'spread': '0.0755'}, {'groupId': 'OG001', 'value': '0.0943', 'spread': '0.1264'}, {'groupId': 'OG002', 'value': '-0.1047', 'spread': '0.0665'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '0.0209', 'spread': '0.0599'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.526', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.0679', 'ciPctValue': '95', 'ciLowerLimit': '-0.1520', 'ciUpperLimit': '0.2866'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg', 'nonInferiorityType': 'OTHER', 'pValue': '0.569', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.0882', 'ciPctValue': '95', 'ciLowerLimit': '-0.2653', 'ciUpperLimit': '0.4416'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.166', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.1257', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.0677', 'ciUpperLimit': '0.3191'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Ratio of C-peptide to Glucose Level Between 10 and 0 Minutes (ΔC10/ΔG10)', 'description': 'Effects of AZD9567 on ΔC10/ΔG10 of beta cell function from the MMTT compared to Prednisolone was evaluated.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'Ratio', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '17'}, {'groupId': 'OG001', 'value': '6'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.0004', 'spread': '0.0095'}, {'groupId': 'OG001', 'value': '0.0059', 'spread': '0.0041'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '20'}, {'groupId': 'OG001', 'value': '4'}, {'groupId': 'OG002', 'value': '6'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.0103', 'spread': '0.0092'}, {'groupId': 'OG001', 'value': '0.0026', 'spread': '0.0047'}, {'groupId': 'OG002', 'value': '-0.0033', 'spread': '0.0064'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '7'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '-0.0024', 'spread': '0.0057'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.226', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.0100', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.0072', 'ciUpperLimit': '0.0271'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.619', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.0033', 'ciPctValue': '95', 'ciLowerLimit': '-0.0128', 'ciUpperLimit': '0.0195'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.917', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.0009', 'ciPctValue': '95', 'ciLowerLimit': '-0.0189', 'ciUpperLimit': '0.0207'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Ratio of C-peptide to Glucose Level Between 30 and 0 Minutes (ΔC30/ΔG30)', 'description': 'Effects of AZD9567 on ΔC30/ΔG30 of beta cell function from the MMTT compared to Prednisolone was evaluated.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'Ratio', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.0012', 'spread': '0.0005'}, {'groupId': 'OG001', 'value': '0.0007', 'spread': '0.0005'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.0005', 'spread': '0.0005'}, {'groupId': 'OG001', 'value': '0.0004', 'spread': '0.0005'}, {'groupId': 'OG002', 'value': '-0.0010', 'spread': '0.0005'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '0.0002', 'spread': '0.0005'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.357', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.0007', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.0008', 'ciUpperLimit': '0.0022'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.676', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.0003', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.0012', 'ciUpperLimit': '0.0017'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.096', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.0012', 'ciPctValue': '95', 'ciLowerLimit': '-0.0002', 'ciUpperLimit': '0.0026'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 24-hour Urinary Potassium Excretion', 'description': 'The concentration of potassium in urine was measured over 24 hours to determine the effect of AZD9567 on urinary potassium (U-K) excretion compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mmol/day', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.92', 'spread': '3.27'}, {'groupId': 'OG001', 'value': '-6.05', 'spread': '4.30'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.19', 'spread': '3.27'}, {'groupId': 'OG001', 'value': '4.92', 'spread': '4.29'}, {'groupId': 'OG002', 'value': '-2.49', 'spread': '9.08'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '-2.85', 'spread': '9.07'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.646', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-1.73', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-9.40', 'ciUpperLimit': '5.95'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.110', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-10.97', 'ciPctValue': '95', 'ciLowerLimit': '-25.39', 'ciUpperLimit': '3.44'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.932', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-0.35', 'ciPctValue': '95', 'ciLowerLimit': '-10.32', 'ciUpperLimit': '9.61'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 24-hour Urinary Sodium Excretion', 'description': 'The concentration of sodium in urine was measured over 24 hours to determine the effect of AZD9567 on urinary-sodium (U-Na) excretion compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mmol/day', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '17.4', 'spread': '11.0'}, {'groupId': 'OG001', 'value': '39.9', 'spread': '20.4'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '9.7', 'spread': '11.0'}, {'groupId': 'OG001', 'value': '17.6', 'spread': '20.3'}, {'groupId': 'OG002', 'value': '-18.1', 'spread': '21.4'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '12.9', 'spread': '21.3'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.533', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '7.6', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-17.4', 'ciUpperLimit': '32.7'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.311', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '22.3', 'ciPctValue': '95', 'ciLowerLimit': '-26.7', 'ciUpperLimit': '71.3'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.204', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '31.0', 'ciPctValue': '95', 'ciLowerLimit': '-21.9', 'ciUpperLimit': '83.9'}]}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Quantifiable Concentration (AUClast)', 'description': 'AUClast of AZD9567 following once daily dosing was evaluated.', 'populationDescription': 'Pharmacokinetic analysis set (PKAS) consisted of all patients in the FAS with at least 1 quantifiable AZD9567 concentration and no important protocol deviations, or adverse events (AEs) considered to have an effect upon PK.', 'reportingStatus': 'POSTED', 'paramType': 'GEOMETRIC_MEAN', 'dispersionType': 'Geometric Coefficient of Variation', 'unitOfMeasure': 'hour*nanomole/liter (h*nmol/L)', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '34400', 'spread': '42.97'}, {'groupId': 'OG001', 'value': '18410', 'spread': '46.06'}]}]}]}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours Post-dose [AUC(0-24)]', 'description': 'AUC(0-24) of AZD9567 following once daily dosing was evaluated.', 'populationDescription': 'PKAS consisted of all patients in the FAS with at least 1 quantifiable AZD9567 concentration and no important protocol deviations, or AEs considered to have an effect upon PK.', 'reportingStatus': 'POSTED', 'paramType': 'GEOMETRIC_MEAN', 'dispersionType': 'Geometric Coefficient of Variation', 'unitOfMeasure': 'h*nmol/L', 'timeFrame': '24 hours post dose', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '32920', 'spread': '41.32'}, {'groupId': 'OG001', 'value': '17790', 'spread': '44.86'}]}]}]}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve From Zero to 6 Hours Post-dose [AUC(0-6)]', 'description': 'AUC(0-6) of AZD9567 following once daily dosing was evaluated.', 'populationDescription': 'PKAS consisted of all patients in the FAS with at least 1 quantifiable AZD9567 concentration and no important protocol deviations, or AEs considered to have an effect upon PK.', 'reportingStatus': 'POSTED', 'paramType': 'GEOMETRIC_MEAN', 'dispersionType': 'Geometric Coefficient of Variation', 'unitOfMeasure': 'h*nmol/L', 'timeFrame': '6 hours post dose', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '17050', 'spread': '30.45'}, {'groupId': 'OG001', 'value': '9914', 'spread': '35.06'}]}]}]}, {'type': 'SECONDARY', 'title': 'Maximum Observed Drug Concentration (Cmax)', 'description': 'Cmax of AZD9567 following once daily dosing was evaluated.', 'populationDescription': 'PKAS consisted of all patients in the FAS with at least 1 quantifiable AZD9567 concentration and no important protocol deviations, or AEs considered to have an effect upon PK.', 'reportingStatus': 'POSTED', 'paramType': 'GEOMETRIC_MEAN', 'dispersionType': 'Geometric Coefficient of Variation', 'unitOfMeasure': 'nmol/L', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4501', 'spread': '26.90'}, {'groupId': 'OG001', 'value': '2939', 'spread': '31.50'}]}]}]}, {'type': 'SECONDARY', 'title': 'Time to Reach Maximum Observed Drug Concentration (Tmax)', 'description': 'Tmax of AZD9567 following once daily dosing was evaluated.', 'populationDescription': 'PKAS consisted of all patients in the FAS with at least 1 quantifiable AZD9567 concentration and no important protocol deviations, or AEs considered to have an effect upon PK.', 'reportingStatus': 'POSTED', 'paramType': 'MEDIAN', 'dispersionType': 'Full Range', 'unitOfMeasure': 'hours', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.50', 'lowerLimit': '0.25', 'upperLimit': '1.50'}, {'groupId': 'OG001', 'value': '0.50', 'lowerLimit': '0.50', 'upperLimit': '1.00'}]}]}]}, {'type': 'SECONDARY', 'title': 'Terminal Elimination Half-life (t½λz)', 'description': 't½λz of AZD9567 following once daily dosing was evaluated.', 'populationDescription': 'PKAS consisted of all patients in the FAS with at least 1 quantifiable AZD9567 concentration and no important protocol deviations, or AEs considered to have an effect upon PK.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'hours', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.99', 'spread': '1.44'}, {'groupId': 'OG001', 'value': '6.16', 'spread': '1.08'}]}]}]}, {'type': 'SECONDARY', 'title': 'Apparent Total Body Clearance of Drug From Plasma After Extravascular (CL/F)', 'description': 'CL/F of AZD9567 following once daily dosing was evaluated.', 'populationDescription': 'PKAS consisted of all patients in the FAS with at least 1 quantifiable AZD9567 concentration and no important protocol deviations, or AEs considered to have an effect upon PK.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Liter/hour (L/h)', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.766', 'spread': '1.896'}, {'groupId': 'OG001', 'value': '4.924', 'spread': '2.098'}]}]}]}, {'type': 'SECONDARY', 'title': 'Apparent Volume of Distribution Following Extravascular Administration (Vz/F)', 'description': 'Vz/F of AZD9567 was derived using standard non-compartmental methods using WinNonLin version 8.1 or higher (Certara).', 'populationDescription': 'PKAS consisted of all patients in the FAS with at least 1 quantifiable AZD9567 concentration and no important protocol deviations, or AEs considered to have an effect upon PK.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Liter', 'timeFrame': 'Upto 30 hours post dose (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '45.11', 'spread': '11.39'}, {'groupId': 'OG001', 'value': '41.75', 'spread': '14.19'}]}]}]}, {'type': 'SECONDARY', 'title': 'Tumour Necrosis Factor Alpha (TNFα) Concentrations', 'description': 'Relationship between AZD9567 exposure and inhibition of LPS-stimulated TNFα release for high and low dose comparison (Cohort 1 and Cohort 2) was assessed. LPS-stimulated TNFα concentration was measured.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'nanogram/liter (ng/L)', 'timeFrame': 'On Days 3 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'title': 'AZD9567 (0h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '21000.1', 'spread': '15413.92'}, {'groupId': 'OG001', 'value': '23525.0', 'spread': '15260.57'}]}]}, {'title': 'Prednisolone (0h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '21361.5', 'spread': '18124.60'}, {'groupId': 'OG001', 'value': '12385.0', 'spread': '11835.31'}]}]}, {'title': 'AZD9567 (1h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '9100.2', 'spread': '6248.93'}, {'groupId': 'OG001', 'value': '8122.5', 'spread': '5303.16'}]}]}, {'title': 'Prednisolone (1h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3581.1', 'spread': '3642.93'}, {'groupId': 'OG001', 'value': '3617.5', 'spread': '1552.62'}]}]}, {'title': 'AZD9567 (2h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8170.7', 'spread': '5053.69'}, {'groupId': 'OG001', 'value': '8098.0', 'spread': '7709.06'}]}]}, {'title': 'Prednisolone (2h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1648.2', 'spread': '1109.64'}, {'groupId': 'OG001', 'value': '1421.1', 'spread': '591.80'}]}]}, {'title': 'AZD9567 (4h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7534.6', 'spread': '4519.50'}, {'groupId': 'OG001', 'value': '8898.8', 'spread': '5249.73'}]}]}, {'title': 'Prednisolone (4h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2293.1', 'spread': '1329.60'}, {'groupId': 'OG001', 'value': '4292.0', 'spread': '3207.76'}]}]}, {'title': 'AZD9567 (8h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '10674.4', 'spread': '7731.94'}, {'groupId': 'OG001', 'value': '13023.8', 'spread': '8946.33'}]}]}, {'title': 'Prednisolone (8h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4585.7', 'spread': '4453.61'}, {'groupId': 'OG001', 'value': '7247.5', 'spread': '2889.87'}]}]}, {'title': 'AZD9567 (12h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '13332.5', 'spread': '10831.44'}, {'groupId': 'OG001', 'value': '14695.0', 'spread': '11422.87'}]}]}, {'title': 'Prednisolone (12h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '12415.5', 'spread': '9474.44'}, {'groupId': 'OG001', 'value': '16790.0', 'spread': '8010.23'}]}]}, {'title': 'AZD9567 (24h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '22136.7', 'spread': '13414.45'}, {'groupId': 'OG001', 'value': '19741.3', 'spread': '11048.74'}]}]}, {'title': 'Prednisolone (24h)', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '23292.9', 'spread': '15548.12'}, {'groupId': 'OG001', 'value': '20920.0', 'spread': '14802.66'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline AUC(0-4) on Hormones Related to Glucose Homeostasis (Free Fatty Acids)', 'description': 'Effects of AZD9567 on free fatty acids were evaluated following a MMTT compared to prednisolone.\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'min*mmol/L', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-18.1304', 'spread': '1.7543'}, {'groupId': 'OG001', 'value': '-14.0582', 'spread': '3.7038'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-14.1238', 'spread': '1.7542'}, {'groupId': 'OG001', 'value': '-19.8117', 'spread': '3.7060'}, {'groupId': 'OG002', 'value': '-4.1625', 'spread': '3.7212'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '4.8995', 'spread': '3.7153'}]}]}], 'analyses': [{'groupIds': ['OG000'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 72mg vs Prednisolone 40mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.103', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-4.0066', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-8.8880', 'ciUpperLimit': '0.8748'}, {'groupIds': ['OG001'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (AZD9567 40mg vs Prednisolone 20mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.005', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '5.7535', 'ciPctValue': '95', 'ciLowerLimit': '2.6034', 'ciUpperLimit': '8.9036'}, {'groupIds': ['OG002'], 'groupDescription': 'Pairwise Comparisons with Prednisolone (Placebo vs Prednisolone 5mg)', 'nonInferiorityType': 'OTHER', 'pValue': '0.023', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '9.0619', 'ciPctValue': '95', 'ciLowerLimit': '1.6740', 'ciUpperLimit': '16.4499'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Homeostatic Model Assessment- Insulin Resistance (HOMA-IR)', 'description': 'The HOMA-IR was calculated based on glucose and insulin measured prior to MMTT.\\n\\nHOMA-IR= Glucose(mmol/L) x Insulin (mU/L) / 22.5\\n\\nHOMA-IR score estimates the degree of insulin resistance. Higher range indicates greater insulin resistance (i.e. high diabetes risk), while lower range indicates insulin sensitivity (i.e. low diabetes risk)\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Score', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.4406', 'spread': '1.9875'}, {'groupId': 'OG001', 'value': '-0.1738', 'spread': '0.7576'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.7023', 'spread': '1.5896'}, {'groupId': 'OG001', 'value': '0.0721', 'spread': '0.9606'}, {'groupId': 'OG002', 'value': '-0.5662', 'spread': '0.7364'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '-0.9280', 'spread': '0.8173'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in HOMA-insulin Sensitivity (HOMA-S)', 'description': 'Insulin sensitivity is a term used to indicate the responsiveness of the peripheral tissue cells to insulin, and their resultant capacity to uptake glucose out of the bloodstream.\\n\\nHOMA-S score estimates the degree of insulin sensitivity. HOMA-S was calculated as the reciprocal of HOMA-IR.\\n\\nHigher values indicates greater insulin sensitivity (i.e. low diabetes risk), while lower values indicates insulin resistance (i.e. high diabetes risk)\\n\\nIn Cohort 1 and 2, Placebo was not administered, therefore in Placebo row the participants analyzed is kept as 0.\\n\\nIn Cohort 3, AZD9567 was not administered, therefore in AZD9567 row the participants analyzed is kept 0.', 'populationDescription': 'FAS consisted of all randomised patients who received at least 1 dose of study treatment.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Score', 'timeFrame': 'On Day -1 (Baseline), and Day 4 (Treatment period 1 and 2)', 'groups': [{'id': 'OG000', 'title': 'Cohort 1', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 2', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 3', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'classes': [{'title': 'AZD9567', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '26'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.0134', 'spread': '0.2352'}, {'groupId': 'OG001', 'value': '-0.0360', 'spread': '0.1990'}]}]}, {'title': 'Prednisolone', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.0328', 'spread': '0.1400'}, {'groupId': 'OG001', 'value': '-0.0799', 'spread': '0.2077'}, {'groupId': 'OG002', 'value': '0.0750', 'spread': '0.0949'}]}]}, {'title': 'Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG002', 'value': '0.1468', 'spread': '0.0930'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Adverse Events', 'description': 'Safety and tolerability of AZD9567 was assessed.', 'populationDescription': 'Safety Analysis Set (SAF) consisted of all patients who were randomised to one of the 2 sequence groups within the cohort and have received at least 1 dose of study intervention.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'From screening up to 79 days', 'groups': [{'id': 'OG000', 'title': 'Cohort 1: AZD9567 72mg', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG001', 'title': 'Cohort 1: Prednisolone 40mg', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD9567'}, {'id': 'OG002', 'title': 'Cohort 2: AZD9567 40mg', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG003', 'title': 'Cohort 2: Prednisolone 20mg', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567'}, {'id': 'OG004', 'title': 'Cohort 3: Placebo', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}, {'id': 'OG005', 'title': 'Cohort 3: Prednisolone 5mg', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '27'}, {'groupId': 'OG001', 'value': '27'}, {'groupId': 'OG002', 'value': '8'}, {'groupId': 'OG003', 'value': '8'}, {'groupId': 'OG004', 'value': '9'}, {'groupId': 'OG005', 'value': '9'}]}], 'classes': [{'title': 'Any Adverse Event (AE)', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '7'}, {'groupId': 'OG002', 'value': '2'}, {'groupId': 'OG003', 'value': '5'}, {'groupId': 'OG004', 'value': '1'}, {'groupId': 'OG005', 'value': '0'}]}]}, {'title': 'Any AE with outcome = death', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}, {'groupId': 'OG003', 'value': '0'}, {'groupId': 'OG004', 'value': '0'}, {'groupId': 'OG005', 'value': '0'}]}]}, {'title': 'Any SAE (including events with outcome = death)', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}, {'groupId': 'OG003', 'value': '0'}, {'groupId': 'OG004', 'value': '0'}, {'groupId': 'OG005', 'value': '0'}]}]}, {'title': 'Any AE leading to discontinuation of Investigational Product', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}, {'groupId': 'OG003', 'value': '0'}, {'groupId': 'OG004', 'value': '0'}, {'groupId': 'OG005', 'value': '0'}]}]}, {'title': 'Any AE leading to drug interruption', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}, {'groupId': 'OG003', 'value': '0'}, {'groupId': 'OG004', 'value': '0'}, {'groupId': 'OG005', 'value': '0'}]}]}, {'title': 'Any AE leading to withdrawal from study', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}, {'groupId': 'OG003', 'value': '0'}, {'groupId': 'OG004', 'value': '0'}, {'groupId': 'OG005', 'value': '0'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '0', 'timeFrame': 'From Screening up to Final/ end of treatment visit (Day 79).', 'description': 'Safety Analysis Set (SAF) consisted of all patients who were randomised to one of the 2 sequence groups within the cohort and have received at least 1 dose of study intervention. The SAF was analysed according to actual treatment.\\n\\nThree additional arms were created to capture Adverse Events for each treatment within the cohort.', 'eventGroups': [{'id': 'EG000', 'title': 'Cohort 1: AZD9567 72mg', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD956', 'deathsNumAffected': 0, 'deathsNumAtRisk': 27, 'seriousNumAffected': 0, 'seriousNumAtRisk': 27, 'otherNumAffected': 4, 'otherNumAtRisk': 27}, {'id': 'EG001', 'title': 'Cohort 1: Prednisolone 40mg', 'description': 'Patients were randomised in a ratio of 1:1 to receive 72 mg AZD9567 followed by 40 mg prednisolone or 40 mg prednisolone followed by 72 mg AZD956', 'deathsNumAffected': 0, 'deathsNumAtRisk': 27, 'seriousNumAffected': 0, 'seriousNumAtRisk': 27, 'otherNumAffected': 7, 'otherNumAtRisk': 27}, {'id': 'EG002', 'title': 'Cohort 2: AZD9567 40mg', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD9567', 'deathsNumAffected': 0, 'deathsNumAtRisk': 8, 'seriousNumAffected': 0, 'seriousNumAtRisk': 8, 'otherNumAffected': 2, 'otherNumAtRisk': 8}, {'id': 'EG003', 'title': 'Cohort 2: Prednisolone 20mg', 'description': 'Patients were randomised in a ratio of 1:1 to receive 40 mg AZD9567 followed by 20 mg prednisolone or 20 mg prednisolone followed by 40 mg AZD956', 'deathsNumAffected': 0, 'deathsNumAtRisk': 8, 'seriousNumAffected': 0, 'seriousNumAtRisk': 8, 'otherNumAffected': 5, 'otherNumAtRisk': 8}, {'id': 'EG004', 'title': 'Cohort 3: Placebo', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo', 'deathsNumAffected': 0, 'deathsNumAtRisk': 9, 'seriousNumAffected': 0, 'seriousNumAtRisk': 9, 'otherNumAffected': 1, 'otherNumAtRisk': 9}, {'id': 'EG005', 'title': 'Cohort 3: Prednisolone 5mg', 'description': 'Patients were randomised in a ratio of 1:1 to receive placebo followed by 5 mg prednisolone or 5 mg prednisolone followed by placebo', 'deathsNumAffected': 0, 'deathsNumAtRisk': 9, 'seriousNumAffected': 0, 'seriousNumAtRisk': 9, 'otherNumAffected': 0, 'otherNumAtRisk': 9}], 'otherEvents': [{'term': 'Cellulitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Conjunctivitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Nasopharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Hyperglycaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Hypoglycaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Dizziness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Pollakiuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Administration site phlebitis', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Catheter site erythema', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Fatigue', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Mucosal inflammation', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Haematochezia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Back pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Catheter site related reaction', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Blood pressure increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 0, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}, {'term': 'Diarrhoea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA version 24.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 27}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG004', 'numAffected': 1, 'numAtRisk': 9}, {'groupId': 'EG005', 'numAffected': 0, 'numAtRisk': 9}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictionType': 'OTHER', 'restrictiveAgreement': True, 'otherDetails': 'No unpublished information may be disclosed without prior written approval from AstraZeneca.'}, 'pointOfContact': {'title': 'Global Clinical Head', 'organization': 'AstraZeneca Clinical Study Information Center', 'email': 'information.center@astrazeneca.com', 'phone': '1-877-240-94 79'}}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot', 'hasProtocol': True, 'hasSap': False, 'hasIcf': False, 'label': 'Study Protocol', 'date': '2021-03-03', 'uploadDate': '2022-04-28T10:01', 'filename': 'Prot_000.pdf', 'size': 3693117}, {'typeAbbrev': 'SAP', 'hasProtocol': False, 'hasSap': True, 'hasIcf': False, 'label': 'Statistical Analysis Plan', 'date': '2021-10-28', 'uploadDate': '2022-04-28T10:01', 'filename': 'SAP_001.pdf', 'size': 5882296}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D011239', 'term': 'Prednisolone'}], 'ancestors': [{'id': 'D000893', 'term': 'Anti-Inflammatory Agents'}, {'id': 'D005938', 'term': 'Glucocorticoids'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D018931', 'term': 'Antineoplastic Agents, Hormonal'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M11749', 'name': 'Methylprednisolone', 'relevance': 'LOW'}, {'id': 'M1833', 'name': 'Methylprednisolone Acetate', 'relevance': 'LOW'}, {'id': 'M11750', 'name': 'Methylprednisolone Hemisuccinate', 'relevance': 'LOW'}, {'id': 'M14120', 'name': 'Prednisolone', 'asFound': 'Determined', 'relevance': 'HIGH'}, {'id': 'M229449', 'name': 'Prednisolone acetate', 'relevance': 'LOW'}, {'id': 'M211887', 'name': 'Prednisolone hemisuccinate', 'relevance': 'LOW'}, {'id': 'M248881', 'name': 'Prednisolone phosphate', 'relevance': 'LOW'}, {'id': 'M4217', 'name': 'Anti-Inflammatory Agents', 'relevance': 'LOW'}, {'id': 'M9047', 'name': 'Glucocorticoids', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}, {'id': 'M20966', 'name': 'Antineoplastic Agents, Hormonal', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'}, {'abbrev': 'AnEm', 'name': 'Antiemetics'}, {'abbrev': 'NeuroAg', 'name': 'Neuroprotective Agents'}, {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00622960', 'orgStudyIdInfo': {'id': 'ADA 1-04-CR-05'}, 'organization': {'fullName': 'University of Cincinnati', 'class': 'OTHER'}, 'briefTitle': 'Effect of High Monounsaturated Fat Diet on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes', 'officialTitle': 'Comparison of High Monounsaturated Fat and High Carbohydrate Diets on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2008-02', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2004-04'}, 'primaryCompletionDateStruct': {'date': '2007-04', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2007-04', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2008-02-13', 'studyFirstSubmitQcDate': '2008-02-22', 'studyFirstPostDateStruct': {'date': '2008-02-25', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2008-02-22', 'lastUpdatePostDateStruct': {'date': '2008-02-25', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Bonnie J. Brehm', 'oldOrganization': 'University of Cincinnati'}, 'leadSponsor': {'name': 'University of Cincinnati', 'class': 'OTHER'}, 'collaborators': [{'name': 'American Diabetes Association', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The purpose of this proposed randomized, controlled trial is to compare the effects of high monounsaturated fat diets and high carbohydrate diets on body weight, body composition, glycemic control, plasma lipids, and other cardiovascular risk factors over a period of one year. At present, no such studies of free-living subjects have been performed. The specific aims of the proposed project are to test the hypotheses that (1) a high monounsaturated fat diet will produce greater weight loss/body fat loss and more successful weight maintenance than a high carbohydrate diet and (2) a high monounsaturated fat diet will result in an improved lipid profile and better glycemic control than a high carbohydrate diet.', 'detailedDescription': 'The incidence of type 2 diabetes has increased steadily over the last three decades. Although medical nutrition therapy is an integral component of diabetes management, nutrition recommendations for diabetes have often been based on clinical experience and expert consensus, rather than on carefully controlled clinical trials. The expert consensus on medical nutrition therapy is that carbohydrate and monounsaturated fat together should provide approximately 60-70% of total energy intake. This recommendation accommodates parties on both sides of a debate over what constitutes the optimal macronutrient composition of a diet for type 2 diabetic patients. On one side are proponents of high carbohydrate, low fat diets who contend that this regimen promotes the lowering of total- and LDL-cholesterol and is less calorically dense than diets containing a higher percentage of fat. On the other side are advocates of high monounsaturated fat, Mediterranean-type diets who cite data from short-term studies indicating that this approach decreases postprandial levels of plasma glucose, insulin, and triglycerides, and increases HDL-cholesterol more than isocaloric high carbohydrate diets. However, there is concern about the potential for high fat diets to increase energy intake and weight gain among free-living subjects. To make definitive, scientifically-based diet recommendations, it is essential that controlled long-term trials be conducted to demonstrate the health effects of specific percentages of monounsaturated fats and carbohydrates in the diets of persons with type 2 diabetes.'}, 'conditionsModule': {'conditions': ['Overweight', 'Obesity', 'Type 2 Diabetes'], 'keywords': ['obesity', 'type 2 diabetes', 'weight loss', 'monounsaturated fat', 'diet']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 124, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'High MUFA diet', 'type': 'EXPERIMENTAL', 'description': 'Those subjects assigned to a high monounsaturated fat diet', 'interventionNames': ['Other: High-MUFA diet']}, {'label': 'High CHO diet', 'type': 'ACTIVE_COMPARATOR', 'description': 'Those subjects assigned to a high carbohydrate diet', 'interventionNames': ['Other: High-CHO diet']}], 'interventions': [{'type': 'OTHER', 'name': 'High-MUFA diet', 'description': 'The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.', 'armGroupLabels': ['High MUFA diet']}, {'type': 'OTHER', 'name': 'High-CHO diet', 'description': 'The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.', 'armGroupLabels': ['High CHO diet']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'body weight', 'timeFrame': 'prior to and after 4, 8, and 12 months of dieting'}], 'secondaryOutcomes': [{'measure': 'body fat', 'timeFrame': 'prior to and after 4, 8, and 12 months of dieting'}, {'measure': 'blood pressure', 'timeFrame': 'prior to and after 4, 8, and 12 months of dieting'}, {'measure': 'blood lipid profile', 'timeFrame': 'prior to and after 4, 8, and 12 months of dieting'}, {'measure': 'glycemic control (glucose, insulin, and HbA1c)', 'timeFrame': 'prior to and after 4, 8, and 12 months of dieting'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* BMI of 27-40 kg/m2\\n* 30-75 years of age\\n* Stable body weight for the preceding 6 months\\n* Diagnosis of type 2 diabetes for at least 6 months prior to enrollment\\n* HbA1c of 6.5 to 9.0\\n* Treatment by diet or oral agents only\\n\\nExclusion Criteria:\\n\\n* Pregnancy or lactation\\n* Active cardiac, pulmonary, renal, liver, or gastrointestinal disease\\n* Untreated thyroid disease or hypertension\\n* Hypertriglyceridemia with levels of TG \\\\> 500 mg/dl\\n* Use of insulin\\n* Use of specific medications that may alter lipid or glucose metabolism (other than the statins)\\n* Use of medications that commonly cause significant alterations in body weight (e.g., corticosteroids).', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '30 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Bonnie J Brehm, PhD', 'affiliation': 'University of Cincinnati', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Cincinnati', 'city': 'Cincinnati', 'state': 'Ohio', 'zip': '45221', 'country': 'United States', 'geoPoint': {'lat': 39.12713, 'lon': -84.51435}}]}, 'referencesModule': {'references': [{'pmid': '18957534', 'type': 'DERIVED', 'citation': \"Brehm BJ, Lattin BL, Summer SS, Boback JA, Gilchrist GM, Jandacek RJ, D'Alessio DA. One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. Diabetes Care. 2009 Feb;32(2):215-20. doi: 10.2337/dc08-0687. Epub 2008 Oct 28.\"}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D050177', 'term': 'Overweight'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D001835', 'term': 'Body Weight'}], 'browseLeaves': [{'id': 'M26186', 'name': 'Overweight', 'asFound': 'Overweight', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'}, {'id': 'M18102', 'name': 'Weight Loss', 'relevance': 'LOW'}, {'id': 'M5114', 'name': 'Body Weight', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M25307', 'name': 'Overnutrition', 'relevance': 'LOW'}, {'id': 'M12684', 'name': 'Nutrition Disorders', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06197360', 'orgStudyIdInfo': {'id': 'YZUHL20210088'}, 'organization': {'fullName': 'Yangzhou University', 'class': 'OTHER'}, 'briefTitle': 'Effects of a Health Intervention on Fear of Hypoglycemia : a Pilot Study', 'officialTitle': 'Effects of a Health Education Intervention Based on the Behaviour Change Wheel on Fear of Hypoglycemia in Patients With Type 2 Diabetes Mellitus: a Pilot Study'}, 'statusModule': {'statusVerifiedDate': '2025-01', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-08-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-01-31', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2022-01-31', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2023-12-21', 'studyFirstSubmitQcDate': '2024-01-05', 'studyFirstPostDateStruct': {'date': '2024-01-09', 'type': 'ACTUAL'}, 'resultsFirstSubmitDate': '2024-07-30', 'resultsFirstSubmitQcDate': '2025-01-18', 'resultsFirstPostDateStruct': {'date': '2025-02-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-01-18', 'lastUpdatePostDateStruct': {'date': '2025-02-10', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Zhao Yueqi', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'Yangzhou University'}, 'leadSponsor': {'name': 'Yangzhou University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study was to construct a Fear of Hypoglycemia(FoH) intervention program for type 2 diabetic patients based on the Behaviour Change Wheel (BCW) theory and to investigate the feasibility, acceptability, and initial effects of the program.', 'detailedDescription': 'In this study, eligible participants were randomized in a 1:1 ratio into an intervention group (health education based on BCW theory given on top of regular diabetes health education) and a control group (regular diabetes health education), with a 4-week intervention period and a 4-week follow-up period, for a total of 8 weeks.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus', 'Fear of Hypoglycemia', 'Health Education', 'Impaired Awareness of Hypoglycemia', 'Self-Management'], 'keywords': ['Type 2 Diabetes Mellitus', 'Fear of hypoglycemia', 'Behavior Change Wheel theory', 'Impaired Awareness of Hypoglycemia', 'Self-Management']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 50, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'General diabetes health education', 'type': 'PLACEBO_COMPARATOR', 'description': \"Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\", 'interventionNames': ['Behavioral: General diabetes health education']}, {'label': 'Based on BCW Theory of Health Education', 'type': 'EXPERIMENTAL', 'description': 'A FOH intervention program based on BCW theory was implemented on top of the control group.', 'interventionNames': ['Behavioral: Based on BCW Theory of Health Education']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Based on BCW Theory of Health Education', 'description': 'Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.', 'armGroupLabels': ['Based on BCW Theory of Health Education']}, {'type': 'BEHAVIORAL', 'name': 'General diabetes health education', 'description': \"Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\", 'armGroupLabels': ['General diabetes health education']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Hypoglycemia Fear Behavioral', 'description': \"Hypoglycemia Fear Survey - Behavior Scale consists of 19 entries and is scored on a 5-point Likert scale from 1 to 5, with total scores ranging from 15 (lowest) to 95 (highest), with the higher scores indicating that the patients' hypoglycemia fear-behavior is more pronounced, and the higher the level of fear of hypoglycemia.\", 'timeFrame': 'Baseline, immediately after the intervention and after the 4 weeks follow-up'}, {'measure': 'Hypoglycemia Fear Worry', 'description': \"Hypoglycemic fear Survey - Worry Scale was used to evaluate the patients' hypoglycemic feelings in the past 6 months. There were 13 items in the scale, using 5-point Likert scale, with scores ranging from low to high 0-4, and the total score ranging from 0 (lowest) to 52 (highest). The higher the score, the higher the patient's fear of hypoglycemia.\", 'timeFrame': 'Baseline, immediately after the intervention and after the 4 weeks follow-up'}], 'secondaryOutcomes': [{'measure': 'Gold Rating', 'description': 'Gold Score was first proposed by Professor Gold in the UK in 1994. It is the most commonly used assessment method for Impaired Awareness of Hypoglycemia, which reflects patients\\' awareness of hypoglycemia at the same time. The only question with this approach is, \"Do you know when your low blood sugar started?\" Likert scores 7 on a scale of \"1\" (always aware) to \"7\" (never aware), with an overall score from 1 (lowest) to 7 (highest). An overall score of 1-3 is considered normal hypoglycemic self-awareness, and a score of ≥4 indicates the presence of IAH.', 'timeFrame': 'Baseline, immediately after the intervention and after the 4 weeks follow-up'}, {'measure': 'The Patients Assessment Chronic Illness Care( PACIC)', 'description': 'The Patient Assessment Chronic Care Scale was developed with support from the Johnson Foundation to assess the quality of care provided by healthcare organizations. Patients use this scale to report their perceived level of medical support. The PACIC scale consists of five dimensions and 20 questions, each of which is rated on a 5-point Likert scale (1 to 5), with higher scores (close to 5) indicating greater support from healthcare professionals. The score for each dimension is calculated based on the average score of the items it contains, and the total table score is calculated based on the average score of all 20 items, with a minimum score of 1 and a maximum score of 5. Total scale score ≤1.75 is classified as low level of medical support; An overall average score of 1.75 to 3.5 indicates moderate medical support; Total mean score ≥3.5 was classified as high medical support.', 'timeFrame': 'Baseline, immediately after the intervention and after the 4 weeks follow-up'}, {'measure': 'The Self-management Attitude Scale for Diabetes Patients', 'description': 'The Self-Management Attitude Scale for Diabetic Patients is a sub-scale of the Self-Management Knowledge, Attitude and Behavior Assessment Scale for Diabetic Patients compiled by the Chinese Center for Prevention and Control of Chronic Noncommunicable Diseases (CPCNCD). The scale included five items that assessed patients\\' attitudes toward diabetes health education, diet control, physical activity, medication adherence, and blood glucose monitoring. The 5-point Likert scale was used, with 1 indicating \"very important\" and 5 indicating \"very unimportant\", and the scores were divided into 0.2, 0.4, 0.6, 0.8 and 1.0 in order from low to high. The total score of the five items is the total self-management attitude score (range 1-5), and a score below 3.0 indicates a poor self-management attitude. A score of 3.0 to 4.25 indicates an average self-management attitude, while a score of 4.25 or above indicates a good self-management attitude.', 'timeFrame': 'Baseline, immediately after the intervention and after the 4 weeks follow-up'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Comply with the 2020 Chinese guidelines for the prevention and treatment of type 2 diabetes mellitus\\n* Age ≥18 years\\n* Duration of diabetes mellitus ≥1 year\\n* FOH according to the elevated item endorsement criterion (E I criterion): ≥3 points on any item of the Hypoglycemic Fear-Worry Scale (HFS-WS)\\n* Patients who have the ability to listen, read, write, walk, and cooperate to complete the study\\n* Patients who have a smart phone, and can skillfully use WeChat or telephone to communicate\\n* Voluntarily participate in this study and sign the informed consent form.\\n\\nExclusion Criteria:\\n\\n* Patients with comorbid acute complications or other serious diseases or disorders of consciousness, such as diabetic hypertonic state, tumors, coma, etc.\\n* Patients with comorbid psychiatric diseases or taking psychotropic drugs\\n* Patients who have recently or are participating in other studies on similar topics', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Yueqi Zhao, Bachelor', 'affiliation': 'Yangzhou University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Yangzhou University', 'city': 'Yangzhou', 'state': 'Jiangsu', 'zip': '225000', 'country': 'China', 'geoPoint': {'lat': 32.39722, 'lon': 119.43583}}]}, 'referencesModule': {'references': [{'pmid': '35788767', 'type': 'RESULT', 'citation': 'Zhong W, Lin L, Gong X, Chen Z, Chen Y, Yan S, Zhou Y, Zhang X, Hu H, Tong L, Cheng C, Gu Q, Chen Y, Yu X, Huang Y, Yuan C, Lou M; MISSION investigators. Evaluation of a multicomponent intervention to shorten thrombolytic door-to-needle time in stroke patients in China (MISSION): A cluster-randomized controlled trial. PLoS Med. 2022 Jul 5;19(7):e1004034. doi: 10.1371/journal.pmed.1004034. eCollection 2022 Jul.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'No plans to provide IPD.'}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'Declined to participate (n= 11) Too busy (n= 3) Too sick (n= 2) Not interested (n= 6)', 'groups': [{'id': 'FG000', 'title': 'General Diabetes Health Education', 'description': \"Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\\n\\nGeneral diabetes health education: Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\"}, {'id': 'FG001', 'title': 'Based on BCW Theory of Health Education', 'description': 'A FOH intervention program based on BCW theory was implemented on top of the control group.\\n\\nBased on BCW Theory of Health Education: Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '25'}, {'groupId': 'FG001', 'numSubjects': '25'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '25'}, {'groupId': 'FG001', 'numSubjects': '25'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'General Diabetes Health Education', 'description': \"Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\\n\\nGeneral diabetes health education: Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\"}, {'id': 'BG001', 'title': 'Based on BCW Theory of Health Education', 'description': 'A FOH intervention program based on BCW theory was implemented on top of the control group.\\n\\nBased on BCW Theory of Health Education: Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '25'}, {'groupId': 'BG001', 'value': '25'}, {'groupId': 'BG002', 'value': '50'}]}], 'measures': [{'title': 'Age, Categorical', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '25'}, {'groupId': 'BG001', 'value': '25'}, {'groupId': 'BG002', 'value': '50'}]}], 'categories': [{'title': '<=18 years', 'measurements': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '3'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'groupId': 'BG000', 'value': '7'}, {'groupId': 'BG001', 'value': '11'}, {'groupId': 'BG002', 'value': '18'}]}, {'title': '>=65 years', 'measurements': [{'groupId': 'BG000', 'value': '16'}, {'groupId': 'BG001', 'value': '13'}, {'groupId': 'BG002', 'value': '29'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '25'}, {'groupId': 'BG001', 'value': '25'}, {'groupId': 'BG002', 'value': '50'}]}], 'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '16'}, {'groupId': 'BG001', 'value': '15'}, {'groupId': 'BG002', 'value': '31'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '9'}, {'groupId': 'BG001', 'value': '10'}, {'groupId': 'BG002', 'value': '19'}]}]}]}, {'title': 'Race and Ethnicity Not Collected', 'populationDescription': 'Race and Ethnicity were not collected from any participant.', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'China', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '25'}, {'groupId': 'BG001', 'value': '25'}, {'groupId': 'BG002', 'value': '50'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '25'}, {'groupId': 'BG001', 'value': '25'}, {'groupId': 'BG002', 'value': '50'}]}]}]}, {'title': 'BMI（kg/m^2)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '25'}, {'groupId': 'BG001', 'value': '25'}, {'groupId': 'BG002', 'value': '50'}]}], 'categories': [{'title': '<18.5', 'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '2'}]}, {'title': '18.5~23.9', 'measurements': [{'groupId': 'BG000', 'value': '14'}, {'groupId': 'BG001', 'value': '19'}, {'groupId': 'BG002', 'value': '33'}]}, {'title': '24~28', 'measurements': [{'groupId': 'BG000', 'value': '6'}, {'groupId': 'BG001', 'value': '5'}, {'groupId': 'BG002', 'value': '11'}]}, {'title': '≥28', 'measurements': [{'groupId': 'BG000', 'value': '4'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '4'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Hypoglycemia Fear Behavioral', 'description': \"Hypoglycemia Fear Survey - Behavior Scale consists of 19 entries and is scored on a 5-point Likert scale from 1 to 5, with total scores ranging from 15 (lowest) to 95 (highest), with the higher scores indicating that the patients' hypoglycemia fear-behavior is more pronounced, and the higher the level of fear of hypoglycemia.\", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'score on a scale', 'timeFrame': 'Baseline, immediately after the intervention and after the 4 weeks follow-up', 'groups': [{'id': 'OG000', 'title': 'General Diabetes Health Education', 'description': \"Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\\n\\nGeneral diabetes health education: Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\"}, {'id': 'OG001', 'title': 'Based on BCW Theory of Health Education', 'description': 'A FOH intervention program based on BCW theory was implemented on top of the control group.\\n\\nBased on BCW Theory of Health Education: Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '25'}]}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '59.60', 'spread': '11.61'}, {'groupId': 'OG001', 'value': '63.88', 'spread': '11.63'}]}]}, {'title': 'Immediately after the intervention', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '57.52', 'spread': '12.33'}, {'groupId': 'OG001', 'value': '44.20', 'spread': '5.59'}]}]}, {'title': 'After the 4 weeks follow-up', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '55.16', 'spread': '10.68'}, {'groupId': 'OG001', 'value': '39.72', 'spread': '5.34'}]}]}]}, {'type': 'PRIMARY', 'title': 'Hypoglycemia Fear Worry', 'description': \"Hypoglycemic fear Survey - Worry Scale was used to evaluate the patients' hypoglycemic feelings in the past 6 months. There were 13 items in the scale, using 5-point Likert scale, with scores ranging from low to high 0-4, and the total score ranging from 0 (lowest) to 52 (highest). The higher the score, the higher the patient's fear of hypoglycemia.\", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'score on a scale', 'timeFrame': 'Baseline, immediately after the intervention and after the 4 weeks follow-up', 'groups': [{'id': 'OG000', 'title': 'General Diabetes Health Education', 'description': \"Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\\n\\nGeneral diabetes health education: Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\"}, {'id': 'OG001', 'title': 'Based on BCW Theory of Health Education', 'description': 'A FOH intervention program based on BCW theory was implemented on top of the control group.\\n\\nBased on BCW Theory of Health Education: Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '25'}]}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '32.72', 'spread': '4.09'}, {'groupId': 'OG001', 'value': '32.96', 'spread': '2.89'}]}]}, {'title': 'Immediately after the intervention', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '29.76', 'spread': '2.64'}, {'groupId': 'OG001', 'value': '18.76', 'spread': '3.63'}]}]}, {'title': 'After the 4 weeks follow-up', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '27.16', 'spread': '4.15'}, {'groupId': 'OG001', 'value': '15.44', 'spread': '3.38'}]}]}]}, {'type': 'SECONDARY', 'title': 'Gold Rating', 'description': 'Gold Score was first proposed by Professor Gold in the UK in 1994. It is the most commonly used assessment method for Impaired Awareness of Hypoglycemia, which reflects patients\\' awareness of hypoglycemia at the same time. The only question with this approach is, \"Do you know when your low blood sugar started?\" Likert scores 7 on a scale of \"1\" (always aware) to \"7\" (never aware), with an overall score from 1 (lowest) to 7 (highest). An overall score of 1-3 is considered normal hypoglycemic self-awareness, and a score of ≥4 indicates the presence of IAH.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'score on a scale', 'timeFrame': 'Baseline, immediately after the intervention and after the 4 weeks follow-up', 'groups': [{'id': 'OG000', 'title': 'General Diabetes Health Education', 'description': \"Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\\n\\nGeneral diabetes health education: Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\"}, {'id': 'OG001', 'title': 'Based on BCW Theory of Health Education', 'description': 'A FOH intervention program based on BCW theory was implemented on top of the control group.\\n\\nBased on BCW Theory of Health Education: Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '25'}]}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.84', 'spread': '1.28'}, {'groupId': 'OG001', 'value': '2.88', 'spread': '1.26'}]}]}, {'title': 'Immediately after the intervention', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.32', 'spread': '1.07'}, {'groupId': 'OG001', 'value': '1.68', 'spread': '0.69'}]}]}, {'title': 'After the 4 weeks follow-up', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.84', 'spread': '0.90'}, {'groupId': 'OG001', 'value': '1.28', 'spread': '0.46'}]}]}]}, {'type': 'SECONDARY', 'title': 'The Patients Assessment Chronic Illness Care( PACIC)', 'description': 'The Patient Assessment Chronic Care Scale was developed with support from the Johnson Foundation to assess the quality of care provided by healthcare organizations. Patients use this scale to report their perceived level of medical support. The PACIC scale consists of five dimensions and 20 questions, each of which is rated on a 5-point Likert scale (1 to 5), with higher scores (close to 5) indicating greater support from healthcare professionals. The score for each dimension is calculated based on the average score of the items it contains, and the total table score is calculated based on the average score of all 20 items, with a minimum score of 1 and a maximum score of 5. Total scale score ≤1.75 is classified as low level of medical support; An overall average score of 1.75 to 3.5 indicates moderate medical support; Total mean score ≥3.5 was classified as high medical support.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'score on a scale', 'timeFrame': 'Baseline, immediately after the intervention and after the 4 weeks follow-up', 'groups': [{'id': 'OG000', 'title': 'General Diabetes Health Education', 'description': \"Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\\n\\nGeneral diabetes health education: Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\"}, {'id': 'OG001', 'title': 'Based on BCW Theory of Health Education', 'description': 'A FOH intervention program based on BCW theory was implemented on top of the control group.\\n\\nBased on BCW Theory of Health Education: Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '25'}]}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.42', 'spread': '0.45'}, {'groupId': 'OG001', 'value': '3.40', 'spread': '0.45'}]}]}, {'title': 'Immediately after the intervention', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.69', 'spread': '0.34'}, {'groupId': 'OG001', 'value': '4.45', 'spread': '0.26'}]}]}, {'title': 'After the 4 weeks follow-up', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.55', 'spread': '0.41'}, {'groupId': 'OG001', 'value': '4.46', 'spread': '0.21'}]}]}]}, {'type': 'SECONDARY', 'title': 'The Self-management Attitude Scale for Diabetes Patients', 'description': 'The Self-Management Attitude Scale for Diabetic Patients is a sub-scale of the Self-Management Knowledge, Attitude and Behavior Assessment Scale for Diabetic Patients compiled by the Chinese Center for Prevention and Control of Chronic Noncommunicable Diseases (CPCNCD). The scale included five items that assessed patients\\' attitudes toward diabetes health education, diet control, physical activity, medication adherence, and blood glucose monitoring. The 5-point Likert scale was used, with 1 indicating \"very important\" and 5 indicating \"very unimportant\", and the scores were divided into 0.2, 0.4, 0.6, 0.8 and 1.0 in order from low to high. The total score of the five items is the total self-management attitude score (range 1-5), and a score below 3.0 indicates a poor self-management attitude. A score of 3.0 to 4.25 indicates an average self-management attitude, while a score of 4.25 or above indicates a good self-management attitude.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'score on a scale', 'timeFrame': 'Baseline, immediately after the intervention and after the 4 weeks follow-up', 'groups': [{'id': 'OG000', 'title': 'General Diabetes Health Education', 'description': \"Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\\n\\nGeneral diabetes health education: Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\"}, {'id': 'OG001', 'title': 'Based on BCW Theory of Health Education', 'description': 'A FOH intervention program based on BCW theory was implemented on top of the control group.\\n\\nBased on BCW Theory of Health Education: Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '25'}]}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.91', 'spread': '0.68'}, {'groupId': 'OG001', 'value': '4.10', 'spread': '0.58'}]}]}, {'title': 'Immediately after the intervention', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.21', 'spread': '0.53'}, {'groupId': 'OG001', 'value': '4.78', 'spread': '0.18'}]}]}, {'title': 'After the 4 weeks follow-up', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.28', 'spread': '0.45'}, {'groupId': 'OG001', 'value': '4.83', 'spread': '0.19'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'timeFrame': '2 months', 'description': 'Evaluated through standardized questionnaires, regular assessments by researchers, and periodic laboratory inspections. No participants experienced adverse events.', 'eventGroups': [{'id': 'EG000', 'title': 'General Diabetes Health Education', 'description': \"Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\\n\\nGeneral diabetes health education: Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.\", 'deathsNumAffected': 0, 'deathsNumAtRisk': 25, 'seriousNumAffected': 0, 'seriousNumAtRisk': 25, 'otherNumAffected': 0, 'otherNumAtRisk': 25}, {'id': 'EG001', 'title': 'Based on BCW Theory of Health Education', 'description': 'A FOH intervention program based on BCW theory was implemented on top of the control group.\\n\\nBased on BCW Theory of Health Education: Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.', 'deathsNumAffected': 0, 'deathsNumAtRisk': 25, 'seriousNumAffected': 0, 'seriousNumAtRisk': 25, 'otherNumAffected': 0, 'otherNumAtRisk': 25}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': True, 'restrictiveAgreement': False}, 'pointOfContact': {'title': 'Yueqi Zhao', 'organization': 'Yangzhou University', 'email': 'mz120221975@stu.yzu.edu.cn', 'phone': '13390676131'}}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot_SAP', 'hasProtocol': True, 'hasSap': True, 'hasIcf': False, 'label': 'Study Protocol and Statistical Analysis Plan', 'date': '2021-01-14', 'uploadDate': '2023-12-21T09:59', 'filename': 'Prot_SAP_000.pdf', 'size': 271548}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D007003', 'term': 'Hypoglycemia'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M10053', 'name': 'Hypoglycemia', 'asFound': 'Hypoglycemia', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04190160', 'orgStudyIdInfo': {'id': '141/18 XETD2'}, 'organization': {'fullName': 'University of Rome Tor Vergata', 'class': 'OTHER'}, 'briefTitle': 'Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)', 'officialTitle': 'Unicenter Interventional Study Aimed at Improving the Quality of Life in a Group of Very Old Patients With Type 2 Diabetes With Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)', 'acronym': 'XETD2'}, 'statusModule': {'statusVerifiedDate': '2021-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-11-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-11-22', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2021-03-25', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2019-12-01', 'studyFirstSubmitQcDate': '2019-12-04', 'studyFirstPostDateStruct': {'date': '2019-12-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-08-02', 'lastUpdatePostDateStruct': {'date': '2021-08-03', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Stefano Rizza', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'University of Rome Tor Vergata'}, 'leadSponsor': {'name': 'Stefano Rizza', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This work is aimed at improving the quality of life of older patients affected by type 2 diabetes. The investigators will try to amiliorate the complexity of hypogliceamic treatment in a little group of older patients with type 2 diabetes reducing the number of pills and/or insulin administration using a single daily dose of a fixed combination of insulin degludec and liraglutide. This therapeutic semplification will be done indipendently of pre-existent glicaemic control.', 'detailedDescription': 'Older patients with type 2 diabetes often have numerous coexisting medical problems for which these subjets prescribed multiple medications. Actually, diabetes, hyertension, cardiovascular diseases (CVDs), neurodegenerative diseases (NDDs), digestive and respiratory disorders are common in aged peolple and tend to coexist. Unfortunally, the complex therapy of these diseases increases the risk of adverse drug events. Furthermore, there is marked heterogeneity in health status and functional capacity in older diabetic subjects, often making prescribing decisions complex and challenging. On the other hand, despite of the use of many medicines, undertreatment is also frequent present in the elderly and the probability of underprescription increased significantly with the number of medicines.Both conditions have a detrimental effect on quality of life (QoL) of elderly subjects increasing the risk of disability and death. Therefore, older people should benefit greatly of a simplification of drug regimens and reduction of pill burdens as well as better explanations of the reason for the prescriptions. The combination of insulin degludec (100 units/mL) and liraglutide (3.6 mg/mL), termed IDegLira, was approved in 2014 for the treatment of type 2 diabetes inadequately controlled with oral glucose-lowering agents alone or in combination with a GLP-1 receptor agonist or basal insulin (European indication). Interestingly, RCTs and real-world evidence provided insights into effectiveness and safety in routine clinical practice. However, beyond its known metabolic efficacy IDegLira has a very small hypoglicaemic rate, with a single daily and flexible administration dose and a very good safety profile that makes it suitable for fragile diabetic old patients.'}, 'conditionsModule': {'conditions': ['Type2 Diabetes'], 'keywords': ['elderly, diabetes, safety, quality of life']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 35, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': '6 months treatment', 'type': 'EXPERIMENTAL', 'description': 'replacement of whatever pre-existing hypoglicaemic therapeutic scheme, with or without insulin, with a single daily and flexible administration of IDegLira in a pilot little group of very old diabetic patients', 'interventionNames': ['Drug: IDegLira']}], 'interventions': [{'type': 'DRUG', 'name': 'IDegLira', 'description': 'A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme', 'armGroupLabels': ['6 months treatment']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Self reported quality of Life (CASP-19)', 'description': 'All participants with treatment-related modification of quality of life as assessed by CASP-19', 'timeFrame': '6 months'}, {'measure': 'The Diabetes Treatment Satisfaction (DTSQ)', 'description': 'All participants with treatment-related self reported satisfation for diabetes therapy as assessed by DTSQ', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Glycemic control', 'description': 'Glycaemic control evaluated by treatment-related modification of fasting glucose and HbA1c', 'timeFrame': '6 months'}, {'measure': 'Hypoglycaemia', 'description': 'Self reported hypoglycaemic events rate', 'timeFrame': '6 months'}, {'measure': 'Self reported depression (GDS)', 'description': 'All participants with treatment-related modification of depression as assessed by GDS (Geriatric Depression Scale)', 'timeFrame': '6 months'}, {'measure': 'Hypoglycaemic related hospitalizations', 'description': 'Numbers of treatment-related hypoglycaemic hospitalizations', 'timeFrame': '6 months'}, {'measure': 'Cognitive function (MMSE)', 'description': 'All participants with treatment-related modification of cognitive function as assessed by Mini Mental State Examination (MMSE)', 'timeFrame': '6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* frail very old type 2 diabetes patients without severe cognitive impairment and/or grave depression with 3 or more daily hypoglycaemic drug administrations\\n\\nExclusion Criteria:\\n\\n* e-GFR \\\\< 15 ml/min\\n* any experimental clinical trial participation or every experimental drug use in the previous 6 months before commencing this study\\n* every know or suspected allergic reaction to deglutec or any other GLP-1 agonist\\n* any known contraindication to IDegLira use (as described in product characteristics)\\n* Recent cancer diagnosis (\\\\<3 y) or active radio- or chemo-therapy. Cancer diagnosis older than 3 years before commencing the study is allowed\\n* Mini mental state examination score lower than 14/30 and/or Activity Daily Living score lower than 1/6 and/or Instrumenctal Activity Daily Living lower than 1/8', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '75 Years', 'maximumAge': '99 Years', 'stdAges': ['OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Massimo Federici, Professor', 'affiliation': 'Department of Systems Medicine', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Stefano Rizza', 'city': 'Roma', 'zip': '00133', 'country': 'Italy', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'T6034', 'name': 'Quality of Life', 'asFound': 'Quality of Life', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000629636', 'term': 'Xultophy'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D054795', 'term': 'Incretins'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M419', 'name': 'Liraglutide', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M267475', 'name': 'Xultophy', 'asFound': 'Redo', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M27905', 'name': 'Incretins', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03741660', 'orgStudyIdInfo': {'id': 'Konjac in T2DM'}, 'organization': {'fullName': 'Unity Health Toronto', 'class': 'OTHER'}, 'briefTitle': 'Konjac-Mannan Improves Glycemia and Other Risk Factors for CHD in T2DM', 'officialTitle': 'Konjac-Mannan (Glucomannan) Improves Glycemia and Other Associated Risk Factors for Coronary Heart Disease in Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2018-11', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '1991-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '1992-06', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '1998-06', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-11-07', 'studyFirstSubmitQcDate': '2018-11-13', 'studyFirstPostDateStruct': {'date': '2018-11-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-11-13', 'lastUpdatePostDateStruct': {'date': '2018-11-15', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Unity Health Toronto', 'class': 'OTHER'}, 'collaborators': [{'name': 'Dicofarm', 'class': 'OTHER'}, {'name': 'University of Toronto', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'To examine whether Konjac-mannan fiber improves metabolic control measured by glycemia, lipidemia, and blood pressure in individuals with type-2 diabetes.'}, 'conditionsModule': {'conditions': ['Type2 Diabetes', 'Coronary Heart Disease'], 'keywords': ['konjac', 'type2 diabetes', 'fiber', 'coronary heart disease']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 11, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Konjac-mannan', 'type': 'EXPERIMENTAL', 'description': 'Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet', 'interventionNames': ['Dietary Supplement: konjac glucomannan']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'wheat bran fiber biscuits with NCEP Step II metabolically controlled diet', 'interventionNames': ['Dietary Supplement: wheat bran']}], 'interventions': [{'type': 'DIETARY_SUPPLEMENT', 'name': 'konjac glucomannan', 'description': 'Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ \\\\[100kcal\\\\] of glucommanan)', 'armGroupLabels': ['Konjac-mannan']}, {'type': 'DIETARY_SUPPLEMENT', 'name': 'wheat bran', 'description': 'Wheat bran (hard red wheat bran) fiber enriched biscuits', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'change in total:HDL cholesterol', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'change in fructosamine', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'change in systolic blood pressure', 'timeFrame': 'change from baseline at week 3, relative to control'}], 'secondaryOutcomes': [{'measure': 'change in total cholesterol', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'change in LDL cholesterol', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'change in HDL cholesterol', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'change in apolipoprotein A-1', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'change in apolipoprotain B', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'change in glucose', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'change in insulin', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'diastolic blood pressure', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'change in body weight', 'timeFrame': 'change from baseline at week 3, relative to control'}, {'measure': 'change in apoB:ApoA-1', 'timeFrame': 'change from baseline at week 3, relative to control'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* hyperlipidemia controlled by medication\\n* hypertension controlled by medication\\n* type 2 diabetes controlled by medication\\n* minimum 3 years since onset of all three conditions\\n* sedentary lifestyle\\n\\nExclusion Criteria:\\n\\n* regular smoking\\n* regular alcohol consumption\\n* family history of premature coronary heart disease\\n* hypothyroidism\\n* renal, hepatic or gastrointestinal disease', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D003327', 'term': 'Coronary Disease'}, {'id': 'D003324', 'term': 'Coronary Artery Disease'}, {'id': 'D017202', 'term': 'Myocardial Ischemia'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D001161', 'term': 'Arteriosclerosis'}, {'id': 'D001157', 'term': 'Arterial Occlusive Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M6546', 'name': 'Coronary Artery Disease', 'asFound': 'Coronary Heart Disease', 'relevance': 'HIGH'}, {'id': 'M19506', 'name': 'Myocardial Ischemia', 'asFound': 'Coronary Heart Disease', 'relevance': 'HIGH'}, {'id': 'M6549', 'name': 'Coronary Disease', 'asFound': 'Coronary Heart Disease', 'relevance': 'HIGH'}, {'id': 'M9419', 'name': 'Heart Diseases', 'asFound': 'Heart Disease', 'relevance': 'HIGH'}, {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}, {'id': 'M4469', 'name': 'Arteriosclerosis', 'relevance': 'LOW'}, {'id': 'M4465', 'name': 'Arterial Occlusive Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C022901', 'term': '(1-6)-alpha-glucomannan'}], 'ancestors': [{'id': 'D002400', 'term': 'Cathartics'}, {'id': 'D005765', 'term': 'Gastrointestinal Agents'}], 'browseLeaves': [{'id': 'M342442', 'name': '(1-6)-alpha-glucomannan', 'asFound': 'Procainamide', 'relevance': 'HIGH'}, {'id': 'M27664', 'name': 'Laxatives', 'relevance': 'LOW'}, {'id': 'M5651', 'name': 'Cathartics', 'relevance': 'LOW'}, {'id': 'M8881', 'name': 'Gastrointestinal Agents', 'relevance': 'LOW'}, {'id': 'T223', 'name': 'Manna', 'asFound': 'Procainamide', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'HB', 'name': 'Herbal and Botanical'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06354660', 'orgStudyIdInfo': {'id': '18804'}, 'secondaryIdInfos': [{'id': 'J1I-MC-GZBY', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}], 'organization': {'fullName': 'Eli Lilly and Company', 'class': 'INDUSTRY'}, 'briefTitle': 'Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)', 'officialTitle': 'A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)'}, 'statusModule': {'statusVerifiedDate': '2025-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-04-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-06', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-07', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-04-03', 'studyFirstSubmitQcDate': '2024-04-04', 'studyFirstPostDateStruct': {'date': '2024-04-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-27', 'lastUpdatePostDateStruct': {'date': '2025-02-28', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.'}, 'conditionsModule': {'conditions': ['Diabetes Type 2'], 'keywords': ['Glucose Metabolism Disorders', 'Metabolic Diseases', 'Endocrine System Diseases']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 480, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Retatrutide Dose Level 1', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive retatrutide administered subcutaneously (SC).', 'interventionNames': ['Drug: Retatrutide']}, {'label': 'Retatrutide Dose Level 2', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive retatrutide administered SC.', 'interventionNames': ['Drug: Retatrutide']}, {'label': 'Retatrutide Dose Level 3', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive retatrutide administered SC.', 'interventionNames': ['Drug: Retatrutide']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Participants will receive placebo administered SC.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Retatrutide', 'description': 'Administered SC.', 'armGroupLabels': ['Retatrutide Dose Level 1', 'Retatrutide Dose Level 2', 'Retatrutide Dose Level 3'], 'otherNames': ['LY3437943']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Administered SC.', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from Baseline in Hemoglobin A1c (HbA1c) (%)', 'timeFrame': 'Baseline, Week 40'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants Who Achieve HbA1c < 7.0%', 'timeFrame': 'Week 40'}, {'measure': 'Percentage of Participants Who Achieve HbA1c ≤ 6.5%', 'timeFrame': 'Week 40'}, {'measure': 'Percentage of Participants Who Achieve HbA1c < 5.7%', 'timeFrame': 'Week 40'}, {'measure': 'Change from Baseline in Fasting Serum Glucose', 'timeFrame': 'Baseline, Week 40'}, {'measure': 'Percent Change from Baseline in Body Weight', 'timeFrame': 'Baseline, Week 40'}, {'measure': 'Change from Baseline in Body Weight', 'timeFrame': 'Baseline, Week 40'}, {'measure': 'Percentage of Participants Who Achieve Weight Reduction of ≥ 5%', 'timeFrame': 'Week 40'}, {'measure': 'Percentage of Participants Who Achieve Weight Reduction of ≥ 10%', 'timeFrame': 'Week 40'}, {'measure': 'Percentage of Participants Who Achieve Weight Reduction of ≥ 15%', 'timeFrame': 'Week 40'}, {'measure': 'Percentage of Participants Who Achieve HbA1c ≤ 6.5% and ≥ 10% Weight Reduction', 'timeFrame': 'Week 40'}, {'measure': 'Percent Change from Baseline in Triglycerides', 'timeFrame': 'Baseline, Week 40'}, {'measure': 'Percent Change from Baseline in Non- High-Density Lipoprotein (HDL) Cholesterol', 'timeFrame': 'Baseline, Week 40'}, {'measure': 'Change from Baseline in Systolic Blood Pressure (SBP)', 'timeFrame': 'Baseline, Week 40'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Have Type 2 Diabetes (T2D)\\n* Have HbA1c ≥ 7.0% to ≤ 9.5%\\n* Are naïve to insulin therapy and have not used oral or injectable antihyperglycemic (diabetes) medication for at least 90 days prior to screening\\n* Are of stable weight for at least 90 days prior to screening\\n* Have a Body Mass Index (BMI) ≥ 23.0 kilograms per meter squared (kg/m\\\\^2)\\n\\nExclusion Criteria:\\n\\n* Have Type 1 Diabetes (T1D)\\n* Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening\\n* Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening\\n* Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema\\n* Have an estimated glomerular filtration rate (eGFR) \\\\<15 milliliters/minute/1.73 meter squared (mL/min/1.73 m\\\\^2) as determined by the central laboratory\\n* Have a prior or planned surgical treatment for obesity\\n* Have New York Heart Association Functional Classification IV congestive heart failure\\n* Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening\\n* Have a known clinically significant gastric emptying abnormality\\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years\\n* Have any lifetime history of a suicide attempt\\n* Had chronic or acute pancreatitis\\n* Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2\\n* Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or', 'role': 'CONTACT', 'phone': '1-317-615-4559', 'email': 'clinical_inquiry_hub@lilly.com'}], 'overallOfficials': [{'name': 'Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)', 'affiliation': 'Eli Lilly and Company', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Scottsdale Clinical Trials', 'status': 'RECRUITING', 'city': 'Scottsdale', 'state': 'Arizona', 'zip': '85260', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '480-382-7909'}, {'name': 'Ernest Lee', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'facility': 'Tucson Clinical Research Institute', 'status': 'RECRUITING', 'city': 'Tucson', 'state': 'Arizona', 'zip': '85712', 'country': 'United States', 'contacts': [{'name': 'Girish Karamchandani', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'facility': 'San Fernando Valley Health Institute', 'status': 'RECRUITING', 'city': 'Canoga Park', 'state': 'California', 'zip': '91304', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '818-222-6868'}, {'name': 'Jeffrey London', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.20112, 'lon': -118.59814}}, {'facility': 'Ark Clinical Research', 'status': 'RECRUITING', 'city': 'Long Beach', 'state': 'California', 'zip': '90815', 'country': 'United States', 'contacts': [{'name': 'Martha Navarro', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'facility': 'Northeast Research Institute (NERI)', 'status': 'RECRUITING', 'city': 'Fleming Island', 'state': 'Florida', 'zip': '32003', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '904-541-8225'}, {'name': 'Senan Sultan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 30.0933, 'lon': -81.71898}}, {'facility': 'New Horizon Research Center', 'status': 'RECRUITING', 'city': 'Miami', 'state': 'Florida', 'zip': '33165', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '305-226-3933'}, {'name': 'Lazaro Nunez', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'facility': 'Ezy Medical Research', 'status': 'RECRUITING', 'city': 'Miami', 'state': 'Florida', 'zip': '33175', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '786-483-8162'}, {'name': 'Manuel Fernandez', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'facility': 'Clinical Research of Central Florida', 'status': 'RECRUITING', 'city': 'Winter Haven', 'state': 'Florida', 'zip': '33880', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '863-293-1191 x3674'}, {'name': 'Eduardo Torres', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 28.02224, 'lon': -81.73286}}, {'facility': 'Trinity Research Centers', 'status': 'RECRUITING', 'city': 'Marietta', 'state': 'Georgia', 'zip': '30064', 'country': 'United States', 'contacts': [{'name': 'Jean Philippe', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 33.9526, 'lon': -84.54993}}, {'facility': \"Cotton O'Neil Clinical Research Center\", 'status': 'RECRUITING', 'city': 'Topeka', 'state': 'Kansas', 'zip': '66606', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '785-354-9591'}, {'name': 'Michael Cox', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.04833, 'lon': -95.67804}}, {'facility': 'NECCR PrimaCare Research', 'status': 'RECRUITING', 'city': 'Fall River', 'state': 'Massachusetts', 'zip': '02721', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '508-672-7450'}, {'name': 'Ehab Sorial', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.70149, 'lon': -71.15505}}, {'facility': 'Clinical Research Professionals', 'status': 'RECRUITING', 'city': 'Chesterfield', 'state': 'Missouri', 'zip': '63005', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '636-220-1200'}, {'name': 'Timothy Jennings', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 38.66311, 'lon': -90.57707}}, {'facility': 'Boeson Research MSO', 'status': 'RECRUITING', 'city': 'Missoula', 'state': 'Montana', 'zip': '59804', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '406-763-8833'}, {'name': 'Aubrey Remmers', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 46.87215, 'lon': -113.994}}, {'facility': 'NJ MedCare & NJ Heart', 'status': 'RECRUITING', 'city': 'Linden', 'state': 'New Jersey', 'zip': '07036', 'country': 'United States', 'contacts': [{'name': 'Preet Randhawa', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.62205, 'lon': -74.24459}}, {'facility': 'Accellacare - Wilmington - 1917 Tradd Court', 'status': 'RECRUITING', 'city': 'Wilmington', 'state': 'North Carolina', 'zip': '28401', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '910-815-6108'}, {'name': 'John Parker', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.22573, 'lon': -77.94471}}, {'facility': 'Providence Health Partners-Center for Clinical Research', 'status': 'RECRUITING', 'city': 'Dayton', 'state': 'Ohio', 'zip': '45439', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '937-297-8994'}, {'name': 'Paul Opsahl', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'facility': 'Clinical Research of Philadelphia', 'status': 'RECRUITING', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19114', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '215-676-6696'}, {'name': 'JOSEPH HEETHER', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}, {'facility': 'Preferred Primary Care Physicians', 'status': 'RECRUITING', 'city': 'Uniontown', 'state': 'Pennsylvania', 'zip': '15401', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '724-438-1479'}, {'name': 'Richard Cook II', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.90008, 'lon': -79.71643}}, {'facility': 'Delricht Research - Tobias Gadson Boulevard - Charleston', 'status': 'RECRUITING', 'city': 'Charleston', 'state': 'South Carolina', 'zip': '29407', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '843-432-2477'}, {'name': 'Edward Newton', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.77657, 'lon': -79.93092}}, {'facility': 'Lifedoc Research - Lenox Park Drive', 'status': 'RECRUITING', 'city': 'Memphis', 'state': 'Tennessee', 'zip': '38115', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '901-335-9189'}, {'name': 'Pedro Velasquez-Mieyer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}}, {'facility': 'Clinical Research Associates Inc', 'status': 'RECRUITING', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '615-329-0197'}, {'name': 'Stephan Sharp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'Velocity Clinical Research, Dallas', 'status': 'RECRUITING', 'city': 'Dallas', 'state': 'Texas', 'zip': '75230', 'country': 'United States', 'contacts': [{'name': 'Dan Lender', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'Prime Revival Research Institute, LLC', 'status': 'RECRUITING', 'city': 'Flower Mound', 'state': 'Texas', 'zip': '75028', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '214-432-1198'}, {'name': 'WASIM HAQUE', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 33.01457, 'lon': -97.09696}}, {'facility': 'Valley Institute of Research - Fort Worth', 'status': 'RECRUITING', 'city': 'Fort Worth', 'state': 'Texas', 'zip': '76164', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '817-625-7733'}, {'name': 'alex guevara', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.72541, 'lon': -97.32085}}, {'facility': 'Consano Clinical Research, LLC', 'status': 'RECRUITING', 'city': 'Shavano Park', 'state': 'Texas', 'zip': '78231', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '210-545-4900'}, {'name': 'Michelle Welch', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 29.58495, 'lon': -98.55252}}, {'facility': 'Texas Valley Clinical Research', 'status': 'RECRUITING', 'city': 'Weslaco', 'state': 'Texas', 'zip': '78596', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '956-431-8090'}, {'name': 'Eduardo Luna', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 26.15952, 'lon': -97.99084}}, {'facility': 'Manassas Clinical Research Center', 'status': 'RECRUITING', 'city': 'Manassas', 'state': 'Virginia', 'zip': '20110', 'country': 'United States', 'contacts': [{'name': 'Nabil Andrawis', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 38.75095, 'lon': -77.47527}}, {'facility': 'MultiCare Rockwood Cheney Clinic', 'status': 'RECRUITING', 'city': 'Cheney', 'state': 'Washington', 'zip': '99004', 'country': 'United States', 'contacts': [{'name': 'Jonathan Staben', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.48739, 'lon': -117.57576}}, {'facility': 'Eastside Research Associates', 'status': 'RECRUITING', 'city': 'Redmond', 'state': 'Washington', 'zip': '98052', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '425-869-6828'}, {'name': 'Chad Crystal', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.67399, 'lon': -122.12151}}, {'facility': 'All India Institute of Medical Sciences', 'status': 'RECRUITING', 'city': 'Raipur', 'state': 'Chhattisgarh', 'zip': '492099', 'country': 'India', 'contacts': [{'name': 'Amritava Ghosh', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 21.23333, 'lon': 81.63333}}, {'facility': 'Gujarat Endocrin Pvt Ltd', 'status': 'RECRUITING', 'city': 'Ahmedabad', 'state': 'Gujarat', 'zip': '380052', 'country': 'India', 'contacts': [{'role': 'CONTACT', 'phone': '91-9824042688'}, {'name': 'parag Shah', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 23.02579, 'lon': 72.58727}}, {'facility': 'Nirmal Hospital Pvt Ltd.', 'status': 'RECRUITING', 'city': 'Surat', 'state': 'Gujarat', 'zip': '395002', 'country': 'India', 'contacts': [{'role': 'CONTACT', 'phone': '9825144453'}, {'name': 'Piyush Desai', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 21.19594, 'lon': 72.83023}}, {'facility': 'Victoria Hospital, Bangalore Medical College And Research Institute', 'status': 'RECRUITING', 'city': 'Bangalore', 'state': 'Karnataka', 'zip': '560002', 'country': 'India', 'contacts': [{'name': 'Sivaranjani Holigi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 12.97194, 'lon': 77.59369}}, {'facility': 'Government Medical College - Kozhikode', 'status': 'RECRUITING', 'city': 'Kozhikode', 'state': 'Kerala', 'zip': '673008', 'country': 'India', 'contacts': [{'role': 'CONTACT', 'phone': '9447202748'}, {'name': 'Chandni R', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 11.24802, 'lon': 75.7804}}, {'facility': 'All India Institute of Medical Sciences', 'status': 'NOT_YET_RECRUITING', 'city': 'Bhubaneswar', 'state': 'Odisha', 'zip': '751019', 'country': 'India', 'contacts': [{'role': 'CONTACT', 'phone': '0674-2476789'}, {'name': 'Kishore Behera', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 20.27241, 'lon': 85.83385}}, {'facility': 'Eternal Heart Care Center and Research Institute', 'status': 'RECRUITING', 'city': 'Jaipur', 'state': 'Rajasthan', 'zip': '302020', 'country': 'India', 'contacts': [{'name': 'Jugal Gupta', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 26.91962, 'lon': 75.78781}}, {'facility': 'Brij Medical Centre Private Limited', 'status': 'RECRUITING', 'city': 'Kanpur', 'state': 'Uttar Pradesh', 'zip': '208020', 'country': 'India', 'contacts': [{'name': 'brij mohan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 26.46523, 'lon': 80.34975}}, {'facility': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran', 'status': 'RECRUITING', 'city': 'Mexico City', 'state': 'Distrito Federal', 'zip': '14080', 'country': 'Mexico', 'contacts': [{'role': 'CONTACT', 'phone': '52 5528431978'}, {'name': 'Emma Chávez Manzanera', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'facility': 'Grupo Ollin Care', 'status': 'NOT_YET_RECRUITING', 'city': 'Pachuca', 'state': 'Hidalgo', 'zip': '42000', 'country': 'Mexico', 'contacts': [{'name': 'Eduardo Zambrano Ruiz', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 20.11697, 'lon': -98.73329}}, {'facility': 'Instituto Jalisciense de Investigacion en Diabetes y Obesidad', 'status': 'RECRUITING', 'city': 'Guadalajara', 'state': 'Jalisco', 'zip': '04460', 'country': 'Mexico', 'contacts': [{'role': 'CONTACT', 'phone': '+523336153477'}, {'name': 'Guillermo Gonzalez Galvez', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 20.66682, 'lon': -103.39182}}, {'facility': 'Unidad biomedica avanzada monterrey', 'status': 'RECRUITING', 'city': 'Monterrey', 'state': 'Nuevo León', 'zip': '64460', 'country': 'Mexico', 'contacts': [{'role': 'CONTACT', 'phone': '8113578896'}, {'name': 'Raymundo Garcia Reza', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 25.67507, 'lon': -100.31847}}, {'facility': 'Clínica García Flores SC', 'status': 'RECRUITING', 'city': 'Monterrey', 'state': 'Nuevo León', 'zip': '64610', 'country': 'Mexico', 'contacts': [{'role': 'CONTACT', 'phone': '528183482015'}, {'name': 'Pedro Garcia', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 25.67507, 'lon': -100.31847}}, {'facility': 'Centro de investigación y control metabólico', 'status': 'RECRUITING', 'city': 'San Nicolás de los Garza', 'state': 'Nuevo León', 'zip': '66465', 'country': 'Mexico', 'contacts': [{'role': 'CONTACT', 'phone': '8183094965'}, {'name': 'Ramiro Banda Elizondo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 25.74167, 'lon': -100.30222}}, {'facility': 'Medical Care and Research SA de CV', 'status': 'RECRUITING', 'city': 'Merida', 'state': 'Yucatán', 'zip': '97070', 'country': 'Mexico', 'contacts': [{'role': 'CONTACT', 'phone': '9999203879'}, {'name': 'Christian González Montaño', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 20.97537, 'lon': -89.61696}}, {'facility': 'EME RED Hospitalaria', 'status': 'RECRUITING', 'city': 'Mérida', 'state': 'Yucatán', 'zip': '97000', 'country': 'Mexico', 'contacts': [{'role': 'CONTACT', 'phone': '9992855178'}, {'name': 'Hugo Laviada Molina', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 20.97537, 'lon': -89.61696}}, {'facility': 'Arké SMO S.A de C.V', 'status': 'RECRUITING', 'city': 'Veracruz', 'zip': '91910', 'country': 'Mexico', 'contacts': [{'role': 'CONTACT', 'phone': '2299314102'}, {'name': 'Luis Aguilar Espinoza', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 19.18095, 'lon': -96.1429}}, {'facility': 'Dorado Medical Complex', 'status': 'RECRUITING', 'city': 'Dorado', 'zip': '00646', 'country': 'Puerto Rico', 'contacts': [{'role': 'CONTACT', 'phone': '787278-1576'}, {'name': 'Luis Pagan-Cardona', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 18.45883, 'lon': -66.26767}}, {'facility': 'Ponce Medical School Foundation Inc.', 'status': 'RECRUITING', 'city': 'Ponce', 'zip': '00716', 'country': 'Puerto Rico', 'contacts': [{'role': 'CONTACT', 'phone': '1-787-840-2505'}, {'name': 'Elizabeth Barranco-Santana', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 18.01108, 'lon': -66.61406}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)', 'url': 'https://trials.lilly.com/en-US/trial/472275'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'], 'timeFrame': 'Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.', 'accessCriteria': 'A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.', 'url': 'http://vivli.org/'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05059860', 'orgStudyIdInfo': {'id': '299847'}, 'organization': {'fullName': 'NHS Lothian', 'class': 'OTHER_GOV'}, 'briefTitle': 'Dexcom Hybrid Closed Loop Insulin Pump Study in Type 1 Diabetes', 'officialTitle': 'An Evaluation of the Tandem IQ Insulin Pump and DEXCOM G6 Continuous Glucose Monitoring Hybrid Closed Loop Insulin Delivery System (Control-IQ) on Patient Wellbeing and Diabetes Control in Adults With Type 1 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2024-11', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-06-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-08-11', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-11', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-09-08', 'studyFirstSubmitQcDate': '2021-09-16', 'studyFirstPostDateStruct': {'date': '2021-09-28', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-11-13', 'lastUpdatePostDateStruct': {'date': '2024-11-15', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'NHS Lothian', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'DexCom, Inc.', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Treatment of Type 1 diabetes requires daily insulin therapy given by either multiple daily injections or by continuous infusion via a pump. The insulin dose is calculated taking into consideration blood glucose levels, food intake and activity levels, aiming to avoid high and low readings.\\n\\nThe Tandem t:slim X2™ insulin pump has recently become available in NHS Scotland and can link with the Dexcom G6 continuous glucose monitoring (CGM) system.\\n\\nThe Tandem Control IQ hybrid closed loop system is made up of the Tandem insulin pump communicating wirelessly with the Dexcom G6 CGM. The algorithm within the pump then automatically controls the background (basal) insulin infusion rate. Manually delivered bolus insulin is still required for meals. This system is designed to finely tune insulin delivery and increase the amount of time that glucose is in the target range, reducing hypoglycaemia and hyperglycaemia.\\n\\nInsulin pumps are funded by NHS Scotland, but the Dexcom G6 continuous glucose monitoring system is not, so this hybrid closed loop system is not currently routinely available in NHS Scotland.\\n\\nThe purpose of this study is to gain experience of this system and investigate how effective and acceptable the hybrid closed loop system is for people in Scotland. Participants will be provided with the Dexcom G6 CGM device to link to their current pump to create the hybrid closed loop system for the duration of the study.\\n\\n30 people with Type 1 diabetes who have been using the Tandem pump for at least one month will be invited to participate.\\n\\nThe study will include a screening visit, a 30 day run-in period, 52 week treatment period and 12 week follow-up period. Diabetes control will be measured using HbA1c and downloaded information from the hybrid closed loop system. Participants will also complete questionnaires and a reflective diary.', 'detailedDescription': \"In those without diabetes insulin is automatically secreted according to requirement. The background insulin secretion rate will vary depending on need, and is affected by many factors e.g. activity or stress levels. When a person eats the rise of glucose is sensed and insulin automatically secreted to keep the glucose within a narrow range.\\n\\nPeople with Type 1 diabetes cannot make insulin to control their blood glucose. Insulin is therefore required as treatment. This is given subcutaneously by injection or using an infusion pump. Both background insulin is required and boluses of insulin given when carbohydrate is eaten.\\n\\nIt is difficult to accurately calculate and deliver the correct amount of insulin. More recently standard treatment involved giving one of two injections of long acting insulin and more frequent injections of fast acting insulin when carbohydrate is ingested. The dose of insulin is determined by measuring the ambient glucose level, knowing the amount of carbohydrate in any meal and predicting activity during the subsequent four or five hours.\\n\\nInsulin pumps can be used to provide a pre-tuned variable background insulin infusion with manual intervention to deliver boluses of insulin with food.\\n\\nIn Scotland many people have now replaced finger prick glucose testing with flash glucose monitoring. This uses a small subcutaneous needle that senses subcutaneous glucose levels and, when scanned this sensor will provide a measure of subcutaneous glucose and information on the last 8 hours of glucose values (Flash Glucose monitoring). This system does not currently link to an insulin pump.\\n\\nThe Tandem insulin pump has recently become available in NHS Scotland for those already established on pump therapy.\\n\\nThe Dexcom G6 continuous glucose monitoring (CGM) system provides continuous glucose monitoring (without requiring any scanning by the patient) but is not currently funded within NHS Scotland, except for special circumstances. This system does communicate via bluetooth with the T-slim insulin pump.\\n\\nThe Tandem Control IQ insulin delivery system uses the link between the dexcom glucose sensor and pump to control the background insulin delivery and has been shown to work well in those studied. Patients still have to administer insulin when ingesting carbohydrate. This system is described as a hybrid closed loop system.\\n\\nProblems that can potentially occur using this system include loss of communication between sensor and pump (bluetooth or wired connection), the algorithm not working or glucose readings out with the set ranges resulting in the automatic system turning off.\\n\\nIt is also unknown how acceptable the 'loss of control' is to a more general diabetes population as individuals with diabetes are used to making all the insulin dose decisions very frequently across each day. Confidence in these systems, both by patients and clinicians will be vital if these are to be introduced into more general use.\\n\\nTherefore, the potential for these systems to have a major impact for people with diabetes is clear, but further understanding of the effectiveness and acceptability of such systems in the Scottish population is required.\\n\\nThe Investigator's aim is to investigate the effect of this system compared to current 'best practice' in Scotland, to gain experience in using this system and to investigate the acceptability of this system in the Scottish population.\"}, 'conditionsModule': {'conditions': ['Type 1 Diabetes Mellitus']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'interventions': [{'type': 'DEVICE', 'name': 'Tandem Control IQ Hybrid Closed Loop Insulin Delivery System', 'description': 'The Tandem Control IQ hybrid closed loop insulin delivery system is made up of an externally worn Tandem insulin pump which communicates wirelessly to the Dexcom G6 CGM worn as a patch on the skin. The CGM measures glucose levels transmitting them into the computer within the pump. The computer then calculates how much insulin is required then dose delivery completes the cycle. The Control-IQ™ advanced technology adjusts insulin delivery to avoid glycaemic excursions, while still allowing the user to manually bolus at mealtimes.'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1c', 'description': 'Measurement of HbA1c', 'timeFrame': 'Change from baseline to 20 days after initiation of the sensor, and at 4, 12, 26, 52 and 64 weeks after initiation of the Control-IQ hybrid closed loop system'}, {'measure': 'Severe hypoglycaemia', 'description': 'Self reported severe hypoglycaemia', 'timeFrame': 'Change from the 12 weeks before baseline measures to 20 days after initiation of the sensor, and at 4, 12, 26, 52 and 64 weeks after initiation of the Control-IQ hybrid closed loop system.'}, {'measure': 'Time in range', 'description': 'Percentage of time glucose is in range (download of Dexcom results)', 'timeFrame': 'Change from baseline to 4, 12, 26 and 52 weeks after initiation of the Control-IQ hybrid closed loop system'}, {'measure': 'Time in hypoglycaemia', 'description': 'Percentage of time hypoglycaemic', 'timeFrame': 'Change from baseline to 4, 12, 26 and 52 weeks after initiation of the Control-IQ hybrid closed loop system.'}, {'measure': 'Time Control IQ system not in use', 'description': 'Time when the Control-IQ hybrid closed loop system is not in use', 'timeFrame': 'From baseline to 4, 12, 26 and 52 weeks after initiation of the system.'}], 'secondaryOutcomes': [{'measure': 'Diabetes distress score', 'description': \"Diabetes distress score. The Diabetes Distress Score yields a total diabetes distress scale score plus 4 sub scale scores, each addressing a different kind of distress. The score is the sum of the patient's responses to the appropriate items divided by the number of items in that scale. A mean question score of 3 or higher (moderate distress) as a level of distress is worthy of clinical attention.\", 'timeFrame': 'Change from baseline to 4, 12, 26, 52 and 64 weeks after initiation of the Control-IQ hybrid closed loop system.'}, {'measure': 'Problem Areas In Diabetes questionnaire', 'description': 'Problem Areas In Diabetes questionnaire. Each question has five possible answers with a value from 0 to 4, with 0 representing \"no problem\" and 4 \"a serious problem\".\\n\\nThe scores are added up and multiplied by 1.25, generating a total score between 0 - 100.\\n\\nPatients scoring 40 or higher may be at the level of \"emotional burnout\" and warrant special attention.\\n\\nPAID scores in these patients may drop 10-15 points in response to educational and medical interventions.\\n\\nAn extremely low score (0-10) combined with poor glycaemic control may be indicative for denial', 'timeFrame': 'Change from baseline to 4, 12, 26, 52 and 64 weeks after initiation of the Control-IQ hybrid closed loop system.'}, {'measure': 'Patient experience diary', 'description': 'Patient written report of experience using hybrid closed loop system', 'timeFrame': 'Change from baseline to 4, 12, 26, 52 and 64 weeks after initiation of the Control-IQ hybrid closed loop system.'}, {'measure': 'Hospital Anxiety and Depression questionnaire', 'description': 'Hospital Anxiety and Depression questionnaire. Minimum score is 0, maximum score is 21. 0-7 = Normal, 8-10 = Borderline abnormal (borderline case), 11-21 = Abnormal (case)', 'timeFrame': 'Change from baseline to 4, 12, 26, 52 and 64 weeks after initiation of the Control-IQ hybrid closed loop system.'}], 'otherOutcomes': [{'measure': 'Gold Hypoglycaemia questionnaire', 'description': 'Gold hypoglycaemia questionnaire. The Gold score measures hypoglycaemia awareness. Minimum score is 1 - always aware, Maximum score is 7 - never aware. The higher the score the greater the risk of severe hypoglycaemia', 'timeFrame': 'Change from baseline to 4, 12, 26, 52 and 64 weeks after initiation of the Control-IQ hybrid closed loop system.'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Clinical diagnosis of Type 1 diabetes\\n* Established on the Tandem pump for at least 1 month, using novorapid or humalog insulin\\n* HbA1c 40-90 mmol/mol inclusive within the previous 30 days or taken at screening\\n* Total daily dose of insulin 10-100 units\\n* Willing to attend study visits and complete all study assessments\\n* Able to give informed consent\\n\\nExclusion Criteria:\\n\\n* Pregnant or planning pregnancy\\n* Any disorder which, in the investigators' opinion might jeopardise the patient's safety or compliance with the protocol\\n* Life expectancy less than one year\\n* Severe renal impairment (eGFR \\\\<30ml/min)\\n* Weight \\\\<25kg\\n* Patients prescribed hydroxycarbamide\", 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': '30 patients with Type 1 diabetes will be recruited in NHS Lothian', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'John McKnight', 'affiliation': 'NHS Lothian', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Professor John McKnight', 'city': 'Edinburgh', 'state': 'Lothian', 'zip': 'EH4 2XU', 'country': 'United Kingdom', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D007328', 'term': 'Insulin'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'asFound': 'Program', 'relevance': 'HIGH'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00690638', 'orgStudyIdInfo': {'id': 'PHX1149-PROT301'}, 'secondaryIdInfos': [{'id': 'EudraCT 2008-002614-22'}], 'organization': {'fullName': 'Phenomix', 'class': 'INDUSTRY'}, 'briefTitle': 'Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus', 'officialTitle': 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotherapy in Subjects With Type 2 Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2010-01', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2008-07'}, 'primaryCompletionDateStruct': {'date': '2010-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2010-04', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2008-06-02', 'studyFirstSubmitQcDate': '2008-06-03', 'studyFirstPostDateStruct': {'date': '2008-06-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2010-04-12', 'lastUpdatePostDateStruct': {'date': '2010-04-13', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Hans-Peter Guler, MD / Chief Medical Officer', 'oldOrganization': 'Phenomix Corporation'}, 'leadSponsor': {'name': 'Phenomix', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Forest Laboratories', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotherapy in Subjects with Type 2 Diabetes Mellitus'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus'], 'keywords': ['dutogliptin', 'PHX1149', 'DPP4 inhibitor']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 480, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1', 'type': 'PLACEBO_COMPARATOR', 'description': 'Placebo', 'interventionNames': ['Drug: Placebo']}, {'label': '2', 'type': 'EXPERIMENTAL', 'description': 'PHX1149T 200 mg', 'interventionNames': ['Drug: PHX1149T']}, {'label': '3', 'type': 'EXPERIMENTAL', 'description': 'PHX1149T 400 mg', 'interventionNames': ['Drug: PHX1149T']}], 'interventions': [{'type': 'DRUG', 'name': 'PHX1149T', 'description': '200 mg', 'armGroupLabels': ['2'], 'otherNames': ['dutogliptin']}, {'type': 'DRUG', 'name': 'PHX1149T', 'description': '400 mg', 'armGroupLabels': ['3'], 'otherNames': ['dutogliptin']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Placebo', 'armGroupLabels': ['1']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To demonstrate changes in HbA1c', 'timeFrame': 'Day 28 to Day 196'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Type 2 diabetes mellitus, drug naïve or willing to wash-out from existing oral therapy\\n* BMI 25 to 48 kg/m2, inclusive\\n* HbA1c 7.0% - 10.0%, inclusive\\n* Age 18 to 75 years, inclusive\\n\\nExclusion Criteria:\\n\\n* Currently on 3 or more oral antidiabetic drugs or insulin.\\n* Type 1 diabetes mellitus', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '85 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'city': 'Norwalk', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 33.90224, 'lon': -118.08173}}, {'city': 'Orange', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'city': 'Santa Ana', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 33.74557, 'lon': -117.86783}}, {'city': 'Daytona Beach', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 29.21081, 'lon': -81.02283}}, {'city': 'Kissimmee', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 28.30468, 'lon': -81.41667}}, {'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'city': 'Honolulu', 'state': 'Hawaii', 'country': 'United States', 'geoPoint': {'lat': 21.30694, 'lon': -157.85833}}, {'city': 'Brockton', 'state': 'Massachusetts', 'country': 'United States', 'geoPoint': {'lat': 42.08343, 'lon': -71.01838}}, {'city': 'St. Louis', 'state': 'Missouri', 'country': 'United States', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'geoPoint': {'lat': 39.12713, 'lon': -84.51435}}, {'city': 'El Paso', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 31.75872, 'lon': -106.48693}}, {'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'city': 'Norfolk', 'state': 'Virginia', 'country': 'United States', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'city': 'Caba', 'state': 'Buenos Aires', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'city': 'La Plata', 'state': 'Buenos Aires', 'country': 'Argentina', 'geoPoint': {'lat': -34.92145, 'lon': -57.95453}}, {'city': 'Lanús', 'state': 'Buenos Aires', 'country': 'Argentina', 'geoPoint': {'lat': -34.70252, 'lon': -58.3955}}, {'city': 'Paraná', 'state': 'Entre Ríos', 'country': 'Argentina', 'geoPoint': {'lat': -31.73197, 'lon': -60.5238}}, {'city': 'Rosario', 'state': 'Santa Fé', 'country': 'Argentina', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'city': 'Corrientes', 'country': 'Argentina', 'geoPoint': {'lat': -27.4806, 'lon': -58.8341}}, {'city': 'Salta', 'country': 'Argentina', 'geoPoint': {'lat': -24.7859, 'lon': -65.41166}}, {'city': 'Hyderabad', 'state': 'Andhara Pradesh', 'country': 'India', 'geoPoint': {'lat': 17.38405, 'lon': 78.45636}}, {'city': 'Bangalore', 'state': 'Karnataka', 'country': 'India', 'geoPoint': {'lat': 12.97194, 'lon': 77.59369}}, {'city': 'Gulbarga', 'state': 'Karnataka', 'country': 'India', 'geoPoint': {'lat': 17.33583, 'lon': 76.83757}}, {'city': 'Mumbai', 'state': 'Maharashtra', 'country': 'India', 'geoPoint': {'lat': 19.07283, 'lon': 72.88261}}, {'city': 'Nagpur', 'state': 'Maharashtra', 'country': 'India', 'geoPoint': {'lat': 21.14631, 'lon': 79.08491}}, {'city': 'Nashik', 'state': 'Maharashtra', 'country': 'India', 'geoPoint': {'lat': 19.99727, 'lon': 73.79096}}, {'city': 'Navi Mumbai', 'state': 'Maharashtra', 'country': 'India', 'geoPoint': {'lat': 19.03681, 'lon': 73.01582}}, {'city': 'Pune', 'state': 'Maharashtra', 'country': 'India', 'geoPoint': {'lat': 18.51957, 'lon': 73.85535}}, {'city': 'Chennai', 'state': 'Tamil Nadu', 'country': 'India', 'geoPoint': {'lat': 13.08784, 'lon': 80.27847}}, {'city': 'Kelantan', 'country': 'Malaysia'}, {'city': 'Kuala Lumpur', 'country': 'Malaysia', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'city': 'Perak', 'country': 'Malaysia'}, {'city': 'Sarawak', 'country': 'Malaysia'}, {'city': 'Arequipa', 'state': 'Arequipa Region', 'country': 'Peru', 'geoPoint': {'lat': -16.39889, 'lon': -71.535}}, {'city': 'Chiclayo-Lambayeque', 'state': 'Chiclayo', 'country': 'Peru'}, {'city': 'Cercado de Lima', 'state': 'Lima', 'country': 'Peru'}, {'city': 'Lince', 'state': 'Lima', 'country': 'Peru', 'geoPoint': {'lat': -12.08295, 'lon': -77.03484}}, {'city': 'San Isisdro', 'state': 'Lima', 'country': 'Peru'}, {'city': 'San Miguel', 'state': 'Lima', 'country': 'Peru', 'geoPoint': {'lat': -13.0125, 'lon': -73.98083}}, {'city': 'Manila', 'state': 'NCR', 'country': 'Philippines', 'geoPoint': {'lat': 14.6042, 'lon': 120.9822}}, {'city': 'Quezon City', 'state': 'NCR', 'country': 'Philippines', 'geoPoint': {'lat': 14.6488, 'lon': 121.0509}}, {'city': 'San Juan', 'state': 'NCR', 'country': 'Philippines', 'geoPoint': {'lat': 14.6, 'lon': 121.0333}}, {'city': 'Cebu City', 'state': 'VII', 'country': 'Philippines', 'geoPoint': {'lat': 10.31672, 'lon': 123.89071}}, {'city': 'Jud. Brasov', 'state': 'Brasov', 'country': 'Romania'}, {'city': 'Sector 1', 'state': 'Bucharest', 'country': 'Romania', 'geoPoint': {'lat': 44.4132, 'lon': 26.12806}}, {'city': 'Sector 2', 'state': 'Bucharest', 'country': 'Romania', 'geoPoint': {'lat': 44.4132, 'lon': 26.12806}}, {'city': 'Brasov', 'country': 'Romania', 'geoPoint': {'lat': 45.64861, 'lon': 25.60613}}, {'city': 'Galati', 'country': 'Romania', 'geoPoint': {'lat': 45.45, 'lon': 28.05}}, {'city': 'Ploiesti', 'country': 'Romania', 'geoPoint': {'lat': 44.95, 'lon': 26.01667}}, {'city': 'Sibiu', 'country': 'Romania', 'geoPoint': {'lat': 45.8, 'lon': 24.15}}, {'city': 'Ratchatavi', 'state': 'Bangkok', 'country': 'Thailand'}, {'city': 'Muang', 'state': 'Khon Kaen', 'country': 'Thailand'}, {'city': 'Simferopol', 'state': 'Crimean Autonomy Republic', 'country': 'Ukraine', 'geoPoint': {'lat': 44.95719, 'lon': 34.11079}}, {'city': '2A Postysheva Pr.', 'state': 'Kharkov', 'country': 'Ukraine'}, {'city': 'Ivano-Frankivsk', 'country': 'Ukraine', 'geoPoint': {'lat': 48.9215, 'lon': 24.70972}}, {'city': 'Kharkiv', 'country': 'Ukraine', 'geoPoint': {'lat': 49.98081, 'lon': 36.25272}}, {'city': 'Kiev', 'country': 'Ukraine', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'city': 'Kyiv', 'country': 'Ukraine', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'city': 'Lviv', 'country': 'Ukraine', 'geoPoint': {'lat': 49.83826, 'lon': 24.02324}}, {'city': 'Poltava', 'country': 'Ukraine', 'geoPoint': {'lat': 49.59373, 'lon': 34.54073}}, {'city': 'Vinnytsa', 'country': 'Ukraine', 'geoPoint': {'lat': 49.23278, 'lon': 28.48097}}, {'city': 'Zaporizhzhia', 'country': 'Ukraine', 'geoPoint': {'lat': 50.60727, 'lon': 31.78792}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M27957', 'name': 'Dipeptidyl-Peptidase IV Inhibitors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03289338', 'orgStudyIdInfo': {'id': 'ZoleMethCNO'}, 'organization': {'fullName': 'PGIMER', 'class': 'UNKNOWN'}, 'briefTitle': \"Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus\", 'officialTitle': \"Zoledronic Acid or Methylprednisolone in the Management of Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus: A Randomized, Double-blind, Placebo Controlled Trial\"}, 'statusModule': {'statusVerifiedDate': '2019-07', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2016-06-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-12-31', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2018-12-31', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2017-09-18', 'studyFirstSubmitQcDate': '2017-09-18', 'studyFirstPostDateStruct': {'date': '2017-09-20', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-07-13', 'lastUpdatePostDateStruct': {'date': '2019-07-16', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Ashu Rastogi', 'investigatorTitle': 'Assistant Professor', 'investigatorAffiliation': 'Post Graduate Institute of Medical Education and Research, Chandigarh'}, 'leadSponsor': {'name': 'Post Graduate Institute of Medical Education and Research, Chandigarh', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'Charcot neuropathic osteoarthropathy (CNO) is a progressively destructive process resulting from significant peripheral neuropathy of almost any aetiology. Diabetes mellitus has emerged as the commonest cause of CNO.\\n\\nThe Charcot foot in diabetes poses many clinical challenges in its diagnosis and management. The lacuna primarily lies in delineation of its etio-pathogenesis and consequently in targeted treatment modalities. Although traditional approaches focus on neurotraumatic and neurovascular theories, these fail to explain all the features of CNO, hence, other hypotheses have been put forward.The current belief is that once the disease is triggered in a susceptible individual, it is mediated through a process of uncontrolled inflammation which, in turn, leads to osteolysis, fractures and joint destruction. Of these processes, the involvement of the receptor activator of nuclear factor- кB (RANK) ligand /RANK/osteoprotegerin (OPG) system in the process of acute CNO is particularly appealing and suggests new pharmacological approaches.\\n\\nStandard modalities of treatment include offloading and casting. Although various trials have analysed the impact of medical agents including bisphosphonates, teriparatide and bone stimulation techniques, the results have been either inconclusive or not translated into clinical practice. Hence, there is no efficacious treatment of active CNO apart from the traditional offloading. In view of recent advances in understanding of the disease process, the target of intervention should, logically, be interruption of the inflammatory cascade and subsequent osteoclast resorption. Zoledronic acid is the most potent bisphosphonate that has been studied in clinical trials to date and has the distinctive profile of strong inhibitory activity on the enzyme farnesyl pyrophosphate synthase, essential for osteoclast function. Methylprednisolone conceivably has a potential benefit by offsetting the RANKL/OPG system involved. There have been conflicting reports with bisphophosphonates in active CNO and Zoledronic acid has been infrequently used despite being the most potent. Glucocorticoids including methylprednisolone have also not been systematically tried in this condition.\\n\\nWe hypothesise that targeting the inflammatory cascade with Methylprednisolone and osteoclast mediated damage by Zoledronic acid will address the basic etiopathogenesis of active CNO and may result in earlier resolution of the disease activity. The above mentioned hypothesis is hence, planned to be tested in a randomised, double-blind, placebo-controlled study.', 'detailedDescription': 'Charcot\\'s neuroarthropathy has been identified since 1883, yet we have much to learn about the pathophysiology and evidence based treatment options. Active CNO is characterised by repetitive trauma leading to inflammation in an insensate foot. This includes polypeptide receptor activator of nuclear factor-kB ligand (RANKL) which triggers the synthesis of the nuclear transcription factor nuclear factor-kb (NF-kb), and this in turn stimulates the maturation of osteoclasts from osteoclast precursor cells. At the same time, NF-kb stimulates the production of the glycopeptide osteoprotegerin (OPG) from osteoblasts. This \"decoy receptor\" acts as an effective antagonist of RANKL . It has been suggested that this results in continual production of proinflammatory cytokines, RANKL, NF-kb, and osteoclasts, which in turn leads to continuing local osteolysis .This has adequately demonstrated by an increase in proinflammatory phenotypes of monocytes in those with active Charcot foot when compared with diabetic control subjects. Also osteoclasts generated in vitro in the presence of macrophage colony-stimulating factor and RANKL from patients with active CN have been shown to be more aggressive and exhibit an increase in their resorptive activity compared with control subjects. Motor neuropathy contributes to altered structure of the foot with resultant abnormal loading. Finally, it is possible that peptides like calcitonin gene-related peptide (CGRP) , which normally antagonizes the synthesis of RANKL, reduced due to neuropathy increase the RANKL expression. Diabetes may predispose to occurrence of CNO through a number of mechanisms. Apart from the presence of neuropathy and possible osteopenia, these include the effects of advanced glycation end products, reactive oxygen species, and oxidized lipids, which may all enhance the expression of RANKL in diabetes.\\n\\nThe average delay in the diagnosis of acute Charcot has been reported to be around 29 weeks. Common misdiagnoses include cellulitis, erysipelas, deep vein thrombosis (DVT), venous insufficiency, gout, pseudogout, acute inflammatory arthritis, fracture, sprain, tumor, septic arthritis, osteomyelitis, Sudeck\\'s atrophy, and rheumatoid arthritis. Delay in prompt diagnosis and initiation of treatment results in progression of the pathology resulting in rigid osseous deformity of the foot increasing the risk of callus formation, ulceration, infection, and lower extremity amputation by 15- to 40-fold .With the propensity for misdiagnosis and high potential for progression to a rigid foot deformity, early recognition and prompt initiation of treatment is paramount.\\n\\nRadiographs are the primary initial imaging method for evaluation of the foot in suspected CNO. However, they may initially be normal or show subtle fractures and dislocations. Magnetic resonance imaging (MRI) has a higher sensitivity that allows detection of subtle changes in the early stages of active CNO when X-rays could still be normal. MRI primarily images protons in fat and water and can depict anatomy and pathology in both soft tissue and bone in great detail because of its unique capability of differentiating tissues with high detail.\\n\\nTreatment of CNO is aimed at offloading the foot, treating bone disease, and preventing further foot fractures. Because of the various etiologies of increased local bone resorption and/or secondary osteoporosis in patients with CNO and limited randomized placebo-controlled trials in this area, treatment guidelines are largely based on professional opinion rather than the highest level of clinical evidence. Hence, there remains a dearth of evidence based medical management for Charcot neuroarthropathy. Offloading at the acute active stage of the Charcot foot is the most important management strategy and could arrest the progression to deformity. Ideally, the foot should be immobilized in an irremovable total contact cast (TCC), which is initially replaced at 3 days, then checked each week. Edema reduction is often remarkable in the first few weeks of treatment. The cast should be changed frequently to avoid \"pistoning\" as the edema subsides.\\n\\nHowever, It is important to take into consideration that TCC may actually have unfavorable consequences including unnatural stress patterns, increased instability, loss of muscle tone, proprioception and boe density.Also, they are not designed to affect the underlying physiological mechanisms that cause bone destruction.In this context, treatment by antiresorptive drugs emerges as an attractive option. Bone turnover in patients with active CNO is excessive, hence bisphosphonates, by inhibiting osteoclast mediated resorption, have an important role to play. However, there is little evidence to support their use at present.Both oral and intravenous bisphosphonates have been studied in the treatment of CNO in small randomized, double-blind, controlled trials or in retrospective controlled studies. Whatever the precise pathophysiological mechanism of CNO, bone resorption and osteoclastic hyperactivity is a major feature of the early acute stage of this condition and makes the use of bone-resorption-inhibiting agents such as bisphosphonates(BPs) a logical therapeutic approach. Theoretically, pharmacological treatment of CNO by BPs, which inhibit osteoclastic resorption and may have direct anti-inflammatory properties, might slow or even stop the bony destruction through its ability to cause macrophage apoptosis.\\n\\nSelby et al first reported the use of a BP in the treatment of CNO. They administered 30 mg pamidronate i.v.,followed by five infusions of pamidronate 60 mg every 2 weeks for 12 weeks in six patients with diabetes and acute CNO. The treatment was associated with improvement in local pain and a significant reduction in the activity of the CNO as measured by the decrease in the temperature of the affected foot, from 3.4±0.7°C (mean±SE) to 1.0±0.5°C (p 0.05). There was also a significant reduction in bone turnover as judged by alkaline phosphatase (ALP) level, which fell by 25±3% compared with initial values (p\\\\<0.001). Stansberry et al in 1999 reported a decrease in peak cutaneous blood flow in response to the infusion of 90 mg pamidronate i.v. over 24 h in 20 patients with diabetes and CNO, suggesting a anti-inflammatory action of pamidronate. In 1999, Young reported anecdotally two cases of diabetic acute CNO treated with i.v. infusions of pamidronate associated with immobilisation. After 3 months, the clinical outcome was judged favourable with a reduction in clinical signs and an absence of deformity. Pakarinen et al. in 2002 retrospectively analysed clinical records and X-rays of 36 feet with CNO from 1994 to 2000. Eighteen patients received BPP treatment (pamidronate 30-60 mg i.v. once a week for 6 weeks) and no complications were registered. There was no statistically significant difference in casting time between patients who received (11 weeks) and patients who did not receive (13 weeks) pamidronate. In this series, pamidronate infusions were used for selected individuals without any striking benefits or disadvantages. Clinically, treatment with BP was associated with a more rapid decrease in skin temperature, but this effect was not sustained. Effect on the pain differed among studies, with one showing improvement but another showing none.Pakarinen et al tried Zoledronic acid and reported that it did not reduce the duration of immobilization. Rather there was an increase in total time for casting in subjects treated with Zoledronic acid.Similar observations about longer time of immobilization with the use of BPs was reported in the the recent multicentric observational audit of acute diabetic CNO in the UK.\\n\\nRandomised trials looking into possible use of glucocorticoids in management of active CNO have not been undertaken, possibly because of only recent understanding of the role of acute inflammation triggering the osteolysis that characterizes CNO. Intravenous supra-pharmacological doses of corticosteroids have been used in various inflammatory and autoimmune conditions because they are cumulatively less toxic than sustained steroid treatment at lower quantitative dosage. Their action is supposed to be mediated through non-genomic actions within the cell. When corticosteroids are administered as pulses, an immediate profound anti-inflammatory effect is achieved, inflammatory damage is minimized , toxicity is low and there is no prolonged suppressive effect on the hypothalamic-pituitary axis. But there are no randomized trials looking into the efficacy and potential benefit of methylprednisolone in CNO as of date.\\n\\nHence this trial was designed to compare the therapeutic efficacy and profiles of two well known agents Zoledronic acid (antiresorptive) and Methylprednisolone (anti-inflammatory) in patients of diabetes mellitus with active CNO of foot.'}, 'conditionsModule': {'conditions': ['Charcot Arthropathy', 'Diabetes Complications'], 'keywords': ['Zoledronic acid', 'Methylprednisolone', \"Active Charcot's disease\"]}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 36, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Zoledronic acid', 'type': 'EXPERIMENTAL', 'description': 'Bisphosphonate Zoledronic acid', 'interventionNames': ['Drug: Zoledronic Acid']}, {'label': 'Methylprednisolone', 'type': 'ACTIVE_COMPARATOR', 'description': 'Glucocorticoid Methylprednisolone', 'interventionNames': ['Drug: Methylprednisolone']}, {'label': 'Placebos', 'type': 'PLACEBO_COMPARATOR', 'description': 'Placebo normal saline', 'interventionNames': ['Drug: Placebos']}], 'interventions': [{'type': 'DRUG', 'name': 'Zoledronic Acid', 'description': 'Zoledronic acid 5mg intravenous once a month for 3 months', 'armGroupLabels': ['Zoledronic acid'], 'otherNames': ['Zoledronate']}, {'type': 'DRUG', 'name': 'Methylprednisolone', 'description': 'Methylprednisolone 1gm intravenous once a month for 3 months', 'armGroupLabels': ['Methylprednisolone'], 'otherNames': ['MPS']}, {'type': 'DRUG', 'name': 'Placebos', 'description': 'Normal saline intravenous once a month for 3 months', 'armGroupLabels': ['Placebos'], 'otherNames': ['NS']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Time for resolution of active Charcot foot', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Time for reduction in levels of inflammatory cytokines (>= 50%)', 'timeFrame': '6 months'}, {'measure': 'Time for radiologic resolution/reduction on MRI', 'timeFrame': '6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients with Diabetes mellitus with active Charcot neuroarthropathy of foot as per following criteria:\\n\\nClinical criteria\\n\\n1. Warm, swollen and erythematous foot\\n2. Skin temperature exceeding 2°C at the clinically suspected site of the affected foot compared with a similar site on the contralateral foot (infrared thermometer)\\n\\nRadiologic criteria MRI suggestive of acute CNO-\\n\\n1. Osteopenia\\n2. Joint subluxation\\n3. Normal or low normal marrow signal on T1 MRI\\n4. Bone marrow edema on T2W MRI\\n5. Microfractures\\n6. Cortical disruption\\n7. Several joints or bones\\n8. Preserved periarticular subcutaneous fat\\n\\nExclusion Criteria:\\n\\n1. Infected foot ulcer\\n2. Osteoporosis at lumbar spine or hip\\n3. Gouty arthritis\\n4. Active peptic ulcer disease\\n5. Any prior long term steroid intake for asthma, SLE, RA or IBD in the last 3 months\\n6. eGFR 45 ml/min or less\\n7. Active dental caries\\n8. Active upper gastrointestinal disease\\n9. Uncorrected Vitamin D deficiency\\n10. Peripheral vascular disease (ABI 0.9 or less)', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Anil Bhansali, DM', 'affiliation': 'Post Graduate Institute of Medical Education and Research, Chandigarh', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Department of Endocrinology, PGIMER', 'city': 'Chandigarh', 'zip': '160012', 'country': 'India', 'geoPoint': {'lat': 30.73629, 'lon': 76.7884}}]}, 'referencesModule': {'references': [{'pmid': '34748565', 'type': 'DERIVED', 'citation': 'Das L, Rastogi A, Jude EB, Prakash M, Dutta P, Bhansali A. Long-term foot outcomes following differential abatement of inflammation and osteoclastogenesis for active Charcot neuroarthropathy in diabetes mellitus. PLoS One. 2021 Nov 8;16(11):e0259224. doi: 10.1371/journal.pone.0259224. eCollection 2021.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001177', 'term': 'Arthropathy, Neurogenic'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D048909', 'term': 'Diabetes Complications'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M10621', 'name': 'Joint Diseases', 'relevance': 'LOW'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'relevance': 'LOW'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'relevance': 'LOW'}, {'id': 'M26004', 'name': 'Diabetes Complications', 'asFound': 'Diabetes Complications', 'relevance': 'HIGH'}, {'id': 'M4485', 'name': 'Arthropathy, Neurogenic', 'asFound': 'Charcot Arthropathy', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077211', 'term': 'Zoledronic Acid'}, {'id': 'D008775', 'term': 'Methylprednisolone'}, {'id': 'D000077555', 'term': 'Methylprednisolone Acetate'}, {'id': 'D008776', 'term': 'Methylprednisolone Hemisuccinate'}, {'id': 'D011239', 'term': 'Prednisolone'}, {'id': 'C009935', 'term': 'Prednisolone acetate'}, {'id': 'C021322', 'term': 'Prednisolone hemisuccinate'}, {'id': 'C009022', 'term': 'Prednisolone phosphate'}], 'ancestors': [{'id': 'D000893', 'term': 'Anti-Inflammatory Agents'}, {'id': 'D000932', 'term': 'Antiemetics'}, {'id': 'D001337', 'term': 'Autonomic Agents'}, {'id': 'D018373', 'term': 'Peripheral Nervous System Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D005765', 'term': 'Gastrointestinal Agents'}, {'id': 'D005938', 'term': 'Glucocorticoids'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D018696', 'term': 'Neuroprotective Agents'}, {'id': 'D020011', 'term': 'Protective Agents'}, {'id': 'D018931', 'term': 'Antineoplastic Agents, Hormonal'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}, {'id': 'D050071', 'term': 'Bone Density Conservation Agents'}], 'browseLeaves': [{'id': 'M11749', 'name': 'Methylprednisolone', 'asFound': 'Who are', 'relevance': 'HIGH'}, {'id': 'M1833', 'name': 'Methylprednisolone Acetate', 'asFound': 'Who are', 'relevance': 'HIGH'}, {'id': 'M11750', 'name': 'Methylprednisolone Hemisuccinate', 'asFound': 'Who are', 'relevance': 'HIGH'}, {'id': 'M14120', 'name': 'Prednisolone', 'asFound': 'Who are', 'relevance': 'HIGH'}, {'id': 'M229449', 'name': 'Prednisolone acetate', 'asFound': 'Who are', 'relevance': 'HIGH'}, {'id': 'M211887', 'name': 'Prednisolone hemisuccinate', 'asFound': 'Who are', 'relevance': 'HIGH'}, {'id': 'M248881', 'name': 'Prednisolone phosphate', 'asFound': 'Who are', 'relevance': 'HIGH'}, {'id': 'M9047', 'name': 'Glucocorticoids', 'relevance': 'LOW'}, {'id': 'M1699', 'name': 'Zoledronic Acid', 'asFound': 'Sitting', 'relevance': 'HIGH'}, {'id': 'M7346', 'name': 'Diphosphonates', 'relevance': 'LOW'}, {'id': 'M4217', 'name': 'Anti-Inflammatory Agents', 'relevance': 'LOW'}, {'id': 'M4251', 'name': 'Antiemetics', 'relevance': 'LOW'}, {'id': 'M8881', 'name': 'Gastrointestinal Agents', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}, {'id': 'M20773', 'name': 'Neuroprotective Agents', 'relevance': 'LOW'}, {'id': 'M21869', 'name': 'Protective Agents', 'relevance': 'LOW'}, {'id': 'M20966', 'name': 'Antineoplastic Agents, Hormonal', 'relevance': 'LOW'}, {'id': 'M26165', 'name': 'Bone Density Conservation Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'}, {'abbrev': 'AnEm', 'name': 'Antiemetics'}, {'abbrev': 'NeuroAg', 'name': 'Neuroprotective Agents'}, {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'BDCA', 'name': 'Bone Density Conservation Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01375738', 'orgStudyIdInfo': {'id': '4-2011-0109'}, 'organization': {'fullName': 'Yonsei University', 'class': 'OTHER'}, 'briefTitle': 'Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With Diabetes Mellitus', 'officialTitle': 'The Effect and Mechanism of Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With DM Who Receive Surgical Treatment'}, 'statusModule': {'statusVerifiedDate': '2012-09', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2011-07'}, 'primaryCompletionDateStruct': {'date': '2013-06', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2014-05', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2011-05-27', 'studyFirstSubmitQcDate': '2011-06-15', 'studyFirstPostDateStruct': {'date': '2011-06-17', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2012-09-12', 'lastUpdatePostDateStruct': {'date': '2012-09-13', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'ji yeong an', 'investigatorTitle': 'assistant professor', 'investigatorAffiliation': 'Yonsei University'}, 'leadSponsor': {'name': 'Yonsei University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'This study is to investigate the effect of gastrectomy on remission of type 2 diabetes in patients with gastric cancer and type 2 diabetes, to investigate the mechanism of blood glucose alteration and intestinal hormonal signaling by the reconstruction methods, and to evaluate the applicability and efficacy of Roux-en-Y gastrojejunostomy after gastrectomy in gastric cancer patients with diabetes.', 'detailedDescription': 'Purpose:\\n\\n* To investigate the effect of gastrectomy on remission of type 2 diabetes in patients with gastric cancer and type 2 diabetes\\n* To investigate the mechanism of blood glucose alteration and intestinal hormonal signaling by the reconstruction methods\\n* To evaluate the applicability and efficacy of Roux-en-Y gastrojejunostomy after gastrectomy in gastric cancer patients with diabetes\\n\\nContents:\\n\\n* Evaluation of the status of diabetes in gastric cancer patients with DM after gastrectomy\\n\\n  * Comparison of two reconstruction types after gastrectomy Bypass duodenum and upper jejunum: Roux-en-Y gastrojejunostomy Preservation of duodenal passage: Gastroduodenostomy\\n  * Analysis for biochemical markers reflecting diabetic status: fasting glucose, postprandial 2h glucose, HbA1c, C-peptide, lipid profile\\n* Correlation of parameters associated with diabetes and GI hormones\\n\\n  * Measurement of GI hormones which have an effect on glucose tolerance\\n\\n    * Insulin, glucagon, IGF-1, GLP-1, Neuropeptide Y, Ghrelin, Leptin\\n  * Correlation of reconstruction methods, parameters of diabetes and GI hormone levels\\n  * Evaluation of mechanism of Roux-en-Y gastrojejunostomy on controlling diabetes\\n* Evaluation of Feasibility of Roux-en-Y gastrojejunostomy in gastric cancer surgery in patients with DM\\n\\n  * Degree of high blood glucose control, the amount of antidiabetic medication, costs for DM treatment, quality of life assessment\\n  * Analysis for the mechanism of gastrointestinal physiology to diabetes control'}, 'conditionsModule': {'conditions': ['Gastric Cancer', 'Diabetes'], 'keywords': ['Early gastric cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Gastroduodenostomy', 'type': 'ACTIVE_COMPARATOR', 'description': 'Arm 1: undergo gastroduodenostomy after distal gastrectomy for gastric cancer', 'interventionNames': ['Procedure: Gastroduodenostomy']}, {'label': 'Roux-en Y gastrojejunostomy', 'type': 'EXPERIMENTAL', 'description': 'Arm 2: undergo Roux-en Y gastrojejunostomy after distal gastrectomy for gastric cancer', 'interventionNames': ['Procedure: Roux-en Y gastrojejunostomy']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Roux-en Y gastrojejunostomy', 'description': 'After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25\\\\~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30\\\\~40cm from the new gastric-jejunal junction.', 'armGroupLabels': ['Roux-en Y gastrojejunostomy']}, {'type': 'PROCEDURE', 'name': 'Gastroduodenostomy', 'description': 'After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.', 'armGroupLabels': ['Gastroduodenostomy']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Blood sugar stabilization after gastrectomy', 'description': 'By comparing the difference between fasting blood sugar and postprandial blood glucose, blood sugar stabilization after gastrectomy will be maesured.', 'timeFrame': 'three months after surgery'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patient who are older than 20 years and younger than 80 years\\n* Histologically confirmed gastric adenocarcinoma located lower one third of stomach\\n* Postoperative confirmed pT1N0, pT2N0, pT1N1\\n* Informed consent\\n\\nExclusion Criteria:\\n\\n* Previous history of treatment for other malignancy or inflammatory disease\\n* Preoperative uncontrolled serious comorbidity\\n* Vulnerable Subjects(pregnant women, children, cognitively impaired persons etc.)\\n* Patient who experience any complications requiring reoperation following gastrectomy', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '20 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Severance Hospital', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '120-752', 'country': 'Korea, Republic of', 'contacts': [{'name': 'Ji Yeong An, MD', 'role': 'CONTACT', 'phone': '82-2-2228-2100', 'email': 'jar319@yuhs.ac'}, {'name': 'Yoo-Min Kim, MD', 'role': 'CONTACT', 'email': 'AUG79@yuhs.ac'}], 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}]}, 'referencesModule': {'references': [{'pmid': '20863527', 'type': 'BACKGROUND', 'citation': 'Yang J, Li C, Liu H, Gu H, Chen P, Liu B. Effects of subtotal gastrectomy and Roux-en-Y gastrojejunostomy on the clinical outcome of type 2 diabetes mellitus. J Surg Res. 2010 Nov;164(1):e67-71. doi: 10.1016/j.jss.2010.07.004. Epub 2010 Jul 30.'}, {'pmid': '34523717', 'type': 'DERIVED', 'citation': 'Nishizaki D, Ganeko R, Hoshino N, Hida K, Obama K, Furukawa TA, Sakai Y, Watanabe N. Roux-en-Y versus Billroth-I reconstruction after distal gastrectomy for gastric cancer. Cochrane Database Syst Rev. 2021 Sep 15;9(9):CD012998. doi: 10.1002/14651858.CD012998.pub2.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D013274', 'term': 'Stomach Neoplasms'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D013272', 'term': 'Stomach Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M16064', 'name': 'Stomach Neoplasms', 'asFound': 'Gastric Cancer', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'}, {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'}, {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'}, {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'}, {'id': 'M16062', 'name': 'Stomach Diseases', 'relevance': 'LOW'}, {'id': 'T5486', 'name': 'Stomach Cancer', 'asFound': 'Gastric Cancer', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06190938', 'orgStudyIdInfo': {'id': 'Observation'}, 'organization': {'fullName': 'Syrian Private University', 'class': 'OTHER'}, 'briefTitle': 'Diabetes Complications and Hearing Loss', 'officialTitle': 'The Relationship Between Diabetes, Its Neurological and Optical Complications, and Hearing Loss.'}, 'statusModule': {'statusVerifiedDate': '2023-12', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-06-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-11-12', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2022-12-22', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2023-10-20', 'studyFirstSubmitQcDate': '2023-12-19', 'studyFirstPostDateStruct': {'date': '2024-01-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-12-19', 'lastUpdatePostDateStruct': {'date': '2024-01-05', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Mohamad Zaid Mohamad Samer Ahmad Abdalla', 'investigatorTitle': 'Dr in Damascus university in general internal medicine', 'investigatorAffiliation': 'Syrian Private University'}, 'leadSponsor': {'name': 'Syrian Private University', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Observation study, shows the relation between diabetes, its neurological and optical complication and hearing loss, by asking participants questions about there age,BMI,job,the history of any cataract,diabetes retinopathy or heart attack,hypertension,swollen or tingling legs and take there consent to measure the hearing impairment.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus', 'Diabetes Complications', 'Hearing Loss'], 'keywords': ['Diabetes retinopathy', 'Cataract']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '2 Weeks', 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 87, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'The relation between diabetes, its neurological and optical complications with hearing loss'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The Demographic characteristics were classified into four groups: Gender, Financial status, Educational level, and Profession.', 'description': 'Gender was either male or female. Income was divided into three categories: Low Income (those who were unable to provide even the basics for themselves), Fair Income (basics and some additional expenses), and High Income. Professions were divided into four types: Retired, Housewife, Worker and Student. Educational degree was categorized as Lower than High School, High School, or Higher than High School. Hypertension was measured and considered higher than normal when exceeded 140/90 mmHg. Both height and weight were measured to calculate the BMI of each subject.\\n\\nWeight was measured in kilograms. Height was measured in meters. BMI that scored less than 25, between 25-30, 30 or more was considered, underweight normal, and obese respectively.\\n\\n\"The number of patients diagnosed with diabetes who showed signs of hearing impairment at certain stages of their lives, and how this related to other neurological signs, is being investigated.', 'timeFrame': 'The study took 6 months to finish it with hard work, it was hard to reach our participants so it tooks 2 weeks from us for each participant to finish our survey'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Diabetics who signed consent for the study.\\n* Diabetics who have filled out the form completely.\\n* Diabetics who have undergone a pure tone hearing screening test .\\n\\nExclusion Criteria:\\n\\n* Patients with glandular disease causing hearing loss.\\n* Patients with traumatic ear injury.\\n* Patients who have recently had a middle or inner ear infection.\\n* History of acoustic neuroma.\\n* Patients are under active treatment with medications that have a toxic effect on the auditory cells.\\n* Patients with diabetic foot.\\n* The patient's occupation or residence is within a noisy environment.\", 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'We collected participants from the clinical of Damascus hospital', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'locations': [{'facility': 'Mohamad Zaid Ahmad Abdalla', 'city': 'Damascus', 'country': 'Syrian Arab Republic', 'geoPoint': {'lat': 33.5102, 'lon': 36.29128}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot_SAP', 'hasProtocol': True, 'hasSap': True, 'hasIcf': False, 'label': 'Study Protocol and Statistical Analysis Plan', 'date': '2022-12-11', 'uploadDate': '2023-12-19T08:43', 'filename': 'Prot_SAP_000.pdf', 'size': 416211}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D034381', 'term': 'Hearing Loss'}, {'id': 'D003638', 'term': 'Deafness'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D048909', 'term': 'Diabetes Complications'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D006311', 'term': 'Hearing Disorders'}, {'id': 'D004427', 'term': 'Ear Diseases'}, {'id': 'D010038', 'term': 'Otorhinolaryngologic Diseases'}, {'id': 'D012678', 'term': 'Sensation Disorders'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}], 'browseLeaves': [{'id': 'M14999', 'name': 'Retinal Diseases', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M5638', 'name': 'Cataract', 'relevance': 'LOW'}, {'id': 'M24420', 'name': 'Hearing Loss', 'asFound': 'Hearing Loss', 'relevance': 'HIGH'}, {'id': 'M6840', 'name': 'Deafness', 'asFound': 'Hearing Loss', 'relevance': 'HIGH'}, {'id': 'M26004', 'name': 'Diabetes Complications', 'asFound': 'Diabetes Complications', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M9400', 'name': 'Hearing Disorders', 'relevance': 'LOW'}, {'id': 'M7601', 'name': 'Ear Diseases', 'relevance': 'LOW'}, {'id': 'M12961', 'name': 'Otorhinolaryngologic Diseases', 'relevance': 'LOW'}, {'id': 'M15490', 'name': 'Sensation Disorders', 'relevance': 'LOW'}, {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC11', 'name': 'Eye Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC09', 'name': 'Ear, Nose, and Throat Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06331338', 'orgStudyIdInfo': {'id': '202310085RIND'}, 'organization': {'fullName': 'National Taiwan University Hospital', 'class': 'OTHER'}, 'briefTitle': 'Effects of Using Decision Cycle for Person-Centered Glycemic Management in Type 2 Diabetes', 'officialTitle': 'Research on the Effectiveness of Using Decision Cycle for Person-Centered Glycemic Management on Self-Care Behaviors in Outpatients With Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2025-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-02-14', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-10-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-03-20', 'studyFirstSubmitQcDate': '2024-03-20', 'studyFirstPostDateStruct': {'date': '2024-03-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-10', 'lastUpdatePostDateStruct': {'date': '2025-02-12', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'National Taiwan University Hospital', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Decision cycle for person-centered glycemic management is a new diabetes decision making .It is defined as a purposefully designed holistic care intervention .The goal is to improve the self-care behavior of patients with type 2 diabetes, thereby improving glycated hemoglobin levels and delaying the occurrence of complications.', 'detailedDescription': 'The \"Decision Cycle for Person-Centered Glycemic management\" jointly proposed by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) in 2018 , which develops treatment goals and plans based on the patient\\'s personal preferences, values, and goals.\\n\\nParticipants will be divided into two groups(treatment group 、control group).Treatment group will accept the \"Decision Cycle for Person-Centered Glycemic Management \" .It is a person-centered diabetes decision making. Control group will accept the traditional diabetes self-management education. It content focuses more on teaching relevant knowledge and some skills.It is a educator-centered approach.\\n\\nBaseline / pre-intervention test (after signing informed consent form) post-intervention test (after finishing intervention) Researchers will compare treatment group and control group to see if treatment group has better performance on self-care Behaviors and glycated hemoglobin levels .'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes'], 'keywords': ['Decision Cycle for Person-Centered Glycemic Management', 'Self-Care Behaviors', 'Type 2 Diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 130, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'New health education:use [Decision Cycle for Person-Centered Glycemic Management ]', 'type': 'EXPERIMENTAL', 'description': 'It is a person-centered approach to care. Treatment goals and plans should be cotreated with people with diabetes based on their individual preferences, values, and goals.', 'interventionNames': ['Behavioral: Decision Cycle for Person-Centered Glycemic Management']}, {'label': 'Traditional diabetes self-management education', 'type': 'ACTIVE_COMPARATOR', 'description': 'It is a educator-centered approach to care.', 'interventionNames': ['Other: Traditional diabetes self-management education']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Decision Cycle for Person-Centered Glycemic Management', 'description': 'It is defined as a purposefully designed holistic care intervention that improve self-management .', 'armGroupLabels': ['New health education:use [Decision Cycle for Person-Centered Glycemic Management ]']}, {'type': 'OTHER', 'name': 'Traditional diabetes self-management education', 'description': 'Traditional diabetes self-management education content focuses more on teaching relevant knowledge and some skills.', 'armGroupLabels': ['Traditional diabetes self-management education']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'glycemic control (HbA1c)', 'description': 'The HbA1c level is a marker of the average blood glucose levels over a period of the last 2-3 months.', 'timeFrame': 'Before the task and 3 months post intervention'}], 'secondaryOutcomes': [{'measure': 'Diabetes Self-Care Behavior Scale', 'description': 'It is contains 20 likert-scaled (1-5) items, it assessed the frequency with which patients performed the diabetes self-care behaviors, including how often took diabetes medications, exercise, blood glucose monitor, diet . A higher score indicates greater self care behavior .', 'timeFrame': 'Before the task and 3 months post intervention'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Patients diagnosed with type 2 diabetes by a physician.\\n2. Age: 18 years or above.\\n3. Glycated hemoglobin (HbA1c ) test value: 7.5-9.0 %\\n4. No diabetic oral medications, insulin and glucagon-like peptide-1 were replaced in the outpatient when the case was admitted.\\n5. No pregnancy during the study period.\\n6. After the researcher explains the purpose of the research, the research subjects agree to join this researcher.\\n7. Those who are conscious and able to take care of themselves.\\n8. There is no diagnostic certificate from the American Psychiatric Association's Diagnostic Manual of Mental Disorders, Fourth Edition (DSM-IV)of all mental illnesses.\\n9. Those who can communicate in Mandarin and Taiwanese.\\n\\nExclusion Criteria:\\n\\n1. Patients diagnosed with type 1 diabetes by a physician.\\n2. Age: Under 18 years old.\\n3. Glycated hemoglobin test value: less than 7.5 % and greater than 9.0 %\\n4. Those who replaced oral diabetes medications, insulin and glucagon-like peptide- 1 at the outpatient at the time of admission.\\n5. Pregnancy during the study period.\\n6. Those who are unable to take care of themselves and express themselves.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Chia-Hui Tsai', 'role': 'CONTACT', 'phone': '886926124093', 'email': 'mtsai0322@gmail.com'}, {'name': 'Kang-Chih Fan', 'role': 'CONTACT', 'phone': '886972654308', 'email': 'ntuhendocrine@gmail.com'}], 'overallOfficials': [{'name': 'Kang-Chih Fan', 'affiliation': 'National Taiwan University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'National Taiwan University Hospital', 'status': 'RECRUITING', 'city': 'Hsinchu', 'zip': '302', 'country': 'Taiwan', 'contacts': [{'name': 'Chia-Hui Tsai', 'role': 'CONTACT', 'phone': '886926124093', 'email': 'mtsai0322@gmail.com'}], 'geoPoint': {'lat': 24.80361, 'lon': 120.96861}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03037190', 'orgStudyIdInfo': {'id': 'LUDU'}, 'organization': {'fullName': 'Lund University', 'class': 'OTHER'}, 'briefTitle': 'Preservation of Residual Beta Cell Mass and Prevention of Celiac Disease in Children With Recent Onset Type 1 Diabetes', 'officialTitle': 'Investigation Whether a Gluten Free Diet After the Onset of Type 1 Diabetes (T1D) Can Better Preserve the Remaining Beta Cell Mass and at the Same Time Prevent the Development of Celiac Disease (CD) in These Patients.', 'acronym': 'Diabglut'}, 'statusModule': {'statusVerifiedDate': '2018-08', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2015-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2020-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2017-01-26', 'studyFirstSubmitQcDate': '2017-01-30', 'studyFirstPostDateStruct': {'date': '2017-01-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2018-08-22', 'lastUpdatePostDateStruct': {'date': '2018-08-23', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Annelie Carlsson', 'investigatorTitle': 'Associate Professor', 'investigatorAffiliation': 'Lund University'}, 'leadSponsor': {'name': 'Lund University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The overall aim of this project is to investigate whether a gluten free diet after the onset of type 1 diabetes (T1D) can better preserve the remaining beta cell mass and at the same time prevent the development of Celiac Disease (CD) in these patients.\\n\\nSpecific aims\\n\\n• To study whether gluten free diet during one year after the onset of diabetes influence the appearance and duration of clinical remission in children with Type 1 diabetes.\\n\\nNew data show that a gluten free diet is beneficial concerning the insulin production after the onset of diabetes. The investigators want to investigate if gluten is a triggering protein for the destruction of the beta cell function after the onset of diabetes by comparing children who have a normal diet compared to children with a gluten free diet during one year after the onset of the disease.\\n\\n* To study whether a gluten free diet during one year after the onset of diabetes prevent the development of Celiac Disease in these children and the impact of having two diseases It is known that it is almost 10 times more common that children with Type 1 Diabetes (IDDM) develop Celiac Disease (CD) than the general population and that most of these children (6-7 %) develop CD after the onset of Diabetes and within 5 years. Based on our new data that CD is preventable to some extent the investigators plan to perform randomized controlled studies if it is possible to prevent or postpone CD by means after the onset of IDDM.\\n* To investigate the impact of gluten free diet on the regulation of autoimmune responses The investigators will test the hypothesis that gluten free diet in children with recent onset T1D will implement immune regulation and inhibit the activation of potentially autoreactive T cells.', 'detailedDescription': 'General project outline Our aim is to perform a intervention study whether one year gluten free diet in children with newly diagnosed TID would make it possible to influence the speed of the beta-cells destruction and if this diet decrease the risk to develop CD after the disease A power calculation shows that we would need 600 participants to detect clinically relevant effects (see power calculation). As the power calculation is based on estimated effects we plan to first perform a pilot study including 100 patients. Based on the results of the pilot study we then plan to continue to design a larger study to get more robust information.\\n\\nAll children will also at the start study and, after 1 and 2 years receive a KID-screen form to study the quality of life of time in children with diabetes and to compare children with diabetes without CD and to them who will develop or have undiagnosed CD. Furthermore all children will also be monitored by a dietician during the study period, at onset, after 1 and 2 years according to the content (protein, fat, carbohydrate, gluten and vitamins) during the study.\\n\\nPopulation Consecutive patients with recent onset of diabetes at Swedish paediatric clinics are given information about the study and they and their parents are asked to participate in the trial.\\n\\nInformed consent given by patients and guardians/parents and inclusion criteria are; 1. Type 1 diabetes according to the ADA classification with \\\\< 1 months diabetes duration at time of screening 2. Age 3.00 -17.99 years at time of screening 3. Fasting C-peptide at time of screening ≥ 0.12 nmol/L Exclusion Criteria\\n\\n1. Inability or unwillingness to comply with the provisions of this protocol\\n2. Deemed by the investigator not being able to follow instructions and/or follow the study protocol Recruitment and Screening Eligible subjects and their parent(s) / guardian(s) will have the study explained to them, and will receive a written patient information. If, after this, the subjects agree to participate, they will personally sign and date the written informed consent form. In accordance with the Declaration of Helsinki, the investigator must explain to the patient that they have the right to withdraw from the study at any time, and that this will in no way prejudice their future treatment\\n\\nSample size, power calculation:\\n\\nWe are planning the study as a continuous response from independent control and experimental subjects with 1 control per experimental subject. In a similar study the response within each subject group was normally distributed with standard deviation 0,19. If the true difference in the experimental and control means is 0,05 we will need to study 250 subjects and 250 controls to be able to reject the null hypothesis that the population means of the experimental and control group are equal with a probability (power) 0,8. The Type 1 error probability associated with this test of this null hypothesis is 0,05. Recalculation of sample size is needed on a pilot study, which we have chosen to 100 subjects, 50 in each group. This field also benefit from that smaller and shorter trials are conducted to obtain initial sense of efficacy prior to undertake a fully powered study.\\n\\nThe risk to develop CD in the children with gluten free diet will be compared to the 8000 children in the BDD who had been followed yearly with transglutaminse autoantibodies for CD.\\n\\nStudy Design The trial is designed as a 2-arm not randomized, open, multicentre study comparing 1 year of gluten free diet with normal diet. In the pilot study 100 patients will be recruited at 7 sites in Sweden (and if the pilot study shows expected results we will include all 43 Swedish pediatric clinics and altogether an estimated 600 patients). The patients will not be randomized into two parallel groups as it could influence the compliance to a normal diet. Instead we will recruit group A (50 patients) during the first year and group B with 50 age and sex-matched patients during the second year. Group A will eat gluten free diet for a year after the onset of diabetes and B normal diet. Both groups will follow the same procedures according to the study visits and clinical routines in our diabetes care and follow up.\\n\\nEligibility: Patients who qualify for the study have to have a C-peptide over above 0.12 nmol/L and will be assigned with a number and this screening number together with the clinics, site number, will be used as patient identification. The patients will be assessed for eligibility at the screening visit (Visit 1) prior to the start of treatment with glutenfree diet and screened with a MMTT (mixed meal tolerance test) and fasting C-peptide levels.\\n\\nThe patients will be followed for a total study period of 60 months which includes not more than 6 extra visits for the study (however these visits may be combined with regular diabetes care visits though all children with diabetes use to attend outpatient clinic at least every 3 month and more often at the onset of the disease) Visit 1; 2 month within the onset, MMT and fasting C-peptide Visit 2; If eligible, randomized to group A (the first 50), contact with a dietitian, information of GFD, within 3 month from onset Visit 3; at 6 months; fasting C-peptide, immunological analyses and contact with a dietician; questionnaire and a registry (before the visit one week registry of the diet intake) Visit 4; at 12 months; MMTT fasting C-peptide, HbA1c, immunological analyses. HbA1c, immunological analyses for research, contact with a dietician; questionnaire and a registry (before the visit one week registry of the diet intake) Visit 5; at 18 months, MMTT fasting C-peptide, HbA1c, immunological analyses. HbA1c, immunological analyses, including Ttg (transglutaminse) Visit 6; at 24 months, MMTT fasting C-peptide, HbA1c, immunological analyses. HbA1c, immunological analyses, including Ttg (transglutaminse) yearly until 60 months. Questionnaire about quality of life and gluten content.\\n\\nBoth group A and B will have same information and visits according to the diabetes care where contacts with a dietician is mandatory, but arm A will need special information about a gluten free diet and will also have x-support according to gluten free products.\\n\\nBoth group A and B will be followed according to CD risk during 5 years with Ttg annually as a clinical routine.\\n\\nExperimental strategy\\n\\nAIM 1\\n\\n* To investigate changes in beta-cell function the patients will undergo an MMTT (measuring C-peptide, 90 minute value and AUCmean 0-120 min) at basile baseline (Visit 1) to 12 and 18 months). Our research nurse will perform this test on all patients included at the different sites and the samples are analyzed at the Clinical Chemistry at SUS, Malmö.\\n* We will also investigate and compare the proportion of patients with a stimulated maximum C-peptide level above 0.2 nmol/L after 12 and 18 months respectively as well as fasting C-peptide, change between baseline and month 6, 12 and 18 months between the groups.\\n* Differences between metabolic control, Hemoglobin A1c (HbA1c), change between baseline and subsequent visits\\n* Hemoglobin A1c (HbA1c, marker of metabolic control)) as marker for long term hyperglycemia will be analyzed at baseline and subsequent visits in both groups. We will also study if there are differences in exogenous insulin dose per kg body weight and 24 hours, change between baseline and subsequent visits as indirect marker of beta cell insulin secretion.\\n\\nAIM 2 To follow the development of gluten-induced humoral autoimmunity, IgA anti-tissue-transglutaminase autoantibodies (Ttg) will be determined in blood samples collected at the onset, before insulin therapy,, and yearly up to five year after the onset of TID. Ttg autoantibodies will be analyzed by enzyme-linked immunosorbent assay Aim 3\\n\\n• To investigate the immunoregulatory effect of gluten-free diet we will perform a detailed analysis of the magnitude and the phenotype of both gliadin- and tTG-specific T cells. Quantitative analysis of antigen-specific T cells will be performed using multicolor flow cytometry and cytokine secretion Gender and ethnicity All our data will respect to gender and ethnicity is evaluated if there are any predictive factors associated: Diabetes is the autoimmune disease, which is more common in boys than girl, and the reason for this is unknown and Celiac Disease is more common in girls.\\n\\nEthical considerations In spite of a very heavy, intensive, expensive treatment many patients with TID get life-threatening serious both acute and late complications. At diagnosis many patients have some slight residual insulin secretion. As long as this is the case it is much easier to keep blood glucose stable, the incidence of hypoglycaemia decreases as well as the risk of keto-acidosis. A trial with a gluten free diet is not very complicated and it is safe but may be a burden for the children and families involved. Gluten free special products are often more expensive, few products and are often considered not so tasty but when summarizing the pros and cons, there is a clear possibility of therapeutic benefit of great importance with no risk.\\n\\nClinical implications Toward an individualized treatment: To find predictive a factors determining the remission period is important for people who develop diabetes. Every month in remission increase the quality of life, increase metabol control and thereby postpone late complications. To find triggering factors for to rate of beta-cells destruction unable us to design a more individualized treatment in respective individual. Increased remission period and decreased risk of developing Celiac Disease. Gluten free diet is a safe administer, well tolerable for the patients and the main long-term goal is to find a treatment at onset of Type 1 diabetes in young patients which is easy and safe and preserve residual insulin secretion and give the patients a better quality of life, with less acute complications and in the long run less risk of late complications. The identification of exogenous factors triggering and driving beta-cell destruction offers a potential means for intervention aimed at the prevention of T1D. Environmental modification is likely to offer the most powerful strategy for effective prevention of T1D, because such an approach can target the whole population or at least that proportion of the population carrying increased genetic disease susceptibility.\\n\\nDiet is a cornerstone in the diabetes treatment and individuals with diabetes must always be much aware of the carbohydrate content in the food which limits the arena of different beverages and make life more complicated and if the individual has both IDDM and CD this is even more complicated and limit the social and quality of life. If this study could prevent some individuals to develop CD it would increase their life quality extensively.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 1', 'Remission', 'Celiac Disease in Children']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': '•The trial is designed as a 2-arm not randomized, open, multicentre study comparing 1 year of gluten free diet with normal diet', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 160, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Group A', 'type': 'EXPERIMENTAL', 'description': 'Group A:withdrawal of gluten from the diet, Group A will have a gluten free diet for a year after the onset of diabetes', 'interventionNames': ['Other: withdrawal of gluten from the diet']}, {'label': 'B normal diet', 'type': 'NO_INTERVENTION', 'description': 'Group B will have normal not glutenfree diet, no planned intervention'}], 'interventions': [{'type': 'OTHER', 'name': 'withdrawal of gluten from the diet', 'description': 'Gluten free diet the same recommendations as for patients with diabetes and known celiac disease', 'armGroupLabels': ['Group A']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Preservation of beta cells function', 'description': 'Differences in c-peptide production between the Groups A and B, 12 and 18 months after the onset of diabetes.', 'timeFrame': 'within 2years after the onset of type 1 diabetes'}], 'secondaryOutcomes': [{'measure': 'Prevention of Celiac DIsease', 'description': 'Differencies in incidence of Celiac Disease between the two groups, after onset of diabetes', 'timeFrame': 'Five years after the onset of Diabetes'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Type 1 diabetes according to the ADA classification with \\\\< 1 months diabetes duration at time of screening\\n* Age 3.00 -17.99 years at time of screening\\n* Fasting C-peptide at time of screening ≥ 0.12 nmol/L\\n\\nExclusion Criteria:\\n\\n* Inability or unwillingness to comply with the provisions of this protocol\\n* Deemed by the investigator not being able to follow instructions and/or follow the study protocol\\n\\nNB: new ethical approval will be applied for children between 1-3 years of age', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '3 Years', 'maximumAge': '18 Years', 'stdAges': ['CHILD', 'ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Annelie Carlsson, MD PhD', 'role': 'CONTACT', 'phone': '+46768267170', 'email': 'annelie.carlsson@med.lu.se'}, {'name': 'Iren Tiberg, MD PhD', 'role': 'CONTACT', 'email': 'iren.tiberg@med.lu.se'}], 'overallOfficials': [{'name': 'Annelie Carlsson, MD PhD', 'affiliation': 'Lund University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Skanes University Hospital', 'status': 'RECRUITING', 'city': 'Lund', 'state': 'Region Skane', 'zip': '22185', 'country': 'Sweden', 'contacts': [{'name': 'Annelie Carlsson, MD PhD', 'role': 'CONTACT', 'phone': '+46768267170', 'email': 'annelie.carlsson@med.lu.se'}, {'name': 'Iren Tiberg, PhD, nurse', 'role': 'CONTACT', 'email': 'iren.tiberg@med.lu.se'}], 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}]}, 'referencesModule': {'references': [{'pmid': '12519846', 'type': 'BACKGROUND', 'citation': 'Pastore MR, Bazzigaluppi E, Belloni C, Arcovio C, Bonifacio E, Bosi E. Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab. 2003 Jan;88(1):162-5. doi: 10.1210/jc.2002-021177.'}, {'pmid': '21515839', 'type': 'BACKGROUND', 'citation': 'Hummel S, Pfluger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care. 2011 Jun;34(6):1301-5. doi: 10.2337/dc10-2456. Epub 2011 Apr 22.'}, {'pmid': '22729336', 'type': 'BACKGROUND', 'citation': 'Sildorf SM, Fredheim S, Svensson J, Buschard K. Remission without insulin therapy on gluten-free diet in a 6-year old boy with type 1 diabetes mellitus. BMJ Case Rep. 2012 Jun 21;2012:bcr0220125878. doi: 10.1136/bcr.02.2012.5878.'}, {'pmid': '23420914', 'type': 'BACKGROUND', 'citation': 'Ivarsson A, Myleus A, Norstrom F, van der Pals M, Rosen A, Hogberg L, Danielsson L, Halvarsson B, Hammarroth S, Hernell O, Karlsson E, Stenhammar L, Webb C, Sandstrom O, Carlsson A. Prevalence of childhood celiac disease and changes in infant feeding. Pediatrics. 2013 Mar;131(3):e687-94. doi: 10.1542/peds.2012-1015. Epub 2013 Feb 18.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002446', 'term': 'Celiac Disease'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D008286', 'term': 'Malabsorption Syndromes'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Diabetes Mellitus, Type 1', 'relevance': 'HIGH'}, {'id': 'M5696', 'name': 'Celiac Disease', 'asFound': 'Celiac Disease', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}, {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'}, {'id': 'M11278', 'name': 'Malabsorption Syndromes', 'relevance': 'LOW'}, {'id': 'M10444', 'name': 'Intestinal Diseases', 'relevance': 'LOW'}, {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'}, {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}, {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01286090', 'orgStudyIdInfo': {'id': 'CR003946'}, 'secondaryIdInfos': [{'id': 'CIS-INT-25'}], 'organization': {'fullName': 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.', 'class': 'INDUSTRY'}, 'briefTitle': 'An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus', 'officialTitle': 'Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2011-01', 'overallStatus': 'TERMINATED', 'whyStopped': 'Sponsor request', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2003-07'}, 'completionDateStruct': {'date': '2003-10', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2011-01-13', 'studyFirstSubmitQcDate': '2011-01-27', 'studyFirstPostDateStruct': {'date': '2011-01-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2011-01-27', 'lastUpdatePostDateStruct': {'date': '2011-01-31', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Portfolio/CDT Leader', 'oldOrganization': 'Johnson & Johnson Pharmaceutical Research and Development, L.L.C.'}, 'leadSponsor': {'name': 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to assess the effectiveness of cisapride at improving symptoms associated with gastroparesis (a stomach disorder) in patients with diabetes mellitus.', 'detailedDescription': 'This is a double-blind (neither the physician nor the patient will know the name of assigned treatment) study to determine the effectiveness of cisapride tablets compared to placebo tablets (a tablet identical in appearance to cisapride but does not contain active drug) at improving symptoms associated with diabetic gastroparesis when administered orally (by mouth) to patients with insulin dependent or non-insulin dependent diabetes mellitus. Gastroparesis is a disorder also called delayed gastric emptying, in which the stomach takes too long to empty food into the small intestine for digestion. Symptoms of gastroparesis may include vomiting, nausea, early feeling of fullness after only a few bites of food, weight loss due to poor absorption of nutrients or low calorie intake, abdominal bloating, poor glycemic (blood sugar) control, lack of appetite, and pain in the stomach area. Patients will take study drug (one 10-mg tablet of cisapride, or one tablet of placebo), orally, 4 times a day, for a period of 8 weeks. Study drug will be taken approximately 15 minutes before each meal and, with a beverage, before going to bed.'}, 'conditionsModule': {'conditions': ['Gastroparesis', 'Diabetes Mellitus'], 'keywords': ['Cisapride (PREPULSID)', 'Placebo', 'Diabetes mellitus', 'Diabetic gastroparesis']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 4, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': '001', 'type': 'EXPERIMENTAL', 'description': 'Cisapride One 10-mg tablet taken orally 4 times a day for up to 8 weeks.', 'interventionNames': ['Drug: Cisapride']}, {'label': '002', 'type': 'EXPERIMENTAL', 'description': 'Placebo One tablet taken orally 4 times a day for up to 8 weeks.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Cisapride', 'description': 'One 10-mg tablet taken orally 4 times a day for up to 8 weeks.', 'armGroupLabels': ['001']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'One tablet taken orally 4 times a day for up to 8 weeks.', 'armGroupLabels': ['002']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The change from baseline in Gastroparesis Cardinal Symptoms Index (GCSI) score', 'timeFrame': 'At baseline (Visit 2) and weekly during the treatment phase of the trial for up to 8 weeks'}], 'secondaryOutcomes': [{'measure': 'The number of adverse events reported', 'timeFrame': 'For the duration of the study (up to 8 weeks)'}, {'measure': 'The type of adverse events reported', 'timeFrame': 'For the duration of the study (up to 8 weeks)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Diagnosed with insulin dependent or non-insulin dependent diabetes mellitus\\n* Experienced inadequate responses to, or have been intolerant of, treatment with at least one previous drug therapy for gastroparesis\\n* Have exacerbation of gastroparesis symptoms requiring medical attention\\n* Demonstrate delayed gastric emptying as assessed by a \\\\[1-13C\\\\]-Sodium Acetate Breath Test within 14 days before randomization\\n\\nExclusion Criteria:\\n\\n* Received prior treatment with cisapride\\n* Have a glycosylated hemoglobin (HbA1c) \\\\>10% at screening, as determined by clinical laboratory testing\\n* Have any upper gastrointestinal (GI) pathology other than diabetic gastroparesis that would require therapy other than that provided in this trial\\n* Have any organic/neurological disease that is suspected to be causing gastroparesis, other than diabetes\\n* Currently vomiting, or receiving therapy for a severe exacerbation of gastroparesis, that would prevent the patient from receiving oral therapy or a diet', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial', 'affiliation': 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.', 'role': 'STUDY_DIRECTOR'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D018589', 'term': 'Gastroparesis'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D013272', 'term': 'Stomach Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D010243', 'term': 'Paralysis'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M20685', 'name': 'Gastroparesis', 'asFound': 'Gastroparesis', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M16062', 'name': 'Stomach Diseases', 'relevance': 'LOW'}, {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'}, {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'}, {'id': 'M13157', 'name': 'Paralysis', 'relevance': 'LOW'}, {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'}, {'id': 'T2445', 'name': 'Gastroparesis', 'asFound': 'Gastroparesis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D020117', 'term': 'Cisapride'}], 'ancestors': [{'id': 'D000897', 'term': 'Anti-Ulcer Agents'}, {'id': 'D005765', 'term': 'Gastrointestinal Agents'}, {'id': 'D017366', 'term': 'Serotonin Receptor Agonists'}, {'id': 'D018490', 'term': 'Serotonin Agents'}, {'id': 'D018377', 'term': 'Neurotransmitter Agents'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M21955', 'name': 'Cisapride', 'asFound': 'Lebanese', 'relevance': 'HIGH'}, {'id': 'M4188', 'name': 'Antacids', 'relevance': 'LOW'}, {'id': 'M4219', 'name': 'Anti-Ulcer Agents', 'relevance': 'LOW'}, {'id': 'M8881', 'name': 'Gastrointestinal Agents', 'relevance': 'LOW'}, {'id': 'M15512', 'name': 'Serotonin', 'relevance': 'LOW'}, {'id': 'M19648', 'name': 'Serotonin Receptor Agonists', 'relevance': 'LOW'}, {'id': 'M20504', 'name': 'Neurotransmitter Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02498990', 'orgStudyIdInfo': {'id': '2015/628-31'}, 'organization': {'fullName': 'Karolinska University Hospital', 'class': 'OTHER'}, 'briefTitle': 'Low Calorie Diet and Diabetes', 'officialTitle': 'Long-term Metabol Control After Weight Reduction With Low Calorie Diet in Type 2 Diabetes', 'acronym': 'LCD'}, 'statusModule': {'statusVerifiedDate': '2021-02', 'overallStatus': 'ENROLLING_BY_INVITATION', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2015-08'}, 'primaryCompletionDateStruct': {'date': '2024-02', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-08', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2015-07-03', 'studyFirstSubmitQcDate': '2015-07-13', 'studyFirstPostDateStruct': {'date': '2015-07-15', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-02-17', 'lastUpdatePostDateStruct': {'date': '2021-02-18', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Johan Hoffstedt', 'investigatorTitle': 'Associate Professor', 'investigatorAffiliation': 'Karolinska University Hospital'}, 'leadSponsor': {'name': 'Karolinska University Hospital', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The primary hypothesis is to investigate whether a low calorie diet for 7 weeks followed by continuous lifestyle advice is an effective option to achieve an improvement in glucose control as measured by HbA1c after 52 and 104 weeks as compared to baseline values in obese type 2 diabetes patients on either tablet or insulin treatment. The secondary hypothesis is to investigate whether the weight reduction therapy also has significant impact on various anthropometric, clinical and metabolic parameters associated with obesity.', 'detailedDescription': 'This is a prospective study on the impact of low calorie diet followed by a weight maintenance program on 12 and 24 month glucose control in a cohort of patients with obesity and diabetes mellitus. The study will consist of 3 phases:\\n\\n1. Screening period (up to 12 weeks).\\n2. Low calorie diet weeks 1-9. Seven weeks of low-calorie diet including 800 kcal/day followed by 2 weeks of gradual introduction of normal diet of eventually 1500-2000 kcal/day, i.e. 600 kcal/day deficit, based on present body weight and sex. At entry of the LCD-period, all medication for diabetes mellitus, with the exception of metformin and insulin, will be removed. During the LCD-period, insulin treatment will gradually be reduced and, if possible, withdrawn. Patients will perform daily self-monitoring of fasting and post-prandial plasma glucose. At each visit, which will take place once a week, the patients will see a physician, a nurse and a dietician. The patients will be given specific advice to increase their physical activity. Patients will remain on medication for dyslipidemia. Blood pressure will be measured at each visit and in case of blood pressure \\\\< 110/70 mmHg and/or in case of symptoms associated with hypotension including dizziness, medication for hypertension will be reduced or removed.\\n3. Weight-maintenance program weeks 10-52.\\n4. Follow up visits at months 15, 18, 21 and 24.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus Type 2', 'Dyslipidemia', 'Non-alcoholic Fatty Liver Disease', 'Obesity']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Weight reduction', 'type': 'EXPERIMENTAL', 'interventionNames': ['Behavioral: Low calorie diet followed by life style intervention']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Low calorie diet followed by life style intervention', 'description': '1. Low calorie diet of 800 kcal/day for 7 weeks.\\n2. Life style intervention for the remaining study period', 'armGroupLabels': ['Weight reduction']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from Baseline in HbA1c (mmol/mol) at 12 and 24 months', 'timeFrame': '12 months and 24 months'}], 'secondaryOutcomes': [{'measure': 'Change from Baseline in BMI (kg/m2) at 7 weeks, 6,12, and 24 months', 'timeFrame': '7 weeks, 6, 12 and 24 months'}, {'measure': 'Change from Baseline in Liver Fat (Controlled Attenuation Parameter, db/m) at 7 weeks, 6, 12 and 24 months', 'description': 'Liver Fat Measured by Fibroscan', 'timeFrame': '7 weeks, 6, 12 and 24 months'}, {'measure': 'Change from Baseline in Cholesterol (mmo/l) and Triglycerides (mmol/l) at 7 weeks, 6, 12 and 24 months', 'timeFrame': '7 weeks, 6,12 and 24 months'}, {'measure': 'Change from Baseline in 2-hour Glucose (mmol/l) and Insulin (mU/l) by Glucose tolerance test at 7 weeks, 6, 12 and 24 months', 'description': 'Glucose tolerance test: oral administration of 75 g Glucose', 'timeFrame': '7 weeks, 6,12, 24 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Men and women of age 18-65 years at screening.\\n2. Diagnosis of type 2 diabetes mellitus.\\n3. BMI \\\\> 30 kg/m2.\\n4. HbA1c \\\\> 52 mmol/mol.\\n5. Stable weight ± 5% for at least 12 weeks prior to screening.\\n6. Informed consent must be obtained by each subject before enrollment in the study.\\n\\nExclusion Criteria:\\n\\n1. Pregnant or brest-feeding women or women who are planning to become pregnant or breast-feeding.\\n2. Type 1 diabetes mellitus or secondary forms of diabetes including pancreatic injury, cushing syndrome etc.\\n3. Clinically significant diabetic complications\\n4. Clinically symptomatic gastrointestinal or hepatic disease.\\n5. History of gastric bypass, antrectomy or small bowel disease.\\n6. History of pancreatitis.\\n7. Myocardial infarction within the past six months.\\n8. Symptomatic ischemic heart disease, heart failure or stroke.\\n9. Atrial fibrillation.\\n10. Patients on treatment with warfarin.\\n11. Diagnosed and/or treated malignancy within the past 5 years.\\n12. Any of the following laboratory abnormalities at screening:\\n\\n    * ALT and/or AST \\\\> 3 times the upper limit of the normal range.\\n    * Serum creatinine levels \\\\> 130 µmol/l.\\n    * Clinically significant TSH out of the normal range.\\n    * Uric acid \\\\> 50% above normal level.\\n13. History of alcohol or other substance abuse within the past 2 years.\\n14. Psychiatric disease including eating disorder, bulimia nervosa, depression, anxiety, psychotic disease.\\n15. Potentially unreliable patients and those judged by the investigator to be unsuitable for the study.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Johan Hoffstedt, MD, PhD', 'affiliation': 'Karilonska University Hospital', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Karolinska University Hospital', 'city': 'Stockholm', 'zip': '14186', 'country': 'Sweden', 'geoPoint': {'lat': 59.33258, 'lon': 18.0649}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D005234', 'term': 'Fatty Liver'}, {'id': 'D065626', 'term': 'Non-alcoholic Fatty Liver Disease'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D050171', 'term': 'Dyslipidemias'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D052439', 'term': 'Lipid Metabolism Disorders'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus Type 2', 'relevance': 'HIGH'}, {'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'}, {'id': 'M18102', 'name': 'Weight Loss', 'relevance': 'LOW'}, {'id': 'M8375', 'name': 'Fatty Liver', 'asFound': 'Fatty Liver', 'relevance': 'HIGH'}, {'id': 'M11107', 'name': 'Liver Diseases', 'asFound': 'Liver Disease', 'relevance': 'HIGH'}, {'id': 'M30540', 'name': 'Non-alcoholic Fatty Liver Disease', 'asFound': 'Non-alcoholic Fatty Liver Disease', 'relevance': 'HIGH'}, {'id': 'M5114', 'name': 'Body Weight', 'relevance': 'LOW'}, {'id': 'M26181', 'name': 'Dyslipidemias', 'asFound': 'Dyslipidemia', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'}, {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'}, {'id': 'M27029', 'name': 'Lipid Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'T5868', 'name': 'Visceral Steatosis', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02727790', 'orgStudyIdInfo': {'id': '129/12'}, 'secondaryIdInfos': [{'id': 'HTA6446', 'type': 'OTHER', 'domain': 'Israel: Ministry of Health'}], 'organization': {'fullName': 'Assaf-Harofeh Medical Center', 'class': 'OTHER_GOV'}, 'briefTitle': 'Effect of Short Peripheral Electrical Stimulation (PES) on Blood Glucose', 'officialTitle': 'Effect of Short Peripheral Electrical Stimulation (PES) on Blood Glucose Lowering Action in Type 2 Diabetes Patients'}, 'statusModule': {'statusVerifiedDate': '2016-03', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2014-07'}, 'primaryCompletionDateStruct': {'date': '2016-06', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2016-06', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2016-02-28', 'studyFirstSubmitQcDate': '2016-03-30', 'studyFirstPostDateStruct': {'date': '2016-04-05', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2016-06-06', 'lastUpdatePostDateStruct': {'date': '2016-06-07', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Assaf-Harofeh Medical Center', 'class': 'OTHER_GOV'}}, 'descriptionModule': {'briefSummary': 'The epidemic nature of type 2 diabetes mellitus, along with the downsides of current treatments, has raised the need for therapeutic alternatives. The aim of this study is to evaluate safety, tolerability, and the glucose-lowering effect of noninvasive peripheral electrical stimulation (PES) as an alternative treatment for diabetes.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 12, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'PES Treatment', 'type': 'EXPERIMENTAL', 'description': 'Eligible patients will receive daily 5 min PES treatment for two weeks. Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) continuous glucose monitor (CGM) System', 'interventionNames': ['Device: Stimulator']}, {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) CGM System'}], 'interventions': [{'type': 'DEVICE', 'name': 'Stimulator', 'armGroupLabels': ['PES Treatment'], 'otherNames': ['BEAC Biomedical Intellistim BE-28TC']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of participants with hypoglycemia, and/ or adverse events that are related to treatment', 'timeFrame': 'Baseline through 2 months'}], 'secondaryOutcomes': [{'measure': 'Incidence of minor side effects related to treatment', 'timeFrame': 'Baseline through 2 months'}, {'measure': 'Changes in mean interstitial glucose levels measured by CGM', 'timeFrame': 'Baseline, 1, 2, 5, and 6 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients diagnosed with type II diabetes, for at least one year prior to randomization\\n* Body mass index BMI \\\\< 35 Kg/m2\\n* Stable glucose lowering drugs regimen for at least one month prior to randomization\\n* Capable of giving informed consent\\n\\nExclusion Criteria:\\n\\n* Pregnancy, or nursing\\n* 10\\\\< HbA1c \\\\< 6\\n* Permanent pacemakers\\n* Metal prosthesis\\n* Resting blood pressure \\\\> 160/ 100 mmHg\\n* Skin disease\\n* Treatment with steroids or beta-blockers treatment with psychiatric medications', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Assaf-Harofeh Medical Center', 'city': 'Zerifin', 'zip': '70300', 'country': 'Israel', 'geoPoint': {'lat': 31.95857, 'lon': 4.83723}}]}, 'referencesModule': {'references': [{'pmid': '27997608', 'type': 'DERIVED', 'citation': 'Catalogna M, Doenyas-Barak K, Sagi R, Abu-Hamad R, Nevo U, Ben-Jacob E, Efrati S. Effect of Peripheral Electrical Stimulation (PES) on Nocturnal Blood Glucose in Type 2 Diabetes: A Randomized Crossover Pilot Study. PLoS One. 2016 Dec 20;11(12):e0168805. doi: 10.1371/journal.pone.0168805. eCollection 2016.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04424238', 'orgStudyIdInfo': {'id': 'JS-1012'}, 'organization': {'fullName': 'Peking Union Medical College Hospital', 'class': 'OTHER'}, 'briefTitle': 'the Effect of Mobile Medical Used for the Standardized Management of Gestational Diabetes', 'officialTitle': 'Clinical Research on Mobile Medical Used for the Standardized Management of Gestational Diabetes: a Randomized Control Trail'}, 'statusModule': {'statusVerifiedDate': '2020-05', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2016-03-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-06-15', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2020-06-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2020-06-05', 'studyFirstSubmitQcDate': '2020-06-05', 'studyFirstPostDateStruct': {'date': '2020-06-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-06-13', 'lastUpdatePostDateStruct': {'date': '2020-06-16', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Peking Union Medical College Hospital', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'A multicenter, randomized controlled trial was conducted to investigate whether health education and life style management through WeChat group chat was more effective in controlling blood glucose (BG) than standard clinic prenatal care in women with GDM.', 'detailedDescription': 'Most gestational diabetes mellitus (GDM) can be well controlled by health education and life style management, expecting a better pregnancy outcome. But standard clinic prenatal care which consist of clinic visit every two weeks may not give full play to the effects of GDM management. Telemedicine shows its potential to fill this gap. A multicenter, randomized controlled trial was designed to investigate whether health education and life style management through WeChat group chat was more effective in controlling blood glucose (BG) than standard clinic prenatal care in women with GDM. Women with GDM diagnosed by oral glucose tolerance test between 23-30+6 gestational weeks were randomized to a WeChat group chat-based blood glucose management group or routine clinic prenatal care. In PUMCH, investigators also equip CGM for m-health group allowing a more detailed BG information. The primary outcome was change of glycemic qualification rate during follow up period in both groups. The second outcome was pregnancy outcomes. Also, a case-control study is designed to compare the glucose control status between rice-richen meal and wheaten-richen meal, and all other macronutrients and micronutrients are all calculated and same between two groups, which may provide more clues for type of carbohydrate recommendation for Chinese women with GDM.'}, 'conditionsModule': {'conditions': ['GDM', 'Blood Glucose', 'Compliance, Patient', 'Diet Habit'], 'keywords': ['GDM', 'CGM', 'm-health', 'diet modification', 'blood glucose', 'compliance']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 400, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Standard Clinic Prenatal Care (Control Group)', 'type': 'NO_INTERVENTION', 'description': \"pregnancy's prenatal care appointment would be changed to once every two weeks when diagnosed with GDM. Doctors generally ask GDM women record their daily diet, exercise, weight, BG and blood pressure for at least three days between two visits and give lifestyle guidance according to the records. If they fail to show diaries, doctors would ask them come back with record next week. If BG control is poor, medicine intervention would be considered.\"}, {'label': 'm-health group (Intervention Group)', 'type': 'EXPERIMENTAL', 'description': 'participants were managed continuously through WeChat group chat.', 'interventionNames': ['Behavioral: m-health management']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'm-health management', 'description': 'Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care.', 'armGroupLabels': ['m-health group (Intervention Group)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'glycemic qualification rate', 'description': 'Glycemic qualification rate was calculated by the number of BG within the control range /30\\\\*100%. BG control range were fasting BG (fasting and before-sleep BG)\\\\<95 mg/dL (5.3 mmol/L) and two-hour postprandial BG (post-breakfast, post-lunch, post-dinner BG)\\\\<120 mg/dL (6.7 mmol/L)', 'timeFrame': 'From enrollment to 42 days postpartum'}], 'secondaryOutcomes': [{'measure': 'pregnancy outcome', 'description': 'delivery mode, premature rupture of the membranes, preterm birth, birthweight and postpartum hemorrhage', 'timeFrame': 'delivery'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Aged between 18 and 45 years.\\n* With singleton pregnancy\\n* Diagnosed as GDM by 75g oral glucose tolerance test (OGTT) and insulin treatment is not required assessed by multi-disciplinary consultation.\\n* Be able to use smart phone for chatting, read and write basic Chinese.\\n* Volunteer for research.\\n\\nExclusion Criteria:\\n\\n* Pregnancies with diagnosed chronic disease\\n* Pregnancies with other pregnancy complications except GDM\\n* Pregnancies had recent trauma and treatment of glucocorticoids', 'healthyVolunteers': False, 'sex': 'FEMALE', 'minimumAge': '18 Years', 'maximumAge': '45 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Liangkun Ma', 'affiliation': 'Chinese Academy of Medical Science & Peking Union Medical College Hospital', 'role': 'STUDY_CHAIR'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016640', 'term': 'Diabetes, Gestational'}], 'ancestors': [{'id': 'D011248', 'term': 'Pregnancy Complications'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M19012', 'name': 'Diabetes, Gestational', 'asFound': 'Gestational Diabetes', 'relevance': 'HIGH'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00340938', 'orgStudyIdInfo': {'id': '999905030'}, 'secondaryIdInfos': [{'id': '05-CH-N030'}], 'organization': {'fullName': 'National Institutes of Health Clinical Center (CC)', 'class': 'NIH'}, 'briefTitle': 'Family Management of Childhood Diabetes Study', 'officialTitle': 'Family Management of Childhood Diabetes Study'}, 'statusModule': {'statusVerifiedDate': '2019-11-01', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2004-11-08'}, 'primaryCompletionDateStruct': {'date': '2009-03-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2009-08-20', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2006-06-19', 'studyFirstSubmitQcDate': '2006-06-19', 'studyFirstPostDateStruct': {'date': '2006-06-21', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-12-14', 'lastUpdatePostDateStruct': {'date': '2019-12-17', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)', 'class': 'NIH'}}, 'descriptionModule': {'briefSummary': \"This study will test the effectiveness of a practical, low-cost, problem-solving method called WE CAN that can be taught to families at diabetes clinics. The goal is to see if this teaching and support can help with controlling the level of blood sugar in children with type 1 diabetes as they approach adolescence. Attention would go to young people's completion of tasks necessary to manage diabetes, quality of life, and psychological adjustments, plus the role of the family in these situations. Type 1 diabetes mellitus, accounting for less than 10% of the disease cases, is marked by the inability of the pancreas to secrete insulin. People who have it must consistently manage their disease. Successful disease management for children depends on the family's adaptation to treatment demands. Yet maintaining acceptable blood sugar control becomes more difficult for adolescents, owing to changes in the body during that period of life. Also, early adolescence is a vital time in people's development of health outcomes. The title WE CAN is a way to remember the steps of the problem-solving method:\\n\\n* Work together to set goals\\n* Explore barriers and solutions\\n* Choose the best solutions\\n* Act on your plan\\n* Note the results\\n\\nChildren who have reached age 9 but are not yet 14.5 years who have had type 1 diabetes for at least 1 year and who have had at least two visits to diabetes clinics at one of four clinical sites may be eligible for this study. A total of 120 children will participate in clinic visits once every 3 months.\\n\\nParticipants and their families will attend diabetes clinic visits once every 3 months. They will be assigned to one of two groups: standard care or WE CAN. Those in the WE CAN group will have visits about 15 to 45 minutes longer than those involved in the standard care group. All participants will have two home visits: at the beginning and at 6 months. There will also be telephone interviews, about 20 minutes long, once every 3 months with the children and their parents. Medical data will be collected during each visit to the clinic, including blood samples. A health advisor will work with the families. Questionnaires given to parents and children separately will measure diabetes-related family conflict, parent child sharing of responsibilities for the disease, attitudes and emotions about diabetes, and impact of the disease on the child's life. Also, parents and children together will take part in a 10-minute discussion of a diabetes-related issue that has caused friction among family members. They will discuss the problem, come up with possible solutions, and to try to decide on a solution within 10 minutes. Family discussions will be videotaped at the first home visit and at the 6-month home visit.\\n\\nFamilies in both groups will receive more detailed monitoring of family diabetes management than is usually the case. Those in the WE CAN group may be able to control diabetes more effectively during the child's early adolescence, though that result is not guaranteed. If the family guidance and support provided by the WE CAN health advisor is effective, children in that group may have better results in blood sugar than they would if they did not participate in the study. Each family member completing the first and 6-month visits and completing each telephone interview will receive payment for participating.\", 'detailedDescription': 'This protocol describes a multi-center, randomized controlled trial to test whether a clinic-integrated, low intensity, multi-component behavioral intervention is effective in preventing the deterioration in glycemic control, treatment adherence, and quality of life that commonly occur during late childhood and early adolescence in youth with type 1 diabetes. The study will also examine mechanisms and processes that influence the effectiveness of family management of diabetes during this developmental period.'}, 'conditionsModule': {'conditions': ['Diabetes', 'Type 1 Diabetes'], 'keywords': ['Adherence', 'Education', 'Problem Solving', 'Motivation', 'Locus of Responsibility']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'primaryPurpose': 'TREATMENT'}, 'enrollmentInfo': {'count': 1298, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'interventions': [{'type': 'PROCEDURE', 'name': 'Blood testing'}]}, 'eligibilityModule': {'eligibilityCriteria': \"* INCLUSION CRITERIA - CHILD CRITERIA:\\n\\nAge 9.0 to 14.5\\n\\nType I diabetes diagnosis (diagnosed by ADA criteria) for a minimum of 1 year requiring insulin treatment\\n\\nInsulin dose greater than or equal to 0.5 u/kg/day\\n\\nMean A1c over last 8 months is less than 13.0%\\n\\nNo major chronic diseases (except well-controlled thyroid, asthma)\\n\\nNo major visual/auditory impairments\\n\\nChild is not in self-contained special education class throughout the school day\\n\\nNo DSM-IV diagnosis of bipolar, addiction, psychosis, or eating disorder documented in existing medical chart. No record of inpatient hospitalization for mental disorder in past six months including substance abuse rehabilitation, eating disorder units or day treatment programs. No history of anti-psychotic medications for the past 6 months.\\n\\nNo diagnosis of mental retardation.\\n\\nLiterate (reading, writing) in English/Spanish at 2nd grade level\\n\\nWilling to provide informed assent\\n\\nChildren who are currently enrolled in any other study (observational or interventional) are not eligible for enrollment. Children cannot enroll in another study during the course of this study. Those who have been in an intervention arm of a trial of a behavioral, psychological or psychoeducational intervention and concluded their study follow-up within the past 12 months are also ineligible to participate. However, children who were in a standard care control group in an intervention study or who were in an observational study are eligible once they have completed all scheduled study follow-ups.\\n\\nPARENT/FAMILY ENVIRONMENT CRITERIA:\\n\\nChild lives in geographically stable home, no multiple foster homes, boarding school, or institutions expected to next 2 years.\\n\\nThe same 1 or 2 adult caregivers have accompanied the child to every diabetes clinic visit in the past year, and a single adult, who has primary responsibility for the child's diabetes care and monitoring, agrees to participate in all aspects of the protocol (single-parent families, blended families and separated parents will be eligible).\\n\\nFamily has no plan to re-locate out of area within the next 2 years of the study.\\n\\nHome has telephone access\\n\\nPrimary parent is not currently undergoing treatment for substance abuse.\\n\\nPrimary parent has not been hospitalized in past 6 months for mental disorder.\\n\\nPrimary caretaker has no history of psychosis.\\n\\nChild had at least 2 clinic visits within last 12 months\\n\\nParent and child wiling to come to clinic every 3 months for duration (2 years) of study.\\n\\nFamilies who are currently enrolled in any other study (observational or interventional) are not eligible for enrollment. Families cannot enroll in another study during the course of this study. Those who have been in an intervention arm of a trial of a behavioral, psychological or psychoeducational intervention and concluded their study follow-up within the past 12 month are also ineligible to participate. However, families who were in a standard care control group in an intervention study or who were in an observational study are eligible once they have completed all scheduled study follow-ups.\\n\\nIf a family has more than one eligible child, all qualifying children who provide consent/assent will participate in assessment and intervention or control activities; however, only the oldest qualifying child will be included in statistical analyses.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '9 Years', 'maximumAge': '70 Years', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Tonja R. Nansel, Ph.D.', 'affiliation': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Childrens Memorial Hospital, Chicago', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60614-3394', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'facility': 'Joslin Diabetes Center', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02215', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': \"Texas Children's Hospital\", 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}]}, 'referencesModule': {'references': [{'pmid': '6875761', 'type': 'BACKGROUND', 'citation': 'Allen DA, Tennen H, McGrade BJ, Affleck G, Ratzan S. Parent and child perceptions of the management of juvenile diabetes. J Pediatr Psychol. 1983 Jun;8(2):129-41. doi: 10.1093/jpepsy/8.2.129. No abstract available.'}, {'pmid': '3523245', 'type': 'BACKGROUND', 'citation': 'Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986 Jul 24;315(4):215-9. doi: 10.1056/NEJM198607243150402.'}, {'pmid': '10332671', 'type': 'BACKGROUND', 'citation': 'Anderson BJ, Brackett J, Ho J, Laffel LM. An office-based intervention to maintain parent-adolescent teamwork in diabetes management. Impact on parent involvement, family conflict, and subsequent glycemic control. Diabetes Care. 1999 May;22(5):713-21. doi: 10.2337/diacare.22.5.713.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00646438', 'orgStudyIdInfo': {'id': 'USCDP'}, 'organization': {'fullName': 'Providence Heart & Vascular Institute', 'class': 'OTHER'}, 'briefTitle': 'United States Coronary Artery Bypass Surgery (CABG) Diabetes Project (USCDP) Pilot Study', 'officialTitle': 'United States CABG Diabetes Project (USCDP) Pilot Study', 'acronym': 'USCDP'}, 'statusModule': {'statusVerifiedDate': '2008-03', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2009-03'}, 'primaryCompletionDateStruct': {'date': '2012-02', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2012-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2008-03-25', 'studyFirstSubmitQcDate': '2008-03-27', 'studyFirstPostDateStruct': {'date': '2008-03-28', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2009-02-03', 'lastUpdatePostDateStruct': {'date': '2009-02-04', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Anthony Furnary, MD / Principal Investigator', 'oldOrganization': 'Providence Heart & Vascular Institute'}, 'leadSponsor': {'name': 'Providence Heart & Vascular Institute', 'class': 'OTHER'}, 'collaborators': [{'name': 'Sanofi', 'class': 'INDUSTRY'}, {'name': 'LifeScan', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Standard care for patients with diabetes having CABG surgery at Providence St. Vincent Medical Center includes strict control of blood sugar (glucose) levels for 3 days after surgery. This is done through frequent monitoring of blood sugar levels and by giving insulin continuously through a needle into a vein (intravenously). This intensive glucose control has resulted in fewer complications such as serious infections and death, and has shortened the length of the hospital stay for patients.\\n\\nThis study treatment is different from standard treatment in that it extends the intensive glucose control beyond the third postoperative day to one full year. Once discharged from the hospital following the CABG procedure, the intense glucose control is done using subcutaneous insulin (a shot under the skin), oral medications, and by measuring blood sugar levels frequently.\\n\\nThe purpose of this study is to see how safe and effective strict glucose control is when extended beyond 3 days and hospital discharge for one year. Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.', 'detailedDescription': 'Purpose Pilot study to gather information for \"United States CABG Diabetes Project\" (USCDP) Multi-center Randomized Trial.\\n\\nFor 14 years our research team has successfully implemented an increasingly aggressive series of intravenous insulin protocols that normalize blood glucose levels for 3 postoperative days in patients with diabetes who undergo cardiac surgery. This has resulted in significant reductions in mortality, infection and length of stay (LOS) and has normalized those outcomes to those of the population without diabetes (DM). The current protocol ends on the morning of the 3rd postoperative day.\\n\\nWe believe that a logical expansion of this groundbreaking work is to extend the duration of intensive glycemic control beyond the third postoperative day and into the outpatient period. However it would be impossible to do so with the continued use of CII therapy. Therefore, we propose to employ intensive subcutaneous insulin therapies and oral hypoglycemic agents to affect continued tight glycemic control following discontinuation of CII and continue such therapy beyond hospital discharge for a period of at least one year.\\n\\nWe hypothesize that this will lead to further reductions in major adverse cardiac outcomes in the high-risk diabetes coronary artery bypass grafts (CABG) subgroup. The optimal method to test this hypothesis is with a very large, multi-center clinical trial. However, before embarking on such a resource-consuming endeavor, we intend to test the concepts, methods, implementation strategies, patient acceptability and compliance, proposed biomarkers and clinical outcomes of such a trial with this proposed limited pilot study.\\n\\nIf the information obtained from this pilot study is favorable, we will submit for full funding of the multicenter USCDP clinical trial to the NIDDK and NHLBI divisions of the NIH. In order to test all aspects of the proposed trial, we intend to randomize patients into this pilot study.'}, 'conditionsModule': {'conditions': ['Diabetes', 'Coronary Artery Disease'], 'keywords': ['Diabetes', 'CABG']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1', 'type': 'ACTIVE_COMPARATOR', 'description': 'strict glucose control (study arm)', 'interventionNames': ['Drug: Strict Glycemic Control for one year post-op CABG']}, {'label': '2', 'type': 'NO_INTERVENTION', 'description': 'standard insulin treatment (control arm)'}], 'interventions': [{'type': 'DRUG', 'name': 'Strict Glycemic Control for one year post-op CABG', 'description': 'The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.\\n\\nPost-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.\\n\\nFor all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control.', 'armGroupLabels': ['1'], 'otherNames': ['USCDP', 'Portlan Protocol']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The purpose of this study is to see how safe and effective strict glucose control is when extended beyond 3 days and hospital discharge for one year.', 'timeFrame': '3 years'}], 'secondaryOutcomes': [{'measure': 'Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.', 'timeFrame': '3 Years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients 18 - 80 years old\\n* Pre-op diagnosis of diabetes\\n* Scheduled for elective or urgent CABG surgery\\n* Able to sign informed consent for research study\\n\\nExclusion Criteria:\\n\\n* Patients less than 18 years old or greater than 80 years old\\n* Emergent or salvage CABG surgery\\n* Other surgical intervention planned in same setting ( Valve surgery, TMR, MAZE...)', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Eric M. Johnson, BA/CCRC', 'role': 'CONTACT', 'phone': '503-216-2075', 'email': 'eric.johnson@providence.org'}, {'name': 'Tony Furnary, MD', 'role': 'CONTACT', 'phone': '503-297-1419', 'email': 'tfurnary@mac.com'}], 'overallOfficials': [{'name': 'Anthony Furnary, MD', 'affiliation': 'Providence Heart & Vascular Institute', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Providence St. Vincent Medical Center', 'city': 'Portland', 'state': 'Oregon', 'zip': '97225', 'country': 'United States', 'contacts': [{'name': 'Eric M. Johnson, BA/CCRC', 'role': 'CONTACT', 'phone': '503-216-2075', 'email': 'eric.johnson@providence.org'}, {'name': 'Tony Furnary, MD', 'role': 'CONTACT', 'phone': '503-297-1419', 'email': 'tfurnary@mac.com'}, {'name': 'Anthony Furnary, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003324', 'term': 'Coronary Artery Disease'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D003327', 'term': 'Coronary Disease'}, {'id': 'D017202', 'term': 'Myocardial Ischemia'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D001161', 'term': 'Arteriosclerosis'}, {'id': 'D001157', 'term': 'Arterial Occlusive Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M6546', 'name': 'Coronary Artery Disease', 'asFound': 'Coronary Artery Disease', 'relevance': 'HIGH'}, {'id': 'M19506', 'name': 'Myocardial Ischemia', 'relevance': 'LOW'}, {'id': 'M6549', 'name': 'Coronary Disease', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}, {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}, {'id': 'M4469', 'name': 'Arteriosclerosis', 'relevance': 'LOW'}, {'id': 'M4465', 'name': 'Arterial Occlusive Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04907838', 'orgStudyIdInfo': {'id': 's-20180040'}, 'organization': {'fullName': 'University of Southern Denmark', 'class': 'OTHER'}, 'briefTitle': 'Insulin Stimulated Vasodilation in Patients With Type 2 Diabetes', 'officialTitle': 'Insulin Stimulated Vasodilation in Patients With Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2021-05', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-05-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-07-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2021-07-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2019-05-04', 'studyFirstSubmitQcDate': '2021-05-28', 'studyFirstPostDateStruct': {'date': '2021-06-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-05-28', 'lastUpdatePostDateStruct': {'date': '2021-06-01', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Stefan Mortensen', 'investigatorTitle': 'Professor', 'investigatorAffiliation': 'University of Southern Denmark'}, 'leadSponsor': {'name': 'University of Southern Denmark', 'class': 'OTHER'}, 'collaborators': [{'name': 'The University of Texas at Arlington', 'class': 'OTHER'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This study evaluates the role of endothelin in insulin stimulated vasodilation and glucose uptake. The subjects will complete an hyperinsulinemic euglycemic clamp with and without blockade of the endothelin receptors.'}, 'conditionsModule': {'conditions': ['Type2 Diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 22, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Type 2 diabetics', 'type': 'EXPERIMENTAL', 'description': 'BQ123 (25 nmol/min), BQ788 (25 nmol/min)', 'interventionNames': ['Drug: Insulin clamp', 'Drug: BQ123', 'Drug: BQ123 + BQ788']}, {'label': 'Healthy controls', 'type': 'EXPERIMENTAL', 'description': 'BQ123 (25 nmol/min), BQ788 (25 nmol/min)', 'interventionNames': ['Drug: Insulin clamp', 'Drug: BQ123', 'Drug: BQ123 + BQ788']}], 'interventions': [{'type': 'DRUG', 'name': 'Insulin clamp', 'description': 'Continous infusion insulin + glucose', 'armGroupLabels': ['Healthy controls', 'Type 2 diabetics']}, {'type': 'DRUG', 'name': 'BQ123', 'description': 'Continuous infusion of Insulin + glucose + BQ123', 'armGroupLabels': ['Healthy controls', 'Type 2 diabetics']}, {'type': 'DRUG', 'name': 'BQ123 + BQ788', 'description': 'Continous infusion of insulin + glucose + BQ123 + BQ788', 'armGroupLabels': ['Healthy controls', 'Type 2 diabetics']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Glucose infusion rate', 'description': 'Glucose infusion rate required to maintain euglycemia during insulin clamp with and without endothelin blockade', 'timeFrame': '3.5 hours'}, {'measure': 'Leg blood flow', 'description': 'Effect of endothelin receptor blockade on leg blood flow (ultrasound Doppler) during insulin clamp with and without endothelin blockade', 'timeFrame': '3.5 hours'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Type 2 diabetes OR healthy control (no type 2 diabetes)\\n* BMI\\\\<32\\n\\nExclusion Criteria:\\n\\n* heart disease\\n* pregnancy or birth within 3 month\\n* smoking\\n* Kidney disease\\n* beta-blockers\\n* insulin treatment (for type 2 diabetics)', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '40 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Stefan Mortensen, DMSc', 'affiliation': 'Professor', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Cardiovascular and Renal Research', 'city': 'Odense', 'zip': '5000', 'country': 'Denmark', 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}]}, 'referencesModule': {'references': [{'pmid': '35084435', 'type': 'DERIVED', 'citation': 'Young BE, Padilla J, Finsen SH, Fadel PJ, Mortensen SP. Role of Endothelin-1 Receptors in Limiting Leg Blood Flow and Glucose Uptake During Hyperinsulinemia in Type 2 Diabetes. Endocrinology. 2022 Mar 1;163(3):bqac008. doi: 10.1210/endocr/bqac008.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C072247', 'term': 'cyclo(Trp-Asp-Pro-Val-Leu)'}, {'id': 'C086539', 'term': 'BQ 788'}], 'ancestors': [{'id': 'D000959', 'term': 'Antihypertensive Agents'}, {'id': 'D065128', 'term': 'Endothelin Receptor Antagonists'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D065131', 'term': 'Endothelin B Receptor Antagonists'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M255666', 'name': 'cyclo(Trp-Asp-Pro-Val-Leu)', 'asFound': 'Neural Network', 'relevance': 'HIGH'}, {'id': 'M244726', 'name': 'BQ 788', 'asFound': 'Dacplat', 'relevance': 'HIGH'}, {'id': 'M4277', 'name': 'Antihypertensive Agents', 'relevance': 'LOW'}, {'id': 'M30466', 'name': 'Endothelin Receptor Antagonists', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AnAg', 'name': 'Antihypertensive Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01144338', 'orgStudyIdInfo': {'id': 'D5551C00003'}, 'secondaryIdInfos': [{'id': 'MB001-002', 'type': 'OTHER', 'domain': 'Bristol Myers Squibb'}, {'id': 'BCB109', 'type': 'OTHER', 'domain': 'Bristol-Myers Squibb'}], 'organization': {'fullName': 'AstraZeneca', 'class': 'INDUSTRY'}, 'briefTitle': 'Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus', 'officialTitle': 'Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.'}, 'statusModule': {'statusVerifiedDate': '2018-07', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2010-06-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-04-21', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2017-04-24', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2010-06-10', 'studyFirstSubmitQcDate': '2010-06-14', 'studyFirstPostDateStruct': {'date': '2010-06-15', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2018-04-13', 'resultsFirstSubmitQcDate': '2018-07-13', 'resultsFirstPostDateStruct': {'date': '2018-08-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-07-13', 'lastUpdatePostDateStruct': {'date': '2018-08-08', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'AstraZeneca', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus'], 'keywords': ['exenatide once weekly', 'cardiovascular', 'Bydureon', 'Amylin']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 14752, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Exenatide Once Weekly', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Exenatide Once Weekly']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Exenatide Once Weekly', 'description': 'Subcutaneous injection, 2 mg, administered once weekly.', 'armGroupLabels': ['Exenatide Once Weekly']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Subcutaneous injection, matching volume of placebo, administered once weekly.', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Primary Efficacy Outcome MACE Events', 'description': 'The primary efficacy outcome variable is defined as the composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke. The number of participants who had an event is reported in the results.\\n\\nThe primary efficacy endpoint is the same as the primary safety endpoint, and the statistical analysis tests the superiority of exenatide against the placebo.', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).'}, {'measure': 'Primary Safety Outcome MACE Events', 'description': 'The primary safety outcome variable is defined as the composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke. The number of participants who had an event is reported in the results.\\n\\nThe primary safety endpoint is the same as the primary efficacy endpoints, and the statistical analysis tests the non-inferiority of exenatide against placebo.', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).'}], 'secondaryOutcomes': [{'measure': 'Secondary Efficacy Outcome All-Cause Mortality', 'description': 'The secondary efficacy outcome variable is defined as the all-cause mortality (deaths). The number of participants who had an event is reported in the results.', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).'}, {'measure': 'Secondary Efficacy Outcome CV Death', 'description': 'Component of the primary efficacy outcome: cardiovascular death. The number of participants who had an event is reported in the results.', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).'}, {'measure': 'Secondary Efficacy Outcome MI', 'description': 'Component of primary efficacy outcome: fatal or non-fatal MI. The number of participants who had an event is reported in the results.', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).'}, {'measure': 'Secondary Efficacy Outcome Stroke', 'description': 'Component of primary efficacy outcome: fatal or non-fatal stroke. The number of participants who had an event is reported in the results.', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).'}, {'measure': 'Secondary Efficacy Outcome Hospitalization for ACS', 'description': 'The secondary efficacy outcome variable is defined as hospitalization for acute coronary syndrome. The number of participants who had an event is reported in the results.', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).'}, {'measure': 'Secondary Efficacy Outcome Hospitalization for HF', 'description': 'The secondary efficacy outcome variable is defined as hospitalization for heart failure. The number of participants who had an event is reported in the results.', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patient has type 2 diabetes mellitus\\n* Patient has an HbA1c of ≥ 6.5 % and ≤ 10.0% and is currently using one of the following treatment regimens: A) Treatment with 0-3 oral antihyperglycemic agents B) Insulin therapy, either alone or in combination with up to two oral agents\\n* Female patients must not be breast feeding and agree to use an effective method of contraception or must not otherwise be at risk of becoming pregnant.\\n\\nExclusion Criteria:\\n\\n* Patient has a diagnosis of type 1 diabetes mellitus, or a history of ketoacidosis.\\n* Patient has ever been treated with an approved or investigational GLP-1 receptor agonist.\\n* Patient is enrolled in another experimental protocol which involves the use of an investigational drug or device, or an intervention that would interfere with the conduct of the trial.\\n* Patient has a planned or anticipated revascularization procedure.\\n* Pregnancy or planned pregnancy during the trial period.\\n* Patient has end-stage renal disease or an estimated glomerular filtration rate (eGFR) of \\\\<30 mL/min/1.73m2.\\n* Patient has a history of gastroparesis or pancreatitis.\\n* Personal or family history of medullary thyroid cancer or MEN2 (Multiple EndocrineNeoplasia Type 2) or calcitonin level of \\\\>40 ng/L at baseline.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '130 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Stephanie Gustavson, PhD', 'affiliation': 'AstraZeneca', 'role': 'STUDY_DIRECTOR'}, {'name': 'Group Director Global Clinical Research', 'affiliation': 'Bristol-Myers Squibb', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Research Site', 'city': 'Birmingham', 'state': 'Alabama', 'zip': '35294', 'country': 'United States', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'facility': 'Research Site', 'city': 'Glendale', 'state': 'Arizona', 'zip': '85306', 'country': 'United States', 'geoPoint': {'lat': 33.53865, 'lon': -112.18599}}, {'facility': 'Research Site', 'city': 'Phoenix', 'state': 'Arizona', 'zip': '85012', 'country': 'United States', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'facility': 'Research Site', 'city': 'Jonesboro', 'state': 'Arkansas', 'zip': '72401', 'country': 'United States', 'geoPoint': {'lat': 35.8423, 'lon': -90.70428}}, {'facility': 'Research Site', 'city': 'Little Rock', 'state': 'Arkansas', 'zip': '72204', 'country': 'United States', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'facility': 'Research Site', 'city': 'Chula Vista', 'state': 'California', 'zip': '91911-1350', 'country': 'United States', 'geoPoint': {'lat': 32.64005, 'lon': -117.0842}}, {'facility': 'Research Site', 'city': 'Concord', 'state': 'California', 'zip': '94520', 'country': 'United States', 'geoPoint': {'lat': 37.97798, 'lon': -122.03107}}, {'facility': 'Research Site', 'city': 'Escondido', 'state': 'California', 'zip': '92029', 'country': 'United States', 'geoPoint': {'lat': 33.11921, 'lon': -117.08642}}, {'facility': 'Research Site', 'city': 'Fullerton', 'state': 'California', 'zip': '92835', 'country': 'United States', 'geoPoint': {'lat': 33.87029, 'lon': -117.92534}}, {'facility': 'Research Site', 'city': 'Greenbrae', 'state': 'California', 'zip': '94904', 'country': 'United States', 'geoPoint': {'lat': 37.94854, 'lon': -122.5247}}, {'facility': 'Research Site', 'city': 'La Mesa', 'state': 'California', 'zip': '91942', 'country': 'United States', 'geoPoint': {'lat': 32.76783, 'lon': -117.02308}}, {'facility': 'Research Site', 'city': 'Laguna Hills', 'state': 'California', 'zip': '92653', 'country': 'United States', 'geoPoint': {'lat': 33.61252, 'lon': -117.71283}}, {'facility': 'Research Site', 'city': 'Long Beach', 'state': 'California', 'zip': '90822', 'country': 'United States', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'facility': 'Research Site', 'city': 'Los Angeles', 'state': 'California', 'zip': '90033', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'Research Site', 'city': 'Northridge', 'state': 'California', 'zip': '91325', 'country': 'United States', 'geoPoint': {'lat': 34.22834, 'lon': -118.53675}}, {'facility': 'Research Site', 'city': 'Oceanside', 'state': 'California', 'zip': '92056', 'country': 'United States', 'geoPoint': {'lat': 33.19587, 'lon': -117.37948}}, {'facility': 'Research Site', 'city': 'Orange', 'state': 'California', 'zip': '92868', 'country': 'United States', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'facility': 'Research Site', 'city': 'Redondo Beach', 'state': 'California', 'zip': '90277', 'country': 'United States', 'geoPoint': {'lat': 33.84918, 'lon': -118.38841}}, {'facility': 'Research Site', 'city': 'San Diego', 'state': 'California', 'zip': '92120', 'country': 'United States', 'geoPoint': {'lat': 32.71533, 'lon': -117.15726}}, {'facility': 'Research Site', 'city': 'San Diego', 'state': 'California', 'zip': '92161', 'country': 'United States', 'geoPoint': {'lat': 32.71533, 'lon': -117.15726}}, {'facility': 'Research Site', 'city': 'Sylmar', 'state': 'California', 'zip': '91342', 'country': 'United States', 'geoPoint': {'lat': 34.30778, 'lon': -118.44925}}, {'facility': 'Research Site', 'city': 'Torrance', 'state': 'California', 'zip': '90505', 'country': 'United States', 'geoPoint': {'lat': 33.83585, 'lon': -118.34063}}, {'facility': 'Research Site', 'city': 'Tustin', 'state': 'California', 'zip': '92780', 'country': 'United States', 'geoPoint': {'lat': 33.74585, 'lon': -117.82617}}, {'facility': 'Research Site', 'city': 'Victorville', 'state': 'California', 'zip': '92392', 'country': 'United States', 'geoPoint': {'lat': 34.53611, 'lon': -117.29116}}, {'facility': 'Research Site', 'city': 'Aurora', 'state': 'Colorado', 'zip': '80045', 'country': 'United States', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'facility': 'Research Site', 'city': 'Colorado Springs', 'state': 'Colorado', 'zip': '80920', 'country': 'United States', 'geoPoint': {'lat': 38.83388, 'lon': -104.82136}}, {'facility': 'Research Site', 'city': 'Littleton', 'state': 'Colorado', 'zip': '80120', 'country': 'United States', 'geoPoint': {'lat': 39.61332, 'lon': -105.01665}}, {'facility': 'Research Site', 'city': 'Thomaston', 'state': 'Connecticut', 'zip': '06787', 'country': 'United States', 'geoPoint': {'lat': 41.67399, 'lon': -73.07316}}, {'facility': 'Research Site', 'city': 'Washington', 'state': 'District of Columbia', 'zip': '20037', 'country': 'United States', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'facility': 'Research Site', 'city': 'Cape Coral', 'state': 'Florida', 'zip': '33904', 'country': 'United States', 'geoPoint': {'lat': 26.56285, 'lon': -81.94953}}, {'facility': 'Research Site', 'city': 'Fort Lauderdale', 'state': 'Florida', 'zip': '33308', 'country': 'United States', 'geoPoint': {'lat': 26.12231, 'lon': -80.14338}}, {'facility': 'Research Site', 'city': 'Jacksonville', 'state': 'Florida', 'zip': '32216', 'country': 'United States', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'facility': 'Research Site', 'city': 'Sarasota', 'state': 'Florida', 'zip': '34239', 'country': 'United States', 'geoPoint': {'lat': 27.33643, 'lon': -82.53065}}, {'facility': 'Research Site', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30339', 'country': 'United States', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': 'Research Site', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30342', 'country': 'United States', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': 'Research Site', 'city': 'Decatur', 'state': 'Georgia', 'zip': '30033', 'country': 'United States', 'geoPoint': {'lat': 33.77483, 'lon': -84.29631}}, {'facility': 'Research Site', 'city': 'Marietta', 'state': 'Georgia', 'zip': '30067', 'country': 'United States', 'geoPoint': {'lat': 33.9526, 'lon': -84.54993}}, {'facility': 'Research Site', 'city': 'Roswell', 'state': 'Georgia', 'zip': '30076', 'country': 'United States', 'geoPoint': {'lat': 34.02316, 'lon': -84.36159}}, {'facility': 'Research Site', 'city': 'Pocatello', 'state': 'Idaho', 'zip': '83201', 'country': 'United States', 'geoPoint': {'lat': 42.8713, 'lon': -112.44553}}, {'facility': 'Research Site', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60607', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'facility': 'Research Site', 'city': 'Hines', 'state': 'Illinois', 'zip': '60141', 'country': 'United States', 'geoPoint': {'lat': 41.85364, 'lon': -87.8395}}, {'facility': 'Research Site', 'city': 'Rock Island', 'state': 'Illinois', 'zip': '61201', 'country': 'United States', 'geoPoint': {'lat': 41.50948, 'lon': -90.57875}}, {'facility': 'Research Site', 'city': 'Springfield', 'state': 'Illinois', 'zip': '62704', 'country': 'United States', 'geoPoint': {'lat': 39.80172, 'lon': -89.64371}}, {'facility': 'Research Site', 'city': 'Avon', 'state': 'Indiana', 'zip': '46123', 'country': 'United States', 'geoPoint': {'lat': 39.76282, 'lon': -86.39972}}, {'facility': 'Research Site', 'city': 'Gary', 'state': 'Indiana', 'zip': '46403', 'country': 'United States', 'geoPoint': {'lat': 41.59337, 'lon': -87.34643}}, {'facility': 'Research Site', 'city': 'Indianapolis', 'state': 'Indiana', 'zip': '46260', 'country': 'United States', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'facility': 'Research Site', 'city': 'Des Moines', 'state': 'Iowa', 'zip': '50263', 'country': 'United States', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'facility': 'Research Site', 'city': 'Kansas City', 'state': 'Kansas', 'zip': '66160', 'country': 'United States', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'facility': 'Research Site', 'city': 'Covington', 'state': 'Kentucky', 'zip': '41011', 'country': 'United States', 'geoPoint': {'lat': 39.08367, 'lon': -84.50855}}, {'facility': 'Research Site', 'city': 'Evansville', 'state': 'Kentucky', 'zip': '47713', 'country': 'United States'}, {'facility': 'Research Site', 'city': 'Lexington', 'state': 'Kentucky', 'zip': '40502', 'country': 'United States', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'facility': 'Research Site', 'city': 'Alexandria', 'state': 'Louisiana', 'zip': '71301', 'country': 'United States', 'geoPoint': {'lat': 31.31129, 'lon': -92.44514}}, {'facility': 'Research Site', 'city': 'Auburn', 'state': 'Maine', 'zip': '04210', 'country': 'United States', 'geoPoint': {'lat': 44.09785, 'lon': -70.23117}}, {'facility': 'Research Site', 'city': 'Baltimore', 'state': 'Maryland', 'zip': '21215', 'country': 'United States', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'facility': 'Research Site', 'city': 'Randallstown', 'state': 'Maryland', 'zip': '21133', 'country': 'United States', 'geoPoint': {'lat': 39.36733, 'lon': -76.79525}}, {'facility': 'Research Site', 'city': 'Rockville', 'state': 'Maryland', 'zip': '20874', 'country': 'United States', 'geoPoint': {'lat': 39.084, 'lon': -77.15276}}, {'facility': 'Research Site', 'city': 'Alpena', 'state': 'Michigan', 'zip': '49707', 'country': 'United States', 'geoPoint': {'lat': 45.06168, 'lon': -83.43275}}, {'facility': 'Research Site', 'city': 'Ann Arbor', 'state': 'Michigan', 'zip': '48109', 'country': 'United States', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'facility': 'Research Site', 'city': 'Bloomfield Hills', 'state': 'Michigan', 'zip': '48302', 'country': 'United States', 'geoPoint': {'lat': 42.58364, 'lon': -83.24549}}, {'facility': 'Research Site', 'city': 'Detroit', 'state': 'Michigan', 'zip': '48201', 'country': 'United States', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'facility': 'Research Site', 'city': 'Detroit', 'state': 'Michigan', 'zip': '48202', 'country': 'United States', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'facility': 'Research Site', 'city': 'Duluth', 'state': 'Minnesota', 'zip': '55805', 'country': 'United States', 'geoPoint': {'lat': 46.78327, 'lon': -92.10658}}, {'facility': 'Research Site', 'city': 'Minneapolis', 'state': 'Minnesota', 'zip': '55416', 'country': 'United States', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'facility': 'Research Site', 'city': 'Minneapolis', 'state': 'Minnesota', 'zip': '55454', 'country': 'United States', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'facility': 'Research Site', 'city': 'Saint Cloud', 'state': 'Minnesota', 'zip': '56303', 'country': 'United States', 'geoPoint': {'lat': 45.5608, 'lon': -94.16249}}, {'facility': 'Research Site', 'city': 'Bridgeton', 'state': 'Missouri', 'zip': '63044', 'country': 'United States', 'geoPoint': {'lat': 38.767, 'lon': -90.41151}}, {'facility': 'Research Site', 'city': 'Chesterfield', 'state': 'Missouri', 'zip': '63017', 'country': 'United States', 'geoPoint': {'lat': 38.66311, 'lon': -90.57707}}, {'facility': 'Research Site', 'city': 'Billings', 'state': 'Montana', 'zip': '59101', 'country': 'United States', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'facility': 'Research Site', 'city': 'Butte', 'state': 'Montana', 'zip': '59701', 'country': 'United States', 'geoPoint': {'lat': 46.00382, 'lon': -112.53474}}, {'facility': 'Research Site', 'city': 'Omaha', 'state': 'Nebraska', 'zip': '68154', 'country': 'United States', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'facility': 'Research Site', 'city': 'Las Vegas', 'state': 'Nevada', 'zip': '89121', 'country': 'United States', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'facility': 'Research Site', 'city': 'Reno', 'state': 'Nevada', 'zip': '89511', 'country': 'United States', 'geoPoint': {'lat': 39.52963, 'lon': -119.8138}}, {'facility': 'Research Site', 'city': 'Hamilton', 'state': 'New Jersey', 'zip': '08690', 'country': 'United States', 'geoPoint': {'lat': 40.20706, 'lon': -74.08125}}, {'facility': 'Research Site', 'city': 'Lyons', 'state': 'New Jersey', 'zip': '07939', 'country': 'United States', 'geoPoint': {'lat': 40.68538, 'lon': -74.5471}}, {'facility': 'Research Site', 'city': 'Margate City', 'state': 'New Jersey', 'zip': '08402', 'country': 'United States', 'geoPoint': {'lat': 39.32789, 'lon': -74.50349}}, {'facility': 'Research Site', 'city': 'South Plainfield', 'state': 'New Jersey', 'zip': '07080', 'country': 'United States', 'geoPoint': {'lat': 40.57927, 'lon': -74.41154}}, {'facility': 'Research Site', 'city': 'Albany', 'state': 'New York', 'zip': '12203', 'country': 'United States', 'geoPoint': {'lat': 42.65258, 'lon': -73.75623}}, {'facility': 'Research Site', 'city': 'Bronx', 'state': 'New York', 'zip': '10461', 'country': 'United States', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'facility': 'Research Site', 'city': 'Manhasset', 'state': 'New York', 'zip': '11030', 'country': 'United States', 'geoPoint': {'lat': 40.79788, 'lon': -73.69957}}, {'facility': 'Research Site', 'city': 'New York', 'state': 'New York', 'zip': '10001', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Research Site', 'city': 'New York', 'state': 'New York', 'zip': '10032', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Research Site', 'city': 'North Massapequa', 'state': 'New York', 'zip': '11758', 'country': 'United States', 'geoPoint': {'lat': 40.70093, 'lon': -73.46207}}, {'facility': 'Research Site', 'city': 'Rosedale', 'state': 'New York', 'zip': '11422', 'country': 'United States', 'geoPoint': {'lat': 40.66205, 'lon': -73.73541}}, {'facility': 'Research Site', 'city': 'Smithtown', 'state': 'New York', 'zip': '11787', 'country': 'United States', 'geoPoint': {'lat': 40.85593, 'lon': -73.20067}}, {'facility': 'Research Site', 'city': 'Charlotte', 'state': 'North Carolina', 'zip': '28207', 'country': 'United States', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'facility': 'Research Site', 'city': 'Durham', 'state': 'North Carolina', 'zip': '27705', 'country': 'United States', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'facility': 'Research Site', 'city': 'Greensboro', 'state': 'North Carolina', 'zip': '27401', 'country': 'United States', 'geoPoint': {'lat': 36.07264, 'lon': -79.79198}}, {'facility': 'Research Site', 'city': 'Hickory', 'state': 'North Carolina', 'zip': '28602', 'country': 'United States', 'geoPoint': {'lat': 35.73319, 'lon': -81.3412}}, {'facility': 'Research Site', 'city': 'Mooresville', 'state': 'North Carolina', 'zip': '28117', 'country': 'United States', 'geoPoint': {'lat': 35.58486, 'lon': -80.81007}}, {'facility': 'Research Site', 'city': 'Morehead City', 'state': 'North Carolina', 'zip': '28557', 'country': 'United States', 'geoPoint': {'lat': 34.72294, 'lon': -76.72604}}, {'facility': 'Research Site', 'city': 'Raleigh', 'state': 'North Carolina', 'zip': '27609', 'country': 'United States', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'facility': 'Research Site', 'city': 'Salisbury', 'state': 'North Carolina', 'zip': '28144', 'country': 'United States', 'geoPoint': {'lat': 35.67097, 'lon': -80.47423}}, {'facility': 'Research Site', 'city': 'Statesville', 'state': 'North Carolina', 'zip': '28625', 'country': 'United States', 'geoPoint': {'lat': 35.78264, 'lon': -80.8873}}, {'facility': 'Research Site', 'city': 'Wilmington', 'state': 'North Carolina', 'zip': '28401', 'country': 'United States', 'geoPoint': {'lat': 34.22573, 'lon': -77.94471}}, {'facility': 'Research Site', 'city': 'Winston-Salem', 'state': 'North Carolina', 'zip': '27103', 'country': 'United States', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'facility': 'Research Site', 'city': 'Fargo', 'state': 'North Dakota', 'zip': '58103', 'country': 'United States', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'facility': 'Research Site', 'city': 'Barberton', 'state': 'Ohio', 'zip': '44203', 'country': 'United States', 'geoPoint': {'lat': 41.01283, 'lon': -81.60512}}, {'facility': 'Research Site', 'city': 'Canal Fulton', 'state': 'Ohio', 'zip': '44614', 'country': 'United States', 'geoPoint': {'lat': 40.88978, 'lon': -81.59762}}, {'facility': 'Research Site', 'city': 'Cleveland', 'state': 'Ohio', 'zip': '44121', 'country': 'United States', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'facility': 'Research Site', 'city': 'Cleveland', 'state': 'Ohio', 'zip': '44122', 'country': 'United States', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'facility': 'Research Site', 'city': 'Cleveland', 'state': 'Ohio', 'zip': '44195', 'country': 'United States', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'facility': 'Research Site', 'city': 'Columbus', 'state': 'Ohio', 'zip': '43210', 'country': 'United States', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'facility': 'Research Site', 'city': 'Kettering', 'state': 'Ohio', 'zip': '45429', 'country': 'United States', 'geoPoint': {'lat': 39.6895, 'lon': -84.16883}}, {'facility': 'Research Site', 'city': 'Mentor', 'state': 'Ohio', 'zip': '44060', 'country': 'United States', 'geoPoint': {'lat': 41.66616, 'lon': -81.33955}}, {'facility': 'Research Site', 'city': 'Toledo', 'state': 'Ohio', 'zip': '43614', 'country': 'United States', 'geoPoint': {'lat': 41.66394, 'lon': -83.55521}}, {'facility': 'Research Site', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'zip': '73103', 'country': 'United States', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'facility': 'Research Site', 'city': 'Bethlehem', 'state': 'Pennsylvania', 'zip': '18015', 'country': 'United States', 'geoPoint': {'lat': 40.62593, 'lon': -75.37046}}, {'facility': 'Research Site', 'city': 'Feasterville', 'state': 'Pennsylvania', 'zip': '19053', 'country': 'United States', 'geoPoint': {'lat': 40.144, 'lon': -75.00517}}, {'facility': 'Research Site', 'city': 'Lansdale', 'state': 'Pennsylvania', 'zip': '19446', 'country': 'United States', 'geoPoint': {'lat': 40.2415, 'lon': -75.28379}}, {'facility': 'Research Site', 'city': 'Newport', 'state': 'Pennsylvania', 'zip': '17011', 'country': 'United States', 'geoPoint': {'lat': 40.47786, 'lon': -77.13054}}, {'facility': 'Research Site', 'city': 'Newport', 'state': 'Pennsylvania', 'zip': '17074', 'country': 'United States', 'geoPoint': {'lat': 40.47786, 'lon': -77.13054}}, {'facility': 'Research Site', 'city': 'Penndel', 'state': 'Pennsylvania', 'zip': '19047', 'country': 'United States', 'geoPoint': {'lat': 40.15205, 'lon': -74.91656}}, {'facility': 'Research Site', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19114', 'country': 'United States', 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}, {'facility': 'Research Site', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19134', 'country': 'United States', 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}, {'facility': 'Research Site', 'city': 'Tipton', 'state': 'Pennsylvania', 'zip': '16684', 'country': 'United States', 'geoPoint': {'lat': 40.6359, 'lon': -78.29585}}, {'facility': 'Research Site', 'city': 'Pawtucket', 'state': 'Rhode Island', 'zip': '02860', 'country': 'United States', 'geoPoint': {'lat': 41.87871, 'lon': -71.38256}}, {'facility': 'Research Site', 'city': 'Charleston', 'state': 'South Carolina', 'zip': '29401', 'country': 'United States', 'geoPoint': {'lat': 32.77657, 'lon': -79.93092}}, {'facility': 'Research Site', 'city': 'Mount Pleasant', 'state': 'South Carolina', 'zip': '29464', 'country': 'United States', 'geoPoint': {'lat': 32.79407, 'lon': -79.86259}}, {'facility': 'Research Site', 'city': 'Murrells Inlet', 'state': 'South Carolina', 'zip': '29576', 'country': 'United States', 'geoPoint': {'lat': 33.551, 'lon': -79.04143}}, {'facility': 'Research Site', 'city': 'Rapid City', 'state': 'South Dakota', 'zip': '57701', 'country': 'United States', 'geoPoint': {'lat': 44.08054, 'lon': -103.23101}}, {'facility': 'Research Site', 'city': 'Bristol', 'state': 'Tennessee', 'zip': '37620', 'country': 'United States', 'geoPoint': {'lat': 36.59511, 'lon': -82.18874}}, {'facility': 'Research Site', 'city': 'Chattanooga', 'state': 'Tennessee', 'zip': '37403', 'country': 'United States', 'geoPoint': {'lat': 35.04563, 'lon': -85.30968}}, {'facility': 'Research Site', 'city': 'Jackson', 'state': 'Tennessee', 'zip': '38305', 'country': 'United States', 'geoPoint': {'lat': 35.61452, 'lon': -88.81395}}, {'facility': 'Research Site', 'city': 'Johnson City', 'state': 'Tennessee', 'zip': '37601', 'country': 'United States', 'geoPoint': {'lat': 36.31344, 'lon': -82.35347}}, {'facility': 'Research Site', 'city': 'Kingsport', 'state': 'Tennessee', 'zip': '37660', 'country': 'United States', 'geoPoint': {'lat': 36.54843, 'lon': -82.56182}}, {'facility': 'Research Site', 'city': 'Knoxville', 'state': 'Tennessee', 'zip': '37912', 'country': 'United States', 'geoPoint': {'lat': 35.96064, 'lon': -83.92074}}, {'facility': 'Research Site', 'city': 'McKenzie', 'state': 'Tennessee', 'zip': '38201', 'country': 'United States', 'geoPoint': {'lat': 36.13256, 'lon': -88.51866}}, {'facility': 'Research Site', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'Research Site', 'city': 'Arlington', 'state': 'Texas', 'zip': '76012', 'country': 'United States', 'geoPoint': {'lat': 32.73569, 'lon': -97.10807}}, {'facility': 'Research Site', 'city': 'Dallas', 'state': 'Texas', 'zip': '75218', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'Research Site', 'city': 'Dallas', 'state': 'Texas', 'zip': '75231', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'Research Site', 'city': 'Dallas', 'state': 'Texas', 'zip': '75251', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'Research Site', 'city': 'Dallas', 'state': 'Texas', 'zip': '75390', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'Research Site', 'city': 'El Paso', 'state': 'Texas', 'zip': '79925', 'country': 'United States', 'geoPoint': {'lat': 31.75872, 'lon': -106.48693}}, {'facility': 'Research Site', 'city': 'Friendswood', 'state': 'Texas', 'zip': '77546', 'country': 'United States', 'geoPoint': {'lat': 29.5294, 'lon': -95.20104}}, {'facility': 'Research Site', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'Research Site', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'Research Site', 'city': 'Webster', 'state': 'Texas', 'zip': '77598', 'country': 'United States', 'geoPoint': {'lat': 29.53773, 'lon': -95.11826}}, {'facility': 'Research Site', 'city': 'Layton', 'state': 'Utah', 'zip': '84041', 'country': 'United States', 'geoPoint': {'lat': 41.06022, 'lon': -111.97105}}, {'facility': 'Research Site', 'city': 'Buenos Aires', 'zip': 'C1425AGC', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Research Site', 'city': 'Buenos Aires', 'zip': 'C1437BZL', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Research Site', 'city': 'Caba', 'zip': '1426', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Research Site', 'city': 'Caba', 'zip': 'C1119ACN', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Research Site', 'city': 'Caba', 'zip': 'C1120AAC', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Research Site', 'city': 'Capital Federal', 'zip': 'C1425DES', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Research Site', 'city': 'CiudadAutonoma De Buenos Aires', 'zip': 'C1419AHL', 'country': 'Argentina'}, {'facility': 'Research Site', 'city': 'Cordoba', 'zip': '5000', 'country': 'Argentina', 'geoPoint': {'lat': -31.4135, 'lon': -64.18105}}, {'facility': 'Research Site', 'city': 'Cordoba', 'zip': 'X5003DCE', 'country': 'Argentina', 'geoPoint': {'lat': -31.4135, 'lon': -64.18105}}, {'facility': 'Research Site', 'city': 'Cordoba', 'zip': 'X5004FHP', 'country': 'Argentina', 'geoPoint': {'lat': -31.4135, 'lon': -64.18105}}, {'facility': 'Research Site', 'city': 'Cordoba', 'zip': 'X5008HHW', 'country': 'Argentina', 'geoPoint': {'lat': -31.4135, 'lon': -64.18105}}, {'facility': 'Research Site', 'city': 'Godoy Cruz', 'zip': 'M5501ARP', 'country': 'Argentina', 'geoPoint': {'lat': -32.92863, 'lon': -68.8351}}, {'facility': 'Research Site', 'city': 'Jujuy', 'country': 'Argentina'}, {'facility': 'Research Site', 'city': 'Mar Del Plata Buenos Aires', 'zip': 'B7600DIA', 'country': 'Argentina'}, {'facility': 'Research Site', 'city': 'Rosario', 'zip': 'S2000CVD', 'country': 'Argentina', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'facility': 'Research Site', 'city': 'Salta', 'zip': 'A4400ANG', 'country': 'Argentina', 'geoPoint': {'lat': -24.7859, 'lon': -65.41166}}, {'facility': 'Research Site', 'city': 'San Miguel de Tucuman', 'zip': '4000', 'country': 'Argentina', 'geoPoint': {'lat': -26.82414, 'lon': -65.2226}}, {'facility': 'Research Site', 'city': 'Santa Rosa', 'country': 'Argentina', 'geoPoint': {'lat': -36.61667, 'lon': -64.28333}}, {'facility': 'Research Site', 'city': 'Adelaide', 'zip': '5000', 'country': 'Australia', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'facility': 'Research Site', 'city': 'Camperdown', 'zip': '2050', 'country': 'Australia', 'geoPoint': {'lat': -33.88965, 'lon': 151.17642}}, {'facility': 'Research Site', 'city': 'Clayton', 'zip': '3168', 'country': 'Australia', 'geoPoint': {'lat': -37.91667, 'lon': 145.11667}}, {'facility': 'Research Site', 'city': 'East Gosford', 'zip': '2250', 'country': 'Australia', 'geoPoint': {'lat': -33.43874, 'lon': 151.35338}}, {'facility': 'Research Site', 'city': 'Elizabeth Vale', 'zip': '5112', 'country': 'Australia', 'geoPoint': {'lat': -34.74857, 'lon': 138.66819}}, {'facility': 'Research Site', 'city': 'Fitzroy', 'zip': '3065', 'country': 'Australia', 'geoPoint': {'lat': -37.79839, 'lon': 144.97833}}, {'facility': 'Research Site', 'city': 'Garran', 'zip': '2605', 'country': 'Australia', 'geoPoint': {'lat': -35.34206, 'lon': 149.10846}}, {'facility': 'Research Site', 'city': 'Geelong', 'zip': '3220', 'country': 'Australia', 'geoPoint': {'lat': -38.14711, 'lon': 144.36069}}, {'facility': 'Research Site', 'city': 'Heidelberg West', 'zip': '3081', 'country': 'Australia', 'geoPoint': {'lat': -37.75, 'lon': 145.03333}}, {'facility': 'Research Site', 'city': 'Meadobank', 'zip': '4131', 'country': 'Australia'}, {'facility': 'Research Site', 'city': 'Milton', 'zip': '4064', 'country': 'Australia', 'geoPoint': {'lat': -35.31644, 'lon': 150.4361}}, {'facility': 'Research Site', 'city': 'Parkville', 'zip': '3050', 'country': 'Australia', 'geoPoint': {'lat': -37.78333, 'lon': 144.95}}, {'facility': 'Research Site', 'city': 'Sydney', 'zip': '2006', 'country': 'Australia', 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'facility': 'Research Site', 'city': 'Feldkirch', 'zip': '6807', 'country': 'Austria', 'geoPoint': {'lat': 47.23306, 'lon': 9.6}}, {'facility': 'Research Site', 'city': 'Graz', 'zip': '8036', 'country': 'Austria', 'geoPoint': {'lat': 47.06667, 'lon': 15.45}}, {'facility': 'Research Site', 'city': 'Innsbruck', 'zip': '6020', 'country': 'Austria', 'geoPoint': {'lat': 47.26266, 'lon': 11.39454}}, {'facility': 'Research Site', 'city': 'Salzburg', 'zip': '5020', 'country': 'Austria', 'geoPoint': {'lat': 47.79941, 'lon': 13.04399}}, {'facility': 'Research Site', 'city': 'Wien', 'zip': '1030', 'country': 'Austria', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'facility': 'Research Site', 'city': 'Wien', 'zip': '1090', 'country': 'Austria', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'facility': 'Research Site', 'city': 'Wien', 'zip': '1130', 'country': 'Austria', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'facility': 'Research Site', 'city': 'Wien', 'zip': '1160', 'country': 'Austria', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'facility': 'Research Site', 'city': 'Zams', 'zip': '6511', 'country': 'Austria', 'geoPoint': {'lat': 47.15844, 'lon': 10.5897}}, {'facility': 'Research Site', 'city': 'Bruxelles', 'zip': '1200', 'country': 'Belgium', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'facility': 'Research Site', 'city': 'Leuven', 'zip': '3000', 'country': 'Belgium', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'facility': 'Research Site', 'city': 'Merksem', 'zip': '2170', 'country': 'Belgium', 'geoPoint': {'lat': 51.24623, 'lon': 4.44903}}, {'facility': 'Research Site', 'city': 'Ronse', 'zip': '9600', 'country': 'Belgium', 'geoPoint': {'lat': 50.74574, 'lon': 3.6005}}, {'facility': 'Research Site', 'city': 'Aparecida de Goiânia', 'zip': '74905-350', 'country': 'Brazil', 'geoPoint': {'lat': -16.82333, 'lon': -49.24389}}, {'facility': 'Research Site', 'city': 'Belém', 'zip': '66073-000', 'country': 'Brazil', 'geoPoint': {'lat': -1.45583, 'lon': -48.50444}}, {'facility': 'Research Site', 'city': 'Brasilia', 'zip': '71625-175', 'country': 'Brazil', 'geoPoint': {'lat': -15.77972, 'lon': -47.92972}}, {'facility': 'Research Site', 'city': 'Campinas', 'zip': '13010-001', 'country': 'Brazil', 'geoPoint': {'lat': -22.90556, 'lon': -47.06083}}, {'facility': 'Research Site', 'city': 'Campinas', 'zip': '13060-904', 'country': 'Brazil', 'geoPoint': {'lat': -22.90556, 'lon': -47.06083}}, {'facility': 'Research Site', 'city': 'Curitiba', 'zip': '80060-900', 'country': 'Brazil', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'facility': 'Research Site', 'city': 'Curitiba', 'zip': '80730-150', 'country': 'Brazil', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'facility': 'Research Site', 'city': 'Fortaleza', 'zip': '60115282', 'country': 'Brazil', 'geoPoint': {'lat': -3.71722, 'lon': -38.54306}}, {'facility': 'Research Site', 'city': 'Fortaleza', 'zip': '60430-350', 'country': 'Brazil', 'geoPoint': {'lat': -3.71722, 'lon': -38.54306}}, {'facility': 'Research Site', 'city': 'Goiânia', 'zip': '74125-170', 'country': 'Brazil', 'geoPoint': {'lat': -16.67861, 'lon': -49.25389}}, {'facility': 'Research Site', 'city': 'Marília', 'zip': '17515-460', 'country': 'Brazil', 'geoPoint': {'lat': -22.21389, 'lon': -49.94583}}, {'facility': 'Research Site', 'city': 'Passo Fundo', 'zip': '99010-080', 'country': 'Brazil', 'geoPoint': {'lat': -28.26278, 'lon': -52.40667}}, {'facility': 'Research Site', 'city': 'Recife', 'zip': '52020010', 'country': 'Brazil', 'geoPoint': {'lat': -8.05389, 'lon': -34.88111}}, {'facility': 'Research Site', 'city': 'Sao Paulo', 'zip': '04022001', 'country': 'Brazil', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'facility': 'Research Site', 'city': 'São Paulo', 'zip': '01244-030', 'country': 'Brazil', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'facility': 'Research Site', 'city': 'Blagoevgrad', 'zip': '2700', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.01667, 'lon': 23.1}}, {'facility': 'Research Site', 'city': 'Gabrovo', 'zip': '5300', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.87472, 'lon': 25.33417}}, {'facility': 'Research Site', 'city': 'Gulyantsi', 'zip': '5960', 'country': 'Bulgaria', 'geoPoint': {'lat': 43.64088, 'lon': 24.69385}}, {'facility': 'Research Site', 'city': 'Plovdiv', 'zip': '4000', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.15, 'lon': 24.75}}, {'facility': 'Research Site', 'city': 'Plovdiv', 'zip': '4002', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.15, 'lon': 24.75}}, {'facility': 'Research Site', 'city': 'Sevlievo', 'zip': '5400', 'country': 'Bulgaria', 'geoPoint': {'lat': 43.02583, 'lon': 25.11361}}, {'facility': 'Research Site', 'city': 'Sliven', 'zip': '8800', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.68583, 'lon': 26.32917}}, {'facility': 'Research Site', 'city': 'Sofia', 'zip': '1233', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'Research Site', 'city': 'Sofia', 'zip': '1431', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'Research Site', 'city': 'Sofia', 'zip': '1606', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'Research Site', 'city': 'Sofia', 'zip': '1632', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'Research Site', 'city': 'Sofia', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'Research Site', 'city': 'Stara Zagora', 'zip': '6000', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.43278, 'lon': 25.64194}}, {'facility': 'Research Site', 'city': 'Calgary', 'state': 'Alberta', 'zip': 'T2T 5C7', 'country': 'Canada', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'facility': 'Research Site', 'city': 'Delta', 'state': 'British Columbia', 'zip': 'V4K 2K5', 'country': 'Canada', 'geoPoint': {'lat': 49.14399, 'lon': -122.9068}}, {'facility': 'Research Site', 'city': 'New Westminster', 'state': 'British Columbia', 'zip': 'V3L 3W4', 'country': 'Canada', 'geoPoint': {'lat': 49.20678, 'lon': -122.91092}}, {'facility': 'Research Site', 'city': 'Surrey', 'state': 'British Columbia', 'zip': 'V3V 0C6', 'country': 'Canada', 'geoPoint': {'lat': 49.10635, 'lon': -122.82509}}, {'facility': 'Research Site', 'city': 'Vancouver', 'state': 'British Columbia', 'zip': 'V5Z 1M9', 'country': 'Canada', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'facility': 'Research Site', 'city': 'Winnipeg', 'state': 'Manitoba', 'zip': 'R2H 0R8', 'country': 'Canada', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'facility': 'Research Site', 'city': 'Winnipeg', 'state': 'Manitoba', 'zip': 'R3E 3P4', 'country': 'Canada', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'facility': 'Research Site', 'city': 'Moncton', 'state': 'New Brunswick', 'zip': 'E1G 1A7', 'country': 'Canada', 'geoPoint': {'lat': 46.09454, 'lon': -64.7965}}, {'facility': 'Research Site', 'city': 'Bridgewater', 'state': 'Nova Scotia', 'zip': 'B4V 3N2', 'country': 'Canada', 'geoPoint': {'lat': 44.37856, 'lon': -64.51882}}, {'facility': 'Research Site', 'city': 'Liverpool', 'state': 'Nova Scotia', 'zip': 'B0T 1K0', 'country': 'Canada', 'geoPoint': {'lat': 44.03639, 'lon': -64.72044}}, {'facility': 'Research Site', 'city': 'Cambridge', 'state': 'Ontario', 'zip': 'N1R 6V6', 'country': 'Canada', 'geoPoint': {'lat': 43.3601, 'lon': -80.31269}}, {'facility': 'Research Site', 'city': 'Guelph', 'state': 'Ontario', 'zip': 'N1H 1B1', 'country': 'Canada', 'geoPoint': {'lat': 43.54594, 'lon': -80.25599}}, {'facility': 'Research Site', 'city': 'Hamilton', 'state': 'Ontario', 'zip': 'L8L 5G8', 'country': 'Canada', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'facility': 'Research Site', 'city': 'Hamilton', 'state': 'Ontario', 'zip': 'L8M 1K7', 'country': 'Canada', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'facility': 'Research Site', 'city': 'Hamilton', 'state': 'Ontario', 'zip': 'L8N 3Z5', 'country': 'Canada', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'facility': 'Research Site', 'city': 'Kitchener', 'state': 'Ontario', 'zip': 'N2M 5N6', 'country': 'Canada', 'geoPoint': {'lat': 43.42537, 'lon': -80.5112}}, {'facility': 'Research Site', 'city': 'London', 'state': 'Ontario', 'zip': 'N6B 2E5', 'country': 'Canada', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'facility': 'Research Site', 'city': 'North York', 'state': 'Ontario', 'zip': 'M3M 3E5', 'country': 'Canada', 'geoPoint': {'lat': 43.76681, 'lon': -79.4163}}, {'facility': 'Research Site', 'city': 'Ottawa', 'state': 'Ontario', 'zip': 'K1H 1A2', 'country': 'Canada', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'facility': 'Research Site', 'city': 'Scarborough', 'state': 'Ontario', 'zip': 'M1E 5E9', 'country': 'Canada', 'geoPoint': {'lat': 43.77223, 'lon': -79.25666}}, {'facility': 'Research Site', 'city': 'Smiths Falls', 'state': 'Ontario', 'zip': 'K7A 4W8', 'country': 'Canada', 'geoPoint': {'lat': 44.90452, 'lon': -76.02333}}, {'facility': 'Research Site', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M5C 2T2', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Research Site', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M5T 3L9', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Research Site', 'city': 'Laval', 'state': 'Quebec', 'zip': 'H7T 2P5', 'country': 'Canada', 'geoPoint': {'lat': 45.56995, 'lon': -73.692}}, {'facility': 'Research Site', 'city': 'Montreal', 'state': 'Quebec', 'zip': 'H1M 1B1', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'facility': 'Research Site', 'city': 'Montreal', 'state': 'Quebec', 'zip': 'H3A 1A1', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'facility': 'Research Site', 'city': 'Sainte Foy', 'state': 'Quebec', 'zip': 'G1V 4G5', 'country': 'Canada', 'geoPoint': {'lat': 46.75615, 'lon': -71.29543}}, {'facility': 'Research Site', 'city': 'Terrebonne', 'state': 'Quebec', 'zip': 'J6V 1S8', 'country': 'Canada', 'geoPoint': {'lat': 45.70004, 'lon': -73.64732}}, {'facility': 'Research Site', 'city': 'Osorno', 'zip': '5290000', 'country': 'Chile', 'geoPoint': {'lat': -40.57395, 'lon': -73.13348}}, {'facility': 'Research Site', 'city': 'Puerto Varas', 'country': 'Chile', 'geoPoint': {'lat': -41.31946, 'lon': -72.98538}}, {'facility': 'Research Site', 'city': 'Santiago', 'zip': '7500710', 'country': 'Chile', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'facility': 'Research Site', 'city': 'Santiago', 'zip': '8053095', 'country': 'Chile', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'facility': 'Research Site', 'city': 'Temuco', 'zip': '4781173', 'country': 'Chile', 'geoPoint': {'lat': -38.73965, 'lon': -72.59842}}, {'facility': 'Research Site', 'city': 'Vina del Mar', 'zip': '2570017', 'country': 'Chile', 'geoPoint': {'lat': -33.02457, 'lon': -71.55183}}, {'facility': 'Research Site', 'city': 'Beijing', 'zip': '100029', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'Research Site', 'city': 'Beijing', 'zip': '100034', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'Research Site', 'city': 'Beijing', 'zip': '100044', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'Research Site', 'city': 'Beijing', 'zip': '100853', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'Research Site', 'city': 'Chongqing', 'zip': '400010', 'country': 'China', 'geoPoint': {'lat': 29.56278, 'lon': 106.55278}}, {'facility': 'Research Site', 'city': 'Chongqing', 'zip': '400016', 'country': 'China', 'geoPoint': {'lat': 29.56278, 'lon': 106.55278}}, {'facility': 'Research Site', 'city': 'Chuangchun', 'zip': '130012', 'country': 'China'}, {'facility': 'Research Site', 'city': 'Guangzhou', 'zip': '510080', 'country': 'China', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'facility': 'Research Site', 'city': 'Guangzhou', 'zip': '510120', 'country': 'China', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'facility': 'Research Site', 'city': 'Hangzhou', 'zip': '310009', 'country': 'China', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'facility': 'Research Site', 'city': 'Hong Kong', 'country': 'China', 'geoPoint': {'lat': 22.39407, 'lon': 114.13737}}, {'facility': 'Research Site', 'city': 'Nanjing', 'zip': '210012', 'country': 'China', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'facility': 'Research Site', 'city': 'Nanjing', 'zip': '210029', 'country': 'China', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'facility': 'Research Site', 'city': 'Nanning', 'zip': '530021', 'country': 'China', 'geoPoint': {'lat': 22.81667, 'lon': 108.31667}}, {'facility': 'Research Site', 'city': 'Shanghai', 'zip': '200072', 'country': 'China', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'facility': 'Research Site', 'city': 'Shijiazhuang', 'zip': '050000', 'country': 'China', 'geoPoint': {'lat': 38.04139, 'lon': 114.47861}}, {'facility': 'Research Site', 'city': 'Siping', 'zip': '136000', 'country': 'China', 'geoPoint': {'lat': 43.16143, 'lon': 124.37785}}, {'facility': 'Research Site', 'city': 'Suzhou', 'zip': '215004', 'country': 'China', 'geoPoint': {'lat': 31.30408, 'lon': 120.59538}}, {'facility': 'Research Site', 'city': 'Wenzhou', 'country': 'China', 'geoPoint': {'lat': 27.99942, 'lon': 120.66682}}, {'facility': 'Research Site', 'city': 'Wuhan', 'zip': '430000', 'country': 'China', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'facility': 'Research Site', 'city': 'Xian', 'zip': '710061', 'country': 'China', 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}, {'facility': 'Research Site', 'city': 'Yinchuan', 'zip': '750004', 'country': 'China', 'geoPoint': {'lat': 38.46806, 'lon': 106.27306}}, {'facility': 'Research Site', 'city': 'Barranquilla', 'zip': '80020', 'country': 'Colombia', 'geoPoint': {'lat': 10.96854, 'lon': -74.78132}}, {'facility': 'Research Site', 'city': 'Barranquilla', 'country': 'Colombia', 'geoPoint': {'lat': 10.96854, 'lon': -74.78132}}, {'facility': 'Research Site', 'city': 'Bogotá D.C.', 'country': 'Colombia'}, {'facility': 'Research Site', 'city': 'Bogotá', 'country': 'Colombia', 'geoPoint': {'lat': 4.60971, 'lon': -74.08175}}, {'facility': 'Research Site', 'city': 'Cali', 'zip': '760035', 'country': 'Colombia', 'geoPoint': {'lat': 3.43722, 'lon': -76.5225}}, {'facility': 'Research Site', 'city': 'Manizales', 'zip': '17001', 'country': 'Colombia', 'geoPoint': {'lat': 5.06889, 'lon': -75.51738}}, {'facility': 'Research Site', 'city': 'Medellin', 'zip': '5001000', 'country': 'Colombia', 'geoPoint': {'lat': 6.25184, 'lon': -75.56359}}, {'facility': 'Research Site', 'city': 'Medellín', 'country': 'Colombia', 'geoPoint': {'lat': 6.25184, 'lon': -75.56359}}, {'facility': 'Research Site', 'city': 'Olomouc-Lazce', 'zip': '779 00', 'country': 'Czechia'}, {'facility': 'Research Site', 'city': 'Praha 10, Prague', 'zip': '100 34', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'Research Site', 'city': 'Praha 4', 'zip': '140 00', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'Research Site', 'city': 'Svitavy', 'zip': '568 25', 'country': 'Czechia', 'geoPoint': {'lat': 49.75594, 'lon': 16.46829}}, {'facility': 'Research Site', 'city': 'Znojmo', 'zip': '669 02', 'country': 'Czechia', 'geoPoint': {'lat': 48.8555, 'lon': 16.0488}}, {'facility': 'Research Site', 'city': 'Aachen', 'zip': '52074', 'country': 'Germany', 'geoPoint': {'lat': 50.77664, 'lon': 6.08342}}, {'facility': 'Research Site', 'city': 'Aschaffenburg', 'zip': '63739', 'country': 'Germany', 'geoPoint': {'lat': 49.97704, 'lon': 9.15214}}, {'facility': 'Research Site', 'city': 'Bad Nauheim', 'zip': '61231', 'country': 'Germany', 'geoPoint': {'lat': 50.36463, 'lon': 8.73859}}, {'facility': 'Research Site', 'city': 'Bad Oeynhausen', 'zip': '32545', 'country': 'Germany', 'geoPoint': {'lat': 52.20699, 'lon': 8.80365}}, {'facility': 'Research Site', 'city': 'Berlin', 'zip': '10787', 'country': 'Germany', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'facility': 'Research Site', 'city': 'Berlin', 'zip': '13125', 'country': 'Germany', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'facility': 'Research Site', 'city': 'Berlin', 'zip': '13353', 'country': 'Germany', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'facility': 'Research Site', 'city': 'Bochum', 'zip': '44791', 'country': 'Germany', 'geoPoint': {'lat': 51.48165, 'lon': 7.21648}}, {'facility': 'Research Site', 'city': 'Burghausen', 'zip': '84489', 'country': 'Germany', 'geoPoint': {'lat': 48.16925, 'lon': 12.83139}}, {'facility': 'Research Site', 'city': 'Burg', 'zip': '03096', 'country': 'Germany', 'geoPoint': {'lat': 51.83448, 'lon': 14.14856}}, {'facility': 'Research Site', 'city': 'Chemnitz', 'zip': '09111', 'country': 'Germany', 'geoPoint': {'lat': 50.8357, 'lon': 12.92922}}, {'facility': 'Research Site', 'city': 'Dortmund', 'zip': '44137', 'country': 'Germany', 'geoPoint': {'lat': 51.51494, 'lon': 7.466}}, {'facility': 'Research Site', 'city': 'Dresden', 'zip': '01067', 'country': 'Germany', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'facility': 'Research Site', 'city': 'Dresden', 'zip': '01219', 'country': 'Germany', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'facility': 'Research Site', 'city': 'Dresden', 'zip': '01307', 'country': 'Germany', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'facility': 'Research Site', 'city': 'Eschweiler', 'zip': '52249', 'country': 'Germany', 'geoPoint': {'lat': 50.81854, 'lon': 6.27184}}, {'facility': 'Research Site', 'city': 'Essen', 'zip': '45355', 'country': 'Germany', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'facility': 'Research Site', 'city': 'Gießen', 'zip': '35392', 'country': 'Germany', 'geoPoint': {'lat': 50.58727, 'lon': 8.67554}}, {'facility': 'Research Site', 'city': 'Herne', 'zip': '44653', 'country': 'Germany', 'geoPoint': {'lat': 51.5388, 'lon': 7.22572}}, {'facility': 'Research Site', 'city': 'Hohenmölsen', 'zip': '06679', 'country': 'Germany', 'geoPoint': {'lat': 51.15769, 'lon': 12.1}}, {'facility': 'Research Site', 'city': 'Kassel', 'zip': '34121', 'country': 'Germany', 'geoPoint': {'lat': 51.31667, 'lon': 9.5}}, {'facility': 'Research Site', 'city': 'Kiel-Kronshagen', 'zip': '24119', 'country': 'Germany'}, {'facility': 'Research Site', 'city': 'Köthen', 'zip': '06366', 'country': 'Germany', 'geoPoint': {'lat': 51.75185, 'lon': 11.97093}}, {'facility': 'Research Site', 'city': 'Lichtenfels', 'zip': '96215', 'country': 'Germany', 'geoPoint': {'lat': 50.14567, 'lon': 11.05928}}, {'facility': 'Research Site', 'city': 'Mainz', 'zip': '55116', 'country': 'Germany', 'geoPoint': {'lat': 49.98419, 'lon': 8.2791}}, {'facility': 'Research Site', 'city': 'Mayen', 'zip': '56727', 'country': 'Germany', 'geoPoint': {'lat': 50.32797, 'lon': 7.22277}}, {'facility': 'Research Site', 'city': 'München', 'zip': '80336', 'country': 'Germany', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}}, {'facility': 'Research Site', 'city': 'München', 'zip': '81925', 'country': 'Germany', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}}, {'facility': 'Research Site', 'city': 'Münster', 'zip': '48145', 'country': 'Germany', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'facility': 'Research Site', 'city': 'Obermichelbach', 'zip': '90587', 'country': 'Germany', 'geoPoint': {'lat': 49.53117, 'lon': 10.90891}}, {'facility': 'Research Site', 'city': 'Osnabrueck', 'zip': '49080', 'country': 'Germany'}, {'facility': 'Research Site', 'city': 'Riesa', 'zip': '01587', 'country': 'Germany', 'geoPoint': {'lat': 51.30777, 'lon': 13.29168}}, {'facility': 'Research Site', 'city': 'Rotenburg', 'zip': '36199', 'country': 'Germany', 'geoPoint': {'lat': 53.11125, 'lon': 9.41082}}, {'facility': 'Research Site', 'city': 'Stuttgart', 'zip': '70376', 'country': 'Germany', 'geoPoint': {'lat': 48.78232, 'lon': 9.17702}}, {'facility': 'Research Site', 'city': 'Würzburg', 'zip': '97072', 'country': 'Germany', 'geoPoint': {'lat': 49.79391, 'lon': 9.95121}}, {'facility': 'Research Site', 'city': 'Hong Kong', 'country': 'Hong Kong', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'facility': 'Research Site', 'city': 'Shatin', 'country': 'Hong Kong', 'geoPoint': {'lat': 22.38333, 'lon': 114.18333}}, {'facility': 'Research Site', 'city': 'Balatonfüred', 'zip': '8230', 'country': 'Hungary', 'geoPoint': {'lat': 46.96188, 'lon': 17.87187}}, {'facility': 'Research Site', 'city': 'Budapest', 'zip': '1036', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Research Site', 'city': 'Budapest', 'zip': '1045', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Research Site', 'city': 'Budapest', 'zip': '1083', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Research Site', 'city': 'Budapest', 'zip': '1085', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Research Site', 'city': 'Budapest', 'zip': '1096', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Research Site', 'city': 'Budapest', 'zip': '1145', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Research Site', 'city': 'Budapest', 'zip': '1204', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Research Site', 'city': 'Budapest', 'zip': '1213', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Research Site', 'city': 'Budapest', 'zip': 'H-1096', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Research Site', 'city': 'Csongrad', 'zip': '6640', 'country': 'Hungary', 'geoPoint': {'lat': 46.71332, 'lon': 20.14241}}, {'facility': 'Research Site', 'city': 'Debrecen', 'zip': '4032', 'country': 'Hungary', 'geoPoint': {'lat': 47.53333, 'lon': 21.63333}}, {'facility': 'Research Site', 'city': 'Eger', 'zip': '3300', 'country': 'Hungary', 'geoPoint': {'lat': 47.90265, 'lon': 20.37329}}, {'facility': 'Research Site', 'city': 'Gyor', 'zip': '9023', 'country': 'Hungary', 'geoPoint': {'lat': 47.68333, 'lon': 17.63512}}, {'facility': 'Research Site', 'city': 'Hodmezovasarhely', 'zip': '6800', 'country': 'Hungary', 'geoPoint': {'lat': 46.41667, 'lon': 20.33333}}, {'facility': 'Research Site', 'city': 'Jászberény', 'zip': '5100', 'country': 'Hungary', 'geoPoint': {'lat': 47.5, 'lon': 19.91667}}, {'facility': 'Research Site', 'city': 'Kaposvár', 'zip': '7400', 'country': 'Hungary', 'geoPoint': {'lat': 46.36667, 'lon': 17.8}}, {'facility': 'Research Site', 'city': 'Kecskemét', 'zip': '6000', 'country': 'Hungary', 'geoPoint': {'lat': 46.90618, 'lon': 19.69128}}, {'facility': 'Research Site', 'city': 'Komarom', 'zip': '2921', 'country': 'Hungary', 'geoPoint': {'lat': 47.74318, 'lon': 18.11913}}, {'facility': 'Research Site', 'city': 'Mosonmagyarovar', 'zip': 'H-9200', 'country': 'Hungary', 'geoPoint': {'lat': 47.86789, 'lon': 17.26994}}, {'facility': 'Research Site', 'city': 'Nagykanizsa', 'zip': '8800', 'country': 'Hungary', 'geoPoint': {'lat': 46.45347, 'lon': 16.99104}}, {'facility': 'Research Site', 'city': 'Nyíregyháza', 'zip': '4400', 'country': 'Hungary', 'geoPoint': {'lat': 47.95539, 'lon': 21.71671}}, {'facility': 'Research Site', 'city': 'Pápa', 'zip': '8500', 'country': 'Hungary', 'geoPoint': {'lat': 47.33004, 'lon': 17.4674}}, {'facility': 'Research Site', 'city': 'Pécs', 'zip': '7624', 'country': 'Hungary', 'geoPoint': {'lat': 46.08333, 'lon': 18.23333}}, {'facility': 'Research Site', 'city': 'Szekszárd', 'zip': '7100', 'country': 'Hungary', 'geoPoint': {'lat': 46.35014, 'lon': 18.70905}}, {'facility': 'Research Site', 'city': 'Szentes', 'zip': '6600', 'country': 'Hungary', 'geoPoint': {'lat': 46.65628, 'lon': 20.27194}}, {'facility': 'Research Site', 'city': 'Szentes', 'zip': 'H-6600', 'country': 'Hungary', 'geoPoint': {'lat': 46.65628, 'lon': 20.27194}}, {'facility': 'Research Site', 'city': 'Szigetvár', 'zip': '7900', 'country': 'Hungary', 'geoPoint': {'lat': 46.04865, 'lon': 17.80554}}, {'facility': 'Research Site', 'city': 'Szikszo', 'zip': '3800', 'country': 'Hungary', 'geoPoint': {'lat': 48.2, 'lon': 20.93333}}, {'facility': 'Research Site', 'city': 'Székesfehérvár', 'zip': '8000', 'country': 'Hungary', 'geoPoint': {'lat': 47.18995, 'lon': 18.41034}}, {'facility': 'Research Site', 'city': 'Sátoraljaújhely', 'zip': '3980', 'country': 'Hungary', 'geoPoint': {'lat': 48.39492, 'lon': 21.65871}}, {'facility': 'Research Site', 'city': 'Veszprem', 'zip': '8200', 'country': 'Hungary', 'geoPoint': {'lat': 47.09327, 'lon': 17.91149}}, {'facility': 'Research Site', 'city': 'Zalaegerszeg', 'zip': '8900', 'country': 'Hungary', 'geoPoint': {'lat': 46.84, 'lon': 16.84389}}, {'facility': 'Research Site', 'city': 'Givatayim', 'zip': '53583', 'country': 'Israel', 'geoPoint': {'lat': 32.07225, 'lon': 34.81253}}, {'facility': 'Research Site', 'city': 'Hadera', 'zip': '38100', 'country': 'Israel', 'geoPoint': {'lat': 32.44192, 'lon': 34.9039}}, {'facility': 'Research Site', 'city': 'Hadera', 'zip': '3842207', 'country': 'Israel', 'geoPoint': {'lat': 32.44192, 'lon': 34.9039}}, {'facility': 'Research Site', 'city': 'Haifa', 'zip': '31048', 'country': 'Israel', 'geoPoint': {'lat': 32.81841, 'lon': 34.9885}}, {'facility': 'Research Site', 'city': 'Haifa', 'zip': '34362', 'country': 'Israel', 'geoPoint': {'lat': 32.81841, 'lon': 34.9885}}, {'facility': 'Research Site', 'city': 'Holon', 'zip': '58100', 'country': 'Israel', 'geoPoint': {'lat': 32.01034, 'lon': 34.77918}}, {'facility': 'Research Site', 'city': 'Jerusalem', 'zip': '9103102', 'country': 'Israel', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'facility': 'Research Site', 'city': 'Jerusalem', 'zip': '91120', 'country': 'Israel', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'facility': 'Research Site', 'city': 'Kfar Saba', 'zip': '49281', 'country': 'Israel', 'geoPoint': {'lat': 32.175, 'lon': 34.90694}}, {'facility': 'Research Site', 'city': 'Nahariya', 'zip': '22100', 'country': 'Israel', 'geoPoint': {'lat': 33.00892, 'lon': 35.09814}}, {'facility': 'Research Site', 'city': 'Nazareth', 'zip': '16100', 'country': 'Israel', 'geoPoint': {'lat': 32.69925, 'lon': 35.30483}}, {'facility': 'Research Site', 'city': 'Petah Tikva', 'zip': '49100', 'country': 'Israel', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'facility': 'Research Site', 'city': 'Safed', 'zip': '13100', 'country': 'Israel', 'geoPoint': {'lat': 32.96465, 'lon': 35.496}}, {'facility': 'Research Site', 'city': 'Tel-Aviv', 'zip': '62038', 'country': 'Israel', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'facility': 'Research Site', 'city': 'Tel-Aviv', 'zip': '64239', 'country': 'Israel', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'facility': 'Research Site', 'city': 'Firenze', 'zip': '50134', 'country': 'Italy', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'facility': 'Research Site', 'city': 'Foggia', 'zip': '71100', 'country': 'Italy', 'geoPoint': {'lat': 41.45845, 'lon': 15.55188}}, {'facility': 'Research Site', 'city': 'Milano', 'zip': '20138', 'country': 'Italy', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'facility': 'Research Site', 'city': 'Pisa', 'zip': '56100', 'country': 'Italy', 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}}, {'facility': 'Research Site', 'city': 'Roma', 'zip': '00128', 'country': 'Italy', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'facility': 'Research Site', 'city': 'Sesto San Giovanni', 'zip': '20099', 'country': 'Italy', 'geoPoint': {'lat': 45.53329, 'lon': 9.22585}}, {'facility': 'Research Site', 'city': 'Terni', 'zip': '05100', 'country': 'Italy', 'geoPoint': {'lat': 42.56335, 'lon': 12.64329}}, {'facility': 'Research Site', 'city': 'Udine', 'zip': '33100', 'country': 'Italy', 'geoPoint': {'lat': 46.0693, 'lon': 13.23715}}, {'facility': 'Research Site', 'city': 'Busan', 'zip': '49241', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.10278, 'lon': 129.04028}}, {'facility': 'Research Site', 'city': 'Daegu', 'zip': '41931', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'facility': 'Research Site', 'city': 'Daegu', 'zip': '700-721', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'facility': 'Research Site', 'city': 'Daegu', 'zip': '705-718', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'facility': 'Research Site', 'city': 'Gwangjin-gu', 'zip': '110-744', 'country': 'Korea, Republic of'}, {'facility': 'Research Site', 'city': 'Gyeonggi-do', 'zip': '411-706', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.58944, 'lon': 126.76917}}, {'facility': 'Research Site', 'city': 'Incheon', 'zip': '403-720', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'facility': 'Research Site', 'city': 'Seongnam', 'zip': '463-707', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'facility': 'Research Site', 'city': 'Seoul', 'zip': '08308', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Research Site', 'city': 'Seoul', 'zip': '110746', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Research Site', 'city': 'Seoul', 'zip': '134-727', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Research Site', 'city': 'Seoul', 'zip': '135-720', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Research Site', 'city': 'Seoul', 'zip': '137-701', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Research Site', 'city': 'Suwon-si', 'zip': '16247', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.29111, 'lon': 127.00889}}, {'facility': 'Research Site', 'city': 'Suwon', 'zip': '443-721', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.29111, 'lon': 127.00889}}, {'facility': 'Research Site', 'city': 'Ulsan', 'zip': '682-714', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.53722, 'lon': 129.31667}}, {'facility': 'Research Site', 'city': 'Daugavpils', 'zip': '5417', 'country': 'Latvia', 'geoPoint': {'lat': 55.88333, 'lon': 26.53333}}, {'facility': 'Research Site', 'city': 'Jelgava', 'zip': 'LV-3000', 'country': 'Latvia', 'geoPoint': {'lat': 56.65, 'lon': 23.71278}}, {'facility': 'Research Site', 'city': 'Kuldiga', 'zip': 'LV-3301', 'country': 'Latvia', 'geoPoint': {'lat': 56.97399, 'lon': 21.95721}}, {'facility': 'Research Site', 'city': 'Kuldiga', 'zip': 'LV3301', 'country': 'Latvia', 'geoPoint': {'lat': 56.97399, 'lon': 21.95721}}, {'facility': 'Research Site', 'city': 'Ogre', 'zip': 'LV-5001', 'country': 'Latvia', 'geoPoint': {'lat': 56.8162, 'lon': 24.61401}}, {'facility': 'Research Site', 'city': 'Riga', 'zip': '1012', 'country': 'Latvia', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'facility': 'Research Site', 'city': 'Riga', 'zip': 'LV-1002', 'country': 'Latvia', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'facility': 'Research Site', 'city': 'Riga', 'zip': 'LV-1050', 'country': 'Latvia', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'facility': 'Research Site', 'city': 'Riga', 'zip': 'LV1002', 'country': 'Latvia', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'facility': 'Research Site', 'city': 'Talsi', 'zip': 'LV-3201', 'country': 'Latvia', 'geoPoint': {'lat': 57.24562, 'lon': 22.58137}}, {'facility': 'Research Site', 'city': 'Tukums', 'zip': 'LV3101', 'country': 'Latvia', 'geoPoint': {'lat': 56.96694, 'lon': 23.15528}}, {'facility': 'Research Site', 'city': 'Kaunas', 'zip': '48259', 'country': 'Lithuania', 'geoPoint': {'lat': 54.90272, 'lon': 23.90961}}, {'facility': 'Research Site', 'city': 'Kaunas', 'zip': '49449', 'country': 'Lithuania', 'geoPoint': {'lat': 54.90272, 'lon': 23.90961}}, {'facility': 'Research Site', 'city': 'Kaunas', 'zip': '50009', 'country': 'Lithuania', 'geoPoint': {'lat': 54.90272, 'lon': 23.90961}}, {'facility': 'Research Site', 'city': 'Kaunas', 'zip': 'LT-48426', 'country': 'Lithuania', 'geoPoint': {'lat': 54.90272, 'lon': 23.90961}}, {'facility': 'Research Site', 'city': 'Kaunas', 'zip': 'LT-49287', 'country': 'Lithuania', 'geoPoint': {'lat': 54.90272, 'lon': 23.90961}}, {'facility': 'Research Site', 'city': 'Kaunas', 'zip': 'LT-49427', 'country': 'Lithuania', 'geoPoint': {'lat': 54.90272, 'lon': 23.90961}}, {'facility': 'Research Site', 'city': 'Kedainiai', 'zip': 'LT-57445', 'country': 'Lithuania', 'geoPoint': {'lat': 55.28782, 'lon': 23.97276}}, {'facility': 'Research Site', 'city': 'Klaipeda', 'zip': 'LT-92288', 'country': 'Lithuania', 'geoPoint': {'lat': 55.70888, 'lon': 21.14311}}, {'facility': 'Research Site', 'city': 'Klaipeda', 'zip': 'LT-94198', 'country': 'Lithuania', 'geoPoint': {'lat': 55.70888, 'lon': 21.14311}}, {'facility': 'Research Site', 'city': 'Panevezys', 'zip': 'LT-37355', 'country': 'Lithuania', 'geoPoint': {'lat': 55.73333, 'lon': 24.35}}, {'facility': 'Research Site', 'city': 'Ukmerge', 'zip': 'LT-20184', 'country': 'Lithuania', 'geoPoint': {'lat': 55.25, 'lon': 24.75}}, {'facility': 'Research Site', 'city': 'Utena', 'zip': 'LT-28151', 'country': 'Lithuania', 'geoPoint': {'lat': 55.49765, 'lon': 25.59918}}, {'facility': 'Research Site', 'city': 'Vilnius', 'zip': '04318', 'country': 'Lithuania', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'facility': 'Research Site', 'city': 'Vilnius', 'zip': '08661', 'country': 'Lithuania', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'facility': 'Research Site', 'city': 'Vilnius', 'zip': '09112', 'country': 'Lithuania', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'facility': 'Research Site', 'city': 'Alor Setar', 'zip': '5460', 'country': 'Malaysia', 'geoPoint': {'lat': 6.12104, 'lon': 100.36014}}, {'facility': 'Research Site', 'city': 'Batu Caves', 'zip': '68100', 'country': 'Malaysia', 'geoPoint': {'lat': 3.23333, 'lon': 101.66667}}, {'facility': 'Research Site', 'city': 'Kota Samarahan', 'zip': '94300', 'country': 'Malaysia'}, {'facility': 'Research Site', 'city': 'Kuala Lumpur', 'zip': '59100', 'country': 'Malaysia', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'facility': 'Research Site', 'city': 'Kuching', 'zip': '93586', 'country': 'Malaysia', 'geoPoint': {'lat': 1.54999, 'lon': 110.33333}}, {'facility': 'Research Site', 'city': 'Sungai Buloh', 'zip': '47000', 'country': 'Malaysia', 'geoPoint': {'lat': 3.2, 'lon': 101.58333}}, {'facility': 'Research Site', 'city': 'Taiping', 'zip': '34000', 'country': 'Malaysia', 'geoPoint': {'lat': 4.85, 'lon': 100.73333}}, {'facility': 'Research Site', 'city': 'Aguascalientes', 'zip': '20127', 'country': 'Mexico', 'geoPoint': {'lat': 21.88234, 'lon': -102.28259}}, {'facility': 'Research Site', 'city': 'Cuautla', 'zip': '62746', 'country': 'Mexico', 'geoPoint': {'lat': 18.8106, 'lon': -98.93525}}, {'facility': 'Research Site', 'city': 'Durango', 'zip': '34080', 'country': 'Mexico', 'geoPoint': {'lat': 24.02032, 'lon': -104.65756}}, {'facility': 'Research Site', 'city': 'Guadalajara', 'zip': '44670', 'country': 'Mexico', 'geoPoint': {'lat': 20.66682, 'lon': -103.39182}}, {'facility': 'Research Site', 'city': 'Mexico', 'zip': '06700', 'country': 'Mexico', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'facility': 'Research Site', 'city': 'Mexico', 'zip': '10700', 'country': 'Mexico', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'facility': 'Research Site', 'city': 'Mexico', 'zip': '52763', 'country': 'Mexico', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'facility': 'Research Site', 'city': 'Mexico', 'zip': '6090', 'country': 'Mexico', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'facility': 'Research Site', 'city': 'Monterrey', 'zip': '64710', 'country': 'Mexico', 'geoPoint': {'lat': 25.67507, 'lon': -100.31847}}, {'facility': 'Research Site', 'city': 'Puebla', 'zip': '72190', 'country': 'Mexico', 'geoPoint': {'lat': 19.03793, 'lon': -98.20346}}, {'facility': 'Research Site', 'city': 'Queretaro', 'zip': '76000', 'country': 'Mexico'}, {'facility': 'Research Site', 'city': 'San Luis Potosí', 'zip': '78240', 'country': 'Mexico', 'geoPoint': {'lat': 22.14982, 'lon': -100.97916}}, {'facility': 'Research Site', 'city': 'Amersfoort', 'zip': '3813 TZ', 'country': 'Netherlands', 'geoPoint': {'lat': 52.155, 'lon': 5.3875}}, {'facility': 'Research Site', 'city': 'Amsterdam', 'zip': '1081 HV', 'country': 'Netherlands', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'facility': 'Research Site', 'city': 'Eindhoven', 'zip': '5611 NV', 'country': 'Netherlands', 'geoPoint': {'lat': 51.44083, 'lon': 5.47778}}, {'facility': 'Research Site', 'city': 'Groningen', 'zip': '9711 SG', 'country': 'Netherlands', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}, {'facility': 'Research Site', 'city': 'Hardenberg', 'zip': '7772 SE', 'country': 'Netherlands', 'geoPoint': {'lat': 52.57583, 'lon': 6.61944}}, {'facility': 'Research Site', 'city': 'Hoogeveen', 'zip': '7909 AA', 'country': 'Netherlands', 'geoPoint': {'lat': 52.7225, 'lon': 6.47639}}, {'facility': 'Research Site', 'city': 'Meppel', 'zip': '7943 KA', 'country': 'Netherlands', 'geoPoint': {'lat': 52.69583, 'lon': 6.19444}}, {'facility': 'Research Site', 'city': 'Rotterdam', 'zip': '3039 BD', 'country': 'Netherlands', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'facility': 'Research Site', 'city': 'Sneek', 'zip': '8601 ZK', 'country': 'Netherlands', 'geoPoint': {'lat': 53.03297, 'lon': 5.6589}}, {'facility': 'Research Site', 'city': 'Utrecht', 'zip': '3584 CX', 'country': 'Netherlands', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}, {'facility': 'Research Site', 'city': 'Christchurch', 'zip': '08011', 'country': 'New Zealand', 'geoPoint': {'lat': -43.53333, 'lon': 172.63333}}, {'facility': 'Research Site', 'city': 'Christchurch', 'zip': '8024', 'country': 'New Zealand', 'geoPoint': {'lat': -43.53333, 'lon': 172.63333}}, {'facility': 'Research Site', 'city': 'Christchurch', 'zip': '8041', 'country': 'New Zealand', 'geoPoint': {'lat': -43.53333, 'lon': 172.63333}}, {'facility': 'Research Site', 'city': 'Hamilton', 'zip': '3240', 'country': 'New Zealand', 'geoPoint': {'lat': -37.78333, 'lon': 175.28333}}, {'facility': 'Research Site', 'city': 'Nelson', 'zip': '7010', 'country': 'New Zealand', 'geoPoint': {'lat': -41.27078, 'lon': 173.28404}}, {'facility': 'Research Site', 'city': 'Newtown', 'zip': '6242', 'country': 'New Zealand', 'geoPoint': {'lat': -41.31115, 'lon': 174.77935}}, {'facility': 'Research Site', 'city': 'Palmerston North', 'zip': '4410', 'country': 'New Zealand', 'geoPoint': {'lat': -40.35636, 'lon': 175.61113}}, {'facility': 'Research Site', 'city': 'Takapuna', 'zip': '0622', 'country': 'New Zealand', 'geoPoint': {'lat': -36.79167, 'lon': 174.77583}}, {'facility': 'Research Site', 'city': 'Tauranga', 'zip': '3112', 'country': 'New Zealand', 'geoPoint': {'lat': -37.68611, 'lon': 176.16667}}, {'facility': 'Research Site', 'city': 'Tauranga', 'zip': '3143', 'country': 'New Zealand', 'geoPoint': {'lat': -37.68611, 'lon': 176.16667}}, {'facility': 'Research Site', 'city': 'Wellington', 'zip': '6021', 'country': 'New Zealand', 'geoPoint': {'lat': -41.28664, 'lon': 174.77557}}, {'facility': 'Research Site', 'city': 'Cebu', 'zip': '6000', 'country': 'Philippines', 'geoPoint': {'lat': 10.31672, 'lon': 123.89071}}, {'facility': 'Research Site', 'city': 'Iloilo City', 'zip': '5000', 'country': 'Philippines', 'geoPoint': {'lat': 10.69694, 'lon': 122.56444}}, {'facility': 'Research Site', 'city': 'Manila', 'zip': '1000', 'country': 'Philippines', 'geoPoint': {'lat': 14.6042, 'lon': 120.9822}}, {'facility': 'Research Site', 'city': 'Marikina City', 'zip': '1810', 'country': 'Philippines', 'geoPoint': {'lat': 14.6481, 'lon': 121.1133}}, {'facility': 'Research Site', 'city': 'Marikina', 'zip': '1810', 'country': 'Philippines'}, {'facility': 'Research Site', 'city': 'Pasig', 'zip': '1605', 'country': 'Philippines', 'geoPoint': {'lat': 14.58691, 'lon': 121.0614}}, {'facility': 'Research Site', 'city': 'Quezon City', 'zip': '1101', 'country': 'Philippines', 'geoPoint': {'lat': 14.6488, 'lon': 121.0509}}, {'facility': 'Research Site', 'city': 'Quezon', 'zip': '1000', 'country': 'Philippines', 'geoPoint': {'lat': 7.73028, 'lon': 125.09889}}, {'facility': 'Research Site', 'city': 'Quezon', 'zip': '1110', 'country': 'Philippines', 'geoPoint': {'lat': 7.73028, 'lon': 125.09889}}, {'facility': 'Research Site', 'city': 'Quezon', 'zip': '1113', 'country': 'Philippines', 'geoPoint': {'lat': 7.73028, 'lon': 125.09889}}, {'facility': 'Research Site', 'city': 'San Juan', 'country': 'Philippines', 'geoPoint': {'lat': 14.6, 'lon': 121.0333}}, {'facility': 'Research Site', 'city': 'Elbląg', 'zip': '82-300', 'country': 'Poland', 'geoPoint': {'lat': 54.1522, 'lon': 19.40884}}, {'facility': 'Research Site', 'city': 'Gdynia', 'zip': '81-472', 'country': 'Poland', 'geoPoint': {'lat': 54.51889, 'lon': 18.53188}}, {'facility': 'Research Site', 'city': 'Grodzisk Mazowiecki', 'zip': '05-825', 'country': 'Poland', 'geoPoint': {'lat': 52.10387, 'lon': 20.6337}}, {'facility': 'Research Site', 'city': 'Grudziadz', 'zip': '86-300', 'country': 'Poland', 'geoPoint': {'lat': 53.48411, 'lon': 18.75366}}, {'facility': 'Research Site', 'city': 'Katowice', 'zip': '40-752', 'country': 'Poland', 'geoPoint': {'lat': 50.25841, 'lon': 19.02754}}, {'facility': 'Research Site', 'city': 'Lublin', 'zip': '20-090', 'country': 'Poland', 'geoPoint': {'lat': 51.25, 'lon': 22.56667}}, {'facility': 'Research Site', 'city': 'Ostrołęka', 'zip': '07-400', 'country': 'Poland', 'geoPoint': {'lat': 53.08621, 'lon': 21.57566}}, {'facility': 'Research Site', 'city': 'Poznań', 'zip': '60-659', 'country': 'Poland', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'facility': 'Research Site', 'city': 'Płock', 'zip': '09-402', 'country': 'Poland', 'geoPoint': {'lat': 52.54682, 'lon': 19.70638}}, {'facility': 'Research Site', 'city': 'Słupsk', 'zip': '76-200', 'country': 'Poland', 'geoPoint': {'lat': 54.46405, 'lon': 17.02872}}, {'facility': 'Research Site', 'city': 'Warszawa', 'zip': '04-635', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'facility': 'Research Site', 'city': 'Wroclaw', 'zip': '50-127', 'country': 'Poland', 'geoPoint': {'lat': 51.1, 'lon': 17.03333}}, {'facility': 'Research Site', 'city': 'Wrocław', 'zip': '50-403', 'country': 'Poland', 'geoPoint': {'lat': 51.1, 'lon': 17.03333}}, {'facility': 'Research Site', 'city': 'Wrocław', 'zip': '51-124', 'country': 'Poland', 'geoPoint': {'lat': 51.1, 'lon': 17.03333}}, {'facility': 'Research Site', 'city': 'Łódź', 'zip': '94-074', 'country': 'Poland', 'geoPoint': {'lat': 51.75, 'lon': 19.46667}}, {'facility': 'Research Site', 'city': 'Łęczna', 'zip': '21-010', 'country': 'Poland', 'geoPoint': {'lat': 51.30121, 'lon': 22.88135}}, {'facility': 'Research Site', 'city': 'Bacau', 'zip': '600164', 'country': 'Romania', 'geoPoint': {'lat': 46.56718, 'lon': 26.91384}}, {'facility': 'Research Site', 'city': 'Bucharest', 'zip': '010507', 'country': 'Romania', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'facility': 'Research Site', 'city': 'Bucuresti', 'zip': '010627', 'country': 'Romania', 'geoPoint': {'lat': 44.42802, 'lon': 26.09665}}, {'facility': 'Research Site', 'city': 'Bucuresti', 'zip': '020725', 'country': 'Romania', 'geoPoint': {'lat': 44.42802, 'lon': 26.09665}}, {'facility': 'Research Site', 'city': 'Bucuresti', 'zip': '030306', 'country': 'Romania', 'geoPoint': {'lat': 44.42802, 'lon': 26.09665}}, {'facility': 'Research Site', 'city': 'Bucuresti', 'zip': '042122', 'country': 'Romania', 'geoPoint': {'lat': 44.42802, 'lon': 26.09665}}, {'facility': 'Research Site', 'city': 'Buzau', 'zip': '120203', 'country': 'Romania', 'geoPoint': {'lat': 45.15, 'lon': 26.83333}}, {'facility': 'Research Site', 'city': 'Cluj Napoca', 'zip': '400006', 'country': 'Romania', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'facility': 'Research Site', 'city': 'Cluj Napoca', 'zip': '400349', 'country': 'Romania', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'facility': 'Research Site', 'city': 'Craiova', 'zip': '200147', 'country': 'Romania', 'geoPoint': {'lat': 44.31667, 'lon': 23.8}}, {'facility': 'Research Site', 'city': 'Iasi', 'zip': '700111', 'country': 'Romania', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'facility': 'Research Site', 'city': 'Oradea', 'zip': '410169', 'country': 'Romania', 'geoPoint': {'lat': 47.0458, 'lon': 21.91833}}, {'facility': 'Research Site', 'city': 'Ploiesti', 'zip': '100477', 'country': 'Romania', 'geoPoint': {'lat': 44.95, 'lon': 26.01667}}, {'facility': 'Research Site', 'city': 'Satu-Mare', 'zip': '440055', 'country': 'Romania', 'geoPoint': {'lat': 47.79926, 'lon': 22.86255}}, {'facility': 'Research Site', 'city': 'Timisoara', 'zip': '300125', 'country': 'Romania', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'facility': 'Research Site', 'city': 'Timișoara', 'zip': '300456', 'country': 'Romania', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'facility': 'Research Site', 'city': 'Zalau', 'zip': '450129', 'country': 'Romania', 'geoPoint': {'lat': 47.2, 'lon': 23.05}}, {'facility': 'Research Site', 'city': 'Ekaterinburg', 'zip': '620219', 'country': 'Russian Federation', 'geoPoint': {'lat': 56.8519, 'lon': 60.6122}}, {'facility': 'Research Site', 'city': 'Kemerovo', 'zip': '650002', 'country': 'Russian Federation', 'geoPoint': {'lat': 55.33333, 'lon': 86.08333}}, {'facility': 'Research Site', 'city': 'Krasnoyarsk', 'zip': '660022', 'country': 'Russian Federation', 'geoPoint': {'lat': 56.01839, 'lon': 92.86717}}, {'facility': 'Research Site', 'city': 'Moscow', 'zip': '105120', 'country': 'Russian Federation', 'geoPoint': {'lat': 55.75222, 'lon': 37.61556}}, {'facility': 'Research Site', 'city': 'Moscow', 'zip': '129110', 'country': 'Russian Federation', 'geoPoint': {'lat': 55.75222, 'lon': 37.61556}}, {'facility': 'Research Site', 'city': 'Nizhnii Novgorod', 'zip': '603018', 'country': 'Russian Federation', 'geoPoint': {'lat': 56.32867, 'lon': 44.00205}}, {'facility': 'Research Site', 'city': 'Novosibirsk', 'zip': '630087', 'country': 'Russian Federation', 'geoPoint': {'lat': 55.0415, 'lon': 82.9346}}, {'facility': 'Research Site', 'city': 'Saint Petersburg', 'zip': '196601', 'country': 'Russian Federation', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'facility': 'Research Site', 'city': 'St. Peterburg', 'zip': '195112', 'country': 'Russian Federation', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'facility': 'Research Site', 'city': 'St.Рetersburg', 'zip': '198035', 'country': 'Russian Federation', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'facility': 'Research Site', 'city': 'Thymen', 'zip': '625023', 'country': 'Russian Federation'}, {'facility': 'Research Site', 'city': 'Tomsk', 'zip': '634012', 'country': 'Russian Federation', 'geoPoint': {'lat': 56.49771, 'lon': 84.97437}}, {'facility': 'Research Site', 'city': 'Tomsk', 'zip': '634050', 'country': 'Russian Federation', 'geoPoint': {'lat': 56.49771, 'lon': 84.97437}}, {'facility': 'Research Site', 'city': 'Yaroslavl', 'zip': '150010', 'country': 'Russian Federation', 'geoPoint': {'lat': 57.62987, 'lon': 39.87368}}, {'facility': 'Research Site', 'city': 'Yaroslavl', 'zip': '150062', 'country': 'Russian Federation', 'geoPoint': {'lat': 57.62987, 'lon': 39.87368}}, {'facility': 'Research Site', 'city': 'Bardejov', 'zip': '085 01', 'country': 'Slovakia', 'geoPoint': {'lat': 49.29175, 'lon': 21.27271}}, {'facility': 'Research Site', 'city': 'Bratislava', 'zip': '813 69', 'country': 'Slovakia', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'facility': 'Research Site', 'city': 'Bratislava', 'zip': '82606', 'country': 'Slovakia', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'facility': 'Research Site', 'city': 'Kosice', 'zip': '040 01', 'country': 'Slovakia', 'geoPoint': {'lat': 48.71395, 'lon': 21.25808}}, {'facility': 'Research Site', 'city': 'Kosice', 'zip': '04022', 'country': 'Slovakia', 'geoPoint': {'lat': 48.71395, 'lon': 21.25808}}, {'facility': 'Research Site', 'city': 'Kosice', 'zip': '044 24', 'country': 'Slovakia', 'geoPoint': {'lat': 48.71395, 'lon': 21.25808}}, {'facility': 'Research Site', 'city': 'Lucenec', 'zip': '984 01', 'country': 'Slovakia', 'geoPoint': {'lat': 48.33249, 'lon': 19.66708}}, {'facility': 'Research Site', 'city': 'Presov', 'zip': '080 01', 'country': 'Slovakia', 'geoPoint': {'lat': 48.99839, 'lon': 21.23393}}, {'facility': 'Research Site', 'city': 'Roznava', 'zip': '048 01', 'country': 'Slovakia', 'geoPoint': {'lat': 48.66009, 'lon': 20.53758}}, {'facility': 'Research Site', 'city': 'Trebisov', 'zip': '075 01', 'country': 'Slovakia', 'geoPoint': {'lat': 48.62858, 'lon': 21.71954}}, {'facility': 'Research Site', 'city': 'Zilina', 'zip': '010 01', 'country': 'Slovakia', 'geoPoint': {'lat': 49.22315, 'lon': 18.73941}}, {'facility': 'Research Site', 'city': 'Boksburg', 'zip': '1459', 'country': 'South Africa', 'geoPoint': {'lat': -26.21197, 'lon': 28.25958}}, {'facility': 'Research Site', 'city': 'Brits', 'zip': '0250', 'country': 'South Africa', 'geoPoint': {'lat': -25.63473, 'lon': 27.78022}}, {'facility': 'Research Site', 'city': 'Cape Town', 'zip': '7460', 'country': 'South Africa', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'facility': 'Research Site', 'city': 'Cape Town', 'zip': '7500', 'country': 'South Africa', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'facility': 'Research Site', 'city': 'Cape Town', 'zip': '7700', 'country': 'South Africa', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'facility': 'Research Site', 'city': 'Centurion', 'zip': '0157', 'country': 'South Africa', 'geoPoint': {'lat': -25.85891, 'lon': 28.18577}}, {'facility': 'Research Site', 'city': 'Durban', 'zip': '4001', 'country': 'South Africa', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'facility': 'Research Site', 'city': 'Durban', 'zip': '4052', 'country': 'South Africa', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'facility': 'Research Site', 'city': 'Johannesburg', 'zip': '2198', 'country': 'South Africa', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'facility': 'Research Site', 'city': 'Kempton Park', 'zip': '1619', 'country': 'South Africa', 'geoPoint': {'lat': -26.10859, 'lon': 28.2377}}, {'facility': 'Research Site', 'city': 'Lenasia', 'zip': '1827', 'country': 'South Africa', 'geoPoint': {'lat': -26.32052, 'lon': 27.83564}}, {'facility': 'Research Site', 'city': 'Paarl', 'zip': '7646', 'country': 'South Africa', 'geoPoint': {'lat': -33.73378, 'lon': 18.97523}}, {'facility': 'Research Site', 'city': 'Parktown', 'zip': '2193', 'country': 'South Africa', 'geoPoint': {'lat': -26.18205, 'lon': 28.02671}}, {'facility': 'Research Site', 'city': 'Phoenix', 'zip': '4068', 'country': 'South Africa'}, {'facility': 'Research Site', 'city': 'Port Elizabeth', 'zip': '6014', 'country': 'South Africa', 'geoPoint': {'lat': -33.91799, 'lon': 25.57007}}, {'facility': 'Research Site', 'city': 'Potchefstroom', 'zip': '2531', 'country': 'South Africa', 'geoPoint': {'lat': -26.71667, 'lon': 27.1}}, {'facility': 'Research Site', 'city': 'Pretoria', 'zip': '0001', 'country': 'South Africa', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'facility': 'Research Site', 'city': 'Pretoria', 'zip': '0014', 'country': 'South Africa', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'facility': 'Research Site', 'city': 'Pretoria', 'zip': '0101', 'country': 'South Africa', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'facility': 'Research Site', 'city': 'Somerset West', 'zip': '7130', 'country': 'South Africa', 'geoPoint': {'lat': -34.08401, 'lon': 18.82113}}, {'facility': 'Research Site', 'city': 'Soweto', 'zip': '2013', 'country': 'South Africa', 'geoPoint': {'lat': -26.26781, 'lon': 27.85849}}, {'facility': 'Research Site', 'city': 'Umkomaas', 'zip': '4170', 'country': 'South Africa', 'geoPoint': {'lat': -30.20674, 'lon': 30.79776}}, {'facility': 'Research Site', 'city': 'A Coruña', 'zip': '15006', 'country': 'Spain', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'facility': 'Research Site', 'city': 'Alcalá de Henares', 'zip': '28805', 'country': 'Spain', 'geoPoint': {'lat': 40.48205, 'lon': -3.35996}}, {'facility': 'Research Site', 'city': 'Avila', 'zip': '05004', 'country': 'Spain', 'geoPoint': {'lat': 40.65724, 'lon': -4.69951}}, {'facility': 'Research Site', 'city': 'Ferrol', 'zip': '15405', 'country': 'Spain', 'geoPoint': {'lat': 43.4896, 'lon': -8.21942}}, {'facility': 'Research Site', 'city': 'Girona', 'zip': '17007', 'country': 'Spain', 'geoPoint': {'lat': 41.98311, 'lon': 2.82493}}, {'facility': 'Research Site', 'city': 'Granada', 'zip': '18004', 'country': 'Spain', 'geoPoint': {'lat': 37.18817, 'lon': -3.60667}}, {'facility': 'Research Site', 'city': 'Granada', 'zip': '18012', 'country': 'Spain', 'geoPoint': {'lat': 37.18817, 'lon': -3.60667}}, {'facility': 'Research Site', 'city': 'Lleida', 'zip': '25198', 'country': 'Spain', 'geoPoint': {'lat': 41.61674, 'lon': 0.62218}}, {'facility': 'Research Site', 'city': 'Madrid', 'zip': '28007', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Research Site', 'city': 'Madrid', 'zip': '28034', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Research Site', 'city': 'Madrid', 'zip': '28046', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Research Site', 'city': 'Madrid', 'zip': '28702', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Research Site', 'city': 'Manacor', 'zip': '07500', 'country': 'Spain', 'geoPoint': {'lat': 39.56964, 'lon': 3.20955}}, {'facility': 'Research Site', 'city': 'Málaga', 'zip': '29006', 'country': 'Spain', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'facility': 'Research Site', 'city': 'Palma de Mallorca', 'zip': '07198', 'country': 'Spain', 'geoPoint': {'lat': 39.56939, 'lon': 2.65024}}, {'facility': 'Research Site', 'city': 'Palma deMallorca', 'zip': '07010', 'country': 'Spain', 'geoPoint': {'lat': 39.56939, 'lon': 2.65024}}, {'facility': 'Research Site', 'city': 'Salamanca', 'zip': '37003', 'country': 'Spain', 'geoPoint': {'lat': 40.96882, 'lon': -5.66388}}, {'facility': 'Research Site', 'city': 'Sevilla', 'zip': '41010', 'country': 'Spain', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'facility': 'Research Site', 'city': 'Tarragona', 'zip': '43007', 'country': 'Spain', 'geoPoint': {'lat': 41.11667, 'lon': 1.25}}, {'facility': 'Research Site', 'city': 'Changhua', 'zip': '500', 'country': 'Taiwan', 'geoPoint': {'lat': 24.07327, 'lon': 120.56276}}, {'facility': 'Research Site', 'city': 'Kaohsiung Hsien', 'zip': '83301', 'country': 'Taiwan'}, {'facility': 'Research Site', 'city': 'Kaohsiung', 'zip': '80756', 'country': 'Taiwan', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'facility': 'Research Site', 'city': 'Kweishan Shiang', 'zip': '333', 'country': 'Taiwan'}, {'facility': 'Research Site', 'city': 'New Taipei City', 'zip': '23148', 'country': 'Taiwan', 'geoPoint': {'lat': 25.01111, 'lon': 121.44583}}, {'facility': 'Research Site', 'city': 'Taichung', 'zip': '40705', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'facility': 'Research Site', 'city': 'Taichung', 'zip': '433', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'facility': 'Research Site', 'city': 'Tainan County', 'country': 'Taiwan'}, {'facility': 'Research Site', 'city': 'Taipei', 'zip': '100', 'country': 'Taiwan', 'geoPoint': {'lat': 25.04776, 'lon': 121.53185}}, {'facility': 'Research Site', 'city': 'Taipei', 'zip': '11490', 'country': 'Taiwan', 'geoPoint': {'lat': 25.04776, 'lon': 121.53185}}, {'facility': 'Research Site', 'city': 'Bangkok', 'zip': '10400', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'facility': 'Research Site', 'city': 'Chernivtsi', 'zip': '58022', 'country': 'Ukraine', 'geoPoint': {'lat': 48.29149, 'lon': 25.94034}}, {'facility': 'Research Site', 'city': 'Dnepropetrovsk', 'zip': '49006', 'country': 'Ukraine', 'geoPoint': {'lat': 48.4593, 'lon': 35.03864}}, {'facility': 'Research Site', 'city': 'Dnipropetrovsk', 'zip': '49027', 'country': 'Ukraine', 'geoPoint': {'lat': 48.4593, 'lon': 35.03864}}, {'facility': 'Research Site', 'city': 'Donetck', 'zip': '83045', 'country': 'Ukraine'}, {'facility': 'Research Site', 'city': 'Donetsk', 'zip': '83059', 'country': 'Ukraine', 'geoPoint': {'lat': 48.023, 'lon': 37.80224}}, {'facility': 'Research Site', 'city': 'Donetsk', 'zip': '83114', 'country': 'Ukraine', 'geoPoint': {'lat': 48.023, 'lon': 37.80224}}, {'facility': 'Research Site', 'city': 'Ivano-Frankivsk', 'zip': '76000', 'country': 'Ukraine', 'geoPoint': {'lat': 48.9215, 'lon': 24.70972}}, {'facility': 'Research Site', 'city': 'Kharkiv', 'zip': '61029', 'country': 'Ukraine', 'geoPoint': {'lat': 49.98081, 'lon': 36.25272}}, {'facility': 'Research Site', 'city': 'Kharkiv', 'zip': '61037', 'country': 'Ukraine', 'geoPoint': {'lat': 49.98081, 'lon': 36.25272}}, {'facility': 'Research Site', 'city': 'Kharkiv', 'zip': '61039', 'country': 'Ukraine', 'geoPoint': {'lat': 49.98081, 'lon': 36.25272}}, {'facility': 'Research Site', 'city': 'Kharkiv', 'zip': '61178', 'country': 'Ukraine', 'geoPoint': {'lat': 49.98081, 'lon': 36.25272}}, {'facility': 'Research Site', 'city': 'Kiev', 'zip': '04114', 'country': 'Ukraine', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'facility': 'Research Site', 'city': 'Kiev', 'zip': '07050', 'country': 'Ukraine', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'facility': 'Research Site', 'city': 'Kyiv', 'zip': '2091', 'country': 'Ukraine', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'facility': 'Research Site', 'city': 'Kyiv', 'zip': '3680', 'country': 'Ukraine', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'facility': 'Research Site', 'city': 'Odesa', 'zip': '65025', 'country': 'Ukraine', 'geoPoint': {'lat': 46.47747, 'lon': 30.73262}}, {'facility': 'Research Site', 'city': 'Odesa', 'zip': '65114', 'country': 'Ukraine', 'geoPoint': {'lat': 46.47747, 'lon': 30.73262}}, {'facility': 'Research Site', 'city': 'Sumy', 'zip': '40022', 'country': 'Ukraine', 'geoPoint': {'lat': 50.9216, 'lon': 34.80029}}, {'facility': 'Research Site', 'city': 'Ternopil', 'zip': '46002', 'country': 'Ukraine', 'geoPoint': {'lat': 49.55589, 'lon': 25.60556}}, {'facility': 'Research Site', 'city': 'Uzhgorod', 'zip': '88014', 'country': 'Ukraine', 'geoPoint': {'lat': 48.61667, 'lon': 22.3}}, {'facility': 'Research Site', 'city': 'Vinnytsia', 'zip': '21010', 'country': 'Ukraine', 'geoPoint': {'lat': 49.23278, 'lon': 28.48097}}, {'facility': 'Research Site', 'city': 'Zaporizhia', 'zip': '69001', 'country': 'Ukraine', 'geoPoint': {'lat': 47.82289, 'lon': 35.19031}}, {'facility': 'Research Site', 'city': 'Zaporizhzhya', 'zip': '69118', 'country': 'Ukraine', 'geoPoint': {'lat': 50.60727, 'lon': 31.78792}}, {'facility': 'Research Site', 'city': 'Zhytomyr', 'zip': '10002', 'country': 'Ukraine', 'geoPoint': {'lat': 50.26487, 'lon': 28.67669}}, {'facility': 'Research Site', 'city': 'Aberdeen', 'zip': 'AB25 2ZD', 'country': 'United Kingdom', 'geoPoint': {'lat': 57.14369, 'lon': -2.09814}}, {'facility': 'Research Site', 'city': 'Addlestone', 'zip': 'KT15 2BH', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.37135, 'lon': -0.49353}}, {'facility': 'Research Site', 'city': 'Birmingham', 'zip': 'B9 5SS', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'facility': 'Research Site', 'city': 'Blackpool', 'zip': 'FY4 3AD', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.81667, 'lon': -3.05}}, {'facility': 'Research Site', 'city': 'Bradford', 'zip': 'BD9 6RJ', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.79391, 'lon': -1.75206}}, {'facility': 'Research Site', 'city': 'Bristol', 'zip': 'BS10 5NB', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'facility': 'Research Site', 'city': 'Cambridge', 'zip': 'CB2 0QQ', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'facility': 'Research Site', 'city': 'Chippenham', 'zip': 'SN14 6GT', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.46, 'lon': -2.12472}}, {'facility': 'Research Site', 'city': 'Coventry', 'zip': 'CV2 2DX', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.40656, 'lon': -1.51217}}, {'facility': 'Research Site', 'city': 'Dundee', 'zip': 'DD1 9SY', 'country': 'United Kingdom', 'geoPoint': {'lat': 56.46913, 'lon': -2.97489}}, {'facility': 'Research Site', 'city': 'Edinburgh', 'zip': 'EH4 2XU', 'country': 'United Kingdom', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}}, {'facility': 'Research Site', 'city': 'Glasgow', 'zip': 'G12 8TA', 'country': 'United Kingdom', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'facility': 'Research Site', 'city': 'Hull', 'zip': 'HU3 2JZ', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.7446, 'lon': -0.33525}}, {'facility': 'Research Site', 'city': 'Inverness', 'zip': 'IV2 3JH', 'country': 'United Kingdom', 'geoPoint': {'lat': 57.47908, 'lon': -4.22398}}, {'facility': 'Research Site', 'city': 'Irvine', 'zip': 'KA12 0AY', 'country': 'United Kingdom', 'geoPoint': {'lat': 55.6194, 'lon': -4.65508}}, {'facility': 'Research Site', 'city': 'Leicester', 'zip': 'LE5 4PW', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.6386, 'lon': -1.13169}}, {'facility': 'Research Site', 'city': 'Liverpool', 'zip': 'L7 8XP', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'facility': 'Research Site', 'city': 'Manchester', 'zip': 'M8 5RB', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'facility': 'Research Site', 'city': 'Northampton', 'zip': 'NN1 5BD', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.25, 'lon': -0.88333}}, {'facility': 'Research Site', 'city': 'Ormskirk', 'zip': 'L39 2AZ', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.56685, 'lon': -2.88178}}, {'facility': 'Research Site', 'city': 'Peterborough', 'zip': 'PE8 6PL', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.57364, 'lon': -0.24777}}, {'facility': 'Research Site', 'city': 'Plymouth', 'zip': 'PL5 3JB', 'country': 'United Kingdom', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'facility': 'Research Site', 'city': 'Plymouth', 'zip': 'PL6 8BX', 'country': 'United Kingdom', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'facility': 'Research Site', 'city': 'Redhill', 'zip': 'RH1 5RH', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.24048, 'lon': -0.17044}}, {'facility': 'Research Site', 'city': 'Sheffield', 'zip': 'S5 7AU', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.38297, 'lon': -1.4659}}, {'facility': 'Research Site', 'city': 'Suffolk', 'zip': 'IP33 2QZ', 'country': 'United Kingdom'}, {'facility': 'Research Site', 'city': 'Swansea', 'zip': 'SN6 6NL', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.62079, 'lon': -3.94323}}, {'facility': 'Research Site', 'city': 'Trowbridge', 'zip': 'BA14 8QA', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.31889, 'lon': -2.20861}}, {'facility': 'Research Site', 'city': 'West Sussex', 'zip': 'RH10 7DX', 'country': 'United Kingdom'}]}, 'referencesModule': {'references': [{'pmid': '35761271', 'type': 'DERIVED', 'citation': 'Davis TME, Giczewska A, Lokhnygina Y, Mentz RJ, Sattar N, Holman RR; EXSCEL Study Group. Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Cardiovasc Diabetol. 2022 Jun 27;21(1):116. doi: 10.1186/s12933-022-01555-z.'}, {'pmid': '34813910', 'type': 'DERIVED', 'citation': 'Becker F, Dakin HA, Reed SD, Li Y, Leal J, Gustavson SM, Wittbrodt E, Hernandez AF, Gray AM, Holman RR. Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. Diabetes Res Clin Pract. 2022 Jan;183:109152. doi: 10.1016/j.diabres.2021.109152. Epub 2021 Nov 20.'}, {'pmid': '32098501', 'type': 'DERIVED', 'citation': 'Bethel MA, Stevens SR, Buse JB, Choi J, Gustavson SM, Iqbal N, Lokhnygina Y, Mentz RJ, Patel RA, Ohman P, Schernthaner G, Lecube A, Hernandez AF, Holman RR. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. Circulation. 2020 Apr 28;141(17):1360-1370. doi: 10.1161/CIRCULATIONAHA.119.043353. Epub 2020 Feb 26.'}, {'pmid': '31882409', 'type': 'DERIVED', 'citation': 'Standl E, Stevens SR, Lokhnygina Y, Bethel MA, Buse JB, Gustavson SM, Maggioni AP, Mentz RJ, Hernandez AF, Holman RR; EXSCEL Study Group. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care. 2020 Mar;43(3):643-652. doi: 10.2337/dc19-1079. Epub 2019 Dec 27.'}, {'pmid': '31806653', 'type': 'DERIVED', 'citation': 'Reed SD, Li Y, Dakin HA, Becker F, Leal J, Gustavson SM, Kartman B, Wittbrodt E, Mentz RJ, Pagidipati NJ, Bethel MA, Gray AM, Holman RR, Hernandez AF; EXSCEL Study Group. Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care. 2020 Feb;43(2):374-381. doi: 10.2337/dc19-0950. Epub 2019 Dec 5.'}, {'pmid': '31752517', 'type': 'DERIVED', 'citation': 'Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, Pagidipati NJ, Sattar N, Holman RR, Hernandez AF, Mentz RJ, Patel MR, Jones WS. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. Circ Cardiovasc Interv. 2019 Dec;12(12):e008018. doi: 10.1161/CIRCINTERVENTIONS.119.008018. Epub 2019 Nov 22.'}, {'pmid': '31640705', 'type': 'DERIVED', 'citation': 'Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, Gustavson S, Sjostrom CD, Ruggles JA, Hernandez AF, Buse JB, Mentz RJ, Holman RR. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol. 2019 Oct 22;18(1):138. doi: 10.1186/s12933-019-0942-x.'}, {'pmid': '31542942', 'type': 'DERIVED', 'citation': 'Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Ohman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. Circulation. 2019 Nov 12;140(20):1613-1622. doi: 10.1161/CIRCULATIONAHA.119.041659. Epub 2019 Sep 23.'}, {'pmid': '31010875', 'type': 'DERIVED', 'citation': 'Bethel MA, Patel RA, Thompson VP, Merrill P, Reed SD, Li Y, Ahmadi S, Katona BG, Gustavson SM, Ohman P, Iqbal N, Gagel RF, Hernandez AF, Buse JB, Holman RR; EXSCEL Study Group. Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care. 2019 Jun;42(6):1075-1080. doi: 10.2337/dc18-2028. Epub 2019 Apr 22.'}, {'pmid': '30371301', 'type': 'DERIVED', 'citation': 'Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felicio JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Ohman P, Pagidipati NJ, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF; EXSCEL Study Group. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. J Am Heart Assoc. 2018 Oct 2;7(19):e009304. doi: 10.1161/JAHA.118.009304.'}, {'pmid': '29693361', 'type': 'DERIVED', 'citation': 'Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018 Apr;24(8 Suppl):S146-S155.'}, {'pmid': '28910237', 'type': 'DERIVED', 'citation': 'Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.'}, {'pmid': '28454792', 'type': 'DERIVED', 'citation': 'Mentz RJ, Bethel MA, Gustavson S, Thompson VP, Pagidipati NJ, Buse JB, Chan JC, Iqbal N, Maggioni AP, Marso SP, Ohman P, Poulter N, Ramachandran A, Zinman B, Hernandez AF, Holman RR. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Am Heart J. 2017 May;187:1-9. doi: 10.1016/j.ahj.2017.02.005. Epub 2017 Feb 12.'}, {'pmid': '26995376', 'type': 'DERIVED', 'citation': 'Holman RR, Bethel MA, George J, Sourij H, Doran Z, Keenan J, Khurmi NS, Mentz RJ, Oulhaj A, Buse JB, Chan JC, Iqbal N, Kundu S, Maggioni AP, Marso SP, Ohman P, Pencina MJ, Poulter N, Porter LE, Ramachandran A, Zinman B, Hernandez AF. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J. 2016 Apr;174:103-10. doi: 10.1016/j.ahj.2015.12.009. Epub 2015 Dec 21.'}, {'pmid': '22566747', 'type': 'DERIVED', 'citation': 'Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag. 2012;8:255-64. doi: 10.2147/VHRM.S28744. Epub 2012 Apr 23.'}], 'seeAlsoLinks': [{'label': 'd5551c00003_bcb109_csp_amendment_6_updated_Redacted', 'url': 'http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3675&filename=d5551c00003_bcb109_csp_amendment_6_updated_Redacted.pdf'}, {'label': 'd5551c00003 SAP Redacted', 'url': 'http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3675&filename=d5551c00003_SAP_Redacted.pdf'}, {'label': 'd5551c00003 CSP Redacted', 'url': 'http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3675&filename=d5551c00003_CSP_Redacted.pdf'}]}}, 'resultsSection': {'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections'}, {'id': 'FG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7396'}, {'groupId': 'FG001', 'numSubjects': '7356'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7093'}, {'groupId': 'FG001', 'numSubjects': '7094'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '303'}, {'groupId': 'FG001', 'numSubjects': '262'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections'}, {'id': 'BG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '7396'}, {'groupId': 'BG001', 'value': '7356'}, {'groupId': 'BG002', 'value': '14752'}]}], 'measures': [{'title': 'Age, Continuous', 'description': 'Age at enrollment', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'Years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '61.9', 'spread': '9.4'}, {'groupId': 'BG001', 'value': '61.8', 'spread': '9.4'}, {'groupId': 'BG002', 'value': '61.9', 'spread': '9.4'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '2809'}, {'groupId': 'BG001', 'value': '2794'}, {'groupId': 'BG002', 'value': '5603'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '4587'}, {'groupId': 'BG001', 'value': '4562'}, {'groupId': 'BG002', 'value': '9149'}]}]}]}, {'title': 'Race/Ethnicity, Customized', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'WHITE', 'measurements': [{'groupId': 'BG000', 'value': '5621'}, {'groupId': 'BG001', 'value': '5554'}, {'groupId': 'BG002', 'value': '11175'}]}, {'title': 'BLACK OR AFRICAN AMERICAN', 'measurements': [{'groupId': 'BG000', 'value': '436'}, {'groupId': 'BG001', 'value': '442'}, {'groupId': 'BG002', 'value': '878'}]}, {'title': 'ASIAN', 'measurements': [{'groupId': 'BG000', 'value': '727'}, {'groupId': 'BG001', 'value': '725'}, {'groupId': 'BG002', 'value': '1452'}]}, {'title': 'INDIAN (AMERICAN ) OR ALASKA NATIVE', 'measurements': [{'groupId': 'BG000', 'value': '35'}, {'groupId': 'BG001', 'value': '38'}, {'groupId': 'BG002', 'value': '73'}]}, {'title': 'NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER', 'measurements': [{'groupId': 'BG000', 'value': '17'}, {'groupId': 'BG001', 'value': '18'}, {'groupId': 'BG002', 'value': '35'}]}, {'title': 'HISPANIC', 'measurements': [{'groupId': 'BG000', 'value': '557'}, {'groupId': 'BG001', 'value': '577'}, {'groupId': 'BG002', 'value': '1134'}]}, {'title': 'MISSING', 'measurements': [{'groupId': 'BG000', 'value': '3'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '5'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'title': 'Global', 'categories': [{'title': 'ASIA PACIFIC', 'measurements': [{'groupId': 'BG000', 'value': '760'}, {'groupId': 'BG001', 'value': '769'}, {'groupId': 'BG002', 'value': '1529'}]}, {'title': 'EUROPE', 'measurements': [{'groupId': 'BG000', 'value': '3399'}, {'groupId': 'BG001', 'value': '3389'}, {'groupId': 'BG002', 'value': '6788'}]}, {'title': 'LATIN AMERICA', 'measurements': [{'groupId': 'BG000', 'value': '1363'}, {'groupId': 'BG001', 'value': '1364'}, {'groupId': 'BG002', 'value': '2727'}]}, {'title': 'NORTH AMERICA', 'measurements': [{'groupId': 'BG000', 'value': '1874'}, {'groupId': 'BG001', 'value': '1834'}, {'groupId': 'BG002', 'value': '3708'}]}]}]}, {'title': 'Prior CV Event', 'description': 'Patient had prior cardiovascular event or not at randomization', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Yes', 'measurements': [{'groupId': 'BG000', 'value': '5388'}, {'groupId': 'BG001', 'value': '5394'}, {'groupId': 'BG002', 'value': '10782'}]}, {'title': 'No', 'measurements': [{'groupId': 'BG000', 'value': '2008'}, {'groupId': 'BG001', 'value': '1962'}, {'groupId': 'BG002', 'value': '3970'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Primary Efficacy Outcome MACE Events', 'description': 'The primary efficacy outcome variable is defined as the composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke. The number of participants who had an event is reported in the results.\\n\\nThe primary efficacy endpoint is the same as the primary safety endpoint, and the statistical analysis tests the superiority of exenatide against the placebo.', 'populationDescription': 'ITT population: all patients consented and randomized in the study without a major GCP violation. ITT population is analyzed as randomized.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections'}, {'id': 'OG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7396'}, {'groupId': 'OG001', 'value': '7356'}]}], 'classes': [{'categories': [{'title': 'Number of patients who had a MACE event', 'measurements': [{'groupId': 'OG000', 'value': '905'}, {'groupId': 'OG001', 'value': '839'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Superiority test of EQW over Placebo H0: HR ≥ 1 vs. H1: HR \\\\< 1', 'pValue': '0.061', 'statisticalMethod': 'Regression, Cox', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.91', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.832', 'ciUpperLimit': '1.004'}]}, {'type': 'PRIMARY', 'title': 'Primary Safety Outcome MACE Events', 'description': 'The primary safety outcome variable is defined as the composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke. The number of participants who had an event is reported in the results.\\n\\nThe primary safety endpoint is the same as the primary efficacy endpoints, and the statistical analysis tests the non-inferiority of exenatide against placebo.', 'populationDescription': 'ITT population: all patients consented and randomized in the study without a major GCP violation. ITT population is analyzed as randomized.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections'}, {'id': 'OG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7396'}, {'groupId': 'OG001', 'value': '7356'}]}], 'classes': [{'categories': [{'title': 'Number of patients who had a MACE event', 'measurements': [{'groupId': 'OG000', 'value': '905'}, {'groupId': 'OG001', 'value': '839'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'This analysis uses the same endpoint and cox regression method as the primary efficacy analysis. However, the statistical hypothesis is a non-inferiority test with a margin of HR=1.3.', 'nonInferiorityType': 'NON_INFERIORITY', 'nonInferiorityComment': 'Non-inferiority test of EQW over Placebo H0: HR ≥ 1.3 vs. H1: HR \\\\< 1.3', 'pValue': '< 0.001', 'statisticalMethod': 'Regression, Cox', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.91', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.832', 'ciUpperLimit': '1.004'}]}, {'type': 'SECONDARY', 'title': 'Secondary Efficacy Outcome All-Cause Mortality', 'description': 'The secondary efficacy outcome variable is defined as the all-cause mortality (deaths). The number of participants who had an event is reported in the results.', 'populationDescription': 'ITT population: all patients consented and randomized in the study without a major GCP violation. ITT population is analyzed as randomized.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections'}, {'id': 'OG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7396'}, {'groupId': 'OG001', 'value': '7356'}]}], 'classes': [{'categories': [{'title': 'Number of patients who died', 'measurements': [{'groupId': 'OG000', 'value': '584'}, {'groupId': 'OG001', 'value': '507'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Superiority test of EQW over Placebo H0: HR ≥ 1 vs. H1: HR \\\\< 1', 'pValue': '0.016', 'statisticalMethod': 'Regression, Cox', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.86', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.77', 'ciUpperLimit': '0.97'}]}, {'type': 'SECONDARY', 'title': 'Secondary Efficacy Outcome CV Death', 'description': 'Component of the primary efficacy outcome: cardiovascular death. The number of participants who had an event is reported in the results.', 'populationDescription': 'ITT population: all patients consented and randomized in the study without a major GCP violation. ITT population is analyzed as randomized.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections'}, {'id': 'OG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7396'}, {'groupId': 'OG001', 'value': '7356'}]}], 'classes': [{'categories': [{'title': 'Number of patients who had CV death', 'measurements': [{'groupId': 'OG000', 'value': '383'}, {'groupId': 'OG001', 'value': '340'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Superiority test of EQW over Placebo H0: HR ≥ 1 vs. H1: HR \\\\< 1', 'pValue': '0.096', 'statisticalMethod': 'Regression, Cox', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.88', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.76', 'ciUpperLimit': '1.02'}]}, {'type': 'SECONDARY', 'title': 'Secondary Efficacy Outcome MI', 'description': 'Component of primary efficacy outcome: fatal or non-fatal MI. The number of participants who had an event is reported in the results.', 'populationDescription': 'ITT population: all patients consented and randomized in the study without a major GCP violation. ITT population is analyzed as randomized.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections'}, {'id': 'OG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7396'}, {'groupId': 'OG001', 'value': '7356'}]}], 'classes': [{'categories': [{'title': 'Number of patients who died', 'measurements': [{'groupId': 'OG000', 'value': '493'}, {'groupId': 'OG001', 'value': '483'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Superiority test of EQW over Placebo H0: HR ≥ 1 vs. H1: HR \\\\< 1', 'pValue': '0.622', 'statisticalMethod': 'Regression, Cox', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.97', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.85', 'ciUpperLimit': '1.10'}]}, {'type': 'SECONDARY', 'title': 'Secondary Efficacy Outcome Stroke', 'description': 'Component of primary efficacy outcome: fatal or non-fatal stroke. The number of participants who had an event is reported in the results.', 'populationDescription': 'ITT population: all patients consented and randomized in the study without a major GCP violation. ITT population is analyzed as randomized.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections'}, {'id': 'OG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7396'}, {'groupId': 'OG001', 'value': '7356'}]}], 'classes': [{'categories': [{'title': 'Number of patients who had stroke', 'measurements': [{'groupId': 'OG000', 'value': '218'}, {'groupId': 'OG001', 'value': '187'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Superiority test of EQW over Placebo H0: HR ≥ 1 vs. H1: HR \\\\< 1', 'pValue': '0.095', 'statisticalMethod': 'Regression, Cox', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.85', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.70', 'ciUpperLimit': '1.03'}]}, {'type': 'SECONDARY', 'title': 'Secondary Efficacy Outcome Hospitalization for ACS', 'description': 'The secondary efficacy outcome variable is defined as hospitalization for acute coronary syndrome. The number of participants who had an event is reported in the results.', 'populationDescription': 'ITT population: all patients consented and randomized in the study without a major GCP violation. ITT population is analyzed as randomized.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections'}, {'id': 'OG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7396'}, {'groupId': 'OG001', 'value': '7356'}]}], 'classes': [{'categories': [{'title': 'Num of pts with hospitalization due to ACS', 'measurements': [{'groupId': 'OG000', 'value': '570'}, {'groupId': 'OG001', 'value': '602'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Superiority test of EQW over Placebo H0: HR ≥ 1 vs. H1: HR \\\\< 1', 'pValue': '0.402', 'statisticalMethod': 'Regression, Cox', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '1.05', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.94', 'ciUpperLimit': '1.18'}]}, {'type': 'SECONDARY', 'title': 'Secondary Efficacy Outcome Hospitalization for HF', 'description': 'The secondary efficacy outcome variable is defined as hospitalization for heart failure. The number of participants who had an event is reported in the results.', 'populationDescription': 'ITT population: all patients consented and randomized in the study without a major GCP violation. ITT population is analyzed as randomized.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Time to first event. Information collected during study period (anticipated to be up to 7.5 years).', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections'}, {'id': 'OG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7396'}, {'groupId': 'OG001', 'value': '7356'}]}], 'classes': [{'categories': [{'title': 'Number of patients who died', 'measurements': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '219'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Superiority test of EQW over Placebo H0: HR ≥ 1 vs. H1: HR \\\\< 1', 'pValue': '0.485', 'statisticalMethod': 'Regression, Cox', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.94', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.78', 'ciUpperLimit': '1.13'}]}]}, 'adverseEventsModule': {'frequencyThreshold': '0', 'timeFrame': 'During study period up to 7.5 years', 'description': 'Only SAEs are collected in this study. Other (not including non-serious) adverse events are not monitored/assessed.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo', 'description': 'Matching placebo subcutaneous injections', 'deathsNumAffected': 584, 'deathsNumAtRisk': 7372, 'seriousNumAffected': 1222, 'seriousNumAtRisk': 7372, 'otherNumAffected': 0, 'otherNumAtRisk': 0}, {'id': 'EG001', 'title': 'Exenatide Once Weekly', 'description': 'Exenatide 2mg once weekly subcutaneous injections', 'deathsNumAffected': 507, 'deathsNumAtRisk': 7344, 'seriousNumAffected': 1234, 'seriousNumAtRisk': 7344, 'otherNumAffected': 0, 'otherNumAtRisk': 0}], 'seriousEvents': [{'term': 'Anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 31, 'numAffected': 26, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 16, 'numAffected': 15, 'numAtRisk': 7344}]}, {'term': 'Antiphospholipid syndrome', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Autoimmune haemolytic anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Bone marrow disorder', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Bone marrow oedema', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Coagulopathy', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Disseminated intravascular coagulation', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Febrile neutropenia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Haemolytic anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Haemorrhagic anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Immune thrombocytopenic purpura', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Iron deficiency anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 11, 'numAtRisk': 7344}]}, {'term': 'Lymphadenopathy', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Lymphadenopathy mediastinal', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Mastocytosis', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Microcytic anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Neutropenia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Thrombocytopenia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Angina pectoris', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Myocardial ischaemia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Arteriovenous malformation', 'organSystem': 'Congenital, familial and genetic disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal arteriovenous malformation', 'organSystem': 'Congenital, familial and genetic disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Haemorrhagic arteriovenous malformation', 'organSystem': 'Congenital, familial and genetic disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hydrocele', 'organSystem': 'Congenital, familial and genetic disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Phimosis', 'organSystem': 'Congenital, familial and genetic disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': \"Rathke's cleft cyst\", 'organSystem': 'Congenital, familial and genetic disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Sacralisation', 'organSystem': 'Congenital, familial and genetic disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Thalassaemia beta', 'organSystem': 'Congenital, familial and genetic disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Acute vestibular syndrome', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Deafness', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hypoacusis', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Mixed deafness', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Tympanic membrane disorder', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Tympanic membrane perforation', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Vertigo', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Vertigo positional', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Vestibular disorder', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Adrenal mass', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Autoimmune thyroiditis', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': \"Cushing's syndrome\", 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Goitre', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7344}]}, {'term': 'Hyperaldosteronism', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hyperthyroidism', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hypothyroidism', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Thyroid disorder', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Thyroid mass', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Toxic nodular goitre', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Angle closure glaucoma', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Blindness unilateral', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cataract', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Diplopia', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Extraocular muscle disorder', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Eye disorder', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Eye pain', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Glaucoma', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lens dislocation', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Macular fibrosis', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Macular hole', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Macular oedema', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Open angle glaucoma', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Retinal detachment', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Retinal haemorrhage', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Ulcerative keratitis', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Visual impairment', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Vitreous haemorrhage', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Abdominal adhesions', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Abdominal hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7344}]}, {'term': 'Abdominal incarcerated hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Abdominal pain', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Abdominal pain upper', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Abdominal strangulated hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Abdominal wall haematoma', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Anal fissure', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Anal fistula', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Anal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Anorectal stenosis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Anorectal varices', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Ascites', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Chronic gastritis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Colitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Colitis ischaemic', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Colitis ulcerative', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Constipation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': \"Crohn's disease\", 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Diaphragmatic hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Diverticular perforation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Diverticulum', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Diverticulum intestinal', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Diverticulum intestinal haemorrhagic', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Duodenal ulcer', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Duodenal ulcer haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Duodenitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Duodenitis haemorrhagic', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Dyspepsia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Dysphagia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Enterocele', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Enterocutaneous fistula', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Epigastric discomfort', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Erosive oesophagitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Faecaloma', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gastric antral vascular ectasia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gastric fistula', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gastric perforation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gastric polyps', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Gastric ulcer', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Gastric ulcer haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Gastric ulcer perforation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gastric varices haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gastritis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 12, 'numAffected': 12, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Gastritis erosive', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gastroduodenal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal disorder', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 37, 'numAffected': 34, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 30, 'numAffected': 27, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal hypomotility', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal inflammation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal melanosis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal obstruction', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Gastrooesophageal reflux disease', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Gingival bleeding', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Haematochezia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Haemorrhoids', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hiatus hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Ileus', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Impaired gastric emptying', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Incarcerated umbilical hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Inflammatory bowel disease', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Inguinal hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7344}]}, {'term': 'Intestinal haematoma', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Intestinal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Intestinal obstruction', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Intestinal perforation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Jejunal perforation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Large intestinal ulcer', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Large intestinal ulcer haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Large intestine perforation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Large intestine polyp', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 11, 'numAffected': 10, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lower gastrointestinal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Lumbar hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Mallory-weiss syndrome', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Melaena', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Oesophageal obstruction', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Oesophageal perforation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Oesophageal polyp', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Oesophageal ulcer', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Oesophageal varices haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Oesophagitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Oral dysaesthesia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Oroantral fistula', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Pancreatic cyst', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Pancreatic mass', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Pancreatitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 24, 'numAffected': 22, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 37, 'numAffected': 37, 'numAtRisk': 7344}]}, {'term': 'Peptic ulcer', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Peritoneal haematoma', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Rectal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Rectal polyp', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Rectourethral fistula', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Retroperitoneal haematoma', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Retroperitoneal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Retroperitoneal mass', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Small intestinal obstruction', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 8, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7344}]}, {'term': 'Small intestinal perforation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Strangulated umbilical hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Subileus', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Tongue haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Umbilical hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 14, 'numAffected': 14, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Upper gastrointestinal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 10, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7344}]}, {'term': 'Varices oesophageal', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Adverse drug reaction', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Asthenia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Chest discomfort', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Chest pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Complication associated with device', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Cyst', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Drug interaction', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Fatigue', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gait disturbance', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'General physical health deterioration', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Generalised oedema', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Granuloma', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Haemorrhagic cyst', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hernia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Impaired healing', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Impaired self-care', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Injection site inflammation', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Malaise', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Non-cardiac chest pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 90, 'numAffected': 79, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 104, 'numAffected': 87, 'numAtRisk': 7344}]}, {'term': 'Oedema', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Oedema peripheral', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Polyp', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Pyrexia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Strangulated hernia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Acute hepatic failure', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Bile duct stenosis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Biliary cirrhosis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Biliary colic', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Biliary cyst', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Chronic hepatic failure', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cirrhosis alcoholic', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Drug-induced liver injury', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gallbladder fistula', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gallbladder polyp', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hepatic cirrhosis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Hepatic haematoma', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hepatic lesion', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hepatic mass', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hepatomegaly', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hepatosplenomegaly', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Jaundice', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Jaundice cholestatic', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Liver injury', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Portal vein thrombosis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Anaphylactic reaction', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Drug hypersensitivity', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Food allergy', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hypersensitivity', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Sarcoidosis', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Bronchitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Cellulitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Chronic sinusitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Chronic tonsillitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Cystitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Dengue fever', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Endophthalmitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Epiglottitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hepatitis e', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Herpes zoster', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Herpes zoster oticus', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Infective exacerbation of chronic obstructive airways disease', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Keratouveitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Pseudomembranous colitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Pulmonary tuberculosis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Sinusitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Vestibular neuronitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Viral infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Accident', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Accidental overdose', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Acetabulum fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Alcohol poisoning', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Anastomotic ulcer', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Ankle fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 11, 'numAtRisk': 7344}]}, {'term': 'Arthropod sting', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Brain contusion', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Carbon monoxide poisoning', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Cervical vertebral fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Clavicle fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Comminuted fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Complicated fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Concussion', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Contrast media reaction', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Contusion', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Craniocerebral injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Ear injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Exposure to toxic agent', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Extradural haematoma', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Eye injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Facial bones fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Fall', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 15, 'numAffected': 14, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 12, 'numAffected': 12, 'numAtRisk': 7344}]}, {'term': 'Femoral neck fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 10, 'numAffected': 10, 'numAtRisk': 7344}]}, {'term': 'Femur fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 14, 'numAffected': 13, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7344}]}, {'term': 'Fibula fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Foot fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Forearm fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Foreign body', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal anastomotic leak', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Haematuria traumatic', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hand fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Head injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hepatic haematoma', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hip fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 14, 'numAtRisk': 7344}]}, {'term': 'Humerus fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 10, 'numAffected': 10, 'numAtRisk': 7344}]}, {'term': 'Ilium fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Incarcerated incisional hernia', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Incisional hernia', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Intentional overdose', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Joint dislocation', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Laceration', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Ligament injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Limb injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Lower limb fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Lumbar vertebral fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Meniscus injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Multiple fractures', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Multiple injuries', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Muscle injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Muscle rupture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Muscle strain', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Nail injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Overdose', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Patella fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Pelvic fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Periprosthetic fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Perirenal haematoma', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Post laminectomy syndrome', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Post procedural haematoma', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Post procedural haemorrhage', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Postoperative fever', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Postoperative ileus', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Postoperative respiratory failure', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Postoperative thoracic procedure complication', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Postoperative wound complication', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Procedural haemorrhage', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Procedural pain', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Procedural pneumothorax', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Pubis fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Radiation pneumonitis', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Radius fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Rib fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 14, 'numAffected': 14, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Road traffic accident', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Scapula fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Seroma', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Skin abrasion', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Skin injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Skull fractured base', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Soft tissue injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Spinal column injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Spinal compression fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Spinal cord injury cervical', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Spinal fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Splenic injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Splenic rupture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Subdural haematoma', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 11, 'numAtRisk': 7344}]}, {'term': 'Subdural haemorrhage', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Tendon rupture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Thermal burn', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Thoracic vertebral fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Tibia fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 7344}]}, {'term': 'Toxicity to various agents', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Traumatic haemothorax', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Traumatic liver injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Ulna fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Upper limb fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7344}]}, {'term': 'Wound', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Wound dehiscence', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Wound evisceration', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Wrist fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Anticoagulation drug level increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Blood calcitonin increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Blood potassium decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Eosinophil count increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hiv test positive', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'International normalised ratio abnormal', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'International normalised ratio increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Weight decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Acidosis', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Dehydration', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 10, 'numAffected': 10, 'numAtRisk': 7344}]}, {'term': 'Electrolyte imbalance', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Fluid overload', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hypercalcaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hyperkalaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Hypernatraemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hypocalcaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hypokalaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Hypomagnesaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hyponatraemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 8, 'numAtRisk': 7344}]}, {'term': 'Hypovolaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lactic acidosis', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lactose intolerance', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Obesity', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Ankylosing spondylitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Arthralgia', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Arthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Arthrofibrosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Arthropathy', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Articular calcification', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Back pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 14, 'numAffected': 12, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 14, 'numAtRisk': 7344}]}, {'term': 'Bursitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Cervical spinal stenosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Chest wall haematoma', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Chondrocalcinosis pyrophosphate', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Costochondritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Crystal arthropathy', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Deformity thorax', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': \"Dupuytren's contracture\", 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Exostosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Foot deformity', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Fracture nonunion', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Haemarthrosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Intervertebral disc compression', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Intervertebral disc degeneration', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Intervertebral disc disorder', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Intervertebral disc protrusion', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 19, 'numAffected': 17, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 18, 'numAffected': 15, 'numAtRisk': 7344}]}, {'term': 'Intervertebral disc space narrowing', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Joint adhesion', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Joint effusion', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Joint instability', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lumbar spinal stenosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 21, 'numAffected': 20, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 12, 'numAtRisk': 7344}]}, {'term': 'Meniscal degeneration', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Monarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Muscle spasms', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Muscular weakness', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Musculoskeletal chest pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 10, 'numAtRisk': 7344}]}, {'term': 'Musculoskeletal deformity', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Musculoskeletal pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Myopathy', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Myositis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Neck pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Neuropathic arthropathy', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Osteoarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 89, 'numAffected': 79, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 76, 'numAffected': 69, 'numAtRisk': 7344}]}, {'term': 'Osteochondritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Osteochondrosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Osteonecrosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Pain in extremity', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Pathological fracture', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Periarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Periostitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Polyarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Polymyalgia rheumatica', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Psoriatic arthropathy', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Rhabdomyolysis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Rheumatic disorder', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Rheumatoid arthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Rotator cuff syndrome', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Sacroiliitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Spinal column stenosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 10, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Spinal disorder', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Spinal osteoarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 11, 'numAtRisk': 7344}]}, {'term': 'Spinal pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Spondyloarthropathy', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Spondylolisthesis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Synovial cyst', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Synovitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Tendon pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Tendonitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Vertebral foraminal stenosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Vertebral osteophyte', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Acth-producing pituitary tumour', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Acute myeloid leukaemia', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Adenocarcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Adenocarcinoma gastric', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Adenocarcinoma of appendix', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Adenocarcinoma of colon', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 12, 'numAffected': 12, 'numAtRisk': 7344}]}, {'term': 'Adenoma benign', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Adrenal adenoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Adrenal neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Anal cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Angiosarcoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Appendix cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'B-cell lymphoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Basal cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 33, 'numAffected': 25, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 42, 'numAffected': 25, 'numAtRisk': 7344}]}, {'term': 'Basosquamous carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Benign gastric neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Benign laryngeal neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Benign lung neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Benign neoplasm of bladder', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Benign neoplasm of thyroid gland', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Benign oesophageal neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Benign ovarian tumour', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Benign salivary gland neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Benign small intestinal neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Bile duct cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Bladder cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7344}]}, {'term': 'Bladder cancer recurrent', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Bladder cancer stage 0, with cancer in situ', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Bladder neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Bladder papilloma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Bladder transitional cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Bladder transitional cell carcinoma recurrent', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Bone cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': \"Bowen's disease\", 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Brain neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Brain neoplasm malignant', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Breast cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Breast cancer female', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 14, 'numAffected': 14, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 16, 'numAffected': 16, 'numAtRisk': 7344}]}, {'term': 'Breast cancer male', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Breast cancer metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Breast neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Bronchial carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Cancer pain', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Carotid body tumour', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cerebral haemangioma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cervix carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Cervix carcinoma recurrent', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cholangiocarcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Choroid melanoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Chronic lymphocytic leukaemia', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Chronic myeloid leukaemia', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Clear cell endometrial carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Clear cell renal cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Colon adenoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Colon cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 16, 'numAffected': 16, 'numAtRisk': 7344}]}, {'term': 'Colon cancer metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Colon cancer stage i', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Colon neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Colorectal adenocarcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Colorectal cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Desmoplastic melanoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Diffuse large b-cell lymphoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Ear neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Endometrial adenocarcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Endometrial adenoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Endometrial cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Epithelioid mesothelioma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Essential thrombocythaemia', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Extradural neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Fibroma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Fibrosarcoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gallbladder cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Gastric adenoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Gastric cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Gastric neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal stromal tumour', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gastrointestinal submucosal tumour', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Glioblastoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Glioblastoma multiforme', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Haemangioblastoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Haemangioma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hairy cell leukaemia', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hepatic adenoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hepatic cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Hepatic cancer metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hepatocellular carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': \"Hodgkin's disease\", 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Intraductal proliferative breast lesion', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Invasive ductal breast carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Laryngeal cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Laryngeal squamous cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Leukaemia', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Lip neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lip squamous cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Lipoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Lung adenocarcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lung adenocarcinoma metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Lung cancer metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Lung carcinoma cell type unspecified stage iv', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Lung neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Lung neoplasm malignant', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 12, 'numAffected': 12, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 12, 'numAffected': 12, 'numAtRisk': 7344}]}, {'term': 'Lung squamous cell carcinoma metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lymphoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Malignant anorectal neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Malignant ascites', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Malignant melanoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 7344}]}, {'term': 'Malignant melanoma in situ', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Malignant neoplasm of unknown primary site', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Malignant neoplasm progression', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Malignant pleural effusion', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Mantle cell lymphoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Melanocytic naevus', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Meningioma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Mesothelioma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Mesothelioma malignant', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Metastases to adrenals', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Metastases to bone', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Metastases to central nervous system', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Metastases to liver', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Metastases to lymph nodes', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Metastasis', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Metastatic neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Metastatic renal cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Metastatic uterine cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Myelodysplastic syndrome', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Myeloid leukaemia', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Myeloproliferative neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Nasal sinus cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Neoplasm malignant', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Neoplasm prostate', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Neuroendocrine carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Neuroendocrine carcinoma of the skin', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Neuroendocrine tumour', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': \"Non-hodgkin's lymphoma\", 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Non-small cell lung cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Non-small cell lung cancer metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Non-small cell lung cancer stage iv', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Oesophageal adenocarcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Oesophageal cancer metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Oesophageal carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Oropharyngeal cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Oropharyngeal squamous cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Ovarian adenoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Ovarian cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Ovarian neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Pancreatic carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 15, 'numAffected': 15, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 15, 'numAtRisk': 7344}]}, {'term': 'Pancreatic neuroendocrine tumour', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Papillary cystadenoma lymphomatosum', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Papillary thyroid cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Paraproteinaemia', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Parathyroid tumour benign', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Penile cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Peripheral t-cell lymphoma unspecified', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Pituitary tumour benign', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Plasma cell myeloma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Prostate cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 26, 'numAffected': 26, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 20, 'numAffected': 20, 'numAtRisk': 7344}]}, {'term': 'Prostate cancer metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Prostate cancer recurrent', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Prostate cancer stage i', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Rectal adenocarcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Rectal adenoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Rectal cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Rectal cancer metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Rectal neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Rectosigmoid cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Renal cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Renal cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Renal neoplasm', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Renal oncocytoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Respiratory papilloma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Retinal melanoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Salivary gland cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Seborrhoeic keratosis', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Sinonasal papilloma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Skin cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Small cell lung cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Small intestine carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Spinal meningioma benign', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Squamous cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 16, 'numAffected': 13, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 12, 'numAtRisk': 7344}]}, {'term': 'Squamous cell carcinoma of head and neck', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Squamous cell carcinoma of lung', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Squamous cell carcinoma of skin', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 7, 'numAtRisk': 7344}]}, {'term': 'Squamous cell carcinoma of the hypopharynx', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Squamous cell carcinoma of the oral cavity', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Squamous cell carcinoma of the tongue', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Thyroid cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 14, 'numAtRisk': 7344}]}, {'term': 'Tongue neoplasm malignant stage unspecified', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Tonsil cancer metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Transitional cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Transitional cell carcinoma urethra', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Uterine cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Uterine leiomyoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Vulval cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Xanthogranuloma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Altered state of consciousness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Amputation stump pain', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Asterixis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Ataxia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Autonomic neuropathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Brain injury', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Carpal tunnel syndrome', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Cauda equina syndrome', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cerebellar haemorrhage', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cerebellar syndrome', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Cerebral haemorrhage', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cerebrospinal fluid leakage', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Cervical myelopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cervical radiculopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Cervicobrachial syndrome', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Cervicogenic headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cognitive disorder', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Coma', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Coordination abnormal', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Dementia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': \"Dementia alzheimer's type\", 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Demyelinating polyneuropathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Dizziness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Encephalopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Epilepsy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Facial paralysis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Facial paresis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Frontotemporal dementia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Generalised tonic-clonic seizure', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Guillain-barre syndrome', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Haemorrhage intracranial', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Hepatic encephalopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Hydrocephalus', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hypoaesthesia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hypotonia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Iiird nerve paralysis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Idiopathic generalised epilepsy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Intracranial aneurysm', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Intracranial pressure increased', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Loss of consciousness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lumbar radiculopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Lumbosacral radiculopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Memory impairment', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Metabolic encephalopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Migraine', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Mixed dementia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Multiple sclerosis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Myasthenia gravis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Myelitis transverse', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Nerve compression', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Nerve root compression', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Neuralgia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Neuralgic amyotrophy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Neuritis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Neurodegenerative disorder', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Neuropathy peripheral', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Normal pressure hydrocephalus', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Paraesthesia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Parkinsonism', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Partial seizures', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Peripheral sensory neuropathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Post herpetic neuralgia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Post stroke seizure', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Radicular syndrome', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Restless legs syndrome', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Sciatica', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Seizure', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 10, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Senile dementia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Spinal claudication', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Spinal cord compression', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Spondylitic myelopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Status epilepticus', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Subacute combined cord degeneration', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Subarachnoid haemorrhage', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Subdural hygroma', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Toxic encephalopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Trigeminal neuralgia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Vith nerve paralysis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Vascular dementia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Vascular headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Vertebrobasilar insufficiency', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Cephalhaematoma', 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cephalo-pelvic disproportion', 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Pre-eclampsia', 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Device battery issue', 'organSystem': 'Product Issues', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Device dislocation', 'organSystem': 'Product Issues', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Device failure', 'organSystem': 'Product Issues', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Device loosening', 'organSystem': 'Product Issues', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Device malfunction', 'organSystem': 'Product Issues', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Device occlusion', 'organSystem': 'Product Issues', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Patient-device incompatibility', 'organSystem': 'Product Issues', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Alcohol abuse', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Alcohol withdrawal syndrome', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Alcoholism', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Anxiety', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Bipolar disorder', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Confusional state', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Delirium', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Depressed mood', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Depression', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 15, 'numAffected': 14, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Depression suicidal', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Major depression', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Mental status changes', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7344}]}, {'term': 'Personality change due to a general medical condition', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Post-traumatic stress disorder', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Psychogenic seizure', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Psychotic disorder', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Suicidal ideation', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Suicide attempt', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Acute kidney injury', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Azotaemia', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Bladder discomfort', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Bladder diverticulum', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Bladder mass', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Calculus bladder', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Calculus urethral', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Calculus urinary', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Dysuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Glomerulonephritis chronic', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Haematuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 7344}]}, {'term': 'Hydronephrosis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hypertonic bladder', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Hypotonic urinary bladder', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Nephrolithiasis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 13, 'numAffected': 13, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 16, 'numAffected': 15, 'numAtRisk': 7344}]}, {'term': 'Nephrosclerosis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Obstructive uropathy', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Pelvi-ureteric obstruction', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Renal colic', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 7344}]}, {'term': 'Renal cyst', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Renal cyst haemorrhage', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Renal impairment', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Renal mass', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Stress urinary incontinence', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Ureteric stenosis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Ureterolithiasis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 10, 'numAffected': 10, 'numAtRisk': 7344}]}, {'term': 'Urethral haemorrhage', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Urethral stenosis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Urinary bladder polyp', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Urinary incontinence', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Urinary retention', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 7344}]}, {'term': 'Urinary tract obstruction', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Acquired phimosis', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Atrophic vulvovaginitis', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Benign prostatic hyperplasia', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 11, 'numAffected': 11, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 7344}]}, {'term': 'Breast mass', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cervical dysplasia', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Cystocele', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Endometrial hyperplasia', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Epididymal cyst', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Female genital tract fistula', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Genital lesion', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Gynaecomastia', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Menorrhagia', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Metrorrhagia', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Organic erectile dysfunction', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Ovarian cyst', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Ovarian vein thrombosis', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Postmenopausal haemorrhage', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Prostatitis', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Prostatomegaly', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Uterine haemorrhage', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Uterine polyp', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Uterine prolapse', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Acquired diaphragmatic eventration', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Acute pulmonary oedema', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Acute respiratory distress syndrome', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Acute respiratory failure', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 10, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 7344}]}, {'term': 'Alveolitis allergic', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Aspiration', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Asthma', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Asthmatic crisis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Bronchitis chronic', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7344}]}, {'term': 'Bronchospasm', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Chronic obstructive pulmonary disease', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 81, 'numAffected': 49, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 84, 'numAffected': 48, 'numAtRisk': 7344}]}, {'term': 'Cough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Dyspnoea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 18, 'numAffected': 18, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 11, 'numAtRisk': 7344}]}, {'term': 'Dyspnoea exertional', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Emphysema', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Epistaxis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 4, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Haemoptysis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Haemothorax', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hiccups', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hydrothorax', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Hypoxia', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Interstitial lung disease', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Lung disorder', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Nasal septum perforation', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Nasal turbinate hypertrophy', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Pleural effusion', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 10, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 10, 'numAffected': 9, 'numAtRisk': 7344}]}, {'term': 'Pleural fibrosis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Pleuritic pain', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Pneumothorax', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Pneumothorax spontaneous', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Pulmonary fibrosis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Pulmonary mass', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Pulmonary oedema', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Respiratory acidosis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Respiratory failure', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 14, 'numAffected': 13, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 12, 'numAtRisk': 7344}]}, {'term': 'Restrictive pulmonary disease', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Sleep apnoea syndrome', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 7344}]}, {'term': 'Stridor', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Tracheal stenosis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Tracheomalacia', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Upper-airway cough syndrome', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Actinic keratosis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Angioedema', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 5, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 7344}]}, {'term': 'Decubitus ulcer', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Dermal cyst', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Dermatitis allergic', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Dermatitis atopic', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Dermatitis bullous', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Drug eruption', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Drug reaction with eosinophilia and systemic symptoms', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Eczema', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Granuloma skin', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Ingrowing nail', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Keloid scar', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lichen planus', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Lichenoid keratosis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Parapsoriasis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Prurigo', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Psoriasis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Rash', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Rash generalised', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Skin ulcer', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Stasis dermatitis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Umbilical haemorrhage', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Urticaria', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}, {'term': 'Alcohol use', 'organSystem': 'Social circumstances', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Arterial rupture', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Bleeding varicose vein', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Haematoma', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 7344}]}, {'term': 'Haemorrhage', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Lymphocele', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Peripheral artery thrombosis', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Post thrombotic syndrome', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 7344}]}, {'term': 'Temporal arteritis', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 7344}]}, {'term': 'Varicose vein', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 7372}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 7344}]}]}, 'moreInfoModule': {'limitationsAndCaveats': {'description': 'Only SAE are collected in this study.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}, 'pointOfContact': {'title': 'Peter Ohman', 'organization': 'Astrazaneca Inc.', 'email': 'Peter.Ohman@astrazeneca.com', 'phone': '1(301)398-0120'}}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot', 'hasProtocol': True, 'hasSap': False, 'hasIcf': False, 'label': 'Study Protocol', 'date': '2009-12-24', 'uploadDate': '2018-04-13T06:22', 'filename': 'Prot_000.pdf', 'size': 1290284}, {'typeAbbrev': 'SAP', 'hasProtocol': False, 'hasSap': True, 'hasIcf': False, 'label': 'Statistical Analysis Plan', 'date': '2017-02-23', 'uploadDate': '2018-04-13T06:22', 'filename': 'SAP_001.pdf', 'size': 1487220}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28', 'removedCountries': ['Czech Republic', 'France', 'India', 'Peru']}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077270', 'term': 'Exenatide'}], 'ancestors': [{'id': 'D000097789', 'term': 'Glucagon-Like Peptide-1 Receptor Agonists'}, {'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D019440', 'term': 'Anti-Obesity Agents'}, {'id': 'D054795', 'term': 'Incretins'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}], 'browseLeaves': [{'id': 'M1726', 'name': 'Exenatide', 'asFound': '90 minutes', 'relevance': 'HIGH'}, {'id': 'M29005', 'name': 'Islet Amyloid Polypeptide', 'relevance': 'LOW'}, {'id': 'M3401', 'name': 'Glucagon-Like Peptide-1 Receptor Agonists', 'relevance': 'LOW'}, {'id': 'M9043', 'name': 'Glucagon', 'relevance': 'LOW'}, {'id': 'M26997', 'name': 'Glucagon-Like Peptide 1', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M21396', 'name': 'Anti-Obesity Agents', 'relevance': 'LOW'}, {'id': 'M27905', 'name': 'Incretins', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'AnObAg', 'name': 'Anti-Obesity Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01798238', 'orgStudyIdInfo': {'id': 'MP_C302'}, 'organization': {'fullName': 'Handok Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus', 'officialTitle': 'A Phase III Double-blind, Parallel Group, Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of MP-513 Monotherapy in Patients With Type 2 Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2014-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2012-11'}, 'primaryCompletionDateStruct': {'date': '2014-05', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2014-05', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2013-02-18', 'studyFirstSubmitQcDate': '2013-02-22', 'studyFirstPostDateStruct': {'date': '2013-02-25', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2014-08-04', 'lastUpdatePostDateStruct': {'date': '2014-08-05', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Handok Inc.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The study design of this trial is double blind, parallel-group, randomized, placebo controlled study', 'detailedDescription': \"* Although many different oral antidiabetic agents are currently available, approximately 50% of treated Type 2 diabetic subjects do not reach currently accepted goals for HbA1c(Oral communication, American Diabetic Association, 2008)Subjects are frequently prescribed agents which can cause hypoglycemia, and/or weight gain.\\n* In many countries, the most commonly prescribed primary oral diabetes drug that does not cause hypoglycemia or weight gain, is metformin, but metformin can cause gastrointestinal adverse drug reactions, nausea, vomiting, diarrhea, abdominal pain and loss of appetite and other symptoms, and rare but life-threatening lactic acidosis.\\n* This decrease in the Power of Hydrogen Ions of the blood (\\\\<7.25) and the increase in blood lactate (\\\\> 5 mmol / L) is associated with a reduced kidney failure and if there is kidney impairment, decreased metformin clearance and thus accumulated metformin may occur lactic acidosis more frequently. Also there is inconvenience, such as adjusting metformin dose depending on patient's condition.\\n* MP-513 is expected to be safely used as a treatment for type 2 diabetes because it has no risk of hypoglycemia and/or weight gain which are reported in pre-existing diabetes therapies and no inconvenience related to dose adjustment depending on patient's condition, and no cases of fatal side effects.\\n* Furthermore the inhibitory effect on Dipeptidyl peptidase-IV was stronger and half-life was longer compared with other dipeptidyl peptidase-IV inhibitors in non-clinical trial, and blood glucose moderating effects are proven to be clinically significant in clinical trials conducted in Europe and Japan in that its development as a therapeutic agent for patients with type 2 diabetes is considered to be promising.\\n* Based on these previous studies, the objective of this study is to investigate the efficacy and safety in subjects with type 2 diabetes mellitus that is not adequately controlled with exercise and diet.\"}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus'], 'keywords': ['Type 2 Diabetes Mellitus / Dipeptidyl peptidase-IV inhibitors']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 142, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Placebo group', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Drug: Placebo']}, {'label': 'MP-513 group', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: MP-513']}], 'interventions': [{'type': 'DRUG', 'name': 'MP-513', 'description': 'form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day', 'armGroupLabels': ['MP-513 group']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day', 'armGroupLabels': ['Placebo group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Glycosylated hemoglobin', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}], 'secondaryOutcomes': [{'measure': 'Mean fasting plasma glucose', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Weight', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Glycosylated hemoglobin <7.0% subject percent', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Triglycerides', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Homeostatic model assessment of insulin Resistance', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Body mass index', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Low Density Lipoprotein', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'High Density Lipoprotein', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Cholesterol', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Connecting peptide', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Insulin', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Homeostatic model assessment of beta-cell function', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}, {'measure': 'Glycosylated hemoglobin <6.5% subject percent', 'timeFrame': 'Visit 1(Baseline Visit) vs Visit 7(week 24)'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. The subject is aged ≥18 years at signature of the informed consent form\\n2. The subject has a documented diagnosis of Type 2 diabetes\\n3. The subject's HbA1c is 7.0%≤HbA1c\\\\<10.0% at screening visit and run-in visit\\n4. The subject's BMI is 20.0≤BMI≤40.0kg/m2\\n5. The subject's fasting plasma glucose is \\\\<15 mmol/L (270 mg/dL)at screening visit and run-in visit\\n6. The subject conducts a proper diet and exercise therapy for diabetes and its contents have not been changed for at least 8 week(56 days) at run-in visit(this does not apply to a subject with complications as as result of that exercise therapy is impossible)\\n7. The subject has not used other diabetic medicine for at least 8 week(56 days) at run-in visit\\n8. The subject is capable of giving informed consent, complying with the restrictions and requirements of the protocol\\n\\nExclusion Criteria:\\n\\n1. The subject has a history of Type 1 diabetes or a secondary form of diabetes(Diabetes caused by the pancreatic diseases, such as chronic pancreatitis, pancreatic cancer, hemochromatosis or the overproduction of hormones antagonistic to insulin, Cushing's syndrome, Basedow's disease, pheochromocytoma, drug, insulin receptor abnormalities)\\n2. The subject has a history of MP-513 treatment\\n3. The subject has a history of habitual and excessive alcohol abuse or drug abuse, or concerns\\n4. The subject has a medical history of unstable angina, or heart failure(New York Heart Association class Ⅲ-IV) or any clinically significant ECG abnormalities such as ventricular tachycardia or a medical history of ventricular tachycardia\\n5. The subject has participated in any other clinical study involving administration of an unlicensed medicinal product within 12 weeks prior to the screening visit or is participating any other clinical study\\n6. The subject has received insulin within 12 months prior to the screening visit, with the exception of insulin therapy during hospitalization, insulin therapy for medical conditions not requiring hospitalization (\\\\<2 weeks duration) or use in gestational diabetes\\n7. Female subjects whose pregnancy test is positive or who are pregnant, lactating, or are planning to become pregnant during the study\\n8. The subject has serum creatinine \\\\>1.5 mg/dL(male) or \\\\>1.4 mg/dL(female)\\n9. The subject has aspartate-amino-transferase (AST) and alanine-amino-transferase (ALT) \\\\>2.5 times the upper limit of normal (ULN)\\n10. The subject has diastolic blood pressure \\\\>100 mmHg and/or systolic blood pressure \\\\>180 mmHg\\n11. The presence of any other condition that leads the investigator to conclude that the patient is inappropriate for inclusion in the clinical study\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Sungwoo Park', 'affiliation': 'Kangbuk Samsung Hospital', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Handok INC', 'city': 'Seoul', 'state': 'Gangnam-Gu', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Handok Pharmaceuticals CO. LTD', 'city': 'Seoul', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M27957', 'name': 'Dipeptidyl-Peptidase IV Inhibitors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03917238', 'orgStudyIdInfo': {'id': 'NL61915.091.17'}, 'organization': {'fullName': 'Radboud University Medical Center', 'class': 'OTHER'}, 'briefTitle': 'Beta Cell Imaging During and Shortly After the Honeymoon Phase of T1D', 'officialTitle': 'Comparison of the Beta Cell Mass During and Shortly After the Honeymoon Phase of Type 1 Diabetes Using Gallium-68-exendin PET', 'acronym': 'Honeymoon'}, 'statusModule': {'statusVerifiedDate': '2024-01', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-10-11', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-11-25', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-12-25', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2019-03-13', 'studyFirstSubmitQcDate': '2019-04-15', 'studyFirstPostDateStruct': {'date': '2019-04-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-01-04', 'lastUpdatePostDateStruct': {'date': '2024-01-05', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Radboud University Medical Center', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The primary goal is to correlate beta cell mass to beta cell function from measurements during and shortly after the honeymoon phase of type 1 diabetes, to improve understanding of the change in metabolic control after the honeymoon phase.', 'detailedDescription': \"The exact role of beta cell mass during the development and course of diabetes is still poorly understood. Further research on beta cell mass is essential to obtain more insights that might aid in the development of diabetes treatment. This study aims at a specific phase of T1D that is called the 'honeymoon phase' or period of partial remission. Once insulin treatment has started, the honeymoon phase will arise in most patients. In this period, T1D patients become temporarily less insulin-dependent. Unfortunately, the honeymoon phase is only temporary, in which a decline in blood glucose regulation will be seen afterwards, leading to an increasing demand for insulin. To increase understanding of this change in metabolic control after the honeymoon phase, repeated measurements of the beta cell mass and function are performed during and shortly after the honeymoon phase. The comparison of both measurements might lead to an increased understanding whether changes in insulin demand after the honeymoon phase is mainly dependent on a decline in the beta cell mass, or because of a decrease in functional beta cells. The outcome of this study can provide new insights, which can contribute to the development of novel treatment options.\"}, 'conditionsModule': {'conditions': ['Type 1 Diabetes Mellitus']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 14, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patients with T1D', 'type': 'OTHER', 'description': 'gallium-68-exendin followed by a PET/CT scan (twice)', 'interventionNames': ['Radiation: gallium-68-exendin injection followed by PET/CT scan']}], 'interventions': [{'type': 'RADIATION', 'name': 'gallium-68-exendin injection followed by PET/CT scan', 'description': 'After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended', 'armGroupLabels': ['Patients with T1D']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Pancreatic uptake of gallium-68-NODAGA-exendin-4', 'description': 'Pancreatic uptake is measured by quantitative analysis of PET/CT scan', 'timeFrame': '2 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Age ≥ 16 years\\n* Diagnosed with T1D\\n* Presence of anti-GAD\\n* Subject is in honeymoon phase\\n* 17 ≤ BMI ≥ 30 kg/m\\\\^2 at moment of visit\\n* Ability to sign informed consent\\n\\nExclusion Criteria:\\n\\n* Previous treatment (within 6 months) with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV inhibitors\\n* Liver disease\\n* Renal disease\\n* Pregnancy or the wish to become pregnant within 6 months after the study\\n* Breastfeeding\\n* BMI \\\\<17 kg/m2 or BMI \\\\>30 kg/m2\\n* Age \\\\<16 years\\n* When the end of the honeymoon phase is not observed within 11 to 13 months after the inclusion of the subject\\n* Inability to sign informed consent', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '16 Years', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Martin Gotthardt, Prof. Dr.', 'affiliation': 'Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Radboud university medical center', 'city': 'Nijmegen', 'state': 'Gelderland', 'zip': '6525 GA', 'country': 'Netherlands', 'geoPoint': {'lat': 51.8425, 'lon': 5.85278}}, {'facility': 'Diabeter', 'city': 'Rotterdam', 'state': 'Zuid-Holland', 'zip': '3011 TA', 'country': 'Netherlands', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03570138', 'orgStudyIdInfo': {'id': 'SPIDER-STYLE'}, 'organization': {'fullName': 'Poitiers University Hospital', 'class': 'OTHER'}, 'briefTitle': 'Efficacy of Flash Glucose-Sensing Technology on the Occurrence of Cardiac Arrhythmias Associated With Hypoglycemia', 'officialTitle': 'Efficacy of Flash Continuous Glucose Monitoring (FREESTYLE LIBRE) on the Occurrence of Cardiac Arrhythmias Associated With Hypoglycemia in Patients With Type 2 Diabetes, High Risk of Hypoglycemia and Insulin Therapy : Open-label Randomized Controlled Trial'}, 'statusModule': {'statusVerifiedDate': '2020-10', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-06-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-09-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2021-09-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2018-06-15', 'studyFirstSubmitQcDate': '2018-06-15', 'studyFirstPostDateStruct': {'date': '2018-06-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-10-19', 'lastUpdatePostDateStruct': {'date': '2020-10-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Poitiers University Hospital', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Hypoglycemia, frequently asymptomatic, may lead to cardiac arrythmias and induce an increased risk of cardiovascular morbidity and mortality in patients with type 2 diabetes (T2D). The study hypothesize is that the hypoglycemia reduction, achieved with the FREESTYLE LIBRE device, a Glucose Continuous Monitoring system, may decrease cardiac arrythmias associated with hypoglycemia. So the main objective is to evaluate the efficacy of the FREESTYLE LIBRE system, associated with a specific therapeutic education on the cardiac arrythmias reduction, compared to a capillary ASG system with standard therapeutic education, in patient with T2D with high risk of hypoglycemia.\\n\\nThis is a open, multicenter, controlled, randomized study in parallel group.'}, 'conditionsModule': {'conditions': ['Insulin Treated Type 2 Diabetes With High Risk of Hypoglycemia'], 'keywords': ['Freestyle libre', 'Type 2 diabetes', 'Hypoglycemia-induced cardiac arrhythmias', 'Flash Continuous Glucose Monitoring']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 200, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Flash continuous glucose monitoring system', 'type': 'EXPERIMENTAL', 'description': 'Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.', 'interventionNames': ['Device: FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System']}, {'label': 'Standard self monitoring blood glucose system', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.', 'interventionNames': ['Device: Usual self monitoring Blood Glucose device']}], 'interventions': [{'type': 'DEVICE', 'name': 'FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System', 'description': 'Specific therapeutic education for diabetes self management', 'armGroupLabels': ['Flash continuous glucose monitoring system']}, {'type': 'DEVICE', 'name': 'Usual self monitoring Blood Glucose device', 'description': 'Standard therapeutic education for diabetes self management', 'armGroupLabels': ['Standard self monitoring blood glucose system']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Prevalence of cardiac arrythmic events during a 14 days Continuous ECG Monitoring', 'description': 'Cardiac arrythmic events :\\n\\n* Bradycardia \\\\< 45 bpm for ≥ 10 seconds\\n* or Asystole ≥ 3 seconds\\n* or Atrial Fibrillation ≥ 30 seconds\\n* or Non-sustained ventricular tachycardia defined as runs of beats arising from the ventricles with duration between 3 beats and 30 s with QRS ≥ 120ms and with RR intervall ≤ 600 ms (\\\\>100 bpm)', 'timeFrame': '14 days'}], 'secondaryOutcomes': [{'measure': 'Prevalence of each component of the primary outcome', 'timeFrame': '14 days'}, {'measure': 'Prevalence of ≥ 5 minutes Atrial Fibrillation episodes', 'timeFrame': '14 days'}, {'measure': 'Mean QT interval', 'timeFrame': 'First 24 hours'}, {'measure': 'Prevalence of ventricular extrasystoles', 'timeFrame': 'First 24 hours'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion criteria:\\n\\n* Type 2 diabetes (diagnosis based on the World Health Organization criteria)\\n* Treatment with insulin therapy (continuous subcutaneous insulin Infusion or more than 1 daily injection)\\n* Resting heart beat ≥ 60bpm\\n* High risk of hypoglycemia defined as :\\n\\n  * Estimated glomerular filtration rate 15-59 ml/min/1.73 m² (according to CKD-EPI formula)\\n  * Or history of stable proliferative diabetic retinopathy\\n  * Or body mass index ≤ 30 kg/m²\\n  * Or history of severe hypoglycemia in the previous 6 months\\n  * Or history of non-severe ≤70mg/dL hypoglycemia in the previous 4 weeks\\n\\nExclusion criteria:\\n\\n* Type 1 diabetes mellitus or diabetes due to other cause\\n* History of atrial fibrillation\\n* Pacemaker\\n* Estimated glomerular filtration rate \\\\<15 ml/min/1.73 m² (according to CKD-EPI formula)\\n* Currently using a flash continuous Glucose Monitoring device\\n* In the investigator's opinion, acute or chronic medical condition considered as unsuitable for inclusion in the study .\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '45 Years', 'maximumAge': '85 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'SAULNIER Pierre-Jean, Prof.', 'role': 'CONTACT', 'phone': '+33 549444689', 'email': 'pierre-jean.saulnier@chu-poitiers.fr'}, {'name': 'BONNIN Marie, Project chief', 'role': 'CONTACT', 'phone': '+33 549443317', 'email': 'Marie.BONNIN@chu-poitiers.fr'}], 'locations': [{'facility': 'University Hospital, Bordeaux', 'status': 'RECRUITING', 'city': 'Bordeaux', 'zip': '33000', 'country': 'France', 'contacts': [{'name': 'MOHAMMEDI Kamel, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 44.84044, 'lon': -0.5805}}, {'facility': 'University Hospital, Limoges', 'status': 'RECRUITING', 'city': 'Limoges', 'zip': '87000', 'country': 'France', 'contacts': [{'name': 'TEISSIER Marie-Pierre, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 45.83153, 'lon': 1.25781}}, {'facility': 'University Hospital, Nantes', 'status': 'RECRUITING', 'city': 'Nantes', 'zip': '44000', 'country': 'France', 'contacts': [{'name': 'CARIOU Bertrand, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'facility': 'Hospital, Niort', 'status': 'NOT_YET_RECRUITING', 'city': 'Niort', 'zip': '79000', 'country': 'France', 'contacts': [{'name': 'TEYNIE Julie, Dr.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 46.32313, 'lon': -0.45877}}, {'facility': 'Hospital, Pau', 'status': 'RECRUITING', 'city': 'Pau', 'zip': '64000', 'country': 'France', 'contacts': [{'name': 'TEYNIE Julie, Dr.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.3, 'lon': -0.36667}}, {'facility': 'University Hospital, Poitiers', 'status': 'RECRUITING', 'city': 'Poitiers', 'zip': '86000', 'country': 'France', 'contacts': [{'name': 'SAULNIER Pierre-Jean, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 46.58333, 'lon': 0.33333}}, {'facility': 'University Hospital, Toulouse', 'status': 'RECRUITING', 'city': 'Toulouse', 'zip': '31000', 'country': 'France', 'contacts': [{'name': 'GOURDY Pierre, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001145', 'term': 'Arrhythmias, Cardiac'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D007003', 'term': 'Hypoglycemia'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D010335', 'term': 'Pathologic Processes'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M4453', 'name': 'Arrhythmias, Cardiac', 'asFound': 'Cardiac Arrhythmia', 'relevance': 'HIGH'}, {'id': 'M10053', 'name': 'Hypoglycemia', 'asFound': 'Hypoglycemia', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06418464', 'orgStudyIdInfo': {'id': '2023YFE0204100'}, 'organization': {'fullName': \"Peking University People's Hospital\", 'class': 'OTHER'}, 'briefTitle': 'Efficacy and Safety of an Artificial-pancreas-like Learning-based Control in Type 1 Diabetes on Multiple Daily Injection Therapy', 'officialTitle': 'Efficacy and Safety of an Artificial-pancreas-like Learning-based Control in Type 1 Diabetes on Multiple Daily Injection Therapy: Protocol of a Multi-center, Non-inferiority, Randomized Controlled Trial (ELITE Study)', 'acronym': 'ELITE'}, 'statusModule': {'statusVerifiedDate': '2024-05', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-07-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2025-03-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-05-13', 'studyFirstSubmitQcDate': '2024-05-13', 'studyFirstPostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-05-13', 'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Wei Liu', 'investigatorTitle': 'Associate Professor', 'investigatorAffiliation': \"Peking University People's Hospital\"}, 'leadSponsor': {'name': \"Peking University People's Hospital\", 'class': 'OTHER'}, 'collaborators': [{'name': \"Hebei Provincial People's Hospital\", 'class': 'UNKNOWN'}, {'name': \"Xingtai People's Hospital\", 'class': 'OTHER'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"This study is designed as a blinded, multi-center, non-inferiority randomized controlled clinical trial. It aims to enroll hospitalized T1D diabetes patients, ensuring an equal distribution with a 1:1 ratio between the intervention and control groups. The trial is set to take place across three locations in China: Peking University People's Hospital, Hebei Provincial People's Hospital, and Xingtai People's Hospital. Before participating, all subjects are required to provide their consent by signing a written informed consent form. Within the framework of the trial, the intervention group will receive insulin dosage recommendations from AP-A, subject to approval by a physician, whereas the control group will be treated with insulin dosages according to the current clinical guidelines established by their physicians.\"}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 1']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'AP-A Dosage Decision Support System', 'type': 'EXPERIMENTAL', 'description': 'The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.', 'interventionNames': ['Device: AP-A Dosage Decision Support System']}, {'label': 'Physician decision-making', 'type': 'ACTIVE_COMPARATOR', 'description': 'The injection dose of the control group was determined by the doctor solely.', 'interventionNames': ['Device: AP-A Dosage Decision Support System']}], 'interventions': [{'type': 'DEVICE', 'name': 'AP-A Dosage Decision Support System', 'description': 'The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.', 'armGroupLabels': ['AP-A Dosage Decision Support System', 'Physician decision-making']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Time in Range (TIR)', 'description': 'The proportion of time that the glucose levels, as recorded by CGM during the treatment period, are within the range of 3.9mmol/L to 10.0mmol/L. This metric can be directly obtained by the algorithm system through closed-loop reading of CGM data.', 'timeFrame': 'At the end of the treatment period'}], 'secondaryOutcomes': [{'measure': 'Time Below Range (TBR)', 'description': 'The proportion of time that the glucose levels, as recorded by CGM during the treatment adjustment period, are below 3.9mmol/L.', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes1', 'description': 'The proportion of glucose data stored by CGM during the treatment period that is in the range of 3.0-3.8mmol/L.', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes2', 'description': 'The proportion of glucose data stored by CGM during the treatment adjustment period that is below 3.0mmol/L.', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes3', 'description': 'The area under the curve (AUC) of glucose levels below 3.9mmol/L in the Ambulatory Glucose Profile (AGP) during the treatment adjustment period.', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes4', 'description': 'The proportion of glucose data stored by CGM during the treatment adjustment period that is above 10.0mmol/L.', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes5', 'description': 'The proportion of glucose data stored by CGM during the treatment adjustment period that is above 13.3mmol/L.', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes6', 'description': 'The area under the curve (AUC) of glucose levels below 10.0mmol/L in the AGP during the treatment adjustment period.', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes7', 'description': 'The mean of the glucose data stored by CGM during the treatment adjustment period (MEAN).', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes8', 'description': 'The standard deviation of the glucose data stored by CGM during the treatment adjustment period (SD).', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes9', 'description': 'The discrepancy between the physician-approved dosage and the AI-recommended dosage in the intervention group.', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes10', 'description': 'The number of times the physician-approved dosage differs from the AI-recommended dosage in the intervention group.', 'timeFrame': 'At the end of the treatment period'}, {'measure': 'Other Secondary Outcomes11', 'description': 'In the intervention group, the proportion of time that the glucose levels are within the range of 3.9mmol/L to 10.0mmol/L within 4 hours after insulin injection when there is a discrepancy between the physician-approved dosage and the algorithm-recommended dosage.', 'timeFrame': 'At the end of the treatment period'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Voluntary signing of an informed consent form.\\n2. Age between 18 and 70 years, with a T1D diagnosis of at least one year.\\n3. A confirmed diagnosis of T1D diabetes by at least two endocrinologists and fulfillment of at least one of the following conditions: a) Fasting C-peptide level less than 0.3 ng/mL. b) Fasting C-peptide level between 0.3 ng/mL and 0.6 ng/mL with at least one positive diabetic autoantibody.\\n4. Receiving intensified treatment regimen with multiple daily subcutaneous insulin injections upon screening and during the whole study period.\\n\\nExclusion Criteria:\\n\\n1. Conditions such as diabetic ketoacidosis, diabetic ketosis, hyperglycemic hyperosmolar state, or other acute complications related to diabetes.\\n2. The presence of concurrent fever, severe infections, acute abdominal conditions, uncontrolled thyroid dysfunction, or the acute phase of any organ system disease.\\n3. A history within the last 3 months of serious cardiovascular issues including decompensated heart failure (NYHA Class III or IV), myocardial infarction, coronary artery bypass grafting, or coronary stent implantation, as well as uncontrolled severe arrhythmias or ischemic or hemorrhagic stroke.\\n4. Laboratory test abnormalities that exceed certain thresholds, such as alanine transaminase or aspartate transaminase levels greater than three times the upper limit of normal, total bilirubin levels more than twice the upper limit of normal, hemoglobin levels below 100 g/L, albumin levels below 30 g/L, or an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m².\\n5. Individuals who are required to fast or are unable to eat normally due to special circumstances.\\n6. Pregnant or breastfeeding women.\\n7. Individuals suffering from psychiatric illnesses or other cognitive impairments that may affect their ability to participate in the study.\\n8. Participants who are unable to wear a CGM due to severe allergies, skin diseases, or conditions at the sensor site such as lesions, scarring, redness, infection, or edema, which could interfere with the sensor's adhesion or the accuracy of glucose measurements in the interstitial fluid.\\n9. The systemic use of corticosteroids within the last month, with the exception of inhaled or topical steroids.\\n10. Any other condition or reason that the researcher deems to make the participant unsuitable for inclusion in the study.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Diabetes Mellitus, Type 1', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M22554', 'name': 'Pancrelipase', 'relevance': 'LOW'}, {'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M13114', 'name': 'Pancreatin', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05319990', 'orgStudyIdInfo': {'id': '22-0250'}, 'organization': {'fullName': 'University of Colorado, Denver', 'class': 'OTHER'}, 'briefTitle': 'Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)', 'officialTitle': 'Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)', 'acronym': 'PANDA'}, 'statusModule': {'statusVerifiedDate': '2024-04', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-03-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-06-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-04-01', 'studyFirstSubmitQcDate': '2022-04-01', 'studyFirstPostDateStruct': {'date': '2022-04-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-04-09', 'lastUpdatePostDateStruct': {'date': '2024-04-10', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'University of Colorado, Denver', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Diabetic kidney disease (DKD) occurs in up to 40% of people with type 1 diabetes (T1D), often leading to kidney failure and markedly magnifying risks of cardiovascular disease and premature death. Landmark T1D kidney biopsy studies identified the classic pathological lesions of DKD, which have been attributed largely to hyperglycemia. Recent advances in continuous glucose monitoring (CGM) and automated insulin delivery have facilitated improved glycemic control, but the residual risk of DKD continues to be high. In addition, obesity and insulin resistance (IR) have accompanied intensive glycemic therapy and may promote mitochondrial dysfunction and inflammation. Deciphering the molecular underpinnings of DKD in modern-day T1D and identifying modifiable risk factors could lead to more effective and targeted therapies to prevent DKD.', 'detailedDescription': 'The overall goal of this project is to characterize the molecular, morphometric, and metabolic features of DKD over the modern clinical course of T1D. The investigators hypothesize that perturbed kidney energetics and hypoxia are central metabolic pathways in the development of DKD. Kidney hypoxia stems from a mismatch between increased renal energy demand (e.g., increased glomerular filtration rate \\\\[GFR\\\\] and tubular reabsorption of sodium) and impaired substrate metabolism (e.g., IR and mitochondrial dysfunction) and results in activation of the hypoxia-inducible factor (HIF) system. Although upregulation of HIF1α confers favorable short-term effects, sustained activation promotes cellular injury. Supporting these hypotheses, data from our group and others have shown that obesity, IR, and The investigators also found that youth with T1D exhibit kidney hypoxia by MRI that strongly associates with IR and mitochondrial dysfunction. Moreover, our preliminary single-cell RNA sequencing (scRNA-seq) data from kidney biopsies demonstrate upregulated tubular expression of HIF1α in adults with T1D vs. healthy controls. The investigators propose to build a unique new longitudinal kidney biopsy cohort (N=100) spanning the critical duration of T1D over which DKD initiates and progresses (5-30 years). Participants will be enrolled from our existing CROCODILE study (adding longitudinal follow-up to completed kidney biopsies and baseline data and biosample acquisition) and from new enrollment at the University of Colorado and University of Washington. Normative kidney biopsy data will be provided from our existing cohort of healthy controls (N=20) and the Kidney Precision Medicine Project (KPMP). The investigators will implement state-of-the-art molecular (scRNA-seq) and morphometric interrogation of kidney tissue and rigorous metabolic phenotyping to include kidney magnetic resonance imaging (MRI), direct measurements of glycemia (continuous glucose monitoring), intraabdominal fat (dual-energy X-ray absorptiometry), estimation of insulin sensitivity by a T1D-validated equation, and (in a subset) GFR (iohexol clearance) and renal plasma flow (p-aminohippurate clearance). Participants will be followed longitudinally for DKD outcomes. A subset of 20 participants will undergo repeat kidney biopsies and associated procedures 3 years after baseline kidney biopsy.'}, 'conditionsModule': {'conditions': ['Type 1 Diabetes', 'Diabetic Kidney Disease', 'Diabetes Complications', 'Diabetic Nephropathies', 'Autoimmune Diabetes']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'During the study, the investigators will collect blood, urine, and tissue samples for assessment of kidney function and kidney injury markers.'}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'PANDA, T1D', 'description': 'New participants with T1D will be enrolled at the University of Colorado and University of Washington.'}, {'label': 'PANDA Sub Study, Former CROCODILE Participants', 'description': 'Participants will be enrolled from the existing CROCODILE study (COMIRB # 19-1282), adding longitudinal follow-up to completed kidney biopsies and baseline data and biosample acquisition.', 'interventionNames': ['Drug: Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)', 'Drug: Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)']}], 'interventions': [{'type': 'DRUG', 'name': 'Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)', 'description': 'PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.', 'armGroupLabels': ['PANDA Sub Study, Former CROCODILE Participants'], 'otherNames': ['Sodium 4-amino hippurate (PAH) inj 20% 2g/10mL', 'Para-aminohippurate']}, {'type': 'DRUG', 'name': 'Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)', 'description': 'Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.', 'armGroupLabels': ['PANDA Sub Study, Former CROCODILE Participants'], 'otherNames': ['omnipaque 300']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Renal Oxygenation', 'description': 'Blood oxygen level dependent (BOLD) MRI', 'timeFrame': '30 min'}, {'measure': 'Renal Perfusion', 'description': 'Arterial Spin Labeling (ASL) MRI', 'timeFrame': '30 min'}, {'measure': 'Insulin Sensitivity', 'description': 'Hyperinsulinemic-Euglycemic Clamp', 'timeFrame': '4.5 hours'}], 'secondaryOutcomes': [{'measure': 'Glomerular Filtration Rate (GFR)', 'description': 'Iohexol Clearance Study', 'timeFrame': '3 hours'}, {'measure': 'Effective Renal Plasma Flow (ERPF)', 'description': 'PAH Clearance Study', 'timeFrame': '2.5 hours'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Age ≥ 18 years at enrollment (rationale: this study focuses on determinants of early DKD over the course of T1D in adults)\\n* T1D duration \\\\>5 years (rationale: DKD in T1D rarely manifests prior to 5 years of disease duration)\\n* HbA1c \\\\<11% (rationale: HbA1c ≥ 11% exceeds the average HbA1c at most academic center and would limiting the generalizability of our study findings)\\n\\nExclusion Criteria:\\n\\n* T2D and monogenic diabetes (rationale: our study focuses on T1D)\\n* Recent diabetic ketoacidosis, i.e., \\\\<1 month (rationale: safety and insulin resistance and tubular dysfunction of DKA can confound study findings)\\n* eGFR \\\\< 30 ml/min/1.73m2 or dialysis treatment (rationale: to reduce the likelihood of identifying secondary pathways that are not specific to kidney injury from T1D)\\n* Kidney transplant recipients (rationale: molecular confounding from immunosuppression)\\n* Kidney biopsy contraindications (rationale: safety - kidney biopsy):\\n\\n  * Evidence of bleeding disorder or complications from bleeding\\n  * Use of aspirin, Nonsteroidal anti-inflammatory drugs (NSAIDS) or other blood thinner that cannot be safely stopped for a sufficient time before and after the biopsy to avoid additional risk of bleeding.\\n  * INR \\\\> 1.4\\n  * Hemoglobin (Hgb) \\\\< 10 mg/dL (Colorado) \\\\[altitude\\\\]\\n  * Hemoglobin (Hgb) \\\\< 9 mg/dL (Washington)\\n  * Platelet count \\\\< 100,000 / µL\\n  * Uncontrolled or difficult to control hypertension (\\\\> 150/90 mmHg at the day of biopsy)\\n  * Single kidney (either by history, documented by prior imaging or ultrasound performed prior to the biopsy)\\n  * Kidney size: One or both kidneys \\\\< 8 cm\\n  * Hydronephrosis or other important renal ultrasound findings such as significant stone disease\\n  * Any evidence of a current urinary tract infection as indicated on day of biopsy\\n  * Clinical evidence of non-diabetic renal disease\\n  * Positive urine pregnancy test or pregnancy', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'The investigators propose to address the specific aims of this study in a cross-sectional project with 70 newly enrolled adults with T1D and 30 former CROCODILE participants (COMIRB #19-1282).', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Carissa Birznieks, MS', 'role': 'CONTACT', 'phone': '720-777-4659', 'email': 'Carissa.Birznieks@childrenscolorado.org'}, {'name': 'Petter M Bjornstad, MD', 'role': 'CONTACT', 'phone': '720-777-4659', 'email': 'petter.m.bjornstad@cuanschutz.edu'}], 'locations': [{'facility': \"Children's Hospital Colorado\", 'status': 'RECRUITING', 'city': 'Aurora', 'state': 'Colorado', 'zip': '80045', 'country': 'United States', 'contacts': [{'name': 'Carissa Birznieks, MS', 'role': 'CONTACT', 'phone': '720-777-4659', 'email': 'Carissa.Birznieks@childrenscolorado.org'}, {'name': 'Petter M Bjornstad, MD', 'role': 'CONTACT', 'phone': '720-777-4659', 'email': 'petter.m.bjornstad@cuanschutz.edu'}], 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D003928', 'term': 'Diabetic Nephropathies'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}, {'id': 'D048909', 'term': 'Diabetes Complications'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M10698', 'name': 'Kidney Diseases', 'asFound': 'Kidney Disease', 'relevance': 'HIGH'}, {'id': 'M7123', 'name': 'Diabetic Nephropathies', 'asFound': 'Diabetic Nephropathy', 'relevance': 'HIGH'}, {'id': 'M26004', 'name': 'Diabetes Complications', 'asFound': 'Diabetes Complications', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M17319', 'name': 'Urologic Diseases', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}, {'id': 'T4392', 'name': 'PANDAS', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'T401', 'name': 'Inulin', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02341690', 'orgStudyIdInfo': {'id': 'INTERWALK'}, 'organization': {'fullName': 'University of Copenhagen', 'class': 'OTHER'}, 'briefTitle': 'Intervention Study - Effectiveness of Smartphone Delivered Interval Walking Training to Patients With Type 2 Diabetes', 'officialTitle': 'The Effectiveness of Smartphone Delivered Interval Walking Training on Physical Activity and Glycemic Control in Patients With Type 2 Diabetes: a Pragmatic Randomized Controlled Trial - Part of The InterWalk Study'}, 'statusModule': {'statusVerifiedDate': '2018-05', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2015-01'}, 'primaryCompletionDateStruct': {'date': '2017-12-17', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2017-12-17', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2015-01-09', 'studyFirstSubmitQcDate': '2015-01-14', 'studyFirstPostDateStruct': {'date': '2015-01-19', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2018-05-23', 'lastUpdatePostDateStruct': {'date': '2018-05-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Laura Staun Valentiner', 'investigatorTitle': 'PhD-student', 'investigatorAffiliation': 'University of Copenhagen'}, 'leadSponsor': {'name': 'University of Copenhagen', 'class': 'OTHER'}, 'collaborators': [{'name': 'Center for Physical Activity Research (CFAS)', 'class': 'UNKNOWN'}, {'name': 'The Danish Center for Strategic Research on Type 2 Diabetes', 'class': 'OTHER'}, {'name': 'The Danish Diabetes Association', 'class': 'OTHER'}, {'name': 'Copenhagen University Hospital Bispebjerg', 'class': 'UNKNOWN'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': \"Type 2 Diabetes (T2D) is one of the most common chronic diseases world vide. Patients with T2D experiences reduced quality of life and have a lower physical activity level. Physical activity is well documented treatment to the patient group. The effect of physical activity is shown to reduce co-morbidity, and better functional level and quality of life.\\n\\nInterval Walking Training (IWT) is a new and effective exercise type. IWT is done by walking in a slow and a fast tempo. InterWalk is an application to a smartphone. By using InterWalk the patient can to IWT independently and when used, the app has, as an exercise tool, the potential to better the individual functional level and to measure the physical activity level with the integrated personalised walking test.\\n\\nMotivation for change of habits and lifestyle is subjectively determined by the individual, his or hers individual resources and environment. It is important to get insight in these individual challenges in order to be better structure possible help.\\n\\nThe combination of an exercise log, a measure of physical activity fromInterWalk and insight in motivational aspects on an individual level, is essential for successful individualised training.\\n\\nThe primary objective of the study is to investigate if the InterWalk app is more effective in increasing the physical activity level compared to a standard care offer in a sample of newly T2D diabetes patients across 52 weeks.\\n\\nSecondarily, we will investigate if the IW app can reduce sitting time, induce weight loss, improve glycaemic control, increase quality of life, improve cardio-respiratory fitness and reduce the use of diabetes medication.\\n\\nThe study is designed to test the hypothesis that replacing a standard exercise program in the normal municipal standard care with the Interval Walking Training delivered by the IW app with and without a motivational support program, can increase the long-term physical activity level in patients with T2D for a period of 52 weeks.\\n\\nFrom January 2015 to June 2016 all patient's with T2D, who are referred to the promotion centres in the municipality, will be offered to participate in the study. In total 513 patients with T2D from different municipalities in Denmark will be included and randomly allocated into three groups. One group will receive standard care and the two other groups will do IWT with the InterWalk app. All three groups are followed by the promotion centre for 8-14 weeks (according to the rehabilitation in the municipality) and hereafter only one of the IWT groups will receive motivational support up to 52 weeks.\\n\\nAll patients, no mater group allocation, will be tested and fulfill questionnaires, three times during the intervention period - at baseline, after 8-14 weeks and after 52 weeks. The interventions take place at the promotion centres in the municipalities two times a week and the patient will be encouraged train by them selves one time a week.\", 'detailedDescription': 'Background Type 2 diabetes (T2D) is one of the most common long-term medical conditions worldwide. The patients have a two-fold increased mortality rate compared to the general population T2D is a major problem in Denmark and the incidence is estimated to rise from 280.000 today to approximately 500.000 people by 2020 (5).\\n\\nThe T2D rehabilitation program in the Danish municipalities has the overall purpose of introducing and helping patients to a healthier lifestyle (6). The program is conducted in a period of 8-14 week with some or no exercise intervention, with no long-term follow-up. Not much is known on the amount and integration of PA in the patient\\'s everyday life following the intervention (7). This major variation across municipalities poses a problem in the rehabilitation of TD2, as the quality of rehabilitation depends on the geographical location of the T2D patient.\\n\\nSeveral studies have shown that supervised PA is advantageous; in patients with T2D on key metabolic factors (6-9) and that it improves quality of life and reduces the risk of all-cause mortality (1,2,6,10,11,12). Due to the many beneficial effects of PA on T2D patients, PA is an important factor in the prevention and treatment of T2D (13). Long-term PA interventions have employed supervised exercise regimes (14,15) that are effective, but also demanding and expensive. Attempts to increase the daily physical activity level on a large scale, in a free-living \"real life\", have very little effect (14-16) despite well-established patient education programs. In general, the exercise adherence is low and dropout rates are high in this group of patients. A large number of patients with T2D experience diminished quality of life, decreased physical functioning, diminished exercise tolerance (17), numerous patients are unmotivated or incapable to change behaviour and the prevalence of depressive and anxiety symptoms are highly prevalent in T2D patients (17,18,19). Collectively this could pose important barriers to engagement in exercise and reaching the recommended level of PA (20).\\n\\nKarstoft et al (2013) examined the feasibility of implementing a free-living interval walking (IWT) and continuous walking training program in a smaller sample of patients with T2D. IWT was initiated and monitored by a Japanese training device, the JD-mate (10). The study found remarkable effects on physical fitness level, body composition and glycaemic control and with a compliance rate of more than 85% and a very low dropout level (9). Based on the experiences by Karstoft et al and several pilot testing\\'s in the Danish Diabetes Association (DF), we believe that IWT can be an approach to handle lack of PA in patients with T2D. However the JD-mate, is expensive (3500 kr.), Japanese instructions, lacks automatic transmission of data and is thus not user-friendly on a larger scale. It is evident that novel low cost, more sustainable exercise solutions and suitable vehicle are needed and through this, improve quality of life and increase life expectancy in these patients.\\n\\nThe use of Tele-Health interventions (THI) have the potential to educate and engage patients with T2D in self-management in the long-term and the evidence suggests that THI could be effective and feasible in improving clinical outcomes in diabetes care (14,15,22,23). The widespread and increasing use of smartphone applications is opening new ways to improve health and health care delivery. It might be ideal to use THI to increase physical activity and hereby target a large part of the population by simple and inexpensive means. The smartphone has been used as a tool among others to register exercise, diet, weight and plasma glucose levels, but the evidence of using a smartphone as an exercise device is lacking (24).\\n\\nIn 2010 the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) and TrygFondens Centre for Aktiv Sundhed (CFAS), Rigshospitalet, Denmark, developed the InterWalk Application (IW app) to the smartphone to promote IWT on a larger scale. IWT has the potential to increase physical activity in a large group of T2D patients and hopefully improve lifestyle in patients with T2D. However, motivation for lifestyle changes is subjectively driven and individually determined (25-27). The personal resources and the close environment are key determinants of how challenges are handled in everyday life (28,29). Motivational factors are important for changing physical activity behaviour in patients with T2D, but knowledge on how motivation is maintained for a sustainable active lifestyle is limited. Studies of the effectiveness of employing smartphones as a vehicle to improve physical activity behaviour in everyday life in the long-term in patients with T2D is therefore needed.\\n\\nAim/purpose - (Hypothesis) The primary objective of the study is to investigate if the InterWalk app is more effective in increasing the moderate-and-vigorous physical activity level compared to a standard care offer in a sample of T2D patients across 52 weeks.\\n\\nSecondarily, we will investigate to what extend the IW app can reduce sitting time, induce weight loss, improve glycaemic control, increase quality of life, improve cardio-respiratory fitness and reduce the use of diabetes medication.\\n\\nThe primary hypothesis is to test the hypothesis, that replacing a standard exercise program in the normal municipal standard care with the Interval Walking Training delivered by the IW app, the patient will become more physical active. The secondary and explorative hypothesis is that motivational support will increase the individual long-term physical activity level in everyday in patients with T2D.\\n\\nMethods Study design The study is a 52-weeks single-blinded pragmatic randomized controlled trial, where the participants are allocated into three arms. Two of the arms will receive IWT with or without additional support. The control arm will receive the standard care. The interventions are delivered by the Danish municipalities. A detailed description of the three arms is found below. The study is carried out in a subgroup of the DD2 cohort.\\n\\nParticipants, Recruitment and eligibility All patients referred to the promotion centre in the municipalities from January 2015 will be screened for eligibility. The patients will be informed about the study and will be given formalized oral and written material, a consent form and a free post envelope. Upon reception of the consent form by the health professional at the municipality, the patient will be contacted by one of the health professionals assigned to the study and a date for the first visit is arranged.\\n\\nEnrolment is anticipated to take approximately 18 month and begins in January 2015, and is expected to be completed in July 2017. The intervention will take place at the promotion centres in municipalities in Denmark.\\n\\nSample size considerations The minimum difference of interest (MDI) is 10 minutes per day. After applying Bonferroni adjustment due to multiple comparisons in the three group trial and shared end-points, a total of 393 participants are needed using an sample SD of 25 minutes per day (30) with an α of 0.017 (two-tailed) to obtain a statistical power (1-β) of 80%. Allowing for an attrition rate of 30%, 513 patients (171 in each group) are allocated in the three arms.\\n\\nAllocation, randomization and concealment Patients are randomized using random permuted blocks (2x2x2) and stratified by gender to ensure an equal number of participants in all groups across the allocation period. The allocation sequence is generated through a standardized computer program by an independent researcher not affiliated to the study and is concealed until the study arms are assigned. Randomization of each patient to one of the three groups in the study is done after the baseline tests have been conducted by the health professionals at the promotion centres. The scientific staff is blinded to the allocation. The health professionals at the promotion centre are not blinded to allocation according to control group (1/3) or intervention groups (1/3: IWT and 1/3: IWTsupport). After the intervention period at the promotion centre, the allocation to either control, IWT or IWTsupport is unsealed to the patients and the health professionals at the promotion centres. The scientific staff is still blinded.\\n\\nInterventions Group 1 (control group): Patients in this group will receive the standard rehabilitation program with the overall purpose of lifestyle changing in T2D patients in a multimodal setting in the municipality including physical activity. In addition to exercise, the rehabilitation consists of education, smoking cessation and dietary change with the purpose of weight loss, motivation groups and self-care. The duration of the rehabilitation differs between municipalities with duration from 8 to 14 weeks. There will be no follow-up from the municipality, which is the normal procedure in the municipality.\\n\\nGroup 2 (IWT with without motivational support after 8-14 weeks): Patients in this group will be engaged to IWT with the IW app (see: The InterWalk Application). The intervention period will follow the period in which the rehabilitation program is carried out in the municipality (duration from 8-14 weeks). The patients are encouraged to perform IWT three times per week, 60 minutes per session. The municipality offers to walk with the patient´s two times per week for 60 minutes per session in group sessions with additional 30 minutes of group discussion afterwards. The last and third time the patients have to walk by themselves for 60 minutes per session. The participating patients will receive a thorough introduction to the IW app and follow-up during the intervention (8-14 weeks) from the health professionals. At the end of the intervention period, the health professionals, conducts a transition program, preparing the patients to continue IWT with IW app on their own. There will be no follow-up from the municipality, which is the normal procedure in the municipality.\\n\\nGroup 3 (IWTsuppport) IWT with motivational support after 8-14 weeks: Patients in this group will like patient´s in intervention group 2 be engaged to IWT with the IW app. The intervention period will be 52 weeks. The first 8-14 weeks will be conducted together with group 2 with a thorough introduction to the IW app and IWT three times per week for 60 minutes. In addition to the IWT from week 0 to 52, the patients in this group will receive motivational support from week 8-14 to week 52 by the health professionals at the promotion centre (see below for information regarding the IW app and the motivational support part).\\n\\nThe InterWalk Application The IW App is a personal trainer as well as a monitor unit, which allows continuous and automatic transmission of physical activity data to a central data base in DD2. The IW app guides the user in IWT with repeated cycles of 3 minutes fast and slow walking. During IWT the app provides the patients with continuous feedback on the walking intensity (10). The feedback is personalized through a standardized eight-minute walking test, performed before engaging in IWT. The patients are able to track exercise history and receive historic feedback on the quality of the IWT sessions. The feedback system employs the on-board accelerometer and GPS system to assess intensity and geographical location.\\n\\nThe patients are obligated to enter their social security (CPR) number before using the app. Uniquely, this will allow the scientific teams to integrate the app into the health care system, link the data with the Danish disease and demographic registers and thus, will enable the study of long term nation-wide effects of IWT in T2D rehabilitation.\\n\\nThe application has been through extensive piloting in different groups of patients with T2D. Information on training intensity, total number of steps per day and IWT-data and data from the standardized walking test is stored on the smartphone or IPod and automatically transmitted to a central database when connected to Wi-Fi or mobile data network.\\n\\nIndividual motivation (IWTsupport) Motivational support will in addition to the IWT be offered in intervention group 2 after the intervention at the promotion centre. The support is initiated and conducted by the health professionals at the promotion centres.\\n\\n* SMS-track: The patient i intervention group 2 will receive motivational support which consists of Short Message Service -Track (SMS-Track), phone calls, goal setting and i motivational interviews (see below). The different parts of the motivation intervention will be handled and executed by the health professionals at the promotion centres in the municipalities.\\n* Short Message Service - Track: The first Sunday after enrolment a SMS-track is send to all patients in either group 2 or 3. The patients will be asked to confirm that they are part of the study, before the next SMS regarding their IWT is send. The patient can receive up to 3 SMS\\'s regarding IWT depending on their answers.\\n* Phone calls: The patient\\'s answers to the SMS-track, constitute whether a personal phone call from a health professional if necessary. The aim of the call is to help and support the patient in continuing to keep doing IWT with IW app. Questions from the health professionals addresses how the patient is doing in general, why the patient has answered that they haven\\'t been doing IWT the past week, questions regarding how to help the patient doing IWT, or questions about the IW app. The patient will have time to ask questions of concern to the health professional.\\n* Standardized walking test: Every 4th week a SMS will be send to the patient regarding new goal setting.\\n\\nIndividual goal setting: To measure the patients motivation for physical activity using the IW app in group 2 and 3, we ask the patients to set individual goals every 4th week, related to their everyday life, during the intervention period (group 2 (4-18 weeks) and group 3 (0-52 weeks) (40) - The goal setting is based on the S.M.A.R.T.-principle where S stands for Specific, M for Measurable, A for achievable , R for relevant and T for timely (41).\\n\\n- IWTsupport group sessions: Patients in group 3 have the opportunity to participate in IWT with other patient and a InterWalk ambassador at the municipality once a week after the intervention at the promotion centre.\\n\\nMotivational interviews: Four motivational interviews will be scheduled for patients in group 2, in the period where the patient no longer is part of the formalised IWT in the municipality (week 12-52). The aim of these interviews is to help he patients to maintain motivation and focus tin prioritizing IWT in their everyday life. The interview will take place at the promotion centre.\\n\\nMeasurements\\n\\n* Level of daily physical activity To evaluate the level of moderate-to-vigorous-intensity physical activity all participants will be equipped with an accelerometer (Axivity AX3, Newcastle, UK) for 10 consecutive days, 3 times during the intervention period - at baseline and after 4-18 weeks and 52 weeks after enrolment. One accelerometer will be placed with patch (Leukomed T, BSN medical, Germany) on the lateral side of the right thigh and one accelerometer on the lumbar spine. The patients will be instructed not to remove the accelerometer during the three periods. The accelerometers can be worn when taking a shower, swimming etc.\\n* Smart-phone administered standardized walking test The walking test in the IW app consists of 5 stages; 1) 30 sec. of standing still, 2) 2 min. of slow walking 3) 2 min. of walking at moderate intensity 4) 2 min. walking at high intensity 5) 1 min. walking at highest intensity possible. The four later paces are self-selected. The test is performed with the Smartphone placed at a pocked at the hip and the instructions are communicated auditory through earphones. To ensure the right walking intensity in the intervention period, the patients are asked to perform the test every 4th week.\\n* Sit-to-Stand Test The test measures the lower body strength and will be administrated using a chair without arms, with a seat height of 43 cm. The patient is encouraged to complete as many full stands as possible within a 30-sec time limit (32).\\n\\nElectronic log of data from IWT to the central database Adherence to the intervention is determined by an evaluation of the electronic log of data from IW app to a central database. All the uploaded data can be quantified into adherence.\\n\\n* Physical Activity Questionnaire \"The Resent Physical Activity Questionnaire\" (RPAQ) is a self-rated physical activity questionnaire. The RPAQ has 9 main questions which covers 4 domains of physical activity: domestic life, work, recreation and transport. Physical Activity is estimated in MET (Metabolic Equivalent) (35).\\n* Short Form -12 (SF-12) The SF-12 was developed as a short form of the 36-item Short-Form Health Survey (SF-36). The questionnaire consists of 12 questions and uses a Likert scale of 1 to 3 for the physical function items; 1 to 5 for the bodily pain, social function, and general health perceptions items; 1 to 6 for the vitality and mental health; and a dichotomous scale of yes/no for the presence of role function limitations. The higher score, the higher level of health or functioning (34).\\n* Behavioural exercise regulation questionnaire (BREQ-2) Behavioural exercise regulation questionnaire (BREQ-2) measures individual motivation for physical activity. The Questionnaire consists of 19 questions in a 0-4 Likert format.\\n* Questions on motivation for physical activity for patients with Type 2 Diabetes All patients will be asked to answer four questions in a 0-4 Likert format, regarding their habits for doing physical activity after being diagnosed with T2D.\\n* Personality Questionnaires The patient will be asked to complete two questionnaire regarding personality, the NEO-Five Factor Inventory (NEO-FFI) and a Sensation Seeking Scale (SES).\\n\\nThe NEO-FFI consists of 60 questions in a 0-4 Likert format constructed by selecting 2 items from each of the six facets characterizing each of the five personality traits (Neuroticism, Extraversion, Openness, Agreeableness, Conscientiousness) assessed by NEO-PI-R (36).\\n\\nThe Sensation Seeking Scale is a 40 items self-administered questionnaire and consists of 40 questions designed to test the tendency towards varied, novel and intense sensations (37). The SES-questionnaire is in its design impertinent as it consists of only two possible response options for each question. The patient will be encouraged to answer the questions, but is not required an answer.\\n\\nWe do not know much about what characterizes the individual to either participate or to decline an intervention e.g. diet, smoking cessation or physical activity. The two personality questionnaires are part of the project because it is essential to get more knowledge on personality traits, risk behavior and adherence to an intervention in this case physical activity. By this knowledge it will be possible to better individualize the intervention and by this hopefully get a higher adherence in the long term.\\n\\n* Monitoring of body temperature To detect possible effects of exercise on mitochondrial function a measure of body temperature with an ear thermometer will be performed. Time of measure, season and weather conditions, diseases within the last week and meals before the measure will be noted.\\n* Demographic and social economic Information: Information on demographic will be obtained using standard procedures (height, weight, waist and hip circumference). The demographic data will be obtained from the patient\\'s journal at the Promotion Centre. A tape measure and a weight will be provided to each promotion centre to ensure standardization among health professionals.\\n* Relevant national registers will be used for information regarding co-morbidities, medical history and use of medicine. All the information from the patient\\'s journal and from relevant registers will be used when all data, from all patients, are collected. The data will be protected by the \"Lov om behandling af personlige oplysninger\" (see \\'Protection of personal information\\', page 12).\\n* Metabolic markers The patients are encouraged to maintain the recommended regular visits every 3th month at the general practitioner (GP) in the intervention period (52 weeks). Results from the visits including the blood sample are collected from the national database DSAM.\\n\\nRisk, side effects, and discomfort General considerations The exercise intervention (Interval Walking Training) is expected as a minimum to be as effective as the standard care programme currently offered to patients with T2D at the municipality. Interval walking Training with the use of a Tele-Health solution is providing patients with T2D with a feasible option on how to implement and maintain a physical active lifestyle in a gentle and flexible way. The intervention is expected to result in remarkably health benefits on a long-term basis in terms of improved increased VO2max, blood glucose regulation, and quality of life and motivation for a more active everyday life.\\n\\nThe study is important and will contribute to great knowledge about how to implement and thus increase public health in a large and growing cohort of patient´s with T2D.\\n\\nMeasurements Smartphone administered walking test: The patients are expected to reach 80-85% of VO2max during the IW walking test. This will cause some degree of breathlessness.\\n\\nAX3 Axivity accelerometers: Due to the patched by which the accelerometers are hold on the thigh and lower bag, itching and redness may occur in allergic subjects. In those cases the subjects are encouraged to remove the patches immediately and if necessary consult a general practitioner. The patients will be informed on procedures in writing containing pictures of the application of accelerometers and possible discomfort.\\n\\nInterval walking training: The IWT will cause some degree of breathlessness in the fast walking interval periods.\\n\\nAnthropometric measurements, sit-to-stand test, temperature, questionnaires and motivational initiatives: These methods are not associated with any known risk or other unpleasant.\\n\\nStatistical analysis All analyses will be conducted according to the Intention-to-treat principle. Mixed model analyses will be employed to determine the group X treatment effects of the intervention across twelve months. The secondary outcomes will be analyzed using the same approach. Assuming that the data on potential drop-outs are missing at random multiple imputation procedures will employed to handle missing data. Patterns of missing data will be investigated. Per protocol analyses will be performed to support the primary analysis.\\n\\nEthical considerations The study is expected to result in limited risks, adverse effects and discomfort to the patients. No invasive methods will be used besides blood samples taken by the GP at regular visits. The patients will benefit from the study in terms of enhanced physical capacity and by introduction to effective training methods.\\n\\nThe randomization of the participating patients into three groups is necessary to evaluate the effectiveness of the InterWalk app. The intervention groups (group 2 and 3) are alike as long as the standard rehabilitation with physical activity proceeds in the municipality. From hereafter only group 3 will be supervised and will receive motivational support from the health professionals. This differentiation between groups is needed in order to obtain insight regarding motivational factors of importance to the individual, to maintain a physical active everyday life.\\n\\nThe two personality questionnaires in the study will help to get insight on personality, physical activity and motivation for behavioural changes (e.g. more physical active everyday life). With this knowledge, the results from the study can help the health professionals at the promotion centres, to better allocate patients with T2D, into a rehabilitation offer adjusted to the individual and not as a standard offer in the municipality.\\n\\nExpected outcomes Performing IWT might be a suitable and effective way to exercise for at large group of patients with T2D. The patient can walk everywhere and IWT can hereby be integrated and maintained in the patient\\'s everyday life. Experiences from the study can be used in planning interventions with the IW app and IWT, to patients with other lifestyle diseases e.g. Constructive Obstructive Pulmonary Lung Disease (COPD) and Heart Diseases. The aim is to obtain lifelong physical activity for the individual in their everyday life.\\n\\nPatient insurance The intervention takes place at the promotion centres in the Municipality and the patient is, if anything should happen during the intervention period, insured by \\'Patient Forsikringen\\'. The law says \\'...personer, der deltager i biomedicinske forsøg m.v., der udføres af private firmaer, foreninger m.v. er omfattet af lovens område, hvis forsøget udføres under direkte ansvar af et sygehus, en statslig højere uddannelsesinstitution m.fl.\\'. The University of Copenhagen is the \\'statslige højere uddannelsesinstitution in this study.\\n\\nProtection of personal information All personal information on the patient\\'s identities are protected by the \"Lov om behandling af personlige oplysninger\". A unique subject ID number will be subscribed to all patients in order to anonymize data. The identification key (ID to personal information) will be encrypted and stored securely and separately from the unique ID number on a secure database. In this way no information on patient´s can be assigned to the ID number. All data is automatically backed up on a secure server. Questionnaires is completed online and automatically uploaded with the ID number to the secure data base.\\n\\nEach promotion centre will be assigned with secured logons to the database and only the health professional assigned to the study, will get logons and will only be able to see the patients included in the study at their promotional centre. The scientific members have access to the secure database and data from all the included patients. All data will be secured in the database and a bag up of all the data is stored in an extern hard disk which is also secured. It is possible to track all logons to the database as well as all tasks done in the database.\\n\\nTo enter the IW app the patients are obligated to enter their CPR number, which immediately are encrypted to protect against inappropriate use of the number from unauthorised people not connected to the study. The health professionals in the municipalities will be educated in data entry and will only have access to their own promotion centre. Only the research team will have access to data processing.\\n\\nThe IW app is already approved by \"Datatilsynet\" (2008-58-0035 (paraplygodkendelse i Region Syddanmark)) and the RCT-study will in addition be reported to \"Datatilsynet\".\\n\\nCompensation There will be no compensation given to the patient. All participating patients are treated in accordance with the national guidelines regarding rehabilitation in the municipality.\\n\\nDissemination The data will be published in international peer-reviewed journals. The results are to be reported according to the CONSORT guidelines (38). All results will be disseminated (negative, positive and inconclusive findings). All result will be published (positive, negative and inconclusive).\\n\\nFor references - see the section \\'References\\''}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2'], 'keywords': ['Type 2 diabetes', 'Interval Walking Training', 'Motivation']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['INVESTIGATOR']}}, 'enrollmentInfo': {'count': 226, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Control', 'type': 'ACTIVE_COMPARATOR', 'description': 'Standard rehabilitation with exercise', 'interventionNames': ['Other: control']}, {'label': 'Intervention (Interval Walking Training)', 'type': 'EXPERIMENTAL', 'description': 'Interval Walking Training with the InterWalk app, 3 times per week, 60 min. per sessions for 52 weeks. The intervention period is divided into\\n\\n1. a period that follows standard care in the municipality (from 8-14 weeks according to the municipality.\\n2. a period (from week 8-14 to week 52) the patients will do Interval Walking on their own.\\n3. After the intervention at the promotion centre (8-14 weeks), the intervention group will be divided into to groups - a Interval Walking group (IWT) and a Interval Walking group with support (IWTsupport).\\n\\nIWTsupport: Patients in this group (after intervention at the promotion centre) will in addition to the IWT receive motivational support from week 8-14 to week 52 by the health professionals at the promotion centre.', 'interventionNames': ['Other: Interval walking training']}], 'interventions': [{'type': 'OTHER', 'name': 'Interval walking training', 'description': 'Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.\\n\\nIWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger', 'armGroupLabels': ['Intervention (Interval Walking Training)']}, {'type': 'OTHER', 'name': 'control', 'description': 'Standard care at the promotion centre in the municipality', 'armGroupLabels': ['Control']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Changes in Physical activity from baseline to 52 weeks, measured with accelerometrics', 'description': 'Physical activity is measured with accelerometrics, where the patient wear two accelerometers (one on the thigh and one on the back) for 7 days at home, at baseline, after 8-14 weeks (according to the muncipality) and after 52 weeks.', 'timeFrame': '52 weeks'}], 'secondaryOutcomes': [{'measure': 'Changes in VO2-peak from baseline to 52 weeks, measured by the standardised walking test (in the InterWalk)', 'description': 'VO2-peak is measured by the standardised walking test (in the InterWalk)', 'timeFrame': '52 weeks'}, {'measure': 'Change in Endurance in the lower extremities from baseline to 52 weeks, measured by sit-to-stand (30 seconds)', 'description': 'Endurance in the lower extremities is measured by sit-to-stand (30 seconds)', 'timeFrame': 'January 2015 to July 2017'}, {'measure': 'Changes in Self-rated physical activity from baseline to 52 weeks, measured by \"The Resent Physical Activity Questionnaire\" (RPAQ)', 'description': 'Self-rated physical activity by \"The Resent Physical Activity Questionnaire\" (RPAQ)', 'timeFrame': '52 weeks'}, {'measure': 'Changes in Health related quality of life from baseline to 52 weeks, measured by SF-12', 'description': 'Health related quality of life by SF-12', 'timeFrame': '52 weeks'}, {'measure': 'Changes in Motivation for physical activity and behaviour change from baseline to 52 weeks, measured by the Behavioural exercise regulation questionnaire (BREQ-2).', 'description': 'Motivation for physical activity and behaviour change will be measure by the Behavioural exercise regulation questionnaire (BREQ-2).', 'timeFrame': '52 weeks'}, {'measure': 'Body temperature, measured by an ear thermometer', 'description': 'Body temperature will be measured by an ear thermometer, to detect possible mitochondrial effects of exercise.', 'timeFrame': '52 weeks'}], 'otherOutcomes': [{'measure': 'Exploratory secondary outcome - Personality (measured once at baseline), measured by the NEO-Five Factor Inventory (NEO-FFI) and a Sensation Seeking Scale (SES).', 'description': 'The patient will be asked to complete two questionnaire regarding personality, the NEO-Five Factor Inventory (NEO-FFI) and a Sensation Seeking Scale (SES).\\n\\nWe do not know much about what characterizes the individual to either participate or to decline an intervention e.g. diet, smoking cessation or physical activity. The two personality questionnaires are part of the project because it is essential to get more knowledge on personality traits, risk behavior and adherence to an intervention in this case physical activity. By this knowledge it will be possible to better individualize the intervention and by this hopefully get a higher adherence in the long term.', 'timeFrame': '12 weeks'}, {'measure': 'Changes in physical activity habits and diabetic motivation from baseline to 52 weeks - patients will be asked to answer 4 questions regarding their physical activity habits', 'description': 'Changing habits is difficult and when having a lifestyle disease it can be even more difficult. It is important to get knowledge on the diabetic motivation for the physical activity habits when being diagnosed with type 2 diabetes.\\n\\nThe patients will be asked to answer 4 questions regarding their physical activity habits at baseline, after 8-14 weeks (according to the municipality) and after 52 weeks.', 'timeFrame': '52 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients are eligible if they are diagnosed with T2D and are more than 18 years of age.\\n\\nExclusion Criteria:\\n\\n* Medical contraindications to exercise e.g. if the patient has developed chronic complications in the locomotive apparatus, e.g. painful osteoarthritis or heart conditions (30,39) and already is participating in other studies at the promotion centres concerning PA.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Laura S Valentiner', 'affiliation': 'University of Copenhagen', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Copenhagen', 'city': 'Copenhagen', 'zip': '1014', 'country': 'Denmark', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}]}, 'referencesModule': {'references': [{'pmid': '19896746', 'type': 'BACKGROUND', 'citation': 'Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 Jan;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007. Epub 2009 Nov 6.'}, {'pmid': '19962207', 'type': 'BACKGROUND', 'citation': 'Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action. Diabetes Res Clin Pract. 2010 Jan;87(1):2-3. doi: 10.1016/j.diabres.2009.11.006. Epub 2009 Dec 4. No abstract available.'}, {'pmid': '23152706', 'type': 'BACKGROUND', 'citation': 'Sorensen HT, Friborg S, Rungby J, Christensen JS, Vaag A, Beck-Nielsen H. The Danish national type 2 diabetes cohort - the DD2 study. Clin Epidemiol. 2012;4(Suppl 1):1-5. doi: 10.2147/CLEP.S31104. Epub 2012 Sep 21. No abstract available. Erratum In: Clin Epidemiol. 2012;4:49.'}, {'pmid': '23543567', 'type': 'BACKGROUND', 'citation': 'Pal K, Eastwood SV, Michie S, Farmer AJ, Barnard ML, Peacock R, Wood B, Inniss JD, Murray E. Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.'}, {'pmid': '23071407', 'type': 'BACKGROUND', 'citation': 'Thomsen RW, Friborg S, Nielsen JS, Schroll H, Johnsen SP. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2): organization of diabetes care in Denmark and supplementary data sources for data collection among DD2 study participants. Clin Epidemiol. 2012;4(Suppl 1):15-9. doi: 10.2147/CLEP.S30082. Epub 2012 Sep 21.'}, {'pmid': '20546267', 'type': 'BACKGROUND', 'citation': 'Pouwer F, Geelhoed-Duijvestijn PH, Tack CJ, Bazelmans E, Beekman AJ, Heine RJ, Snoek FJ. Prevalence of comorbid depression is high in out-patients with Type 1 or Type 2 diabetes mellitus. Results from three out-patient clinics in the Netherlands. Diabet Med. 2010 Feb;27(2):217-24. doi: 10.1111/j.1464-5491.2009.02903.x.'}, {'type': 'BACKGROUND', 'citation': 'Lloyd CE, Hermanns N, Nouwen A, Pouwer F, Underwood L, Winkley K. The epidemiology of depression and diabetes: In: Katon W, May M, Sartorius N, eds. Depression and Diabetes.Oxford:Wiley-Blackwell, 2010'}, {'pmid': '11559268', 'type': 'BACKGROUND', 'citation': 'Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001 Sep 12;286(10):1218-27. doi: 10.1001/jama.286.10.1218.'}, {'pmid': '23002086', 'type': 'BACKGROUND', 'citation': 'Karstoft K, Winding K, Knudsen SH, Nielsen JS, Thomsen C, Pedersen BK, Solomon TP. The effects of free-living interval-walking training on glycemic control, body composition, and physical fitness in type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2013 Feb;36(2):228-36. doi: 10.2337/dc12-0658. Epub 2012 Sep 21.'}, {'pmid': '15920042', 'type': 'BACKGROUND', 'citation': 'Di Loreto C, Fanelli C, Lucidi P, Murdolo G, De Cicco A, Parlanti N, Ranchelli A, Fatone C, Taglioni C, Santeusanio F, De Feo P. Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. Diabetes Care. 2005 Jun;28(6):1295-302. doi: 10.2337/diacare.28.6.1295.'}, {'pmid': '20054522', 'type': 'BACKGROUND', 'citation': 'Sone H, Tanaka S, Iimuro S, Tanaka S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Yamashita H, Ito H, Yoshimura Y, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010 Mar;53(3):419-28. doi: 10.1007/s00125-009-1622-2. Epub 2010 Jan 7.'}, {'pmid': '16451303', 'type': 'BACKGROUND', 'citation': 'Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports. 2006 Feb;16 Suppl 1:3-63. doi: 10.1111/j.1600-0838.2006.00520.x.'}, {'pmid': '23173137', 'type': 'BACKGROUND', 'citation': 'Avery L, Flynn D, van Wersch A, Sniehotta FF, Trenell MI. Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions. Diabetes Care. 2012 Dec;35(12):2681-9. doi: 10.2337/dc11-2452.'}, {'pmid': '23372566', 'type': 'BACKGROUND', 'citation': 'Plotnikoff RC, Costigan SA, Karunamuni ND, Lubans DR. Community-based physical activity interventions for treatment of type 2 diabetes: a systematic review with meta-analysis. Front Endocrinol (Lausanne). 2013 Jan 29;4:3. doi: 10.3389/fendo.2013.00003. eCollection 2013.'}, {'pmid': '17342472', 'type': 'BACKGROUND', 'citation': 'Conn VS, Hafdahl AR, Mehr DR, LeMaster JW, Brown SA, Nielsen PJ. Metabolic effects of interventions to increase exercise in adults with type 2 diabetes. Diabetologia. 2007 May;50(5):913-21. doi: 10.1007/s00125-007-0625-0. Epub 2007 Mar 7.'}, {'pmid': '22681530', 'type': 'BACKGROUND', 'citation': 'Barnard KD, Peyrot M, Holt RI. Psychosocial support for people with diabetes: past, present and future. Diabet Med. 2012 Nov;29(11):1358-60. doi: 10.1111/j.1464-5491.2012.03727.x. No abstract available.'}, {'pmid': '22971291', 'type': 'BACKGROUND', 'citation': 'Beck-Nielsen H, Henriksen JE. [Type 2 diabetes in Denmark]. Ugeskr Laeger. 2012 Sep 10;174(37):2132-8. Danish.'}, {'pmid': '23235644', 'type': 'BACKGROUND', 'citation': 'de Jongh T, Gurol-Urganci I, Vodopivec-Jamsek V, Car J, Atun R. Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD007459. doi: 10.1002/14651858.CD007459.pub2.'}, {'pmid': '21115771', 'type': 'BACKGROUND', 'citation': 'Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, Chasan-Taber L, Albright AL, Braun B; American College of Sports Medicine; American Diabetes Association. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care. 2010 Dec;33(12):2692-6. doi: 10.2337/dc10-1548. No abstract available.'}, {'pmid': '24773254', 'type': 'BACKGROUND', 'citation': 'Little JP, Jung ME, Wright AE, Wright W, Manders RJ. Effects of high-intensity interval exercise versus continuous moderate-intensity exercise on postprandial glycemic control assessed by continuous glucose monitoring in obese adults. Appl Physiol Nutr Metab. 2014 Jul;39(7):835-41. doi: 10.1139/apnm-2013-0512. Epub 2014 Feb 18.'}, {'pmid': '23439183', 'type': 'BACKGROUND', 'citation': 'El-Gayar O, Timsina P, Nawar N, Eid W. Mobile applications for diabetes self-management: status and potential. J Diabetes Sci Technol. 2013 Jan 1;7(1):247-62. doi: 10.1177/193229681300700130.'}, {'pmid': '23792137', 'type': 'BACKGROUND', 'citation': 'El-Gayar O, Timsina P, Nawar N, Eid W. A systematic review of IT for diabetes self-management: are we there yet? Int J Med Inform. 2013 Aug;82(8):637-52. doi: 10.1016/j.ijmedinf.2013.05.006. Epub 2013 Jun 21.'}, {'pmid': '22324486', 'type': 'BACKGROUND', 'citation': 'Ahlin K, Billhult A. Lifestyle changes - a continuous, inner struggle for women with type 2 diabetes: a qualitative study. Scand J Prim Health Care. 2012 Mar;30(1):41-7. doi: 10.3109/02813432.2011.654193. Epub 2012 Feb 12.'}, {'pmid': '18848413', 'type': 'BACKGROUND', 'citation': 'Malpass A, Andrews R, Turner KM. Patients with Type 2 Diabetes experiences of making multiple lifestyle changes: a qualitative study. Patient Educ Couns. 2009 Feb;74(2):258-63. doi: 10.1016/j.pec.2008.08.018. Epub 2008 Oct 9.'}, {'pmid': '17488511', 'type': 'BACKGROUND', 'citation': 'Welschen LM, van Oppen P, Dekker JM, Bouter LM, Stalman WA, Nijpels G. The effectiveness of adding cognitive behavioural therapy aimed at changing lifestyle to managed diabetes care for patients with type 2 diabetes: design of a randomised controlled trial. BMC Public Health. 2007 May 8;7:74. doi: 10.1186/1471-2458-7-74.'}, {'pmid': '16567822', 'type': 'BACKGROUND', 'citation': 'Sarkar U, Fisher L, Schillinger D. Is self-efficacy associated with diabetes self-management across race/ethnicity and health literacy? Diabetes Care. 2006 Apr;29(4):823-9. doi: 10.2337/diacare.29.04.06.dc05-1615.'}, {'pmid': '24442514', 'type': 'BACKGROUND', 'citation': \"Centis E, Trento M, Dei Cas A, Pontiroli AE, De Feo P, Bruno A, Sasdelli AS, Arturi F, Strollo F, Vigili De' Kreutzenberg S, Invitti C, Di Bonito P, Di Mauro M, Pugliese G, Molteni A, Marchesini G. Stage of change and motivation to healthy diet and habitual physical activity in type 2 diabetes. Acta Diabetol. 2014 Aug;51(4):559-66. doi: 10.1007/s00592-013-0551-1. Epub 2014 Jan 20.\"}, {'pmid': '19252168', 'type': 'BACKGROUND', 'citation': 'Ekelund U, Brage S, Griffin SJ, Wareham NJ; ProActive UK Research Group. Objectively measured moderate- and vigorous-intensity physical activity but not sedentary time predicts insulin resistance in high-risk individuals. Diabetes Care. 2009 Jun;32(6):1081-6. doi: 10.2337/dc08-1895. Epub 2009 Feb 27.'}, {'pmid': '23071408', 'type': 'BACKGROUND', 'citation': 'Beck-Nielsen H, Solomon TP, Lauridsen J, Karstoft K, Pedersen BK, Johnsen SP, Nielsen JS, Kryger TB, Sortso C, Vaag A. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: expected outcome from the DD2 project and two intervention studies. Clin Epidemiol. 2012;4(Suppl 1):21-6. doi: 10.2147/CLEP.S30655. Epub 2012 Sep 21.'}, {'pmid': '10380242', 'type': 'BACKGROUND', 'citation': 'Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999 Jun;70(2):113-9. doi: 10.1080/02701367.1999.10608028.'}, {'pmid': '19889820', 'type': 'BACKGROUND', 'citation': 'Besson H, Brage S, Jakes RW, Ekelund U, Wareham NJ. Estimating physical activity energy expenditure, sedentary time, and physical activity intensity by self-report in adults. Am J Clin Nutr. 2010 Jan;91(1):106-14. doi: 10.3945/ajcn.2009.28432. Epub 2009 Nov 4.'}, {'pmid': '8628042', 'type': 'BACKGROUND', 'citation': 'Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33. doi: 10.1097/00005650-199603000-00003.'}, {'pmid': '24667343', 'type': 'BACKGROUND', 'citation': 'Golubic R, May AM, Benjaminsen Borch K, Overvad K, Charles MA, Diaz MJ, Amiano P, Palli D, Valanou E, Vigl M, Franks PW, Wareham N, Ekelund U, Brage S. Validity of electronically administered Recent Physical Activity Questionnaire (RPAQ) in ten European countries. PLoS One. 2014 Mar 25;9(3):e92829. doi: 10.1371/journal.pone.0092829. eCollection 2014. Erratum In: PLoS One. 2014;9(11):e114103.'}, {'pmid': '24584258', 'type': 'BACKGROUND', 'citation': 'Mortensen EL, Flensborg-Madsen T, Molbo D, Christensen U, Osler M, Avlund K, Lund R. Personality in late midlife: associations with demographic factors and cognitive ability. J Aging Health. 2014 Feb;26(1):21-36. doi: 10.1177/0898264313519317.'}, {'pmid': '14242306', 'type': 'BACKGROUND', 'citation': 'KOLIN EA, PRICE L, ZOOB I. DEVELOPMENT OF A SENSATION-SEEKING SCALE. J Consult Psychol. 1964 Dec;28:477-82. doi: 10.1037/h0040995. No abstract available.'}, {'pmid': '20332509', 'type': 'BACKGROUND', 'citation': 'Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c332. doi: 10.1136/bmj.c332.'}, {'pmid': '14660192', 'type': 'BACKGROUND', 'citation': 'Siegert RJ, Taylor WJ. Theoretical aspects of goal-setting and motivation in rehabilitation. Disabil Rehabil. 2004 Jan 7;26(1):1-8. doi: 10.1080/09638280410001644932.'}, {'type': 'BACKGROUND', 'citation': 'Meyer PJ. \"What would you do if you knew you couldn\\'t fail? Creating S.M.A.R.T. Goals\". Attitude is everything: If you want to succeed above and beyond. Meyer Resource Group Incorporated, ISBN 978-0-89811-304-4'}, {'pmid': '36170002', 'type': 'DERIVED', 'citation': 'Thorsen IK, Yang Y, Valentiner LS, Glumer C, Karstoft K, Brond JC, Nielsen RO, Brons C, Christensen R, Nielsen JS, Vaag AA, Pedersen BK, Langberg H, Ried-Larsen M. The Effects of a Lifestyle Intervention Supported by the InterWalk Smartphone App on Increasing Physical Activity Among Persons With Type 2 Diabetes: Parallel-Group, Randomized Trial. JMIR Mhealth Uhealth. 2022 Sep 28;10(9):e30602. doi: 10.2196/30602.'}, {'pmid': '28389489', 'type': 'DERIVED', 'citation': 'Valentiner LS, Ried-Larsen M, Karstoft K, Brinklov CF, Brons C, Nielsen RO, Christensen R, Nielsen JS, Vaag AA, Pedersen BK, Langberg H. Long-term effect of smartphone-delivered Interval Walking Training on physical activity in patients with type 2 diabetes: protocol for a parallel group single-blinded randomised controlled trial. BMJ Open. 2017 Apr 7;7(4):e014036. doi: 10.1136/bmjopen-2016-014036.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00974090', 'orgStudyIdInfo': {'id': '3000-A6'}, 'organization': {'fullName': 'Mitsubishi Tanabe Pharma Corporation', 'class': 'INDUSTRY'}, 'briefTitle': 'Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes', 'officialTitle': 'A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2014-04', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2009-09'}, 'primaryCompletionDateStruct': {'date': '2011-03', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2011-03', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2009-09-08', 'studyFirstSubmitQcDate': '2009-09-09', 'studyFirstPostDateStruct': {'date': '2009-09-10', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2014-04-07', 'resultsFirstSubmitQcDate': '2014-04-07', 'resultsFirstPostDateStruct': {'date': '2014-05-08', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2014-04-07', 'lastUpdatePostDateStruct': {'date': '2014-05-08', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Mitsubishi Tanabe Pharma Corporation', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with Sulfonylurea with an extension treatment for up to 52 weeks.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus'], 'keywords': ['insulin resistance']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 194, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Placebo / Teneli + SU', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Drug: Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)']}, {'label': 'Teneli / Teneli + SU', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Teneli / Teneli + SU']}], 'interventions': [{'type': 'DRUG', 'name': 'Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)', 'description': 'Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea', 'armGroupLabels': ['Placebo / Teneli + SU'], 'otherNames': ['MP-513', 'Amaryl', 'glimepiride']}, {'type': 'DRUG', 'name': 'Teneli / Teneli + SU', 'description': 'Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea', 'armGroupLabels': ['Teneli / Teneli + SU'], 'otherNames': ['MP-513', 'Amaryl', 'glimepiride']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline in HbA1c at Week 12', 'description': 'The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.', 'timeFrame': 'at Week 0 and Week 12'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in Fasting Plasma Glucose at Week 12', 'description': 'The change from Baseline in Fasting Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate.', 'timeFrame': 'at Week 0 and Week 12'}, {'measure': 'Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12', 'description': 'The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate.', 'timeFrame': '0, 0.5, 1, 2 hours post-dose at Week 0 and Week 12'}, {'measure': 'Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12', 'description': 'The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate.', 'timeFrame': 'at Week 0 and Week 12'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients who are 20 - 75 years old\\n* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug\\n* Patients whose HbA1c is between 7.0% and 10.0%\\n* Patients who took Sulfonylurea for diabetes over 12 weeks before administration of investigational drug\\n* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug\\n\\nExclusion Criteria:\\n\\n* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)\\n* Patients with Class III/IV heart failure symptoms according to NYHA functional classification\\n* Patients who are gastrointestinal disorder (diarrhea, vomiting)\\n* Patients with serious diabetic complications\\n* Patients who are the excessive alcohol addicts\\n* Patients with severe hepatic disorder or severe renal disorder\\n* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '20 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Takashi Kadowaki, Professor', 'affiliation': 'Tokyo University', 'role': 'STUDY_DIRECTOR'}, {'name': 'Kazuoki Kondo, MD', 'affiliation': 'Mitsubishi Tanabe Pharma Corporation', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'city': 'Sapporo-shi', 'state': 'Hokkaidou', 'country': 'Japan', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}]}, 'referencesModule': {'references': [{'pmid': '24205974', 'type': 'BACKGROUND', 'citation': 'Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab. 2014 May;16(5):418-25. doi: 10.1111/dom.12235. Epub 2013 Dec 10.'}]}}, 'resultsSection': {'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo / Teneli + SU', 'description': 'Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}, {'id': 'FG001', 'title': 'Teneli / Teneli + SU', 'description': 'Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}], 'periods': [{'title': 'Period 1: Double Blind Period', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '98'}, {'groupId': 'FG001', 'numSubjects': '96'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '95'}, {'groupId': 'FG001', 'numSubjects': '95'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}, {'title': 'Period 2: Open-label Period', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '95'}, {'groupId': 'FG001', 'numSubjects': '95'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '87'}, {'groupId': 'FG001', 'numSubjects': '85'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '10'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '6'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '3'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Placebo / Teneli + SU', 'description': 'Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}, {'id': 'BG001', 'title': 'Teneli / Teneli + SU', 'description': 'Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '98'}, {'groupId': 'BG001', 'value': '96'}, {'groupId': 'BG002', 'value': '194'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '60.3', 'spread': '7.8'}, {'groupId': 'BG001', 'value': '58.4', 'spread': '8.6'}, {'groupId': 'BG002', 'value': '59.4', 'spread': '8.2'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '32'}, {'groupId': 'BG001', 'value': '34'}, {'groupId': 'BG002', 'value': '66'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '66'}, {'groupId': 'BG001', 'value': '62'}, {'groupId': 'BG002', 'value': '128'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in HbA1c at Week 12', 'description': 'The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.', 'populationDescription': 'The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after randomization. Analysis based on last observation carried forward, where the last postbaseline double-blind observed value was carried forward and used for Week 12 where data was missing.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'percentage of HbA1c', 'timeFrame': 'at Week 0 and Week 12', 'groups': [{'id': 'OG000', 'title': 'Placebo / Teneli + SU', 'description': 'Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}, {'id': 'OG001', 'title': 'Teneli / Teneli + SU', 'description': 'Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '98'}, {'groupId': 'OG001', 'value': '96'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.29', 'spread': '0.06'}, {'groupId': 'OG001', 'value': '-0.71', 'spread': '0.06'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Plasma Glucose at Week 12', 'description': 'The change from Baseline in Fasting Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate.', 'populationDescription': 'The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after randomization. Analysis based on last observation carried forward, where the last postbaseline double-blind observed value was carried forward and used for Week 12 where data was missing.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mg / dL', 'timeFrame': 'at Week 0 and Week 12', 'groups': [{'id': 'OG000', 'title': 'Placebo / Teneli + SU', 'description': 'Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}, {'id': 'OG001', 'title': 'Teneli / Teneli + SU', 'description': 'Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '98'}, {'groupId': 'OG001', 'value': '96'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '9.8', 'spread': '2.2'}, {'groupId': 'OG001', 'value': '-17.3', 'spread': '2.2'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12', 'description': 'The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate.', 'populationDescription': 'The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after randomization.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mg・hr/dL', 'timeFrame': '0, 0.5, 1, 2 hours post-dose at Week 0 and Week 12', 'groups': [{'id': 'OG000', 'title': 'Placebo / Teneli + SU', 'description': 'Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}, {'id': 'OG001', 'title': 'Teneli / Teneli + SU', 'description': 'Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '92'}, {'groupId': 'OG001', 'value': '92'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '15.514', 'spread': '6.072'}, {'groupId': 'OG001', 'value': '-65.544', 'spread': '6.072'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12', 'description': 'The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate.', 'populationDescription': 'The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after randomization.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mg / dL', 'timeFrame': 'at Week 0 and Week 12', 'groups': [{'id': 'OG000', 'title': 'Placebo / Teneli + SU', 'description': 'Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}, {'id': 'OG001', 'title': 'Teneli / Teneli + SU', 'description': 'Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '92'}, {'groupId': 'OG001', 'value': '93'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.0', 'spread': '4.4'}, {'groupId': 'OG001', 'value': '-43.1', 'spread': '4.4'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '0', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo/Teneli + SU (Data Through Week 12)', 'description': 'Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride. The adverse events which occured from Week 0 to Week 12 were shown.\\n\\nMedDRA 13.0', 'seriousNumAffected': 2, 'seriousNumAtRisk': 98, 'otherNumAffected': 60, 'otherNumAtRisk': 98}, {'id': 'EG001', 'title': 'Teneli/Teneli + SU (Data Through Week 12)', 'description': 'Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride. The adverse events which occured from Week 0 to Week 12 were shown.\\n\\nMedDRA 13.0', 'seriousNumAffected': 0, 'seriousNumAtRisk': 96, 'otherNumAffected': 62, 'otherNumAtRisk': 96}, {'id': 'EG002', 'title': 'Placebo/Teneli + SU (Data From Week 12 to Week 52)', 'description': 'Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride. The adverse events which occured from Week 12 to Week 52 were shown.\\n\\nMedDRA 13.1', 'seriousNumAffected': 2, 'seriousNumAtRisk': 95, 'otherNumAffected': 89, 'otherNumAtRisk': 95}, {'id': 'EG003', 'title': 'Teneli/Teneli + SU (Data Through Week 52)', 'description': 'Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with glimepiride. The adverse events which occured from Week 12 to Week 52 were shown.\\n\\nMedDRA 13.1', 'seriousNumAffected': 7, 'seriousNumAtRisk': 96, 'otherNumAffected': 89, 'otherNumAtRisk': 96}], 'seriousEvents': [{'term': 'Pneumonia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Sudden hearing loss', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Gastric cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Large intestine carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Maculopathy', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Cataract', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Retinal vein occlusion', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Colonic polyp', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Cholangitis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Bile duct stone', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Loose body in joint', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Ovarian enlargement', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Meniscus lesion', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}], 'otherEvents': [{'term': 'Body tinea', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Bronchitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 8, 'numAtRisk': 96}]}, {'term': 'Bronchopneumonia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Cellulitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Cystitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Dermatitis infected', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Folliculitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Gastroenteritis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 5, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Gastroenteritis vibrio', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Herpes zoster', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Impetigo', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Infected bites', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Influenza', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Nasopharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 16, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 19, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 26, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 32, 'numAtRisk': 96}]}, {'term': 'Onychomycosis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Otitis externa', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Pharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 3, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 4, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 11, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 5, 'numAtRisk': 96}]}, {'term': 'Tinea cruris', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Tinea pedis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Urinary tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Wound infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Anal abscess', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Infected epidermal cyst', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Gingival abscess', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Helicobacter infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Enteritis infectious', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Conjunctivitis bacterial', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Oral herpes', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Lipoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Seborrhoeic keratosis', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Iron deficiency anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Lymphadenitis', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Hypoglycaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 3, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 12, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 9, 'numAtRisk': 96}]}, {'term': 'Depression', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Insomnia', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Sleep disorder', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Cerebral infarction', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Cervicobrachial syndrome', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Diabetic neuropathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 4, 'numAtRisk': 96}]}, {'term': 'Dizziness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Hypoaesthesia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Migraine', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Post herpetic neuralgia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'VIIth nerve paralysis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': \"Parkinson's disease\", 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Carotid arteriosclerosis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Occipital neuralgia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Cataract', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Conjunctivitis', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Conjunctivitis allergic', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 2, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Diabetic retinopathy', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 8, 'numAtRisk': 96}]}, {'term': 'Eyelid ptosis', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Keratitis', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Trichiasis', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Vision blurred', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Visual acuity reduced', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Vitreous floaters', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Normal tension glaucoma', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Tinnitus', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Vertigo', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Vertigo positional', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'External ear pain', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Atrial fibrillation', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Palpitations', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Hypertension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 4, 'numAtRisk': 96}]}, {'term': 'Hot flush', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Asthma', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Bronchitis chronic', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Cough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Emphysema', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Haemoptysis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Pulmonary fibrosis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Rhinitis allergic', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Rhinorrhoea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Sleep apnoea syndrome', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Upper respiratory tract inflammation', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 3, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 5, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 7, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 9, 'numAtRisk': 96}]}, {'term': 'Oropharyngeal discomfort', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Abdominal discomfort', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Abdominal distension', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Abdominal pain upper', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Cheilitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Colonic polyp', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Constipation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 6, 'numAtRisk': 96}]}, {'term': 'Dental caries', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Diarrhoea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 3, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 4, 'numAtRisk': 96}]}, {'term': 'Duodenal ulcer', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Dyspepsia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Enterocolitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Flatulence', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Gastric ulcer', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Gastritis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Gastritis atrophic', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Gastritis erosive', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Gingivitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Haemorrhoids', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Nausea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Periodontal disease', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 2, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 4, 'numAtRisk': 96}]}, {'term': 'Periodontitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 4, 'numAtRisk': 96}]}, {'term': 'Periproctitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Reflux oesophagitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Stomatitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Toothache', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Hepatic function abnormal', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Hepatic steatosis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Jaundice', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Cutaneous amyloidosis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Dermatitis contact', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Drug eruption', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Eczema', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 4, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 6, 'numAtRisk': 96}]}, {'term': 'Eczema asteatotic', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Eczema nummular', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Erythema', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Haemorrhage subcutaneous', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Heat rash', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Hyperhidrosis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Hyperkeratosis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Intertrigo', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Papule', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Photosensitivity reaction', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Pruritus', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Pustular psoriasis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Rash', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Seborrhoeic dermatitis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Senile pruritus', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Urticaria', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Xeroderma', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Hyperkeratosis palmaris and plantaris', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Pruritus generalised', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Toxic skin eruption', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Arthralgia', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 10, 'numAtRisk': 96}]}, {'term': 'Arthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Back pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Lumbar spinal stenosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Musculoskeletal pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Myalgia', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 2, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Osteoarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Pain in extremity', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Periarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 3, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 4, 'numAtRisk': 96}]}, {'term': 'Spinal osteoarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Tendonitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Trigger finger', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Intervertebral disc protrusion', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Musculoskeletal chest pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Musculoskeletal stiffness', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Calculus ureteric', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Hypertonic bladder', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Nephrolithiasis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Pollakiuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Benign prostatic hyperplasia', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Dysmenorrhoea', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Erectile dysfunction', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Chest pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Feeling abnormal', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Malaise', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Oedema peripheral', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Thirst', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Alanine aminotransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 4, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 6, 'numAtRisk': 96}]}, {'term': 'Aspartate aminotransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 4, 'numAtRisk': 96}]}, {'term': 'Blood creatine phosphokinase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 2, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 8, 'numAtRisk': 96}]}, {'term': 'Blood potassium increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Blood pressure decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Blood triglycerides increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 2, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 3, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 4, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 5, 'numAtRisk': 96}]}, {'term': 'Blood urea increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Blood uric acid increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 4, 'numAtRisk': 96}]}, {'term': 'Gamma-glutamyltransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Glucose urine present', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 21, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 17, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 11, 'numAtRisk': 96}]}, {'term': 'Blood urine present', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 3, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 7, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 6, 'numAtRisk': 96}]}, {'term': 'Platelet count decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'White blood cell count decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'White blood cell count increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Protein urine present', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 5, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 4, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 13, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 16, 'numAtRisk': 96}]}, {'term': 'Urine ketone body present', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 2, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 6, 'numAtRisk': 96}]}, {'term': 'Blood alkaline phosphatase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 2, 'numAtRisk': 96}]}, {'term': 'Carotid intima-media thickness increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Helicobacter test positive', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Animal bite', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Arthropod sting', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 5, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 5, 'numAtRisk': 96}]}, {'term': 'Bite', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Eye penetration', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Foot fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Foreign body in eye', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Hand fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Joint dislocation', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Joint sprain', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Muscle injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Muscle rupture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Nail avulsion', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Stab wound', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Tendon rupture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Excoriation', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Muscle strain', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Contusion', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 3, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 6, 'numAtRisk': 96}]}, {'term': 'Thermal burn', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Skin laceration', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Open wound', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 3, 'numAtRisk': 96}]}, {'term': 'Skeletal injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Ear abrasion', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Procedural hypotension', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Tooth fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Avulsion fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 1, 'numAtRisk': 96}]}, {'term': 'Loose body in joint', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 13.0', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}, {'term': 'Meniscus lesion', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 13.0 and 13.1', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 98}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 96}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 95}, {'groupId': 'EG003', 'numAffected': 0, 'numAtRisk': 96}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictionType': 'OTHER', 'restrictiveAgreement': True}, 'pointOfContact': {'title': 'Clinical Trials, Information Desk', 'organization': 'Mitsubishi Tanabe Pharma Corporation', 'email': 'cti-inq-ml@ml.mt-pharma.co.jp'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M10370', 'name': 'Insulin Resistance', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C057619', 'term': 'Glimepiride'}], 'ancestors': [{'id': 'D000889', 'term': 'Anti-Arrhythmia Agents'}, {'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D007166', 'term': 'Immunosuppressive Agents'}, {'id': 'D007155', 'term': 'Immunologic Factors'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M252104', 'name': 'Glimepiride', 'asFound': 'Kinase', 'relevance': 'HIGH'}, {'id': 'M4213', 'name': 'Anti-Arrhythmia Agents', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'}, {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AnArAg', 'name': 'Anti-Arrhythmia Agents'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05162690', 'orgStudyIdInfo': {'id': 'PGIMER1'}, 'organization': {'fullName': 'PGIMER', 'class': 'UNKNOWN'}, 'briefTitle': 'Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy', 'officialTitle': 'Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy: A Randomized Placebo Controlled Trial', 'acronym': 'DINE'}, 'statusModule': {'statusVerifiedDate': '2022-06', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-05-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2023-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-10-27', 'studyFirstSubmitQcDate': '2021-12-06', 'studyFirstPostDateStruct': {'date': '2021-12-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-06-02', 'lastUpdatePostDateStruct': {'date': '2022-06-07', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Ashu Rastogi', 'investigatorTitle': 'Associate Professor', 'investigatorAffiliation': 'Post Graduate Institute of Medical Education and Research, Chandigarh'}, 'leadSponsor': {'name': 'Post Graduate Institute of Medical Education and Research, Chandigarh', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'Diabetic peripheral neuropathy(DPN) is a length dependent axonal neuropathy that affects at least 50% of patients with diabetes mellitus. DPN is often asymptomatic during the early stages of diabetes ,however, once symptoms and overt deficits have developed, it cannot be reversed. Early diagnosis of neuropathy is important because early diagnosis and timely intervention might prevent the development and progression of diabetic neuropathy.Though glycemic control has been shown to prevent the progression of diabetic microvascular complications including diabetic peripheral neuropathy in Type I DM, such strict glycemic control has not shown to improve diabetic peripheral neuropathy in Type 2 DM. There are only few animal studies conducted so far which have shown that the use of SGLT2 inhibitors prevents the progression of diabetic peripheral neuropathy.Thus the investigators postulate that the use of SGLT2 inhibitor in patients with Type 2 Diabetes Mellitus might be beneficial in the prevention of progression of diabetic peripheral neuropathy as well as reverse it.', 'detailedDescription': 'Diabetic peripheral neuropathy is a length dependent axonal neuropathy that affects at least 50% of patients with diabetes mellitus. It is characterized by sensory loss and pain that initially affects small unmyelinated C fibers which is followed by involvement of the large myelinated fibers as diabetes progresses. DPN is often asymptomatic during the early stages of diabetes ,however, once symptoms and overt deficits have developed, it cannot be reversed. Early diagnosis of neuropathy is thus important because early diagnosis and timely intervention might prevent the development and progression if diabetic neuropathy and might provide us with a means to identify patients at high risk for future complications of DPN which includes risk of foot ulcers and lower limb amputation.\\n\\nMethods to quantify neuropathy include clinical scores based on symptoms and neurological tests, quantitative sensory testing, electrophysiological measurements, in the form of nerve conduction studies and intraepidermal nerve fiber density in skin biopsy specimens. The neurological examination involves an assessment, such as modified neuropathy disability score, a composite score that assesses touch, temperature and vibration perception and reflexes, which require expert clinical judgement, a strong element of subjectivity and hence poor reproducibility. Neurophysiology is objective and reproducible and is currently considered to be the most reliable measurements for confirming the diagnosis of diabetic neuropathy. However, these measures mainly assess large nerve fibers, making them less sensitive to early DPN,which is more likely to involve the small fibers to begin with.\\n\\nObjective measures are thus required to accurately determine nerve pathology to detect early stages of DPN, which may be more susceptible to intervention than late-stage sequelae. Small ﬁbers, which constitute 70-90% of peripheral nerve ﬁber, may be measured in skin biopsies by assessing intraepidermal nerve ﬁber density, which is considered to be the gold standard for the evaluation of small fibers damage. Indeed, the European Federation of the Neurological Societies and the Peripheral Nerve Society endorse intraepidermal nerve fiber quantification to confirm the clinical diagnosis of small fiber neuropathy with a strong (Level A)recommendation.\\n\\nRecently, corneal confocal microscopy (CCM), a noninvasive modality for the study of the human cornea, has emerged as a promising technique for the detection of small nerve ﬁber alterations. CCM is a rapid non-invasive imaging technique for the quantitative assessment of small fiber damage. Several studies have shown that it has good diagnostic utility for sub-clinical DPN, predicts incident DPN and correlates with other measures of neuropathy . Furthermore, automated quantification of corneal nerve parameters allows rapid, unbiased and objective assessment of small fiber damage with comparable diagnostic capability to intraepithelial nerve fiber density (IENFD). Recent data also suggest that CCM shows good reproducibility and could be useful to document nerve regeneration after treatment and simultaneous pancreas and kidney transplantation.\\n\\nThere is currently no Food and Drug Administration (FDA) approved therapy to prevent or reverse human DPN. The current management approach focuses on reasonable glycemic control, and management of associated pain. Sodium-glucose cotransporter 2 (SGLT2) inhibitors as oral hypoglycemic agents have been approved for treating type 2 diabetes mellitus (T2DM). The insulin-independent action mechanism and extra-metabolic benefits of these agents have encouraged ongoing preclinical and clinical trials for evaluating the efficacy and safety of SGLT2 inhibitors. In addition to glucose-lowering effects without hypoglycemia, SGLT2 inhibitors retard the development and progression of diabetic complications. However, it is uncertain whether this effect of SGLT2 inhibitors is due to their glucose-lowering effect or not. In addition, unlike diabetic nephropathy, the effects of SGLT2 inhibitors on diabetic peripheral neuropathy are unexplored.\\n\\nTo date, only three studies regarding the effects of SGLT2 inhibitors for DPN in T2DM animal models are reported. Investigators evaluated neuronal effects in terms of simple functional parameters, such as motor nerve conduction velocity and tail flick test. Results of these studies verified the beneficial effects of SGLT2 inhibitors for DPN, and these effects were considered to indirect effects of the improvement of hyperglycemia.\\n\\nSince no human studies have yet been conducted using SGLT2 inhibitors in the prevention and progression of diabetic neuropathy, hence, investigators plan to conduct a randomized controlled trial evaluating the efficacy of dapagliflozin in diabetic peripheral neuropathy'}, 'conditionsModule': {'conditions': ['Diabetic Peripheral Neuropathy'], 'keywords': ['Diabetes', 'SGLT2 inhibitors', 'dapagliflozin', 'CCM', 'IENFD', 'Skin Biopsy', 'Peripheral Neuropathy', 'Corneal confocal microscopy', 'intraepithelial nerve fiber density', 'Diabetic Sensory Polyneuropathy(DSPN)', 'DSPN']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'The Drug Arm', 'type': 'ACTIVE_COMPARATOR', 'description': 'Dapagliflozin 10 milligram Once a day\\n\\n1 year', 'interventionNames': ['Drug: Dapagliflozin 10 milligram']}, {'label': 'The Placebo Arm', 'type': 'PLACEBO_COMPARATOR', 'description': 'Metformin 1gram Per Oral Twice a day Glimepiride 2 milligram oral twice a day Dipeptidyl peptidase 4 inhibitors (DPP4 inhibitors)', 'interventionNames': ['Other: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Dapagliflozin 10 milligram', 'description': '10mg per day of Dapagliflozin will be given to the patients', 'armGroupLabels': ['The Drug Arm']}, {'type': 'OTHER', 'name': 'Placebo', 'description': 'Metformin DPP4 inhibitors', 'armGroupLabels': ['The Placebo Arm']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Intraepithelial nerve fiber density', 'description': 'mean change in intraepithelial nerve fiber density(F/mm) will be evaluate at baseline and after 24 weeks of treatment with dapagliflozin.', 'timeFrame': '24 weeks'}], 'secondaryOutcomes': [{'measure': 'corneal nerve fiber density', 'description': 'mean change in corneal nerve fiber density (total number of nerves per square millimeter of corneal tissue) will be evaluated at baseline and after 24 weeks of treatment with dapagliflozin.', 'timeFrame': '24 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n-\\n\\nType 2 Diabetes Mellitus \\\\< 5 years duration\\n\\nAge \\\\>18yrs\\n\\nPresence of neuropathy at baseline (accessed by Michigan Neuropathy Screening Instrument score \\\\>7 )\\n\\nestimated Glomerular Filtration rate (eGFR) \\\\> 45ml/min/m2\\n\\nHBA1c \\\\< 9\\n\\nExclusion Criteria:\\n\\nUntreated Hypothyroidism\\n\\nPatients currently on SGLT2 inhibitors History of Leprosy\\n\\nPatients with history of and current foot ulcers\\n\\nPresence of Peripheral Vascular disease(ABI \\\\<0.9)\\n\\nB12(\\\\<200 pg/ml)/ Folate (\\\\<4.6 ng/ml)\\n\\nHistory of alcohol abuse (\\\\>2 standard drink per day for males and \\\\>1 standard drink for females)\\n\\nFactors affecting corneal nerves( severe dry eyes, severe corneal dystrophies, ocular trauma or surgery in the preceding 6 months)\\n\\nNegative consent\\n\\n-', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Ashu Rastogi, MD, DM', 'role': 'CONTACT', 'phone': '9781001046', 'email': 'rastogi.ashu@pgi.ac.in'}], 'overallOfficials': [{'name': 'Ashu Rastogi, DM', 'affiliation': 'PGIMER, India', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Department of Endocrinology, PGIMER', 'status': 'RECRUITING', 'city': 'Chandigarh', 'zip': '160012', 'country': 'India', 'contacts': [{'name': 'Ashu Rastogi, DM', 'role': 'CONTACT', 'phone': '9781001046', 'email': 'rastogi.ashu@pgimer.ac.in'}], 'geoPoint': {'lat': 30.73629, 'lon': 76.7884}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010523', 'term': 'Peripheral Nervous System Diseases'}], 'ancestors': [{'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M13432', 'name': 'Peripheral Nervous System Diseases', 'asFound': 'Peripheral Neuropathy', 'relevance': 'HIGH'}, {'id': 'M13999', 'name': 'Polyneuropathies', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C529054', 'term': 'Dapagliflozin'}], 'ancestors': [{'id': 'D000077203', 'term': 'Sodium-Glucose Transporter 2 Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M11667', 'name': 'Metformin', 'relevance': 'LOW'}, {'id': 'M348449', 'name': 'Dapagliflozin', 'asFound': 'Opioid', 'relevance': 'HIGH'}, {'id': 'M1691', 'name': 'Sodium-Glucose Transporter 2 Inhibitors', 'relevance': 'LOW'}, {'id': 'M27957', 'name': 'Dipeptidyl-Peptidase IV Inhibitors', 'relevance': 'LOW'}, {'id': 'M252104', 'name': 'Glimepiride', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AnArAg', 'name': 'Anti-Arrhythmia Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03862690', 'orgStudyIdInfo': {'id': 'BIASP-4439'}, 'secondaryIdInfos': [{'id': 'U1111-1208-5168', 'type': 'OTHER', 'domain': 'World Health Organization (WHO)'}], 'organization': {'fullName': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}, 'briefTitle': 'A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria', 'officialTitle': 'A Prospective Non-interventional Study Investigating the Treatment Effect of NovoMix® 30 (Biphasic Insulin Aspart 30) in a Real World Adult Population With Type 2 Diabetes in Algeria', 'acronym': 'B Simple'}, 'statusModule': {'statusVerifiedDate': '2020-07', 'overallStatus': 'WITHDRAWN', 'whyStopped': 'Sponsor decision', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2020-05-28', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2021-06-28', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2021-06-28', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2019-02-25', 'studyFirstSubmitQcDate': '2019-03-01', 'studyFirstPostDateStruct': {'date': '2019-03-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-07-17', 'lastUpdatePostDateStruct': {'date': '2020-07-20', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"The purpose of the study is to collect information about how NovoMix® 30 works in real world adult population with type 2 diabetes. Participants will get NovoMix® 30 as prescribed by the study doctor. The study will last for about 6-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their study doctor's appointment.\"}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Participants with Type 2 Diabetes Mellitus', 'description': 'A broad adult population of patients with type 2 diabetes (T2D) requiring insulin therapy in different basal-bolus treatment regimens.', 'interventionNames': ['Drug: BIAsp 30']}], 'interventions': [{'type': 'DRUG', 'name': 'BIAsp 30', 'description': \"Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.\", 'armGroupLabels': ['Participants with Type 2 Diabetes Mellitus'], 'otherNames': ['NovoMix®']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in glycosylated haemoglobin A1c (HbA1c)', 'description': 'Measured in % point.', 'timeFrame': 'From baseline (week 0) to end of study (week 24)'}], 'secondaryOutcomes': [{'measure': 'Participants achieving HbA1c below 7.0%', 'description': 'Number of participants achieving HbA1c less than 7.0% at end of study (week 24) (yes/no).', 'timeFrame': 'At end of study (week 24)'}, {'measure': 'Particpants achieving HbA1c below 7.5%', 'description': 'Number of participants achieving HbA1c less than 7.5% at end of study (week 24) (yes/no).', 'timeFrame': 'At end of study (week 24)'}, {'measure': 'Partcipants achieving HbA1c below 8.0%', 'description': 'Number of participants achieving HbA1c less than 8.0% at end of study (week 24) (yes/no).', 'timeFrame': 'At end of study (week 24)'}, {'measure': 'Change in rate of severe hypoglycaemia', 'description': 'Measured in episodes/person-year.', 'timeFrame': 'From baseline (week 0) to end of study visit (as recalled at week 24)'}, {'measure': 'Change in total insulin dose', 'description': 'Measured in units/day.', 'timeFrame': 'From baseline (week 0) to end of study (week 24)'}, {'measure': 'Change in Diabetes Treatment Satisfaction (DTSQ) score', 'description': \"The DTSQs is a self-completion questionnaire used to assess subject's treatment satisfaction. The DTSQ total score will be based on item 1 and 4-8, which are scored on a scale from 0 to 36, a higher score related to a better perception of treatment satisfaction. Items 2 and 3 will be reported separately on a scale from 0 to 6 as per instruction in the DTSQs manual.\", 'timeFrame': 'From baseline (week 0) to end of study (week 24)'}, {'measure': 'Change in health-related quality of life (EQ-5D)', 'description': \"The EQ-5D questionnaire will be used to assess subject's health-related quality of life. This instrument contains 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and measures 5 levels of severity (no problems, slight problems, moderate problems, severe problems and extreme problems). The EQ visual analogue scale (EQ VAS) records the patient's self-rated health on a vertical VAS with scores 0-100.\", 'timeFrame': 'From baseline (week 0) to end of study (week 24)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)\\n* The decision to initiate treatment with commercially available NovoMix® 30 has been made by the patient and the treating physician before and independently from the decision to include the patient in this study\\n* Male or female, greater than or equal to 19 years at the time of signing informed consent\\n* Diagnosed with type 2 diabetes and treated with basal insulin plus 1-3 bolus insulin injections per day for at least 24 weeks prior to informed consent\\n* Available and documented HbA1c value less than or equal to 12 weeks prior to initiation of NovoMix® 30 treatment\\n\\nExclusion Criteria:\\n\\n* Previous participation in this study. Participation is defined as having given informed consent in this study\\n* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation\\n* Participation in any clinical trial of an approved or non- approved investigational medicinal product within 24 weeks prior to initiation of NovoMix® 30 treatment. Clinical trials do not include non-interventional studies\\n* Hypersensitivity to NovoMix® 30 or to any of the excipients\\n* Pregnancy or intention of becoming pregnant', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '19 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Participants with type 2 diabetes mellitus, previously treated with basal insulin plus 1-3 bolus insulin injections per day for at least 24 weeks prior to the study,', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Clinical Reporting Anchor and Disclosure 1452', 'affiliation': 'Novo Nordisk A/S', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Novo Nordisk Investigational Site', 'city': 'Algiers', 'zip': 'P.C. 16000, Hydra', 'country': 'Algeria', 'geoPoint': {'lat': 36.73225, 'lon': 3.08746}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Constantine', 'zip': '25000', 'country': 'Algeria', 'geoPoint': {'lat': 36.365, 'lon': 6.61472}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'According to the Novo Nordisk disclosure commitment on novonordisk-trials.com', 'url': 'https://www.novonordisk-trials.com'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C557564', 'term': 'Insulin aspart, insulin aspart protamine drug combination 30:70'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M29801', 'name': 'Insulin Aspart', 'relevance': 'LOW'}, {'id': 'M29799', 'name': 'Biphasic Insulins', 'relevance': 'LOW'}, {'id': 'M14342', 'name': 'Protamines', 'relevance': 'LOW'}, {'id': 'M350709', 'name': 'Insulin aspart, insulin aspart protamine drug combination 30:70', 'asFound': 'CB 2041', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Coag', 'name': 'Coagulants'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01947790', 'orgStudyIdInfo': {'id': '2013Wze051'}, 'organization': {'fullName': 'Wuhan General Hospital of Guangzhou Military Command', 'class': 'OTHER'}, 'briefTitle': 'Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease', 'officialTitle': 'Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease'}, 'statusModule': {'statusVerifiedDate': '2015-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-09'}, 'primaryCompletionDateStruct': {'date': '2015-07', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2015-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2013-09-02', 'studyFirstSubmitQcDate': '2013-09-17', 'studyFirstPostDateStruct': {'date': '2013-09-20', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-08-17', 'lastUpdatePostDateStruct': {'date': '2015-08-19', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Xiang Guang-da', 'investigatorTitle': 'Pioglitazone regress the left ventricular mass in normotensive type 2 diabetic patients with ischeamia heart disease', 'investigatorAffiliation': 'Wuhan General Hospital of Guangzhou Military Command'}, 'leadSponsor': {'name': 'Xiang Guang-da', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'Cardiovascular complications account for the highest mortality in type 2 diabetic patients, mainly due to ischeamia heart disease (IHD). Most of the attention in treating IHD in type 2 diabetes is understandably directed toward treating coronary artery conditions. However there are other treatable culprits in these patients.\\n\\nLeft ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with IHD, even in the absence of hypertension. It is a strong predictor of cardiovascular events and all-cause mortality. In one study, the presence of LVH was a stronger predictor of mortality than either multivessel coronary disease or impaired left ventricular function. Regression of LVH has been associated with an improved prognosis, independent of change in blood pressure (BP). Therefore, cardiovascular events and mortality in type 2 diabetes with IHD might will be reduced if we can find novel therapies to regress LVH.\\n\\nPioglitazone can improve atherosclerosis. Therefore, we hypothesied that pioglitazone can regress the left ventricular mass (LVM) in type 2 diabetes with IHD.Therefore, in this study, we will treat patients with pioglitazone, and we will also metformin as control.'}, 'conditionsModule': {'conditions': ['LVM', 'Type 2 Diabetic Patients With IHD', 'Endothelial Function'], 'keywords': ['Type 2 diabetes', 'left ventricular mass', 'pioglitazone']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 120, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Pioglitazone group', 'type': 'EXPERIMENTAL', 'description': 'Pioglitazone 15 mg/day will be given in this group for 9 months', 'interventionNames': ['Drug: pioglitazone group']}, {'label': 'Metformin group', 'type': 'ACTIVE_COMPARATOR', 'description': 'Metformin 0.85 twice daily will be given in this group for 9 months as control.', 'interventionNames': ['Drug: Metformin group']}], 'interventions': [{'type': 'DRUG', 'name': 'pioglitazone group', 'armGroupLabels': ['Pioglitazone group']}, {'type': 'DRUG', 'name': 'Metformin group', 'armGroupLabels': ['Metformin group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The changes of LVM', 'timeFrame': 'The LVM will be measured at baseline, 6 momth and 9 month'}], 'secondaryOutcomes': [{'measure': 'The changes of endothelial function', 'timeFrame': 'The endothelial function will be measured at baseline, 6 month and 9 month'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* type 2 diabetes\\n* aged 40～75 years old\\n* with IHD\\n\\nExclusion Criteria:\\n\\n* heart failure\\n* renal failure\\n* hypertension (\\\\>130/80 mmHg)\\n* hemoglobin A1c 9%', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '40 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'city': 'Wuhan City', 'state': 'Hubei', 'zip': '43000', 'country': 'China'}, {'facility': 'Xiang Guangda', 'city': 'Wuhan', 'state': 'Hubei', 'zip': '430070', 'country': 'China', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M9419', 'name': 'Heart Diseases', 'asFound': 'Heart Disease', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D008687', 'term': 'Metformin'}, {'id': 'D000077205', 'term': 'Pioglitazone'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M11667', 'name': 'Metformin', 'asFound': 'Tumor', 'relevance': 'HIGH'}, {'id': 'M1693', 'name': 'Pioglitazone', 'asFound': '/min', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02068638', 'orgStudyIdInfo': {'id': '001/14'}, 'secondaryIdInfos': [{'id': '320030_149321/1', 'type': 'OTHER', 'domain': 'Swiss National Science Foundation (SNF)'}, {'id': '191/10', 'type': 'OTHER', 'domain': 'Ethics Committee (approval of measurements for healthy controls)'}], 'organization': {'fullName': 'Insel Gruppe AG, University Hospital Bern', 'class': 'OTHER'}, 'briefTitle': 'Impact of Physical Activity on Blood Glucose Stability and Energy Stores in Individuals With Type 1 Diabetes', 'officialTitle': 'Exercise-related Fuel Metabolism and Glucose Stability in Individuals With Type 1 Diabetes Mellitus', 'acronym': 'CARBEX1'}, 'statusModule': {'statusVerifiedDate': '2016-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2014-02'}, 'primaryCompletionDateStruct': {'date': '2016-07', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2016-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2014-02-18', 'studyFirstSubmitQcDate': '2014-02-19', 'studyFirstPostDateStruct': {'date': '2014-02-21', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2016-08-09', 'lastUpdatePostDateStruct': {'date': '2016-08-10', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Insel Gruppe AG, University Hospital Bern', 'class': 'OTHER'}, 'collaborators': [{'name': 'University of Bern', 'class': 'OTHER'}, {'name': 'University of Lausanne', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Whereas physical activity clearly results in improvements in glycemic control in type 2 diabetes, in individuals with type 1 diabetes (T1DM) the impact of exercise on blood sugar control is more complex. In type 1 diabetes T1DM the inability to reduce exogenous insulin levels during exercise is a key factor that contributes to an increased risk of exercise-induced hypoglycemia. Since rapid adaptation of insulin dosage may be especially difficult in patients on a multiple daily injection regimen, alternative strategies are required to improve exercise-associated glucose stability. There is increasing evidence that the combination of steady state continuous low to moderate intensity exercise with short bursts of high intensity exertion (eg in the form of sprints) is an effective, well tolerated, novel strategy to prevent exercise-related hypoglycemia. A further promising option to stabilize blood sugar levels during and after exercise may be the ingestion of fructose in addition to glucose in form of a sport drink.', 'detailedDescription': 'Background\\n\\nRegular physical activity enhances insulin sensitivity in both healthy subjects and patients with diabetes mellitus. However, while the effects of physical activity on glucose control are undoubtedly beneficial in patients with type 2 diabetes, exercise can cause major disturbances in blood glucose levels in type 1 diabetic individuals. Hypoglycemia is a common complication in patients with T1DM engaging in endurance activities such as running and cycling. So far there are limited strategies suggested to improve exercise-related blood sugar self-management. Current recommendations focus on variation in timing and dosage of insulin administration and adjustments in carbohydrate intake. Since rapid adaptation of insulin dosage may be difficult, alternative strategies to improve exercise-related glucose stability are required. Increasing evidence suggests that intermittent high intensity exercise (IHE), by triggering a counterregulatory hormone response, may counter-balance the risk of exercise-associated hypoglycemia. However, previous studies investigating IHE in T1DM were limited by heterogeneous study populations, comparably short exercise protocols, and deficits in standardization procedures. In addition, a comprehensive assessment of the underlying fuel metabolism has not been performed so far. As a consequence, the results remain controversial and their interpretation as well as applicability are restricted.\\n\\nA further alternative strategy to maintain stable glycemia during exercise may be deduced from recent studies in non-diabetic individuals suggesting that the combined ingestion of fructose and glucose during exercise provides the liver with an increased amount of gluconeogenic precursors, thereby reducing consumption of endogenous glycogen stores.Moreover, conversion of fructose into glucose and lactate may provide constant and efficient fuel for working muscles. However, studies assessing the impact of fructose ingestion during exercise in patients with T1DM have not been performed so far.\\n\\nObjective\\n\\nThe investigators aim to assess the impact of two novel non-pharmaceutical and easily feasible approaches on exercise-related blood glucose stability and its underlying exercise-related fuel metabolism in patients with T1DM.\\n\\nSubstudy A will assess the influence on exercise-related glycemia and fuel metabolism of an IHE protocol compared to an iso-energetic continuous exercise (CONT). It will be investigated whether individuals reach more stable blood glucose levels when engaging in IHE compared to CONT.\\n\\nSubstudy B will investigate whether fueling the patients with a mixed oral 1:1 glucose-fructose carbohydrate solution will maintain glucose values within a more stable range when compared to carbohydrate supplementation by glucose alone.\\n\\nMethods\\n\\nBlood glucose levels, counterregulatory hormones, metabolites such as lactate and free fatty acids as well as inflammatory biomarkers will be assessed by regular blood samplings. By means of oral and intravenously given stable isotopes (U-13 C glucose and 2H glucose) exercise-related glucose kinetics will be investigated. Exercise-induced glycogen consumption will be measured using magnetic resonance spectroscopy technology. Late glycemic excursions will be recorded by continuous glucose monitoring systems.\\n\\nIn order to validate 13C magnetic resonance spectroscopy (MRS) measurement of hepatic and myocellular glycogen content a pre-study involving 10 patients and an equal number of matched healthy controls will be performed (validation and reproducibility study).'}, 'conditionsModule': {'conditions': ['Type 1 Diabetes Mellitus', 'Exercise', 'Hypoglycemia', 'Carbohydrate Metabolism'], 'keywords': ['exercise', 'isotope labeling, stable', 'spectroscopy, magnetic resonance', 'monitoring, home blood glucose', 'hormones']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 27, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'IHE first, CONT second, CSII and MDI therapy', 'type': 'EXPERIMENTAL', 'description': 'IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes', 'interventionNames': ['Procedure: IHE first, CONT second']}, {'label': 'CONT first, IHE second,CSII and MDI therapy', 'type': 'EXPERIMENTAL', 'description': 'CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes', 'interventionNames': ['Procedure: CONT first, IHE second']}, {'label': 'GLU first, GLUFRU second, CSII and MDI therapy', 'type': 'EXPERIMENTAL', 'description': 'GLU: ingestion of a 6% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.', 'interventionNames': ['Procedure: GLU first, GLU-FRU second']}, {'label': 'GLU-FRU first, GLU second, CSII therapy', 'type': 'EXPERIMENTAL', 'description': 'GLU-FRU : ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): ingestion of a 10% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.', 'interventionNames': ['Procedure: GLU-FRU first, GLU second']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'IHE first, CONT second', 'description': 'IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes', 'armGroupLabels': ['IHE first, CONT second, CSII and MDI therapy']}, {'type': 'PROCEDURE', 'name': 'CONT first, IHE second', 'description': 'CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes', 'armGroupLabels': ['CONT first, IHE second,CSII and MDI therapy']}, {'type': 'PROCEDURE', 'name': 'GLU first, GLU-FRU second', 'description': ': ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes', 'armGroupLabels': ['GLU first, GLUFRU second, CSII and MDI therapy']}, {'type': 'PROCEDURE', 'name': 'GLU-FRU first, GLU second', 'description': 'GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.', 'armGroupLabels': ['GLU-FRU first, GLU second, CSII therapy']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Amount of exogenous glucose required to maintain glycemia within a range between 7-10mM', 'timeFrame': '30 minutes (last 30 minutes of 90 min exercise period)'}], 'secondaryOutcomes': [{'measure': 'Exercise - related glycogen consumption', 'timeFrame': '90 minutes'}, {'measure': 'Glucose kinetics', 'description': 'Rate of glucose appearance and disappearance', 'timeFrame': '180 minutes'}, {'measure': 'Counterregulatory hormones, metabolites, and inflammatory response', 'timeFrame': '300 minutes'}, {'measure': 'Spiroergometric parameters', 'description': 'CO2 and O2 production, RER', 'timeFrame': '180 minutes'}, {'measure': 'Pre- and post-exercise glycemic excursions', 'timeFrame': '72 h pre-exercise and 72 h post-exercise respectively'}, {'measure': 'Heart rate variability', 'timeFrame': '90 minutes'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Male\\n* Aged 18 to 35 years\\n* Diabetes mellitus duration for at least 5 years\\n* No change in insulin regimen for at least 3 months prior to the study\\n* Under acceptable to good metabolic control\\n* Normal insulin sensitivity\\n* Regular physical activity\\n* BMI in the range of 18-25 kg/m2\\n* Written informed consent\\n\\nExclusion Criteria\\n\\n* Diabetes-related complications (macro and microvascular)\\n* Anemia (hemoglobin concentration \\\\<130g/l)\\n* Abnormal thyroid function\\n* Dyslipidemia\\n* Major depression, psychosis and other severe personality disorders, claustrophobia\\n* Active neoplasia\\n* Contraindications to exposure to a 3 T magnetic field\\n* Abnormal liver or renal function\\n* Smoking, drug abuse, or daily alcohol consumption \\\\>60g\\n* Participation in another study\\n* Medication other than insulin', 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '18 Years', 'maximumAge': '35 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Christoph Stettler, Professor, MD', 'affiliation': 'University of Bern', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital', 'city': 'Bern', 'zip': '3010', 'country': 'Switzerland', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}]}, 'referencesModule': {'references': [{'pmid': '16302286', 'type': 'RESULT', 'citation': 'Stettler C, Jenni S, Allemann S, Steiner R, Hoppeler H, Trepp R, Christ ER, Zwahlen M, Diem P. Exercise capacity in subjects with type 1 diabetes mellitus in eu- and hyperglycaemia. Diabetes Metab Res Rev. 2006 Jul-Aug;22(4):300-6. doi: 10.1002/dmrr.608.'}, {'pmid': '18512043', 'type': 'RESULT', 'citation': 'Jenni S, Oetliker C, Allemann S, Ith M, Tappy L, Wuerth S, Egger A, Boesch C, Schneiter P, Diem P, Christ E, Stettler C. Fuel metabolism during exercise in euglycaemia and hyperglycaemia in patients with type 1 diabetes mellitus--a prospective single-blinded randomised crossover trial. Diabetologia. 2008 Aug;51(8):1457-65. doi: 10.1007/s00125-008-1045-5. Epub 2008 May 30.'}, {'pmid': '16505513', 'type': 'RESULT', 'citation': 'Bussau VA, Ferreira LD, Jones TW, Fournier PA. The 10-s maximal sprint: a novel approach to counter an exercise-mediated fall in glycemia in individuals with type 1 diabetes. Diabetes Care. 2006 Mar;29(3):601-6. doi: 10.2337/diacare.29.03.06.dc05-1764.'}, {'pmid': '17583795', 'type': 'RESULT', 'citation': 'Bussau VA, Ferreira LD, Jones TW, Fournier PA. A 10-s sprint performed prior to moderate-intensity exercise prevents early post-exercise fall in glycaemia in individuals with type 1 diabetes. Diabetologia. 2007 Sep;50(9):1815-1818. doi: 10.1007/s00125-007-0727-8. Epub 2007 Jun 22.'}, {'pmid': '15920041', 'type': 'RESULT', 'citation': 'Guelfi KJ, Jones TW, Fournier PA. The decline in blood glucose levels is less with intermittent high-intensity compared with moderate exercise in individuals with type 1 diabetes. Diabetes Care. 2005 Jun;28(6):1289-94. doi: 10.2337/diacare.28.6.1289.'}, {'pmid': '17339500', 'type': 'RESULT', 'citation': 'Guelfi KJ, Ratnam N, Smythe GA, Jones TW, Fournier PA. Effect of intermittent high-intensity compared with continuous moderate exercise on glucose production and utilization in individuals with type 1 diabetes. Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E865-70. doi: 10.1152/ajpendo.00533.2006.'}, {'pmid': '21388440', 'type': 'RESULT', 'citation': 'Iscoe KE, Riddell MC. Continuous moderate-intensity exercise with or without intermittent high-intensity work: effects on acute and late glycaemia in athletes with Type 1 diabetes mellitus. Diabet Med. 2011 Jul;28(7):824-32. doi: 10.1111/j.1464-5491.2011.03274.x.'}, {'pmid': '20826630', 'type': 'RESULT', 'citation': 'Lecoultre V, Benoit R, Carrel G, Schutz Y, Millet GP, Tappy L, Schneiter P. Fructose and glucose co-ingestion during prolonged exercise increases lactate and glucose fluxes and oxidation compared with an equimolar intake of glucose. Am J Clin Nutr. 2010 Nov;92(5):1071-9. doi: 10.3945/ajcn.2010.29566. Epub 2010 Sep 8.'}, {'pmid': '33184152', 'type': 'DERIVED', 'citation': 'Eckstein ML, Farinha JB, McCarthy O, West DJ, Yardley JE, Bally L, Zueger T, Stettler C, Boff W, Reischak-Oliveira A, Riddell MC, Zaharieva DP, Pieber TR, Muller A, Birnbaumer P, Aziz F, Brugnara L, Haahr H, Zijlstra E, Heise T, Sourij H, Roden M, Hofmann P, Bracken RM, Pesta D, Moser O. Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis. Diabetes Care. 2021 Jan;44(1):240-247. doi: 10.2337/dc20-1496. Epub 2020 Nov 12.'}, {'pmid': '26739816', 'type': 'DERIVED', 'citation': 'Bally L, Zueger T, Buehler T, Dokumaci AS, Speck C, Pasi N, Ciller C, Paganini D, Feller K, Loher H, Rosset R, Wilhelm M, Tappy L, Boesch C, Stettler C. Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover study. Diabetologia. 2016 Apr;59(4):776-84. doi: 10.1007/s00125-015-3854-7. Epub 2016 Jan 6.'}, {'pmid': '26739116', 'type': 'DERIVED', 'citation': 'Bally L, Zueger T, Pasi N, Carlos C, Paganini D, Stettler C. Accuracy of continuous glucose monitoring during differing exercise conditions. Diabetes Res Clin Pract. 2016 Feb;112:1-5. doi: 10.1016/j.diabres.2015.11.012. Epub 2015 Dec 19.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}, {'id': 'D007003', 'term': 'Hypoglycemia'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M10053', 'name': 'Hypoglycemia', 'asFound': 'Hypoglycemia', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03663738', 'orgStudyIdInfo': {'id': 'PIFUN32/17'}, 'organization': {'fullName': 'Servicio Canario de Salud', 'class': 'OTHER'}, 'briefTitle': 'Impact Evaluation of a Mobile Health App to Improve Self-control and Health Outcomes of Patients With Type 2 Diabetes Mellitus (T2DM): Pilot Study \"NOVAME\"', 'officialTitle': 'Evaluation of the Impact of a Mobile Health App to Improve Self-control and Health Outcomes of Patients With Type 2 Diabetes Mellitus: Pilot Study \"NOVAME\"', 'acronym': 'NOVAME'}, 'statusModule': {'statusVerifiedDate': '2020-02', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-02-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-09-20', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2019-09-20', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-09-06', 'studyFirstSubmitQcDate': '2018-09-06', 'studyFirstPostDateStruct': {'date': '2018-09-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-02-26', 'lastUpdatePostDateStruct': {'date': '2020-02-28', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Servicio Canario de Salud', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"The objective of this project is to evaluate the effectiveness and cost effectiveness of a health app (NOVAME) designed to improve the self-control of patients with T2DM and their health outcomes. The central focus of NOVAME is the continuous support to the patient and monitoring through the app that will act as a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management The design of the evaluation is the randomized clinical trial, in the intervention arm patients will use the app NOVAME and in the control group, patients don't receive any additional educational or supporting activities beyond the usual activities provided by the Canary Islands Health Service (CIHS). The main outcome measure is the change in HbA1c at 3 months, requiring a total of 197 patients to detect a difference of at least 0.4% considering a 10% loss. As secondary measures HbA1c is collected at 12 months and other biochemical results (lipids and glucose), BMI and a series of questionnaires to measure changes in life habits (diet, physical activity), anxiety and depression, knowledge about their disease , degree of empowerment, satisfaction and usability of the app, .. Will be collected at 3 and 12 months. The differences between the arms will be measured with mixed generalized linear models. The cost effectiveness will be calculated by calculating life years adjusted for quality (QALY) and the cost of the disease, including the use of resources reported by patients. The benefits of the technology will be expressed in terms of HbA1c and QALY.\"}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'Researchers who recruited participants and applied the baseline and 3-month questionnaires were not blinded to the allocation sequence. Given the nature of the intervention patients could not be blinded'}}, 'enrollmentInfo': {'count': 199, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'health mobile app for T2DM patients', 'type': 'ACTIVE_COMPARATOR', 'description': 'It consists of a mobile app that will be provided to patients during a period of 12 months, the patient can also continue with the usual care. The application will be synchronized with a server where all the information is recorded for further analysis. The central focus of the application consists of continuous support and monitoring through the app that has a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management', 'interventionNames': ['Behavioral: mobile app NOVAME']}, {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'Receives the usual care as established in the Canary Islands Atherosclerotic Vascular Disease Prevention and Control Program (EVA)'}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'mobile app NOVAME', 'description': 'The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.', 'armGroupLabels': ['health mobile app for T2DM patients']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1c', 'description': 'glycosylated hemoglobin', 'timeFrame': 'Baseline, 3 months, 12 months'}], 'secondaryOutcomes': [{'measure': 'Total cholesterol and its fractions (LDL, HDL and nonHDL), and triglycerides', 'description': 'triglycerides, Total Cholesterol, LDL Cholesterol, HDL Cholesterol', 'timeFrame': 'Baseline, 3 months, 12 months'}, {'measure': 'Glucose', 'description': 'glucose level', 'timeFrame': 'Baseline, 3 months, 12 months'}, {'measure': 'BMI', 'description': 'Body mass index', 'timeFrame': 'Baseline, 3 months, 12 months'}, {'measure': 'Quality of life related to health', 'description': 'EQ-5D-5L questionnaire. The EQ-5D is a generic instrument of HRQL measurement where the individual assesses their state of health, first in levels of severity by dimensions (descriptive system) and then in a visual analogue scale (VAS) of more general evaluation. The index ranges between the value 1 (best health status) and 0 (death), although there are negative values for the index, corresponding to health status that are valued as worse than death.', 'timeFrame': 'Baseline, 3 months, 12 months'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Patients with T2DM diagnosed at least one year prior to study enrolment\\n2. 18-65 years of age\\n3. Formal consent to participate in the study\\n4. Regular use of mobile phone\\n\\nExclusion Criteria:\\n\\n1. Chronic kidney disease≥stage 3b, as defined by the National Kidney Foundation's Kidney Disease Outcomes and Quality Improvement Initiative (KDOQI); urinary albumin to creatinine ratio (UACR) ≥ 300 mg/g and/or urinary protein excretion ≥ 300 mg/24 hours.\\n2. Acute coronary syndrome (documented angina or myocardial infarction) or stroke in the last six months or class III or IV heart failure, according to the New York Heart Association (NYHA).\\n3. Proliferative diabetic retinopathy or clinically significant diabetic macular edema requiring previous treatment with retinal photocoagulation, vitrectomy, or intravitreal injections of antivascular endothelial growth factor or triamcinolone acetonide 6 months prior to study inclusion.\\n4. Uncorrected severe hearing or visual impairment; or corrected visual acuity ≤ 20/40 by any cause.\\n5. Diabetic foot with ulcers ≥ 2 according to Wagner scale.\\n6. Liver cirrhosis\\n7. Cancer unless disease free five years after diagnosis\\n8. Other terminal illnesses\\n9. Intellectual retardation, dementia, psychotic diseases.\\n10. Active substance abuse, alcohol or drugs (must be sober for one year)\\n11. Pregnancy\\n12. Insufficient (Spanish) language skills\\n13. Physical disability limiting participation in group education activities\\n14. Concurrent participation in another clinical trial or any other investigational study.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Servicio de Evaluación. Servicio Canario de Salud', 'city': 'Santa Cruz de Tenerife', 'zip': '38004', 'country': 'Spain', 'geoPoint': {'lat': 28.46824, 'lon': -16.25462}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01252082', 'orgStudyIdInfo': {'id': '86067'}, 'organization': {'fullName': 'Mashhad University of Medical Sciences', 'class': 'OTHER'}, 'briefTitle': 'Non-surgical Periodontal Therapy Effects Metabolic Control in Diabetics', 'officialTitle': 'Evaluation of Effect of Nonsurgical Periodontal Therapy on Metabolic Control in Patients With Type II Diabetes'}, 'statusModule': {'statusVerifiedDate': '2015-04', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2007-06'}, 'primaryCompletionDateStruct': {'date': '2008-09', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2008-09', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2010-12-01', 'studyFirstSubmitQcDate': '2010-12-01', 'studyFirstPostDateStruct': {'date': '2010-12-02', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-04-07', 'lastUpdatePostDateStruct': {'date': '2015-04-08', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Amir Moeintaghavi', 'investigatorTitle': 'associate professor of periodontics', 'investigatorAffiliation': 'Mashhad University of Medical Sciences'}, 'leadSponsor': {'name': 'Mashhad University of Medical Sciences', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine whether nonsurgical periodontal therapy is effective in the metabolic control of patients with type II Diabetes mellitus.', 'detailedDescription': 'Type 2 diabetes mellitus (DM2), the most common type of diabetes, is characterized by hyperglycemia, hyperlipidemia, and associated complications. The classic major complications of diabetes are microangiopathy, nephropathy, neuropathy, macrovascular disease, delayed wound healing, and periodontitis. There is an interacting, complex relationship between diabetes and periodontitis.Many studies have shown a greater incidence and a greater severity of periodontitis in diabetic patients.Meanwhile, a number of studies have suggested that periodontitis may actually be a risk factor for diabetic complications as well. This study is performed to investigate the effects of non-surgical periodontal therapy on metabolic control in DM2 patients.'}, 'conditionsModule': {'conditions': ['Metabolic Control'], 'keywords': ['metabolic control', 'fasting plasma glucose', 'glycated hemoglobin']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 40, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Scalig and Rootplaning', 'type': 'ACTIVE_COMPARATOR', 'description': 'patients will receive scaling and root planing therapy', 'interventionNames': ['Procedure: Scaling and Rootplaning']}, {'label': 'control', 'type': 'NO_INTERVENTION', 'description': 'patients in control group will not receive periodontal treatment in the time period of the study'}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Scaling and Rootplaning', 'description': 'All patients in the test group receive scaling and rootplaning under local anesthesia', 'armGroupLabels': ['Scalig and Rootplaning'], 'otherNames': ['test group', 'control group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Metabolic control', 'description': 'fasting plasma glucose (FPG), HbA1c, TG, TC, high density lipoprotein cholesterol (HDL), and LDL are measured at baseline and 3 months after treatment.', 'timeFrame': '3 months after treatment'}], 'secondaryOutcomes': [{'measure': 'periodontal improvement after scaling and rootplaning', 'description': 'Periodontal parameters (Plaque index, Gingival index, Clinical Attachment level and Probing depth)are Measured at baseline and 3 months after treatment', 'timeFrame': '3 months after treatment'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n(1) mild to moderate periodontitis according to the criteria of the American Academy of Periodontology (32); (2) diagnosis of DM2 with glycated hemoglobin (HbA1c) values over 7%; (3) no major diabetic complications; (4) blood sugar controlled with glybenclamide and metformin, without insulin administration; and (5) no systemic antibiotic administration or periodontal treatment within the last 6 months.\\n\\nExclusion Criteria:\\n\\n(1) presence of systemic diseases other than DM2 that may influence the course of periodontal disease; (2) intake of immunosuppressive drugs, steroids, hydantoin, or non-steroidal anti-inflammatory drugs; (3) tobacco use; (4) pregnancy or intention to become pregnant during the study period; (5) fixed orthodontic appliances; and (5) refusal or inability to give informed consent', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '30 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Amir Moeintaghavi, DDS.,Ms.', 'affiliation': 'Associate professor,Mashhad Dental School, Mashhad University of Medical Sciences', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Mashhad Dental School, Mashhad University of Medical Sciences', 'city': 'Mashhad', 'state': 'Khorasan Razavi', 'zip': '91735-984', 'country': 'Iran, Islamic Republic of', 'geoPoint': {'lat': 36.31559, 'lon': 59.56796}}]}, 'referencesModule': {'references': [{'pmid': '22369555', 'type': 'RESULT', 'citation': 'Moeintaghavi A, Arab HR, Bozorgnia Y, Kianoush K, Alizadeh M. Non-surgical periodontal therapy affects metabolic control in diabetics: a randomized controlled clinical trial. Aust Dent J. 2012 Mar;57(1):31-7. doi: 10.1111/j.1834-7819.2011.01652.x.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M4107', 'name': 'Anesthetics', 'relevance': 'LOW'}, {'id': 'M207501', 'name': 'Chrysarobin', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'}, {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'}, {'abbrev': 'Analg', 'name': 'Analgesics'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04177420', 'orgStudyIdInfo': {'id': 'B10701016'}, 'organization': {'fullName': 'Nanhua University', 'class': 'OTHER'}, 'briefTitle': \"Investigation for Health Efficacy of Infrared-C Radiation on Diabetes Patients in Senior's Activity Center\", 'officialTitle': \"Investigation for Health Efficacy of Infrared-C Radiation on Diabetes Patients in Senior's Activity Center\"}, 'statusModule': {'statusVerifiedDate': '2019-11', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-03-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2020-02-15', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2019-06-08', 'studyFirstSubmitQcDate': '2019-11-22', 'studyFirstPostDateStruct': {'date': '2019-11-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-11-22', 'lastUpdatePostDateStruct': {'date': '2019-11-26', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Nanhua University', 'class': 'OTHER'}, 'collaborators': [{'name': 'Buddhist Dalin Tzu Chi General Hospital', 'class': 'UNKNOWN'}, {'name': 'Solano Semiconductor Technology., LTD.', 'class': 'UNKNOWN'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Hyperglycemia caused by diabetes will bring us the long-term damage，it causes glycation. The combination of sugar molecules and protein molecules will transform to advanced glycation end products (AGEs) and produce a lot of free radicals to caused inflammatory reactions, forming various comorbidities, affecting the function of different organs, especially the eyes, kidneys, nervous system, heart, blood vessels and damage to bone structure and bone Quality, which leads to bone loss. Therefore, the development of alternative therapies is important for the treatment of diabetes. We assume the 4 months experiment can normalize subjects HbA1c.', 'detailedDescription': \"In the past research from our team, it was found that far infrared ray (FIR) helps to reduce oxidative stress in the body and is expected to contribute to the treatment of diabetes. Therefore, the team hopes to effectively reduce glycated hemoglobin (HbA1c), fasting blood glucose (GLU-AC), insulin (insulin), reduce the body's oxidative stress index, increase Total Antioxidant Capacity (TAC) inhibit the inflammatory response and reduce complications through 4 months of IR-C intervention. Which expected to reduce the index of the nitrogen-type first collagen element (Procollagen-I N -telopeptide, PINP) and C-telopeptide of type I collagen (CTx) bone loss index, enhance Osteocalcin's index of bone growth indicators. Along with the Pittsburgh sleep quality index (PSQI), numeric rating scale-knee (NRS-knee) and Geriatric depression Scale-15 (GDS-15) to reduce the number of times the elderly take medication and improve their health and quality of life.\"}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2'], 'keywords': ['Types 2 Diabetes Mellitus', 'Glycation', 'AGEs', 'hemoglobin A1c, HbA1c', 'Fasting blood sugar, GLU-AC', 'Insulin', 'Procollagen-I N-telopeptide, PINP', 'C-telopeptide of type I collagen, CTx', 'osteocalcin', 'Pittsburgh sleep quality index, PSQI', 'numeric rating scale-knee, NRS-knee', 'Geriatric depression Scale-15, GDS-15', 'Total Antioxidant Capacity, TAC', 'Infrared-C', 'Hyperglycemia']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 64, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Experiment Group', 'type': 'EXPERIMENTAL', 'description': 'lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night.', 'interventionNames': ['Device: FIR-C mattress', 'Device: FIR-C abdominal pad']}, {'label': 'Control Group', 'type': 'PLACEBO_COMPARATOR', 'description': 'lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night. the FIR-C mattress and the FIR-C abdominal pad is malfunction and it can not produce the FIR-C.', 'interventionNames': ['Device: fake FIR-C mattress', 'Device: fake FIR-C abdominal pad']}], 'interventions': [{'type': 'DEVICE', 'name': 'FIR-C mattress', 'description': 'infrared-C irradiation by hot mattress with a powered heating compress', 'armGroupLabels': ['Experiment Group']}, {'type': 'DEVICE', 'name': 'FIR-C abdominal pad', 'description': 'infrared-C irradiation by hot abdominal pad with a powered heating compress', 'armGroupLabels': ['Experiment Group']}, {'type': 'DEVICE', 'name': 'fake FIR-C mattress', 'description': 'normal mattress with fake controller, custom make for placebo group', 'armGroupLabels': ['Control Group']}, {'type': 'DEVICE', 'name': 'fake FIR-C abdominal pad', 'description': 'normal abdominal pad with fake controller, custom make for placebo group', 'armGroupLabels': ['Control Group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Hemoglobin A1c, HbA1c', 'description': 'The hemoglobin A1c can show us our average level of blood sugar over the past 2 to 3 months. Below 6% is normal, over 6% is abnormal.', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Fasting Blood Sugar, GLU-AC', 'description': 'A blood sample will be taken after an overnight fast which to estimate blood sugar levels. Below 100mg/dL is normal, 100 to 125mg/dL is prediabetes, 125mg/dL above is consider diabetes.', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Insulin', 'description': 'Is a hormone that is produced and stored in the beta cells of the pancreas. this test can measures the amount of insulin in the blood which to analyze the insulin resistance of the body.', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Superoxide, O2-', 'description': 'superoxide is one type of the free radical. The assay of superoxide can show us the ability to inhibit free radical contained in blood. The highest value of it means the highest injured did. The data of the post-test should be lower than the data of the pre-test.', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Osteocalcin', 'description': 'Is a noncollagenous protein hormone found in bone and dentin, it implicated in bone mineralization and calcium ion homeostasis. The normal range for female: 12-23ng/dL; the normal range for male: 17-26ng/dL.', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Procollagen-I N-telopeptide, PINP', 'description': \"This market is a specific indicator of type I collagen deposition therefore can set as an indicator of bone formation velocity. The reference's range for PINP: 16.27 - 73.87 ng/mL.\", 'timeFrame': 'Baseline to 4 months'}, {'measure': 'C-telopeptide of type I collagen，CTx', 'description': \"It is the carbon-terminal fragment of the first type of collagen in the bone, which is the final product of bone decomposition and can be used as an indicator of bone loss. The reference's range for female: 0.104-1.008ng/mL; for male: 0.000-0.854ng/mL\", 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Total Antioxidant Capacity, TAC', 'description': \"to assess the antioxidant status of blood to evaluate the antioxidant response against the free radicals produced in the blood. The reference's range for male: \\\\>=0.65mmol/L; female: \\\\>=0.54mmol/L\", 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Advanced glycation end-product，AGEs', 'description': 'AGEs are proteins or lipids that become glycated as a result of exposure to sugars. Its can be a factor in aging and in the development from diabetes. The highest value of it means the highest injured did. The data of the post-test should be lower than the data of the pre-test.', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Insulin resistance assessment', 'description': 'to measure the insulin sensitivity of the cells, the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) method will be applied in this study. The highest value of it means the highest injured did. The data of the post-test should be lower than the data of the pre-test.', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Beta-cell function assessment', 'description': 'to measure the function of the Beta-cell, the HOMA-beta-cell method will be applied in this study. The highest value of it means the function of the Beta-cell more normal. The data of the post-test should be higher than the data of the pre-test.', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Autonomic nervous system assessment - Heart Rate', 'description': 'the measurement of Autonomic nervous system assessment is to measure the functions of sympathetic and the parasympathetic. The scale of this assessment is HR(Heart Rate).\\n\\nHR(1/min):normal range(60-100),abnormal range(lower than 60 or higher than 100)', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Autonomic nervous system assessment - blood pressure', 'description': 'the measurement of Autonomic nervous system assessment is to measure the functions of sympathetic and the parasympathetic. The scale of this assessment is about blood pressure.\\n\\nSYS(mmHg):normal range(90-140), abnormal range(higher than 140) DIA(mmHg):normal range(60-90), abnormal range(higher than 90) SYS(mmHg) and DIA(mmHg) will be combined to report blood pressure in SYS/DIA(mmHg)', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Autonomic nervous system assessment - Heart Rate Variability', 'description': 'the measurement of Autonomic nervous system assessment is to measure the functions of sympathetic and the parasympathetic. The scale of this assessment is about HRV(Heart Rate Variability).\\n\\nHRV(ms): normal range(25-100), abnormal range(lower than 15)', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Autonomic nervous system assessment - Low Frequency', 'description': 'the measurement of Autonomic nervous system assessment is to measure the functions of sympathetic and the parasympathetic. The scale of this assessment is about LF(Low Frequency %).\\n\\nLF(%): normal range(40-70), abnormal range(higher than 80)', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Autonomic nervous system assessment - High Frequency', 'description': 'the measurement of Autonomic nervous system assessment is to measure the functions of sympathetic and the parasympathetic. The scale of this assessment is about HF(High Frequency %).\\n\\nHF(%): normal range(25-40), abnormal range(lower than 20)', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Autonomic nervous system assessment - Low/High Frequency standard', 'description': 'the measurement of Autonomic nervous system assessment is to measure the functions of sympathetic and the parasympathetic. The scale of this assessment is about LF/HF(Low/High Frequency standard).\\n\\nLF/HF: normal range(0.5-2.5), abnormal range(higher than 3)', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Autonomic nervous system assessment - Irregular Heartbeat standard', 'description': 'the measurement of Autonomic nervous system assessment is to measure the functions of sympathetic and the parasympathetic. The scale of this assessment is about IR(Irregular Heartbeat standard).\\n\\nIR: normal range(0-3), abnormal range(higher than 4)', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Pittsburgh sleep quality index (PSQI)', 'description': 'The PSQI is a questionnaire to measure sleep quality over the past month. the 19 items question can be grouped into 7 components, its (1)sleep duration; (2) sleep disturbance;(3) sleep latency; (4) daytime dysfunction due to sleepiness; (5) sleep efficiency; (6) overall sleep quality; (7) sleep medication use. The sleep component scores are summed to a total score ranging from 0 to 21. The higher of the total score means the sleep quality worse.', 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Knee Pain - Numeric Rating Scale, Knee Pain - NRS', 'description': \"To measure the Knee's painfulness. The higher of the score means the knee's more painful.\", 'timeFrame': 'Baseline to 4 months'}, {'measure': 'Geriatric Depression Scale-15, GDS-15', 'description': 'to assess depressive symptoms among old people with differing level of cognitive function.\\n\\n1-5 : healthy 6-9 : light depression 10 and above : serious depression', 'timeFrame': 'Baseline to 4 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* HbA1c higher than 6.8% or fasting blood sugar higher than 126mg/dL;\\n* Conscious, mental and cognitively normal;\\n* no obstacles in action;\\n* can read, write and communicate with mandarin, taiwanese and hakka.\\n\\nExclusion Criteria:\\n\\n* Inflammatory skin wounds on the neck, back, lower back or lower leg;\\n* obstacles in communication;\\n* People with disabilities, epilepsy, and other unacceptable warming treatments;\\n* When the subject finds that he or she is unwell during the procedure, the experiment is terminated and take care by the medical staff.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '50 Years', 'maximumAge': '85 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'PIN-FAN CHEN, Doctor', 'role': 'CONTACT', 'phone': '+886929206688', 'email': 'pinfan1973@gmail.com'}, {'name': 'Chun-Chih Lin, Professor', 'role': 'CONTACT', 'phone': '+886972019645', 'email': 'benjasado@gmail.com'}], 'overallOfficials': [{'name': 'Ching Yong Chin, Master', 'affiliation': 'Nanhua University', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Yi-Wen Huang, Master', 'affiliation': 'Nanhua University', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Jin-Bang Shang, Master', 'affiliation': 'Nanhua University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': \"Department of Natural Biotechnology, Master's program in Natural Healing Sciences Nanhua University\", 'status': 'RECRUITING', 'city': 'Dalin', 'state': 'Chiayi', 'zip': '62249', 'country': 'Taiwan', 'contacts': [{'name': 'YA YUN JUANG', 'role': 'CONTACT', 'phone': '+88652721001', 'phoneExt': '2641', 'email': 'minie0126@nhu.edu.tw'}], 'geoPoint': {'lat': 23.88713, 'lon': 120.94613}}]}, 'referencesModule': {'references': [{'pmid': '4973243', 'type': 'BACKGROUND', 'citation': 'Cegrell L. The occurrence of biogenic monoamines in the mammalian endocrine pancreas. Acta Physiol Scand Suppl. 1968;314:1-60. No abstract available.'}, {'pmid': '19885944', 'type': 'BACKGROUND', 'citation': 'Chang Y, Liu YP, Liu CF. The effect on serotonin and MDA levels in depressed patients with insomnia when far-infrared rays are applied to acupoints. Am J Chin Med. 2009;37(5):837-42. doi: 10.1142/S0192415X09007272.'}, {'pmid': '13513506', 'type': 'BACKGROUND', 'citation': 'COUPLAND RE. The innervation of pan creas of the rat, cat and rabbit as revealed by the cholinesterase technique. J Anat. 1958 Jan;92(1):143-9. No abstract available.'}, {'pmid': '14698276', 'type': 'BACKGROUND', 'citation': 'Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004 Jan;25(1):4-7. doi: 10.1016/j.it.2003.10.013.'}, {'pmid': '21030723', 'type': 'BACKGROUND', 'citation': 'Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545.'}, {'pmid': '16319806', 'type': 'BACKGROUND', 'citation': 'Haag M, Dippenaar NG. Dietary fats, fatty acids and insulin resistance: short review of a multifaceted connection. Med Sci Monit. 2005 Dec;11(12):RA359-67. Epub 2005 Nov 24.'}, {'pmid': '8886564', 'type': 'BACKGROUND', 'citation': 'Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care. 1996 Oct;19(10):1138-41. doi: 10.2337/diacare.19.10.1138.'}, {'pmid': '3410585', 'type': 'BACKGROUND', 'citation': 'Honda K, Inoue S. Sleep-enhancing effects of far-infrared radiation in rats. Int J Biometeorol. 1988 Jun;32(2):92-4. doi: 10.1007/BF01044900. No abstract available.'}, {'pmid': '8660627', 'type': 'BACKGROUND', 'citation': 'Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of \"antioxidant power\": the FRAP assay. Anal Biochem. 1996 Jul 15;239(1):70-6. doi: 10.1006/abio.1996.0292.'}, {'pmid': '8608815', 'type': 'BACKGROUND', 'citation': 'Lu FJ, Lin JT, Wang HP, Huang WC. A simple, sensitive, non-stimulated photon counting system for detection of superoxide anion in whole blood. Experientia. 1996 Feb 15;52(2):141-4. doi: 10.1007/BF01923359.'}, {'pmid': '17968683', 'type': 'BACKGROUND', 'citation': 'Ishibashi J, Yamashita K, Ishikawa T, Hosokawa H, Sumida K, Nagayama M, Kitamura S. The effects inhibiting the proliferation of cancer cells by far-infrared radiation (FIR) are controlled by the basal expression level of heat shock protein (HSP) 70A. Med Oncol. 2008;25(2):229-37. doi: 10.1007/s12032-007-9020-4. Epub 2007 Oct 30.'}, {'pmid': '17167471', 'type': 'BACKGROUND', 'citation': 'Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006 Dec 14;444(7121):840-6. doi: 10.1038/nature05482.'}, {'pmid': '22718504', 'type': 'BACKGROUND', 'citation': 'Kasznicki J, Kosmalski M, Sliwinska A, Mrowicka M, Stanczyk M, Majsterek I, Drzewoski J. Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Mol Biol Rep. 2012 Sep;39(9):8669-78. doi: 10.1007/s11033-012-1722-9. Epub 2012 Jun 21.'}, {'pmid': '24991883', 'type': 'BACKGROUND', 'citation': 'Lin CC, Chiang YS, Lung CC. Effect of infrared-C radiation on skin temperature, electrodermal conductance and pain in hemiparetic stroke patients. Int J Radiat Biol. 2015 Jan;91(1):42-53. doi: 10.3109/09553002.2014.937512. Epub 2014 Aug 11.'}, {'pmid': '12616644', 'type': 'BACKGROUND', 'citation': 'Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17(1):24-38. doi: 10.1002/jbt.10058.'}, {'pmid': '15992574', 'type': 'BACKGROUND', 'citation': 'Masuda A, Kihara T, Fukudome T, Shinsato T, Minagoe S, Tei C. The effects of repeated thermal therapy for two patients with chronic fatigue syndrome. J Psychosom Res. 2005 Apr;58(4):383-7. doi: 10.1016/j.jpsychores.2004.11.005.'}, {'pmid': '3899825', 'type': 'BACKGROUND', 'citation': 'Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9. doi: 10.1007/BF00280883.'}, {'pmid': '15297079', 'type': 'BACKGROUND', 'citation': 'Riccardi G, Giacco R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr. 2004 Aug;23(4):447-56. doi: 10.1016/j.clnu.2004.02.006.'}, {'pmid': '25791570', 'type': 'BACKGROUND', 'citation': 'Saito M, Marumo K. Effects of Collagen Crosslinking on Bone Material Properties in Health and Disease. Calcif Tissue Int. 2015 Sep;97(3):242-61. doi: 10.1007/s00223-015-9985-5. Epub 2015 Mar 20.'}, {'pmid': '29716886', 'type': 'BACKGROUND', 'citation': 'Saslow L, Mason AE, Kim S, Goldman V, Ploutz-Snyder R, Bayandorian H, Daubenmier J, Hecht FM, Moskowitz JT. Authors\\' Reply: Comment on \"An Online Intervention Comparing a Very Low-Carbohydrate Ketogenic Diet and Lifestyle Recommendations Versus a Plate Method Diet in Overweight Individuals With Type 2 Diabetes: A Randomized Controlled Trial\". J Med Internet Res. 2018 May 1;20(5):e181. doi: 10.2196/jmir.8776. No abstract available.'}, {'pmid': '10938048', 'type': 'BACKGROUND', 'citation': 'Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12. doi: 10.1136/bmj.321.7258.405.'}, {'pmid': '19931305', 'type': 'BACKGROUND', 'citation': 'Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther. 2010 Feb;125(2):328-61. doi: 10.1016/j.pharmthera.2009.11.001. Epub 2009 Nov 18.'}, {'pmid': '12773705', 'type': 'BACKGROUND', 'citation': 'Toyokawa H, Matsui Y, Uhara J, Tsuchiya H, Teshima S, Nakanishi H, Kwon AH, Azuma Y, Nagaoka T, Ogawa T, Kamiyama Y. Promotive effects of far-infrared ray on full-thickness skin wound healing in rats. Exp Biol Med (Maywood). 2003 Jun;228(6):724-9. doi: 10.1177/153537020322800612.'}, {'pmid': '16606412', 'type': 'BACKGROUND', 'citation': 'Yu SY, Chiu JH, Yang SD, Hsu YC, Lui WY, Wu CW. Biological effect of far-infrared therapy on increasing skin microcirculation in rats. Photodermatol Photoimmunol Photomed. 2006 Apr;22(2):78-86. doi: 10.1111/j.1600-0781.2006.00208.x.'}, {'pmid': '19602651', 'type': 'RESULT', 'citation': 'Beever R. Far-infrared saunas for treatment of cardiovascular risk factors: summary of published evidence. Can Fam Physician. 2009 Jul;55(7):691-6.'}, {'pmid': '9492234', 'type': 'RESULT', 'citation': 'Burleson MH, Malarkey WB, Cacioppo JT, Poehlmann KM, Kiecolt-Glaser JK, Berntson GG, Glaser R. Postmenopausal hormone replacement: effects on autonomic, neuroendocrine, and immune reactivity to brief psychological stressors. Psychosom Med. 1998 Jan-Feb;60(1):17-25. doi: 10.1097/00006842-199801000-00004.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M9994', 'name': 'Hyperglycemia', 'relevance': 'LOW'}, {'id': 'M7058', 'name': 'Depression', 'relevance': 'LOW'}, {'id': 'M7061', 'name': 'Depressive Disorder', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M207501', 'name': 'Chrysarobin', 'relevance': 'LOW'}, {'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M16974', 'name': 'Triamcinolone', 'relevance': 'LOW'}, {'id': 'M16975', 'name': 'Triamcinolone Acetonide', 'relevance': 'LOW'}, {'id': 'M237966', 'name': 'Triamcinolone hexacetonide', 'relevance': 'LOW'}, {'id': 'M209573', 'name': 'Triamcinolone diacetate', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M4292', 'name': 'Antioxidants', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'}, {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'}, {'abbrev': 'Analg', 'name': 'Analgesics'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00099320', 'orgStudyIdInfo': {'id': 'H8O-MC-GWAP'}, 'organization': {'fullName': 'AstraZeneca', 'class': 'INDUSTRY'}, 'briefTitle': 'Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin', 'officialTitle': 'Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin'}, 'statusModule': {'statusVerifiedDate': '2015-01', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2004-05'}, 'primaryCompletionDateStruct': {'date': '2005-08', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2005-08', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2004-12-10', 'studyFirstSubmitQcDate': '2004-12-10', 'studyFirstPostDateStruct': {'date': '2004-12-13', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-02-20', 'lastUpdatePostDateStruct': {'date': '2015-02-23', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'AstraZeneca', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'This study is designed to compare the effects of twice-daily exenatide plus oral antidiabetic (OAD) agents and twice-daily placebo plus OAD with respect to glycemic control, as measured by hemoglobin A1c (HbA1c), in patients with type 2 diabetes who experience inadequate glycemic control with OAD alone.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus'], 'keywords': ['exenatide', 'exendin-4', 'diabetes', 'Amylin', 'Lilly']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 182, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Exenatide', 'type': 'EXPERIMENTAL', 'description': \"After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen\", 'interventionNames': ['Drug: exenatide']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'exenatide', 'description': 'After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units \\\\[5 μg\\\\] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units \\\\[10 μg\\\\] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.', 'armGroupLabels': ['Exenatide'], 'otherNames': ['Byetta', 'AC2993', 'synthetic exendin-4']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16, and if measured, any visits in between', 'description': 'Change in HbA1c from Baseline (Visit 3) to study termination at Week 16, and at all study visits in between', 'timeFrame': 'Baseline, Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Change from Baseline to Week 16 in fasting serum glucose (FSG) and glucose', 'description': 'Change from Baseline to Week 16 in FSG and glucose measured at different times throughout the day derived from 7-point self-monitored glucose (SMG) profile (glucose measurements before and 2 hours after the start of the morning, midday, and evening meals, and at bedtime)', 'timeFrame': 'Baseline, Week 16'}], 'secondaryOutcomes': [{'measure': 'Percentage of subjects reaching the target HbA1c (<7%)', 'description': 'The percentage of subjects reaching the target HbA1c (\\\\<7%) will be summarized and compared by treatment', 'timeFrame': 'Baseline, Week 2, Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Change in body weight from Baseline to Week 16', 'description': 'Change in body weight (kg) from Baseline to Week 16', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change from Baseline to Week 16 in fasting serum glucose (FSG) and glucose', 'description': 'Change from Baseline to Week 16 in FSG and glucose measured at different times throughout the day derived from 7-point self-monitored glucose (SMG) profile (glucose measurements before and 2 hours after the start of the morning, midday, and evening meals, and at bedtime)', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Changes in beta cell function and insulin sensitivity between Baseline and Week 16', 'description': 'Changes in beta cell function and insulin sensitivity as assessed by homeostasis model assessment (HOMA) analyses and the proinsulin/insulin ratio Between Baseline and Week 16', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Changes in lipids between Baseline and Week 16', 'description': 'Changes from Baseline to Week 16 in serum lipids (total cholesterol \\\\[TC\\\\], high-density lipoprotein cholesterol \\\\[HDL-C\\\\], fasting triglycerides, calculated low-density lipoprotein cholesterol \\\\[LDL-C\\\\]', 'timeFrame': 'Baseline, Week 16'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Treated with thiazolidinedione (TZD) alone or in combination with metformin. TZD dose stable for at least 120 days prior to screening, and those patients on metformin must have been on a stable dose for at least 30 days prior to screening.\\n* HbA1c between 7.1% and 10.0%, inclusive.\\n* Body mass index (BMI) between 25 kg/m\\\\^2 and 45 kg/m\\\\^2.\\n\\nExclusion Criteria:\\n\\n* Patient previously in a study using exenatide or GLP-1 analogs.\\n* Treated with oral anti-diabetic medications other than TZD and metformin within 3 months of screening.\\n* Treated with oral insulin within 3 months of screening.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '21 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'James Malone, MD', 'affiliation': 'Eli Lilly and Company', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Research Site', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'facility': 'Research Site', 'city': 'La Jolla', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'facility': 'Research Site', 'city': 'San Mateo', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 37.56299, 'lon': -122.32553}}, {'facility': 'Research Site', 'city': 'Santa Barbara', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 34.42083, 'lon': -119.69819}}, {'facility': 'Research Site', 'city': 'Spring Valley', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 32.74477, 'lon': -116.99892}}, {'facility': 'Research Site', 'city': 'Hialeah', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 25.8576, 'lon': -80.27811}}, {'facility': 'Research Site', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'facility': 'Research Site', 'city': 'Melbourne', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 28.08363, 'lon': -80.60811}}, {'facility': 'Research Site', 'city': 'West Palm Beach', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'facility': 'Research Site', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': 'Research Site', 'city': 'Honolulu', 'state': 'Hawaii', 'country': 'United States', 'geoPoint': {'lat': 21.30694, 'lon': -157.85833}}, {'facility': 'Research Site', 'city': 'Idaho Falls', 'state': 'Idaho', 'country': 'United States', 'geoPoint': {'lat': 43.46658, 'lon': -112.03414}}, {'facility': 'Research Site', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'facility': 'Research Site', 'city': 'Baton Rouge', 'state': 'Louisiana', 'country': 'United States', 'geoPoint': {'lat': 30.45075, 'lon': -91.15455}}, {'facility': 'Research Site', 'city': 'Kalamazoo', 'state': 'Michigan', 'country': 'United States', 'geoPoint': {'lat': 42.29171, 'lon': -85.58723}}, {'facility': 'Research Site', 'city': 'Troy', 'state': 'Michigan', 'country': 'United States', 'geoPoint': {'lat': 42.60559, 'lon': -83.14993}}, {'facility': 'Research Site', 'city': 'Butte', 'state': 'Montana', 'country': 'United States', 'geoPoint': {'lat': 46.00382, 'lon': -112.53474}}, {'facility': 'Research Site', 'city': 'McCook', 'state': 'Nebraska', 'country': 'United States', 'geoPoint': {'lat': 40.20195, 'lon': -100.62571}}, {'facility': 'Research Site', 'city': 'North Platte', 'state': 'Nebraska', 'country': 'United States', 'geoPoint': {'lat': 41.12389, 'lon': -100.76542}}, {'facility': 'Research Site', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'facility': 'Research Site', 'city': 'Scottsbluff', 'state': 'Nebraska', 'country': 'United States', 'geoPoint': {'lat': 41.86663, 'lon': -103.66717}}, {'facility': 'Research Site', 'city': 'Princeton', 'state': 'New Jersey', 'country': 'United States', 'geoPoint': {'lat': 40.34872, 'lon': -74.65905}}, {'facility': 'Research Site', 'city': 'Albuquerque', 'state': 'New Mexico', 'country': 'United States', 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'facility': 'Research Site', 'city': 'Albany', 'state': 'New York', 'country': 'United States', 'geoPoint': {'lat': 42.65258, 'lon': -73.75623}}, {'facility': 'Research Site', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Research Site', 'city': 'Rochester', 'state': 'New York', 'country': 'United States', 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'facility': 'Research Site', 'city': 'Greenville', 'state': 'North Carolina', 'country': 'United States', 'geoPoint': {'lat': 35.61266, 'lon': -77.36635}}, {'facility': 'Research Site', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'facility': 'Research Site', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'facility': 'Research Site', 'city': 'Chattanooga', 'state': 'Tennessee', 'country': 'United States', 'geoPoint': {'lat': 35.04563, 'lon': -85.30968}}, {'facility': 'Research Site', 'city': 'Knoxville', 'state': 'Tennessee', 'country': 'United States', 'geoPoint': {'lat': 35.96064, 'lon': -83.92074}}, {'facility': 'Research Site', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'Research Site', 'city': 'Georgetown', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 30.63269, 'lon': -97.67723}}, {'facility': 'Research Site', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'Research Site', 'city': 'The Colony', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 33.08901, 'lon': -96.88639}}, {'facility': 'Research Site', 'city': 'Olympia', 'state': 'Washington', 'country': 'United States', 'geoPoint': {'lat': 47.03787, 'lon': -122.9007}}, {'facility': 'Research Site', 'city': 'Renton', 'state': 'Washington', 'country': 'United States', 'geoPoint': {'lat': 47.48288, 'lon': -122.21707}}, {'facility': 'Research Site', 'city': 'Tacoma', 'state': 'Washington', 'country': 'United States', 'geoPoint': {'lat': 47.25288, 'lon': -122.44429}}, {'facility': 'Research Site', 'city': 'Charleston', 'state': 'West Virginia', 'country': 'United States', 'geoPoint': {'lat': 38.34982, 'lon': -81.63262}}, {'facility': 'Research Site', 'city': 'Huntington', 'state': 'West Virginia', 'country': 'United States', 'geoPoint': {'lat': 38.41925, 'lon': -82.44515}}, {'facility': 'Research Site', 'city': 'Calgary', 'state': 'Alberta', 'country': 'Canada', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'facility': 'Research Site', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'facility': 'Research Site', 'city': 'Dartmouth', 'state': 'Nova Scotia', 'country': 'Canada', 'geoPoint': {'lat': 44.67134, 'lon': -63.57719}}, {'facility': 'Research Site', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'facility': 'Research Site', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Research Site', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'facility': 'Research Site', 'city': 'Granada', 'country': 'Spain', 'geoPoint': {'lat': 37.18817, 'lon': -3.60667}}, {'facility': 'Research Site', 'city': 'Sevilla', 'country': 'Spain', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'facility': 'Research Site', 'city': 'Valencia', 'country': 'Spain', 'geoPoint': {'lat': 39.46975, 'lon': -0.37739}}, {'facility': 'Research Site', 'city': 'Valladolid', 'country': 'Spain', 'geoPoint': {'lat': 41.65518, 'lon': -4.72372}}, {'facility': 'Research Site', 'city': 'Zaragoza', 'country': 'Spain', 'geoPoint': {'lat': 41.65606, 'lon': -0.87734}}]}, 'referencesModule': {'references': [{'pmid': '22236356', 'type': 'DERIVED', 'citation': 'Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012 Jun;14(6):546-54. doi: 10.1111/j.1463-1326.2012.01561.x. Epub 2012 Feb 10.'}, {'pmid': '17404349', 'type': 'DERIVED', 'citation': 'Zinman B, Hoogwerf BJ, Duran Garcia S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007 Apr 3;146(7):477-85. doi: 10.7326/0003-4819-146-7-200704030-00003. Erratum In: Ann Intern Med. 2007 Jun 19;146(12):896.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077270', 'term': 'Exenatide'}], 'ancestors': [{'id': 'D000097789', 'term': 'Glucagon-Like Peptide-1 Receptor Agonists'}, {'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D019440', 'term': 'Anti-Obesity Agents'}, {'id': 'D054795', 'term': 'Incretins'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}], 'browseLeaves': [{'id': 'M11667', 'name': 'Metformin', 'relevance': 'LOW'}, {'id': 'M244708', 'name': '2,4-thiazolidinedione', 'relevance': 'LOW'}, {'id': 'M1726', 'name': 'Exenatide', 'asFound': '90 minutes', 'relevance': 'HIGH'}, {'id': 'M29005', 'name': 'Islet Amyloid Polypeptide', 'relevance': 'LOW'}, {'id': 'M3401', 'name': 'Glucagon-Like Peptide-1 Receptor Agonists', 'relevance': 'LOW'}, {'id': 'M9043', 'name': 'Glucagon', 'relevance': 'LOW'}, {'id': 'M26997', 'name': 'Glucagon-Like Peptide 1', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M21396', 'name': 'Anti-Obesity Agents', 'relevance': 'LOW'}, {'id': 'M27905', 'name': 'Incretins', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AnObAg', 'name': 'Anti-Obesity Agents'}, {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03579420', 'orgStudyIdInfo': {'id': 'bPEGT2'}, 'organization': {'fullName': 'Azienda Ospedaliero-Universitaria Careggi', 'class': 'OTHER'}, 'briefTitle': 'Efficacy of a Brief Lifestyle Intervention in Type 2 Diabetes, Compared With a Longer Group Educational Program', 'officialTitle': 'Efficacy of a Brief Group Program Versus a Longer Structured Program for Therapeutic Education of Patients With Type 2 Diabetes.'}, 'statusModule': {'statusVerifiedDate': '2021-01', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-03-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-10-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2024-04-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2018-06-01', 'studyFirstSubmitQcDate': '2018-06-25', 'studyFirstPostDateStruct': {'date': '2018-07-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-01-12', 'lastUpdatePostDateStruct': {'date': '2021-01-13', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Edoardo Mannucci', 'investigatorTitle': 'Director, Diabetology', 'investigatorAffiliation': 'Azienda Ospedaliero-Universitaria Careggi'}, 'leadSponsor': {'name': 'Azienda Ospedaliero-Universitaria Careggi', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The study will compare two different programs for lifestyle intervention in type 2 diabetes:\\n\\n1. A brief group program, with three weekly sessions\\n2. A longer group program, with six weekly sessions, which has been routinely used for the management of type 2 diabetic patients in this hospital for several years.\\n\\nThe aim is that of demonstrating the non-inferiority of the new brief, and more sustainable, program, in comparison with the more traditional approach.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 226, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Brief lifestyle program', 'type': 'EXPERIMENTAL', 'description': '3-session lifestyle group intervention program focussed on physical activity and eating habits, using interactive methods and a behavioral approach', 'interventionNames': ['Behavioral: Brief lifestyle program']}, {'label': 'Traditional lifestyle longer program', 'type': 'ACTIVE_COMPARATOR', 'description': '6-session lifestyle group intervention program focussed on physical activity and eating habits, using traditional lessons and interactive methods', 'interventionNames': ['Behavioral: Conventional lifestyle program']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Brief lifestyle program', 'description': '3-session program for modification of lifestyle habits (exercise and diet)', 'armGroupLabels': ['Brief lifestyle program']}, {'type': 'BEHAVIORAL', 'name': 'Conventional lifestyle program', 'description': '6-session program for modification of lifestyle habits (exercise and diet)', 'armGroupLabels': ['Traditional lifestyle longer program']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1c at 6 months', 'timeFrame': '6 months'}, {'measure': 'Treatment success at 6 months', 'description': 'HbA1c within predefined target without any increase in pharmacological therapy', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Treatment success at 24 months', 'description': 'HbA1c within predefined target without any increase in pharmacological therapy', 'timeFrame': '24 months'}, {'measure': 'HbA1c at 24 months', 'timeFrame': '24 months'}, {'measure': 'MEditerranean DIet adherence LITErature-based (MEDI-LITE) questionnaire scores', 'description': '14-item questionnaire with scores ranging from 0 (low adherence) to 18 (high adherence)', 'timeFrame': '24 months'}, {'measure': 'International Physical Activity Questionnaire-Short Form (IPAQ-SF) scores', 'description': '7-item questionnaire with scores ranging from 0 (no activity) to 7 (high activity)', 'timeFrame': '24 months'}, {'measure': 'Well-being Enquiry in Diabetics (WED) questionnaire total score', 'description': '50-item questionnaire measuring diabetes-specific health-related quality of life, with scores ranging from 0 (low) to 50 (high). Only total score will be used in analysis 1. Mannucci E, et al., Diabetes Nutr Metab 9: 89-102, 1996).', 'timeFrame': '24 months'}, {'measure': 'Body Mass Index', 'timeFrame': '6 months'}, {'measure': 'Waist circumference', 'timeFrame': '6 months'}, {'measure': 'Body Mass Index', 'timeFrame': '24 months'}, {'measure': 'Waist circumference', 'timeFrame': '24 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Type 2 diabetes\\n* HbA1c between 48 and 75 mmol/mol\\n\\nExclusion Criteria:\\n\\n* Axis I Mental Disorders\\n* Heart failure (NYHA Class III or IV)\\n* Foot ulcers or lower limb amputations', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Mattreo Monami, MD', 'role': 'CONTACT', 'phone': '3384027484', 'email': 'matteo.monami@unifi.it'}], 'locations': [{'facility': 'Diabetologia AOU Careggi', 'status': 'RECRUITING', 'city': 'Florence', 'zip': '50134', 'country': 'Italy', 'contacts': [{'name': 'Matteo Monami, MD', 'role': 'CONTACT', 'phone': '3384027484', 'email': 'matteo.monami@unifi.it'}], 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04667182', 'orgStudyIdInfo': {'id': '17420'}, 'secondaryIdInfos': [{'id': 'F3Z-MC-IORN', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}], 'organization': {'fullName': 'Eli Lilly and Company', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes', 'officialTitle': 'Meal-centric Insulin Dosing for Optimized Post-Prandial Glucose Control in People Using Multiple Daily Injections'}, 'statusModule': {'statusVerifiedDate': '2021-09', 'overallStatus': 'WITHDRAWN', 'whyStopped': 'Study was withdrawn prior to enrolment due to business decision.', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-01-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2021-12-06', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2021-12-06', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2020-12-11', 'studyFirstSubmitQcDate': '2020-12-11', 'studyFirstPostDateStruct': {'date': '2020-12-14', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-09-10', 'lastUpdatePostDateStruct': {'date': '2021-09-17', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The main purpose of this study is to determine whether combining meal, glucose and insulin data in a web-based system will improve management of type 1 (T1D) and type 2 diabetes (T2D). No study drug will be given. The study will last about 18 weeks.'}, 'conditionsModule': {'conditions': ['Type 1 Diabetes', 'Type 2 Diabetes'], 'keywords': ['T1D', 'T2D']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Combined Diabetes Management Data', 'description': 'Participants with type 1 and type 2 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their insulin pen and continuous glucose monitor (CGM). Combined data will be used as a complement to standard of care for diabetes management.', 'interventionNames': ['Other: Meal-Tagging App and Web-based Portal:', 'Device: Fitness Tracker']}], 'interventions': [{'type': 'OTHER', 'name': 'Meal-Tagging App and Web-based Portal:', 'description': 'Meal tagging app to capture frequently eaten meals and test meals for 18 weeks.', 'armGroupLabels': ['Combined Diabetes Management Data']}, {'type': 'DEVICE', 'name': 'Fitness Tracker', 'description': 'Fitness tracker will be worn around the clock for 18 weeks.', 'armGroupLabels': ['Combined Diabetes Management Data']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from Baseline in Area Under the Curve (AUC) of CGM', 'description': 'Change from Baseline in AUC of CGM', 'timeFrame': 'Baseline, Week 17'}], 'secondaryOutcomes': [{'measure': 'Qualitative data from study investigators and participants', 'description': 'Qualitative data describing experience from study investigators and participants', 'timeFrame': 'Baseline through Week 17'}, {'measure': 'Percent Time-in-Range (TIR)', 'description': 'Percent Time-in-Range defined as glucose \\\\>70 and ≤180 milligrams per deciliter \\\\[mg/dL\\\\])', 'timeFrame': 'Baseline through Week 17'}, {'measure': 'Postprandial TIR', 'description': 'Postprandial TIR is defined as TIR glucose: glucose \\\\>=70 and ≤180 mg/dL', 'timeFrame': 'Baseline through Week 17'}, {'measure': 'Time Above Range (TAR)', 'description': 'TAR is defined as glucose \\\\> 180 mg/dL', 'timeFrame': 'Baseline through Week 17'}, {'measure': 'Time Below Range (TBR) <70 mg/dL', 'description': 'TBR is defined as glucose \\\\< 70 mg/dL', 'timeFrame': 'Baseline through Week 17'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Individuals with type 1 or type 2 diabetes for \\\\>3 years by clinical diagnosis who use basal insulin, in addition to at least one injection of meal time insulin per day\\n* Insulin pen use for at least 3 months\\n* Current use of or willingness to use Dexcom G6 at least 6 out of 7 days per week\\n* A1c 6.5-9.5%\\n\\nExclusion Criteria:\\n\\n* Currently using any form of insulin pump, including hybrid closed-loop system (e.g., Medtronic 670G)\\n* Individuals requiring single insulin boluses of \\\\>40 units\\n* Individuals planning to follow a specific diet plan for weight loss\\n* Inability to consume regular, consistent meals\\n* Individuals who have had severe hypoglycemia with seizure or coma within the past 6 months\\n* Individuals who have been hospitalized for diabetic ketoacidosis (DKA) within the past 6 months', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '25 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Adults with T1D and T2D', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)', 'affiliation': 'Eli Lilly and Company', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Boston Medical Center', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02118', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'University of North Carolina, Chapel Hill', 'city': 'Chapel Hill', 'state': 'North Carolina', 'zip': '27599', 'country': 'United States', 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'relevance': 'LOW'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M6392', 'name': 'Complement System Proteins', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01862120', 'orgStudyIdInfo': {'id': 'P101106'}, 'organization': {'fullName': 'Assistance Publique - Hôpitaux de Paris', 'class': 'OTHER'}, 'briefTitle': 'Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes', 'officialTitle': 'Induction of Regulatory T Cells for the Treatment of Recently Diagnosed Type 1 Diabetes: Dose Finding Study of the Lowest Active Dose of IL-2 in Children', 'acronym': 'DFIL2-Child'}, 'statusModule': {'statusVerifiedDate': '2020-11', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-06-27', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-07-08', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2017-03-16', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2012-12-10', 'studyFirstSubmitQcDate': '2013-05-23', 'studyFirstPostDateStruct': {'date': '2013-05-24', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2020-11-10', 'lastUpdatePostDateStruct': {'date': '2020-11-12', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Assistance Publique - Hôpitaux de Paris', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'Human recombinant interleukin-2 (rhIL-2) is a biological signalling protein playing a key role in the regulation of the immune system. At high doses, rhIL-2 activates the immune effectors T cells (TEFFS) while at low doses rhIL-2 induces and activates regulatory T cells (TREGS), a population of immune cells controlling the immune Teff response. In patients with Type 1 Diabetes (T1D), TREGS fail to control the autoimmune destruction by TEFFS of pancreatic beta-cells producing insulin. The investigator recently showed that rhIL-2 at low dose is well tolerated in patients with an autoimmune disease and in adults with established T1D, inducing TREGS without effects on TEFFS. The investigators aim to use rhIL-2 at low dose to induce/stimulate TREGS in young recently diagnosed T1D patients. This study will investigate the dose effect relationship of low dose rhIL-2 on TREG induction such as to optimize the risk benefit ratio of this treatment in T1D. Through Treg induction, the investigators aim to protect the remaining/regenerating pancreatic β-cells from autoimmune destruction, thus improving or even curing T1D.', 'detailedDescription': 'Main objective:\\n\\nDefine the lowest dose of rhIL-2 inducing TREGS in children with recently diagnosed type 1 diabetes.\\n\\nConduct of the study:\\n\\nThree doses will be studied versus placebo in parallel groups of six patients. Each dose or placebo will be studied according to three periods of treatment:\\n\\n1. Induction of TREGS following a cure of 5 days repeated once daily administration \\\\[day 1 - day 5\\\\].\\n2. Maintenance of TREGS following repeated administration once every two weeks for one year \\\\[day 15 - day 337\\\\].\\n\\nAt each treatment period, Treg response and tolerance will be evaluated. In addition, overall response on T1D parameters will be assessed throughout the study.'}, 'conditionsModule': {'conditions': ['Type 1 Diabetes'], 'keywords': ['Recently diagnosed', 'Regulatory T Cells', 'Tolerance Induction', 'Paediatrics', 'Low dose', 'IL-2']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 24, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'interleukin-2', 'type': 'EXPERIMENTAL', 'description': 'Dose D1 of interleukin-2', 'interventionNames': ['Drug: Dose D1 of interleukin-2']}, {'label': 'Dose D2 of interleukin-2', 'type': 'EXPERIMENTAL', 'description': 'Dose D2 of interleukin-2', 'interventionNames': ['Drug: Dose D2 of Interleukin-2']}, {'label': 'Dose D3 of interleukin-2', 'type': 'EXPERIMENTAL', 'description': 'Dose D3 of interleukin-2', 'interventionNames': ['Drug: Dose D3 of interleukin-2']}, {'label': 'placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'placebo', 'interventionNames': ['Drug: placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Dose D1 of interleukin-2', 'description': 'subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).', 'armGroupLabels': ['interleukin-2']}, {'type': 'DRUG', 'name': 'placebo', 'description': 'subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).', 'armGroupLabels': ['placebo']}, {'type': 'DRUG', 'name': 'Dose D2 of Interleukin-2', 'description': 'subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).', 'armGroupLabels': ['Dose D2 of interleukin-2']}, {'type': 'DRUG', 'name': 'Dose D3 of interleukin-2', 'description': 'subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).', 'armGroupLabels': ['Dose D3 of interleukin-2']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Treg response following the induction cure period', 'description': 'expressed as % total CD4 cells', 'timeFrame': 'day 5'}], 'secondaryOutcomes': [{'measure': 'Fasting plasma concentration of C-peptide', 'timeFrame': 'at Day 0, 99, 183, 267, 351, 436'}, {'measure': 'C-peptide AUC response to a mixed meal tolerance test', 'timeFrame': 'at baseline, at months 6, 12, 15'}, {'measure': 'IDAA1C score', 'description': 'is a score defined as A1C (percent) + \\\\[4 x insulin dose (units per kilogram per 24 h)\\\\] without unit', 'timeFrame': 'at baseline, at months 3, 6, 9, 12, 15'}, {'measure': 'HbA1c', 'timeFrame': 'at baseline, at months 3, 6, 9, 12, 15'}, {'measure': 'Treg response after the last administration', 'timeFrame': 'day 351, day 436'}, {'measure': 'Treg response during the maintenance period compare to the baseline', 'description': 'Treg response expressed as the % / CD4 will be measured several times', 'timeFrame': 'day 15, day 29, day 43, day 99, day 183, day 267'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion criteria :\\n\\n* Age \\\\[7-13\\\\] years for girls and \\\\[7-14\\\\] years for boys\\n\\n  * With a T1D diagnosis (as ADA)\\n  * Treated with insulin for ≤ 3 months,\\n  * With at least one auto-antibody among: anti-insulin, anti-GAD, anti-IA2, anti-ZnT8 ;\\n* No clinically relevant abnormal findings for haematology, biochemistry, liver and kidney functions\\n* Informed consent signed by the patient, the parents, and the investigator before any intervention necessary for the trial.\\n\\nExclusion criteria :\\n\\n* Contra-indications to IL-2 :\\n\\n  * Hyper sensibility to IL-2 or its excipients,\\n  * Severe cardiopathy\\n  * Previous organ allograft\\n  * Ongoing infection requiring antibiotherapy,\\n  * O2 Saturation ≤ 90 %\\n  * Severe impairment of any vital organ\\n  * Documented history of other auto-immune diseases (except for auto-antibodies for, IAA, GADA, IA-2A, anti-ZnT8A, and stable thyroiditis with normal TSH (\\\\<10 mUI/L), T3 and, T4 levels.\\n  * Diabetes onset characteristics including:\\n\\n    * Continuous nocturnal polyuria ≥ 3 months ;\\n    * Inaugural acidosis (with venous Ph \\\\< 7.25) ;\\n    * HbA1c at diagnostic ≥ 13%;\\n    * Weight loss ≥ 10 % at diagnosis ;\\n    * Positive autoantibodies to 21-hydroxylase\\n    * Stage 2 obesity\\n* Non authorized concomitant treatment : immuno-modulators, cytotoxic drugs, drug modifying plasma glycemia\\n* vaccination ≤ 4 weeks with life vaccin\\n* Positive serology (IgM) to the Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV), reflecting an acute infection.\\n* Participation to another clinical investigation in previous 3 months\\n* No affiliation to National Health Insurance', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '7 Years', 'maximumAge': '14 Years', 'stdAges': ['CHILD']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'David Klatzmann, MD, PhD', 'affiliation': 'APHP', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': \"Service d'Endocrinologie Pédiatrique\", 'city': 'Le Kremlin Bicetre', 'zip': '94275', 'country': 'France', 'geoPoint': {'lat': 48.81471, 'lon': 2.36073}}, {'facility': 'Service de Pédiatrie - CHU de Nîmes', 'city': 'Nimes', 'zip': '30029 cedex 9', 'country': 'France', 'geoPoint': {'lat': 43.83333, 'lon': 4.35}}, {'facility': 'CIC pédiatrique - CHU de Necker', 'city': 'Paris', 'zip': '75015', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': \"Service d'endocrinologie pédiatrique - CHU de Necker\", 'city': 'Paris', 'zip': '75015', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'CIC 9202 CHU Rober Débré', 'city': 'Paris', 'zip': '75019', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': \"Service d'endocrinologie Diabétologie pédiatrique CHU Robert Débré\", 'city': 'Paris', 'zip': '75019', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}]}, 'referencesModule': {'references': [{'pmid': '32607749', 'type': 'DERIVED', 'citation': 'Rosenzwajg M, Salet R, Lorenzon R, Tchitchek N, Roux A, Bernard C, Carel JC, Storey C, Polak M, Beltrand J, Amouyal C, Hartemann A, Corbeau P, Vicaut E, Bibal C, Bougneres P, Tran TA, Klatzmann D. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia. 2020 Sep;63(9):1808-1821. doi: 10.1007/s00125-020-05200-w. Epub 2020 Jul 1.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D007376', 'term': 'Interleukin-2'}], 'ancestors': [{'id': 'D000970', 'term': 'Antineoplastic Agents'}, {'id': 'D018712', 'term': 'Analgesics, Non-Narcotic'}, {'id': 'D000700', 'term': 'Analgesics'}, {'id': 'D018689', 'term': 'Sensory System Agents'}, {'id': 'D018373', 'term': 'Peripheral Nervous System Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M10411', 'name': 'Interleukin-2', 'asFound': 'Guide', 'relevance': 'HIGH'}, {'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'}, {'id': 'M20786', 'name': 'Analgesics, Non-Narcotic', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'Analg', 'name': 'Analgesics'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03766620', 'orgStudyIdInfo': {'id': 'DA14'}, 'organization': {'fullName': 'Abbott Nutrition', 'class': 'INDUSTRY'}, 'briefTitle': 'A Tube Feeding Study in Malnourished Population With Diabetes', 'officialTitle': 'A Prospective, Observational Study, of a High Calorie, High Protein Tube Feeding With Slow Release Carbohydrates and Monounsaturated Fatty Acids (MUFA), in a Malnourished Population With Diabetes'}, 'statusModule': {'statusVerifiedDate': '2020-07', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-11-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-07-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2020-07-01', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-12-05', 'studyFirstSubmitQcDate': '2018-12-05', 'studyFirstPostDateStruct': {'date': '2018-12-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-07-23', 'lastUpdatePostDateStruct': {'date': '2020-07-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Abbott Nutrition', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is a prospective, non-interventional, observational study. Malnourished subjects with diabetes, who are receiving a high calorie, high protein tube feeding with slow release carbohydrates and MUFA by their health care professional (HCP) per standard of care will be enrolled into the study.'}, 'conditionsModule': {'conditions': ['Malnutrition; Diabetes']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 49, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Tube Fed Participants', 'description': 'Individuals with diabetes and malnutrition receiving tube feed as sole source nutrition.'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Body Weight Change', 'description': 'Measured in Kg', 'timeFrame': 'Baseline to Study Exit Week 12'}], 'secondaryOutcomes': [{'measure': 'Malnutrition Universal Screening Tool (MUST)', 'description': 'HCP completed screening tool', 'timeFrame': 'Baseline to Study Exit Week 12'}, {'measure': 'Subjective Global Assessment (SGA)', 'description': 'HCP completed nutrition assessment', 'timeFrame': 'Baseline to Study Exit Week 12'}, {'measure': 'Quality of life (EuroQol EQ-5D-5L)', 'description': 'Subject rated health state of 5 dimensions. Each dimension has 5-levels scaled in negative direction resulting in an overall 5-digit number describing the health state; EQ VAS Score 0-100 points scaled in positive direction', 'timeFrame': 'Baseline to Study Exit Week 12'}, {'measure': 'Glucose control', 'description': 'HbA1c levels', 'timeFrame': 'Baseline to Study Exit Week 12'}, {'measure': 'Body Mass Index', 'description': 'BMI calculated Weight (kg)/Height (m)2', 'timeFrame': 'Baseline to Study Exit Week 12'}, {'measure': 'Product Compliance', 'description': 'Product consumption diary', 'timeFrame': 'Baseline to Study Exit Week 12'}, {'measure': 'Albumin Levels', 'description': 'Nutrition status parameter collected per standard of care', 'timeFrame': 'Baseline to Study Exit Week 12'}], 'otherOutcomes': [{'measure': 'Functionality', 'description': 'Barthel Index of Activities of Daily Living; Subject completed assessment of 10 functions; Sum of scores range from 0-20 scaled in positive direction', 'timeFrame': 'Baseline to Study Exit Week 12'}, {'measure': 'Physician Product Satisfaction', 'description': 'Physician Completed Questionnaire; 3 to 5 category responses scaled in negative direction', 'timeFrame': 'Baseline to Study Exit Week 12'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Voluntarily signed and dated an informed consent form, approved by an Independent Ethics Committee, prior to any participation in the study\\n* Considered malnourished, or at risk for malnutrition\\n* Diagnosed with diabetes mellitus type 1 or 2 and treated with oral hypoglycemic medications and/or exogenous insulin\\n* Conforms to the requirements set forth on the study product label\\n* Under the care of a health care professional for malnutrition and has recently been prescribed tube feeding as a sole-source of nutrition by their health care professional\\n* Free living, residing in a nursing home or admitted to the hospital and has anticipated length of hospital stay \\\\> 3 days and \\\\< 12 days\\n\\nExclusion Criteria:\\n\\n* Severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures\\n* Cannot safely consume the study product, or known to be allergic or intolerant to any ingredient found in the study product\\n* Renal or liver failure\\n* Participates in another study that has not been approved as a concomitant study by AN', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Subjects, men and women who meet all enrollment criteria, will be enrolled from study centers in Spain.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Maria Camprubi Robles, PhD', 'affiliation': 'Abbott', 'role': 'STUDY_CHAIR'}, {'name': 'Angela M Palmero, MD', 'affiliation': 'Hospital San Pedro de La Rioja', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Hospital San Pedro', 'city': 'Logroño', 'state': 'La Rioja', 'zip': '26006', 'country': 'Spain', 'geoPoint': {'lat': 42.46667, 'lon': -2.45}}, {'facility': 'Hospital Costa del Sol 3095', 'city': 'Marbella', 'state': 'Málaga', 'zip': '29603', 'country': 'Spain', 'geoPoint': {'lat': 36.51543, 'lon': -4.88583}}, {'facility': 'Hospital Costa del Sol 3178', 'city': 'Marbella', 'state': 'Málaga', 'zip': '29603', 'country': 'Spain', 'geoPoint': {'lat': 36.51543, 'lon': -4.88583}}, {'facility': 'Hospital Universitario La Paz', 'city': 'Madrid', 'zip': '28046', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Gomez-Ulla', 'city': 'Madrid', 'zip': '28047', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Centro Médico San juan de la Cruz', 'city': 'Málaga', 'zip': '29007', 'country': 'Spain', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'facility': 'Hospital Clínico Universitario de Valladolid', 'city': 'Valladolid', 'zip': '47003', 'country': 'Spain', 'geoPoint': {'lat': 41.65518, 'lon': -4.72372}}, {'facility': 'Hospital General Universitario de Valencia', 'city': 'València', 'zip': '46014', 'country': 'Spain', 'geoPoint': {'lat': 39.46975, 'lon': -0.37739}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044342', 'term': 'Malnutrition'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M25306', 'name': 'Malnutrition', 'asFound': 'Malnutrition', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M12684', 'name': 'Nutrition Disorders', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03544320', 'orgStudyIdInfo': {'id': '829150'}, 'organization': {'fullName': 'University of Pennsylvania', 'class': 'OTHER'}, 'briefTitle': 'Prediction Using Connected Technologies for Diabetes', 'officialTitle': 'Prediction Using a Randomized Evaluation of Data Collection Integrated Through Connected Technologies for Diabetes Management', 'acronym': 'PREDICT-DM'}, 'statusModule': {'statusVerifiedDate': '2019-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-07-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-08-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2019-08-01', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-05-18', 'studyFirstSubmitQcDate': '2018-05-18', 'studyFirstPostDateStruct': {'date': '2018-06-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-08-28', 'lastUpdatePostDateStruct': {'date': '2019-08-29', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'University of Pennsylvania', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'In this study, adults with pre-diabetes will be prospectively enrolled for data collection to design prediction models that integrate electronic health record data and patient-generated activity data. Patients will be randomized to receive either a waist-worn or wrist-worn wearable device for 6 months to capture patient-generated activity data.', 'detailedDescription': 'Patients with suboptimal glycemic control could be better managed if these higher risk patients could be identified and effective interventions were then targeted towards them. However, most practice settings perform infrequent laboratory testing every 3 to 6 months, if not at longer intervals. Current models to predict change in glycemic control perform poorly and do not take into account the behaviors that occur between these intervals. In this study, we will compare different methods to use data on daily health behaviors collected by wearable devices to enhance risk prediction models. Adults with pre-diabetes will complete a series of surveys and baseline assessments and then will be randomly assigned to use a waist-worn or wrist-worn wearable device for 6 months. Measures of HbA1c and LDL will be obtained at baseline and at 6 months.'}, 'conditionsModule': {'conditions': ['Pre-Diabetes'], 'keywords': ['Pre-diabetes', 'diabetes', 'wearable devices', 'mobile health']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Participants are randomized to one of two wearable devices and will wear that device for the duration of the study.', 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': 'The participants will be aware of the two different study arms and the wearable devices used in both. The study investigator will not have not have knowledge of the participants assigned to each arm.', 'whoMasked': ['INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 186, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Activity Monitoring-Wrist worn wearable', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants in the activity monitoring-wrist worn wearable group will be randomly assigned to track their activity using a Fitbit Charge 2 for 6 months.', 'interventionNames': ['Device: Activity Monitoring-Wrist worn wearable']}, {'label': 'Activity Monitoring-Waist-worn wearable', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants in the activity monitoring-waist worn wearable group will be randomly assigned to track their activity using a Fitbit Zip for 6 months.', 'interventionNames': ['Device: Activity Monitoring-Waist-worn wearable']}], 'interventions': [{'type': 'DEVICE', 'name': 'Activity Monitoring-Wrist worn wearable', 'description': 'Participants wear an activity monitor on their wrist.', 'armGroupLabels': ['Activity Monitoring-Wrist worn wearable']}, {'type': 'DEVICE', 'name': 'Activity Monitoring-Waist-worn wearable', 'description': 'Participants wear an activity monitor on their waist.', 'armGroupLabels': ['Activity Monitoring-Waist-worn wearable']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in hemoglobin A1c', 'description': 'Change in hemoglobin A1c from baseline to 6 months', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Change in low-density lipoprotein (LDL) levels', 'description': 'Change in LDL level from baseline to 6 months', 'timeFrame': '6 months'}], 'otherOutcomes': [{'measure': 'Hospitalization', 'description': 'Admission to the hospital', 'timeFrame': '6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Be 18 years or older\\n2. Be able to provide informed consent\\n3. Have a smartphone or tablet compatible with the wearable device smartphone application and be willing to use the wearable device for 6 months\\n4. Baseline hemoglobin A1c of 5.7 to 6.4\\n\\nExclusion Criteria:\\n\\nParticipants will no be eligible if they have any medical condition or other reason that will likely prohibit them from completing the 6-month study', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Mitesh S Patel, MD', 'affiliation': 'University of Pennsylvania', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Penn Medicine', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19103', 'country': 'United States', 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D011236', 'term': 'Prediabetic State'}, {'id': 'D018149', 'term': 'Glucose Intolerance'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D006943', 'term': 'Hyperglycemia'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M14117', 'name': 'Prediabetic State', 'asFound': 'Pre-diabetes', 'relevance': 'HIGH'}, {'id': 'M20295', 'name': 'Glucose Intolerance', 'asFound': 'Pre-diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M9994', 'name': 'Hyperglycemia', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00451620', 'orgStudyIdInfo': {'id': 'H02-70584'}, 'secondaryIdInfos': [{'id': 'H02-70584'}], 'organization': {'fullName': 'University of British Columbia', 'class': 'OTHER'}, 'briefTitle': 'Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes', 'officialTitle': 'Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2018-01', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2003-11'}, 'primaryCompletionDateStruct': {'date': '2011-09', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2011-09', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2007-03-21', 'studyFirstSubmitQcDate': '2007-03-22', 'studyFirstPostDateStruct': {'date': '2007-03-23', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2018-01-16', 'lastUpdatePostDateStruct': {'date': '2018-01-18', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Graydon Meneilly', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'University of British Columbia'}, 'leadSponsor': {'name': 'University of British Columbia', 'class': 'OTHER'}, 'collaborators': [{'name': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The results from the DECODE Study have shown that postprandial (1 - 2 hours after a meal) hyperglycemia (elevated blood sugar) is more common in elderly people with diabetes than younger people with diabetes and is the best predictor of the development of complications. The DECODE Study involved 6941 people who already had diabetes and 702 who did not have diabetes. Diabetes is diagnosed when the blood sugar 1st thing in the morning is over 7.0 mmol/L. The DECODE Study showed that people at risk for diabetes can have a normal blood sugar 1st thing in the morning but have a high blood sugar 2 hours after a meal and that these people are at risk for developing heart disease and other complications of diabetes. These people would not be identified as at risk if only a fasting blood sugar is done. Studies in younger people with diabetes have shown that after a meal, insulin levels are more like a person without diabetes and glucose (blood sugar) levels are lower with GlucoNorm than with Glyburide. There is no data available that demonstrates this in elderly people with type 2 diabetes.\\n\\nYou have been invited to participate in this study because you have type 2 diabetes controlled by diet and/or exercise or metformin only and are over 65 years of age.\\n\\nThe purpose of this study is to determine whether GlucoNorm has a greater effect than Glyburide on insulin levels and glucose (blood sugar) levels after a meal in elderly people with type 2 diabetes who control their diabetes with diet and exercise.', 'detailedDescription': 'The results from the DECODE Study have shown that postprandial hyperglycemia is more common in elderly people with diabetes than younger people and is the best predictor of mortality and morbidity. Studies in younger people with diabetes have shown that in response to a meal, insulin profiles are more physiologic and glucose levels are lower with GlucoNorm than with Glyburide. There is no data available that demonstrates this in elderly people with type 2 diabetes.\\n\\nThis is a randomized, open-label, cross-over study. Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes'], 'keywords': ['Type 2 diabetes', 'Hypoglycemia', 'Oral hypoglycemic agents', 'Insulin levels']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': '2.', 'type': 'EXPERIMENTAL', 'description': 'GlucoNorm', 'interventionNames': ['Drug: GlucoNorm']}, {'label': '1.', 'type': 'EXPERIMENTAL', 'description': 'Glyburide', 'interventionNames': ['Drug: glyburide']}], 'interventions': [{'type': 'DRUG', 'name': 'glyburide', 'description': 'Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.', 'armGroupLabels': ['1.']}, {'type': 'DRUG', 'name': 'GlucoNorm', 'description': 'Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.', 'armGroupLabels': ['2.']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The objective of this study is to determine whether GlucoNorm has a greater effect than Glyburide on insulin levels and postprandial glucose levels in elderly people with type 2 diabetes who are diet controlled.', 'timeFrame': '2 hours'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Type 2 diabetes \\\\> 3 months duration\\n* Male or female\\n* Over 65 years of age\\n* Diet controlled only\\n* HgbA1C \\\\< 8.5%\\n\\nExclusion Criteria:\\n\\n* Treatment with oral hypoglycemic agents or insulin or the likelihood of requiring treatment with these during the study.\\n* Anemia - hgb below 130 g/L (males) and below 120 g/L (females).\\n* Taking medications that known to interfere with glucose metabolism eg systemic corticosteriods, non-selective beta blockers.\\n* Known or suspected allergy to glyburide, sulfa drugs or GlucoNorm impaired liver function, as shown by but not limited to AST and/or ALT \\\\> 2x the upper limit of normal.\\n* Impaired renal function, as shown by but not limited to serum creatinine \\\\> 133 µmol/L (males) or 124 µmol/L (females).\\n* Participated in another clinical trial within the past 30 days.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '65 Years', 'stdAges': ['OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Graydon Meneilly, MD', 'affiliation': 'University of British Columbia', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of British Columbia', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D006943', 'term': 'Hyperglycemia'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M9994', 'name': 'Hyperglycemia', 'asFound': 'Hyperglycemia', 'relevance': 'HIGH'}, {'id': 'M10053', 'name': 'Hypoglycemia', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D005905', 'term': 'Glyburide'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M354161', 'name': 'Repaglinide', 'relevance': 'LOW'}, {'id': 'M9017', 'name': 'Glyburide', 'asFound': 'cTBS', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03542682', 'orgStudyIdInfo': {'id': '2000022726'}, 'organization': {'fullName': 'Yale University', 'class': 'OTHER'}, 'briefTitle': 'The Effect of Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes', 'officialTitle': 'The Effect of Insulin Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2024-01', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-05-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-09-23', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2022-09-23', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-04-30', 'studyFirstSubmitQcDate': '2018-05-30', 'studyFirstPostDateStruct': {'date': '2018-05-31', 'type': 'ACTUAL'}, 'resultsFirstSubmitDate': '2023-12-21', 'resultsFirstSubmitQcDate': '2024-01-23', 'resultsFirstPostDateStruct': {'date': '2024-02-13', 'type': 'ACTUAL'}, 'dispFirstSubmitDate': '2023-07-03', 'dispFirstPostDateStruct': {'date': '2024-02-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-01-23', 'lastUpdatePostDateStruct': {'date': '2024-02-13', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Yale University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True, 'isUsExport': True}, 'descriptionModule': {'briefSummary': 'Rapid Action Insulin (RAI) absorption and action measured by time to reach maximum insulin concentration and glucose infusion rate.', 'detailedDescription': 'The investigators hypothesize that RAI absorption and action measured by time to reach maximum insulin concentration and glucose infusion rate during the clamp study will be significantly faster when insulin bolus is delivered using the \"Quick Bolus\" feature as compared to the \"Standard Bolus\".\\n\\nOutcomes were updated at time of results entry.'}, 'conditionsModule': {'conditions': ['Type1diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'interventionModelDescription': 'This study will be a cross-over, randomized order, single blinded clinical study in subjects with Type 1 Diabetes.', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'SINGLE', 'maskingDescription': 'single blinded', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 11, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Individuals given Standard Bolus first, then quick bolus', 'type': 'ACTIVE_COMPARATOR', 'description': 'Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.', 'interventionNames': ['Device: Quick Bolus', 'Device: Standard Bolus']}, {'label': 'Individuals given Quick bolus first, then standard bolus', 'type': 'ACTIVE_COMPARATOR', 'description': 'Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.', 'interventionNames': ['Device: Quick Bolus', 'Device: Standard Bolus']}], 'interventions': [{'type': 'DEVICE', 'name': 'Quick Bolus', 'description': 'Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"quick bolus\" of 15 units per minute during a euglycemic clamp.', 'armGroupLabels': ['Individuals given Quick bolus first, then standard bolus', 'Individuals given Standard Bolus first, then quick bolus']}, {'type': 'DEVICE', 'name': 'Standard Bolus', 'description': 'Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"standard bolus\" of 1.5 units per minute during a euglycemic clamp.', 'armGroupLabels': ['Individuals given Quick bolus first, then standard bolus', 'Individuals given Standard Bolus first, then quick bolus']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Time to Maximum Glucose Infusion Rate', 'description': 'time to maximum glucose infusion rate (GIR) in minutes', 'timeFrame': '300 minutes'}], 'secondaryOutcomes': [{'measure': 'Earlier Clearance of Exogenous Insulin.', 'description': 'Time to reach baseline insulin concentrations is used to determine the completion of insulin as part bolus of bioavailability.', 'timeFrame': 'up to 5 hours'}, {'measure': 'Maximum Glucose Infusion Rate', 'description': 'maximum glucose infusion rate (GIRmax)', 'timeFrame': '300 minutes'}, {'measure': 'Area Under the Curve for the Glucose Infusion Rate', 'description': 'area under the curve for the glucose infusion rate', 'timeFrame': '300 minutes'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Age 18 - 30 (inclusive)\\n2. Clinical diagnosis of T1D of at least one year's duration\\n3. On Continuous Subcutaneous Insulin Infusion (CSII) therapy for at least three months\\n4. HbA1c \\\\<10%\\n5. Minimum weight requirement of at least 37.9 kg\\n6. Ability to comprehend written and spoken English\\n7. Total daily requirement of insulin between 0.6 and1.2 U/kg/day\\n8. Not have any other medical condition or disease known to affect insulin action and glucose control aside from T1D or treated hypothyroidism\\n\\nExclusion Criteria:\\n\\n1. Medication besides insulin known to alter blood glucose or insulin action\\n2. Female subjects of reproductive potential that are pregnant or breast feeding, or not consistently using a barrier method or abstinence as contraception.\\n3. Inability to comprehend written and spoken English\\n4. Any other condition, which in the judgment of the investigators, would interfere with the subject's ability to provide informed consent or the investigator's ability to perform the study\\n5. Hematocrit less than 35% or a serum potassium less than 3.4 mmol/L\", 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '30 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Eda Cengiz, MD', 'affiliation': 'Yale University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Yale University', 'city': 'New Haven', 'state': 'Connecticut', 'zip': '06520', 'country': 'United States', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': '11 participants consented to participate but 2 were lost to follow up prior to randomization', 'groups': [{'id': 'FG000', 'title': 'Individuals Given Standard Bolus First, Then Quick Bolus', 'description': 'Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.\\n\\nQuick Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"quick bolus\" of 15 units per minute during a euglycemic clamp.\\n\\nStandard Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"standard bolus\" of 1.5 units per minute during a euglycemic clamp.'}, {'id': 'FG001', 'title': 'Individuals Given Quick Bolus First, Then Standard Bolus', 'description': 'Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.\\n\\nQuick Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"quick bolus\" of 15 units per minute during a euglycemic clamp.\\n\\nStandard Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"standard bolus\" of 1.5 units per minute during a euglycemic clamp.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'comment': 'Participants randomized', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Completed First Stage', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Completed Second Stage', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '3'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '3'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'COVID-19 Protocol', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'populationDescription': 'Baseline demographics were collected from the 8 who completed.', 'groups': [{'id': 'BG000', 'title': 'Individuals Given Standard Bolus First, Then Quick Bolus', 'description': 'Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.\\n\\nQuick Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"quick bolus\" of 15 units per minute during a euglycemic clamp.\\n\\nStandard Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"standard bolus\" of 1.5 units per minute during a euglycemic clamp.'}, {'id': 'BG001', 'title': 'Individuals Given Quick Bolus First, Then Standard Bolus', 'description': 'Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.\\n\\nQuick Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"quick bolus\" of 15 units per minute during a euglycemic clamp.\\n\\nStandard Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"standard bolus\" of 1.5 units per minute during a euglycemic clamp.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '5'}, {'groupId': 'BG001', 'value': '3'}, {'groupId': 'BG002', 'value': '8'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '22.8', 'spread': '3.3'}, {'groupId': 'BG001', 'value': '20.7', 'spread': '3.1'}, {'groupId': 'BG002', 'value': '22', 'spread': '3.2'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '3'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '5'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '3'}]}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '1'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '5'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '7'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Race (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '1'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '4'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '6'}]}, {'title': 'More than one race', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '1'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '5'}, {'groupId': 'BG001', 'value': '3'}, {'groupId': 'BG002', 'value': '8'}]}]}]}, {'title': 'Baseline mean percent Hemoglobin A1c', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'percent Hemoglobin A1c', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '7.6', 'spread': '1.3'}, {'groupId': 'BG001', 'value': '7.9', 'spread': '1.1'}, {'groupId': 'BG002', 'value': '7.7', 'spread': '1.1'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Time to Maximum Glucose Infusion Rate', 'description': 'time to maximum glucose infusion rate (GIR) in minutes', 'populationDescription': 'Complete case analysis', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'minutes', 'timeFrame': '300 minutes', 'groups': [{'id': 'OG000', 'title': 'Quick Bolus', 'description': 'Quick Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"quick bolus\" of 15 units per minute during a euglycemic clamp.'}, {'id': 'OG001', 'title': 'Standard Bolus', 'description': 'Standard Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"standard bolus\" of 1.5 units per minute during a euglycemic clamp.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '8'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '116.54', 'lowerLimit': '74.74', 'upperLimit': '158.34'}, {'groupId': 'OG001', 'value': '172.21', 'lowerLimit': '130.41', 'upperLimit': '214.01'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'statisticalMethod': 'Mixed Models Analysis', 'statisticalComment': 'The model adjusted for order of the clamps and accounting for within subject correlation.', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '-55.67', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-124.63', 'ciUpperLimit': '13.30'}]}, {'type': 'SECONDARY', 'title': 'Earlier Clearance of Exogenous Insulin.', 'description': 'Time to reach baseline insulin concentrations is used to determine the completion of insulin as part bolus of bioavailability.', 'populationDescription': 'Outcome was not part of the study protocol and therefore was not collected.', 'reportingStatus': 'POSTED', 'timeFrame': 'up to 5 hours', 'groups': [{'id': 'OG000', 'title': 'Standard Bolus', 'description': 'Standard Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"standard bolus\" of 1.5 units per minute during a euglycemic clamp.'}, {'id': 'OG001', 'title': 'Quick Bolus', 'description': 'Quick Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"quick bolus\" of 15 units per minute during a euglycemic clamp.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}]}]}, {'type': 'SECONDARY', 'title': 'Maximum Glucose Infusion Rate', 'description': 'maximum glucose infusion rate (GIRmax)', 'populationDescription': 'Complete case analysis.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'mg/kg/min', 'timeFrame': '300 minutes', 'groups': [{'id': 'OG000', 'title': 'Quick Bolus', 'description': 'Quick Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"quick bolus\" of 15 units per minute during a euglycemic clamp.'}, {'id': 'OG001', 'title': 'Standard Bolus', 'description': 'Standard Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"standard bolus\" of 1.5 units per minute during a euglycemic clamp.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '8'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8.42', 'lowerLimit': '4.91', 'upperLimit': '11.92'}, {'groupId': 'OG001', 'value': '7.45', 'lowerLimit': '3.95', 'upperLimit': '10.96'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'statisticalMethod': 'Mixed Models Analysis', 'statisticalComment': 'The model adjusted for order of the clamps and accounting for within subject correlation.', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '0.96', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.10', 'ciUpperLimit': '3.02'}]}, {'type': 'SECONDARY', 'title': 'Area Under the Curve for the Glucose Infusion Rate', 'description': 'area under the curve for the glucose infusion rate', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'mg/kg', 'timeFrame': '300 minutes', 'groups': [{'id': 'OG000', 'title': 'Quick Bolus', 'description': 'Quick Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"quick bolus\" of 15 units per minute during a euglycemic clamp.'}, {'id': 'OG001', 'title': 'Standard Bolus', 'description': 'Standard Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"standard bolus\" of 1.5 units per minute during a euglycemic clamp.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '8'}, {'groupId': 'OG001', 'value': '8'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1204.29', 'lowerLimit': '716.72', 'upperLimit': '1691.86'}, {'groupId': 'OG001', 'value': '1072.44', 'lowerLimit': '584.86', 'upperLimit': '1560.01'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'statisticalMethod': 'Mixed Models Analysis', 'statisticalComment': 'The model adjusted for order of the clamps and accounting for within subject correlation.', 'paramType': 'Mean Difference (Final Values)', 'paramValue': '131.85', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-246.70', 'ciUpperLimit': '510.41'}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'timeFrame': 'Up to 5 hours post intervention for each intervention', 'eventGroups': [{'id': 'EG000', 'title': 'Individuals Given Standard Bolus', 'description': 'Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.\\n\\nStandard Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"standard bolus\" of 1.5 units per minute during a euglycemic clamp.', 'deathsNumAffected': 0, 'deathsNumAtRisk': 8, 'seriousNumAffected': 0, 'seriousNumAtRisk': 8, 'otherNumAffected': 0, 'otherNumAtRisk': 8}, {'id': 'EG001', 'title': 'Individuals Given Quick Bolus', 'description': 'Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.\\n\\nQuick Bolus: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via \"quick bolus\" of 15 units per minute during a euglycemic clamp.', 'deathsNumAffected': 0, 'deathsNumAtRisk': 9, 'seriousNumAffected': 0, 'seriousNumAtRisk': 9, 'otherNumAffected': 1, 'otherNumAtRisk': 9}], 'otherEvents': [{'term': 'Common Cold', 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 9}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': True}, 'pointOfContact': {'title': 'Laura Marie Nally, MD', 'organization': 'Yale School of Medicine', 'email': 'laura.nally@yale.edu', 'phone': '(877) 925-3637'}}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot_SAP', 'hasProtocol': True, 'hasSap': True, 'hasIcf': False, 'label': 'Study Protocol and Statistical Analysis Plan', 'date': '2021-06-30', 'uploadDate': '2023-12-20T22:13', 'filename': 'Prot_SAP_000.pdf', 'size': 450006}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2024-01-18', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M29800', 'name': 'Insulin, Short-Acting', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01047982', 'orgStudyIdInfo': {'id': 'INOGDM-2010'}, 'organization': {'fullName': 'University of Messina', 'class': 'OTHER'}, 'briefTitle': 'Myo-inositol in Obese Pregnant Women', 'officialTitle': 'Myo-inositol May Prevent Gestational Diabetes in Obese Women'}, 'statusModule': {'statusVerifiedDate': '2014-02', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2010-03'}, 'primaryCompletionDateStruct': {'date': '2013-07', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2013-12', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2010-01-12', 'studyFirstSubmitQcDate': '2010-01-12', 'studyFirstPostDateStruct': {'date': '2010-01-13', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2014-02-27', 'lastUpdatePostDateStruct': {'date': '2014-02-28', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': \"Rosario D'anna\", 'investigatorTitle': 'associate professor', 'investigatorAffiliation': 'University of Messina'}, 'leadSponsor': {'name': 'University of Messina', 'class': 'OTHER'}}, 'descriptionModule': {'briefSummary': 'Myo-Inositol is classified as a member of the vitamin B complex. It is a constituent of living cells and is widespread in many food. It is involved in a number of biological processes, including insulin signal transduction, resulting in modulating insulin sensitivity. This is a prospective, randomized, double center, placebo-controlled study. Two hundred and twenty obese pregnant women will be included in the trial and, after an informed consent, will assume randomly 2 g of myo-inositol twice a day or placebo from 12-13th weeks gestation until delivery. Then,they will perform an Oral Glucose Tolerance Test (OGTT) at 24-28th weeks gestation. Records about delivery (gestational age, neonatal weight...) will be registered.'}, 'conditionsModule': {'conditions': ['Gestational Diabetes'], 'keywords': ['gestational diabetes', 'macrosomia', 'hypertension in pregnancy', 'HOMA-IR', 'obesity']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 220, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'myo-inositol', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Dietary Supplement: myo-inositol']}, {'label': 'placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'acid folic 400 mcg twice per day', 'interventionNames': ['Other: folic acid 400 mcg']}], 'interventions': [{'type': 'DIETARY_SUPPLEMENT', 'name': 'myo-inositol', 'description': 'myo-inositol 2 grams plus folic acid 400 mcg twice a day', 'armGroupLabels': ['myo-inositol']}, {'type': 'OTHER', 'name': 'folic acid 400 mcg', 'description': '2 pills a day', 'armGroupLabels': ['placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'number of gestational diabetes cases diagnosed with OGTT', 'timeFrame': '24-28th weeks gestation'}, {'measure': 'difference in HOMA values', 'timeFrame': 'from first trimester to OGTT'}], 'secondaryOutcomes': [{'measure': 'incidence of pregnancy complications: hypertension, preterm delivery. macrosomia, shoulder dystocia, etc.', 'timeFrame': 'at delivery'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Obese pregnant women: BMI \\\\> 30 Kg/cm2\\n* first trimester fast glycaemia \\\\< 126 mg/dl\\n* single pregnancy\\n\\nExclusion Criteria:\\n\\n* Pregnant women with BMI \\\\< 30 Kg/cm2\\n* first trimester fast glycaemia \\\\> 126 mg/dl\\n* previous gestational diabetes\\n* twin pregnancy\\n* pregestational diabetes\\n* associated therapies with corticosteroids', 'healthyVolunteers': False, 'sex': 'FEMALE', 'minimumAge': '18 Years', 'maximumAge': '45 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': \"Rosario D'Anna, professor\", 'affiliation': 'University of Messina, ITALY', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Obstetrics and Gynecology Unit, University of Messina and Obstetrics and Gynecology Unit of Modena University', 'city': 'Messina and Modena', 'country': 'Italy'}]}, 'referencesModule': {'references': [{'pmid': '26241420', 'type': 'DERIVED', 'citation': \"D'Anna R, Di Benedetto A, Scilipoti A, Santamaria A, Interdonato ML, Petrella E, Neri I, Pintaudi B, Corrado F, Facchinetti F. Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial. Obstet Gynecol. 2015 Aug;126(2):310-315. doi: 10.1097/AOG.0000000000000958.\"}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016640', 'term': 'Diabetes, Gestational'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D011248', 'term': 'Pregnancy Complications'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'}, {'id': 'M10024', 'name': 'Hypertension', 'relevance': 'LOW'}, {'id': 'M19012', 'name': 'Diabetes, Gestational', 'asFound': 'Gestational Diabetes', 'relevance': 'HIGH'}, {'id': 'M25635', 'name': 'Hypertension, Pregnancy-Induced', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D005492', 'term': 'Folic Acid'}, {'id': 'D007294', 'term': 'Inositol'}], 'ancestors': [{'id': 'D006397', 'term': 'Hematinics'}, {'id': 'D014803', 'term': 'Vitamin B Complex'}, {'id': 'D014815', 'term': 'Vitamins'}, {'id': 'D018977', 'term': 'Micronutrients'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M8618', 'name': 'Folic Acid', 'asFound': 'Characteristics', 'relevance': 'HIGH'}, {'id': 'M10336', 'name': 'Inositol', 'asFound': 'Uncontrolled', 'relevance': 'HIGH'}, {'id': 'M17546', 'name': 'Vitamin B Complex', 'relevance': 'LOW'}, {'id': 'M9485', 'name': 'Hematinics', 'relevance': 'LOW'}, {'id': 'M17558', 'name': 'Vitamins', 'relevance': 'LOW'}, {'id': 'M21009', 'name': 'Micronutrients', 'relevance': 'LOW'}, {'id': 'M16885', 'name': 'Trace Elements', 'relevance': 'LOW'}, {'id': 'T446', 'name': 'Folic Acid', 'asFound': 'Characteristics', 'relevance': 'HIGH'}, {'id': 'T447', 'name': 'Folinic Acid', 'relevance': 'LOW'}, {'id': 'T400', 'name': 'Inositol', 'asFound': 'Uncontrolled', 'relevance': 'HIGH'}, {'id': 'T448', 'name': 'Folate', 'relevance': 'LOW'}, {'id': 'T475', 'name': 'Vitamin B9', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Micro', 'name': 'Micronutrients'}, {'abbrev': 'Hemat', 'name': 'Hematinics'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Vi', 'name': 'Vitamins'}, {'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01537120', 'orgStudyIdInfo': {'id': '0000-258'}, 'organization': {'fullName': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}, 'briefTitle': 'Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)', 'officialTitle': 'Evaluation of Continuous Glucose Monitoring as a Tool to Measure Glucoregulatory Effects of a Twice Daily Oral Insulin Secretagogue'}, 'statusModule': {'statusVerifiedDate': '2015-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2011-12'}, 'primaryCompletionDateStruct': {'date': '2012-10', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2012-10', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2011-12-22', 'studyFirstSubmitQcDate': '2012-02-16', 'studyFirstPostDateStruct': {'date': '2012-02-23', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2013-09-25', 'resultsFirstSubmitQcDate': '2013-09-25', 'resultsFirstPostDateStruct': {'date': '2013-12-03', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-08-17', 'lastUpdatePostDateStruct': {'date': '2015-08-19', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}}, 'descriptionModule': {'briefSummary': 'This trial will attempt to develop the use of Continuous Glucose Monitoring (CGM) as a tool for the evaluation of both new and existing pharmacological treatments for type 2 diabetes, using the twice daily administered dipeptidyl peptidase-4 (DPP4) inhibitor, vildagliptin as a probe. The primary hypothesis is that two weeks of treatment with 50 mg of oral Vildagliptin, twice daily will lead to a statistically significant decrease in 24 hour weighted-mean glucose (WMG) relative to placebo.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 25, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Placebo → Vildagliptin', 'type': 'EXPERIMENTAL', 'description': 'Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily', 'interventionNames': ['Drug: Vildagliptin', 'Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Vildagliptin', 'armGroupLabels': ['Placebo → Vildagliptin']}, {'type': 'DRUG', 'name': 'Placebo', 'armGroupLabels': ['Placebo → Vildagliptin']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': '24 Hour Weighted Mean Glucose (WMG) At 2 Weeks', 'description': 'The 24 hour WMG was measured after 2 weeks of placebo treatment, and again after 2 weeks of vildagliptin treatment. Glucose was measured over a 24 hour period by having participants wear two continuous glucose monitors (CGM), which produced an average glucose value approximately every 5 minutes. Using these values, the concentration of glucose was calculated from Area Under the Curve 0-24 hours (AUC 0-24hr), and was expressed as 24 hour WMG.', 'timeFrame': 'At 2 weeks after Placebo treatment and again at 2 weeks after Vildagliptin treatment'}], 'secondaryOutcomes': [{'measure': 'Hemoglobin A1C (HbA1C) At 2 Weeks', 'description': 'Blood samples were taken after 2 weeks of placebo treatment, and again after 2 weeks of vildagliptin treatment to measure the percentage of glycated hemoglobin, HbA1C. Units are therefore presented as HbA1c (%).', 'timeFrame': 'At 2 weeks after Placebo treatment and again at 2 weeks after Vildagliptin treatment'}, {'measure': 'HbA1C At 12 Weeks', 'description': 'Blood samples were taken after 2 weeks of placebo treatment, and again after 12 weeks of vildagliptin treatment to measure the percentage of glycated hemoglobin, HbA1C. Units are therefore presented as HbA1c (%).', 'timeFrame': 'At 2 weeks after Placebo treatment and again at 12 weeks after Vildagliptin treatment'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Clinical diagnosis of type 2 diabetes mellitus on a clinical regimen that is metformin alone, up to a maximum of 3 gram per day, on a background of lifestyle measures, and has a Hemoglobin A1C at screening of \\\\> 7%.\\n* If on antihyperglycemic therapy with both metformin and sulfonylurea with a Screening Visit/Visit 1 Hemoglobin A1C of \\\\>= 6.5% and =\\\\< 7.5%, should then discontinue sulfonylurea usage and undergo washout of sulfonylurea.\\n\\nExclusion Criteria:\\n\\n* History of either stroke, chronic seizures or major neurological disorder within the last 6 months.\\n* Untreated hypertension with a blood pressure of \\\\> 160/95 mmHg.\\n* History of neoplastic disease within the past 5 years.\\n* History of hypersensitivity to vildagliptin or other DPP4 inhibitors.\\n* Had major surgery, or donated or lost 1 unit (500 mL) of blood, or participated in another investigational study within 4 weeks prior to screen.\\n* Used any illicit drug or abusively used alcohol within the past 3 months.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '79 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'After enrollment, participants previously treated with both metformin and sulfonylurea, discontinued sulfonylurea usage and underwent washout of sulfonylurea over a period of 8 weeks prior to treatment. Non-washout participants were enrolled on a clinical regimen of metformin alone.', 'groups': [{'id': 'FG000', 'title': 'Placebo → Vildagliptin', 'description': 'Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily'}], 'periods': [{'title': 'Enrolled', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '25'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '25'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}, {'title': '8 Weeks Washout', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '25'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '24'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Inclusion/exclusion criteria not met', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}]}]}, {'title': '3 Weeks Placebo', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '24'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '23'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}]}]}, {'title': '12 Weeks Vildagliptin', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '23'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '23'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Placebo → Vildagliptin', 'description': 'Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '25'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'Years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '62', 'spread': '5.6'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '1'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '24'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': '24 Hour Weighted Mean Glucose (WMG) At 2 Weeks', 'description': 'The 24 hour WMG was measured after 2 weeks of placebo treatment, and again after 2 weeks of vildagliptin treatment. Glucose was measured over a 24 hour period by having participants wear two continuous glucose monitors (CGM), which produced an average glucose value approximately every 5 minutes. Using these values, the concentration of glucose was calculated from Area Under the Curve 0-24 hours (AUC 0-24hr), and was expressed as 24 hour WMG.', 'populationDescription': 'Per-Protocol Population: all participants who complied with the assigned medication during each period of study.', 'reportingStatus': 'POSTED', 'paramType': 'GEOMETRIC_MEAN', 'dispersionType': 'Geometric Coefficient of Variation', 'unitOfMeasure': 'mg/dL', 'timeFrame': 'At 2 weeks after Placebo treatment and again at 2 weeks after Vildagliptin treatment', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablets twice daily for 3 weeks'}, {'id': 'OG001', 'title': 'Vildagliptin', 'description': 'Vildagliptin tablets 50 mg twice daily for 12 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '24'}, {'groupId': 'OG001', 'value': '23'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '126.9', 'spread': '16'}, {'groupId': 'OG001', 'value': '114.2', 'spread': '17'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'paramType': 'Geometric Mean Ratio', 'paramValue': '0.91', 'ciPctValue': '90', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.85', 'ciUpperLimit': '0.96'}]}, {'type': 'SECONDARY', 'title': 'Hemoglobin A1C (HbA1C) At 2 Weeks', 'description': 'Blood samples were taken after 2 weeks of placebo treatment, and again after 2 weeks of vildagliptin treatment to measure the percentage of glycated hemoglobin, HbA1C. Units are therefore presented as HbA1c (%).', 'populationDescription': 'Per-Protocol Population: all participants who complied with the assigned medication during each period of study.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'HbA1c (%)', 'timeFrame': 'At 2 weeks after Placebo treatment and again at 2 weeks after Vildagliptin treatment', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablets twice daily for 3 weeks'}, {'id': 'OG001', 'title': 'Vildagliptin', 'description': 'Vildagliptin tablets 50 mg twice daily for 12 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '24'}, {'groupId': 'OG001', 'value': '23'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7.12', 'spread': '0.54'}, {'groupId': 'OG001', 'value': '6.82', 'spread': '0.55'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'paramType': 'Least Squares Mean Difference', 'paramValue': '-0.30', 'ciPctValue': '90', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.36', 'ciUpperLimit': '-0.23'}]}, {'type': 'SECONDARY', 'title': 'HbA1C At 12 Weeks', 'description': 'Blood samples were taken after 2 weeks of placebo treatment, and again after 12 weeks of vildagliptin treatment to measure the percentage of glycated hemoglobin, HbA1C. Units are therefore presented as HbA1c (%).', 'populationDescription': 'Per-Protocol Population: all participants who complied with the assigned medication during each period of study.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'HbA1c (%)', 'timeFrame': 'At 2 weeks after Placebo treatment and again at 12 weeks after Vildagliptin treatment', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablets twice daily for 3 weeks'}, {'id': 'OG001', 'title': 'Vildagliptin', 'description': 'Vildagliptin tablets 50 mg twice daily for 12 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '24'}, {'groupId': 'OG001', 'value': '23'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7.12', 'spread': '0.54'}, {'groupId': 'OG001', 'value': '6.66', 'spread': '0.74'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'paramType': 'Least Squares Mean Difference', 'paramValue': '-0.46', 'ciPctValue': '90', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.62', 'ciUpperLimit': '-0.30'}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'eventGroups': [{'id': 'EG000', 'title': 'Vildagliptin 50 mg', 'description': 'Vildagliptin tablets 50 mg twice daily for 12 weeks', 'seriousNumAffected': 0, 'seriousNumAtRisk': 23, 'otherNumAffected': 8, 'otherNumAtRisk': 23}, {'id': 'EG001', 'title': 'Placebo', 'description': 'Placebo tablets twice daily for 3 weeks', 'seriousNumAffected': 0, 'seriousNumAtRisk': 24, 'otherNumAffected': 6, 'otherNumAtRisk': 24}], 'otherEvents': [{'term': 'Reaction CGM Site', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 15.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 23}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 24}]}, {'term': 'Reaction site cannula', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 15.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 23}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 24}]}, {'term': 'Tiredness', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 15.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 23}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 24}]}, {'term': 'Upper respiratory tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 15.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 23}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 24}]}, {'term': 'Nausea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 15.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 23}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 24}]}, {'term': 'Vomiting', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 15.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 23}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 24}]}, {'term': 'Dizziness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 15.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 23}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 24}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 15.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 23}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 24}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictionType': 'OTHER', 'restrictiveAgreement': True, 'otherDetails': 'The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.'}, 'pointOfContact': {'title': 'Senior Vice President, Global Clinical Development', 'organization': 'Merck Sharp & Dohme Corp.', 'email': 'ClinicalTrialsDisclosure@merck.com', 'phone': '1-800-672-6372'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28', 'removedCountries': ['Netherlands']}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077597', 'term': 'Vildagliptin'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D054873', 'term': 'Dipeptidyl-Peptidase IV Inhibitors'}, {'id': 'D011480', 'term': 'Protease Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}], 'browseLeaves': [{'id': 'M1857', 'name': 'Vildagliptin', 'asFound': 'Grafting', 'relevance': 'HIGH'}, {'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M1985', 'name': 'Secretagogues', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M27957', 'name': 'Dipeptidyl-Peptidase IV Inhibitors', 'relevance': 'LOW'}, {'id': 'M19609', 'name': 'HIV Protease Inhibitors', 'relevance': 'LOW'}, {'id': 'M14343', 'name': 'Protease Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02297620', 'orgStudyIdInfo': {'id': 'SGL001'}, 'organization': {'fullName': 'Astellas Pharma Inc', 'class': 'INDUSTRY'}, 'briefTitle': 'The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients', 'officialTitle': 'Specified Drug Use resulTs survEy of IpragLifLozin treAtment in ELDERly type2 Diabetes Patients (STELLA-ELDER)', 'acronym': 'STELLA-ELDER'}, 'statusModule': {'statusVerifiedDate': '2015-10', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2014-04'}, 'primaryCompletionDateStruct': {'date': '2015-07', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2015-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2014-11-14', 'studyFirstSubmitQcDate': '2014-11-19', 'studyFirstPostDateStruct': {'date': '2014-11-21', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-10-14', 'lastUpdatePostDateStruct': {'date': '2015-10-15', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Astellas Pharma Inc', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The objective of this survey is to confirm the safety of Suglat Tablets when used in the elderly.', 'detailedDescription': 'Elderly patients (65 years or older at the time of first administration) with type 2 diabetes who used Suglat Tablets within 3 months from its launch are included in this study. Followings are measured with the patients.\\n\\n1. Specify incidence rates of adverse drug reactions associated with a decrease in body fluids and their risk factors.\\n2. Investigate the occurrence of urinary tract infection.\\n3. Investigate the occurrence of adverse drug reactions in patients at a high risk (those who have poorly controlled blood sugar levels, concurrent organic abnormalities in the urinary system, advanced diabetic neuropathy, etc).\\n4. Investigate the occurrence of adverse drug reactions other than the above.\\n5. Factors that may possibly influence the safety of Suglat Tablets.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes'], 'keywords': ['SGLT-2 inhibitor', 'Elderly patients', 'ASP1941']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 8687, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Suglat group', 'interventionNames': ['Drug: Suglat®']}], 'interventions': [{'type': 'DRUG', 'name': 'Suglat®', 'description': 'oral', 'armGroupLabels': ['Suglat group'], 'otherNames': ['ipragliflozin']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Specify incidence rates of adverse drug reactions associated with a decrease in body fluids and their risk factors', 'timeFrame': 'Up to 12 months'}], 'secondaryOutcomes': [{'measure': 'Investigate the occurrence of urinary tract infection', 'timeFrame': '1-month, 3-month, 6-month, 9-month and 12-month (or at treatment discontinuation time)'}, {'measure': 'Investigate the occurrence of adverse drug reactions in patients at a high risk (those who have poorly controlled blood sugar levels, concurrent organic abnormalities in the urinary system, advanced diabetic neuropathy, etc).', 'timeFrame': '1-month, 3-month, 6-month, 9-month and 12-month (or at treatment discontinuation time)'}, {'measure': 'Investigate the occurrence of adverse drug reactions other than the above', 'timeFrame': '1-month, 3-month, 6-month, 9-month and 12-month (or at treatment discontinuation time)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* type 2 diabetes who used Suglat Tablets within 3 months from its launch\\n\\nExclusion Criteria:\\n\\n* off-label use patients', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '65 Years', 'stdAges': ['OLDER_ADULT'], 'studyPopulation': 'Elderly patients with type 2 diabetes who used Suglat Tablets within 3 months from its launch', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Medical Director', 'affiliation': 'Astellas Pharma Inc', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'city': 'Chubu', 'country': 'Japan', 'geoPoint': {'lat': 35.43379, 'lon': 140.2797}}, {'city': 'Chugoku', 'country': 'Japan'}, {'city': 'Hokkaido', 'country': 'Japan', 'geoPoint': {'lat': 43.41104, 'lon': 142.88878}}, {'city': 'Kansai', 'country': 'Japan'}, {'city': 'Kantou', 'country': 'Japan'}, {'city': 'Kyusyu', 'country': 'Japan'}, {'city': 'Shikoku', 'country': 'Japan'}, {'city': 'Tohoku', 'country': 'Japan', 'geoPoint': {'lat': 35.81882, 'lon': 139.57138}}]}, 'referencesModule': {'references': [{'pmid': '26800061', 'type': 'DERIVED', 'citation': 'Terauchi Y, Yokote K, Nakamura I, Sugamori H. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study. Expert Opin Pharmacother. 2016;17(4):463-71. doi: 10.1517/14656566.2016.1145668. Epub 2016 Feb 5.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C572941', 'term': 'Ipragliflozin'}], 'ancestors': [{'id': 'D000077203', 'term': 'Sodium-Glucose Transporter 2 Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M1691', 'name': 'Sodium-Glucose Transporter 2 Inhibitors', 'relevance': 'LOW'}, {'id': 'M254126', 'name': 'Ipragliflozin', 'asFound': 'Syphilis', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01073020', 'orgStudyIdInfo': {'id': '2009P-001610'}, 'organization': {'fullName': 'Joslin Diabetes Center', 'class': 'OTHER'}, 'briefTitle': 'Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes', 'officialTitle': 'Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes (SLIMM-T2D)', 'acronym': 'SLIMM-T2D'}, 'statusModule': {'statusVerifiedDate': '2021-05', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2010-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2014-12', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2016-11', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2010-02-16', 'studyFirstSubmitQcDate': '2010-02-19', 'studyFirstPostDateStruct': {'date': '2010-02-22', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2021-01-26', 'resultsFirstSubmitQcDate': '2021-04-08', 'resultsFirstPostDateStruct': {'date': '2021-05-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-06-01', 'lastUpdatePostDateStruct': {'date': '2021-06-28', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Joslin Diabetes Center', 'class': 'OTHER'}, 'collaborators': [{'name': \"Brigham and Women's Hospital\", 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'descriptionModule': {'briefSummary': 'There is substantial clinical evidence regarding the safety and efficacy of currently practiced bariatric surgical techniques to improve metabolic control and/or resolve type 2 diabetes (T2DM) in clinically severe obese patients (class 3 obesity). Evidence suggests such procedures have greater effects on insulin secretion and insulin action than that expected from weight loss alone, which has led to the recent claim that such procedures may be useful as a primary treatment for T2DM in the moderately obese population. Concurrently, there have also been substantial advances in the non-surgical medical management of T2DM. As a result, the best treatment algorithm for T2DM patients with class 1 \\\\& 2 obesity is increasingly controversial. This trial investigates the utility of currently practiced and available bariatric surgical procedures as compared with multidisciplinary intensive medical and weight management for the treatment of T2DM with class 1 and 2 obesity.', 'detailedDescription': \"Primary Specific Aim 1: To evaluate the effectiveness of laparoscopic adjustable gastric band versus intensive medical and weight management in the treatment of T2DM.\\n\\nThere has been only one randomized control trial to date comparing surgical to medical management of T2DM in the less obese population, which demonstrated substantial superiority of the laparoscopic adjustable gastric band (LAGB) in the improvement of glycemic and metabolic measures. However, these findings remain controversial as the magnitude of weight loss in this study was far superior to that generally reported following LAGB. Thus, we propose a second prospective randomized trial to evaluate the effectiveness of intensive medical and weight management (IMWM) vs. LAGB in T2DM patients with BMI in the 30-42 kg/m\\\\^2 range. This range does extend LAGB surgery to BMI limits below those currently used in medical care, FDA Investigational Device Exemption (IDE) G090163. The primary outcome variable will be attaining glycemic control (as defined by fasting plasma glucose levels \\\\<126 mg/dL and HbA1c \\\\<6.5%) at one year of follow-up. The study was subsequently extended to 3 years, with the same outcome measures.\\n\\nPrimary Specific Aim 2: To evaluate the effectiveness of laparoscopic Roux-en-Y gastric bypass versus intensive medical and weight management in the treatment of T2DM.\\n\\nAlthough observational studies and meta-analyses suggest rapid and sustained improvement or resolution of diabetes following laparoscopic Roux-en-Y gastric bypass (LRYGB), to date there has been no randomized trial directly comparing these effects to those produced by IMWM. We propose a prospective randomized trial comparing the effectiveness of IMWM vs. LRYGB in T2DM patients with BMI's in the 30-42 kg/m\\\\^2 range. This range extends LRYGB surgery to BMI limits below those currently used in medical care to explore the use of this type of surgical procedure in type 2 diabetes with lesser magnitude obesity. The primary outcome variable will be attaining glycemic control (as defined by fasting plasma glucose levels \\\\<126 mg/dL and HbA1c \\\\<6.5%) at one year of follow-up. The study was subsequently extended to 3 years, with the same outcome measures.\\n\\nThe trial is designed to allow for strong patient preference towards specific surgical procedures, and as such is designed as two parallel trials with each of the two surgical procedures judged against intensive medical weight management. Subjects without strong preference will be randomly assigned to one of the four study arms.\\n\\nSecondary Specific Aims:\\n\\nDetermination of suitable study design: In addition to testing the effectiveness of current and available surgical techniques as compared to medical management, this trial will also test the utility of this trial design in future multi-institutional comparative effectiveness studies of these therapies, or alternatively, in future trials evaluating new surgical procedures being designed specifically for less obese T2DM patients.\\n\\nMeasurement of metabolic factors: Insulin secretion and action will be assessed during provocative mixed meal tolerance tests (MMTT) using the corrected incremental insulin response (CIR) and the composite insulin sensitivity index (CISI). MMTT will be performed in all groups at baseline and repeated at the time point of 10% weight loss (matched for weight loss), and at 12 months following randomization (matched for time).\\n\\nMeasurement of cardiovascular risk factors: Each group will be studied for evidence of changes in cardiovascular disease risk factors. Multiple surrogate measures of cardiovascular health will be compared, including blood pressure, fasting lipid profiles, endothelium-dependent vasodilatation and plasma will be collected for circulating markers of endothelial function. The study was subsequently extended to 3 years, with the same outcome measures.\\n\\nMeasurement of metabolic rate: Each group will be studied for change in energy expenditure and respiratory quotient using the non-invasive indirect calorimetry technique.\\n\\nQuality of life and cost utility outcomes: Longitudinal measures of patient reported quality of life outcomes, and cost utility measures will also be collected to generate preliminary data for future studies.\"}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus', 'Obesity'], 'keywords': ['Type 2 Diabetes Mellitus', 'Obesity', 'Lifestyle', 'Bariatric Surgery', 'Laparoscopic Adjustable Gastric Band', 'Laparoscopic Roux-en-Y Gastric Bypass']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 88, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Gastric Band vs Intensive Diabetes & Weight Management', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients will be randomized to receive either 1) laparoscopic placement of an adjustable gastric band (LAGB) or 2) treatment with an intensive medical and weight management (IMWM) program.\\n\\nLAGB will be placed using the \"pars flaccida\" technique. The Allergan laparoscopic band \"LAP BAND\" system will be utilized. LAGB ports will be placed in subcutaneous pockets in the right upper abdomen.\\n\\nThe IMWM group will participate in the Weight Achievement and Intensive Treatment (Why WAIT) program, which is a multidisciplinary program for weight control and intensive diabetes management designed by Joslin Diabetes Center. Key aspects include: 1) Intensive and interactive medication adjustments, 2) Structured modified dietary intervention, 3) Graded, balanced, and individualized exercise intervention, 4) Cognitive behavioral intervention and 5) Group education.', 'interventionNames': ['Device: Allergan Adjustable Gastric Band Surgery', 'Other: Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group']}, {'label': 'RYGB vs Intensive Diabetes & Weight Management', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients will be randomized to receive either 1) Roux-en-Y gastric bypass (RYGB) surgery or 2) treatment with an intensive medical and weight management (IMWM) program.\\n\\nRYGB will be performed using a 75 cm antecolic, ante-gastric Roux limb created with a 50 cm pancreaticobiliary limb. A 15-20 cc gastric pouch will be created lying along the lesser curve of the stomach, with division of the vagal trunks at the lower border of the pouch.\\n\\nThe IMWM group will participate in the Weight Achievement and Intensive Treatment (Why WAIT) program, which is a multidisciplinary program for weight control and intensive diabetes management designed by Joslin Diabetes Center. Key aspects include: 1) Intensive and interactive medication adjustments, 2) Structured modified dietary intervention, 3) Graded, balanced, and individualized exercise intervention, 4) Cognitive behavioral intervention and 5) Group education.', 'interventionNames': ['Procedure: Roux-en-Y Gastric Bypass (RYGB) Surgery', 'Other: Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group']}], 'interventions': [{'type': 'DEVICE', 'name': 'Allergan Adjustable Gastric Band Surgery', 'armGroupLabels': ['Gastric Band vs Intensive Diabetes & Weight Management']}, {'type': 'OTHER', 'name': 'Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group', 'description': 'Intensive Medical Diabetes \\\\& Weight Management (Why WAIT) - Band Group', 'armGroupLabels': ['Gastric Band vs Intensive Diabetes & Weight Management']}, {'type': 'PROCEDURE', 'name': 'Roux-en-Y Gastric Bypass (RYGB) Surgery', 'armGroupLabels': ['RYGB vs Intensive Diabetes & Weight Management']}, {'type': 'OTHER', 'name': 'Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group', 'description': 'Intensive Medical Diabetes \\\\& Weight Management (Why WAIT) - Bypass Group', 'armGroupLabels': ['RYGB vs Intensive Diabetes & Weight Management']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up.', 'description': 'The primary outcome variable of both parallel trials will be the percent of patients attaining glycemic control (defined as fasting plasma glucose \\\\< 126 mg/dL and HbA1c \\\\< 6.5%) at three years of follow-up.', 'timeFrame': '3 years'}], 'secondaryOutcomes': [{'measure': 'Glycemic Control, as Measured by Hemoglobin A1c', 'description': 'All participants had type 2 diabetes. Long-term diabetes control is typically evaluated in both clinical and research settings using the measurement of Hemoglobin A1c (a measure of glycated hemoglobin, proportional to average glucose levels over approximately 3 months). This endpoint (hemoglobin A1c) was measured at 3 years after intervention. Reported values are changes from baseline derived from the mixed effects model analysis, adjusted for baseline.', 'timeFrame': '3 years'}, {'measure': 'Body Mass Index', 'description': 'Change in body mass index 3 years after intervention', 'timeFrame': '3 years'}, {'measure': 'Cardiovascular Risk', 'description': 'UKPDS risk of coronary heart disease, reported as change from baseline', 'timeFrame': '3 years'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Potential participants will be those with T2DM, with a diagnosis of diabetes of at least one year in duration,\\n* BMI 30-45 kg/m\\\\^2 for the LAGB compared to intensive medical weight and diabetes management and BMI 30-42 kg/m\\\\^2 for LRYGB compared to intensive medical weight and diabetes management,\\n* Age 21-65 years,\\n* With a strong desire for substantial weight loss, who are free from active cardiovascular or other diseases that would render them unable to partake in a structured exercise program or to undergo a bariatric surgical procedure, and who are committed to life long medical and nutritional follow up.\\n\\nExclusion Criteria:\\n\\n* Detectable levels of glutamic acid decarboxylase (GAD) antibody or a history of diabetic ketoacidosis or uncontrolled T2DM (consistent fasting blood glucose \\\\>200 mg/dl or HbA1c above twice normal);\\n* Previous gastrointestinal surgery, inflammatory bowel disease, esophageal diseases including severe intractable esophagitis, Barrett's Disease, esophageal dysmotility or other impaired gastric motility (gastroparesis), or hiatal hernia \\\\>3 cm in size, chronic or acute bleeding conditions including peptic ulcer disease, portal hypertension (gastric or esophageal varices), chronic pancreatitis, or cirrhosis of the liver;\\n* Malignant or debilitating medical conditions, severe cardiopulmonary disease including uncontrolled hypertension (repeated systolic measures \\\\>160 or diastolic \\\\> 95 mm Hg on more than one day), unstable angina pectoris, recent myocardial infarction within 6 months, history of coronary artery bypass surgery or angioplasty, congestive heart failure, arrhythmia, stroke or transient ischemic attacks, urinary albumin excretion \\\\>300 mcg/mg creatinine and/or serum creatinine \\\\>1.5 mg/dL (permitting safety of increased dietary protein intake),\\n* Any endocrine disorder other than T2DM or thyroid disease which is stable on replacement therapy, including Cushing's syndrome;\\n* Any previous history of eating disorders, history of drug and/or alcohol abuse within 2 years of the screening visit, history of impaired mental status as defined by Diagnostic and Statistical Manual, 4th Edition (DSM-4) criteria and including, but not limited to active substance abuse, a history of schizophrenia, borderline personality disorder, uncontrolled depression, suicidal attempts within the past two years or current suicidal tendencies or ideations.\\n* Subjects will be excluded if there is a history of significant weight loss (\\\\>3%) within the previous 3 months or participation in alternate medically supervised exercise or weight reduction program within the previous 3 months, or with use of prescription or over the counter weight reduction medications or supplements within one month of the Screening Visit and for the duration of study participation.\\n* Women who are lactating, planning pregnancy, or unwilling to use contraception during the course of the trial.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '21 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Allison B. Goldfine, MD', 'affiliation': 'Joslin Diabetes Center', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Ashley Vernon, MD', 'affiliation': \"Brigham and Women's Hospital\", 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': \"Brigham and Women's Hospital\", 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02215', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Joslin Diabetes Center', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02215', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}]}, 'referencesModule': {'references': [{'pmid': '21357363', 'type': 'BACKGROUND', 'citation': 'Lautz D, Halperin F, Goebel-Fabbri A, Goldfine AB. The great debate: medicine or surgery: what is best for the patient with type 2 diabetes? Diabetes Care. 2011 Mar;34(3):763-70. doi: 10.2337/dc10-1859. No abstract available.'}, {'pmid': '24899464', 'type': 'RESULT', 'citation': 'Halperin F, Ding SA, Simonson DC, Panosian J, Goebel-Fabbri A, Wewalka M, Hamdy O, Abrahamson M, Clancy K, Foster K, Lautz D, Vernon A, Goldfine AB. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014 Jul;149(7):716-26. doi: 10.1001/jamasurg.2014.514.'}, {'pmid': '25909333', 'type': 'RESULT', 'citation': 'Ding SA, Simonson DC, Wewalka M, Halperin F, Foster K, Goebel-Fabbri A, Hamdy O, Clancy K, Lautz D, Vernon A, Goldfine AB. Adjustable Gastric Band Surgery or Medical Management in Patients With Type 2 Diabetes: A Randomized Clinical Trial. J Clin Endocrinol Metab. 2015 Jul;100(7):2546-56. doi: 10.1210/jc.2015-1443. Epub 2015 Apr 24.'}, {'pmid': '26600045', 'type': 'RESULT', 'citation': 'Yu EW, Wewalka M, Ding SA, Simonson DC, Foster K, Holst JJ, Vernon A, Goldfine AB, Halperin F. Effects of Gastric Bypass and Gastric Banding on Bone Remodeling in Obese Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2016 Feb;101(2):714-22. doi: 10.1210/jc.2015-3437. Epub 2015 Nov 24.'}, {'pmid': '27555097', 'type': 'RESULT', 'citation': 'Panosian J, Ding SA, Wewalka M, Simonson DC, Goebel-Fabbri A, Foster K, Halperin F, Vernon A, Goldfine AB. Physical Activity in Obese Type 2 Diabetes After Gastric Bypass or Medical Management. Am J Med. 2017 Jan;130(1):83-92. doi: 10.1016/j.amjmed.2016.07.019. Epub 2016 Aug 20.'}, {'pmid': '29432125', 'type': 'RESULT', 'citation': 'Simonson DC, Halperin F, Foster K, Vernon A, Goldfine AB. Clinical and Patient-Centered Outcomes in Obese Patients With Type 2 Diabetes 3 Years After Randomization to Roux-en-Y Gastric Bypass Surgery Versus Intensive Lifestyle Management: The SLIMM-T2D Study. Diabetes Care. 2018 Apr;41(4):670-679. doi: 10.2337/dc17-0487. Epub 2018 Feb 6.'}, {'pmid': '31931977', 'type': 'RESULT', 'citation': 'Simonson DC, Vernon A, Foster K, Halperin F, Patti ME, Goldfine AB. Adjustable gastric band surgery or medical management in patients with type 2 diabetes and obesity: three-year results of a randomized trial. Surg Obes Relat Dis. 2019 Dec;15(12):2052-2059. doi: 10.1016/j.soard.2019.03.038. Epub 2019 Apr 16.'}, {'pmid': '34845204', 'type': 'DERIVED', 'citation': 'Dreyfuss JM, Yuchi Y, Dong X, Efthymiou V, Pan H, Simonson DC, Vernon A, Halperin F, Aryal P, Konkar A, Sebastian Y, Higgs BW, Grimsby J, Rondinone CM, Kasif S, Kahn BB, Foster K, Seeley R, Goldfine A, Djordjilovic V, Patti ME. High-throughput mediation analysis of human proteome and metabolome identifies mediators of post-bariatric surgical diabetes control. Nat Commun. 2021 Nov 29;12(1):6951. doi: 10.1038/s41467-021-27289-2.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'After initial contact, patients will undergo the following: 1) Telephone screening (review inclusion and exclusion criteria, description of interventions), 2) Attend clinical trial orientation session (detailed description of interventions, protocol, procedures, surgical clearance, nutritional evaluation, risks, benefits), 3) Medical and surgical screening visit (sign informed consent, screening lab tests, history and physical, psychological evaluation for bariatric surgery, exercise clearance).', 'recruitmentDetails': \"Patients will be recruited from the Joslin Diabetes Center and Partners Healthcare. All patients with type 2 diabetes (T2DM) attending the Brigham and Women's Hospital (BWH) Bariatric Surgery Program orientation sessions (\\\\>1200 subjects/year) will be presented with this trial as an option. Recruitment will also be from the \\\\>13,000 T2DM patients who receive their medical care at Joslin Diabetes Center or the Partners Healthcare Primary Care Network.\", 'groups': [{'id': 'FG000', 'title': 'Laparoscopic Adjustable Gastric Band (LAGB)', 'description': 'Laparoscopic Adjustable Gastric Band (LAGB): Allergan Adjustable Gastric Band (Device)\\n\\nParticipants were randomized to LAGB vs. an intensive medical diabetes and weight management program (Why Wait? Program)'}, {'id': 'FG001', 'title': 'Intensive Medical Diabetes & Weight Management (LAGB Grp)', 'description': 'Participants were randomized to LAGB vs. an intensive medical diabetes and weight management program (Why Wait? Program)'}, {'id': 'FG002', 'title': 'RYGB', 'description': 'Roux-en-Y Gastric Bypass (Surgery)\\n\\nParticipants were randomized to RYGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'FG003', 'title': 'Intensive Medical Diabetes & Weight Management (RYGB Grp)', 'description': 'Participants were randomized to RYGB vs. an intensive medical diabetes and weight management program (Why Wait? Program)'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '23'}, {'groupId': 'FG001', 'numSubjects': '22'}, {'groupId': 'FG002', 'numSubjects': '22'}, {'groupId': 'FG003', 'numSubjects': '21'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '16'}, {'groupId': 'FG001', 'numSubjects': '17'}, {'groupId': 'FG002', 'numSubjects': '19'}, {'groupId': 'FG003', 'numSubjects': '19'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '2'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'populationDescription': 'Participants first selected whether they preferred gastric band or RYGB. After consent, they were randomized to either surgery or intensive medical diabetes and weight management. This resulted in 2 independent substudies, one of which compared band to its corresponding intensive medical diabetes and weight management group, and one of which compared RYGB to its corresponding intensive medical diabetes and weight management group..', 'groups': [{'id': 'BG000', 'title': 'Laparoscopic Adjustable Gastric Band (LAGB)', 'description': 'Laparoscopic Adjustable Gastric Band: Allergan Adjustable Gastric Band (Device)'}, {'id': 'BG001', 'title': 'Intensive Medical Diabetes & Weight Management (LAGB Group)', 'description': 'Intensive Medical Diabetes \\\\& Weight Management: Intensive Medical Diabetes \\\\& Weight Management (LAGB Group)\\n\\nThis group selected band as preferred surgery, but were randomized to medical management.'}, {'id': 'BG002', 'title': 'RYGB', 'description': 'Roux-en-Y Gastric Bypass (Surgery)'}, {'id': 'BG003', 'title': 'Intnnsive Medical Diabetes and Weight Management (RYGB Group)', 'description': 'Intensive Medical Diabetes \\\\& Weight Management: Intensive Medical Diabetes \\\\& Weight Management (RYGB Group)\\n\\nThis group selected RYGB as preferred surgery, but were randomized to medical management.'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '23'}, {'groupId': 'BG001', 'value': '22'}, {'groupId': 'BG002', 'value': '22'}, {'groupId': 'BG003', 'value': '21'}, {'groupId': 'BG004', 'value': '88'}]}], 'measures': [{'title': 'Age, Categorical', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}, {'groupId': 'BG004', 'value': '0'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'groupId': 'BG000', 'value': '23'}, {'groupId': 'BG001', 'value': '22'}, {'groupId': 'BG002', 'value': '22'}, {'groupId': 'BG003', 'value': '21'}, {'groupId': 'BG004', 'value': '88'}]}, {'title': '>=65 years', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}, {'groupId': 'BG004', 'value': '0'}]}]}]}, {'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '51.1', 'spread': '12.1'}, {'groupId': 'BG001', 'value': '51.4', 'spread': '7.5'}, {'groupId': 'BG002', 'value': '50.7', 'spread': '7.6'}, {'groupId': 'BG003', 'value': '52.6', 'spread': '4.3'}, {'groupId': 'BG004', 'value': '51.4', 'spread': '8.3'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '12'}, {'groupId': 'BG001', 'value': '9'}, {'groupId': 'BG002', 'value': '16'}, {'groupId': 'BG003', 'value': '10'}, {'groupId': 'BG004', 'value': '47'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '11'}, {'groupId': 'BG001', 'value': '13'}, {'groupId': 'BG002', 'value': '6'}, {'groupId': 'BG003', 'value': '11'}, {'groupId': 'BG004', 'value': '41'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '23'}, {'groupId': 'BG001', 'value': '22'}, {'groupId': 'BG002', 'value': '22'}, {'groupId': 'BG003', 'value': '21'}, {'groupId': 'BG004', 'value': '88'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up.', 'description': 'The primary outcome variable of both parallel trials will be the percent of patients attaining glycemic control (defined as fasting plasma glucose \\\\< 126 mg/dL and HbA1c \\\\< 6.5%) at three years of follow-up.', 'populationDescription': 'Patients not analyzed include: 7 of 23 in LAGB (4 withdrew consent before intervention,1 determined to not be a surgical candidate before intervention, and 2 withdrew consent between 1 and 3 years); 5 of 22 in IMWM (LAGB Grp) (4 withdrew consent, 1 death); 3 of 22 in the RYGB group (1 withdrew consent; 1 breast cancer diagnosis and 1 psychiatric illness pre-intervention); 2 of 21 IMWM (RYGB Grp) withdrew consent before intervention.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': '% of patients', 'timeFrame': '3 years', 'groups': [{'id': 'OG000', 'title': 'LAGB', 'description': 'Laparoscopic Adjustable Gastric Band: Allergan Adjustable Gastric Band (Device)\\n\\nParticipants were randomized to LAGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG001', 'title': 'Intensive Medical Diabetes & Weight Management (LAGB Grp)', 'description': 'Participants were randomized to LAGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG002', 'title': 'RYGB', 'description': 'Roux-en-Y Gastric Bypass (Surgery)\\n\\nParticipants were randomized to RYGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG003', 'title': 'Intensive Medical Diabetes & Weight Management (RYGB Grp)', 'description': 'Participants were randomized to RYGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '16'}, {'groupId': 'OG001', 'value': '17'}, {'groupId': 'OG002', 'value': '19'}, {'groupId': 'OG003', 'value': '19'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '13'}, {'groupId': 'OG001', 'value': '5'}, {'groupId': 'OG002', 'value': '42'}, {'groupId': 'OG003', 'value': '0'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.60', 'statisticalMethod': 'Chi-squared', 'paramType': 'proportion', 'paramValue': '0.08', 'ciNumSides': 'TWO_SIDED', 'estimateComment': 'Estimation parameter is the difference between the proportion of patients in the LAGB group vs. proportion of patients in the Intensive Medical Diabetes \\\\& Weight Management (LAGB Grp) who achieved the primary outcome.'}, {'groupIds': ['OG002', 'OG003'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.005', 'statisticalMethod': 'Chi-squared', 'paramType': 'proportion', 'paramValue': '0.42', 'ciNumSides': 'TWO_SIDED', 'estimateComment': 'Estimation parameter is the difference between the proportion of patients in the RYGB group vs. proportion of patients in the Intensive Medical Diabetes \\\\& Weight Management (RYGB Grp) who achieved the primary outcome.'}]}, {'type': 'SECONDARY', 'title': 'Glycemic Control, as Measured by Hemoglobin A1c', 'description': 'All participants had type 2 diabetes. Long-term diabetes control is typically evaluated in both clinical and research settings using the measurement of Hemoglobin A1c (a measure of glycated hemoglobin, proportional to average glucose levels over approximately 3 months). This endpoint (hemoglobin A1c) was measured at 3 years after intervention. Reported values are changes from baseline derived from the mixed effects model analysis, adjusted for baseline.', 'populationDescription': 'Randomized patients who had at least one post-randomization visit (modified intention to treat).', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'Percent', 'timeFrame': '3 years', 'groups': [{'id': 'OG000', 'title': 'LAGB', 'description': 'Laparoscopic Adjustable Gastric Band: Allergan Adjustable Gastric Band (Device)\\n\\nParticipants were randomized to LAGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG001', 'title': 'Intensive Medical Diabetes & Weight Management (LAGB Grp)', 'description': 'Participants were randomized to LAGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG002', 'title': 'RYGB', 'description': 'Roux-en-Y Gastric Bypass (Surgery)\\n\\nParticipants were randomized to RYGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG003', 'title': 'Intensive Medical Diabetes & Weight Management (RYGB Grp)', 'description': 'Participants were randomized to RYGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '16'}, {'groupId': 'OG001', 'value': '17'}, {'groupId': 'OG002', 'value': '19'}, {'groupId': 'OG003', 'value': '19'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.8', 'lowerLimit': '-1.6', 'upperLimit': '-0.0'}, {'groupId': 'OG001', 'value': '0.2', 'lowerLimit': '-0.6', 'upperLimit': '1.0'}, {'groupId': 'OG002', 'value': '-1.8', 'lowerLimit': '-2.4', 'upperLimit': '-1.2'}, {'groupId': 'OG003', 'value': '-0.4', 'lowerLimit': '-1.1', 'upperLimit': '0.3'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.33', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '1.0', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'estimateComment': 'Estimation parameter is the difference between the change from baseline in HbA1c in the LAGB group vs. change from baseline in HbA1c in the Intensive Medical Diabetes \\\\& Weight Management (LAGB Grp), adjusted for baseline HbA1c.'}, {'groupIds': ['OG002', 'OG003'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '1.4', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'estimateComment': 'Estimation parameter is the difference between the change from baseline in HbA1c in the RYGB group vs. change from baseline in HbA1c in the Intensive Medical Diabetes \\\\& Weight Management (RYGB Grp), adjusted for baseline HbA1c.'}]}, {'type': 'SECONDARY', 'title': 'Body Mass Index', 'description': 'Change in body mass index 3 years after intervention', 'populationDescription': 'Randomized patients who had at least one post-randomization visit (modified intention to treat).', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'kg/m^2', 'timeFrame': '3 years', 'groups': [{'id': 'OG000', 'title': 'LAGB', 'description': 'Laparoscopic Adjustable Gastric Band: Allergan Adjustable Gastric Band (Device)\\n\\nParticipants were randomized to LAGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG001', 'title': 'Intensive Medical Diabetes & Weight Management (LAGB Grp)', 'description': 'Participants were randomized to LAGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG002', 'title': 'RYGB', 'description': 'Roux-en-Y Gastric Bypass (Surgery)\\n\\nParticipants were randomized to RYGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG003', 'title': 'Intensive Medical Diabetes & Weight Management (RYGB Grp)', 'description': 'Participants were randomized to RYGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '16'}, {'groupId': 'OG001', 'value': '17'}, {'groupId': 'OG002', 'value': '19'}, {'groupId': 'OG003', 'value': '19'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-3.9', 'lowerLimit': '-5.2', 'upperLimit': '-2.6'}, {'groupId': 'OG001', 'value': '-1.7', 'lowerLimit': '-3.0', 'upperLimit': '0.4'}, {'groupId': 'OG002', 'value': '-8.7', 'lowerLimit': '-10.3', 'upperLimit': '-7.1'}, {'groupId': 'OG003', 'value': '-4.1', 'lowerLimit': '-8.8', 'upperLimit': '0.6'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '2.2', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'estimateComment': 'Estimation parameter is the difference between the change from baseline in BMI in the LAGB group vs. change from baseline in BMI in the Intensive Medical Diabetes \\\\& Weight Management (LAGB Grp), adjusted for baseline BMI.'}, {'groupIds': ['OG002', 'OG003'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '4.6', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'estimateComment': 'Estimation parameter is the difference between the change from baseline in BMI in the RYGB group vs. change from baseline in BMI in the Intensive Medical Diabetes \\\\& Weight Management (RYGB Grp), adjusted for baseline BMI.'}]}, {'type': 'SECONDARY', 'title': 'Cardiovascular Risk', 'description': 'UKPDS risk of coronary heart disease, reported as change from baseline', 'populationDescription': 'Patients who had at least one post-randomization visit were analyzed (modified intention to treat).', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'percent likelihood of event in next 10 y', 'timeFrame': '3 years', 'groups': [{'id': 'OG000', 'title': 'LAGB', 'description': 'Laparoscopic Adjustable Gastric Band: Allergan Adjustable Gastric Band (Device)\\n\\nParticipants were randomized to LAGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG001', 'title': 'Intensive Medical Diabetes & Weight Management (LAGB Grp)', 'description': 'Participants were randomized to LAGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG002', 'title': 'RYGB', 'description': 'Roux-en-Y Gastric Bypass (Surgery)\\n\\nParticipants were randomized to RYGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}, {'id': 'OG003', 'title': 'Intensive Medical Diabetes & Weight Management (RYGB Grp)', 'description': 'Participants were randomized to RYGB vs. an intensive medical diabetes and weight management program (Why WAIT? Program)'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '16'}, {'groupId': 'OG001', 'value': '17'}, {'groupId': 'OG002', 'value': '19'}, {'groupId': 'OG003', 'value': '19'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.7', 'lowerLimit': '-1.4', 'upperLimit': '2.8'}, {'groupId': 'OG001', 'value': '2.2', 'lowerLimit': '0.2', 'upperLimit': '4.2'}, {'groupId': 'OG002', 'value': '-2.5', 'lowerLimit': '-4.3', 'upperLimit': '-0.7'}, {'groupId': 'OG003', 'value': '0.1', 'lowerLimit': '-2.0', 'upperLimit': '2.1'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.81', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '1.5', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'estimateComment': 'Estimation parameter is the difference between change from baseline in CHD risk over 10 yrs. in LAGB group vs. change from baseline in CHD risk over 10 yrs. in Intensive Medical Diabetes \\\\& Weight Management (LAGB Grp), adjusted for baseline CHD risk.'}, {'groupIds': ['OG002', 'OG003'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.009', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '2.6', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'estimateComment': 'Estimation parameter is the difference between change from baseline in CHD risk over 10 yrs. in RYGB group vs. change from baseline in CHD risk over 10 yrs. in Intensive Medical Diabetes \\\\& Weight Management (RYGB Grp), adjusted for baseline CHD risk.'}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'timeFrame': '3 years', 'description': 'Adverse events (AE), including all-cause mortality, serious, and other adverse events were monitored in all participants, and information is included in this report. For those who were lost to followup, AE were recorded up to the timepoint of loss to followup. The total number of participants indicated is the number who completed 3 years of followup, and thus for whom AE monitoring was complete for the 3 year study.', 'eventGroups': [{'id': 'EG000', 'title': 'Laparoscopic Adjustable Gastric Band Surgery', 'description': 'Surgical Implantation of Allergan Adjustable Gastric Band (Device)', 'deathsNumAffected': 0, 'deathsNumAtRisk': 18, 'seriousNumAffected': 9, 'seriousNumAtRisk': 18, 'otherNumAffected': 0, 'otherNumAtRisk': 18}, {'id': 'EG001', 'title': 'Intensive Medical Diabetes and Weight Management: Band Group', 'deathsNumAffected': 1, 'deathsNumAtRisk': 22, 'seriousNumAffected': 6, 'seriousNumAtRisk': 22, 'otherNumAffected': 0, 'otherNumAtRisk': 22}, {'id': 'EG002', 'title': 'Roux-en-Y Gastric Bypass (RYGB) Surgery', 'deathsNumAffected': 0, 'deathsNumAtRisk': 19, 'seriousNumAffected': 11, 'seriousNumAtRisk': 19, 'otherNumAffected': 0, 'otherNumAtRisk': 19}, {'id': 'EG003', 'title': 'Intensive Medical Diabetes and Weight Management: RYGB Group', 'deathsNumAffected': 0, 'deathsNumAtRisk': 19, 'seriousNumAffected': 5, 'seriousNumAtRisk': 19, 'otherNumAffected': 0, 'otherNumAtRisk': 19}], 'seriousEvents': [{'term': 'sudden death', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': 'hospitalization for diabetes management', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': 'coronary bypass graft or stent', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 2, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': 'cardiac arrest - survived', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 19}]}, {'term': 'presyncope', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 19}]}, {'term': 'syringomyelia repair', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': 'bariatric surgery revisions and complications', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 11, 'numAffected': 8, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': \"Erb's palsy\", 'organSystem': 'Congenital, familial and genetic disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': 'cancer', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': '1 prostate (IMWM-band requiring 2 surgical procedures), 1 breast (RYGB)', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': 'cellulitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': 'orthopedic procedures', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': 'laminectomy (IMWM-band), hip arthroplasty', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 19}]}, {'term': 'renal', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': 'surgical repair for urinary incontinence (IMWM-band), acute kidney injury (RYGB), nephrolithiasis (RYGB), urinary tract infection (RYGB)', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': 'congestive heart failure hospitalization', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 19}]}, {'term': 'supraventricular arrhythmia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 19}]}, {'term': 'pulmonary embolism', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': 'psychiatric hospitalizations', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}, {'term': 'panniculectomy', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 18}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 22}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 19}, {'groupId': 'EG003', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 19}]}]}, 'moreInfoModule': {'limitationsAndCaveats': {'description': 'Small sample size limits generalizability. Study performed at a single academic medical center. Duration of diabetes and insulin use, as proxies for β-cell function, were not inclusion or exclusion criteria.\\n\\nLong-term durability of beneficial effects of reducing weight and HbA1c could not be evaluated after 3 years.\\n\\nNewer bariatric surgical procedures, e.g. sleeve gastrectomy, were not studied.'}, 'certainAgreement': {'piSponsorEmployee': True, 'restrictiveAgreement': False}, 'pointOfContact': {'title': 'Mary Elizabeth Patti MD', 'organization': 'Joslin Diabetes Center', 'email': 'mary.elizabeth.patti@joslin.harvard.edu', 'phone': '617 309 1966'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05784220', 'orgStudyIdInfo': {'id': 'CDPP'}, 'organization': {'fullName': 'LMC Diabetes & Endocrinology Ltd.', 'class': 'OTHER'}, 'briefTitle': 'The Canadian Diabetes Prevention Program', 'officialTitle': 'Prevention of Type 2 Diabetes Using a Digital Wellness Coaching Intervention: The Canadian Diabetes Prevention Program', 'acronym': 'CDPP'}, 'statusModule': {'statusVerifiedDate': '2023-03', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-06-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-06-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2023-09-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-10-22', 'studyFirstSubmitQcDate': '2023-03-14', 'studyFirstPostDateStruct': {'date': '2023-03-24', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-03-14', 'lastUpdatePostDateStruct': {'date': '2023-03-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Dr. Harpreet Bajaj', 'investigatorTitle': 'Endocrinologist and Director of Late-Phase Research, LMC Healthcare', 'investigatorAffiliation': 'LMC Diabetes & Endocrinology Ltd.'}, 'leadSponsor': {'name': 'LMC Diabetes & Endocrinology Ltd.', 'class': 'OTHER'}, 'collaborators': [{'name': 'Public Health Agency of Canada (PHAC)', 'class': 'OTHER_GOV'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'According to Diabetes Canada (\"DC\"), in 2015, the estimated prevalence of prediabetes in Canada (\\\\>20 years of age) is 5.7 million people (22.1%). This rate is estimated to increase to 6.4 million people (23.2%) by 2025. Risk factors contributing to prediabetes and consequently Type 2 Diabetes include rising obesity rates, lack of physical activity, an aging population, and the cultural diversity of Canada .\\n\\nThere is convincing evidence that modifiable risk factors, such as diet and physical activity reduce the development of Type 2 Diabetes with the benefits extending beyond the active intervention stage.\\n\\nThe underlying theory that supports this intervention relates to the imperative need to focus on weight loss and physical activity, with this population that is at risk of developing diabetes, due to its relationship with insulin resistance. DC outlines the importance of intensive and structured lifestyle modification to promote weight loss in order to reduce the progression of prediabetes to diabetes.', 'detailedDescription': 'INTRODUCTION:\\n\\nLMC Healthcare, in collaboration with Diabetes Canada and INTERVENT International, is inviting participants to be part of a new program called the Canadian Diabetes Prevention Program (\"CDPP\") aimed at reducing the risk of developing Type 2 Diabetes. Participants can join the CDPP if participants have been diagnosed with prediabetes or participants score 33 or above on the CANRISK Questionnaire (a validated tool used to assess diabetes risk). Information collected from the CDPP will be used for research purposes.\\n\\nBACKGROUND / RATIONALE:\\n\\nAccording to Diabetes Canada (\"DC\"), in 2015, the estimated number of people with prediabetes in Canada (\\\\>20 years of age) was 5.7 million people (22.1%). Prediabetes can be defined as people with a blood sugar level that is higher than normal but not high enough to be diagnosed with diabetes; these people are at high risk for developing diabetes. This rate is estimated to increase to 6.4 million people (23.2%) by 2025. Risk factors contributing to prediabetes and consequently type 2 diabetes include rising obesity rates, lack of physical activity, an aging population, and the cultural diversity of Canada.\\n\\nThere is convincing evidence that modifiable risk factors, such as diet and physical activity reduce the development of Type 2 Diabetes with the benefits extending beyond the active intervention stage. The underlying theory that supports this intervention relates to the imperative need to focus on weight loss and physical activity, with this population that is at risk of developing diabetes, due to its relationship with insulin resistance. DC outlines the importance of intensive and structured lifestyle modification to promote weight loss in order to reduce the progression of prediabetes to diabetes.\\n\\nThe proposed intervention would target participants who are identified as \"at risk\" using the Canadian Diabetes Risk Assessment Questionnaire (CANRISK) or those participants who have been diagnosed with prediabetes based on blood work.\\n\\nPURPOSE/OBJECTIVE:\\n\\nTo reduce the risk of developing Type 2 Diabetes Mellitus by taking part in a 12-month lifestyle intervention program. A select group of participants, 452 participants, will have a follow up at 18 months to assess a post-study progression.'}, 'conditionsModule': {'conditions': ['Diabetes type2'], 'keywords': ['Diabetes', 'Pre-diabetes', 'Diabetes prevention']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'No masking'}}, 'enrollmentInfo': {'count': 2174, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'DPP', 'type': 'OTHER', 'description': 'The CDC Diabetes Prevention Program (DPP) curriculum for lifestyle intervention, including 21 education topics delivered via text-based education module, and follow-up telephone health coaching call for each topic.', 'interventionNames': ['Behavioral: DPP Curriculum for Lifestyle Intervention']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'DPP Curriculum for Lifestyle Intervention', 'description': 'See arms.', 'armGroupLabels': ['DPP']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in weight assessed by a scale', 'timeFrame': '12 months from baseline'}, {'measure': 'Change in weight assessed by a scale', 'timeFrame': '18 months from baseline'}, {'measure': 'BMI < 25.0 and/or weight loss ≥ 5.0%', 'timeFrame': '12 months from baseline'}, {'measure': 'BMI < 25.0 and/or weight loss ≥ 5.0%', 'timeFrame': '18 months from baseline'}, {'measure': 'Change in waist circumference assessed by measurement in waist circumference', 'timeFrame': '12 months from baseline'}, {'measure': '> 3% and ≥ 5% reduction in waist circumference', 'timeFrame': '12 months from baseline'}, {'measure': '> 3% and ≥ 5% reduction in waist circumference', 'timeFrame': '18 months from baseline'}, {'measure': 'A1c at final visit <6.5% measured by lab test', 'timeFrame': '12 months from baseline'}, {'measure': 'A1c at final visit <6.5% measured by lab test', 'timeFrame': '18 months from baseline'}, {'measure': 'Fasting blood glucose at final visit < 7 mmol/L measured by lab test', 'timeFrame': '12 months from baseline'}, {'measure': 'Fasting blood glucose at final visit < 7 mmol/L measured by lab test', 'timeFrame': '8 months from baseline'}], 'secondaryOutcomes': [{'measure': 'Number of participants in each category and sub-category (of each question) of CANRISK Questionnaire', 'timeFrame': 'Baseline, 6 months and 12 months'}, {'measure': 'Number of participants that are diagnosed with prediabetes vs. at high risk', 'timeFrame': 'Baseline, 6 months and 12 months'}, {'measure': 'The number of people who develop diabetes during the program', 'timeFrame': '6 months and 12 months'}, {'measure': 'Effectiveness of recruitment channels.', 'description': 'The following choices will be given to participants to fill out and the participant will be able to choose all that apply: doctor or health care provider, social media (facebook, instagram, twitter) google/internet search, employer, recommendation from family/friend, and/or other.', 'timeFrame': 'Baseline'}, {'measure': 'Intervention reach assessed by postal code', 'timeFrame': 'Baseline'}, {'measure': 'Participants knowledge about disease risk factors and lifestyle change assessed through the Knowledge Questionnaire', 'timeFrame': 'Baseline, 6 months and 12 months'}, {'measure': 'The proportion of individuals who lower their risk of diabetes (CANRISK score)', 'timeFrame': '6 months and 12 months'}, {'measure': 'The proportion of participants who had an improvement in quality of life assessed by the SF-12 Questionnaire', 'timeFrame': '6 months and 12 months'}, {'measure': 'The proportion of participants who had a change in diet, based on ASA-24 Questionnaire', 'timeFrame': '6 months and 12 months'}, {'measure': 'The number of participants in each category of the stages of change assessed by the Stages of Change Questionnaire', 'timeFrame': 'Baseline, 6 months and 12 months'}, {'measure': 'Participants change in the stage of change assessed by Stages of Change Questionnaire', 'timeFrame': '6 months and 12 months'}, {'measure': 'The number of participants who completed the program', 'description': 'A completed participant is defined as someone who attended 56% of their sessions in the first 6 months of intervention, and at least 50% of their sessions in the last 6 months of their intervention, and has been in the program for a minimum of 9 months in total', 'timeFrame': '9 months'}, {'measure': 'Participant satisfaction by Participant Satisfaction Survey and Post Program Interview', 'timeFrame': '6 months and 12 months'}, {'measure': 'The proportion of participants who had a change in physical activity', 'timeFrame': '6 months and 12 months'}, {'measure': 'The proportion of participants who report a minimum of 150 minutes of moderate- to vigorous-intensity of physical activity spread across the week.', 'description': \"The INTERVENT platform has the ability to measure participants' steps if they have a step-counter; therefore, the amount of time will be identified as self-reported or through a step counter.\", 'timeFrame': 'Baseline, 6 months and 12 months'}, {'measure': 'Change in LDL-c and non-HDL (subgroup analyses for people on cholesterol lowering medications vs. no cholesterol lowering medications during the project)', 'timeFrame': '12 months'}, {'measure': 'Change in HDL', 'timeFrame': '12 months'}, {'measure': 'Change in triglycerides', 'timeFrame': '12 months'}, {'measure': 'Proportion of subjects with improvement of triglyceride levels within normal limit for the lab', 'timeFrame': '12 months'}, {'measure': 'Change in blood pressure', 'description': 'Both systolic and diastolic blood pressure will be measured.', 'timeFrame': '12 months'}], 'otherOutcomes': [{'measure': 'The number of reported technical issues related to software', 'timeFrame': '12 months'}, {'measure': 'Level of participant engagement', 'timeFrame': '6 months and 12 months'}, {'measure': 'Issues with delivery by service providers', 'timeFrame': '12 months from baseline'}, {'measure': 'Subjective scoring of program coach audits', 'description': '0-10, A higher number is a better result', 'timeFrame': '12 months from baseline'}, {'measure': 'Objective scoring of program coach audits', 'description': '0-5. A higher number is a better result', 'timeFrame': '12 months from baseline'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Score of 33 or higher using the Canadian Diabetes Risk Assessment (CANRISK) Questionnaire (aged 18 to 74) or;\\n* Age ≥ 45 and BMI ≥ 30 or;\\n* Or diagnosed with prediabetes age 18 years or older with an A1c of 6.0-6.4% and/or fasting glucose 6.1-6.9 mmol/L and;\\n* Access to phone and internet (options include: home, work, friend's home, relative's home, public library, etc.);\\n\\nExclusion Criteria:\\n\\n* Diagnosis of diabetes\\n* Any glucose lowering medication\\n* Any prescribed weight loss medication\\n* Receiving oral/systemic glucocorticoid (steroid) therapy (not including inhalers or nasal sprays) within the past 3 months, or planning to initiate oral/systemic glucocorticoid (steroid) in the next 3 months\\n* History of acute or chronic pancreatitis\\n* History of an active or untreated malignancy or in remission from a clinically significant malignancy for less than 5 years\\n* History of hemoglobinopathy, which may affect HbA1c measurement\\n* Currently enrolled in a clinical trial involving an investigational drug (need to be free of study medication for 30 days after final visit)\\n* Pregnancy or becoming pregnant during the study (the participant would be excluded due to weight gain and increased of waist circumference as they contradict the outcomes of the study)\\n* Dementia/severe cognitive impairment (the study does not have the proper support staff to support participants with specific needs)\\n* Inability to read English or French, or with personal or family support to interpret material\\n* Outside the catchment area for lab services (blood and anthropometric collection)\\n* Weight at baseline greater than upper limit of the scale used\", 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'LMC Diabetes Ltd', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M4G 3E8', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Type 2', 'relevance': 'HIGH'}, {'id': 'M14117', 'name': 'Prediabetic State', 'relevance': 'LOW'}, {'id': 'M20295', 'name': 'Glucose Intolerance', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05872620', 'orgStudyIdInfo': {'id': '18560'}, 'secondaryIdInfos': [{'id': 'J2A-MC-GZGQ', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}, {'id': '2022-502837-24-00', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}, {'id': 'U1111-1289-8799', 'type': 'OTHER', 'domain': 'UTN Number'}], 'organization': {'fullName': 'Eli Lilly and Company', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes', 'officialTitle': 'A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)', 'acronym': 'ATTAIN-2'}, 'statusModule': {'statusVerifiedDate': '2025-02', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-06-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-08', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-08', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-05-15', 'studyFirstSubmitQcDate': '2023-05-15', 'studyFirstPostDateStruct': {'date': '2023-05-24', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-26', 'lastUpdatePostDateStruct': {'date': '2025-02-27', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.'}, 'conditionsModule': {'conditions': ['Obesity', 'Overweight', 'Type 2 Diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 1500, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Orforglipron Dose 1', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive orforglipron administered orally.', 'interventionNames': ['Drug: Orforglipron']}, {'label': 'Orforglipron Dose 2', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive orforglipron administered orally.', 'interventionNames': ['Drug: Orforglipron']}, {'label': 'Orforglipron Dose 3', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive orforglipron administered orally.', 'interventionNames': ['Drug: Orforglipron']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Participants will receive placebo', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Orforglipron', 'description': 'Administered orally', 'armGroupLabels': ['Orforglipron Dose 1', 'Orforglipron Dose 2', 'Orforglipron Dose 3'], 'otherNames': ['LY3502970']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Administered orally', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Mean Percent Change from Baseline in Body Weight', 'timeFrame': 'Baseline, Week 72'}], 'secondaryOutcomes': [{'measure': 'Mean Change from Baseline in Waist Circumference', 'timeFrame': 'Baseline, Week 72'}, {'measure': 'Mean Change from Baseline in Hemoglobin A1c (HbA1c) %', 'timeFrame': 'Baseline, Week 72'}, {'measure': 'Mean Change from Baseline in Fasting Glucose', 'timeFrame': 'Baseline, Week 72'}, {'measure': 'Mean Change from Baseline in Systolic Blood Pressure (SBP)', 'timeFrame': 'Baseline, Week 72'}, {'measure': 'Mean Change from Baseline in Fasting Triglycerides', 'timeFrame': 'Baseline, Week 72'}, {'measure': 'Mean Percent Change from Baseline in Fasting non-High-Density Lipoprotein (HDL) Cholesterol', 'timeFrame': 'Baseline, Week 72'}, {'measure': 'Mean Percent Change from Baseline in Fasting Insulin', 'timeFrame': 'Baseline, Week 72'}, {'measure': 'Mean Change from Baseline in Diastolic Blood Pressure (DBP)', 'timeFrame': 'Baseline, Week 72'}, {'measure': 'Mean Change from Baseline in Short Form 36 Version 2 Health Survey Acute Form (SF-36v2) Domain Scores', 'timeFrame': 'Baseline, Week 72'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Have a body mass index (BMI) ≥27.0 kilogram/square meter (kg/m²).\\n* Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\\n* Have a diagnosis of Type 2 Diabetes (T2D), with HbA1c ≥7% (≥53 mmol/mol) to ≤10% (86 mmol/mol) and are on stable treatment for T2D for at least 90 days prior to screening, consisting of:\\n\\n  * either diet/exercise alone or\\n  * up to 3 oral antihyperglycemic medications (excluding dipeptidyl peptidase IV inhibitors (DPP-4i) or glucagon-like peptide-1 (GLP-1) receptor agonists (RA).\\n\\nExclusion Criteria:\\n\\n* Have Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.\\n* Have a self-reported change in body weight \\\\>5 kg (11 pounds) within 90 days prior to screening.\\n* Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (for example, laster photocoagulation or intravitreal injections of anti-vascular endothelial growth factor inhibitors).\\n* Have family (first-degree relative) or personal history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia 2 (MEN2) syndrome.\\n* Have had a history of chronic or acute pancreatitis.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)', 'affiliation': 'Eli Lilly and Company', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Cahaba Research - Pelham', 'city': 'Pelham', 'state': 'Alabama', 'zip': '35124', 'country': 'United States', 'geoPoint': {'lat': 33.28567, 'lon': -86.80999}}, {'facility': 'Novak Clinical Research - Tucson - North La Cholla Boulevard', 'city': 'Tucson', 'state': 'Arizona', 'zip': '85741', 'country': 'United States', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'facility': 'Yuma Clinical Trials', 'city': 'Yuma', 'state': 'Arizona', 'zip': '85364', 'country': 'United States', 'geoPoint': {'lat': 32.72532, 'lon': -114.6244}}, {'facility': 'AMCR Institute', 'city': 'Escondido', 'state': 'California', 'zip': '92025', 'country': 'United States', 'geoPoint': {'lat': 33.11921, 'lon': -117.08642}}, {'facility': 'Velocity Clinical Research, Huntington Park', 'city': 'Huntington Park', 'state': 'California', 'zip': '90255', 'country': 'United States', 'geoPoint': {'lat': 33.98168, 'lon': -118.22507}}, {'facility': 'Velocity Clinical Research, Westlake', 'city': 'Los Angeles', 'state': 'California', 'zip': '90057', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'Catalina Research Institute, LLC', 'city': 'Montclair', 'state': 'California', 'zip': '91763', 'country': 'United States', 'geoPoint': {'lat': 34.07751, 'lon': -117.68978}}, {'facility': 'University Clinical Investigators, Inc.', 'city': 'Tustin', 'state': 'California', 'zip': '92780', 'country': 'United States', 'geoPoint': {'lat': 33.74585, 'lon': -117.82617}}, {'facility': 'Encore Medical Research', 'city': 'Hollywood', 'state': 'Florida', 'zip': '33024', 'country': 'United States', 'geoPoint': {'lat': 26.0112, 'lon': -80.14949}}, {'facility': 'East Coast Institute for Research, LLC', 'city': 'Jacksonville', 'state': 'Florida', 'zip': '32216', 'country': 'United States', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'facility': 'South Florida Clinical Research Institute', 'city': 'Margate', 'state': 'Florida', 'zip': '33063', 'country': 'United States', 'geoPoint': {'lat': 26.24453, 'lon': -80.20644}}, {'facility': 'Suncoast Clinical Research, Inc.', 'city': 'New Port Richey', 'state': 'Florida', 'zip': '34652', 'country': 'United States', 'geoPoint': {'lat': 28.24418, 'lon': -82.71927}}, {'facility': 'Balanced Life Health Care Solutions/SKYCRNG', 'city': 'Lawrenceville', 'state': 'Georgia', 'zip': '30046', 'country': 'United States', 'geoPoint': {'lat': 33.95621, 'lon': -83.98796}}, {'facility': 'Endocrine Research Solutions, Inc.', 'city': 'Roswell', 'state': 'Georgia', 'zip': '30076', 'country': 'United States', 'geoPoint': {'lat': 34.02316, 'lon': -84.36159}}, {'facility': 'North Georgia Clinical Research', 'city': 'Woodstock', 'state': 'Georgia', 'zip': '30189', 'country': 'United States', 'geoPoint': {'lat': 34.10149, 'lon': -84.51938}}, {'facility': 'Pacific Diabetes & Endocrine Center', 'city': 'Honolulu', 'state': 'Hawaii', 'zip': '96813', 'country': 'United States', 'geoPoint': {'lat': 21.30694, 'lon': -157.85833}}, {'facility': 'Solaris Clinical Research', 'city': 'Meridian', 'state': 'Idaho', 'zip': '83646', 'country': 'United States', 'geoPoint': {'lat': 43.61211, 'lon': -116.39151}}, {'facility': 'Iowa Diabetes and Endocrinology Research Center', 'city': 'West Des Moines', 'state': 'Iowa', 'zip': '50265', 'country': 'United States', 'geoPoint': {'lat': 41.57721, 'lon': -93.71133}}, {'facility': 'MedStar Good Samaritan Hospital', 'city': 'Baltimore', 'state': 'Maryland', 'zip': '21239', 'country': 'United States', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'facility': 'Arcturus Healthcare , PLC, Troy Internal Medicine Research Division', 'city': 'Troy', 'state': 'Michigan', 'zip': '48098', 'country': 'United States', 'geoPoint': {'lat': 42.60559, 'lon': -83.14993}}, {'facility': 'StudyMetrix Research', 'city': 'Saint Peters', 'state': 'Missouri', 'zip': '63303', 'country': 'United States', 'geoPoint': {'lat': 38.80033, 'lon': -90.62651}}, {'facility': 'Las Vegas Medical Research', 'city': 'Las Vegas', 'state': 'Nevada', 'zip': '89128', 'country': 'United States', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'facility': 'IMA Clinical Research', 'city': 'Albuquerque', 'state': 'New Mexico', 'zip': '87109', 'country': 'United States', 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'facility': 'Albany Medical College, Division of Community Endocrinology', 'city': 'Albany', 'state': 'New York', 'zip': '12203', 'country': 'United States', 'geoPoint': {'lat': 42.65258, 'lon': -73.75623}}, {'facility': 'Albany Stratton VA Medical Center', 'city': 'Albany', 'state': 'New York', 'zip': '12208', 'country': 'United States', 'geoPoint': {'lat': 42.65258, 'lon': -73.75623}}, {'facility': 'NYC Research INC', 'city': 'Long Island City', 'state': 'New York', 'zip': '11106', 'country': 'United States', 'geoPoint': {'lat': 40.74482, 'lon': -73.94875}}, {'facility': 'Accellacare - Raleigh', 'city': 'Raleigh', 'state': 'North Carolina', 'zip': '27609', 'country': 'United States', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'facility': 'Summit Headlands', 'city': 'Portland', 'state': 'Oregon', 'zip': '97210', 'country': 'United States', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'facility': 'Alliance for Multispecialty Research, LLC', 'city': 'Knoxville', 'state': 'Tennessee', 'zip': '37909', 'country': 'United States', 'geoPoint': {'lat': 35.96064, 'lon': -83.92074}}, {'facility': 'Velocity Clinical Research, Dallas', 'city': 'Dallas', 'state': 'Texas', 'zip': '75230', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'Soma Clinical Trials', 'city': 'Denison', 'state': 'Texas', 'zip': '75020', 'country': 'United States', 'geoPoint': {'lat': 33.75566, 'lon': -96.53666}}, {'facility': 'Epic Medical Research - DeSoto', 'city': 'DeSoto', 'state': 'Texas', 'zip': '75115', 'country': 'United States', 'geoPoint': {'lat': 32.58986, 'lon': -96.85695}}, {'facility': 'Biopharma Informatic, LLC', 'city': 'Houston', 'state': 'Texas', 'zip': '77043', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'Diabetes and Glandular Disease Center', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'VIP Trials', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78230', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'Charlottesville Medical Research', 'city': 'Charlottesville', 'state': 'Virginia', 'zip': '22911', 'country': 'United States', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}, {'facility': 'Universal Research Group', 'city': 'Tacoma', 'state': 'Washington', 'zip': '98405', 'country': 'United States', 'geoPoint': {'lat': 47.25288, 'lon': -122.44429}}, {'facility': 'CEMEDIAB', 'city': 'C.a.b.a.', 'state': 'Ciudad Aut', 'zip': 'C1205AAO', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Mautalen Salud e Investigación', 'city': 'Buenos Aires', 'state': 'Ciudad Autónoma De Buenos Aires', 'zip': 'C1128AAF', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Instituto Centenario', 'city': 'Caba', 'state': 'Ciudad Autónoma De Buenos Aire', 'zip': '1204', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Instituto de Investigaciones Clinicas Rosario', 'city': 'Rosario', 'state': 'Santa Fe', 'zip': '2000', 'country': 'Argentina', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'facility': 'Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica', 'city': 'Rosario', 'state': 'Santa Fe', 'zip': '2000', 'country': 'Argentina', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'facility': 'Sanatorio San Martin', 'city': 'Venado Tuerto', 'state': 'Santa Fe', 'zip': '2600', 'country': 'Argentina', 'geoPoint': {'lat': -33.74556, 'lon': -61.96885}}, {'facility': 'Centro de Investigaciones Médicas Tucuman', 'city': 'SAN M. DE Tucuman', 'state': 'Tucumán', 'zip': 'T4000AXL', 'country': 'Argentina'}, {'facility': 'CONEXA Investigacion Clinica S.A.', 'city': 'Buenos Aires', 'zip': '1012', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Centro Diabetológico Dr. Waitman', 'city': 'Córdoba', 'zip': '5000', 'country': 'Argentina', 'geoPoint': {'lat': -31.4135, 'lon': -64.18105}}, {'facility': 'Clínica Universitaria Reina Fabiola', 'city': 'Córdoba', 'zip': 'X50004FHP', 'country': 'Argentina', 'geoPoint': {'lat': -31.4135, 'lon': -64.18105}}, {'facility': 'Centro de Diagnóstico y Rehabilitación (CEDIR)', 'city': 'Santa Fe', 'zip': '3000', 'country': 'Argentina', 'geoPoint': {'lat': -31.63333, 'lon': -60.7}}, {'facility': 'Emeritus Research', 'city': 'Botany', 'state': 'New South Wales', 'zip': '2019', 'country': 'Australia', 'geoPoint': {'lat': -33.94599, 'lon': 151.19591}}, {'facility': 'The AIM Centre / Hunter Diabetes Centre', 'city': 'Merewether', 'state': 'New South Wales', 'zip': '2291', 'country': 'Australia', 'geoPoint': {'lat': -32.94801, 'lon': 151.74325}}, {'facility': \"Royal Brisbane and Women's Hospital\", 'city': 'Brisbane', 'state': 'Queensland', 'zip': '4029', 'country': 'Australia', 'geoPoint': {'lat': -27.46794, 'lon': 153.02809}}, {'facility': 'Core Research Group', 'city': 'Brisbane', 'state': 'Queensland', 'zip': '4064', 'country': 'Australia', 'geoPoint': {'lat': -27.46794, 'lon': 153.02809}}, {'facility': 'Logan Hospital', 'city': 'Meadowbrook', 'state': 'Queensland', 'zip': '4131', 'country': 'Australia', 'geoPoint': {'lat': -27.66401, 'lon': 153.14465}}, {'facility': 'Southern Adelaide Diabetes & Endocrine Services', 'city': 'Oaklands Park', 'state': 'South Australia', 'zip': '5046', 'country': 'Australia', 'geoPoint': {'lat': -35.01408, 'lon': 138.53841}}, {'facility': 'Box Hill Hospital', 'city': 'Box Hill', 'state': 'Victoria', 'zip': '3128', 'country': 'Australia', 'geoPoint': {'lat': -37.81887, 'lon': 145.12545}}, {'facility': 'Emeritus Research', 'city': 'Camberwell', 'state': 'Victoria', 'zip': '3124', 'country': 'Australia', 'geoPoint': {'lat': -37.84205, 'lon': 145.0694}}, {'facility': 'Austin Health - Repatriation Hospital', 'city': 'Heidelberg West', 'state': 'Victoria', 'zip': '3081', 'country': 'Australia', 'geoPoint': {'lat': -37.75, 'lon': 145.03333}}, {'facility': 'Baker IDI Heart and Diabetes Institute - Melbourne', 'city': 'Melbourne', 'state': 'Victoria', 'zip': '3004', 'country': 'Australia', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'facility': 'Advara HeartCare Joondalup', 'city': 'Joondalup', 'state': 'Western Australia', 'zip': '6027', 'country': 'Australia', 'geoPoint': {'lat': -31.74445, 'lon': 115.76835}}, {'facility': 'Centro de Pesquisa Clinica do Brasil', 'city': 'Brasilia', 'state': 'Distrito Federal', 'zip': '71625-175', 'country': 'Brazil', 'geoPoint': {'lat': -15.77972, 'lon': -47.92972}}, {'facility': 'Cendi - Endocrinologia e Diabetes', 'city': 'Goiânia', 'state': 'Goiás', 'zip': '74230-035', 'country': 'Brazil', 'geoPoint': {'lat': -16.67861, 'lon': -49.25389}}, {'facility': 'Instituto Lóbus', 'city': 'Volta Redonda', 'state': 'Rio De Janeiro', 'zip': '27253-003', 'country': 'Brazil', 'geoPoint': {'lat': -22.52306, 'lon': -44.10417}}, {'facility': 'Instituto Méderi de Pesquisa e Saúde', 'city': 'Passo Fundo', 'state': 'Rio Grande Do Sul', 'zip': '99010-120', 'country': 'Brazil', 'geoPoint': {'lat': -28.26278, 'lon': -52.40667}}, {'facility': 'Instituto de Pesquisa clinica de Campinas', 'city': 'Campinas', 'state': 'São Paulo', 'zip': '13060-080', 'country': 'Brazil', 'geoPoint': {'lat': -22.90556, 'lon': -47.06083}}, {'facility': 'Centro de Pesquisa Clínica de Marília - CPCLIM', 'city': 'Marília', 'state': 'São Paulo', 'zip': '17504-072', 'country': 'Brazil', 'geoPoint': {'lat': -22.21389, 'lon': -49.94583}}, {'facility': 'Pesquisare Saude', 'city': 'Santo André', 'state': 'São Paulo', 'zip': '09080-110', 'country': 'Brazil', 'geoPoint': {'lat': -23.66389, 'lon': -46.53833}}, {'facility': 'CEPIC - Centro Paulista de Investigação Clínica', 'city': 'São Paulo', 'zip': '04266-010', 'country': 'Brazil', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'facility': \"The Second People's Hospital of Hefei\", 'city': 'Hefei', 'state': 'Anhui', 'zip': '230011', 'country': 'China', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'facility': 'Chinese PLA General Hospital', 'city': 'Beijing', 'state': 'Beijing', 'zip': '100853', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'Chongqing General Hospital', 'city': 'Chongqing', 'state': 'Chongqing', 'zip': '400014', 'country': 'China', 'geoPoint': {'lat': 29.56278, 'lon': 106.55278}}, {'facility': \"ShenZhen People's Hospital\", 'city': 'Shenzhen', 'state': 'Guangdong', 'zip': '518020', 'country': 'China', 'geoPoint': {'lat': 22.54554, 'lon': 114.0683}}, {'facility': 'The Fourth Affiliated Hospital of Harbin Medical University', 'city': 'Harbin', 'state': 'Heilongjiang', 'zip': '150001', 'country': 'China', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'facility': 'The First Affiliated Hospital of Henan University of Science &Technology', 'city': 'Luoyang Shi', 'state': 'Henan', 'zip': '471003', 'country': 'China'}, {'facility': 'The Second Affiliated Hospital of Zhengzhou University', 'city': 'Zhengzhou', 'state': 'Henan', 'zip': '450014', 'country': 'China', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'facility': 'Nanjing First Hospital', 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210006', 'country': 'China', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'facility': 'Jiangsu Province Official Hospital', 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210008', 'country': 'China', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'facility': 'The Second Affiliated Hospital of Nanjing Medical University', 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210011', 'country': 'China', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'facility': \"Nantong First People's Hospital\", 'city': 'Nantong', 'state': 'Jiangsu', 'zip': '226001', 'country': 'China', 'geoPoint': {'lat': 32.03028, 'lon': 120.87472}}, {'facility': \"Wuxi People's Hospital\", 'city': 'Wuxi', 'state': 'Jiangsu', 'zip': '214023', 'country': 'China', 'geoPoint': {'lat': 31.56887, 'lon': 120.28857}}, {'facility': \"Jiangxi Provincial People's Hospital\", 'city': 'Nanchang', 'state': 'Jiangxi', 'zip': '330006', 'country': 'China', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}, {'facility': 'Dalian Municipal Central Hospital Affiliated of Dalian Medical University', 'city': 'Dalian', 'state': 'Liaoning', 'zip': '116033', 'country': 'China', 'geoPoint': {'lat': 38.91222, 'lon': 121.60222}}, {'facility': 'Jinan Central Hospital', 'city': 'Jinan', 'state': 'Shandong', 'zip': '250013', 'country': 'China', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'facility': 'Tianjin Medical University General Hospital', 'city': 'Tianjin', 'state': 'Tianjin', 'zip': '300052', 'country': 'China', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'facility': 'Tianjin Medical University Zhu Xianyi Memorial Hospital', 'city': 'Tianjin', 'state': 'Tianjin', 'country': 'China', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'facility': \"The First People's Hospital of Yunnan Province\", 'city': 'Kunming', 'state': 'Yunnan', 'zip': '650034', 'country': 'China', 'geoPoint': {'lat': 25.03889, 'lon': 102.71833}}, {'facility': 'MUDr. Alena Vachova', 'city': 'Ceske Budejovice', 'state': 'Jihočeský', 'zip': '37011', 'country': 'Czechia', 'geoPoint': {'lat': 48.97447, 'lon': 14.47434}}, {'facility': 'MUDr. Tomas Edelsberger', 'city': 'Krnov', 'state': 'Moravskosl', 'zip': '79401', 'country': 'Czechia', 'geoPoint': {'lat': 50.08967, 'lon': 17.70385}}, {'facility': 'Diahelp s.r.o', 'city': 'Pardubice V', 'state': 'Pardubice', 'zip': '530 02', 'country': 'Czechia'}, {'facility': 'Dialine - Interni a diabetologicka ambulance', 'city': 'Pilsen', 'state': 'Plzeň-město', 'zip': '301 00', 'country': 'Czechia', 'geoPoint': {'lat': 49.74747, 'lon': 13.37759}}, {'facility': 'Diabet2 s.r.o., diabetologicka a interni ambulance', 'city': 'Praha', 'state': 'Praha 1', 'zip': '11000', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'Milan Kvapil s.r.o., Diabetologicka ambulance', 'city': 'Praha', 'state': 'Praha 4', 'zip': '14900', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'ResTrial s.r.o.', 'city': 'Praha', 'state': 'Praha 8', 'zip': '18100', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'MUDr. Sabina Palova', 'city': 'Jilove u Prahy', 'state': 'Praha-západ', 'zip': '252 42', 'country': 'Czechia', 'geoPoint': {'lat': 49.89545, 'lon': 14.49333}}, {'facility': 'Milan Kvapil s.r.o., Diabetologicka ambulance Pribram', 'city': 'Pribram', 'state': 'Středočeský Kraj', 'zip': '26201', 'country': 'Czechia', 'geoPoint': {'lat': 49.68988, 'lon': 14.01043}}, {'facility': 'Endokrinologie MUDr. Rehorkova s.r.o.', 'city': 'Hradec Kralove', 'zip': '500 12', 'country': 'Czechia', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'facility': 'MUDr. Jitka Zemanová - diabetologie a interna s.r.o.', 'city': 'Plzen', 'zip': '326 00', 'country': 'Czechia', 'geoPoint': {'lat': 49.74747, 'lon': 13.37759}}, {'facility': 'Nemocnice Cesky Krumlov', 'city': 'Český Krumlov', 'zip': '381 01', 'country': 'Czechia', 'geoPoint': {'lat': 48.81091, 'lon': 14.31521}}, {'facility': 'CDG Studienambulanz Hartard', 'city': 'München', 'state': 'Bayern', 'zip': '80809', 'country': 'Germany', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}}, {'facility': 'Gemeinschaftspraxis Dr. med. Josef und Wilma Großkopf', 'city': 'Wallerfing', 'state': 'Bayern', 'zip': '94574', 'country': 'Germany', 'geoPoint': {'lat': 48.68416, 'lon': 12.88035}}, {'facility': 'Ceda-Research', 'city': 'Pohlheim', 'state': 'Hessen', 'zip': '35415', 'country': 'Germany'}, {'facility': 'InnoDiab Forschung Gmbh', 'city': 'Essen', 'state': 'Nordrhein-Westfalen', 'zip': '45136', 'country': 'Germany', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'facility': 'Medizentrum Essen Borbeck', 'city': 'Essen', 'state': 'Nordrhein-Westfalen', 'zip': '45355', 'country': 'Germany', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'facility': 'Universitaetsklinikum Koeln', 'city': 'Köln', 'state': 'Nordrhein-Westfalen', 'zip': '50937', 'country': 'Germany', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'facility': 'Institut für Diabetesforschung GmbH Münster', 'city': 'Münster', 'state': 'Nordrhein-', 'zip': '48145', 'country': 'Germany', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'facility': 'Hausarzt- und Diabetologische Schwerpunktpraxis Hohenmölsen - Weiβenfels', 'city': 'Hohenmölsen', 'state': 'Sachsen-Anhalt', 'zip': '06679', 'country': 'Germany', 'geoPoint': {'lat': 51.15769, 'lon': 12.1}}, {'facility': 'SMO.MD GmbH', 'city': 'Magdeburg', 'state': 'Sachsen-Anhalt', 'zip': '39120', 'country': 'Germany', 'geoPoint': {'lat': 52.12773, 'lon': 11.62916}}, {'facility': 'AmBeNet GmbH', 'city': 'Leipzig', 'state': 'Sachsen', 'zip': '04107', 'country': 'Germany', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'facility': 'Arztpraxis Christine Kosch Pirna', 'city': 'Pirna', 'state': 'Sachsen', 'zip': '01796', 'country': 'Germany', 'geoPoint': {'lat': 50.95843, 'lon': 13.93702}}, {'facility': 'Universität zu Lübeck - Institut für Endokrinologie und Diabetes', 'city': 'Lübeck', 'state': 'Schleswig-Holstein', 'zip': '23562', 'country': 'Germany', 'geoPoint': {'lat': 53.86893, 'lon': 10.68729}}, {'facility': 'RED-Institut GmbH', 'city': 'Oldenburg', 'state': 'Schleswig-Holstein', 'zip': '23758', 'country': 'Germany', 'geoPoint': {'lat': 53.14118, 'lon': 8.21467}}, {'facility': 'Diabetes Zentrum Dr. Tews', 'city': 'Gelnhausen', 'zip': '63571', 'country': 'Germany', 'geoPoint': {'lat': 50.20164, 'lon': 9.18742}}, {'facility': 'Diabetes Zentrum Wilhelmsburg', 'city': 'Hamburg', 'zip': '21109', 'country': 'Germany', 'geoPoint': {'lat': 53.57532, 'lon': 10.01534}}, {'facility': 'Athens Medical Center', 'city': 'Athens', 'state': 'Attikí', 'zip': '151 25', 'country': 'Greece', 'geoPoint': {'lat': 37.97945, 'lon': 23.71622}}, {'facility': 'Ippokrateio General Hospital of Thessaloniki', 'city': 'Thessaloniki', 'state': 'Kentrikí Makedonía', 'zip': '54642', 'country': 'Greece', 'geoPoint': {'lat': 40.64361, 'lon': 22.93086}}, {'facility': 'Euromedica General Clinic of Thessaloniki', 'city': 'Thessaloniki', 'state': 'Thessaloníki', 'zip': '546 45', 'country': 'Greece', 'geoPoint': {'lat': 40.64361, 'lon': 22.93086}}, {'facility': 'Papageorgiou General Hospital of Thessaloniki', 'city': 'Thessaloniki', 'state': 'Thessaloníki', 'zip': '564 29', 'country': 'Greece', 'geoPoint': {'lat': 40.64361, 'lon': 22.93086}}, {'facility': 'Thermi Clinic', 'city': 'Thessaloniki', 'state': 'Thessaloníki', 'zip': '570 01', 'country': 'Greece', 'geoPoint': {'lat': 40.64361, 'lon': 22.93086}}, {'facility': 'University General Hospital of Larissa', 'city': 'Larissa', 'state': 'Thessalía', 'zip': '41110', 'country': 'Greece', 'geoPoint': {'lat': 39.63689, 'lon': 22.41761}}, {'facility': '424 Military General Training Hospital', 'city': 'Thessaloniki', 'zip': '564 29', 'country': 'Greece', 'geoPoint': {'lat': 40.64361, 'lon': 22.93086}}, {'facility': 'Medstar Speciality Hospital', 'city': 'Bangalore', 'state': 'Karnataka', 'zip': '560092', 'country': 'India', 'geoPoint': {'lat': 12.97194, 'lon': 77.59369}}, {'facility': 'Karnataka Institute of Medical Sciences', 'city': 'Hubli', 'state': 'Karnataka', 'zip': '580021', 'country': 'India', 'geoPoint': {'lat': 15.34776, 'lon': 75.13378}}, {'facility': 'TOTALL Diabetes Hormone Institute', 'city': 'Indore', 'state': 'Madhya Pradesh', 'zip': '452010', 'country': 'India', 'geoPoint': {'lat': 22.71792, 'lon': 75.8333}}, {'facility': 'Topiwala National Medical College & B. Y. L. Nair Charitable Hospital', 'city': 'Mumbai', 'state': 'Maharashtra', 'zip': '400008', 'country': 'India', 'geoPoint': {'lat': 19.07283, 'lon': 72.88261}}, {'facility': 'BSES MG Hospital', 'city': 'Mumbai', 'state': 'Maharashtra', 'zip': '400058', 'country': 'India', 'geoPoint': {'lat': 19.07283, 'lon': 72.88261}}, {'facility': 'All India Institute of Medical Sciences (AIIMS) - Nagpur', 'city': 'Nagpur', 'state': 'Maharashtra', 'zip': '441108', 'country': 'India', 'geoPoint': {'lat': 21.14631, 'lon': 79.08491}}, {'facility': 'Sahyadri Super Speciality Hospital', 'city': 'Pune', 'state': 'Maharashtra', 'zip': '411004', 'country': 'India', 'geoPoint': {'lat': 18.51957, 'lon': 73.85535}}, {'facility': 'Arthur Asirvatham Hospital', 'city': 'Madurai', 'state': 'Tamil Nadu', 'zip': '625020', 'country': 'India', 'geoPoint': {'lat': 9.91769, 'lon': 78.11898}}, {'facility': 'Kumudini Devi Diabetes Research Center', 'city': 'Hyderabad', 'state': 'Telangana', 'zip': '500082', 'country': 'India', 'geoPoint': {'lat': 17.38405, 'lon': 78.45636}}, {'facility': 'Yonsei University-Wonju Severance Christian Hospital', 'city': 'Wonju', 'state': 'Kang-won-do', 'zip': '26426', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.35139, 'lon': 127.94528}}, {'facility': 'Seoul National University Bundang Hospital', 'city': 'Seongnam', 'state': 'Kyǒnggi-do', 'zip': '13620', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'facility': 'Yeungnam Univeristy Medical Center', 'city': 'Gyeongsan-si', 'state': 'Kyǒngsangbuk-do', 'zip': '42415', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.82333, 'lon': 128.73778}}, {'facility': 'Korea University Anam Hospital', 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi [Seoul]', 'zip': '02841', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': \"The Catholic Univ. of Korea Seoul St. Mary's Hospital\", 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi [Seoul]', 'zip': '06591', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Kyung Hee University Hospital at Gangdong', 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi [Seoul]', 'zip': '134-090', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Advanced Clinical Research, LLC', 'city': 'Bayamón', 'zip': '00959', 'country': 'Puerto Rico', 'geoPoint': {'lat': 18.39856, 'lon': -66.15572}}, {'facility': 'Isis Clinical Research Center', 'city': 'Guaynabo', 'zip': '00968', 'country': 'Puerto Rico', 'geoPoint': {'lat': 18.35745, 'lon': -66.111}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)', 'url': 'https://trials.lilly.com/en-US/trial/404300'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'], 'timeFrame': 'Time Frame:\\n\\nData are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.', 'accessCriteria': 'A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.', 'url': 'http://vivli.org/'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D009765', 'term': 'Obesity'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D050177', 'term': 'Overweight'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D001835', 'term': 'Body Weight'}], 'browseLeaves': [{'id': 'M26186', 'name': 'Overweight', 'asFound': 'Overweight', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M12701', 'name': 'Obesity', 'asFound': 'Obesity', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M25307', 'name': 'Overnutrition', 'relevance': 'LOW'}, {'id': 'M12684', 'name': 'Nutrition Disorders', 'relevance': 'LOW'}, {'id': 'M5114', 'name': 'Body Weight', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01516320', 'orgStudyIdInfo': {'id': 'AAAO1101'}, 'secondaryIdInfos': [{'id': 'R01DK067561', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/R01DK067561'}], 'organization': {'fullName': 'Columbia University', 'class': 'OTHER'}, 'briefTitle': 'Mechanisms of Diabetes Relapse After Bariatric Surgery', 'officialTitle': 'Mechanisms of Diabetes Relapse After Bariatric Surgery', 'acronym': 'LAF26'}, 'statusModule': {'statusVerifiedDate': '2017-01', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2009-05-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2014-09-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2014-09-01', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2012-01-19', 'studyFirstSubmitQcDate': '2012-01-19', 'studyFirstPostDateStruct': {'date': '2012-01-24', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-01-30', 'lastUpdatePostDateStruct': {'date': '2017-02-01', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Blandine Laferrere', 'investigatorTitle': 'Professor of Medicine, Columbia University', 'investigatorAffiliation': 'Columbia University'}, 'leadSponsor': {'name': 'Blandine Laferrere', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The objective of this study is to investigate the different mechanisms by which Gastric Bypass (GBP), laparoscopic adjustable gastric banding (LAGB) and vertical sleeve gastrectomy (VSG) affect glucose control. We wish to understand the role of weight loss versus changes in gut peptides in the short and long term in morbidly obese patients with Type 2 Diabetes Mellitus after GBP, LAGB or VSG. The 2 surgical groups will be compared at 10% equivalent weight loss and at after surgery in terms of gut hormones levels, insulin secretion and glucose control.', 'detailedDescription': 'The mechanisms of type 2 diabetes (T2DM) remission after gastric bypass surgery (GBP) are unclear. The levels of the gut hormones incretins and their effect on insulin secretion, which is impaired in T2DM, markedly increase after GBP. The anatomical changes of GBP, rather than weight loss, seem to be responsible for the changes of incretins. The objective of this proposal is to investigate the different mechanisms by which GBP, laparoscopic adjustable gastric banding (LAGB) and vertical sleeve gastrectomy (VSG) affect glucose control. We wish to understand the role of weight loss versus changes in gut peptides in the short and long term in morbidly patients with T2DM after GBP, LAGB or VSG.\\n\\nAIM 1: Will study the short term changes of incretins levels and effect in obese individuals with T2DM after GBP, LAGB or VSG, before and 1 month after GBP or before and after equivalent weight loss after LAGB or VSG.\\n\\nAIM 2: Will study the long-term (12 and 24 months after surgery) changes in the incretin effect on insulin secretion, in patients with T2DM after GBP, LAGB or VSG.\\n\\nAIM 3: Will study the changes of insulin secretion to IV glucose (AIRg) and insulin sensitivity (Si), measured by the minimal model, in patients with T2DM after GBP, VSG or LAGB, before and at 24 months after the surgery, at weight stability under condition of controlled diet.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes'], 'keywords': ['Type 2 Diabetes', 'Gastric Bypass', 'Laparoscopic Banding', 'Vertical Sleeve Gastrectomy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 56, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Gastric Bypass (GBP) Subjects', 'type': 'EXPERIMENTAL', 'description': 'Subjects enrolled in the study who are receiving Roux-en-Y Gastric Bypass surgical technique for treatment of their obesity.', 'interventionNames': ['Procedure: Roux-en-Y Gastric Bypass']}, {'label': 'Laparoscopic adjustable gastric banding (LAGB) Subjects', 'type': 'ACTIVE_COMPARATOR', 'description': 'Subjects enrolled in the study who are receiving laparoscopic adjustable gastric banding surgical technique for treatment of their obesity.', 'interventionNames': ['Procedure: Laparoscopic adjustable gastric banding']}, {'label': 'Vertical Sleeve Gastrectomy (VSG) Subjects', 'type': 'ACTIVE_COMPARATOR', 'description': 'Subjects enrolled in the study who are receiving vertical sleeve gastrectomy surgical technique for treatment of their obesity.', 'interventionNames': ['Procedure: Vertical Sleeve Gastrectomy']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Roux-en-Y Gastric Bypass', 'description': 'A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.', 'armGroupLabels': ['Gastric Bypass (GBP) Subjects']}, {'type': 'PROCEDURE', 'name': 'Laparoscopic adjustable gastric banding', 'description': 'A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.', 'armGroupLabels': ['Laparoscopic adjustable gastric banding (LAGB) Subjects']}, {'type': 'PROCEDURE', 'name': 'Vertical Sleeve Gastrectomy', 'description': 'A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.', 'armGroupLabels': ['Vertical Sleeve Gastrectomy (VSG) Subjects']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Difference in insulin secretion between groups.', 'description': 'The investigators will assess insulin secretion in response to oral and intravenous nutrient and hormonal stimuli in the three groups.', 'timeFrame': '0 - 48 months after surgery'}], 'secondaryOutcomes': [{'measure': 'Difference in Incretin hormone response between groups.', 'description': 'The investigators will assess the endogenous incretin response to oral glucose stimulus after GBP.', 'timeFrame': '0 - 48 months after surgery'}, {'measure': 'Difference in Body composition between groups', 'description': 'The investigators will assess body composition (fat mass and fat distribution) in the 3 groups.', 'timeFrame': '0 - 48 months after surgery'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria: Post GBP, LAGB or VSG Subjects\\n\\n* Must be able to attend 4 study visits at St. Luke's Roosevelt Hospital Center in Manhattan, New York City\\n* History of Type 2 Diabetes before surgery\\n\\nInclusion Criteria:\\n\\n* 35 \\\\< BMI \\\\< 50\\n* Non-Smoker\\n* Total Body Weight \\\\< 300 LBS\\n* 30\\\\<Age\\\\<60\\n* HbA1c \\\\< 9%\\n* Resting Blood Pressure \\\\< 160/100 mmHg\\n* Beta Blockers discontinued 2 weeks prior\\n* Fasting Triglyceride Concentration \\\\< 600 mg/dl (patient can be on dyslipidemia medications)\\n* Without recent (within last 6 months) CHD history (prior history of angioplasty or coronary artery bypass surgery with normal stress test ok)\\n\\nExclusion Criteria:\\n\\n1. Patients with abnormal thyroid, renal function, known malabsorption syndrome or a seizure disorder requiring anti epileptic therapy, and/or elevation of liver enzymes three times above the normal limit.\\n2. Patients should not have significant secondary complications from diabetes that would preclude undergoing gastric by-pass surgery. This would include significant psychiatric, renal or neurological, or known active coronary artery disease.\\n3. Any abnormality during the maximum exercise stress test that indicates it would be unsafe to undergo bariatric surgery.\\n4. Currently pregnant or nursing.\\n5. Known cardiovascular disease\\n6. Patient with current mucosal (gastrointestinal, respiratory, urogenital) or skin (cellulitis) infection\\n7. HbA1c \\\\>9% and diabetes diagnosed more than 6 years prior to enrollment, or patients taking insulin or TZD (Avandia, Actos, Exenatide, DPP-IV inhibitors etc.) at the time of enrollment.\\n8. Patients diagnosed with intestinal conditions such as chronic diarrhea, diverticulitis, or irritable bowel syndrome. These clinical conditions would interfere with the collection and interpretation of the H2 breath test.\\n9. Any other condition which, in the opinion of the investigators, may make the candidate unsuitable for participation in this study.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Blandine Laferrere, MD', 'affiliation': 'New York Obesity Nutrition Research Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': \"New York Obesity Nutrition Research Center, St. Luke's-Roosevelt Hospital Center\", 'city': 'New York', 'state': 'New York', 'zip': '10025', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'New York Obesity Nutrition Research Center', 'url': 'http://www.nyorc.org/'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00191282', 'orgStudyIdInfo': {'id': '5509'}, 'secondaryIdInfos': [{'id': 'F3Z-MC-IONM', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}], 'organization': {'fullName': 'Eli Lilly and Company', 'class': 'INDUSTRY'}, 'briefTitle': 'Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes', 'officialTitle': 'Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D)', 'acronym': 'IONM'}, 'statusModule': {'statusVerifiedDate': '2011-01', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2002-10'}, 'primaryCompletionDateStruct': {'date': '2007-10', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2007-10', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2005-09-12', 'studyFirstSubmitQcDate': '2005-09-12', 'studyFirstPostDateStruct': {'date': '2005-09-19', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2008-10-17', 'resultsFirstSubmitQcDate': '2009-06-19', 'resultsFirstPostDateStruct': {'date': '2009-08-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2011-01-18', 'lastUpdatePostDateStruct': {'date': '2011-01-20', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Chief Medical Officer', 'oldOrganization': 'Eli Lilly'}, 'leadSponsor': {'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined adjudicated cardiovascular (CV) event (primary outcome defined as CV death, nonfatal myocardial infarction \\\\[MI\\\\], nonfatal stroke, coronary revascularization, or hospitalized acute coronary syndrome).', 'detailedDescription': 'The purpose of this study is to evaluate the effect of two different treatment strategies on CV outcomes in patients with type 2 diabetes while aiming to achieve and maintain HbA1c \\\\<7.0% in both groups. Only patients who have recently experienced an acute MI will be considered for participation in this trial.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2', 'Acute Myocardial Infarction'], 'keywords': ['diabetes', 'MI', 'heart attack']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 1116, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1', 'type': 'EXPERIMENTAL', 'description': 'Postprandial: Premeal insulin lispro +/- bedtime NPH', 'interventionNames': ['Drug: Insulin lispro', 'Drug: Human insulin isophane suspension (NPH)']}, {'label': '2', 'type': 'ACTIVE_COMPARATOR', 'description': 'Fasting: NPH/insulin glargine or human insulin 30/70', 'interventionNames': ['Drug: Insulin glargine', 'Drug: Human insulin isophane suspension', 'Drug: Human insulin 30/70']}], 'interventions': [{'type': 'DRUG', 'name': 'Insulin lispro', 'description': 'Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study', 'armGroupLabels': ['1'], 'otherNames': ['Humalog']}, {'type': 'DRUG', 'name': 'Human insulin isophane suspension (NPH)', 'description': 'Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%', 'armGroupLabels': ['1']}, {'type': 'DRUG', 'name': 'Insulin glargine', 'description': 'Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.', 'armGroupLabels': ['2']}, {'type': 'DRUG', 'name': 'Human insulin isophane suspension', 'description': 'Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.', 'armGroupLabels': ['2']}, {'type': 'DRUG', 'name': 'Human insulin 30/70', 'description': 'Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.', 'armGroupLabels': ['2'], 'otherNames': ['Human insulin 70/30 (in the United States)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants Who Experienced a Primary Combined Outcome', 'description': 'The combined study outcomes consisted of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for acute coronary syndromes (HACS), and coronary revascularization procedures planned after randomization.', 'timeFrame': 'Randomization (Day 0) until first occurrence of primary combined outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}], 'secondaryOutcomes': [{'measure': 'Number of Participants Who Experienced Death From Any Cause or Any One of the Primary Outcomes', 'description': 'Primary outcomes in this study consisted of: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for acute coronary syndromes (HACS), and coronary revascularization procedure planned after randomization.', 'timeFrame': 'Randomization (Day 0) until death from any cause or one of the primary outcomes (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Any One of the Primary Outcomes Adjusted for Indicators of Metabolic Control', 'description': 'Indicators of metabolic control included glycosylated hemoglobin (HbA1c) and fasting blood glucose concentrations.', 'timeFrame': 'Randomization (Day 0) until occurrence of primary outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Primary Outcomes Adjusted for Metabolic Control and Major Cardiovascular (CV) Risk Factors', 'description': 'Primary outcomes adjusted for major cardiovascular (CV) risk factors (blood pressure, cholesterol \\\\[total, high density lipoprotein (HDL), and low density lipoprotein (LDL)\\\\], triglycerides, smoking, albuminuria, age, gender, and body mass index (BMI).', 'timeFrame': 'Randomization (Day 0) until occurrence of primary outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Death From Any Cause', 'timeFrame': 'Randomization (Day 0) until death from any cause (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Cardiovascular (CV) Death', 'timeFrame': 'Randomization (Day 0) until cardiovascular death (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Myocardial Infarction (MI)', 'description': 'Occurrence of myocardial infarction (MI) (fatal, nonfatal, any).', 'timeFrame': 'Randomization (Day 0) until myocardial infarction (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Stroke', 'description': 'Occurrence of stroke (fatal, nonfatal, any).', 'timeFrame': 'Randomization (Day 0) until stroke (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Hospitalization for Acute Coronary Syndromes (HACS)', 'timeFrame': 'Randomization (Day 0) until HACS (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Coronary Revascularization Procedures', 'description': 'Occurrence of all coronary revascularization procedures (angioplasty or coronary artery by-pass surgery) planned after randomization.', 'timeFrame': 'Randomization (Day 0) until coronary revascularization procedures (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Amputation for Peripheral Vascular Disease Planned After Randomization', 'timeFrame': 'Randomization (Day 0) until amputation (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Congestive Heart Failure', 'description': 'Occurrence of congestive heart failure (newly diagnosed after Visit 2).', 'timeFrame': 'Randomization (Day 0) until congestive heart failure (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Revascularization Procedure for Peripheral Vascular Disease Planned After Randomization', 'timeFrame': 'Randomization (Day 0) until revascularization procedure (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants Who Experienced Coronary Angiography Planned After Randomization', 'timeFrame': 'Randomization (Day 0) until coronary angiography (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}, {'measure': 'Number of Participants With Self-Reported Hypoglycemia During Month 1', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 3 (Month 1)'}, {'measure': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 1', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 3 (Month 1)'}, {'measure': 'Number of Participants With Self-Reported Hypoglycemia During Month 3', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 4 (Month 3)'}, {'measure': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 3', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 4 (Month 3)'}, {'measure': 'Number of Participants With Self-Reported Hypoglycemia During Month 6', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 5 (Month 6)'}, {'measure': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 6', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 5 (Month 6)'}, {'measure': 'Number of Participants With Self-Reported Hypoglycemia During Month 9', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 6 (Month 9)'}, {'measure': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 9', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 6 (Month 9)'}, {'measure': 'Number of Participants With Self-Reported Hypoglycemia During Month 12', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 7 (Month 12)'}, {'measure': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 12', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 7 (Month 12)'}, {'measure': 'Number of Participants With Self-Reported Hypoglycemia During Month 18', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 8 (Month 18)'}, {'measure': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'timeFrame': 'Visit 8 (Month 18)'}], 'otherOutcomes': [{'measure': 'Summary of Reasons for Deaths', 'timeFrame': 'Randomization (Day 0) to death (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Are at least 30 years old\\n* Have had type 2 diabetes for at least 3 months prior to Visit 1\\n* Were admitted to the Coronary Care Unit (CCU) within 18 days prior to Visit 1 for an acute MI\\n* Are capable and willing to do specified study procedures\\n* Have given informed consent to participate in the study in accordance with local regulations\\n\\nExclusion Criteria:\\n\\n* Were on one of the following therapies prior to admission to the CCU for the recent MI: a)diet therapy only and have glycosylated hemoglobin (HbA1c) \\\\<1.15 times the upper limit of normal or b) an intensive basal/bolus insulin regimen\\n* Are using any oral antihyperglycemic medication at the time of Visit 2 and are unwilling to stop the use of such medication for the duration of the study\\n* Have substantial myocardial damage, which would significantly outweigh the potential benefit of the treatment strategies for diabetes\\n* Have the most severe form of congestive heart failure\\n* Have liver disease so severe that it precludes the patient from following and completing the protocol', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '30 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9am-5pm Eastern time (UTC/GMT - 5 hours, EST)', 'affiliation': 'Eli Lilly and Company', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Zagreb', 'country': 'Croatia', 'geoPoint': {'lat': 45.81444, 'lon': 15.97798}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Praha', 'country': 'Czech Republic', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Dresden', 'country': 'Germany', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Budapest', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'New Delhi', 'country': 'India', 'geoPoint': {'lat': 28.63576, 'lon': 77.22445}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Jerusalem', 'country': 'Israel', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Beirut', 'country': 'Lebanon', 'geoPoint': {'lat': 33.88894, 'lon': 35.49442}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Warsaw', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Brasov', 'country': 'Romania', 'geoPoint': {'lat': 45.64861, 'lon': 25.60613}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Saint Petersburg', 'country': 'Russian Federation', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Nitra', 'country': 'Slovakia', 'geoPoint': {'lat': 48.30763, 'lon': 18.08453}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Maribor', 'country': 'Slovenia', 'geoPoint': {'lat': 46.55472, 'lon': 15.64667}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Parktown', 'country': 'South Africa', 'geoPoint': {'lat': -26.18205, 'lon': 28.02671}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Barcelona', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Istanbul', 'country': 'Turkey', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'facility': 'For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician', 'city': 'Liverpool', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}]}, 'referencesModule': {'references': [{'pmid': '19246588', 'type': 'RESULT', 'citation': 'Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009 Mar;32(3):381-6. doi: 10.2337/dc08-1671.'}, {'pmid': '18227478', 'type': 'RESULT', 'citation': 'Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care. 2008 Feb;31 Suppl 2:S155-60. doi: 10.2337/dc08-s240.'}, {'pmid': '15745837', 'type': 'RESULT', 'citation': 'Milicevic Z, Raz I, Strojek K, Skrha J, Tan MH, Wyatt JW, Beattie SD, Robbins DC; HEART2D Study. Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. J Diabetes Complications. 2005 Mar-Apr;19(2):80-7. doi: 10.1016/j.jdiacomp.2004.06.003.'}, {'pmid': '21593301', 'type': 'DERIVED', 'citation': 'Raz I, Ceriello A, Wilson PW, Battioui C, Su EW, Kerr L, Jones CA, Milicevic Z, Jacober SJ. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. Diabetes Care. 2011 Jul;34(7):1511-3. doi: 10.2337/dc10-2375. Epub 2011 May 18.'}]}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'One patient was randomized but discontinued prior to treatment and is not included in any of the analyses. In the Participant Flow table, the term study outcome is used to differentiate it from serious adverse events (SAEs). By definition, the study outcomes were all SAEs as it was a cardiovascular outcome trial.', 'groups': [{'id': 'FG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'FG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '558'}, {'groupId': 'FG001', 'numSubjects': '558'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '338'}, {'groupId': 'FG001', 'numSubjects': '346'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '220'}, {'groupId': 'FG001', 'numSubjects': '212'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '6'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '51'}, {'groupId': 'FG001', 'numSubjects': '51'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '11'}, {'groupId': 'FG001', 'numSubjects': '6'}]}, {'type': 'Noncompliance', 'reasons': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '17'}]}, {'type': 'Patient moved', 'reasons': [{'groupId': 'FG000', 'numSubjects': '11'}, {'groupId': 'FG001', 'numSubjects': '14'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '59'}, {'groupId': 'FG001', 'numSubjects': '44'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '18'}, {'groupId': 'FG001', 'numSubjects': '15'}]}, {'type': 'Protocol entry criteria not met', 'reasons': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '9'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '12'}]}, {'type': 'Severity of outcome', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '5'}]}, {'type': \"Sponsor's decision\", 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '24'}, {'groupId': 'FG001', 'numSubjects': '31'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'BG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '557'}, {'groupId': 'BG001', 'value': '558'}, {'groupId': 'BG002', 'value': '1115'}]}], 'measures': [{'title': 'Age Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '61.1', 'spread': '9.7'}, {'groupId': 'BG001', 'value': '60.9', 'spread': '9.8'}, {'groupId': 'BG002', 'value': '61.0', 'spread': '9.8'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '201'}, {'groupId': 'BG001', 'value': '208'}, {'groupId': 'BG002', 'value': '409'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '356'}, {'groupId': 'BG001', 'value': '350'}, {'groupId': 'BG002', 'value': '706'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'Slovakia (Slovak Republic)', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '8'}, {'groupId': 'BG001', 'value': '11'}, {'groupId': 'BG002', 'value': '19'}]}]}, {'title': 'Slovenia', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '16'}, {'groupId': 'BG001', 'value': '16'}, {'groupId': 'BG002', 'value': '32'}]}]}, {'title': 'Spain', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '5'}, {'groupId': 'BG001', 'value': '3'}, {'groupId': 'BG002', 'value': '8'}]}]}, {'title': 'Lebanon', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '18'}, {'groupId': 'BG001', 'value': '19'}, {'groupId': 'BG002', 'value': '37'}]}]}, {'title': 'Turkey', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '19'}, {'groupId': 'BG001', 'value': '17'}, {'groupId': 'BG002', 'value': '36'}]}]}, {'title': 'Israel', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '38'}, {'groupId': 'BG001', 'value': '38'}, {'groupId': 'BG002', 'value': '76'}]}]}, {'title': 'Russian Federation', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '63'}, {'groupId': 'BG001', 'value': '65'}, {'groupId': 'BG002', 'value': '128'}]}]}, {'title': 'United Kingdom', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '15'}, {'groupId': 'BG001', 'value': '18'}, {'groupId': 'BG002', 'value': '33'}]}]}, {'title': 'India', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '36'}, {'groupId': 'BG001', 'value': '34'}, {'groupId': 'BG002', 'value': '70'}]}]}, {'title': 'Czech Republic', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '26'}, {'groupId': 'BG001', 'value': '24'}, {'groupId': 'BG002', 'value': '50'}]}]}, {'title': 'Hungary', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '41'}, {'groupId': 'BG001', 'value': '41'}, {'groupId': 'BG002', 'value': '82'}]}]}, {'title': 'Canada', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '12'}, {'groupId': 'BG001', 'value': '13'}, {'groupId': 'BG002', 'value': '25'}]}]}, {'title': 'Poland', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '102'}, {'groupId': 'BG001', 'value': '103'}, {'groupId': 'BG002', 'value': '205'}]}]}, {'title': 'Croatia', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '72'}, {'groupId': 'BG001', 'value': '71'}, {'groupId': 'BG002', 'value': '143'}]}]}, {'title': 'Romania', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '33'}, {'groupId': 'BG001', 'value': '31'}, {'groupId': 'BG002', 'value': '64'}]}]}, {'title': 'South Africa', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '44'}, {'groupId': 'BG001', 'value': '45'}, {'groupId': 'BG002', 'value': '89'}]}]}, {'title': 'Germany', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '9'}, {'groupId': 'BG001', 'value': '9'}, {'groupId': 'BG002', 'value': '18'}]}]}]}, {'title': 'Race/Ethnicity', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'Caucasian', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '484'}, {'groupId': 'BG001', 'value': '483'}, {'groupId': 'BG002', 'value': '967'}]}]}, {'title': 'Western Asian', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '61'}, {'groupId': 'BG001', 'value': '58'}, {'groupId': 'BG002', 'value': '119'}]}]}, {'title': 'African Descent', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '6'}, {'groupId': 'BG002', 'value': '7'}]}]}, {'title': 'Other', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '11'}, {'groupId': 'BG001', 'value': '11'}, {'groupId': 'BG002', 'value': '22'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants Who Experienced a Primary Combined Outcome', 'description': 'The combined study outcomes consisted of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for acute coronary syndromes (HACS), and coronary revascularization procedures planned after randomization.', 'populationDescription': 'All randomized patients who took at least one dose of study drug', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until first occurrence of primary combined outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '174'}, {'groupId': 'OG001', 'value': '181'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'To achieve 80% power, 490 pts need to experience primary combined CV outcome to detect diff. between treatments, assuming: \\\\>=18.5% reduction in incidence of outcomes, 18 mo. pt recruitment, 18 mo. pt follow-up, 10% annual drop-out rate, 2-yr outcome incidence rate of \\\\>=40% (pts in least efficacious treatment), and nominal 2-sided signif. of 0.045.', 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.866', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.98', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Death From Any Cause or Any One of the Primary Outcomes', 'description': 'Primary outcomes in this study consisted of: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for acute coronary syndromes (HACS), and coronary revascularization procedure planned after randomization.', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until death from any cause or one of the primary outcomes (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '178'}, {'groupId': 'OG001', 'value': '189'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.715', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.96', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Any One of the Primary Outcomes Adjusted for Indicators of Metabolic Control', 'description': 'Indicators of metabolic control included glycosylated hemoglobin (HbA1c) and fasting blood glucose concentrations.', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until occurrence of primary outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '174'}, {'groupId': 'OG001', 'value': '181'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.914', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '1.01', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Primary Outcomes Adjusted for Metabolic Control and Major Cardiovascular (CV) Risk Factors', 'description': 'Primary outcomes adjusted for major cardiovascular (CV) risk factors (blood pressure, cholesterol \\\\[total, high density lipoprotein (HDL), and low density lipoprotein (LDL)\\\\], triglycerides, smoking, albuminuria, age, gender, and body mass index (BMI).', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until occurrence of primary outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '174'}, {'groupId': 'OG001', 'value': '181'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.706', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '1.05', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Death From Any Cause', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until death from any cause (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '51'}, {'groupId': 'OG001', 'value': '51'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.982', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '1.00', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Cardiovascular (CV) Death', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until cardiovascular death (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '44'}, {'groupId': 'OG001', 'value': '42'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.816', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '1.05', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Myocardial Infarction (MI)', 'description': 'Occurrence of myocardial infarction (MI) (fatal, nonfatal, any).', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until myocardial infarction (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '63'}, {'groupId': 'OG001', 'value': '63'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.948', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '1.01', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Stroke', 'description': 'Occurrence of stroke (fatal, nonfatal, any).', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until stroke (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '20'}, {'groupId': 'OG001', 'value': '17'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.581', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '1.20', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Hospitalization for Acute Coronary Syndromes (HACS)', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until HACS (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '58'}, {'groupId': 'OG001', 'value': '54'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.647', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '1.09', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Coronary Revascularization Procedures', 'description': 'Occurrence of all coronary revascularization procedures (angioplasty or coronary artery by-pass surgery) planned after randomization.', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until coronary revascularization procedures (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '84'}, {'groupId': 'OG001', 'value': '94'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.525', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.91', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Amputation for Peripheral Vascular Disease Planned After Randomization', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until amputation (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '8'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.800', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '1.13', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Congestive Heart Failure', 'description': 'Occurrence of congestive heart failure (newly diagnosed after Visit 2).', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until congestive heart failure (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '33'}, {'groupId': 'OG001', 'value': '37'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.662', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.90', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Revascularization Procedure for Peripheral Vascular Disease Planned After Randomization', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until revascularization procedure (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '11'}, {'groupId': 'OG001', 'value': '12'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.863', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.93', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced Coronary Angiography Planned After Randomization', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) until coronary angiography (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '75'}, {'groupId': 'OG001', 'value': '86'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.471', 'statisticalMethod': 'Log Rank', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.89', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Self-Reported Hypoglycemia During Month 1', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Visit 3 (Month 1)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '557'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '124'}, {'groupId': 'OG001', 'value': '119'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.7168', 'statisticalMethod': 'Chi-squared', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 1', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized participants who self-reported hypoglycemia during Month 1.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'episodes of hypoglycemia', 'timeFrame': 'Visit 3 (Month 1)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '124'}, {'groupId': 'OG001', 'value': '119'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '353'}, {'groupId': 'OG001', 'value': '302'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Self-Reported Hypoglycemia During Month 3', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized patients who took at least one dose of study drug and who were still in the study.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Visit 4 (Month 3)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '511'}, {'groupId': 'OG001', 'value': '525'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '160'}, {'groupId': 'OG001', 'value': '139'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.0860', 'statisticalMethod': 'Chi-squared', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 3', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized participants who self-reported hypoglycemia during Month 3.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'episodes of hypoglycemia', 'timeFrame': 'Visit 4 (Month 3)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '160'}, {'groupId': 'OG001', 'value': '139'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '567'}, {'groupId': 'OG001', 'value': '524'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Self-Reported Hypoglycemia During Month 6', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized patients who took at least one dose of study drug and who were still in the study.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Visit 5 (Month 6)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '493'}, {'groupId': 'OG001', 'value': '504'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '163'}, {'groupId': 'OG001', 'value': '145'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.1424', 'statisticalMethod': 'Chi-squared', 'ciPctValue': '95'}]}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Summary of Reasons for Deaths', 'populationDescription': 'All randomized patients who took at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Randomization (Day 0) to death (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '557'}, {'groupId': 'OG001', 'value': '558'}]}], 'classes': [{'title': 'Fatal MI', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '12'}, {'groupId': 'OG001', 'value': '12'}]}]}, {'title': 'Fatal Stroke', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3'}, {'groupId': 'OG001', 'value': '2'}]}]}, {'title': 'CV Death other than Stroke/MI', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '29'}, {'groupId': 'OG001', 'value': '28'}]}]}, {'title': 'Non-CV Death', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '8'}]}]}, {'title': 'Unknown', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '1'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 6', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized participants with self-reported hypoglycemia during Month 6.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'episodes of hypoglycemia', 'timeFrame': 'Visit 5 (Month 6)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '163'}, {'groupId': 'OG001', 'value': '145'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '770'}, {'groupId': 'OG001', 'value': '576'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Self-Reported Hypoglycemia During Month 9', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized patients who took at least one dose of study drug and who were still in the study.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Visit 6 (Month 9)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '483'}, {'groupId': 'OG001', 'value': '488'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '155'}, {'groupId': 'OG001', 'value': '138'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.1957', 'statisticalMethod': 'Chi-squared', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 9', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized participants with self-reported hypoglycemia during Month 9.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'episodes of hypoglycemia', 'timeFrame': 'Visit 6 (Month 9)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '155'}, {'groupId': 'OG001', 'value': '138'}]}], 'classes': [{'title': 'Number of Episodes', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '747'}, {'groupId': 'OG001', 'value': '569'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Self-Reported Hypoglycemia During Month 12', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized patients who took at least one dose of study drug and who were still in the study.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Visit 7 (Month 12)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '470'}, {'groupId': 'OG001', 'value': '471'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '146'}, {'groupId': 'OG001', 'value': '130'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.2434', 'statisticalMethod': 'Chi-squared', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 12', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized participants with self-reported hypoglycemia during Month 12.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'episodes of hypoglycemia', 'timeFrame': 'Visit 7 (Month 12)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '146'}, {'groupId': 'OG001', 'value': '130'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '710'}, {'groupId': 'OG001', 'value': '486'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Self-Reported Hypoglycemia During Month 18', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized patients who took at least one dose of study drug and who were still in the study.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Visit 8 (Month 18)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '452'}, {'groupId': 'OG001', 'value': '457'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '143'}, {'groupId': 'OG001', 'value': '129'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.2617', 'statisticalMethod': 'Chi-squared', 'ciPctValue': '95'}]}, {'type': 'SECONDARY', 'title': 'Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18', 'description': 'Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).', 'populationDescription': 'All randomized participants with self-reported hypoglycemia during Month 18.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'episodes of hypoglycemia', 'timeFrame': 'Visit 8 (Month 18)', 'groups': [{'id': 'OG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}, {'id': 'OG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '143'}, {'groupId': 'OG001', 'value': '129'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '945'}, {'groupId': 'OG001', 'value': '669'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '3', 'eventGroups': [{'id': 'EG000', 'title': 'Postprandial', 'description': 'Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \\\\>8.0%.', 'seriousNumAffected': 145, 'otherNumAffected': 356}, {'id': 'EG001', 'title': 'Fasting', 'description': 'Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \\\\>8.0%.', 'seriousNumAffected': 142, 'otherNumAffected': 346}], 'seriousEvents': [{'term': 'Anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Hypochromic anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Iron deficiency anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Normochromic normocytic anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Acute coronary syndrome', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Acute left ventricular failure', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Acute myocardial infarction', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Angina pectoris', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 558}]}, {'term': 'Angina unstable', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Atrial fibrillation', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 558}]}, {'term': 'Atrial flutter', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Atrioventricular block', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Atrioventricular block complete', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Atrioventricular block second degree', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Cardiac failure', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Cardiac failure chronic', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Cardiac failure congestive', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 558}]}, {'term': 'Conduction disorder', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Coronary artery insufficiency', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Coronary artery restenosis', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': \"Dressler's syndrome\", 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Intracardiac thrombus', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Left ventricular dysfunction', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Left ventricular failure', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Mitral valve incompetence', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Myocardial infarction', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Sick sinus syndrome', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Sinus bradycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Ventricular extrasystoles', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Ventricular fibrillation', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Ventricular tachyarrhythmia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Ventricular tachycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Hearing impaired', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Sudden hearing loss', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Vertigo', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Vestibular neuronitis', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Hyperthyroidism', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Cataract', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Conjunctivitis', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Diabetic retinopathy', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Glaucoma', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Retinal detachment', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Vitreous haemorrhage', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Abdominal pain', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Abdominal pain upper', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Anal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Colonic polyp', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Diarrhoea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Duodenitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Dyspepsia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Enteritis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Enterocolitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Gastric polyps', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Gastric ulcer haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Gastritis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Gastritis erosive', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Gastrointestinal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Gastrointestinal telangiectasia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Gastrooesophageal reflux disease', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Haemorrhoids', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Hiatus hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Ileus', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Inguinal hernia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Intestinal obstruction', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Melaena', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Mouth cyst', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Nausea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Peptic ulcer', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Peritonitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Upper gastrointestinal haemorrhage', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Vomiting', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Asthenia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Chest discomfort', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Chest pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 558}]}, {'term': 'Cyst', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Hernia obstructive', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Multi-organ failure', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Non-cardiac chest pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Oedema peripheral', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Pyrexia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Bile duct stone', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Biliary colic', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Cholangitis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Cholecystitis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Cholecystitis acute', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Cholelithiasis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 558}]}, {'term': 'Hepatic cirrhosis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Hypersensitivity', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Sarcoidosis', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Abscess limb', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Abscess neck', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Appendicitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Arthritis bacterial', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Bronchitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 558}]}, {'term': 'Bronchopneumonia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 558}]}, {'term': 'Campylobacter gastroenteritis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Cellulitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 558}]}, {'term': 'Chronic tonsillitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Diverticulitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Erysipelas', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Gangrene', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Gastroenteritis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Intervertebral discitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Localised infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Lower respiratory tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Mediastinitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Meningitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Meningitis aseptic', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Nasopharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Osteomyelitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Paronychia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Perianal abscess', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Pneumonia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 558}]}, {'term': 'Postoperative wound infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Purulent pericarditis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Pyelonephritis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Pyelonephritis chronic', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Pyometra', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Respiratory tract infection viral', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Sepsis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Septic arthritis staphylococcal', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Septic shock', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Streptococcal bacteraemia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Subcutaneous abscess', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Urinary tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 558}]}, {'term': 'Wound infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Wound sepsis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Ankle fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Excoriation', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Femur fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Foot fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Glaucoma traumatic', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Hand fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Head injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Soft tissue injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Subdural haemorrhage', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Thermal burn', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Traumatic intracranial haemorrhage', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Wound dehiscence', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Blood pressure increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Hepatic enzyme increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'International normalised ratio increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Troponin increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Diabetes mellitus', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Diabetes mellitus inadequate control', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Diabetic foot', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Gout', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Hyperglycaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Hyperkalaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Hypoglycaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 558}]}, {'term': 'Hypokalaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Insulin resistance', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Fistula', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Intervertebral disc disorder', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Joint swelling', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Musculoskeletal chest pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Musculoskeletal pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Osteoarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Rheumatoid arthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Spinal column stenosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Spinal osteoarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Adenocarcinoma pancreas', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Basal cell carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Bile duct cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Bladder cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Breast cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Choroid melanoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Chronic lymphocytic leukaemia', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Colon cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Endometrial cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Gastric cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Lipoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Lung neoplasm malignant', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Meningioma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Pancreatic carcinoma metastatic', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Prostatic adenoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Renal cell carcinoma stage II', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Renal cell carcinoma stage unspecified', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Uterine leiomyoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Amnesia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Carotid artery occlusion', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Carotid artery stenosis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Cervicobrachial syndrome', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Cluster headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Diabetic neuropathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Dizziness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Epilepsy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Hemiparesis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Hypotonia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Intercostal neuralgia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Mononeuropathy multiplex', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': \"Parkinson's disease\", 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Presyncope', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Psychomotor hyperactivity', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Radiculopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Subarachnoid haemorrhage', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Syncope', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 558}]}, {'term': 'Transient ischaemic attack', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Vertebrobasilar insufficiency', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Mood disorder due to a general medical condition', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Post-traumatic stress disorder', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Psychotic disorder due to a general medical condition', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Calculus ureteric', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Diabetic nephropathy', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Haematuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Renal artery stenosis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Renal colic', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Renal failure', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Renal failure acute', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 558}]}, {'term': 'Renal failure chronic', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Urethral obstruction', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Urinary retention', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Endometrial hyperplasia', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Polycystic ovaries', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Postmenopausal haemorrhage', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Uterine polyp', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Uterine prolapse', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Acute pulmonary oedema', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Asthma', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Bronchitis chronic', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Chronic obstructive pulmonary disease', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 558}]}, {'term': 'Dyspnoea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Epistaxis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Hydrothorax', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Pharyngeal oedema', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Pleural effusion', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 558}]}, {'term': 'Pulmonary congestion', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Pulmonary embolism', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Pulmonary oedema', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Vocal cord polyp', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Angioedema', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Decubitus ulcer', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Erythema', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Hyperhidrosis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Idiopathic urticaria', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Photodermatosis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Skin ulcer', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Implantable defibrillator insertion', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Toe amputation', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Accelerated hypertension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Aortic aneurysm', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 558}]}, {'term': 'Arterial stenosis limb', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Arteriosclerosis obliterans', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Deep vein thrombosis', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Embolism', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Extremity necrosis', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Hypertension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Hypertensive crisis', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Hypotension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Peripheral arterial occlusive disease', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Peripheral embolism', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Peripheral ischaemia', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Post thrombotic syndrome', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Shock', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}, {'term': 'Thrombosis', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Varicose vein', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 558}]}, {'term': 'Venous thrombosis', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 558}]}], 'otherEvents': [{'term': 'Angina pectoris', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 17, 'numAffected': 17, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 22, 'numAffected': 22, 'numAtRisk': 558}]}, {'term': 'Diabetic retinopathy', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 25, 'numAffected': 25, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 29, 'numAffected': 29, 'numAtRisk': 558}]}, {'term': 'Chest pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 19, 'numAffected': 19, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 17, 'numAffected': 17, 'numAtRisk': 558}]}, {'term': 'Oedema peripheral', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 28, 'numAffected': 28, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 28, 'numAffected': 28, 'numAtRisk': 558}]}, {'term': 'Bronchitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 22, 'numAffected': 22, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 23, 'numAffected': 23, 'numAtRisk': 558}]}, {'term': 'Influenza', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 19, 'numAffected': 19, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 29, 'numAffected': 29, 'numAtRisk': 558}]}, {'term': 'Nasopharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 35, 'numAffected': 35, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 36, 'numAffected': 36, 'numAtRisk': 558}]}, {'term': 'Urinary tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 14, 'numAffected': 14, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 19, 'numAtRisk': 558}]}, {'term': 'Arteriogram coronary', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 25, 'numAffected': 25, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 22, 'numAffected': 22, 'numAtRisk': 558}]}, {'term': 'Weight increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 19, 'numAffected': 19, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 16, 'numAffected': 16, 'numAtRisk': 558}]}, {'term': 'Arthralgia', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 20, 'numAffected': 20, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 23, 'numAffected': 23, 'numAtRisk': 558}]}, {'term': 'Back pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 21, 'numAffected': 21, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 28, 'numAffected': 28, 'numAtRisk': 558}]}, {'term': 'Musculoskeletal pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 19, 'numAtRisk': 558}]}, {'term': 'Pain in extremity', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 19, 'numAffected': 19, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 25, 'numAffected': 25, 'numAtRisk': 558}]}, {'term': 'Diabetic neuropathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 23, 'numAffected': 23, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 23, 'numAffected': 23, 'numAtRisk': 558}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 19, 'numAffected': 19, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 18, 'numAffected': 18, 'numAtRisk': 558}]}, {'term': 'Depression', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 20, 'numAffected': 20, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 13, 'numAtRisk': 558}]}, {'term': 'Cough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 27, 'numAffected': 27, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 23, 'numAffected': 23, 'numAtRisk': 558}]}, {'term': 'Hypertension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 10.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 30, 'numAffected': 30, 'numAtRisk': 557}, {'groupId': 'EG001', 'numEvents': 27, 'numAffected': 27, 'numAtRisk': 558}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictionType': 'GT60', 'restrictiveAgreement': True}, 'pointOfContact': {'title': 'Chief Medical Officer', 'organization': 'Eli Lilly and Company', 'phone': '1-800-545-5979'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009203', 'term': 'Myocardial Infarction'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D006943', 'term': 'Hyperglycemia'}, {'id': 'D007238', 'term': 'Infarction'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D007511', 'term': 'Ischemia'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D009336', 'term': 'Necrosis'}, {'id': 'D017202', 'term': 'Myocardial Ischemia'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M9994', 'name': 'Hyperglycemia', 'asFound': 'Hyperglycemia', 'relevance': 'HIGH'}, {'id': 'M10282', 'name': 'Infarction', 'asFound': 'Infarction', 'relevance': 'HIGH'}, {'id': 'M12155', 'name': 'Myocardial Infarction', 'asFound': 'Myocardial Infarction', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}, {'id': 'M12284', 'name': 'Necrosis', 'relevance': 'LOW'}, {'id': 'M6546', 'name': 'Coronary Artery Disease', 'relevance': 'LOW'}, {'id': 'M19506', 'name': 'Myocardial Ischemia', 'relevance': 'LOW'}, {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}, {'id': 'T170', 'name': 'Acute Graft Versus Host Disease', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D007328', 'term': 'Insulin'}, {'id': 'C557859', 'term': 'Insulin, Globin Zinc'}, {'id': 'D000069036', 'term': 'Insulin Glargine'}, {'id': 'D061268', 'term': 'Insulin Lispro'}, {'id': 'D000068880', 'term': 'Isophane Insulin, Human'}, {'id': 'D007336', 'term': 'Insulin, Isophane'}, {'id': 'C557863', 'term': 'Isophane insulin, beef'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'asFound': 'Program', 'relevance': 'HIGH'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'asFound': 'HBV', 'relevance': 'HIGH'}, {'id': 'M347', 'name': 'Insulin Glargine', 'asFound': 'Oral administration', 'relevance': 'HIGH'}, {'id': 'M29802', 'name': 'Insulin Lispro', 'asFound': 'Dapagliflozin', 'relevance': 'HIGH'}, {'id': 'M327', 'name': 'Isophane Insulin, Human', 'asFound': 'Bone autograft', 'relevance': 'HIGH'}, {'id': 'M10373', 'name': 'Insulin, Isophane', 'asFound': 'Bone autograft', 'relevance': 'HIGH'}, {'id': 'M173174', 'name': 'Isophane insulin, beef', 'asFound': 'Bone autograft', 'relevance': 'HIGH'}, {'id': 'M17768', 'name': 'Zinc', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Micro', 'name': 'Micronutrients'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06214520', 'orgStudyIdInfo': {'id': '202304-00020'}, 'organization': {'fullName': 'Singapore General Hospital', 'class': 'OTHER'}, 'briefTitle': 'App-based Motivational Interviewing and Artificial Intelligence in Diabetes Management', 'officialTitle': 'EMPOWERing Patients with Type 2 Diabetes Mellitus (T2DM) in Primary Care Through App-based Motivational Interviewing PLUS Artificial Intelligence Powered Diabetes Management (EMPOWER-PLUS): Randomised Controlled Trial', 'acronym': 'EmpowerPlus'}, 'statusModule': {'statusVerifiedDate': '2024-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-02-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-10-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-12-19', 'studyFirstSubmitQcDate': '2024-01-10', 'studyFirstPostDateStruct': {'date': '2024-01-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-11-12', 'lastUpdatePostDateStruct': {'date': '2024-11-14', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Singapore General Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'SingHealth Polyclinic - Sengkang', 'class': 'UNKNOWN'}, {'name': 'SingHealth Polyclinic - Punggol', 'class': 'UNKNOWN'}, {'name': 'SingHealth Polyclinic - Tampines', 'class': 'UNKNOWN'}, {'name': 'Tiong Bahru Community Health Centre', 'class': 'UNKNOWN'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'There is an urgent need for better control and prevention of complications in type 2 diabetes mellitus (T2DM). Behavioural change is critical, and while literature suggests that motivational interviewing (MI) may be effective in improving glycemic control, none has explored app-based MI designed specifically for T2DM. The overall objective of this project is to determine the effectiveness of primary care model combining app-based MI and AI-powered personalised nudges delivered through a mobile application (app) for diabetes management (EMPOWER-PLUS). The project aims to evaluate the effectiveness and implementation of MI and nudges through EMPOWERPLUS to deliver diabetes management through a randomised controlled trial (RCT). This will be a 3-arm RCT with primary outcome measure being the difference in HbA1c level at week 36 between the intervention and control arms. Secondary outcome measures include cost-effectiveness, quality of life, medication adherence, diet, and physical activity. Eligible poorly controlled T2DM patients with T2DM in polyclinics will be randomized to intervention arm who will receive EMPOWER-PLUS and smartwatch wearable on top of their usual clinical care. The first control group will have access to nudges delivered through app and smartwatch wearable in addition to usual clinical care but will not receive MI. The second control group will receive usual care (no access to MI, nudges and smartwatch wearable). This study is important to improve T2DM outcomes and reduce healthcare utilization by providing scientifically evaluated and transformative primary care model. Leveraging on digital technology and artificial intelligence to drive personalised care, behavioural change and empowerment has huge potential for scale up.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus Type 2']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 525, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Intervention', 'type': 'EXPERIMENTAL', 'description': 'Intervention Group', 'interventionNames': ['Behavioral: App-based Motivational Interviewing & Human health coaching', 'Behavioral: Empower+ App & Smartwatch wearable tracker']}, {'label': 'Control 1', 'type': 'ACTIVE_COMPARATOR', 'description': 'Control group 1', 'interventionNames': ['Behavioral: Empower+ App & Smartwatch wearable tracker']}, {'label': 'Control 2', 'type': 'NO_INTERVENTION', 'description': 'Control group 2'}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'App-based Motivational Interviewing & Human health coaching', 'description': \"Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.\\n\\nApp-based Motivational Interviewing \\\\& Human health coaching:\\n\\nThe health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call.\", 'armGroupLabels': ['Intervention']}, {'type': 'BEHAVIORAL', 'name': 'Empower+ App & Smartwatch wearable tracker', 'description': \"Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.\", 'armGroupLabels': ['Control 1', 'Intervention']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1c', 'description': 'Difference between HbA1c measured at the in-house laboratory at polyclinics, at baseline and the 9-month mark.', 'timeFrame': '9 months'}], 'secondaryOutcomes': [{'measure': 'HbA1c', 'description': 'Difference between HbA1c measured at the in-house laboratory at polyclinics, at baseline and the 6-month mark. HbA1c will be also retrieved from the Electronic Medical Record over the follow-up period (from month 10 to 18, if any).', 'timeFrame': '18 months'}, {'measure': 'Patient activation score', 'description': 'Measured by patient activation measure (PAM), at baseline and the 9-month mark. For each item in PAM, the raw score ranges from 1 (Disagree strongly) to 4 (Agree strongly), and 0 is given to option \"Not Applicable\", with a higher score indicating a higher level of patient activation.', 'timeFrame': '9 months'}, {'measure': 'Physical activity - steps', 'description': 'Measured by the smartphone wearable tracker over 9 months.', 'timeFrame': '9 months'}, {'measure': 'Physical activity - active minutes', 'description': 'Measured by the smartphone wearable tracker over 9 months.', 'timeFrame': '9 months'}, {'measure': 'Sleep quality', 'description': 'Measured by the smartphone wearable tracker over 9 months.', 'timeFrame': '9 months'}, {'measure': 'Sleep pattern', 'description': 'Measured by the smartphone wearable tracker over 9 months.', 'timeFrame': '9 months'}, {'measure': 'Heart rate', 'description': 'Measured by the smartphone wearable tracker over 9 months.', 'timeFrame': '9 months'}, {'measure': 'Medication adherence', 'description': 'Measured by Voils, at baseline and the 9-month mark. For each item in Voils, the raw score ranges from 1 (missed medication none of the time) to 5 (missed medication every time), with a higher score indicating a poor level of medication adherence (or equivalently a higher level of medication non-adherence).', 'timeFrame': '9 months'}, {'measure': 'Dietary changes', 'description': 'Measured with the Empower+ app (calorie intake, carbohydrate and sugar intake) over 9 months.', 'timeFrame': '9 months'}, {'measure': 'Health-related Quality of life', 'description': 'Measured by EuroQol-5D-5L (EQ-5D-5L) combined with global health rating on a visual analogue scale (EQ-VAS) at baseline and the 9-month mark. Each dimension in the EQ-5D-5L has five response levels ranging from no problems (Level 1) to extreme problems (Level 5). There are 3,125 possible health states defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health). For EQ-VAS, the raw score ranges from 0 to 100, with a higher score indicating a better health that the participant can imagine. The converted index value will be ranging from -0.5 to 1.0, where 0 is the value of a health state equivalent to death, negative values representing values as worse than dead, and 1 is the value of full health.', 'timeFrame': '9 months'}, {'measure': 'Direct healthcare cost', 'description': 'Retrieved from the electronic medical records and recorded in survey form: Costs of consultations, lab tests, medications, admissions, at baseline and the 9-month mark.', 'timeFrame': '9 months'}, {'measure': 'Indirect healthcare cost', 'description': 'Measured by survey, including self-reported income, travel cost, at baseline and the 9-month mark.', 'timeFrame': '9 months'}, {'measure': 'Indirect healthcare cost', 'description': 'Measured by survey - Work Productivity and Activity Impairment (WPAI), at baseline and the 9-month mark. The WPAI-GH consists of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working (using a 0 to 10 Visual Analogue Scale (VAS)); 6 = degree health affected productivity in regular unpaid activities (VAS). For the last two items, the raw scores range from 0 to 10, with a higher score indicating the patient being more affected by his/her health problems.', 'timeFrame': '9 months'}, {'measure': 'Usability of the Empower+ app and Motivational Interviewing module', 'description': 'Measured by the System Usability Scale (SUS), at the 1-month mark (for intervention group and control group 1). For each item in SUS, the raw score ranges from 1 to 5, with a higher score for positive statements and a lower score for negative statements indicating a better usability.', 'timeFrame': '1 month'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Aged 21 years and above\\n* Have been diagnosed with diabetes (T2DM)\\n* Had HbA1c result of ≥ 7.5% within past 3 months\\n* Physically able to exercise\\n* Able to read and converse in English\\n* Able to download the Empower+ app, use the smartphone wearable tracker, and conform to the minimum smartwatch and app monitoring schedule\\n\\nExclusion Criteria:\\n\\n* On bolus insulin treatment\\n* Require assistance with basic activities of daily living (BADL)\\n* Have planned major operation or surgical procedure within 9 months from the time of recruitment\\n* Cognitively impaired (scored \\\\&lt; 6 on the Abbreviated Mental Test)\\n* Currently pregnant or lactating\\n* Current participants of ongoing clinical trials involving the usage of a smartphone wearable tracker or mobile health app to assist diabetes management\\n* Past Empower study participants who refused to participate in future Empower studies', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '21 Years', 'maximumAge': '100 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Lian Leng Low', 'role': 'CONTACT', 'phone': '63265872', 'email': 'low.lian.leng@singhealth.com.sg'}], 'overallOfficials': [{'name': 'Lian Leng Low', 'affiliation': 'Singhealth Foundation', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'SingHealth Polyclinic (Punggol)', 'status': 'RECRUITING', 'city': 'Singapore', 'country': 'Singapore', 'contacts': [{'name': 'Yan Ling Quah', 'role': 'CONTACT', 'email': 'quah.yan.ling@singhealth.com.sg'}], 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'facility': 'SingHealth Polyclinic (Sengkang)', 'status': 'RECRUITING', 'city': 'Singapore', 'country': 'Singapore', 'contacts': [{'name': 'Wei Mei Jeremy Koh', 'role': 'CONTACT', 'email': 'jeremy.koh.w.m@singhealth.com.sg'}], 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'facility': 'SingHealth Polyclinic (Tampines)', 'status': 'RECRUITING', 'city': 'Singapore', 'country': 'Singapore', 'contacts': [{'name': 'David Koot', 'role': 'CONTACT', 'email': 'david.koot@singhealth.com.sg'}], 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05541120', 'orgStudyIdInfo': {'id': '00000'}, 'organization': {'fullName': 'MaineHealth', 'class': 'OTHER'}, 'briefTitle': 'Effect of Remote Patient Monitoring and Patient Education on Patient Activation and Glycemic Control in Individuals With Type 2 Diabetes', 'officialTitle': 'Effect of Remote Patient Monitoring and Patient Education on Patient Activation and Glycemic Control in Individuals With Type 2 Diabetes'}, 'statusModule': {'statusVerifiedDate': '2023-02', 'overallStatus': 'WITHDRAWN', 'whyStopped': 'Lack of participants eligible for study', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-10-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-08-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-08-30', 'studyFirstSubmitQcDate': '2022-09-14', 'studyFirstPostDateStruct': {'date': '2022-09-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-02-15', 'lastUpdatePostDateStruct': {'date': '2023-02-16', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Tracy Jalbuena MD', 'investigatorTitle': 'Clinical Lead for Telehealth', 'investigatorAffiliation': 'MaineHealth'}, 'leadSponsor': {'name': 'Tracy Jalbuena MD', 'class': 'OTHER'}, 'collaborators': [{'name': 'MaineHealth', 'class': 'OTHER'}, {'name': 'Health Resources and Services Administration (HRSA)', 'class': 'FED'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"This is a randomized controlled trial of the use of Remote Patient Monitoring (RPM) compared to usual care among rural patients with poorly controlled type 2 diabetes. Usual care is defined as participation in Living Well with Diabetes/Virtual Diabetes Self-Management Program and Primary Care Provider evaluation and management at the providers' discretion, including medication adjustment or interventions, and other types of interventions depending on clinical judgement.\", 'detailedDescription': 'Effect of Remote Patient Monitoring and Patient Education on Patient Activation and Glycemic Control in Individuals with Type 2 Diabetes\\n\\nSummary\\n\\nABSTRACT\\n\\nIn 2021, the MaineHealth Telehealth team was awarded a five-year, $1.7 million \"Evidence-Based Telehealth Network Program\" grant (EB TNPG) from Health Resources and Services Administration (HRSA). This grant is aimed at improving patient access to educational and management services for patients with type 2 diabetes in the rural Maine primary care setting by implementing RPM. The RPM devices will be used to transmit a participant\\'s home point-of-care blood glucose values directly into MaineHealth\\'s electronic medical record in real time. While there is strong evidence for diabetes self-management programs such as Living Well with Diabetes, the importance of patient engagement in clinical outcomes, the validity of the Patient Activation Measure (PAM-13®) survey to measure patient activation, and the overall efficacy of remote patient monitoring, there have been no randomized controlled trials looking at patient activation in remote patient monitoring in this important patient group. The investigators aim to address this in this study by conducting a randomized controlled trial of the use of RPM among rural patients with poorly controlled type 2 diabetes. The control group will have usual primary care provider care, including patient self-management tools, while the intervention group will have usual care + RPM.\\n\\nThe investigators hypothesize that participation in RPM will be associated with decreases in HbA1c, increases in patient activation as measured by PAM-13® survey, and that increases in patient activation will be associated with decreases in HbA1c.\\n\\nSTUDY PROCESS\\n\\nThe study will be conducted over 5 years, and participants will be enrolled on a continuous rolling basis, with 70 total RPM kits available at any one time from a 3rd party vendor, Health Recovery Solutions (HRS). The maximum total number of participants the study can accommodate is 700, with 350 participants in each arm. The study team hopes for total enrollment as close to 700 as possible, but understands that total enrollment may be significantly less than 700. Point-of-care blood glucose values from the RPM study arm will flow into MaineHealth\\'s electronic medical record (Epic) in real time. Every other week, the values will be reviewed by a clinical pharmacist with expertise in diabetes management. If an intervention or adjustment in the patient\\'s regimen is indicated, the pharmacist will reach out to the Primary Care Provider (PCP) team to make this recommendation. The RPM intervention for each participant will be 6 months, at which point HRS will collect the RPM electronic tablet, and the PAM-13® survey will be administered. At 9 months after enrollment, the third HbA1c value will be collected from the electronic medical record, and the third administration of PAM-13® will take place.\\n\\nThe PAM-13® survey will be administered through one of two methods 1) REDCap electronic form, the link for which will be sent to the participant by email, or 2) by telephone, administered by the Study Coordinator.\\n\\nRecruitment of participants will continue through the early part of 2026. Data will be analyzed during spring and summer of 2026, and the grant\\'s end date is August 31, 2026.\\n\\nThis study has been approved by MaineHealth\\'s IRB as of Aug 5, 2022.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2'], 'keywords': ['remote patient monitoring', 'glycemic control']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': \"This study is a randomized controlled trial of the use of RPM compared to usual care among MaineHealth's rural patients with poorly controlled diabetes, where the participant's diabetes is managed primarily by primary care (as opposed to endocrinology). Usual care is defined as participation in Living Well with Diabetes/Virtual Diabetes Self-Management Program, PCP evaluation and management at the providers' discretion, including medication adjustment or interventions, and other types of interventions depending on clinical judgement. This may include eConsults between the provider and a pharmacist, in-person visits between the provider and the patient, synchronous telemedicine visits between the provider and the patient, and synchronous telemedicine visits between the pharmacist and the patient.\", 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Living Well with Diabetes', 'type': 'NO_INTERVENTION', 'description': 'Usual care is defined as participation in Living Well with Diabetes/Virtual Diabetes Self-Management Program, PCP evaluation and management, including medication adjustment or interventions, and other types of interventions depending on clinical judgement. This may include eConsults between the provider and a pharmacist, in-person visits between the provider and the patient, synchronous telemedicine visits between the provider and the patient, and synchronous telemedicine visits between the pharmacist and the patient.'}, {'label': 'Living Well with Diabetes + Remote Patient Monitoring', 'type': 'EXPERIMENTAL', 'description': 'Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.', 'interventionNames': ['Device: Remote Patient Monitoring']}], 'interventions': [{'type': 'DEVICE', 'name': 'Remote Patient Monitoring', 'description': 'Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.', 'armGroupLabels': ['Living Well with Diabetes + Remote Patient Monitoring']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Mean HbA1c%', 'description': 'Average glycated hemoglobin', 'timeFrame': '6 months after enrollment'}, {'measure': 'Mean HbA1c%', 'description': 'Average glycated hemoglobin', 'timeFrame': '9 months after enrollment'}, {'measure': 'Mean change in HbA1c%', 'description': 'Average change in percentage of HbA1c from baseline to 6 months after enrollment', 'timeFrame': '6 months after enrollment'}, {'measure': 'Mean change in HbA1c%', 'description': 'Average change in percentage of HbA1c from baseline to 9 months after enrollment', 'timeFrame': '9 months after enrollment'}, {'measure': 'Percentage of participants in each group who have HbA1c < 7%', 'description': 'Percentage of participants in each group with HbA1c \\\\< 7%', 'timeFrame': '6 months after enrollment'}, {'measure': 'Percentage of participants in each group who have HbA1c < 7%', 'description': 'Percentage of participants in each group with HbA1c \\\\< 7%', 'timeFrame': '9 months after enrollment'}], 'secondaryOutcomes': [{'measure': 'PAM-13 at 6 months after enrollment', 'description': 'PAM-13 Patient Activation Measure Survey\\n\\nUnabbreviated scale title: Patient Activation Measure 13-Item Survey Minimum value: 0 Maximum value: 100 Higher values are associated with better health outcomes', 'timeFrame': '6 months after enrollment'}, {'measure': 'PAM-13 at 9 months after enrollment', 'description': 'PAM-13 Patient Activation Measure Survey\\n\\nPAM-13 Patient Activation Measure Survey\\n\\nUnabbreviated scale title: Patient Activation Measure 13-Item Survey Minimum value: 0 Maximum value: 100 Higher values are associated with better health outcomes', 'timeFrame': '9 months after enrollment'}, {'measure': 'Mean change in PAM-13 at 6 months', 'description': 'Average change in PAM-13 Patient Activation Measure Survey score from baseline to 6 months after enrollment\\n\\nUnabbreviated scale title: Patient Activation Measure 13-Item Survey Minimum value: 0 Maximum value: 100 Higher values are associated with better health outcomes', 'timeFrame': '6 months after enrollment'}, {'measure': 'Mean change in PAM-13 at 9 months', 'description': 'Average change in PAM-13 Patient Activation Measure Survey score from baseline to 9 months after enrollment\\n\\nUnabbreviated scale title: Patient Activation Measure 13-Item Survey Minimum value: 0 Maximum value: 100 Higher values are associated with better health outcomes', 'timeFrame': '9 months after enrollment'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Be enrolled in Living Well with Diabetes education program\\n* Have an HbA1c% ≥ 8 in the prior 6 months\\n* Be capable of providing consent\\n* Be adults (age 18 or over)\\n\\nExclusion Criteria:\\n\\n* Primarily managed by endocrinology for their diabetes (\\\\> 1 visit with endocrinology in the previous 12 months)\\n* Incarcerated\\n* PCP not at one of the 30 primary care practices listed (see attachment List of PCP Practices)\\n* Diagnosed with type 1 diabetes\\n* Candidate for continuous glucose monitoring, as defined by Centers for Medicare and Medicaid Services as using at least three insulin injections per day, any combination of types of insulins\\n* Pregnant\\n* Have previously participated in the Living Well with Diabetes/Virtual Diabetes Self-Management Program\\n* Have previously used a remote patient monitoring device for diabetes management\\n* Have a diagnosis of dementia or other clinical diagnosis that would impair participation capacity\\n* Currently participating in any other clinical trial regarding diabetes care or management\\n* Currently enrolled in hospice\\n* Currently residing in a long term care or rehabilitation facility', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Tracy Jalbuena, MD', 'affiliation': 'MaineHealth', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'PenBay Medical Center', 'city': 'Rockport', 'state': 'Maine', 'zip': '04856', 'country': 'United States', 'geoPoint': {'lat': 44.18452, 'lon': -69.07615}}]}, 'referencesModule': {'references': [{'pmid': '31543458', 'type': 'BACKGROUND', 'citation': 'Almutairi N, Hosseinzadeh H, Gopaldasani V. The effectiveness of patient activation intervention on type 2 diabetes mellitus glycemic control and self-management behaviors: A systematic review of RCTs. Prim Care Diabetes. 2020 Feb;14(1):12-20. doi: 10.1016/j.pcd.2019.08.009. Epub 2019 Sep 20.'}, {'pmid': '29567642', 'type': 'BACKGROUND', 'citation': 'American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018 May;41(5):917-928. doi: 10.2337/dci18-0007. Epub 2018 Mar 22.'}, {'pmid': '32302521', 'type': 'BACKGROUND', 'citation': 'Andersen JA, Scoggins D, Michaud T, Wan N, Wen M, Su D. Racial Disparities in Diabetes Management Outcomes: Evidence from a Remote Patient Monitoring Program for Type 2 Diabetic Patients. Telemed J E Health. 2021 Jan;27(1):55-61. doi: 10.1089/tmj.2019.0280. Epub 2020 Apr 17.'}, {'pmid': '33329860', 'type': 'BACKGROUND', 'citation': 'Bahrom NH, Ramli AS, Isa MR, Baharudin N, Badlishah-Sham SF, Mohamed-Yassin MS, Abdul-Hamid H. Validity and reliability of the Patient Activation Measure(R) (PAM(R))-13 Malay version among patients with Metabolic Syndrome in primary care. Malays Fam Physician. 2020 Nov 10;15(3):22-34. eCollection 2020.'}, {'pmid': '29266283', 'type': 'BACKGROUND', 'citation': 'Bomba F, Markwart H, Muhlan H, Menrath I, Ernst G, Thyen U, Schmidt S. Adaptation and validation of the German Patient Activation Measure for adolescents with chronic conditions in transitional care: PAM(R) 13 for Adolescents. Res Nurs Health. 2018 Feb;41(1):78-87. doi: 10.1002/nur.21831. Epub 2017 Dec 20.'}, {'pmid': '19244564', 'type': 'BACKGROUND', 'citation': 'Boren SA, Fitzner KA, Panhalkar PS, Specker JE. Costs and benefits associated with diabetes education: a review of the literature. Diabetes Educ. 2009 Jan-Feb;35(1):72-96. doi: 10.1177/0145721708326774.'}, {'pmid': '20969750', 'type': 'BACKGROUND', 'citation': 'Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010 Oct 22;8:29. doi: 10.1186/1478-7954-8-29.'}, {'pmid': '24098669', 'type': 'BACKGROUND', 'citation': 'Brenk-Franz K, Hibbard JH, Herrmann WJ, Freund T, Szecsenyi J, Djalali S, Steurer-Stey C, Sonnichsen A, Tiesler F, Storch M, Schneider N, Gensichen J. Validation of the German version of the patient activation measure 13 (PAM13-D) in an international multicentre study of primary care patients. PLoS One. 2013 Sep 30;8(9):e74786. doi: 10.1371/journal.pone.0074786. eCollection 2013.'}, {'pmid': '26658704', 'type': 'BACKGROUND', 'citation': 'Chrvala CA, Sherr D, Lipman RD. Diabetes self-management education for adults with type 2 diabetes mellitus: A systematic review of the effect on glycemic control. Patient Educ Couns. 2016 Jun;99(6):926-43. doi: 10.1016/j.pec.2015.11.003. Epub 2015 Nov 22.'}, {'pmid': '31068494', 'type': 'BACKGROUND', 'citation': 'Cunha CM, da Cunha DCPT, Manzato RO, Nepomuceno E, da Silva D, Dantas RAS. Validation of the Brazilian Version of the Patient Activation Measure 13. J Nurs Meas. 2019 Apr 1;27(1):97-113. doi: 10.1891/1061-3749.27.1.97.'}, {'pmid': '28027366', 'type': 'BACKGROUND', 'citation': 'Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, Hamavid H, Horst C, Johnson EK, Joseph J, Lavado R, Lomsadze L, Reynolds A, Squires E, Campbell M, DeCenso B, Dicker D, Flaxman AD, Gabert R, Highfill T, Naghavi M, Nightingale N, Templin T, Tobias MI, Vos T, Murray CJ. US Spending on Personal Health Care and Public Health, 1996-2013. JAMA. 2016 Dec 27;316(24):2627-2646. doi: 10.1001/jama.2016.16885.'}, {'pmid': '28581821', 'type': 'BACKGROUND', 'citation': 'Egede LE, Williams JS, Voronca DC, Knapp RG, Fernandes JK. Randomized Controlled Trial of Technology-Assisted Case Management in Low Income Adults with Type 2 Diabetes. Diabetes Technol Ther. 2017 Aug;19(8):476-482. doi: 10.1089/dia.2017.0006. Epub 2017 Jun 5.'}, {'pmid': '19356881', 'type': 'BACKGROUND', 'citation': \"Fowles JB, Terry P, Xi M, Hibbard J, Bloom CT, Harvey L. Measuring self-management of patients' and employees' health: further validation of the Patient Activation Measure (PAM) based on its relation to employee characteristics. Patient Educ Couns. 2009 Oct;77(1):116-22. doi: 10.1016/j.pec.2009.02.018. Epub 2009 Apr 7.\"}, {'pmid': '15838407', 'type': 'BACKGROUND', 'citation': 'Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM. Development and validation of the Patient Assessment of Chronic Illness Care (PACIC). Med Care. 2005 May;43(5):436-44. doi: 10.1097/01.mlr.0000160375.47920.8c.'}, {'pmid': '22127797', 'type': 'BACKGROUND', 'citation': 'Greene J, Hibbard JH. Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med. 2012 May;27(5):520-6. doi: 10.1007/s11606-011-1931-2.'}, {'pmid': '24357210', 'type': 'BACKGROUND', 'citation': 'Haas L, Maryniuk M, Beck J, Cox CE, Duker P, Edwards L, Fisher EB, Hanson L, Kent D, Kolb L, McLaughlin S, Orzeck E, Piette JD, Rhinehart AS, Rothman R, Sklaroff S, Tomky D, Youssef G; 2012 Standards Revision Task Force. National standards for diabetes self-management education and support. Diabetes Care. 2014 Jan;37 Suppl 1(Suppl 1):S144-53. doi: 10.2337/dc14-S144. No abstract available.'}, {'pmid': '31856796', 'type': 'BACKGROUND', 'citation': 'Hellstrom A, Kassaye Tessma M, Flink M, Dahlgren A, Schildmeijer K, Ekstedt M. Validation of the patient activation measure in patients at discharge from hospitals and at distance from hospital care in Sweden. BMC Public Health. 2019 Dec 19;19(1):1701. doi: 10.1186/s12889-019-8025-1.'}, {'pmid': '19052169', 'type': 'BACKGROUND', 'citation': 'Hibbard JH. Using systematic measurement to target consumer activation strategies. Med Care Res Rev. 2009 Feb;66(1 Suppl):9S-27S. doi: 10.1177/1077558708326969. Epub 2008 Dec 3.'}, {'pmid': '23381511', 'type': 'BACKGROUND', 'citation': 'Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health Aff (Millwood). 2013 Feb;32(2):207-14. doi: 10.1377/hlthaff.2012.1061.'}, {'pmid': '25716663', 'type': 'BACKGROUND', 'citation': 'Hibbard JH, Greene J, Shi Y, Mittler J, Scanlon D. Taking the long view: how well do patient activation scores predict outcomes four years later? Med Care Res Rev. 2015 Jun;72(3):324-37. doi: 10.1177/1077558715573871. Epub 2015 Feb 24.'}, {'pmid': '16336556', 'type': 'BACKGROUND', 'citation': 'Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. Health Serv Res. 2005 Dec;40(6 Pt 1):1918-30. doi: 10.1111/j.1475-6773.2005.00438.x.'}, {'pmid': '15230939', 'type': 'BACKGROUND', 'citation': 'Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26. doi: 10.1111/j.1475-6773.2004.00269.x.'}, {'pmid': '17170632', 'type': 'BACKGROUND', 'citation': 'Hibbard JH, Tusler M. Assessing activation stage and employing a \"next steps\" approach to supporting patient self-management. J Ambul Care Manage. 2007 Jan-Mar;30(1):2-8. doi: 10.1097/00004479-200701000-00002.'}, {'pmid': '33222755', 'type': 'BACKGROUND', 'citation': 'Hosseinzadeh H, Verma I, Gopaldasani V. Patient activation and Type 2 diabetes mellitus self-management: a systematic review and meta-analysis. Aust J Prim Health. 2020 Dec;26(6):431-442. doi: 10.1071/PY19204.'}, {'pmid': '25744281', 'type': 'BACKGROUND', 'citation': 'Kinney RL, Lemon SC, Person SD, Pagoto SL, Saczynski JS. The association between patient activation and medication adherence, hospitalization, and emergency room utilization in patients with chronic illnesses: a systematic review. Patient Educ Couns. 2015 May;98(5):545-52. doi: 10.1016/j.pec.2015.02.005. Epub 2015 Feb 19.'}, {'pmid': '31149012', 'type': 'BACKGROUND', 'citation': 'Kosar C, Besen DB. Adaptation of a patient activation measure (PAM) into Turkish: reliability and validity test. Afr Health Sci. 2019 Mar;19(1):1811-1820. doi: 10.4314/ahs.v19i1.58.'}, {'pmid': '28634381', 'type': 'BACKGROUND', 'citation': 'Lee MK, Lee KH, Yoo SH, Park CY. Impact of initial active engagement in self-monitoring with a telemonitoring device on glycemic control among patients with type 2 diabetes. Sci Rep. 2017 Jun 20;7(1):3866. doi: 10.1038/s41598-017-03842-2.'}, {'pmid': '28978949', 'type': 'BACKGROUND', 'citation': 'Lee SWH, Chan CKY, Chua SS, Chaiyakunapruk N. Comparative effectiveness of telemedicine strategies on type 2 diabetes management: A systematic review and network meta-analysis. Sci Rep. 2017 Oct 4;7(1):12680. doi: 10.1038/s41598-017-12987-z.'}, {'pmid': '20299481', 'type': 'BACKGROUND', 'citation': 'Lorig K, Ritter PL, Laurent DD, Plant K, Green M, Jernigan VB, Case S. Online diabetes self-management program: a randomized study. Diabetes Care. 2010 Jun;33(6):1275-81. doi: 10.2337/dc09-2153. Epub 2010 Mar 18.'}, {'pmid': '19407333', 'type': 'BACKGROUND', 'citation': 'Lorig K, Ritter PL, Villa FJ, Armas J. Community-based peer-led diabetes self-management: a randomized trial. Diabetes Educ. 2009 Jul-Aug;35(4):641-51. doi: 10.1177/0145721709335006. Epub 2009 Apr 30.'}, {'pmid': '29797292', 'type': 'BACKGROUND', 'citation': 'McDonnell ME. Telemedicine in Complex Diabetes Management. Curr Diab Rep. 2018 May 24;18(7):42. doi: 10.1007/s11892-018-1015-3.'}, {'pmid': '33572717', 'type': 'BACKGROUND', 'citation': 'Melby K, Nygard M, Brobakken MF, Grawe RW, Guzey IC, Reitan SK, Vedul-Kjelsas E, Heggelund J, Lara-Cabrera ML. Test-Retest Reliability of the Patient Activation Measure-13 in Adults with Substance Use Disorders and Schizophrenia Spectrum Disorders. Int J Environ Res Public Health. 2021 Jan 29;18(3):1185. doi: 10.3390/ijerph18031185.'}, {'pmid': '31765684', 'type': 'BACKGROUND', 'citation': 'Michaud TL, Siahpush M, King KM, Ramos AK, Robbins RE, Schwab RJ, Clarke MA, Su D. Program completion and glycemic control in a remote patient monitoring program for diabetes management: Does gender matter? Diabetes Res Clin Pract. 2020 Jan;159:107944. doi: 10.1016/j.diabres.2019.107944. Epub 2019 Nov 23.'}, {'pmid': '29583057', 'type': 'BACKGROUND', 'citation': 'Michaud TL, Siahpush M, Schwab RJ, Eiland LA, DeVany M, Hansen G, Slachetka TS, Boilesen E, Tak HJ, Wilson FA, Wang H, Pagan JA, Su D. Remote Patient Monitoring and Clinical Outcomes for Postdischarge Patients with Type 2 Diabetes. Popul Health Manag. 2018 Oct;21(5):387-394. doi: 10.1089/pop.2017.0175. Epub 2018 Mar 27.'}, {'pmid': '26146239', 'type': 'BACKGROUND', 'citation': 'Moljord IE, Lara-Cabrera ML, Perestelo-Perez L, Rivero-Santana A, Eriksen L, Linaker OM. Psychometric properties of the Patient Activation Measure-13 among out-patients waiting for mental health treatment: A validation study in Norway. Patient Educ Couns. 2015 Nov;98(11):1410-7. doi: 10.1016/j.pec.2015.06.009. Epub 2015 Jun 23.'}, {'pmid': '12087014', 'type': 'BACKGROUND', 'citation': 'Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002 Jul;25(7):1159-71. doi: 10.2337/diacare.25.7.1159.'}, {'pmid': '26414227', 'type': 'BACKGROUND', 'citation': 'Pillay J, Armstrong MJ, Butalia S, Donovan LE, Sigal RJ, Vandermeer B, Chordiya P, Dhakal S, Hartling L, Nuspl M, Featherstone R, Dryden DM. Behavioral Programs for Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. Ann Intern Med. 2015 Dec 1;163(11):848-60. doi: 10.7326/M15-1400. Epub 2015 Sep 29.'}, {'pmid': '24404816', 'type': 'BACKGROUND', 'citation': 'Pressman AR, Kinoshita L, Kirk S, Barbosa GM, Chou C, Minkoff J. A novel telemonitoring device for improving diabetes control: protocol and results from a randomized clinical trial. Telemed J E Health. 2014 Feb;20(2):109-14. doi: 10.1089/tmj.2013.0157. Epub 2014 Jan 3.'}, {'pmid': '22849664', 'type': 'BACKGROUND', 'citation': 'Rademakers J, Nijman J, van der Hoek L, Heijmans M, Rijken M. Measuring patient activation in The Netherlands: translation and validation of the American short form Patient Activation Measure (PAM13). BMC Public Health. 2012 Jul 31;12:577. doi: 10.1186/1471-2458-12-577.'}, {'pmid': '19419972', 'type': 'BACKGROUND', 'citation': 'Rask KJ, Ziemer DC, Kohler SA, Hawley JN, Arinde FJ, Barnes CS. Patient activation is associated with healthy behaviors and ease in managing diabetes in an indigent population. Diabetes Educ. 2009 Jul-Aug;35(4):622-30. doi: 10.1177/0145721709335004. Epub 2009 Apr 28.'}, {'pmid': '34831925', 'type': 'BACKGROUND', 'citation': 'Robson N, Hosseinzadeh H. Impact of Telehealth Care among Adults Living with Type 2 Diabetes in Primary Care: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Int J Environ Res Public Health. 2021 Nov 19;18(22):12171. doi: 10.3390/ijerph182212171.'}, {'pmid': '28159442', 'type': 'BACKGROUND', 'citation': 'Sacks RM, Greene J, Hibbard J, Overton V, Parrotta CD. Does patient activation predict the course of type 2 diabetes? A longitudinal study. Patient Educ Couns. 2017 Jul;100(7):1268-1275. doi: 10.1016/j.pec.2017.01.014. Epub 2017 Jan 25.'}, {'pmid': '32550161', 'type': 'BACKGROUND', 'citation': 'Salehi S, Olyaeemanesh A, Mobinizadeh M, Nasli-Esfahani E, Riazi H. Assessment of remote patient monitoring (RPM) systems for patients with type 2 diabetes: a systematic review and meta-analysis. J Diabetes Metab Disord. 2020 Jan 10;19(1):115-127. doi: 10.1007/s40200-019-00482-3. eCollection 2020 Jun.'}, {'pmid': '19916057', 'type': 'BACKGROUND', 'citation': 'Skolasky RL, Mackenzie EJ, Riley LH 3rd, Wegener ST. Psychometric properties of the Patient Activation Measure among individuals presenting for elective lumbar spine surgery. Qual Life Res. 2009 Dec;18(10):1357-66. doi: 10.1007/s11136-009-9549-0. Epub 2009 Nov 15.'}, {'pmid': '22824531', 'type': 'BACKGROUND', 'citation': 'Steinsbekk A, Rygg LO, Lisulo M, Rise MB, Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res. 2012 Jul 23;12:213. doi: 10.1186/1472-6963-12-213.'}, {'pmid': '23428085', 'type': 'BACKGROUND', 'citation': 'Stellefson M, Dipnarine K, Stopka C. The chronic care model and diabetes management in US primary care settings: a systematic review. Prev Chronic Dis. 2013;10:E26. doi: 10.5888/pcd10.120180.'}, {'pmid': '10938048', 'type': 'BACKGROUND', 'citation': 'Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12. doi: 10.1136/bmj.321.7258.405.'}, {'pmid': '30372366', 'type': 'BACKGROUND', 'citation': 'Su D, Michaud TL, Estabrooks P, Schwab RJ, Eiland LA, Hansen G, DeVany M, Zhang D, Li Y, Pagan JA, Siahpush M. Diabetes Management Through Remote Patient Monitoring: The Importance of Patient Activation and Engagement with the Technology. Telemed J E Health. 2019 Oct;25(10):952-959. doi: 10.1089/tmj.2018.0205. Epub 2018 Oct 27.'}, {'pmid': '30609983', 'type': 'BACKGROUND', 'citation': 'Sun C, Sun L, Xi S, Zhang H, Wang H, Feng Y, Deng Y, Wang H, Xiao X, Wang G, Gao Y, Wang G. Mobile Phone-Based Telemedicine Practice in Older Chinese Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2019 Jan 4;7(1):e10664. doi: 10.2196/10664.'}, {'pmid': '23171659', 'type': 'BACKGROUND', 'citation': 'Tang PC, Overhage JM, Chan AS, Brown NL, Aghighi B, Entwistle MP, Hui SL, Hyde SM, Klieman LH, Mitchell CJ, Perkins AJ, Qureshi LS, Waltimyer TA, Winters LJ, Young CY. Online disease management of diabetes: engaging and motivating patients online with enhanced resources-diabetes (EMPOWER-D), a randomized controlled trial. J Am Med Inform Assoc. 2013 May 1;20(3):526-34. doi: 10.1136/amiajnl-2012-001263. Epub 2012 Nov 20.'}, {'pmid': '30124394', 'type': 'BACKGROUND', 'citation': 'Tchero H, Kangambega P, Briatte C, Brunet-Houdard S, Retali GR, Rusch E. Clinical Effectiveness of Telemedicine in Diabetes Mellitus: A Meta-Analysis of 42 Randomized Controlled Trials. Telemed J E Health. 2019 Jul;25(7):569-583. doi: 10.1089/tmj.2018.0128. Epub 2018 Aug 20.'}, {'pmid': '32186516', 'type': 'BACKGROUND', 'citation': 'Timpel P, Oswald S, Schwarz PEH, Harst L. Mapping the Evidence on the Effectiveness of Telemedicine Interventions in Diabetes, Dyslipidemia, and Hypertension: An Umbrella Review of Systematic Reviews and Meta-Analyses. J Med Internet Res. 2020 Mar 18;22(3):e16791. doi: 10.2196/16791.'}, {'pmid': '18363526', 'type': 'BACKGROUND', 'citation': 'Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008 Apr;28(4):421-36. doi: 10.1592/phco.28.4.421.'}], 'seeAlsoLinks': [{'label': 'Centers For Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. BRFSS Prevalence \\\\& Trend Data', 'url': 'https://nccd.cdc.gov/BRFSSPrevalence/rdPage.aspx?rdReport=DPH_BRFSS.ExploreByLocation&rdProcessAction=&SaveFileGenerated=1&irbLocationType=States&islLocation=23&islState=&islCounty=&islClass=CLASS03&islTopic=TOPIC18&islYear=2020&hidLocationType=States&hidLocation=23&hidClass=CLASS03&hidTopic=TOPIC18&hidTopicName=Diabetes&hidYear=2020&irbShowFootnotes=Show&rdICL-iclIndicators=DIABETE4&iclIndicators_rdExpandedCollapsedHistory=&iclIndicators=DIABETE4&hidPreviouslySelectedIndicators=&DashboardColumnCount=2&rdShowElementHistory=divTopicUpdating%3dHide%2cislTopic%3dShow%2cdivYearUpdating%3dHide%2cislYear%3dShow%2c&rdScrollX=0&rdScrollY=99&rdRnd=57890'}, {'label': 'Centers for Medicare and Medicaid Services. DM-2 (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (\\\\>9%).; 2019. Accessed January 20, 2022.', 'url': 'https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Web-Interface-Measures/2020_Measure_DM-2_CMSWebInterface.pdf'}, {'label': 'International Diabetes Federation. IDF Diabetes Atlas. IDF Diabetes Atlas. Published 2021', 'url': 'https://diabetesatlas.org/'}, {'label': 'Lisa A. States with the biggest rural populations. Stacker. Published April 8, 2019.', 'url': 'https://stacker.com/stories/2779/states-biggest-rural-populations?page=5'}, {'label': 'Maine Center for Disease Control \\\\& Prevention: Rural Health and Primary Care, A Division of the Maine Department of Health and Human Services.', 'url': 'https://www.maine.gov/dhhs/mecdc/public-health-systems/rhpc/hpsa.shtml'}, {'label': 'National Clinical Care Commission. Report to Congress on Leveraging Federal Programs to Prevent and Control Diabetes and Its Complications. Department of Health and Human Services; 2021. Accessed January 31, 2022.', 'url': 'https://health.gov/sites/default/files/2022-01/NCCC%20Report%20to%20Congress.pdf'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02220920', 'orgStudyIdInfo': {'id': 'TA-7284-11'}, 'organization': {'fullName': 'Mitsubishi Tanabe Pharma Corporation', 'class': 'INDUSTRY'}, 'briefTitle': 'Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus', 'officialTitle': 'A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2016-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2014-08'}, 'primaryCompletionDateStruct': {'date': '2015-07', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2015-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2014-08-19', 'studyFirstSubmitQcDate': '2014-08-19', 'studyFirstPostDateStruct': {'date': '2014-08-20', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2016-08-03', 'resultsFirstSubmitQcDate': '2016-10-24', 'resultsFirstPostDateStruct': {'date': '2016-12-15', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2016-10-24', 'lastUpdatePostDateStruct': {'date': '2016-12-15', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Mitsubishi Tanabe Pharma Corporation', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration.', 'detailedDescription': 'This is a randomized, 2-arm, parallel group, double blind study to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with type 2 diabetes mellitus, who are receiving treatment with insulin therapy on diet and exercise and have inadequate glycemic control. The patients will receive either TA-7284 100mg or Placebo orally for 16 weeks.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus'], 'keywords': ['insulin resistance']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 146, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Canagliflozin (TA-7284) ＋insulin', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Canagliflozin (TA-7284)', 'Drug: Insulin']}, {'label': 'Placebo＋insulin', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Drug: Placebo', 'Drug: Insulin']}], 'interventions': [{'type': 'DRUG', 'name': 'Canagliflozin (TA-7284)', 'description': 'The patients will receive Canagliflozin orally for 16 weeks', 'armGroupLabels': ['Canagliflozin (TA-7284) ＋insulin']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'The patients will receive Placebo orally for 16 weeks', 'armGroupLabels': ['Placebo＋insulin']}, {'type': 'DRUG', 'name': 'Insulin', 'armGroupLabels': ['Canagliflozin (TA-7284) ＋insulin', 'Placebo＋insulin']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in HbA1c From Baseline', 'timeFrame': 'baseline and Week 16'}], 'secondaryOutcomes': [{'measure': 'Change in Fasting Plasma Glucose', 'timeFrame': 'baseline and Week 16'}, {'measure': 'Percent Change in Body Weight', 'timeFrame': 'baseline and Week 16'}, {'measure': 'Change in Blood Pressure', 'timeFrame': 'baseline and Week 16'}, {'measure': 'Percentage of Participants With \"Adverse Events\" and \"Hypoglycemia and Blood Glucose Decreased\"', 'timeFrame': 'Week 16'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Patients who has been receiving a stable dose and regimen of insulin over 12 weeks before administration of investigational dug\\n* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug\\n* Patients with HbA1c of ≥7.5% and \\\\<10.5%\\n* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug\\n\\nExclusion Criteria:\\n\\n* Patients with type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (Cushing's syndrome, acromegaly, etc.)\\n* Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy)\\n* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria\\n* Patients with systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg\\n* Patients with serious renal or hepatic disease\\n* Patients with eGFR of \\\\<45 mL/min/1.73 m2\\n* Patients who are the excessive alcohol addicts\\n* Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '20 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Kazuoki Kondo, MD', 'affiliation': 'Mitsubishi Tanabe Pharma Corporation', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Reserch site', 'city': 'Chubu', 'country': 'Japan', 'geoPoint': {'lat': 35.43379, 'lon': 140.2797}}, {'facility': 'Reserch site', 'city': 'Chugoku', 'country': 'Japan'}, {'facility': 'Reserch site', 'city': 'Hokkaido', 'country': 'Japan', 'geoPoint': {'lat': 43.41104, 'lon': 142.88878}}, {'facility': 'Reserch site', 'city': 'Kanto', 'country': 'Japan'}, {'facility': 'Reserch site', 'city': 'Kinki', 'country': 'Japan'}, {'facility': 'Reserch site', 'city': 'Kyushu', 'country': 'Japan'}, {'facility': 'Reserch site', 'city': 'Tohoku', 'country': 'Japan', 'geoPoint': {'lat': 35.81882, 'lon': 139.57138}}]}, 'referencesModule': {'references': [{'pmid': '27316668', 'type': 'RESULT', 'citation': 'Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016 Jun 18;15:89. doi: 10.1186/s12933-016-0407-4.'}]}}, 'resultsSection': {'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Canagliflozin (TA-7284) ＋Insulin', 'description': 'Canagliflozin, once daily for 16 weeks'}, {'id': 'FG001', 'title': 'Placebo＋Insulin', 'description': 'Placebo, once daily for 16 weeks'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '76'}, {'groupId': 'FG001', 'numSubjects': '70'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '73'}, {'groupId': 'FG001', 'numSubjects': '67'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Conflict with the stopping criteria', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Canagliflozin (TA-7284) ＋Insulin', 'description': 'Canagliflozin, once daily for 16 weeks'}, {'id': 'BG001', 'title': 'Placebo＋Insulin', 'description': 'Placebo, once daily for 16 weeks'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '76'}, {'groupId': 'BG001', 'value': '70'}, {'groupId': 'BG002', 'value': '146'}]}], 'measures': [{'title': 'Age, Categorical', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'groupId': 'BG000', 'value': '47'}, {'groupId': 'BG001', 'value': '48'}, {'groupId': 'BG002', 'value': '95'}]}, {'title': '>=65 years', 'measurements': [{'groupId': 'BG000', 'value': '29'}, {'groupId': 'BG001', 'value': '22'}, {'groupId': 'BG002', 'value': '51'}]}]}]}, {'title': 'Gender', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '32'}, {'groupId': 'BG001', 'value': '21'}, {'groupId': 'BG002', 'value': '53'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '44'}, {'groupId': 'BG001', 'value': '49'}, {'groupId': 'BG002', 'value': '93'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change in HbA1c From Baseline', 'populationDescription': 'Full analysis set, last observation carried forward', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'Percent', 'timeFrame': 'baseline and Week 16', 'groups': [{'id': 'OG000', 'title': 'Canagliflozin (TA-7284) ＋Insulin', 'description': 'Canagliflozin, once daily for 16 weeks'}, {'id': 'OG001', 'title': 'Placebo＋Insulin', 'description': 'Placebo, once daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '76'}, {'groupId': 'OG001', 'value': '70'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.97', 'spread': '0.08'}, {'groupId': 'OG001', 'value': '0.13', 'spread': '0.08'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '<0.001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least-Squares Mean Difference', 'paramValue': '-1.10', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.33', 'ciUpperLimit': '-0.87', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.11'}]}, {'type': 'SECONDARY', 'title': 'Change in Fasting Plasma Glucose', 'populationDescription': 'Full analysis set, last observation carried forward. There was a lack of measurement of fasting plasma glucose at the end of treatment visit(Week 4) in one participant who was randomized to \"Canagliflozin(TA-7284) + Insulin\" group.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mg/dL', 'timeFrame': 'baseline and Week 16', 'groups': [{'id': 'OG000', 'title': 'Canagliflozin (TA-7284) ＋Insulin', 'description': 'Canagliflozin, once daily for 16 weeks'}, {'id': 'OG001', 'title': 'Placebo＋Insulin', 'description': 'Placebo, once daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '75'}, {'groupId': 'OG001', 'value': '70'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-34.1', 'spread': '4.8'}, {'groupId': 'OG001', 'value': '-1.4', 'spread': '5.0'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '<0.001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least-Squares Mean Difference', 'paramValue': '-32.6', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-46.3', 'ciUpperLimit': '-18.9', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.9'}]}, {'type': 'SECONDARY', 'title': 'Percent Change in Body Weight', 'populationDescription': 'Full analysis set, last observation carried forward. There was a lack of measurement of body weight at the end of treatment visit(Week 4) in one participant who was randomized to \"Canagliflozin(TA-7284) + Insulin\" group.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'percent change', 'timeFrame': 'baseline and Week 16', 'groups': [{'id': 'OG000', 'title': 'Canagliflozin (TA-7284) ＋Insulin', 'description': 'Canagliflozin, once daily for 16 weeks'}, {'id': 'OG001', 'title': 'Placebo＋Insulin', 'description': 'Placebo, once daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '75'}, {'groupId': 'OG001', 'value': '70'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.13', 'spread': '0.25'}, {'groupId': 'OG001', 'value': '0.24', 'spread': '0.26'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '<0.001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least-Squares Mean Difference', 'paramValue': '-2.37', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-3.09', 'ciUpperLimit': '-1.65', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.36'}]}, {'type': 'SECONDARY', 'title': 'Change in Blood Pressure', 'populationDescription': 'Full analysis set, last observation carried forward', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mmHg', 'timeFrame': 'baseline and Week 16', 'groups': [{'id': 'OG000', 'title': 'Canagliflozin (TA-7284) ＋Insulin', 'description': 'Canagliflozin, once daily for 16 weeks'}, {'id': 'OG001', 'title': 'Placebo＋Insulin', 'description': 'Placebo, once daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '76'}, {'groupId': 'OG001', 'value': '70'}]}], 'classes': [{'title': 'Systolic blood pressure', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-3.58', 'spread': '1.14'}, {'groupId': 'OG001', 'value': '-0.40', 'spread': '1.19'}]}]}, {'title': 'Diastolic blood pressure', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.55', 'spread': '0.71'}, {'groupId': 'OG001', 'value': '-0.31', 'spread': '0.74'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.058', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least-Squares Mean Difference', 'paramValue': '-3.19', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-6.49', 'ciUpperLimit': '0.11', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.67', 'estimateComment': 'Estimated P-Value, Least-Squares Mean Difference, Standard Error of the mean, 95% CI are presented for the change from Baseline in systolic blood pressure for week 16.'}, {'groupIds': ['OG000', 'OG001'], 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '0.232', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least-Squares Mean Difference', 'paramValue': '-1.24', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-3.27', 'ciUpperLimit': '0.80', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.03', 'estimateComment': 'Estimated P-Value, Least-Squares Mean Difference, Standard Error of the mean, 95% CI are presented for the change from Baseline in diastolic blood pressure for week 16.'}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With \"Adverse Events\" and \"Hypoglycemia and Blood Glucose Decreased\"', 'populationDescription': 'Safety analysis set. \"Safety Population\" reflects the \"as treated\" population, and one \"Canagliflozin (TA-7284) + Insulin\" participant actually received \"Placebo + Insulin\".', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Week 16', 'groups': [{'id': 'OG000', 'title': 'Canagliflozin (TA-7284) ＋Insulin', 'description': 'Canagliflozin, once daily for 16 weeks'}, {'id': 'OG001', 'title': 'Placebo＋Insulin', 'description': 'Placebo, once daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '75'}, {'groupId': 'OG001', 'value': '71'}]}], 'classes': [{'title': 'adverse events', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '68.0'}, {'groupId': 'OG001', 'value': '64.8'}]}]}, {'title': 'Hypoglycemia and Blood glucose decreased', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '40.0'}, {'groupId': 'OG001', 'value': '29.6'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'description': '\"Safety Population\" reflects the \"as treated\" population, and one \"Canagliflozin(TA-7284) + Insulin\" participant actually received \"Placebo + Insulin\".', 'eventGroups': [{'id': 'EG000', 'title': 'Canagliflozin (TA-7284) ＋Insulin', 'description': 'Canagliflozin, once daily for 16 weeks', 'seriousNumAffected': 3, 'seriousNumAtRisk': 75, 'otherNumAffected': 39, 'otherNumAtRisk': 75}, {'id': 'EG001', 'title': 'Placebo＋Insulin', 'description': 'Placebo, once daily for 16 weeks', 'seriousNumAffected': 1, 'seriousNumAtRisk': 71, 'otherNumAffected': 34, 'otherNumAtRisk': 71}], 'seriousEvents': [{'term': 'Cataract', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 18.0', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 75}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 71}]}, {'term': 'Retinal detachment', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 18.0', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 75}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 71}]}, {'term': 'Vitreous haemorrhage', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 18.0', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 75}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 71}]}, {'term': 'Alcoholic liver disease', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 18.0', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 75}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 71}]}], 'otherEvents': [{'term': 'Nasopharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 18.0', 'stats': [{'groupId': 'EG000', 'numAffected': 12, 'numAtRisk': 75}, {'groupId': 'EG001', 'numAffected': 13, 'numAtRisk': 71}]}, {'term': 'Hypoglycaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 18.0', 'stats': [{'groupId': 'EG000', 'numAffected': 19, 'numAtRisk': 75}, {'groupId': 'EG001', 'numAffected': 15, 'numAtRisk': 71}]}, {'term': 'Pollakiuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 18.0', 'stats': [{'groupId': 'EG000', 'numAffected': 4, 'numAtRisk': 75}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 71}]}, {'term': 'Blood glucose decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 18.0', 'stats': [{'groupId': 'EG000', 'numAffected': 20, 'numAtRisk': 75}, {'groupId': 'EG001', 'numAffected': 12, 'numAtRisk': 71}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictionType': 'OTHER', 'restrictiveAgreement': True}, 'pointOfContact': {'title': 'Clinical Trials, Information Desk', 'organization': 'Mitsubishi Tanabe Pharma Corporation', 'email': 'cti-inq-ml@ml.mt-pharma.co.jp'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M10370', 'name': 'Insulin Resistance', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068896', 'term': 'Canagliflozin'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D000077203', 'term': 'Sodium-Glucose Transporter 2 Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}], 'browseLeaves': [{'id': 'M331', 'name': 'Canagliflozin', 'asFound': 'Concentrate', 'relevance': 'HIGH'}, {'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M1691', 'name': 'Sodium-Glucose Transporter 2 Inhibitors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': True}], 'nextPageToken': 'NF0g5JCElPYu'}\n",
            "         NCT ID      Acronym Overall Status  Start Date  \\\n",
            "0   NCT06529965    EASE-T2DM     RECRUITING  2024-10-09   \n",
            "1   NCT06097065      Unknown     RECRUITING  2022-05-20   \n",
            "2   NCT02373865      Unknown     TERMINATED     2015-09   \n",
            "3   NCT03709966     DBFitbit      COMPLETED  2017-12-07   \n",
            "4   NCT05389566      DIAFALL      COMPLETED  2022-05-06   \n",
            "..          ...          ...            ...         ...   \n",
            "95  NCT01516320        LAF26      COMPLETED  2009-05-13   \n",
            "96  NCT00191282         IONM      COMPLETED     2002-10   \n",
            "97  NCT06214520  EmpowerPlus     RECRUITING  2024-02-23   \n",
            "98  NCT05541120      Unknown      WITHDRAWN  2022-10-18   \n",
            "99  NCT02220920      Unknown      COMPLETED     2014-08   \n",
            "\n",
            "                                           Conditions  \\\n",
            "0   Glucose Metabolism Disorders (Including Diabet...   \n",
            "1   Prediabetes, Diabetes Mellitus, Gestational Di...   \n",
            "2                            Diabetes Mellitus Type 2   \n",
            "3   Diabetes Mellitus, Type 2, Physical Activity, ...   \n",
            "4   Diabetic Peripheral Neuropathy, Diabetes, Bala...   \n",
            "..                                                ...   \n",
            "95                                    Type 2 Diabetes   \n",
            "96  Diabetes Mellitus, Type 2, Acute Myocardial In...   \n",
            "97                           Diabetes Mellitus Type 2   \n",
            "98                          Diabetes Mellitus, Type 2   \n",
            "99                           Type 2 Diabetes Mellitus   \n",
            "\n",
            "                                        Interventions  \\\n",
            "0                                             covivio   \n",
            "1                         Oral Glucose Tolerance Test   \n",
            "2   Sitagliptin, Glimepiride, Sitagliptin-Placebo,...   \n",
            "3                 Portable monitoring device, Routine   \n",
            "4   Quantative Sensory Testing, NCStat-DPN-Check, ...   \n",
            "..                                                ...   \n",
            "95  Roux-en-Y Gastric Bypass, Laparoscopic adjusta...   \n",
            "96  Insulin lispro, Human insulin isophane suspens...   \n",
            "97  App-based Motivational Interviewing & Human he...   \n",
            "98                          Remote Patient Monitoring   \n",
            "99          Canagliflozin (TA-7284), Placebo, Insulin   \n",
            "\n",
            "                                            Locations Primary Completion Date  \\\n",
            "0                                   Hamburg - Germany              2026-04-09   \n",
            "1                                   Guangzhou - China              2025-12-31   \n",
            "2                                   Dresden - Germany                 2017-01   \n",
            "3                                     Québec - Canada              2019-03-31   \n",
            "4                                   Aalborg - Denmark              2022-05-20   \n",
            "..                                                ...                     ...   \n",
            "95                           New York - United States              2014-09-01   \n",
            "96  Toronto - Canada, Zagreb - Croatia, Praha - Cz...                 2007-10   \n",
            "97  Singapore - Singapore, Singapore - Singapore, ...              2025-10-30   \n",
            "98                           Rockport - United States              2026-06-30   \n",
            "99  Chubu - Japan, Chugoku - Japan, Hokkaido - Jap...                 2015-07   \n",
            "\n",
            "   Study First Post Date Last Update Post Date      Study Type         Phases  \n",
            "0             2024-07-31            2024-11-08  INTERVENTIONAL             NA  \n",
            "1             2023-10-24            2023-10-24   OBSERVATIONAL  Not Available  \n",
            "2             2015-02-27            2019-02-27  INTERVENTIONAL         PHASE4  \n",
            "3             2018-10-17            2020-10-19  INTERVENTIONAL             NA  \n",
            "4             2022-05-25            2024-08-09   OBSERVATIONAL  Not Available  \n",
            "..                   ...                   ...             ...            ...  \n",
            "95            2012-01-24            2017-02-01  INTERVENTIONAL             NA  \n",
            "96            2005-09-19            2011-01-20  INTERVENTIONAL         PHASE4  \n",
            "97            2024-01-19            2024-11-14  INTERVENTIONAL             NA  \n",
            "98            2022-09-15            2023-02-16  INTERVENTIONAL             NA  \n",
            "99            2014-08-20            2016-12-15  INTERVENTIONAL         PHASE4  \n",
            "\n",
            "[100 rows x 12 columns]\n"
          ]
        }
      ],
      "source": [
        "import requests\n",
        "import pandas as pd\n",
        "import json\n",
        "\n",
        "# Initial URL for the first API call\n",
        "base_url = \"https://clinicaltrials.gov/api/v2/studies\"\n",
        "params = {\n",
        "    \"query.titles\": \"Diabetes\",\n",
        "    \"pageSize\": 100\n",
        "}\n",
        "\n",
        "# Initialize an empty list to store the data\n",
        "data_list = []\n",
        "all_data = []\n",
        "\n",
        "\n",
        "# Loop until there is no nextPageToken\n",
        "x=1\n",
        "while x<2:\n",
        "    x = x+1\n",
        "    # Print the current URL (for debugging purposes)\n",
        "    print(\"Fetching data from:\", base_url + '?' + '&'.join([f\"{k}={v}\" for k, v in params.items()]))\n",
        "\n",
        "    # Send a GET request to the API\n",
        "    response = requests.get(base_url, params=params)\n",
        "\n",
        "\n",
        "    # Check if the request was successful\n",
        "    if response.status_code == 200:\n",
        "        data = response.json()  # Parse JSON response\n",
        "        studies = data.get('studies', [])  # Extract the list of studies\n",
        "        print(data)\n",
        "\n",
        "        # Loop through each study and extract specific information\n",
        "        for study in studies:\n",
        "            # Safely access nested keys\n",
        "            nctId = study['protocolSection']['identificationModule'].get('nctId', 'Unknown')\n",
        "            overallStatus = study['protocolSection']['statusModule'].get('overallStatus', 'Unknown')\n",
        "            startDate = study['protocolSection']['statusModule'].get('startDateStruct', {}).get('date', 'Unknown Date')\n",
        "            conditions = ', '.join(study['protocolSection']['conditionsModule'].get('conditions', ['No conditions listed']))\n",
        "            acronym = study['protocolSection']['identificationModule'].get('acronym', 'Unknown')\n",
        "\n",
        "            # Extract interventions safely\n",
        "            interventions_list = study['protocolSection'].get('armsInterventionsModule', {}).get('interventions', [])\n",
        "            interventions = ', '.join([intervention.get('name', 'No intervention name listed') for intervention in interventions_list]) if interventions_list else \"No interventions listed\"\n",
        "\n",
        "            # Extract locations safely\n",
        "            locations_list = study['protocolSection'].get('contactsLocationsModule', {}).get('locations', [])\n",
        "            locations = ', '.join([f\"{location.get('city', 'No City')} - {location.get('country', 'No Country')}\" for location in locations_list]) if locations_list else \"No locations listed\"\n",
        "\n",
        "            # Extract dates and phases\n",
        "            primaryCompletionDate = study['protocolSection']['statusModule'].get('primaryCompletionDateStruct', {}).get('date', 'Unknown Date')\n",
        "            studyFirstPostDate = study['protocolSection']['statusModule'].get('studyFirstPostDateStruct', {}).get('date', 'Unknown Date')\n",
        "            lastUpdatePostDate = study['protocolSection']['statusModule'].get('lastUpdatePostDateStruct', {}).get('date', 'Unknown Date')\n",
        "            studyType = study['protocolSection']['designModule'].get('studyType', 'Unknown')\n",
        "            phases = ', '.join(study['protocolSection']['designModule'].get('phases', ['Not Available']))\n",
        "\n",
        "            # Append the data to the list as a dictionary\n",
        "            data_list.append({\n",
        "                \"NCT ID\": nctId,\n",
        "                \"Acronym\": acronym,\n",
        "                \"Overall Status\": overallStatus,\n",
        "                \"Start Date\": startDate,\n",
        "                \"Conditions\": conditions,\n",
        "                \"Interventions\": interventions,\n",
        "                \"Locations\": locations,\n",
        "                \"Primary Completion Date\": primaryCompletionDate,\n",
        "                \"Study First Post Date\": studyFirstPostDate,\n",
        "                \"Last Update Post Date\": lastUpdatePostDate,\n",
        "                \"Study Type\": studyType,\n",
        "                \"Phases\": phases\n",
        "            })\n",
        "\n",
        "        # Check for nextPageToken and update the params or break the loop\n",
        "        nextPageToken = data.get('nextPageToken')\n",
        "        if nextPageToken:\n",
        "            params['pageToken'] = nextPageToken  # Set the pageToken for the next request\n",
        "        else:\n",
        "            break  # Exit the loop if no nextPageToken is present\n",
        "    else:\n",
        "        print(\"Failed to fetch data. Status code:\", response.status_code)\n",
        "        break\n",
        "\n",
        "# Create a DataFrame from the list of dictionaries\n",
        "df = pd.DataFrame(data_list)\n",
        "\n",
        "print(df)\n",
        "\n",
        "# Print the DataFrame\n",
        "# print(df)\n",
        "\n",
        "# Optionally, save the DataFrame to a CSV file\n",
        "# df.to_csv(\"clinical_trials_data_complete.csv\", index=False)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 38,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-QyvWHG30_JX",
        "outputId": "fd487d04-8c9c-4ce7-dda0-9a60cc407d8f"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Index(['NCT ID', 'Acronym', 'Overall Status', 'Start Date', 'Conditions',\n",
            "       'Interventions', 'Locations', 'Primary Completion Date',\n",
            "       'Study First Post Date', 'Last Update Post Date', 'Study Type',\n",
            "       'Phases'],\n",
            "      dtype='object')\n"
          ]
        }
      ],
      "source": [
        "print(df.columns)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 8,
      "metadata": {
        "id": "UPHhnN3A16uB"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "100"
            ]
          },
          "execution_count": 8,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "len(studies)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 12,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "{'protocolSection': {'identificationModule': {'nctId': 'NCT06529965', 'orgStudyIdInfo': {'id': 'covivio RCT 2024'}, 'organization': {'fullName': 'Gaia AG', 'class': 'INDUSTRY'}, 'briefTitle': 'Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DM', 'officialTitle': 'Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With Type 2 Diabetes Mellitus: Randomized Controlled Trial', 'acronym': 'EASE-T2DM'}, 'statusModule': {'statusVerifiedDate': '2024-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-10-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-04-09', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-04-09', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-07-26', 'studyFirstSubmitQcDate': '2024-07-26', 'studyFirstPostDateStruct': {'date': '2024-07-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-11-06', 'lastUpdatePostDateStruct': {'date': '2024-11-08', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Gaia AG', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'University Hospital Schleswig-Holstein', 'class': 'OTHER'}, {'name': 'Philipps University Marburg', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"This randomized controlled trial (RCT) with 250 patients suffering from type 2 diabetes mellitus (T2DM) aims to investigate the effectiveness of the self-guided digital therapeutic covivio. Inclusion criteria are: male, female or non-binary; age ≥ 18 years; confirmed diagnosis of T2DM; elevated levels of diabetes-specific emotional distress (Problem Areas in Diabetes \\\\[PAID\\\\]-20 score ≥ 33); consent to participate; sufficient German language skills. Exclusion criteria are: a diagnosis of type 1 diabetes mellitus (T1DM); current use of continuous glucose monitoring (CGM) as part of one's diabetes treatment; changes or planned changes in medication within 4 weeks before the baseline visit or in the subsequent 6 months; a bariatric operation within 4 weeks before the baseline visit or such an operation planned in the subsequent 6 months; changes or planned changes in psychotherapeutic treatment within 4 weeks before the baseline visit or in the subsequent 6 months. In addition, participants will be excluded from the study if they did not wear the CGM sensor for at least 6 of 7 days at baseline (before randomization), providing a minimum of 96 hours of glucose values including at least 24 hours overnight.\\n\\nPatients will be randomized and allocated in a 1:1 ratio to either an intervention group, in which they will receive access to covivio in addition to treatment as usual (TAU, n = 125), or to a control group, in which they will receive only TAU (n = 125).\\n\\nCo-primary endpoints of this trial will be the between-groups difference in the PAID-20 total score in the intervention and control group at six months, adjusted for the PAID-20 baseline score as well as the glucose management indicator (estimated HbA1c) assessed using continuous glucose monitoring devices (for a period of 7 days) at six months, adjusted for the baseline score.\\n\\nSecondary endpoints will be diabetes self-management skills, body mass index (BMI), and quality of life.\"}, 'conditionsModule': {'conditions': ['Glucose Metabolism Disorders (Including Diabetes Mellitus)', 'Metabolic Disease', 'Endocrine System Diseases', 'Diabetes Mellitus, Type 2'], 'keywords': ['type 2 diabetes', 'covivio', 'diabetes self-management', 'digital health application']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'randomized controlled trial with two arms: (i) online intervention in addition to treatment-as-usual versus (ii) treatment-as-usual', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 250, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Intervention/Treatment', 'type': 'EXPERIMENTAL', 'description': 'Experimental: covivio + TAU\\n\\nParticipants allocated to the intervention group will receive access to covivio in addition to treatment as usual (TAU).\\n\\ncovivio is a digital health application designed for individuals with type 2 diabetes mellitus who suffer from elevated levels of diabetes-specific emotional distress, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by covivio are disease literacy, physical activity and exercise, nutrition, stress management, sleep management, mood problems, and social resources.\\n\\nThe program operates through interactive \"dialogues\", which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days.', 'interventionNames': ['Behavioral: covivio']}, {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'No Intervention: TAU\\n\\nParticipants allocated to the control group will receive access to treatment as usual (TAU).'}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'covivio', 'description': 'Participants will receive access to the digital health intervention covivio in addition to TAU.', 'armGroupLabels': ['Intervention/Treatment']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Diabetes-specific emotional distress', 'description': 'Assessed with the Problem Areas in Diabetes Questionnaire (PAID-20). Total score ranging from 0-100; higher scores indicate higher diabetes-specific emotional distress (worse outcome).', 'timeFrame': '6 months'}, {'measure': 'Glucose management indicator', 'description': 'The glucose management indicator (GMI) is an estimation of HbA1c from CGM. It is calculated as follows: GMI (%) = 3.31 + 0.02392 x \\\\[mean glucose in mg/dL\\\\].', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Diabetes-specific emotional distress', 'description': 'Assessed with the Problem Areas in Diabetes Questionnaire (PAID-20). Total score ranging from 0-100; higher scores indicate higher diabetes-specific emotional distress (worse outcome).', 'timeFrame': '3 months'}, {'measure': 'Diet self-management skills', 'description': 'Assessed with the Diet Subscale of the Summary of Diabetes Self-Care Activities Measure (SDSCA). The diet subscale contains four items and the score may range from 0-28; higher scores indicate higher diet self-management skills (better outcome).', 'timeFrame': '3 months; 6 months'}, {'measure': 'Exercise self-management skills', 'description': 'Assessed with the Exercise Subscale of the Summary of Diabetes Self-Care Activities (SDSCA). The exercise subscale contains two items and the score may range from 0-14; higher scores indicate higher exercise self-management skills (better outcome).', 'timeFrame': '3 months; 6 months'}, {'measure': 'Health-related quality of life', 'description': 'Quantified with the Assessment of Quality of Life - 8 Dimensions (AQoL-8D). Total score ranging from 0-100; higher scores indicate a higher quality of life (better outcome).', 'timeFrame': '3 months; 6 months'}, {'measure': 'Body mass index (BMI)', 'description': \"The BMI will be computed according to the following formula: kg/m2, where kg is a person's weight in kilograms and m2 is their height in meters squared. If necessary, height will be converted into meters and weight will be converted into kilograms.\", 'timeFrame': '3 months; 6 months'}], 'otherOutcomes': [{'measure': 'Time in range (TIR) derived from CGM', 'description': 'Defined as time spent in the target range between 70 and 180 mg/dL. TIR will be assessed in hours and minutes for a 7-day period, and also expressed as percent.', 'timeFrame': '6 months'}, {'measure': 'Mean sensor glucose derived from CGM', 'description': 'Mean sensor glucose will be calculated over the 7 days of glucose measurements.', 'timeFrame': '6 months'}, {'measure': 'Coefficient of variation derived from CGM', 'description': 'The coefficient of variation will be used to quantify glycemic variability.', 'timeFrame': '6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* male, female or non-binary\\n* age ≥ 18 years\\n* diagnosis of T2DM secured via submission of a medical certificate attesting to the presence of at least one of the following ICD-10-GM diagnoses of T2DM: E11.20, E11.30, E11.40, E11.50, E11.60, E11.72, E11.74, E11.80, E11.90\\n* elevated levels of diabetes-specific emotional distress: cut-off ≥ 33 on the PAID-20\\n* access to CGM-compatible smartphone\\n* consent to participate\\n* sufficient knowledge of the German language\\n\\nExclusion Criteria:\\n\\n* diagnosis of type 1 diabetes mellitus (T1DM)\\n* change in medication (type, frequency of use or dosage) within 4 weeks before the baseline visit or planned within the subsequent 6 months\\n* recent or planned bariatric operation within 4 weeks before the baseline visit or within the subsequent 6 months\\n* change in psychotherapeutic treatment within 4 weeks before the baseline visit or planned within the subsequent 6 months\\n* current use of continuous glucose monitoring (CGM) as part of one's diabetes treatment\\n* experiencing problems with the CGM sensor or insufficient CGM data quality at baseline (T0) (i.e., wearing the CGM sensor on less than 6 of 7 days, providing less than a minimum of 96 hours of glucose values, providing less than 24 hours overnight CGM data)\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Gitta A Jacob, PhD', 'role': 'CONTACT', 'phone': '+49 40 349930-374', 'email': 'gitta.jacob@gaia-group.com'}, {'name': 'Katharina M Rischer, PhD', 'role': 'CONTACT', 'email': 'katharina.rischer@gaia-group.com'}], 'overallOfficials': [{'name': 'Kamila Jauch-Chara, Dr. med.', 'affiliation': 'Zentrum für Integrative Psychiatrie, Universitätsklinikum Schleswig-Holstein', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'GAIA AG', 'status': 'RECRUITING', 'city': 'Hamburg', 'zip': '22085', 'country': 'Germany', 'contacts': [{'name': 'Gitta A Jacob, PhD', 'role': 'CONTACT'}, {'name': 'Katharina M Rischer, PhD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 53.57532, 'lon': 10.01534}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-02-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'asFound': 'Metabolic Diseases', 'relevance': 'HIGH'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'asFound': 'Glucose Metabolism Disorders', 'relevance': 'HIGH'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'asFound': 'Endocrine System Diseases', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}\n"
          ]
        }
      ],
      "source": [
        "\n",
        "\n",
        "with open('example_first_100.json', \"w\") as json_file:\n",
        "    json.dump(studies, json_file, indent=4)\n",
        "\n",
        "print(studies[0])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {},
      "outputs": [],
      "source": []
    }
  ],
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "display_name": "base",
      "language": "python",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.12.8"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}
